FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Thong, T Raitt, MH AF Thong, Tran Raitt, Merritt H. TI Predicting imminent episodes of ventricular tachyarrhythmia using heart rate SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Article DE prediction; ventricular tachyarrhythmia; R-R intervals; ICD; prevention; VT; VF ID RATE-VARIABILITY; SPONTANEOUS INITIATION; RATE DYNAMICS; TACHYCARDIA; ONSET; ARRHYTHMIAS; FIBRILLATION; MECHANISMS; DISEASE; DEATH AB Background: A reliable Predictor of an imminent episode of ventricular tachyarrhythmia that could be incorporated in an implantable defibrillator capable of preventive therapy would have important clinical utility, Method: A test set of 208 R-R records saved by defibrillators spanning a mean of 1.6 hours before sustained tachyarrhythmia were used to derive criteria that would improve the specificity of the previously identified monotonic heart rate acceleration predictor. Additional criteria were used, namely two such patterns need to occur within a period of 1.8 hour and the heart rate during these accelerations exceeds 86 bpm (700 ms). The specificity was tested using R-R records matched in duration from 26 control patients with defibrillators during normal periods. Results: The basic acceleration pattern was found during sinus rhythm in the 1.8-hour period prior to 83% of episodes of ventricular tachyarrhythmia. It was also found in 43% of the matched set of nonarrhythmic records, corresponding to a specificity of 57%. With the two extra requirement of multiplicity within 1.8 hour and peak heart rate, the sensitivity of the proposed predictor is reduced to 53%, but the specificity is increased to 91%, which corresponds to an average false positive rate of 0.8 event/day across the patient population. Conclusion: A ventricular tachyarrhythmia predictor based on a pattern of heart rate acceleration has been proposed that can yield sensitivity from 53% to 69%, with specificity up to 91%. Instances of this predictor increase significantly prior to an episode of tachyarrhythmia. C1 Oregon Hlth & Sci Univ, Dept Biomed Engn, OGI Sch Sci & Engn, Beaverton, OR 97006 USA. Portland VA Med Ctr, Portland, OR USA. RP Thong, T (reprint author), Oregon Hlth & Sci Univ, Dept Biomed Engn, OGI Sch Sci & Engn, 20000 NW Walker Rd,MS OGI 602, Beaverton, OR 97006 USA. EM trant@bme.ogi.edu NR 18 TC 8 Z9 8 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0147-8389 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD JUL PY 2007 VL 30 IS 7 BP 874 EP 884 DI 10.1111/j.1540-8159.2007.00775.x PG 11 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA 187OE UT WOS:000247856800008 PM 17584269 ER PT J AU Bradesi, S Lao, L McLean, PG Winchester, WJ Lee, K Hicks, GA Mayer, EA AF Bradesi, Sylvie Lao, Lijun McLean, Peter G. Winchester, Wendy J. Lee, Kevin Hicks, Gareth A. Mayer, Emeran A. TI Dual role of 5-HT3 receptors in a rat model of delayed stress-induced visceral hyperalgesia SO PAIN LA English DT Article DE 5-HT3 receptors; visceral nociception; hyperalgesia; stress ID IRRITABLE-BOWEL-SYNDROME; COLORECTAL DISTENSION; ANESTHETIZED RAT; SPINAL-CORD; ALOSETRON; RESPONSES; BRAIN; HYPERSENSITIVITY; TROPISETRON; NOCICEPTION AB Despite its beneficial effect in IBS patients, the mechanism of action of the 5-HT3 receptor (5-HT3R) antagonist alosetron is still incompletely understood. We aimed to characterize the effect and site(s) of action in a model of stress-induced sensitization of visceral nociception in rats. Adult male Wistar rats were equipped for recording of visceromotor response (VMR) to phasic colorectal distension (CRD; 10-60 mm Hg). VMR to CRD was recorded 24 h after an acute session of water avoidance (WA) stress (post-WA). Baseline and post-WA responses were measured in rats exposed to WA or sham-WA, treated with alosetron at 0.3 mg/kg subcutaneously (s.c.) 25 nmol intrathecally (i.t.) or vehicle before post-WA CRD. Some rats were treated with capsaicin/vehicle on the cervical vagus nerve and received alosetron (0.3 mg/kg, s.c.) 15 min before post-WA CRD. WA stress led to visceral hyperalgesia 24 h later. Alosetron (0.3 mg/kg, s.c.) failed to inhibit WA-induced exacerbation of VMR to CRD. Stress-induced visceral hyperalgesia was abolished when alosetron was injected intrathecally (P < 0.05) in intact rats or subcutaneously (0.3 mg/kg) in capsaicin-pretreated animals (P < 0.05). Capsaicin-pretreatment did not affect the exacerbating effect of stress on visceral sensitivity. Alosetron had no inhibitory effect on normal visceral pain responses when administered subcutaneously or intrathecally. We demonstrated that 5-HT(3)Rs on central terminals of spinal afferents are engaged in the facilitatory effect of stress on visceral sensory information processing. In addition, we showed that stress-induced sensitization of visceral nociception is independent of 5-HT3R activation on vagal afferents. (C) 2006 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. C1 Ctr Neurovisceral Sci & Womens Hlth, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Nova Pharmaceut Corp, E Hanover, NJ 07936 USA. RP Mayer, EA (reprint author), Ctr Neurovisceral Sci & Womens Hlth, Dept Med, Room 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM emayer@ucla.edu FU NCCIH NIH HHS [R24 AT00281]; NIDDK NIH HHS [P50 DK64539] NR 34 TC 30 Z9 32 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD JUL PY 2007 VL 130 IS 1-2 BP 56 EP 65 DI 10.1016/j.pain.2006.10.028 PG 10 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 186BO UT WOS:000247754300010 PM 17161536 ER PT J AU Parmelee, PA Harralson, TL Smith, LA Schumacher, HR AF Parmelee, Patricia A. Harralson, Tina L. Smith, Lori A. Schumacher, H. Ralph TI Necessary and discretionary activities in knee osteoarthritis: Do they mediate the pain-depression relationship? SO PAIN MEDICINE LA English DT Article DE pain; depression; osteoarthritis; functional status; leisure ID ACTIVITY RESTRICTION; CANCER-PATIENTS; MENTAL-HEALTH; OLDER ADULTS; ARTHRITIS; DISABILITY; AGE; SYMPTOMS; SCALES; IMPACT AB Objective. This study examined direct vs indirect associations of pain and physical function with depression in 369 older adults with osteoarthritis (OA) of the knee. A key focus was the distinction of functional disability in necessary tasks (basic and instrumental activities of daily living) from discretionary, leisure activities. Design. A naturalistic longitudinal study examined effects of demographic variables, indicators of arthritis status, general health, pain, and several measures of functional disability upon depressive symptoms at baseline and 1 year later. Setting and Patients. Participants with diagnosed knee OA were recruited from rheumatological and general geriatric outpatient clinics, as well as public service announcements. Outcome Measure. Depressive symptoms, measured with the Center for Epidemiologic Studies Depression scale. Results. At baseline, the relationships of depression with functional disability and activity limitation were wholly mediated by pain. In contrast, activity participation was independently linked with depression, even controlling health and demographic variables. A 1-year follow-up revealed that depressive symptoms increased with increasing health problems, and with reduction in activity participation over time. Having and retaining favorite pastimes were also associated with reduced depressive symptomatology at baseline and follow-up, respectively. Conclusions. These data highlight the disease-specific nature of paths among depression, pain, and disability, and the importance of considering discretionary as well as necessary activities in evaluating effects of pain upon quality of life. C1 Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Div Geriatr Psychiat, Atlanta, GA 30329 USA. Albert Einstein Med Ctr, Ctr Urban Hlth Policy & Res, Philadelphia, PA 19141 USA. Univ Penn, Sch Med, Div Rheumatol, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Parmelee, PA (reprint author), Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Div Geriatr Psychiat, 1841 Clifton Rd NE, Atlanta, GA 30329 USA. EM pparmel@emory.edu FU PHS HHS [1 R01-51800] NR 46 TC 24 Z9 27 U1 1 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1526-2375 J9 PAIN MED JI Pain Med. PD JUL-AUG PY 2007 VL 8 IS 5 BP 449 EP 461 DI 10.1111/j.1526-4637.2007.00310.x PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 197SA UT WOS:000248575600011 PM 17661863 ER PT J AU Gallun, FJ Mason, CR Kidd, G AF Gallun, Frederick J. Mason, Christine R. Kidd, Gerald, Jr. TI Task-dependent costs in processing two simultaneous auditory stimuli SO PERCEPTION & PSYCHOPHYSICS LA English DT Article; Proceedings Paper CT 149th Meeting of the Acoustical-Society-of-America CY MAY 16-20, 2005 CL Vancouver, CANADA SP Acoust Soc Amer ID ACROSS-EAR INTERFERENCE; PARTY LISTENING TASK; INFORMATIONAL MASKING; SELECTIVE ATTENTION; SPEECH IDENTIFICATION; SPATIAL SEPARATION; ENERGETIC MASKING; DICHOTIC MEMORY; PERCEPTION; RECOGNITION AB A listener presented with two speech signals must at times sacrifice the processing of one signal in order to understand the other. This study was designed to distinguish costs related to interference from a second signal (selective attention) from costs related to performing two tasks simultaneously (divided attention). Listeners presented with two processed speech-in-noise stimuli, one to each ear, either (1) identified keywords in both or (2) identified keywords in one and detected the presence of speech in the other. Listeners either knew which ear to report in advance (single task) or were cued afterward (partial-report dual task). When the dual task required two identification judgments, performance suffered relative to the single-task condition (as measured by percent correct judgments). Two different tasks (identification for one stimulus and detection for the other) resulted in much smaller reductions in performance when the cue came afterward. We concluded that the degree to which listeners can simultaneously process dichotic speech stimuli seems to depend not only on the amount of interference between the two stimuli, but also on whether there is competition for limited processing resources. We suggest several specific hypotheses as to the structural mechanisms that could constitute these limited resources. C1 Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. Boston Univ, Boston, MA 02215 USA. RP Gallun, FJ (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM frederick.gallun@va.gov RI Gallun, Frederick/G-3792-2012 OI Gallun, Frederick/0000-0002-4145-2199 FU NIDCD NIH HHS [DC00100, DC04545, DC04663, F32 DC006526, F32 DC006526-03, R01 DC004545] NR 68 TC 21 Z9 21 U1 1 U2 5 PU PSYCHONOMIC SOC INC PI AUSTIN PA 1710 FORTVIEW RD, AUSTIN, TX 78704 USA SN 0031-5117 J9 PERCEPT PSYCHOPHYS JI Percept. Psychophys. PD JUL PY 2007 VL 69 IS 5 BP 757 EP 771 DI 10.3758/BF03193777 PG 15 WC Psychology; Psychology, Experimental SC Psychology GA 212MQ UT WOS:000249601000010 PM 17929698 ER PT J AU Sevick, MA Napolitano, MA Papandonatos, GD Gordon, AJ Reiser, LM Marcus, BH AF Sevick, Mary Ann Napolitano, Melissa A. Papandonatos, George D. Gordon, Adam J. Reiser, Lorraine M. Marcus, Bess H. TI Cost-effectiveness of alternative approaches for motivating activity in sedentary adults: Results of Project STRIDE SO PREVENTIVE MEDICINE LA English DT Article DE economics; exercise; health promotion; physical fitness; primary prevention; randomized controlled trials ID PHYSICAL-ACTIVITY PROMOTION; PRIMARY-CARE; ACTIVITY INTERVENTION; RECOMMENDATION; RATIONALE; TELEPHONE; URBAN; MEN AB Objective. To evaluate the cost-effectiveness of non-face-to-face interventions for increasing physical activity in sedentary adults. The took place in Providence, Rhode Island between the years 2000 and 2004. Methods. Two hundred and thirty-nine participants were randomized to Phone, Print or a contact control. Phone and Print groups were regular surveys regarding their level of physical activity, motivational readiness and self-efficacy. Surveys were scanned by a computer system to generate feedback reports. Phone group participants received feedback by telephone. Print group participants received feedback by The contact control group received mailings unrelated to physical activity. Intervention costs were assessed prospectively, from a payer Physical activity was measured using the 7-day Physical Activity Recall. Ambulatory health service use was assessed via monthly surveys. Results. The Print intervention was more economically efficient than the Phone intervention in engaging participants in a more active Conclusion. The Print intervention provides an efficient approach to increasing physical activity. Research is needed to determine the effectiveness of the intervention in a more diverse population, within the context of the health service delivery system and over a longer period time. (C) 2007 Elsevier Inc. All rights reserved. C1 Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA. Miriam Hosp, Providence, RI 02906 USA. Brown Med Sch, Providence, RI USA. Carlow Univ, Pittsburgh, PA USA. RP Sevick, MA (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Suite 600,230 McKee Pl, Pittsburgh, PA 15213 USA. EM sevick@pitt.edu RI Papandonatos, George/J-2328-2014 OI Papandonatos, George/0000-0001-6770-932X FU NHLBI NIH HHS [HL64342, R01 HL064342, R01 HL064342-01A1] NR 29 TC 35 Z9 36 U1 1 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD JUL PY 2007 VL 45 IS 1 BP 54 EP 61 DI 10.1016/j.ypmed.2007.04.008 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 196GH UT WOS:000248469200012 PM 17573103 ER PT J AU Klyushnenkova, EN Kouiavskaia, DV Kodak, JA Vandenbark, AA Alexander, RB AF Klyushnenkova, Elena N. Kouiavskaia, Diana V. Kodak, James A. Vandenbark, Arthur A. Alexander, Richard B. TI Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase SO PROSTATE LA English DT Article DE CD4 T lymphocytes; DR2 transgenic mice; HLA-DR15; prostate cancer; prostatitis ID I CLINICAL-TRIAL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; ANTIGEN-PRESENTING CELLS; CANCER-PATIENTS; GRANULOMATOUS PROSTATITIS; DENDRITIC CELLS; TRANSGENIC MICE; SELF-ANTIGEN; PEPTIDE AB BACKGROUND. The crucial role of CD4 T-cells in anti-tumor immune response is widely recognized, yet the identification of HLA class II-restricted epitopes derived from tumor antigens has lagged behind compared to class I epitopes. This is particularly true for prostate cancer. Based on the hypothesis that successful cancer immunotherapy will likely resemble autoimmunity, we searched for the CD4 T-cell epitopes derived from prostatic proteins that are restricted by human leukocyte antigen (HLA)-DRB1*1501, an allele associated with granulomatous prostatitis (GP), a disease that may have an autoimmune etiology. One of the antigens implicated in the development of autoimmunity in the prostate is prostatic acid phosphatase (PAP), which is also considered a promising target for prostate cancer immunotherapy. METHODS. We immunized transgenic (tg) mice engineered to express HLA-DRB1 *1501 with human PAP. A library of overlapping 20-mer pepticles spanning the entire human PAP sequence was screened in vitro for T-cell recognition by proliferative and interferon (IFN)-gamma enzyme-linked immunosorbent spot (ELISPOT) assays. RESULTS. We identified two 20-mer peptides, PAP (133-152), and PAP (173-192), that were immunogenic and naturally processed from whole PAP in HLA-DRB1*1501 tg mice. These peptides were also capable of stimulating CD4 T lymphocytes from HLA-DRB1 *1501 -positive patients with GP and normal donors. CONCLUSIONS. These peptides can be used for the design of a new generation of peptidebased vaccines against prostate cancer. The study can also be helpful in understanding the role of autoirnmunity in the development of some forms of chronic prostatitis. C1 Univ Maryland, Sch Med, Div Urol, Baltimore, MD 21201 USA. VA Maryland Hlth Care Syst, Baltimore, MD USA. Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Neuroimmunol, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Mol & Microbiol, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Immunol, Portland, OR 97201 USA. RP Klyushnenkova, EN (reprint author), Univ Maryland, Sch Med, Dept Surg, 10 S Pine St MSTF,Room 4-00A, Baltimore, MD 21201 USA. EM eklyushnenkova@smail.umaryland.edu NR 49 TC 11 Z9 11 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-4137 J9 PROSTATE JI Prostate PD JUL 1 PY 2007 VL 67 IS 10 BP 1019 EP 1028 DI 10.1002/pros.20575 PG 10 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 180KU UT WOS:000247362800002 PM 17455230 ER PT J AU Saam, T Hatsukami, TS Takaya, N Chu, BC Underhill, H Kerwin, WS Cai, JM Ferguson, MS Yuan, C AF Saam, Tobias Hatsukami, Thomas S. Takaya, Norihide Chu, Baocheng Underhill, Hunter Kerwin, William S. Cai, Jianming Ferguson, Marina S. Yuan, Chun TI The vulnerable, or high-risk, atherosclerotic plaque: Noninvasive MR imaging for characterization and assessment SO RADIOLOGY LA English DT Review ID MAGNETIC-RESONANCE ANGIOGRAPHY; CORONARY-ARTERY-DISEASE; CONTRAST-ENHANCED MR; HIGH-RESOLUTION MRI; ACUTE MYOCARDIAL-INFARCTION; INTERNAL CAROTID-ARTERY; IN-VIVO ACCURACY; FIBROUS CAP; ENDOTHELIAL DYSFUNCTION; INTRAPLAQUE HEMORRHAGE AB "Vulnerable" plaques are atherosclerotic plaques that have a high likelihood to cause thrombotic complications, such as myocardial infarction or stroke. Plaques that tend to progress rapidly are also considered to be vulnerable. Besides luminal stenosis, plaque composition and morphology are key determinants of the likelihood that a plaque will cause cardiovascular events. Noninvasive magnetic resonance ( MR) imaging has great potential to enable characterization of atherosclerotic plaque composition and morphology and thus to help assess plaque vulnerability. A classification for clinical, as well as pathologic, evaluation of vulnerable plaques was recently put forward in which five major and five minor criteria to define vulnerable plaques were proposed. The purpose of this review is to summarize the status of MR imaging with regard to depiction of the criteria that define vulnerable plaques by using existing MR techniques. The use of MR imaging in animal models and in human disease in various vascular beds, particularly the carotid arteries, is presented. (c) RSNA, 2007. C1 Univ Washington, Dept Radiol, Seattle, WA USA. Univ Washington, Dept Surg, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Surg Serv, Seattle, WA USA. RP Saam, T (reprint author), Univ Munich, Dept Clin Radiol, Marchioninistr 15,Grosshadern Campus, D-81377 Munich, Germany. EM Tobias_Saam@med.uni-muenchen.de NR 106 TC 183 Z9 200 U1 0 U2 19 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD JUL PY 2007 VL 244 IS 1 BP 64 EP 77 DI 10.1148/radiol.2441051769 PG 14 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 181KV UT WOS:000247436500007 PM 17581895 ER PT J AU Bartzokis, G Lu, PH Nuechterlein, KH Gitlin, M Doi, C Edwards, N Lieu, C Altshuler, LL Mintz, J AF Bartzokis, George Lu, Po H. Nuechterlein, Keith H. Gitlin, Michael Doi, Clarissa Edwards, Nancy Lieu, Christopher Altshuler, Lori L. Mintz, Jim TI Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article; Proceedings Paper CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat DE schizophrenia; antipsychotic; medication; typical; atypical; frontal lobe; myelin; white matter; gray matter; oligodendrocyte; trajectory; development; lipid; intracortical; age; treatment; prevention; human; primate ID MAJOR DEPRESSIVE DISORDER; INCREASES CELL-PROLIFERATION; RAT FRONTAL-CORTEX; WHITE-MATTER; PREFRONTAL CORTEX; BIPOLAR DISORDER; GRAY-MATTER; ADULT-RAT; HIPPOCAMPAL-FORMATION; MORPHOMETRIC ANALYSIS AB Context: Imaging and post-mortem studies provide converging evidence that patients with schizophrenia have a dysregulated developmental trajectory of frontal lobe myelination even in adulthood. Atypical antipsychotics have been shown to have a wide spectrum of efficacy across multiple psychiatric diseases and to be particularly efficacious in treatment resistant cases of disorders such as schizophrenia. Objective: To test the a priori hypothesis that antipsychotic medications may differentially impact frontal lobe myelination in patients with schizophrenia. Design, setting, and participants: Participants ranged in age from 18-35 years, were all male, and were recruited by a single group of investigators using the same criteria. Two cohorts of subjects with schizophrenia early in their disease who were treated either with oral risperidone (Ris) or fluphenazine decanoate (Fd) were imaged in conjunction with cohorts of healthy controls. Each cohort was imaged using a different MRI instrument using identical imaging sequences. Main outcome measure: MRI measures of frontal lobe white matter volume. Results: We estimated differences due to differences in the MRI instruments used in the two studies in the two healthy control groups matched to the patient samples, adjusting for age and other covariates. We then statistically removed those differences (which we assumed were due to instrument effects) from the data in the schizophrenia samples by subtraction. Relative to the differences seen in controls, the two groups of schizophrenic patients differed in their pattern of frontal lobe structure with the Ris-treated group having significantly larger white matter volume than the Fd group. Conclusions: The results suggest that the choice of antipsychotic treatment may differentially impact brain myelination in adults with schizophrenia. Prospective studies are needed to confirm this finding. MRI can be used to dissect subtle differences in brain tissue characteristics and thus could help clarify the effect of pharmacologic treatments on neurodevelopmental and pathologic processes in vivo. (c) 2007 Elsevier B.V. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuroimaging,Div Brain Mapping, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90073 USA. RP Bartzokis, G (reprint author), Univ Calif Los Angeles, Alzheimers Dis Ctr, 710 Westwood Plaza,Room 2-238, Los Angeles, CA 90095 USA. EM gbar@ucla.edu RI Bartzokis, George/K-2409-2013 FU NCRR NIH HHS [U54 RR021813]; NIA NIH HHS [P50 AG 16570, P50 AG016570]; NIMH NIH HHS [MH51928, MH066029-01A2, MH37705, MH6357-01A1, P50 MH066286, R01 MH037705, R01 MH037705-09S1, R01 MH066029] NR 88 TC 50 Z9 51 U1 1 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD JUL PY 2007 VL 93 IS 1-3 BP 13 EP 22 DI 10.1016/j.schres.2007.02.011 PG 10 WC Psychiatry SC Psychiatry GA 184SU UT WOS:000247663200002 PM 17407804 ER PT J AU Risch, SC Horner, MD McGurk, SR Palecko, S Markowitz, JS Nahas, Z DeVane, CL AF Risch, S. Craig Horner, Michael D. McGurk, Susan R. Palecko, Simmy Markowitz, John S. Nahas, Ziad DeVane, C. Lindsay TI Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: A pilot study SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; cholinesterase inhibitors; pharmacological augmentation ID ADJUNCTIVE DONEPEZIL; COGNITIVE IMPAIRMENT; NICOTINIC RECEPTORS; ALZHEIMERS-DISEASE; DEMENTIA; DEFICITS; GALANTAMINE; TRIAL; SCALE; RIVASTIGMINE AB Thirteen outpatients with chronic but stable schizophrenia received donepezil and placebo augmentation of their maintenance antipsychotic medication regimen. Each subject received in a randomized, counterbalanced order 1) donepezil 5 mg for 6 weeks then donepezil 10 mg for six weeks and 2) placebo donepezil for 12 weeks. Serial ratings of the Positive and Negative Symptom Scale (PANSS) [Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13(2): 261-276] were performed by a trained rater blind to the donepezil order and condition: at baseline, 12 weeks and 24 weeks. On donepezil as compared to baseline or placebo, there was a significant improvement in PANSS negative scores (p = .018, n = 13). These results are discussed with respect to other studies using cholinesterase inhibitors as an augmentation strategy in schizophrenia. (c) 2007 Elsevier B.V. All rights reserved. C1 Univ Calif San Francisco, Langley Porter Psychiat Inst, San Francisco, CA 94143 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. Med Univ S Carolina, Charleston, SC 29425 USA. Dartmouth Coll Sch Med, Hanover, NH USA. RP Risch, SC (reprint author), Univ Calif San Francisco, Langley Porter Psychiat Inst, Room 375,Box F-0984,401 Parnassus Ave, San Francisco, CA 94143 USA. EM craigr@lppi.ucsf.edu NR 36 TC 14 Z9 14 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD JUL PY 2007 VL 93 IS 1-3 BP 131 EP 135 DI 10.1016/j.schres.2007.01.001 PG 5 WC Psychiatry SC Psychiatry GA 184SU UT WOS:000247663200014 PM 17391930 ER PT J AU Gard, DE Kring, AM Gard, MG Horan, WP Green, MF AF Gard, David E. Kring, Ann M. Gard, Marja Germans Horan, William P. Green, Michael F. TI Anhedonia in schizophrenia: Distinctions between anticipatory and consummatory pleasure SO SCHIZOPHRENIA RESEARCH LA English DT Article; Proceedings Paper CT 18th Annual Meeting of the Society-for-Research-in-Psychopathology CY OCT, 2003 CL Toronto, CANADA SP Soc Res Psychopathol DE schizophrenia; pleasure; anhedonia; anticipation; consummatory; TEPS ID STRIATAL REWARD PREDICTION; DYSFUNCTION; EXPERIENCE; COMPONENTS; DOPAMINE; EMOTION; SCALE AB Research on anhedonia in schizophrenia has revealed mixed results, with patients reporting greater anhedonia than healthy controls on self-report measures and semi-structured interviews, but also reporting comparable experiences of positive emotions in response to pleasurable stimuli. Basic science points to the importance of distinguishing between anticipatory and consummatory (or in-the-moment) pleasure experiences, and this distinction may help to reconcile the mixed findings on anhedonia in schizophrenia. In two studies, we tested the hypothesis that anhedonia in schizophrenia reflects a deficit in anticipatory pleasure but not consummatory pleasure. In Study 1, we used experience sampling methodology to assess reported experiences of consummatory, and anticipated pleasure among schizophrenia patients and controls. In Study 2, schizophrenia patients and controls completed a self-report trait measure of anticipatory and consummatory pleasure and interviews that assessed negative symptoms, including anhedonia, and community functioning. In both studies, we found evidence for an anticipatory but not a consummatory pleasure deficit in schizophrenia. In addition, anticipatory pleasure was related to clinical ratings of anhedonia and functional outcome. Clinical and research implications of these findings are discussed. (c) 2007 Elsevier B.V. All rights reserved. C1 San Francisco State Univ, Dept Psychol, San Francisco, CA 94132 USA. Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Gard, DE (reprint author), San Francisco State Univ, Dept Psychol, 1600 Holloway Ave, San Francisco, CA 94132 USA. EM dgard@sfsu.edu; akring@berkeley.edu OI Gard, David/0000-0002-0446-4000 FU NIMH NIH HHS [R01 MH043292, MH43292, MH65707, R01 MH043292-16, R01 MH065707, R01 MH065707-05] NR 38 TC 321 Z9 326 U1 3 U2 50 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD JUL PY 2007 VL 93 IS 1-3 BP 253 EP 260 DI 10.1016/j.schres.2007.03.008 PG 8 WC Psychiatry SC Psychiatry GA 184SU UT WOS:000247663200029 PM 17490858 ER PT J AU Hazlett, EA Romero, MJ Haznedar, MM New, AS Goldstein, KE Newmark, RE Siever, LJ Buchsbaum, MS AF Hazlett, Erin A. Romero, Michelle J. Haznedar, M. Mehmet New, Antonia S. Goldstein, Kim E. Newmark, Randall E. Siever, Larry J. Buchsbaum, Monte S. TI Deficient attentional modulation of startle eyeblink is associated with symptom severity in the schizophrenia spectrum SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; schizotypal personality disorder; startle; attention; prepulse inhibition; prepulse facilitation ID SCHIZOTYPAL PERSONALITY-DISORDER; PREPULSE INHIBITION; ACOUSTIC STARTLE; REFLEX; PERSPECTIVES; HABITUATION AB Patients with schizophrenia-spectrum disorders show deficient prepulse inhibition (PPI) of the startle eyeblink reflex which is thought to reflect an early stage of information processing called automatic sensorimotor gating. They also exhibit deficient attentional modulation of PPI and prepulse facilitation (PPF) of startle which is thought to reflect deficient early and later controlled attentional processing. This is the first study to assess attentional modulation of PPI and PPF in a 3-group schizophrenia-spectrum sample of age- and sex-matched unmedicated schizotypal personality disorder (SPD) and schizophrenia patients, and healthy controls. Participants performed a tone-length judgment task involving attended, ignored, and novel tone prepulses while the acoustic startle eyeblink reflex was measured. Healthy controls showed greater PPI and PPF during the attended prepulses compared with the ignored prepulses. In contrast, both the SPD and schizophrenia patient groups failed to show this pattern, indicating deficient early and later controlled attentional processing. These findings suggest abnormal attentional modulation of PPI and PPF may be a trait-like feature found in patients with schizophrenia-spectrum disorders. Among the schizophrenia-spectrum sample, more deficient PPI during the attended prepulses was associated with greater symptom severity as measured by the total 18-item Brief Psychiatric Rating Scale score. (c) 2007 Elsevier B.V. All rights reserved. C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. Bronx Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. RP Hazlett, EA (reprint author), Mt Sinai Sch Med, Dept Psychiat, Box 1505,1 Gustave L Levy Pl, New York, NY 10029 USA. EM erin.hazlett@mssm.edu NR 28 TC 29 Z9 31 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD JUL PY 2007 VL 93 IS 1-3 BP 288 EP 295 DI 10.1016/j.schres.2007.03.012 PG 8 WC Psychiatry SC Psychiatry GA 184SU UT WOS:000247663200033 PM 17478083 ER PT J AU Schmid, A Duncan, PW Studenski, S Lai, SM Richards, L Perera, S Wu, SS AF Schmid, Arlene Duncan, Pamela W. Studenski, Stephanie Lai, Sue Min Richards, Lorie Perera, Subashan Wu, Samuel S. TI Improvements in speed-based gait classifications are meaningful SO STROKE LA English DT Article DE functional recovery; gait velocity; quality of life; rehabilitation ID STROKE IMPACT SCALE; COMMUNITY AMBULATION; REHABILITATION; RELIABILITY; EXERCISE; VELOCITY; TRIALS AB Background and Purpose - Gait velocity is a powerful indicator of function and prognosis after stroke. Gait velocity can be stratified into clinically meaningful functional ambulation classes, such as household ambulation (< 0.4 m/s), limited community ambulation (0.4 to 0.8 m/s), and full community ambulation (> 0.8 m/ s). The purpose of the current study was to determine whether changes in velocity-based community ambulation classification were related to clinically meaningful changes in stroke-related function and quality of life. Methods - In subacute stroke survivors with mild to moderate deficits who participated in a randomized clinical trial of stroke rehabilitation and had a baseline gait velocity of 0.8 m/ s or less, we assessed the effect of success versus failure to achieve a transition to the next class on function and quality of life according to domains of the Stroke Impact Scale (SIS). Results - Of 64 eligible participants, 19 were initially household ambulators, and 12 of them (68%) transitioned to limited community ambulation, whereas of 45 initially limited community ambulators, 17 (38%) became full community ambulators. Function and quality-of-life SIS scores after treatment were significantly higher among survivors who achieved a favorable transition compared with those who did not. Among household ambulators, those who transitioned to limited or full community ambulation had significantly better SIS scores in mobility (P=0.0299) and participation (P=0.0277). Among limited community ambulators, those who achieved the transition to full community ambulatory status had significantly better scores in SIS participation (P=0.0085). Conclusions - A gait velocity gain that results in a transition to a higher class of ambulation results in better function and quality of life, especially for household ambulators. Household ambulators possibly had more severe stroke deficits, reducing the risk of "ceiling" effects in SIS-measured activities of daily living and instrumental activities of daily living. Outcome assessment based on transitions within a mobility classification scheme that is rooted in gait velocity yields potentially meaningful indicators of clinical benefit. Outcomes should be selected that are clinically meaningful for all levels of severity. C1 Indiana Univ, Dept Occupat Therapy, Sch Hlth & Rehabil Sci, Indianapolis, IN 46202 USA. Richard L Roudebush VA Med Ctr, Indianapolis, IN USA. Duke Univ, Dept Community & Family Med, Div Phys Therapy, Duke Ctr Clin Hlth Policy Res, Durham, NC USA. Univ Pittsburgh, Div Geriatr Med, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA. Univ Kansas, Med Ctr, Theo & Alfred London Ctr Aging, Kansas City, KS USA. Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Vet Affairs, Gainesville, FL 32611 USA. Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Occupat Therapy, Gainesville, FL 32611 USA. Univ Pittsburgh, Div Geriatr Med, Pittsburgh, PA 15260 USA. Univ Florida, Coll Med, Div Biostat, Rehabil Outcomes Res Ctr, Gainesville, FL 32611 USA. RP Schmid, A (reprint author), Indiana Univ, Dept Occupat Therapy, Sch Hlth & Rehabil Sci, 1140 W Michigan St,CF 311, Indianapolis, IN 46202 USA. EM araschmi@iupui.edu FU NIA NIH HHS [5P60AG14635] NR 23 TC 206 Z9 215 U1 3 U2 20 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD JUL PY 2007 VL 38 IS 7 BP 2096 EP 2100 DI 10.1161/STROKEAHA.106.475921 PG 5 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 182OG UT WOS:000247513300033 PM 17510461 ER PT J AU Porter, MP Lin, DW AF Porter, Michael P. Lin, Daniel W. TI Trends in renal cancer surgery and patient provider characteristics associated with partial nephrectomy in the United States SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS LA English DT Article DE neoplasms; kidney; nephrectomy; trends ID CELL CARCINOMA; COMPLICATIONS; EPIDEMIOLOGY; EXPERIENCE AB Objective: Many renal tumors are amenable to either partial or total nephrectomy, but little is known about the relative frequency that these procedures are performed in the United States. We describe recent temporal trends in surgery for renal neoplasm and identified factors associated with partial nephrectomy. Methods: Data from the 1998 through 2002 National Inpatient Sample was analyzed to identify adult patients discharged after renal cancer surgery. The frequency of partial and total nephrectomy in the United States was estimated, and multivariate regression was used to examine patient and provider factors associated with partial nephrectomy. Results: The number of nephrectomies performed for tumor in the United States increased yearly, with an estimated 23,375 total nephrectomies and 4272 partial nephrectomies performed in 2002. The ratio of partial nephrectomies to total nephrectomies also increased (P < 0.001), with partial nephrectomy representing 15.5% of all nephrectomies in 2002. In the multivariate analysis, patient and provider factors significantly associated with undergoing partial nephrectomy included female sex (odds ratio [OR] = 0.86, 95% confidence interval [CI] 0.79-0.94), age (OR = 0.38, 95% CI 0.30-0.49 comparing age older than 79 to younger than 40 years), teaching hospital status (OR = 1.54, 95% CI 1.34-1.76), annual hospital nephrectomy volume (OR = 1.96, 95% CI 1.62-2.39 comparing highest to lowest quartiles), annual surgeon nephrectomy volume (OR = 2.60, 95% CI 2.12-3.20 comparing highest to lowest quartiles), and private insurance/health maintenance organization coverage (OR = 1.25, 95% CI 1.11-1.40 compared to Medicare). Conclusions: The total number of nephrectomies and the proportion of partial nephrectomies performed in the United States increased yearly from 1998 to 2002. Male sex, hospital teaching status, higher hospital and surgeon volume, and insurance status are associated with receiving partial nephrectomy. Published by Elsevier Inc. C1 Univ Washington, Dept Urol, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Porter, MP (reprint author), Univ Washington, Dept Urol, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. EM mporter@u.washington.edu NR 17 TC 36 Z9 37 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1078-1439 J9 UROL ONCOL-SEMIN ORI JI Urol. Oncol.-Semin. Orig. Investig. PD JUL-AUG PY 2007 VL 25 IS 4 BP 298 EP 302 DI 10.1016/j.urolonc.2006.07.016 PG 5 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 193TY UT WOS:000248299100004 PM 17628295 ER PT J AU Wu, YN Johnson, SW AF Wu, Yan-Na Johnson, Steven W. TI Rotenone potentiates NMDA currents in substantia nigra dopamine neurons SO NEUROSCIENCE LETTERS LA English DT Article DE brain slice; excitotoxicity; glutamate; rotenone; strophanthidin; substantia nigra pars compacta ID ELECTROGENIC SODIUM-PUMP; PARKINSONS-DISEASE; MITOCHONDRIAL RESPIRATION; METABOLISM IMPAIRMENT; TYROSINE KINASE; NA+/K+ ATPASE; CELL-DEATH; RECEPTOR; PHOSPHORYLATION; INHIBITION AB Rotenone is a pesticide that produces a rodent model of Parkinson's disease. Although much evidence suggests that oxidative stress mediates the toxicity of rotenone on dopamine neurons, rotenone can also potentiate glutamate excitotoxicity. We used whole-cell patch pipettes to investigate actions of rotenone on currents evoked by N-methyl-D-aspartate (NMDA) in dopamine neurons in slices of rat midbrain. After superfusing the slice for 20-30 min, rotenone (100 nM) caused a 162% increase in the average amplitude of inward current evoked by 30 mu M NMDA. This effect of rotenone was mimicked by the sodium pump inhibitor strophanthidin (10 mu M) and was abolished when pipettes contained an ATP regeneration solution. Although strophanthidin also significantly increased the amplitude of inward currents evoked by (+/-)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA; 10 mu M), rotenone failed to potentiate AMPA currents. Because rotenone potentiated NMDA- but not AMPA-dependent currents, this suggests that rotenone acts selectively to augment NMDA receptor function. Furthermore, the failure of rotenone to mimic strophanthidin suggests that rotenone does not inhibit sodium pump activity. Our results suggest that an excitotoxic mechanism might contribute to rotenone neurotoxicity. (c) 2007 Elsevier Ireland Ltd. All rights reserved. C1 Portland VA Med Ctr, Portland, OR 97207 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. RP Johnson, SW (reprint author), Portland VA Med Ctr, RD 61,3710SW US Vet Hosp Rd, Portland, OR 97207 USA. EM johnsost@ohsu.edu NR 34 TC 18 Z9 18 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD JUN 27 PY 2007 VL 421 IS 2 BP 96 EP 100 DI 10.1016/j.neulet.2007.05.030 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 192IX UT WOS:000248195900002 PM 17560718 ER PT J AU Graham, SM Baeten, JM Richardson, BA Bankson, DD Lavreys, L Ndinya-Achola, JO Mandaliya, K Overbaugh, J McClelland, RS AF Graham, Susan M. Baeten, Jared M. Richardson, Barbra A. Bankson, Daniel D. Lavreys, Ludo Ndinya-Achola, Jeckoniah O. Mandaliya, Kishorchandra Overbaugh, Julie McClelland, R. Scott TI Higher pre-infection vitamin E levels are associated with higher mortality in HIV-1-infected Kenyan women: a prospective study SO BMC INFECTIOUS DISEASES LA English DT Article ID HIV-1 INFECTION; DISEASE PROGRESSION; VIRAL LOAD; HIGH-RISK; PLASMA; SERUM; DEFICIENCY; SUBTYPE; RETINOL AB Background: Low vitamin E levels are often found in HIV-1 infection, and studies have suggested that higher levels may decrease the risk of disease progression. However, vitamin E supplementation has also been reported to increase CCR5 expression, which could increase HIV-1 replication. We hypothesized that vitamin E levels at HIV- 1 acquisition may influence disease progression. Methods: Vitamin E status was measured in stored samples from the last pre-infection visit for 67 Kenyan women with reliably estimated dates of HIV- 1 acquisition. Regression analyses were used to estimate associations between pre-infection vitamin E and plasma viral load, time to CD4 count < 200 cells/mu L, and mortality. Results: After controlling for potential confounding factors, each 1 mg/L increase in pre-infection vitamin E was associated with 0.08 log(10) copies/mL (95% Cl -0.01 to +0.17) higher set point viral load and 1.58-fold higher risk of mortality (95% Cl 1.15-2.16). The association between higher pre-infection vitamin E and mortality persisted after adjustment for set point viral load (HR 1.55, 95% Cl 1.13-2.13). Conclusion: Higher pre-infection vitamin E levels were associated with increased mortality. Further research is needed to elucidate the role vitamin E plays in HIV- 1 pathogenesis. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Pathol & Lab Med, Seattle, WA 98108 USA. Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya. Coast Prov Gen Hosp, Mombasa, Kenya. Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA. RP Graham, SM (reprint author), Univ Washington, Dept Med, Box 356420, Seattle, WA 98195 USA. EM grahamsm@u.washington.edu; jbaeten@u.washington.edu; barbrar@u.washington.edu; daniel.bankson@va.gov; llavreys@wanadoo.fr; Ndinya-Achola@kaviuon.org; kishor@ikenya.com; joverbau@fhcrc.org; mcclell@africaonline.co.ke OI Graham, Susan/0000-0001-7847-8686 FU FIC NIH HHS [D43 TW000007]; NIAID NIH HHS [AI-38518, AI-43844, R01 AI043844, R37 AI038518] NR 21 TC 5 Z9 5 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD JUN 26 PY 2007 VL 7 AR 63 DI 10.1186/1471-2334-7-63 PG 5 WC Infectious Diseases SC Infectious Diseases GA 190YQ UT WOS:000248097200001 PM 17594484 ER PT J AU Diem, SJ Blackwell, TL Stone, KL Yaffe, K Haney, EM Bliziotes, MM Ensrud, KE AF Diem, Susan J. Blackwell, Terri L. Stone, Katie L. Yaffe, Kristine Haney, Elizabeth M. Bliziotes, Michael M. Ensrud, Kristine E. TI Use of antidepressants and rates of hip bone loss in older women SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID MINERAL DENSITY; SEROTONIN; DEPRESSION; TRANSPORTER; FRACTURES; RISK; AGE; EXPRESSION; SYSTEM AB Background: Serotonin transporters have recently been described in bone, raising the possibility that medications that block serotonin reuptake could affect bone metabolism. Methods: We assessed current use of selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) and obtained serial bone mineral density (BMD) measurements in a cohort of 2722 older women (mean age, 78.5 years) participating in the Study of Osteoporotic Fractures, a prospective cohort study of community-dwelling women. Hip BMD was measured at the sixth examination and an average of 4.9 years later at the eighth examination. We categorized women as nonusers (used no SSRIs or TCAs at either examination; n= 2406), SSRI users (used SSRIs but no TCAs at either examination; n= 198), or TCA users (used TCAs but no SSRIs at either examination; n= 118). Depressive symptoms were identified using a cutoff score of at least 6 on the Geriatric Depression Scale. Results: After adjustment for potential confounders, including the Geriatric Depression Scale score, mean total hip BMD decreased 0.47% per year in nonusers compared with 0.82% in SSRI users (P <. 001) and 0.47% in TCA users (P=. 99). Higher rates of bone loss were also observed at the 2 hip subregions for SSRI users. Results were not substantially altered when women who scored at least 6 on the Geriatric Depression Scale were excluded from the analysis. Conclusion: Use of SSRIs but not TCAs is associated with an increased rate of bone loss at the hip in this cohort of older women. C1 Univ Minnesota, Epidemiol Clin Res Ctr, Minneapolis, MN 55415 USA. Univ Minnesota, Dept Med, Minneapolis, MN 55415 USA. Univ Minnesota, Div Epidemiol, Minneapolis, MN 55415 USA. Minneapolis Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. Calif Pacific Med Ctr Res Inst, San Francisco, CA USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Neurol & Epidemiol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Dept Psychiat, San Francisco, CA USA. Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA. RP Diem, SJ (reprint author), Univ Minnesota, Epidemiol Clin Res Ctr, 1100 Washington Ave S,Suite 201, Minneapolis, MN 55415 USA. EM sdiem@umn.edu RI Diem, Susan/B-6479-2013 FU NIA NIH HHS [AG05394, AG05407, AG08415]; NIAMS NIH HHS [AR35582, AR35583, AR35584, K23 AR051926] NR 31 TC 168 Z9 177 U1 1 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JUN 25 PY 2007 VL 167 IS 12 BP 1240 EP 1245 DI 10.1001/archinte.167.12.1240 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 181ZM UT WOS:000247474900004 PM 17592096 ER PT J AU Imperiale, TF Dominitz, JA Provenzale, DT Boes, LP Rose, CM Bowers, JC Musick, BS Azzouz, F Perkins, SM AF Imperiale, Thomas F. Dominitz, Jason A. Provenzale, Dawn T. Boes, Lynn P. Rose, Cynthia M. Bowers, Jill C. Musick, Beverly S. Azzouz, Faouzi Perkins, Susan M. TI Predicting poor outcome from acute upper gastrointestinal hemorrhage SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID CLINICAL GUIDELINE; HOSPITAL LENGTH; ULCER; SCORE; STAY AB Background: Uncertainty about the outcome of acute upper gastrointestinal bleeding often results in a longer-than-necessary hospital stay. Methods: We derived and internally validated clinical prediction rules (CPRs) to predict outcome from upper gastrointestinal bleeding. This multisite, prospective cohort study involved consecutive patients admitted for acute upper gastrointestinal bleeding. Multivariate logistic regression was used to derive CPRs on two thirds of the cohort (derivation set) that predicted bleeding-specific outcomes (rebleeding, need for urgent surgery, or hospital death [poor outcome 1]) and bleeding-specific outcomes plus new or worsening comorbidity (poor outcome 2). Both CPRs were then tested on the remaining third of the cohort (validation set). Results: A total of 391 individuals (99% men; mean age, 63.4 years) were enrolled, of which 4.6% rebled and 3.1% died. Independent predictors of poor outcome 1 were APACHE (Acute Physiology and Chronic Health Evaluation) II score of 11 or greater, esophageal varices, and stigmata of recent hemorrhage. Predictors of poor outcome 2 were these 3 factors plus unstable comorbidity on admission. Of patients with no risk factors, only 1 (1.1%) of 92 experienced poor outcome 1 and only 6 (6.2%) of 97 experienced poor outcome 2. Risks in the validation set were comparable. The CPRs identified 37.8% and 32.2% of patients in the derivation and validation sets, respectively, who were eligible for a shorter hospital stay. Conclusions: Patients admitted with acute upper gastrointestinal bleeding were unlikely to have a poor outcome if these risk factors were absent. These CPRs might make hospital management more efficient by identifying low-risk patients for-whom-early hospital discharge is possible. C1 Regenstrief Inst Inc, Indianapolis, IN 46202 USA. Indiana Univ, Sch Med, Dept Med, Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46204 USA. Indiana Univ, Sch Med, Ctr Excellence Implementing Evidence Based Practi, Indianapolis, IN 46204 USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Med, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. Univ Washington, Sch Med, Seattle, WA 98195 USA. Vet Affairs Med Ctr, Dept Med, Durham, NC USA. Duke Univ, Sch Med, Durham, NC USA. RP Imperiale, TF (reprint author), Regenstrief Inst Inc, 1050 Wishard Blvd RG-6, Indianapolis, IN 46202 USA. OI Dominitz, Jason/0000-0002-8070-7086 NR 18 TC 29 Z9 31 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JUN 25 PY 2007 VL 167 IS 12 BP 1291 EP 1296 DI 10.1001/archinte.167.12.1291 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 181ZM UT WOS:000247474900011 PM 17592103 ER PT J AU Heyworth, MF AF Heyworth, Martin F. TI Cincinnati's rhino breeders bring home the bacon SO NATURE LA English DT Letter C1 Univ Penn, Dept Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Heyworth, MF (reprint author), Vet Affairs Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD JUN 21 PY 2007 VL 447 IS 7147 BP 908 EP 908 DI 10.1038/447908c PG 1 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 180NU UT WOS:000247373100019 PM 17581559 ER PT J AU Rubin, SA AF Rubin, Stanley A. TI Exercise training in heart failure - Contradictory or conventional? SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Editorial Material ID METAANALYSIS; CAPACITY; TRIAL; HF AB The paintings of the Belgian surrealist Rene Magritte (1898 to 1967) juxtapose 2 incongruous, illogical, or even contradictory objects: a steam locomotive projecting from a domestic fireplace (Time Transfixed, 1939); a bright daytime sky over a nighttime scene of a dimly lighted street (The Empire of Light, 1954); or a picture of a pipe with a caption on the canvas that reads, in French, "This is not a pipe" (The Treachery of Images, 1929). On the basis of conventional wisdom, the current palette of therapy for heart failure also would seem incongruous, illogical, or contradictory if it included exercise therapy. However, change is at hand. C1 Univ Calif Los Angeles, Med Program, VA Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90073 USA. RP Rubin, SA (reprint author), Univ Calif Los Angeles, Med Program, VA Greater Los Angeles Healthcare Syst, Dept Vet Affairs, 11301 Wilshire Blvd,Cardiol 111E, Los Angeles, CA 90073 USA. EM sarubin@ucla.edu NR 23 TC 3 Z9 3 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JUN 19 PY 2007 VL 49 IS 24 BP 2337 EP 2340 DI 10.1016/j.jacc.2007.04.013 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 181NK UT WOS:000247443200006 PM 17572249 ER PT J AU Chandra, D Kar, B Idelchik, G Simpson, L Loyalka, P Gregoric, ID Delgado, RM Frazier, OH AF Chandra, Divay Kar, Biswajit Idelchik, Gary Simpson, Leo Loyalka, Pranav Gregoric, Igor D. Delgado, Reynolds M., III Frazier, O. H. TI Usefulness of percutaneous left ventricular assist device as a bridge to recovery from myocarditis SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID CARDIOGENIC-SHOCK; SUPPORT AB The TandemHeart percutaneous left ventricular assist device is a left atrial-to-femoral artery bypass system that can be implanted percutaneously within 30 minutes and provides active circulatory support. The TandemHeart has been used mainly for temporary hemodynamic assistance during high-risk coronary interventions and postcardiotomy heart failure. This report describes initial experience with this device as a successful bridge to cardiac recovery in 3 patients with acute myocarditis. All patients presented with severe cardiogenic shock (mean cardiac index 1.1 L/min/m(2)), and end-organ perfusion could not be maintained despite intra-aortic balloon counterpulsation and the maximal use of vasopressive agents. The patients were successfully bridged to myocardial recovery with the TandemHeart (mean duration of support 5 days, range 2 to 8). The only complication was a short episode of ventricular fibrillation during device placement in 1 patient, which did not result in any morbidity or mortality. All patients were discharged home (mean duration of stay 15 days). In conclusion, the TandemHeart proved to be a safe and effective bridge to myocardial recovery in these patients with acute myocarditis. (c) 2007 Elsevier Inc. All rights reserved. C1 Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Div Cardiol, Houston, TX USA. Texas Heart Inst, Dept Cardiol, Houston, TX 77025 USA. Texas Heart Inst, Dept Cardiovasc Surg, Houston, TX 77025 USA. RP Kar, B (reprint author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA. EM kar@bcm.edu NR 6 TC 15 Z9 16 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD JUN 15 PY 2007 VL 99 IS 12 BP 1755 EP 1756 DI 10.1016/j.amjcard.2007.01.067 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 187RX UT WOS:000247867100026 PM 17560889 ER PT J AU Kahn, KL MacLean, CH Wong, AL Rubenstein, LZ Liu, H Fitzpatrick, DM Harker, JO Chen, WP Traina, SB Mittman, BS Hahn, BH Paulus, HE AF Kahn, K. L. MacLean, C. H. Wong, A. L. Rubenstein, L. Z. Liu, H. Fitzpatrick, D. M. Harker, J. O. Chen, W. P. Traina, S. B. Mittman, B. S. Hahn, B. H. Paulus, H. E. TI Assessment of American college of rheumatology quality criteria for rheumatoid arthritis in a pre-quality criteria patient cohort SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Article DE rheumatoid arthritis; quality of care ID MEDICARE MANAGED CARE; UNITED-STATES; PERFORMANCE; GUIDELINES; TRENDS AB Objective. To evaluate the American College of Rheumatology (ACR) starter set of quality measures for rheumatoid arthritis (RA) in an actual patient cohort that preceded publication of the quality measures. Methods. We retrospectively applied the 2006 ACR quality criteria to a prospectively studied cohort of 568 patients with RA treated by 1,932 unique physicians including 255 different rheumatologists between the years 1999 and 2003. Data on performance were obtained from self-report surveys and medical record review within 12 months. Results. At least 1 joint examination was performed in 98% of patients. Patient and physician global assessments were reported for 79% and 74% of patients, respectively. A total of 85% of patients received disease-modifying antirheumatic drugs (DMARDs). DMARD adjustments were made for 50% of patients in whom increasing disease activity was noted at least once and for 64% of patients in whom increasing disease activity was noted during 2 (of 4) 3-month periods within the year. Compared with self-report surveys, medical records substantially underreported performance on quality measures. Conclusion. The ACR-endorsed quality measures for RA can be assessed using available data sources. When both self-report and medical record data are used, adherence rates, designed to serve as minimum standards of care, were moderate or high for most measures. Prior to using indicators to compare quality across groups, specific strategies for operationalizing measures and for using accurate data sources to assess adherence to the measures should be defined. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. RAND Corp, Santa Monica, CA USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles Cty Olive View, Med Ctr, Sylmar, CA USA. RP Kahn, KL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, 911 Broxton Plaza,Box 951736, Los Angeles, CA 90095 USA. EM kkahn@mednet.ucla.edu FU NIAMS NIH HHS [5-P60-AR-36834] NR 21 TC 21 Z9 21 U1 1 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD JUN 15 PY 2007 VL 57 IS 5 BP 707 EP 715 DI 10.1002/art.22781 PG 9 WC Rheumatology SC Rheumatology GA 177BZ UT WOS:000247129900003 PM 17530663 ER PT J AU Singh, JA Hodges, JS Toscano, JP Asch, SM AF Singh, Jasvinder A. Hodges, James S. Toscano, John P. Asch, Steven M. TI Quality of care for gout in the US needs improvement SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Article DE gout; veterans; quality of care; quality indicators; physician adherence ID VETERANS-AFFAIRS; UNITED-STATES; HEALTH-CARE; ALLOPURINOL; MANAGEMENT; HYPERURICEMIA; EPIDEMIOLOGY; PREVALENCE; INDICATORS; ARTHRITIS AB Objective. To examine evidence-based quality indicators (QIs) in US veterans with gout diagnosis, and to examine the effect of demographics, heath care utilization/access, comorbid conditions, or physican characteristics as predictors of quality of gout care. Methods. Using the Minneapolis Veterans Affairs electronic medical record system, we identified a cohort of veterans receiving medication to treat gout between January 1, 1999 and December 31, 2003, and evaluated 3 recently published evidence-based QIs for gout management: QI 1 = allopurinol dose <300 mg in gout patients with renal insufficiency, QI 2 = uric acid check within 6 months of starting a new allopurinol prescription, and QI 3 = complete blood count and creatine kinase check every 6 months for gout patients receiving prolonged colchicine therapy. We calculated the proportion of patients whose therapy adhered to each QI and to all applicable indicators (overall physician adherence). Logistic regression analysis examined association of overall physician adherence with sociodemographics, health care utilization, comorbidity, and provider characteristics. Results. Of 3,658 patients with a diagnosis of gout, 663 patients qualified for examination of >= 1 QI. Of these 663 patients, therapy in only 144 (22%) adhered to all applicable QIs; 59 (78%) of 76 adhered to QI 1, 155 (24%) of 643 adhered to QI 2, and 18 (35%) of 52 adhered to QI 3. Overall physician adherence to QIs was significantly lower in older veterans and in those with more inpatient visits per year, but was higher in those with more primary care visits or more health care providers. Conclusion. Suboptimal physician adherence to QIs was seen for all 3 QIs tested in this cohort of veterans with gout. These findings can guide quality improvement efforts. C1 VA Med Ctr, Minneapolis, MN 55417 USA. Univ Minnesota, Minneapolis, MN USA. Univ Calif Los Angeles, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Singh, JA (reprint author), VA Med Ctr, 1 Vet Dr, Minneapolis, MN 55417 USA. EM Jasvinder.Singh@med.va.gov OI singh, jasvinder/0000-0003-3485-0006 FU NCRR NIH HHS [KL2 RR024151] NR 27 TC 84 Z9 87 U1 0 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD JUN 15 PY 2007 VL 57 IS 5 BP 822 EP 829 DI 10.1002/art.22767 PG 8 WC Rheumatology SC Rheumatology GA 177BZ UT WOS:000247129900018 PM 17530682 ER PT J AU Rajendran, RR Kao, GD AF Rajendran, Ramji R. Kao, Gary D. TI "No turning Bax" in the combined battle against prostate cancer SO CLINICAL CANCER RESEARCH LA English DT Editorial Material ID ANDROGEN DEPRIVATION THERAPY; BCL-2; RADIOTHERAPY; EXPRESSION; APOPTOSIS; ADJUVANT; CHEMOSENSITIVITY; CHEMOTHERAPY; PARAMETERS; CARCINOMA C1 Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Kao, GD (reprint author), Univ Penn, Sch Med, Dept Radiat Oncol, John Morgan 180 H, Philadelphia, PA 19104 USA. EM Kao@xrt.upenn.edu FU NCI NIH HHS [R01 CA107956] NR 32 TC 3 Z9 5 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JUN 15 PY 2007 VL 13 IS 12 BP 3435 EP 3438 DI 10.1158/1078-0432.CCR-07-0810 PG 4 WC Oncology SC Oncology GA 180BZ UT WOS:000247336200001 PM 17575204 ER PT J AU Ewend, MG Brem, S Gilbert, M Goodkin, R Penar, PL Varia, M Cush, S Carey, LA AF Ewend, Matthew G. Brem, Steven Gilbert, Mark Goodkin, Robert Penar, Paul L. Varia, Mahesh Cush, Sharon Carey, Lisa A. TI Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control SO CLINICAL CANCER RESEARCH LA English DT Article ID NERVOUS-SYSTEM METASTASES; INTERSTITIAL CHEMOTHERAPY; BREAST-CANCER; BIODEGRADABLE POLYMERS; RECURRENT GLIOMAS; RANDOMIZED-TRIAL; RADIOTHERAPY; PACLITAXEL; DELIVERY; RADIOSURGERY AB Purpose: To define the safety and efficacy of carmustine polymer wafers when added to a regimen of surgery and external beam radiotherapy for treatment of a single brain metastasis. Experimental Design: Adult patients underwent craniotomy for a single brain metastasis, and carmustine polymer wafers were placed in the tumor resection cavity. Patients then received whole-brain radiotherapy and were followed for patterns of recurrence in the central nervous system, toxicity, and survival. Results: We enrolled 25 patients with solitary brain metastases from lung (13 patients), melanoma (4 patients), breast (3 patients), and renal carcinoma (3 patients). Two patients had severe adverse events thought to be related to wafer placement, one with seizures alone, and one with seizures and subsequent respiratory compromise. Both responded to medical therapy. There were no wound infections. The local recurrence rate was surprisingly low (0%). Four patients (16%) relapsed elsewhere in the brain, and two patients (8%) relapsed in the spinal cord. Median survival was 33 weeks; 33% of patients survived 1 year, and 25% survived 2 years. Conclusions: The addition of local chemotherapy delivered via carmustine polymer wafers to a regimen of surgical resection and external beam radiotherapy was well tolerated by patients undergoing surgery for a single brain metastasis. There were no local recurrences, suggesting that this treatment further reduced the risk of local relapse. C1 Univ N Carolina, Div Neurosurg, Chapel Hill, NC 27599 USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Vermont, Burlington, VT USA. RP Ewend, MG (reprint author), Univ N Carolina, Div Neurosurg, 3013 Burnett Womack Bldg, Chapel Hill, NC 27599 USA. EM ewend@med.unc.edu NR 28 TC 38 Z9 38 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JUN 15 PY 2007 VL 13 IS 12 BP 3637 EP 3641 DI 10.1158/1078-0432.CCR-06-2095 PG 5 WC Oncology SC Oncology GA 180BZ UT WOS:000247336200028 PM 17575228 ER PT J AU Franciosi, S De Gasperi, R Dickstein, DL English, DF Rocher, AB Janssen, WGM Christoffel, D Sosa, MAG Hof, PR Buxbaum, JD Elder, GA AF Franciosi, Sonia De Gasperi, Rita Dickstein, Dara L. English, Daniel F. Rocher, Anne B. Janssen, William G. M. Christoffel, Daniel Sosa, Miguel A. Gama Hof, Patrick R. Buxbaum, Joseph D. Elder, Gregory A. TI Pepsin pretreatment allows collagen IV immunostaining of blood vessels in adult mouse brain SO JOURNAL OF NEUROSCIENCE METHODS LA English DT Article DE adult; antigen retrieval; blood vessels; brain; collagen IV; immunohistochemistry; mouse; pepsin ID ALZHEIMERS-DISEASE; IMMUNOHISTOCHEMICAL DETECTION; LAMININ IMMUNOHISTOCHEMISTRY; NERVOUS-TISSUE; SECTIONS; MICE; MICROVASCULATURE; IMMUNOREACTIVITY; NEUROGENESIS; EXPRESSION AB While the brain vasculature can be imaged with many methods, immunohistochemistry has distinct advantages due to its simplicity and applicability to archival tissue. However, immumohistochemical staining of the murine brain vasculature in aldehyde fixed tissue has proven elusive and inconsistent using current protocols. Here we investigated whether antigen retrieval methods could improve vascular staining in the adult mouse brain. We found that pepsin digestion prior to immunostaining unmasked widespread collagen IV staining of the cerebrovasculature in the adult mouse brain. Pepsin treatment also unmasked widespread vascular staining with laminin, but only marginally improved isolectin B4 staining and did not enhance vascular staining with fibronectin, perlecan or CD 146. Collagen IV immunoperoxidase staining was easily combined with cresyl violet counterstaining making it suitable for stereological analyses of both vascular and neuronal parameters in the same tissue section. This method should be widely applicable for labeling the brain vasculature of the mouse in aldehyde fixed tissue from both normal and pathological states. (c) 2007 Elsevier B.V. All rights reserved. C1 James J Peters Dept Vet Adm Med Ctr, Res & Dev Serv, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA. Mt Sinai Sch Med, Lab Mol Neuropsychiat, New York, NY 10029 USA. RP Elder, GA (reprint author), James J Peters Dept Vet Adm Med Ctr, Res & Dev Serv, 3F22,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM gregory.elder@mssm.edu RI Dickstein, Dara/F-3036-2013 OI Buxbaum, Joseph/0000-0001-8898-8313; Christoffel, Dan/0000-0002-6303-5134 FU NIA NIH HHS [R01 AG020139-04, AG002219, AG005138, AG010491, AG020139, P01 AG002219, P01 AG002219-26, P01 AG010491, P01 AG010491-11, P50 AG005138, P50 AG005138-23, R01 AG020139] NR 30 TC 30 Z9 30 U1 1 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0270 J9 J NEUROSCI METH JI J. Neurosci. Methods PD JUN 15 PY 2007 VL 163 IS 1 BP 76 EP 82 DI 10.1016/j.jneumeth.2007.02.020 PG 7 WC Biochemical Research Methods; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 174HX UT WOS:000246934100011 PM 17403541 ER PT J AU Meyer, JS Huang, JB Chowdhury, MH AF Meyer, John Stirling Huang, Juebin Chowdhury, Munir H. TI MRI confirms mild cognitive impairments prodromal for Alzheimer's, vascular and Parkinson-Lewy body dementias SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Article; Proceedings Paper CT 4th International Congress on Vascular Dementia CY OCT 20-23, 2005 CL Oporto, PORTUGAL DE mild cognitive impairment (MCI); dementia of Alzheimer's type (DAT); vascular dementia (VaD); Parkinson-Lewy body dementia (PLBD); combined mini-mental-cognitive capacity screening examination (CMC); magnetic resonance imaging (MRI) ID WHITE-MATTER LESIONS; CLINICAL-DIAGNOSIS; CEREBRAL ATROPHY; TEMPORAL-LOBE; INTERNATIONAL WORKSHOP; HIPPOCAMPAL ATROPHY; RATING-SCALE; DISEASE; BODIES; AD AB Objectives: MRI assessments were correlated with serial Combined Mini-Mental Cognitive Capacity Screening Examinations (CMC). Vascular-MCI (VMCI), Neurodegenerative MCI (NMCI) and Parkinson-Lewy body MCI (PLB-MCI) were compared during conversions to dementia. Mild cognitive impairments (MCI) are identifiable prodromes for all dementia subtypes. MRI abnormalities are characterized among MCI subjects prodromal for dementia of Alzheimer's disease (DAT), vascular dementia (VaD) and Parkinson-Lewy body dementia (PLBD). Methods: Aging volunteers (n = 166) were recruited from ongoing longitudinal studies of aging, stroke, cerebrovascular disease and dementia. Cognitively normal (CN, n = 52), MCIs of neurodegenerative (N-MCI, n-30), vascular (V-MCI, n=35) and Parkinson-Lewy Body (PLB-MCI, n = 8) subtypes, plus converted DAT (n = 19), VaD (n = 17) and PLBD (n = 5) were all diagnosed according to established protocol recommendations. Cerebral MRI abnormalities were likewise intercorrelated utilizing quantitative volumetric measurements. Results: V-MCI and converted VAD showed extensive leukoaraiosis with more lacunar infarcts than subjects with N-MCI or PLB-MCI. NMCI, prodromal for DAT, showed medial temporal atrophy, greater enlargement of temporal horns, and fewer vascular lesions. PLB-MCI, prodromal for PLBD, displayed third ventricular enlargement greater than N-MCI and V-MCI, with similar but less severe atrophy of medial temporal lobe than N-MCI and fewer vascular lesions than V-MCI. Cognitive Impairments due to PLB with vascular features (V-PLB-CI) showed more lacunar and microvascular lesions involving both white matter and basal ganglia with greater frontal horn enlargement. Conclusions: This study confirms different MCI subtypes prior to conversion to different dementias listed, recognizable by specific MRI abnormalities. (c) 2007 Elsevier B.V, All rights reserved. C1 Baylor Coll Med, Dept Neurol, Houston, TX 77098 USA. Michael E DeBakey Vet Adm Med Ctr, Cerebrovasc Res Labs, Houston, TX 77098 USA. RP Meyer, JS (reprint author), Baylor Coll Med, Dept Neurol, 2321 SW Freeway, Houston, TX 77098 USA. EM johnstirlingmeyer@yahoo.com NR 65 TC 34 Z9 37 U1 1 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X J9 J NEUROL SCI JI J. Neurol. Sci. PD JUN 15 PY 2007 VL 257 IS 1-2 BP 97 EP 104 DI 10.1016/j.jns.2007.01.016 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 184MV UT WOS:000247646700017 PM 17316690 ER PT J AU Higashi, T Wenger, NS Adams, JL Fung, C Roland, M McGlynn, EA Reeves, D Asch, SM Kerr, EA Shekelle, PG AF Higashi, Takahiro Wenger, Neil S. Adams, John L. Fung, Constance Roland, Martin McGlynn, Elizabeth A. Reeves, David Asch, Steven M. Kerr, Eve A. Shekelle, Paul G. TI Relationship between number of medical conditions and quality of care SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID VULNERABLE OLDER-PEOPLE; UNITED-STATES; HEALTH-CARE; PRACTICE GUIDELINES; PERFORMANCE DATA; DIABETES CARE; DISEASES; ELDERS; PAY; GENERALIST AB BACKGROUND: There is emerging concern that the methods used to measure the quality of care unfairly penalize providers caring for patients with multiple chronic conditions. We therefore sought to study the relationship between the quality of care and the number of medical conditions a patient has. METHODS: We assessed measurements of the quality of medical care received in three cohorts of community-dwelling adult patients in the Community Quality Index study, the Assessing Care of Vulnerable Elders study, and the Veterans Health Administration project (7680 patients in total). We analyzed the relationship between the quality of care that patients received, defined as the percentage of quality indicators satisfied among those for which patients were eligible, and the number of chronic medical conditions each patient had. We further explored the roles of characteristics of patients, use of health care (number of office visits and hospitalizations), and care provided by specialists as explanations for the observed relationship. RESULTS: The quality of care increased as the number of medical conditions increased. Each additional condition was associated with an increase in the quality score of 2.2% (95% confidence interval [CI], 1.7 to 2.7) in the Community Quality Index cohort, of 1.7% (95% CI, 1.1 to 2.4) in the Assessing Care of Vulnerable Elders cohort, and of 1.7% (95% CI, 0.7 to 2.8) in the Veterans Health Administration cohort. The relationship between the quality of care and the number of conditions was little affected by adjustment for the difficulty of delivering the care recommended in a quality indicator and for the fact that, because of multiple conditions requiring the same care, a patient could be eligible to receive the same care process more than once. Adjustment for characteristics of patients, use of health care, and care provided by specialists diminished the relationship, but it remained positive. CONCLUSIONS: The quality of care, measured according to whether patients were offered recommended services, increases as a patient's number of chronic conditions increases. C1 RAND Corp, Santa Monica, CA 90407 USA. Univ Calif Los Angeles, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Kyoto Univ, Kyoto, Japan. Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester, Lancs, England. Vet Affairs Ann Arbor Hlth Care Syst, Ann Arbor, MI USA. Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. RP Shekelle, PG (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. EM shekelle@rand.org RI Kerr, Eve/I-3330-2013; reeves, david/H-6203-2014 OI reeves, david/0000-0001-6377-6859 NR 34 TC 151 Z9 151 U1 1 U2 10 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUN 14 PY 2007 VL 356 IS 24 BP 2496 EP 2504 DI 10.1056/NEJMsa066253 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 178DR UT WOS:000247201900009 PM 17568030 ER PT J AU Keene, CD Sonnen, A Swanson, PD Kopyov, O Leverenz, JB Bird, TD Montine, TJ AF Keene, C. D. Sonnen, A. Swanson, P. D. Kopyov, O. Leverenz, J. B. Bird, T. D. Montine, T. J. TI Neural transplantation in Huntington disease - Long-term grafts in two patients SO NEUROLOGY LA English DT Article ID FETAL STRIATAL TRANSPLANTATION; EFFERENT PROJECTIONS; HOST; MODEL; NEUROTRANSPLANTATION; INTERNEURONS; INNERVATION; ALLOGRAFTS; AFFERENTS; NEURONS AB Objective: Clinical trials of fetal neural tissue transplantation for Huntington disease (HD) have been conducted with variable clinical results. However, no long-term analysis of graft survival and integration has been published. Here, we report the pathologic findings in two patients with HD who died 74 and 79 months after transplantation. Methods: Methods used were pathologic examination, histochemistry, and immunohistochemistry. Results: Neostriatum from both patients showed typical neuropathologic changes of advanced HD. Surviving grafts were identified in both patients (6/6 sites and 7/8 sites, respectively) as well-demarcated nests within host neostriatum with associated needle tracts. Grafted neurons adopted either dominant calbindin/parvalbumin or calretinin immunoreactivity (IR). Few neurofilament, MAP-2, DARPP-32, tyrosine hydroxylase, or calbindin IR processes traversed the host parenchyma - graft interface despite minimal junctional gliosis. Immunohistochemistry for CD68 showed microgliosis that was more pronounced in host striatum than graft. Scattered CD45 and CD3IR cells were present within grafts and host parenchyma. No ubiquitin IR neuronal intranuclear inclusions were identified in graft neurons, although these were prevalent in host cells. Conclusions: These two autopsies confirm previous findings of neuronal differentiation and survival of transplanted fetal tissue from the ganglionic eminence and also demonstrate viability of neurons from fetal transplants in human neostriatum for more than 6 years. Despite prolonged survival, these grafts had poor integration with host striatum that is likely responsible for lack of clear clinical improvement in these patients. C1 Univ Washington, Med Ctr, Dept Pathol, Div Neuropathol, Seattle, WA 98195 USA. Univ Washington, Med Ctr, Dept Neurol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Dept Neurol, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Mental Illness&Parkinsons Dis Res Educ & Clin Ctr, Dept Neurol, Seattle, WA USA. St Johns Reg Med Ctr, Inst Neurosci, Oxnard, CA USA. RP Montine, TJ (reprint author), Univ Washington, Harborview Med Ctr, Dept Pathol, Box 359791, Seattle, WA 98104 USA. EM tmontine@u.washington.edu RI Sonnen, 37382016/H-3738-2016; Keene, Christopher/N-1806-2015 OI Sonnen, 37382016/0000-0001-9267-8705; FU NIA NIH HHS [P50-AG005136-22] NR 26 TC 49 Z9 54 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD JUN 12 PY 2007 VL 68 IS 24 BP 2093 EP 2098 DI 10.1212/01.wnl.0000264504.14301.f5 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 177JK UT WOS:000247149200007 PM 17562830 ER PT J AU Martins, D Wolf, M Pan, D Zadshir, A Tareen, N Thadhani, R Felsenfeld, A Levine, B Mehrotra, R Norris, K AF Martins, David Wolf, Myles Pan, Deyu Zadshir, Ashraf Tareen, Naureen Thadhani, Ravi Felsenfeld, Arnold Levine, Barton Mehrotra, Rajnish Norris, Keith TI Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States - Data from the Third National Health and Nutrition Examination Survey SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 20th Anniversary Symposium of the Research-Centers-for-Minority-Institutions CY DEC 10, 2004 CL Balitmore, MD SP Res Ctr Minor Inst ID VITAMIN-D INSUFFICIENCY; PLASMA-RENIN ACTIVITY; HYPOVITAMINOSIS-D; BLOOD-PRESSURE; 1,25-DIHYDROXYVITAMIN D-3; ESSENTIAL-HYPERTENSION; NOD MICE; BODY-FAT; METABOLISM; PREVENTION AB Background: Results of several epidemiologic and clinical studies have suggested that there is an excess risk of hypertension and diabetes mellitus in persons with suboptimal intake of vitamin D. Methods: We examined the association between serum levels of 25-hydroxyvitamin D ( 25[ OH] D) and select cardiovascular disease risk factors in US adults. A secondary analysis was performed with data from the Third National Health and Nutrition Examination Survey, a national probability survey conducted by the National Center for Health Statistics between January 1, 1988, and December 31, 1994, with oversampling of persons 60 years and older, non-Hispanic black individuals, and Mexican American individuals. Results: There were 7186 male and 7902 female adults 20 years and older with available data in the Third National Health and Nutrition Examination Survey. The mean 25( OH) D level in the overall sample was 30 ng/mL ( 75 nmol/L). The 25( OH) D levels were lower in women, elderly persons ( >= 60 years), racial/ethnic minorities, and participants with obesity, hypertension, and diabetes mellitus. The adjusted prevalence of hypertension ( odds ratio [ OR], 1.30), diabetes mellitus ( OR, 1.98), obesity ( OR, 2.29), and high serum triglyceride levels ( OR, 1.47) was significantly higher in the first than in the fourth quartile of serum 25( OH) D levels ( P < .001 for all). Conclusions: Serum 25( OH) D levels are associated with important cardiovascular disease risk factors in US adults. Prospective studies to assess a direct benefit of cholecalciferol ( vitamin D) supplementation on cardiovascular disease risk factors are warranted. C1 Charles R Drew Univ Med & Sci, Dept Med, Lynwood, CA 90262 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Harvard Univ, Sch Med, Dept Med, Boston, MA USA. VA Greater LA Healthcare Syst, Dept Med, Los Angeles, CA USA. Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA. RP Norris, K (reprint author), Charles R Drew Univ Med & Sci, Dept Med, 11705 Deputy Yamamoto Pl,Suite B, Lynwood, CA 90262 USA. EM knorris@ucla.edu FU NCRR NIH HHS [RR14616, RR019234, RR03026, RR11145, RR18298]; NIA NIH HHS [AG-02-004]; NIDDK NIH HHS [DK71674]; NIMHD NIH HHS [MD00148] NR 48 TC 450 Z9 487 U1 1 U2 20 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JUN 11 PY 2007 VL 167 IS 11 BP 1159 EP 1165 DI 10.1001/archinte.167.11.1159 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 177HE UT WOS:000247143400008 PM 17563024 ER PT J AU Kraveka, JM Li, L Szulc, ZM Bielawski, J Ogretmen, B Hannun, YA Obeid, LM Bielawska, A AF Kraveka, Jacqueline M. Li, Li Szulc, Zdzislaw M. Bielawski, Jacek Ogretmen, Besim Hannun, Yusuf A. Obeid, Lina M. Bielawska, Alicja TI Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID EUKARYOTIC STRESS-RESPONSE; PROTEIN PHOSPHATASE; TELOMERASE ACTIVITY; CANCER CELLS; CERAMIDE; APOPTOSIS; ACID; ACTIVATION; N-(4-HYDROXYPHENYL)RETINAMIDE; DIFFERENTIATION AB The role of dihydroceramide desaturase as a key enzyme in the de novo pathway of ceramide generation was investigated in human neuroblastoma cells (SMS-KCNR). A novel assay using water-soluble analogs of dihydroceramide, dihydroceramidoids (D-erythro-dhCCPS analogs), was used to measure desaturase activity in situ. Conversion of D-erythro-2-N-[12 '-(1 ''-pyridinium)-dodecanoyl]- 4,5-dihydrosphingosine bromide (C-12-dhCCPS) to its 4,5-desaturated counterpart, D-erythro-2-N-[12 '-(1 ''-pyridinium) dodecanoyl]sphingosine bromide (C-12-CCPS), was determined by liquid chromatography/mass spectrometry analysis. The validity of the assay was confirmed using C-8-cyclopropenylceramide, a competitive inhibitor of dihydroceramide desaturase. A human homolog (DEGS-1) of the Drosophila melanogaster des-1 gene was recently identified and reported to have desaturase activity. Transfection of SMS-KCNR cells with small interfering RNA to DEGS-1 significantly blocked the conversion of C-12-dhCCPS to C-12-CCPS. The associated accumulation of endogenous dihydroceramides confirmed DEGS-1 as the main active dihydroceramide desaturase in these cells. The partial loss of DEGS-1 inhibited cell growth, with cell cycle arrest at G(0)/G(1). This was accompanied by a significant decrease in the amount of phosphorylated retinoblastoma protein. This hypophosphorylation was inhibited by tautomycin and not by okadaic acid, suggesting the involvement of protein phosphatase 1. Additionally, we found that treatment of SMS-KCNR cells with fenretinide inhibited desaturase activity in a dose-dependent manner. An increase in dihydroceramides (but not ceramides) paralleled this process as measured by liquid chromatography/mass spectrometry. There were no effects on the mRNA or protein levels of DEGS-1, suggesting that fenretinide acts at the post-translational level as an inhibitor of this enzyme. Tautomycin was also able to block the hypophosphorylation of the retinoblastoma protein observed upon fenretinide treatment. These findings suggest a novel biological function for dihydroceramides. C1 Med Univ S Carolina, Dept Pediat, Div Hematol Oncol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Kraveka, JM (reprint author), Med Univ S Carolina, Dept Pediat, Div Hematol Oncol, 135 Rutledge Ave,POB 250558, Charleston, SC 29425 USA. EM kravekjm@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [K01 CA100767, L40 CA110721, P01 CA097132]; NCRR NIH HHS [C06 RR018823, P20 RR017677]; NIA NIH HHS [R01 AG016583]; NIDCR NIH HHS [R01 DE016572] NR 43 TC 85 Z9 88 U1 1 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUN 8 PY 2007 VL 282 IS 23 BP 16718 EP 16728 DI 10.1074/jbc.M700647200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 174MN UT WOS:000246946500003 PM 17283068 ER PT J AU Gourcerol, G St-Pierre, DH Tache, Y AF Gourcerol, G. St-Pierre, D. H. Tache, Y. TI Lack of obestatin effects on food intake: Should obestatin be renamed ghrelin-associated peptide (GAP)? SO REGULATORY PEPTIDES LA English DT Review DE ghrelin; obestatin; food intake; gastric emptying; GPR39 ID GROWTH-HORMONE SECRETAGOGUE; COUPLED RECEPTOR GPR39; GASTROINTESTINAL HORMONES; SYNERGISTIC INTERACTION; PERIPHERAL GHRELIN; ENERGY-BALANCE; RATS; SECRETION; LEPTIN; RODENTS AB Obestatin is a newly identified ghrelin-associated peptide (GAP) that is derived from post-translational processing of the prepro-ghrelin gene. Obestatin has been reported initially to be the endogenous ligand for the orphan receptor G protein-coupled receptor 39 (GPR39), and to reduce refeeding- and ghrelin-stimulated food intake and gastric transit in fasted mice, and body weight gain upon chronic peripheral injection. However, recent reports indicate that obestatin is unlikely to be the endogenous ligand for GPR39 based on the lack of specific binding on GRP39 receptor expressing cells and the absence of signal transduction pathway activation. In addition, a number of studies provided convergent evidence that ghrelin injected intracerebroventricularly or peripherally did not influence food intake, body weight gain, gastric transit, gastrointestinal motility, and gastric vagal afferent activity, as well as pituitary hormone secretions, in rats or mice. Similarly, obestatin did not alter ghrelin-induced stimulation of food intake or gastric transit. Therefore, the present state-of-knowledge on obestatin and GPR39 is leaving many unanswered questions that deserve further consideration. Those relate not only to redefining the biological action of obestatin that should be renamed GAP, but also the identification of the native ligand for GPR39. (C) 2007 Elsevier B.V. All rights reserved. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Div Digest Dis, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA USA. Univ Calif Los Angeles, Div Digest Dis, David Geffen Sch Med, Digest Dis Res Ctr, Los Angeles, CA USA. CURE, Los Angeles, CA USA. Univ Montreal, Dept Nutr, Montreal, PQ H3C 3J7, Canada. RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU NIDDK NIH HHS [DK-41301, R01 DK-33061] NR 41 TC 83 Z9 86 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-0115 J9 REGUL PEPTIDES JI Regul. Pept. PD JUN 7 PY 2007 VL 141 IS 1-3 BP 1 EP 7 DI 10.1016/j.regpep.2006.12.023 PG 7 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 165SZ UT WOS:000246327300001 PM 17321609 ER PT J AU Glickman, SW Ou, FS DeLong, ER Roe, MT Lytle, BL Mulgund, J Rumsfeld, JS Gibler, WB Ohman, EM Schulman, KA Peterson, ED AF Glickman, Seth W. Ou, Fang-Shu DeLong, Elizabeth R. Roe, Matthew T. Lytle, Barbara L. Mulgund, Jyotsna Rumsfeld, John S. Gibler, W. Brian Ohman, E. Magnus Schulman, Kevin A. Peterson, Eric D. TI Pay for performance, quality of care, and outcomes in acute myocardial infarction SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID ACUTE CORONARY SYNDROMES; HEALTH-CARE; FINANCIAL INCENTIVES; IMPORTANT DIFFERENCE; FOR-PERFORMANCE; UNSTABLE ANGINA; IMPROVEMENT; MANAGEMENT; ASSOCIATION; STRATEGIES AB of Context Pay for performance has been promoted as a tool for improving quality of care. In 2003, the Centers for Medicare & Medicaid Services ( CMS) launched the largest pay-for-performance pilot project to date in the United States, including indicators for acute myocardial infarction. Objective To determine if pay for performance was associated with either improved processes of care and outcomes or unintended consequences for acute myocardial infarction at hospitals participating in the CMS pilot project. Design, Setting, and Participants An observational, patient-level analysis of 105 383 patients with acute non-ST-segment elevation myocardial infarction enrolled in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association ( ACC/AHA) Guidelines ( CRUSADE) national quality-improvement initiative. Patients were treated between July 1, 2003, and June 30, 2006, at 54 hospitals in the CMS program and 446 control hospitals. Main Outcome Measures The differences in the use of ACC/AHA class I guideline recommended therapies and in-hospital mortality between pay for performance and control hospitals. Results Among treatments subject to financial incentives, there was a slightly higher rate of improvement for 2 of 6 targeted therapies at pay-for-performance vs control hospitals ( odds ratio [ OR] comparing adherence scores from 2003 through 2006 at half-year intervals for aspirin at discharge, 1.31; 95% confidence interval [ CI], 1.181.46 vs OR, 1.17; 95% CI, 1.12-1.21; P=. 04) and for smoking cessation counseling ( OR, 1.50; 95% CI, 1.29-1.73 vs OR, 1.28; 95% CI, 1.22-1.35; P=. 05). There was no significant difference in a composite measure of the 6 CMS rewarded therapies between the 2 hospital groups ( change in odds per half-year period of receiving CMS therapies: OR, 1.23; 95% CI, 1.15-1.30 vs OR, 1.17; 95% CI, 1.14-1.20; P=. 16). For composite measures of acute myocardial infarction treatments not subject to incentives, rates of improvement were not significantly different ( OR, 1.09; 95% CI, 1.051.14 vs OR, 1.08; 95% CI, 1.06- 1.09; P=. 49). Overall, there was no evidence that improvements in in-hospital mortality were incrementally greater at pay-for-performance sites ( change in odds of in-hospital death per half-year period, 0.91; 95% CI, 0.84-0.99 vs 0.97; 95% CI, 0.94-0.99; P=. 21). Conclusions Among hospitals participating in a voluntary quality-improvement initiative, the pay-for-performance program was not associated with a significant incremental improvement in quality of care or outcomes for acute myocardial infarction. Conversely, we did not find evidence that pay for performance had an adverse association with improvement in processes of care that were not subject to financial incentives. Additional studies of pay for performance are needed to determine its optimal role in quality-improvement initiatives. C1 Duke Clin Res Inst, Outcomes Res & Assessment Grp, Durham, NC 27715 USA. Duke Clin Res Inst, Ctr Clin & Genet Econ, Durham, NC 27715 USA. Duke Univ, Med Ctr, Dept Surg, Div Emergency Med, Durham, NC USA. Duke Univ, Med Ctr, Hlth Sector Management Program, Fuqua Sch Business, Durham, NC USA. Denver VA Med Ctr, Cardiol Sect, Denver, CO USA. Univ Cincinnati, Coll Med, Dept Emergency Med, Cincinnati, OH USA. RP Peterson, ED (reprint author), Duke Clin Res Inst, Outcomes Res & Assessment Grp, POB 17969, Durham, NC 27715 USA. EM peter016@mc.duke.edu FU NIA NIH HHS [R01 AG025312 01A1] NR 30 TC 182 Z9 182 U1 1 U2 19 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUN 6 PY 2007 VL 297 IS 21 BP 2373 EP 2380 DI 10.1001/jama.297.21.2373 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 175IL UT WOS:000247007200019 PM 17551130 ER PT J AU Heidenreich, PA Gholami, P Sahay, A Massie, B Goldstein, MK AF Heidenreich, Paul A. Gholami, Parisa Sahay, Anju Massie, Barry Goldstein, Mary K. TI Clinical reminders attached to echocardiography reports of patients with reduced left ventricular ejection fraction increase use of beta-blockers - A randomized trial SO CIRCULATION LA English DT Article DE adrenergic beta-antagonists; echocardiography; health services research; heart failure; reminder systems ID CHRONIC HEART-FAILURE; QUALITY-OF-CARE; COST-EFFECTIVENESS; RECOMMENDATIONS; ENDOCARDITIS; ASSOCIATION; CARVEDILOL; METOPROLOL; DIAGNOSIS; UPDATE AB Background-Although beta-blockers are known to prolong survival for patients with reduced left ventricular ejection fraction, they are often underused. We hypothesized that a reminder attached to the echocardiography report would increase the use of beta-blockers for patients with reduced left ventricular ejection fraction. Methods and Results-We randomized 1546 consecutive patients with a left ventricular ejection fraction < 45% found on echocardiography at 1 of 3 laboratories to a reminder for use of beta-blockers or no reminder. Patients were excluded from analysis if they died within 30 days of randomization (n = 89), did not receive medications through the Veterans Affairs system after 30 days ( n = 180), or underwent echocardiography at > 1 laboratory ( n = 6). The primary outcome was a prescription for an oral beta-blocker between 1 and 9 months after randomization. The mean age of the 1271 included patients was 69 years; 60% had a history of heart failure, and 51% were receiving treatment with beta- blockers at the time of echocardiography. More patients randomized to the reminder had a subsequent beta- blocker prescription (74%, 458 of 621) compared with those randomized to no reminder (66%, 428 of 650; P = 0.002). The effect of the reminder was not significantly different for subgroups based on patient location ( inpatient versus outpatient) or prior use of beta-blockers. Conclusions-A reminder attached to the echocardiography report increased the use of beta-blockers in patients with depressed left ventricular systolic function. C1 Palo Alto VA Hlth Care Syst, Palo Alto, CA 94304 USA. Stanford Univ, Dept Med, Stanford, CA 94305 USA. Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP Heidenreich, PA (reprint author), Palo Alto VA Hlth Care Syst, 111C Cardiol,3801 Miranda Ave, Palo Alto, CA 94304 USA. EM heiden@stanford.edu OI Heidenreich, Paul/0000-0001-7730-8490 NR 20 TC 23 Z9 24 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD JUN 5 PY 2007 VL 115 IS 22 BP 2829 EP 2834 DI 10.1161/CIRCULATIONAHA.106.684753 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 174WD UT WOS:000246972600008 PM 17515459 ER PT J AU Udelson, JE McGrew, FA Flores, E Ibrahim, H Katz, S Koshkarian, G O'Brien, T Kronenberg, MW Zimmer, C Orlandi, C Konstam, MA AF Udelson, James E. McGrew, Frank A. Flores, Enrique Ibrahim, Hassan Katz, Stewart Koshkarian, Gregory O'Brien, Terrence Kronenberg, Marvin W. Zimmer, Christopher Orlandi, Cesare Konstam, Marvin A. TI Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID VASOPRESSIN RECEPTOR ANTAGONIST; CONVERTING-ENZYME-INHIBITOR; NEONATAL-RAT CARDIOMYOCYTE; CONTROLLED-TRIAL; MYOCARDIAL-INFARCTION; PROTEIN-SYNTHESIS; ENALAPRIL; HYPONATREMIA; OMAPATRILAT; PROGRESSION AB Objectives This study sought to examine the effects of vasopressin V-2 receptor antagonism with tolvaptan on the changes in left ventricular (LV) volumes over time. Background Vasopressin levels may be increased in patients with heart failure (HF) and may be a factor driving the progression of HF. Methods This was a multicenter, randomized, double-blind, placebo-controlled trial conducted to evaluate the effect of long-term administration of the vasopressin V-2-receptor antagonist tolvaptan (30 mg,/day) on reducing left ventricular end-diastolic volume (LVEDV) compared with placebo in patients with HF and reduced systolic function, using quantitative radionuclide ventriculography at baseline, repeated after 1 year of therapy, and repeated again approximately 1 week after withdrawal of study drug. Results A total of 120 patients were randomized to tolvaptan and 120 were randomized to placebo. In the placebo group, there was no change in LVEDV over the course of follow-up (change of 0.0 +/- 10.0 ml/m(2)). After 1 year of tolvaptan, there was a small reduction in LV volume (decrease of 1.8 +/- 10.7 ml/m(2)); the between-group difference was not significant (p = 0.21). During the course of the trial, there were 6 deaths (5%) and 21 HF hospitalizations (18%) in the tolvaptan group, compared with 11 deaths (9%) and 34 HF hospitalizations (28%) in the placebo group. In a time-to-event analysis, there was a significant favorable effect of tolvaptan on the composite of mortality or heart failure hospitalization (p < 0.03 by log-rank test). Conclusions In a well-treated population of stable HF patients, there was no significant effect of tolvaptan therapy on LV volumes observed during 1 year of therapy. Nonprespecified natural history data favored therapy with tolvaptan, with a reduction in the combined end point of mortality and heart failure hospitalization observed. (Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricuiar Dilatation in Congestive Heart Failure Patients; http://clinicaltrials.gov/ct/ show/NCT00043758?order = 1; NCT00043758). C1 Tufts Univ, New England Med Ctr, Sch Med, Div Cardiol, Boston, MA 02111 USA. Stern Cardiovasc Ctr, Memphis, TN USA. Georgia Heart Specialists, Covington, GA USA. N Ohio Res Ltd, Sandusky, OH USA. Yale Univ, Sch Med, New Haven, CT 06520 USA. Desert Cardiol Tucson, Tucson, AZ USA. Ralph Johnson VA Med Ctr, Charleston, SC USA. Vanderbilt Univ, Div Cardiovasc Med, Nashville, TN USA. Otsuka Amer Pharmaceut Inc, Rockville, MD USA. RP Udelson, JE (reprint author), Tufts Univ, New England Med Ctr, Sch Med, Div Cardiol, 750 Washington St,Box 70, Boston, MA 02111 USA. EM JUdelson@tufts-nemc.org NR 33 TC 76 Z9 83 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JUN 5 PY 2007 VL 49 IS 22 BP 2151 EP 2159 DI 10.1016/j.jacc.2007.01.091 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 174EW UT WOS:000246925400002 PM 17543634 ER PT J AU El-Amouri, SS Zhu, H Yu, J Gage, FH Verma, IM Kindy, MS AF El-Amouri, Salim S. Zhu, Hong Yu, Jin Gage, Fred H. Verma, Inder M. Kindy, Mark S. TI Neprilysin protects neurons against A beta peptide toxicity SO BRAIN RESEARCH LA English DT Article DE Alzheimer's disease; neprilysin; amyloid beta peptide; lentiviral vectors; gene therapy; hippocampus ID CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; LENTIVIRUS VECTOR; MOUSE MODEL; PATHOLOGY; ENDOPEPTIDASE; DEGRADATION; METABOLISM; ENZYME AB In recent years, studies have suggested that accumulation of amyloid beta (A beta) peptide in the brain plays a key role in the development of Alzheimer's disease (AD). The steady-state level of A beta peptide in the brain is determined by the rate of production from amyloid precursor protein (APP) via beta- and gamma-secretases and degradation by the activity of several enzymes. Neprilysin (NEP) appears to be the most potent A beta peptide-degrading enzyme in the brain. Decreasing the activity of NEP (due to genetic mutations, age or diseases that alter the expression or activity of NEP) may lead to accumulation of the neurotoxic A beta peptide in the brain; in turn this leads to neuronal loss. We investigated the efficacy of lentivirus-mediated over-expression of NEP to protect neuronal cells from A beta peptide in vitro. Incubation of hippocampal neuronal cells (HT22) over-expressing NEP with the monomeric from of A beta peptide decreases the toxicity of A beta peptide on the neuronal cells, as measured through cell viability. We conclude that over-expression of NEP by a gene therapy approach in areas vulnerable to A beta peptide aggregation in AD brain may protect the neurons from the toxicity effects of A beta peptide and this promises a great potential target for altering the development of AD. (c) 2007 Elsevier B.V. All rights reserved. C1 Med Univ S Carolina, Dept Mol & Cellular Biochem, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Kindy, MS (reprint author), Med Univ S Carolina, Dept Neurosci, Basic Bldg,Room 403,173 Ashley Ave, Charleston, SC 29425 USA. EM kindyms@musc.edu FU NIA NIH HHS [AG019323, R01 AG019323, R01 AG019323-04] NR 31 TC 36 Z9 38 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD JUN 4 PY 2007 VL 1152 BP 191 EP 200 DI 10.1016/j.brainres.2007.03.072 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 181FY UT WOS:000247423700020 PM 17459354 ER PT J AU Pines, JM Hollander, JE Lee, H Everett, WW Uscher-Pines, L Metlay, JP AF Pines, Jesse M. Hollander, Judd E. Lee, Hoi Everett, Worth W. Uscher-Pines, Lori Metlay, Joshua P. TI Emergency department operational changes in response to pay-for-performance and antibiotic timing in pneumonia SO ACADEMIC EMERGENCY MEDICINE LA English DT Article DE pneumonia; quality of care; pay for performance; emergency department; patient safety ID COMMUNITY-ACQUIRED PNEUMONIA; CARE; MEDICARE; OUTCOMES; QUALITY AB Background: The percentage of adult patients admitted with pneumonia who receive antibiotics within four hours of hospital arrival is publicly reported as a quality and pay-for-performance measure by the Department of Health and Human Services and is called PN-5b. Objectives: To determine attitudes among physician leaders at emergency medicine training programs toward using PN-5b as a quality measure for pay for performance, and to determine what operational changes academic emergency departments (EDs) have made to ensure early antibiotic administration for patients with pneumonia. Methods: The authors administered an online questionnaire to 129 chairpersons and medical directors of 135 academic ED training programs in the United States on attitudes toward performance measurement in pneumonia and changes that academic EDs have made in response to PN-5b; one response was sought from each institution. Respondents were identified through the Society for Academic Emergency Medicine Web site and e-mailed five times to maximize survey participation. Results: Ninety chairpersons and medical directors (70%) completed the survey; 47% were medical directors, 51% were chairpersons, and 2% were medical directors and chairpersons. Forty-five (50%) did not agree that PN-5b was an accurate quality measure, and 61 (69%) did not agree that pay for performance targeting this measure would lead to improved pneumonia care. The most common strategy to address PN-5b was to provide information to providers on the importance of early treatment with antibiotics (n = 63; 70%). For patients with suspected pneumonia, 46 (51 %) automate chest radiograph (CXR) ordering at triage, 37 (41 %) prioritize patients with suspected pneumonia, and 33 (37%) administer antibiotics before obtaining CXR results. Overall ED changes include improved turnaround time for CXR (n = 33; 37%), prioritized CXRs over other radiographs (n = 13; 14%), and improved inpatient bed availability (n = 12; 13%). Of 13 strategies identified to improve PN-5b, the median number that programs have implemented is five finterquartile range, 5-7). All sites reported engaging in at least three operational changes to address PN-5b. Conclusions: All EDs in this study have addressed early antibiotic administration with multiple operational changes despite mixed sentiment that these changes will improve care. Future research is needed to measure the impact of pay-for-performance initiatives. C1 Hosp Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA. Johns Hopkins Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. Univ Penn, Dept Med, Philadelphia, PA 19104 USA. RP Pines, JM (reprint author), Hosp Univ Penn, Dept Emergency Med, 3400 Spruce St, Philadelphia, PA 19104 USA. EM pinesjes@uphs.upenn.edu OI Hollander, Judd/0000-0002-1318-2785 NR 15 TC 24 Z9 24 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD JUN PY 2007 VL 14 IS 6 BP 545 EP 548 DI 10.1197/j.aem.2007.01.022 PG 4 WC Emergency Medicine SC Emergency Medicine GA 172UZ UT WOS:000246831300009 PM 17470905 ER PT J AU Zivkovic, SA Ascherman, D Lacomis, D AF Zivkovic, S. A. Ascherman, D. Lacomis, D. TI Vasculitic neuropathy - electrodiagnostic findings and association with malignancies SO ACTA NEUROLOGICA SCANDINAVICA LA English DT Editorial Material DE electromyography; malignancy; neuropathy; paraneoplastic; vasculitis ID PERIPHERAL NERVOUS-SYSTEM; MUSCLE MICROVASCULITIS; CLINICAL SPECTRUM; CANCER AB Background - Vasculitic neuropathies occur in the context of systemic disorders or in isolation. Histopathologic evaluation remains the gold standard for diagnosis, but certain electrodiagnostic findings may heighten suspicion of vasculitic neuropathy and improve the yield of nerve and muscle biopsy. Aim of the study - Description of electrodiagnostic patterns associated with vasculitic neuropathies, and a report of a possible association with malignancies. Methods Retrospective review of medical records of patients with histopathologically proven vasculitic and non-vasculitic axonal neuropathies evaluated at the University of Pittsburgh Medical Center from November 1995 to November 2003. Results - The most distinctive electrodiagnostic patterns associated with vasculitic neuropathy were mononeuritis multiplex (27.5% vs 4% in controls; P = 0.003) and axonal sensorimotor polyneuropathy with side-to-side amplitude asymmetry (50% vs 32%, P > 0.05). Additionally, six patients (15% vs 2%; P = 0.034) developed various malignancies within 2 years of onset of vasculitic neuropathy. Conclusions - While generalized polyneuropathy was the most common presentation of nerve vasculitis, our study affirms side-to-side amplitude asymmetry and mononeuritis multiplex as the most distinctive electrodiagnostic features. The frequent occurrence of malignancies suggests a possible association with the vasculitic neuropathy and warrants additional investigation. C1 Univ Pittsburgh, Med Ctr, Dept Neurol, Sch Med,Div Rheumatol & Clin Immunol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Med Ctr, Dept Pathol, Sch Med,Div Neuropathol, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Zivkovic, SA (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurol, Sch Med,Div Rheumatol & Clin Immunol, 3471 5th Ave 811, Pittsburgh, PA 15213 USA. EM zivkovics@upmc.edu NR 16 TC 21 Z9 24 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0001-6314 J9 ACTA NEUROL SCAND JI Acta Neurol. Scand. PD JUN PY 2007 VL 115 IS 6 BP 432 EP 436 DI 10.1111/j.1600-0404.2006.00781.x PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 174RK UT WOS:000246960300012 PM 17511855 ER PT J AU Eisenman, D Bogart, LM Bird, CE Collins, RL Golinelli, D Fremont, A Beckman, R Cunningham, W AF Eisenman, David Bogart, Laura M. Bird, Chloe E. Collins, Rebecca L. Golinelli, Daniela Fremont, Allen Beckman, Robin Cunningham, William TI Differential diffusion of HIV technologies by gender: The case of highly active antiretroviral therapy SO AIDS PATIENT CARE AND STDS LA English DT Article ID PROTEASE INHIBITORS; UNITED-STATES; DRUG-USERS; ACCESS; WOMEN; CARE; DISEASE; COHORT; HAART; AIDS AB We sought to examine whether diffusion of new HIV technologies differed by gender in the United States, the source of any such disparities, and whether disparities narrow over time as technologies become more established. In particular, we assess how rates of use of highly active antiretroviral therapy ( HAART) varied between males and females during the late 1990s, when HAART was rapidly diffusing. We examined data from a prospective cohort study of a national probability sample of 1421 HIV- infected adults in medical care who were enrolled in the HIV Cost and Services Utilization Study ( HCSUS) from January 1996 to December 1998. We found that HAART use substantially increased between 1996 and early 1998 for all groups. Women were less likely to receive HAART at all time points, although the diffusion of HAART between 1996 and 1998 reduced gender disparities. Gender disparities in 1998 were only partially explained by women's lower income and educational levels. We conclude that HAART therapy diffused more slowly to HIV- positive females than other groups. Policies that reduce the impact of income and education inequalities on health care may help to narrow gender disparities for new HIV technologies, but other factors may also disadvantage women. C1 RAND Corp, Hlth Sci Program, Santa Monica, CA 90407 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Hlth Serv Res, Los Angeles, CA 90024 USA. W Los Angeles VAMC, Div Med, Los Angeles, CA USA. RP Eisenman, D (reprint author), RAND Corp, Hlth Sci Program, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. EM David_Eisenman@rand.org RI Bird, Chloe/C-7107-2008; Fremont, Allen/A-7752-2009; Golinelli, Daniela/H-2287-2015 OI Golinelli, Daniela/0000-0002-6433-1752 FU AHRQ HHS [U-01HS08578]; NIA NIH HHS [AG-02-004]; NICHD NIH HHS [R01HD35040, R01HD41878]; NIMHD NIH HHS [1P20MD000148-01] NR 28 TC 8 Z9 8 U1 1 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD JUN PY 2007 VL 21 IS 6 BP 390 EP 399 DI 10.1089/apc.2006.0061 PG 10 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 182VG UT WOS:000247531500004 PM 17594248 ER PT J AU Simpson, TL Meredith, CW Gross, CA Raskind, MA Saxon, AJ Rasmussen, DD AF Simpson, T. L. Meredith, C. W. Gross, C. A. Raskind, M. A. Saxon, A. J. Rasmussen, D. D. TI Pilottrial of prazosin for treatment of alcohol dependence SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the Research-Society-on-Alcoholism CY JUL 07-11, 2007 CL Chicago, IL SP Res Soc Alcoholism C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2007 VL 31 IS 6 SU S BP 60A EP 60A PG 1 WC Substance Abuse SC Substance Abuse GA 174RD UT WOS:000246959600207 ER PT J AU Hawkins, EJ Kivlahan, DR Williams, EC Wright, SM Craig, T Bradley, KA AF Hawkins, E. J. Kivlahan, D. R. Williams, E. C. Wright, S. M. Craig, T. Bradley, K. A. TI Comparison of medical record and survey-based alcohol misuse screening results in VA outpatients SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the Research-Society-on-Alcoholism CY JUL 07-11, 2007 CL Chicago, IL SP Res Soc Alcoholism C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2007 VL 31 IS 6 SU S BP 244A EP 244A PG 1 WC Substance Abuse SC Substance Abuse GA 174RD UT WOS:000246959601326 ER PT J AU Donohue, TM Curry-McCoy, TV Todero, SL White, RL Kharbanda, KK Nanji, AA Osna, NA AF Donohue, Terrence M., Jr. Curry-McCoy, Tiana V. Todero, Sandra L. White, Ronda L. Kharbanda, Kusum K. Nanji, Amin A. Osna, Natalia A. TI L-buthionine (S, R) sulfoximine depletes hepatic glutathione but protects against ethanol-induced liver injury SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE ethanol; glutathione; oxidative stress; alcohol dehydrogenase; cytochrome P450 2E1 ID CYTOCHROME-P450 2E1; OXIDIZED PROTEINS; RAT-LIVER; IN-VIVO; CELLS; INTOXICATION; DEGRADATION; INHIBITION; METABOLISM; PROTEASOME AB Background: L-Buthionine (S,R) sulfoximine (BSO) is an inhibitor of glutathione biosynthesis and has been used as an effective means of depleting glutathione from cells and tissues. Here we investigated whether treatment with BSO enhanced ethanol-induced liver injury in mice. Methods: Female C57Bl/6 mice were pair fed with control and ethanol-containing liquid diets in which ethanol was 29.2% of total calories. During the final 7 days of pair feeding, groups of control-fed and ethanol-fed mice were given 0, 5 or 7.6 mM BSO in the liquid diets. Results: Compared with controls, ethanol given alone decreased total liver glutathione. This effect was exacerbated in mice given ethanol with 7.6 mM BSO, causing a 72% decline in hepatic glutathione. While ethanol alone caused no decrease in mitochondrial glutathione, inclusion of 7.6 mM BSO caused a 2-fold decline compared with untreated controls. L-Buthionine (S,R) sulfoximine did not affect ethanol consumption, but serum ethanol levels in BSO-treated mice were nearly 6-fold lower than in mice given ethanol alone. The latter decline in serum ethanol was associated with a significant elevation in the specific activities of cytochrome P450 2E1 and alcohol dehydrogenase in livers of BSO-treated animals. Ethanol consumption caused a 3.5-fold elevation in serum alanine aminotransferase levels but the enzyme fell to control levels when BSO was included in the diet. L-Buthionine (S,R) sulfoximine administration also attenuated ethanol-induced steatosis, prevented the leakage of lysosomal cathepsins into the cytosol, and prevented the ethanol-elicited decline in proteasome activity. Conclusions: L-Buthionine (S,R) sulfoximine, administered with ethanol, significantly depleted hepatic glutathione, compared with controls. However, despite the decrease in hepatic antioxidant levels, liver injury by ethanol was alleviated, due, in part, to a BSO-elicited acceleration of ethanol metabolism. C1 Univ Nebraska, Liver Study Unit, Omaha VA Med Ctr, Med Ctr,US Dept Vet Affairs, Omaha, NE 68105 USA. Univ Nebraska, Dept Internal Med, Med Ctr, Omaha, NE 68105 USA. Univ Nebraska, Dept Biochem & Mol Biol, Med Ctr, Omaha, NE 68105 USA. Univ Nebraska, Dept Pathol & Microbiol, Med Ctr, Omaha, NE 68105 USA. Univ Nebraska, Dept Environm Toxicol, Med Ctr, Omaha, NE 68105 USA. Dalhousie Univ, Dept Pathol & Lab Med, Sch Med, Halifax, NS, Canada. RP Donohue, TM (reprint author), Univ Nebraska, Liver Study Unit, Omaha VA Med Ctr, Med Ctr,US Dept Vet Affairs, 4101 Woolworth Ave, Omaha, NE 68105 USA. EM tdonohue@unmc.edu FU NIAAA NIH HHS [AA09384] NR 25 TC 17 Z9 17 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2007 VL 31 IS 6 BP 1053 EP 1060 DI 10.1111/j.1530-0277.2007.00393.x PG 8 WC Substance Abuse SC Substance Abuse GA 169EW UT WOS:000246576500017 PM 17428293 ER PT J AU Holmes, WC Cohen, A Foa, EB AF Holmes, W. C. Cohen, A. Foa, E. B. TI Men's own childhood physical abuse (CPA) histories as potential predictors of their adult abuse-perpetration. SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Meeting Abstract CT 40th Annual Meeting of the Society-for-Epidemiologic-Research CY JUN 19-22, 2007 CL Boston, MA SP Soc Epidemiolog Res C1 Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. RI Cohen, Abigail/K-9180-2013 OI Cohen, Abigail/0000-0002-7425-7218 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 1 PY 2007 VL 165 IS 11 SU S BP S149 EP S149 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 175SO UT WOS:000247034500596 ER PT J AU Inagami, S Cohen, DA Asch, SM AF Inagami, S. Cohen, D. A. Asch, S. M. TI Neighborhood fast food concentration, location of grocery stores and body mass index. SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Meeting Abstract CT 40th Annual Meeting of the Society-for-Epidemiologic-Research CY JUN 19-22, 2007 CL Boston, MA SP Soc Epidemiolog Res C1 Greater Los Angeles VA Hlth Syst, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 1 PY 2007 VL 165 IS 11 SU S BP S129 EP S129 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 175SO UT WOS:000247034500514 ER PT J AU Poel, A Haselkorn, J Leipertz, S AF Poel, A. Haselkorn, J. Leipertz, S. TI Pulmonary complications in veterans with multiple sclerosis, 2003-2004. SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Meeting Abstract CT 40th Annual Meeting of the Society-for-Epidemiologic-Research CY JUN 19-22, 2007 CL Boston, MA SP Soc Epidemiolog Res C1 Univ Washington, VA Puget Sound, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 1 PY 2007 VL 165 IS 11 SU S BP S35 EP S35 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 175SO UT WOS:000247034500139 ER PT J AU Marro, S Barisani, D Chiabrando, D Fagoonee, S Muckenthaler, M Stolte, J Meneveri, R Haile, D Silengo, L Altruda, F Tolosano, T AF Marro, S. Barisani, D. Chiabrando, D. Fagoonee, S. Muckenthaler, M. Stolte, J. Meneveri, R. Haile, D. Silengo, L. Altruda, F. Tolosano, T. TI Lack of haptoglobin affects iron transport across duodenum by modulating ferroportin expression SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Meeting Abstract C1 Univ Turin, Ctr Mol Biotechnol, Dept Genet Biol & Biochem, Turin, Italy. Univ Milano Bicocca, Dept Expt & Environm Med & Med Biotechnol, Monza, Italy. Univ Heidelberg, Dept Pediat Oncol Hematol & Immunol, Heidelberg, Germany. Genom Core Facil, EMBL, Heidelberg, Germany. Univ Texas, Audie L Murphy Mem Vet Hosp, Hlth Sci Ctr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0361-8609 J9 AM J HEMATOL JI Am. J. Hematol. PD JUN PY 2007 VL 82 IS 6 BP 550 EP 550 PG 1 WC Hematology SC Hematology GA 172ID UT WOS:000246796600170 ER PT J AU Zeber, JE Grazier, KL Valenstein, M Blow, FC Lantz, PM AF Zeber, John E. Grazier, Kyle L. Valenstein, Marcia Blow, Frederic C. Lantz, Paula M. TI Effect of a medication copayment increase in veterans with schizophrenia SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID HEALTH MAINTENANCE ORGANIZATION; PRESCRIPTION DRUG COSTS; ANTIPSYCHOTIC MEDICATION; CHRONICALLY ILL; ADHERENCE; CARE; IMPACT; BENEFITS; BENEFICIARIES; PHYSICIANS AB Objective: To assess the effect of the 2002 Veterans Millennium Health Care Act, which raised pharmacy copayments from $2 to $7 for lower-priority patients, on medication refill decisions and health services utilization among vulnerable veterans with schizophrenia. Study Design: Quasi-experimental. Methods:This study used secondary data contained in the National Psychosis Registry from June 1, 2000, through September 30, 2003, for all veterans diagnosed with schizophrenia and receiving healthcare through the Department of Veterans Affairs (VA). Longitudinal, mixed models were used to observe changes in prescriptions, health services utilization, and pharmacy costs in veterans subject to copayments (N = 40 654) and a control group of exempt individuals (N = 39 983). Analyses controlled for demographics, substance abuse, non-VA utilization, and medical comorbidities. The Health Belief Model supported analytical criteria for factors directly related to medication adherence issues. Results:Total prescriptions and overall pharmacy costs leveled among veterans with copayments after the medication cost increase. However, psychiatric drug refills dropped substantially, nearly 25%. Although outpatient visits were unaffected, psychiatric admissions and total inpatient days increased slightly, particularly 10 to 20 months after the policy change. Factoring in additional copayment revenue, the VA realized a $14.7-million annual net revenue gain from this subpopulation alone. Conclusion: These results suggest the new policy successfully reduced utilization and costs, with perhaps minimal clinical consequences to date. However, higher inpatient utilization resulting from cost-related nonadherence is troubling within an already high-risk and poorly adherent population, especially considering the reduction in psychiatric drug refills. C1 S Texas Vet Hlth Care Syst, VERDICT Ctr 11C6, Vet Affairs Hlth Serv Res & Dev, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. Univ Michigan, Sch Publ Hlth, Dept Hlth Policy & Management, Ann Arbor, MI 48109 USA. Vet Affairs Hlth Serv Res & Dev, Ann Arbor, MI USA. Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA. RP Zeber, JE (reprint author), S Texas Vet Hlth Care Syst, VERDICT Ctr 11C6, Vet Affairs Hlth Serv Res & Dev, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM zeber@uthscsa.edu NR 49 TC 44 Z9 44 U1 1 U2 4 PU AMER MED PUBLISHING, M W C COMPANY PI JAMESBURG PA 241 FORSGATE DR, STE 102, JAMESBURG, NJ 08831 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD JUN PY 2007 VL 13 IS 6 BP 335 EP 346 PN 2 PG 12 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 180VY UT WOS:000247395700003 PM 17567234 ER PT J AU Siegel, RE AF Siegel, Robert E. TI Pneumonia severity index (PSI) lacking in breadth of applicability SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter ID COMMUNITY-ACQUIRED PNEUMONIA; TRIAL C1 Mt Sinai Sch Med, Dept Pulm & Crit Care Med, James J Peters Vet Affairs Med Ctr, Div Pulm Med Crit Care & Sleep, Bronx, NY USA. RP Siegel, RE (reprint author), Mt Sinai Sch Med, Dept Pulm & Crit Care Med, James J Peters Vet Affairs Med Ctr, Div Pulm Med Crit Care & Sleep, Bronx, NY USA. NR 4 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD JUN PY 2007 VL 120 IS 6 BP E23 EP E23 DI 10.1016/j.amjmed.2007.01.031 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 170YA UT WOS:000246700900033 PM 17524737 ER PT J AU Yealy, DM Auble, TE Fine, MJ AF Yealy, Donald M. Auble, Thomas E. Fine, Michael J. TI Using the pneumonia severity index to guide hospitalization decisions SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter ID COMMUNITY-ACQUIRED PNEUMONIA; LOW-RISK PATIENTS; CONTROLLED-TRIAL C1 Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. RP Yealy, DM (reprint author), Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15260 USA. NR 10 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD JUN PY 2007 VL 120 IS 6 BP E21 EP E21 DI 10.1016/j.amjmed.2006.02.017 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 170YA UT WOS:000246700900032 PM 17524736 ER PT J AU Haas, L AF Haas, Linda TI Functional decline in older adults with diabetes - Self-care for older adults with disabilities related to aging, diabetes and its complications, or both. SO AMERICAN JOURNAL OF NURSING LA English DT Article ID VISUAL IMPAIRMENT; ELDERLY PEOPLE; INSULIN SENSITIVITY; GLYCEMIC CONTROL; EXERCISE; ASSOCIATION; POPULATION; PREVENTION; DYSFUNCTION; COMMUNITY C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. RP Haas, L (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. EM linda.haas@med.va.gov NR 32 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-936X J9 AM J NURS JI Am. J. Nurs. PD JUN PY 2007 VL 107 IS 6 SU S BP 50 EP 54 PG 5 WC Nursing SC Nursing GA 178IP UT WOS:000247214700011 PM 17563439 ER PT J AU da Cunha, IT Henson, H Protas, EJ AF da Cunha-Filho, Inacio Teixeira Henson, Helene Protas, Elizabeth J. TI Reliability of a portable gas analyzer during a 5-min walk test SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE oxygen consumption; gait; reliability; walking ID OXYGEN-UPTAKE; COSMED K2; ENERGY-EXPENDITURE; TELEMETRY SYSTEM; VALIDITY; EXERCISE; CONSUMPTION; TREADMILL; DEVICE; GAIT AB Objective: To determine the reliability of a gas analyzer while assessing oxygen consumption (VO2) during a 5-min walking test. Design: Forty healthy participants were connected to the KB 1 -C and walked for 5 mins on a 5-m walkway. TotalVO(2) or energy expenditure (EE) was obtained by averaging the samples for each minute for 5 mins of walking. Walk distance (D), gait speed (S), and gait energy cost (C) were also evaluated. Results: The ICC2,1 for EE, D, S, and C were 0.88, 0.92, 0.92, and 0.67, respectively. The coefficient of variation across trials for each variable was 7.4, 3.6, 3.2, and 9%, respectively. Conclusion: All but C generated high coefficients of reliability. All variables demonstrated acceptable test-retest variability. There was low variability between participants for C. C1 Ctr Univ Belo Horizonte, Belo Horizonte, MG, Brazil. Michael E Debakey Vet Affairs Med Ctr, Dept Phys Med & Rehabil, Houston, TX USA. Michael E Debakey Vet Affairs Med Ctr, Rehabil Res & Dev Ctr Excellence Healthy Aging Di, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Univ Texas, Med Branch, Dept Phys Therapy, Galveston, TX 77550 USA. RP da Cunha, IT (reprint author), Rua Ernani Agr 50-302, BR-30455760 Belo Horizonte, MG, Brazil. FU NIA NIH HHS [P30 AG024832] NR 25 TC 2 Z9 2 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD JUN PY 2007 VL 86 IS 6 BP 469 EP 473 DI 10.1097/PHM.0b013e31805b9505 PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 172UJ UT WOS:000246829600007 PM 17515686 ER PT J AU Cusi, K Kashyap, S Gastaldelli, A Bajaj, M Cersosimo, E AF Cusi, Kenneth Kashyap, Sangeeta Gastaldelli, Amalia Bajaj, Mandeep Cersosimo, Eugenio TI Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE insulin resistance; lipotoxicity; beta-cell; family history of T2DM ID BETA-CELL FUNCTION; NICOTINIC-ACID; GLUCOSE-TOLERANCE; HEALTHY-SUBJECTS; MOLECULAR-IDENTIFICATION; CONTROLLED-TRIAL; FUEL SELECTION; RESISTANCE; MELLITUS; PATHOGENESIS AB Elevated plasma FFA cause beta-cell lipotoxicity and impair insulin secretion in nondiabetic subjects predisposed to type 2 diabetes mellitus [ T2DM; i. e., with a strong family history of T2DM ( FH+)] but not in nondiabetic subjects without a family history of T2DM. To determine whether lowering plasma FFA with acipimox, an antilipolytic nicotinic acid derivative, may enhance insulin secretion, nine FH+ volunteers were admitted twice and received in random order either acipimox or placebo ( double- blind) for 48 h. Plasma glucose/ insulin/ C- peptide concentrations were measured from 0800 to 2400. On day 3, insulin secretion rates ( ISRs) were assessed during a + 125 mg/ dl hyperglycemic clamp. Acipimox reduced 48- h plasma FFA by 36% ( P < 0.001) and increased the plasma C- peptide relative to the plasma glucose concentration or Delta C- peptide/ Delta glucose AUC ( + 177%, P = 0.02), an index of improved beta-cell function. Acipimox improved insulin sensitivity ( M/I) 26.1 +/- 5% ( P < 0.04). First- (+ 19 +/- 6%, P = 0.1) and second- phase ( + 31 +/- 6%, P = 0.05) ISRs during the hyperglycemic clamp also improved. This was particularly evident when examined relative to the prevailing insulin resistance [ 1/( M/I)], as both first- and second- phase ISR markedly increased by 29 +/- 7 ( P < 0.05) and 41 +/- 8% ( P = 0.02). There was an inverse correlation between fasting FFA and first- phase ISR ( r(2) = 0.31, P < 0.02) and acute ( 2 - 4 min) glucose- induced insulin release after acipimox ( r(2) = 0.52, P < 0.04). In this proof-of-concept study in FH + individuals predisposed to T2DM, a 48-h reduction of plasma FFA improves day- long meal and glucose- stimulated insulin secretion. These results provide additional evidence for the important role that plasma FFA play regarding insulin secretion in FH+ subjects predisposed to T2DM. C1 Univ Texas, Hlth Sci Ctr, Diabet Div, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Audie L Murphy Vet Adm Med Ctr, San Antonio, TX 78284 USA. RP Cusi, K (reprint author), Univ Texas, Hlth Sci Ctr, Diabet Div, Dept Med, 7703 Floyd Curl Dr,Rm 3-380S, San Antonio, TX 78284 USA. EM cusi@uthscsa.edu RI Bajaj, Mandeep/B-6060-2009; Gastaldelli, Amalia/H-3319-2014 OI Gastaldelli, Amalia/0000-0003-2594-1651 FU NCRR NIH HHS [M01-RR-01346, KL2 RR024990] NR 54 TC 52 Z9 54 U1 2 U2 11 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD JUN PY 2007 VL 292 IS 6 BP E1775 EP E1781 DI 10.1152/ajpendo.00624.2006 PG 7 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 188SH UT WOS:000247939100031 PM 17299078 ER PT J AU Sanchez-Hidalgo, M Lu, Z Tan, DA Maldonado, MD Reiter, RJ Gregerman, RI AF Sanchez-Hidalgo, M. Lu, Z. Tan, D. A. Maldonado, M. D. Reiter, R. J. Gregerman, R. I. TI Melatonin inhibits fatty acid-induced triglyceride accumulation in ROS17/2.8 cells: implications for osteoblast differentiation and osteoporosis SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE fatty acids; oleic acid; osteogenesis; luzindole; S20928 ID MESENCHYMAL STEM-CELLS; RAT VISCERAL FAT; ADIPOSE-TISSUE; BONE-MARROW; BODY-WEIGHT; LIPOPROTEIN-LIPASE; SYRIAN-HAMSTERS; PLASMA LEPTIN; MIDDLE-AGE; RECEPTORS AB Melatonin is produced not only by the pineal gland but by cells of the bone marrow. Moreover, melatonin is known to promote osteogenic differentiation in several cell line models and in multipotential bone marrow mesenchymal stem cells. Fatty acids have been independently shown to direct such cells to acquire the phenotype and molecular characteristics of adipocytes. To examine the effect of melatonin on intracellular triglyceride accumulation, an indicator of adipogenic differentiation in the rat osteoblastlike ROS17/2.8 cell line, cells were incubated with added oleic acid (100 mu M), fixed and stained with Oil Red O. Cellular lipid accumulation was quantitated by an Oil Red O method highly specific for triglycerides and expressed as a triglyceride accumulation index (TGAI, triglyceride per cell). Melatonin in nanomolar concentrations inhibited oleic acid-induced triglyceride accumulation. To identify the mechanism by which melatonin reduces triglyceride accumulation, cells were incubated with the two melatonin receptor antagonists, luzindole and S20928, or forskolin, a stimulator of adenylyl cyclase and cAMP production. These compounds prevented the inhibitory effect of melatonin on triglyceride accumulation, indicating that melatonin acts through known melatonin receptor-mediated mechanisms. In view of the previously demonstrated positive effects of melatonin in promoting osteoblastic differentiation in ROS17/2.8 cells and their reciprocal adipocytic differentiation induced by fatty acids, our observations may serve to relate the known age-related decreases of melatonin production, the shift in the bone marrow toward an adipocytic line of cell development, and the development of osteoporosis during aging. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Geriat & Gerontol,Dept Med, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Audie L Murphy Div, S Texas Vet Hlth Care Syst,Geriatr Res Educ & Cli, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX USA. RP Gregerman, RI (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Geriat & Gerontol,Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM reiter@uthscsa.edu; gregerman@uthscsa.edu RI Maldonado, MD/A-3847-2008; tan, dun-xian/E-3610-2010; Sanchez-Hidalgo, Marina/E-9231-2010 OI Maldonado, MD/0000-0003-1375-447X; Sanchez Hidalgo, Marina/0000-0002-9210-2404 NR 45 TC 37 Z9 39 U1 0 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD JUN PY 2007 VL 292 IS 6 BP R2208 EP R2215 DI 10.1152/ajpregu.00013.2007 PG 8 WC Physiology SC Physiology GA 185QK UT WOS:000247725300015 PM 17379847 ER PT J AU Strawn, JR Keck, PE Caroff, SN AF Strawn, Jeffrey R. Keck, Paul E. Caroff, Stanley N. TI Neuroleptic malignant syndrome SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Editorial Material ID SERUM IRON; CATATONIA; HYPERACTIVITY; PROGRESSION; DRUGS C1 Univ Cincinnati, Dept Psychiat, Coll Med, Cincinnati, OH 45267 USA. Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Strawn, JR (reprint author), Univ Cincinnati, Dept Psychiat, Coll Med, Box 670559, Cincinnati, OH 45267 USA. EM strawnjr@uc.edu NR 33 TC 150 Z9 163 U1 2 U2 12 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD JUN PY 2007 VL 164 IS 6 BP 870 EP 876 DI 10.1176/appi.ajp.164.6.870 PG 7 WC Psychiatry SC Psychiatry GA 176ZE UT WOS:000247122600009 PM 17541044 ER PT J AU Fujitani, S Liu, CX Finegold, SM Song, YL Mathisen, GE AF Fujitani, Shigeki Liu, Chengxu X. Finegold, Sydney M. Song, Yuli L. Mathisen, Glenn E. TI Clostridium tertium isolated from gas gangrene wound; misidentified as Lactobacillus spp initially due to aerotolerant feature SO ANAEROBE LA English DT Article DE myonecrosis; aerotolerance; Clostridium tertium; gas gangrene; Lactobacillus ID BACTEREMIA AB Clostridium tertium has been increasingly reported as a human pathogen. This organism is an aerotolerant Gram-positive rod that is often mistaken for other organisms, such as Lactobacillus or Bacillus species. We describe a case of a patient with a history of intravenous drug use presenting to UCLA-Olive View Medical Center with gas gangrene of both upper extremities. The organism was initially misidentified as a Lactobacillus species on aerobic culture plates. However, terminal spore formation was detected in this isolate on a sub-cultured anaerobic culture plate and this isolate was confirmed as C tertium biochemically and genetically by 16S rDNA sequencing. Additional DNA cloning libraries made from the formalin-fixed specimen revealed Peptoniphilus species and an uncultured Clostridium clone, but not C tertium. C tertium might be a causative organism of gas-producing myonecrosis but such an association has never been described. Clinicians should be aware of the phenomenon of aerotolerance of some anaerobes and need to clarify the identification of organisms if the clinical picture does not fit the isolated organism. (c) 2007 Elsevier Ltd. All rights reserved. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Olive View UCLA Med Ctr, Infect Dis Serv, Sylmar, CA 91342 USA. RP Fujitani, S (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM shigekifujitani@hotmail.com; chengxu66@yahoo.com; sidfinegol@aol.com; yulisl@yahoo.com; gmatliisen@ladhs.org NR 10 TC 3 Z9 4 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1075-9964 J9 ANAEROBE JI Anaerobe PD JUN-AUG PY 2007 VL 13 IS 3-4 BP 161 EP 165 DI 10.1016/j.anaerobe.2007.03.002 PG 5 WC Microbiology SC Microbiology GA 209DG UT WOS:000249368600010 PM 17446094 ER PT J AU Gandhi, SD Weiskopf, RB Jungheinrich, C Koorn, R Miller, D Shangraw, RE Prough, DS Baus, D Bepperling, F Warltier, DC AF Gandhi, Sweeta D. Weiskopf, Richard B. Jungheinrich, Cornelius Koorn, Robert Miller, Diane Shangraw, Robert E. Prough, Donald S. Baus, Daniela Bepperling, Frank Warltier, David C. TI Volume replacement therapy during major orthopedic surgery using Voluven (R) (hydroxyethyl starch 130/0.4) or hetastarch SO ANESTHESIOLOGY LA English DT Article ID HYDROXYETHYL STARCH HES; INCREASE BLOOD-LOSS; PLASMA-VOLUME; TRANSFUSION REQUIREMENTS; CARDIAC-SURGERY; DOSE INFUSION; COAGULATION; SUBSTITUTION; VOLUNTEERS; 6-PERCENT AB Background: The purpose of this study was to test the equivalence of efficacy and compare the safety of the 6% hydroxyethyl starches (HES) Voluven (R) (HES 130/0.4; Fresenius Kabi, Bad Homburg, Germany) and hetastarch (HES 670/0.75 in saline) for intravascular volume replacement therapy during major orthopedic surgery. Methods: In a prospective, controlled, randomized, double-blind, multicenter trial of patients undergoing major orthopedic surgery, 49 patients were treated with HES 130/0.4 and 51 patients were treated with hetastarch. infusion of colloids was guided by central venous and arterial blood pressures. The primary efficacy endpoint was the volume of colloid solution infused; the primary safety endpoints were calculated total erythrocyte loss, the nadir factor VIII activity, and the nadir von Willebrand factor concentration within 2 h of completion of surgery. Results: The total volume of colloid solution required for intraoperative volume replacement did not differ between HES 130/0.4 and hetastarch (1,613 +/- 778 [SD] ml for HES 130/0.4 and 1,584 +/- 958 ml for hetastarch). The nadir factor VIII activity within 2 h of the end of surgery was lower for hetastarch than for HES 130/0.4 (P = 0.0499); for those who received greater than 1,000 ml colloid, the nadir factor VIII activity and von Willebrand factor concentration within 2 h of end of surgery were lower for hetastarch than for HES 130/0.4 (P = 0.0487 and P = 0.008, respectively). Conclusion: Voluven (R) (HES 130/0.4) and hetastarch are equally efficacious plasma volume substitutes; however, HES 130/0.4 has a lesser effect on coagulation. C1 Med Coll Wisconsin, Milwaukee, WI 53226 USA. Clermont J Zablocki Vet Affairs Med Ctr, Dept Anesthesiol, Milwaukee, WI USA. Clermont J Zablocki Vet Affairs Med Ctr, Dept Anesthesiol Pharmacol & Toxicol, Div Cardiovasc Dis, Milwaukee, WI USA. Clermont J Zablocki Vet Affairs Med Ctr, Dept Anesthesiol Pharmacol & Toxicol, Div Cardiovasc Dis, Milwaukee, WI USA. Clermont J Zablocki Vet Affairs Med Ctr, Dept Med, Div Cardiovasc Dis, Milwaukee, WI USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Fresenius Kabi, Bad Homburg, Germany. Anesthesia Assoc So Connecticut, Norwalk, CT USA. Portland VA Med Ctr, Dept Anesthesiol, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR USA. Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX USA. RP Gandhi, SD (reprint author), Med Coll Wisconsin, MEB M4280,8701 Watertown Plank RD, Milwaukee, WI 53226 USA. EM sdgandhi@mcw.edu RI Prough, Donald/G-5793-2013 OI Prough, Donald/0000-0001-7994-532X NR 33 TC 56 Z9 68 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-3022 J9 ANESTHESIOLOGY JI Anesthesiology PD JUN PY 2007 VL 106 IS 6 BP 1120 EP 1127 DI 10.1097/01.anes.0000265422.07864.37 PG 8 WC Anesthesiology SC Anesthesiology GA 172IM UT WOS:000246797500010 PM 17525586 ER PT J AU Bussey-Smith, KL Rossen, RD AF Bussey-Smith, Kristin L. Rossen, Roger D. TI A systematic review of randomized control trials evaluating the effectiveness of interactive computerized asthma patient education programs SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Review ID INNER-CITY CHILDREN; SELF-MANAGEMENT; INTERVENTION; INSTRUCTION; OUTCOMES; ADULTS AB Background: Educating patients with asthma about the pathophysiology and treatment of their disease is recommended. In recent years, several computer programs have been developed to provide this education. These programs take advantage of the population's increasing skill with computers and the growth of the Internet as a source of health care information. Objective: To evaluate the effectiveness of published interactive computerized asthma patient education programs (CAPEPs) that have been subjected to randomized controlled trials (RCTs). Data Sources: The PubMed, ERIC, CINAHL, Psychinfo, and Clinicaltrials.gov databases were searched (through October 3, 2005) using the following terms: asthma, patient, education, interactive, and computer. Study Selection: RCTs in English that evaluated the effect of an interactive CAPEP on the following primary end points were included in the study: hospitalizations, acute care visits, rescue inhaler use, or lung function. Secondary end points included asthma knowledge and symptoms. Trials were screened by title and abstract before full text review. Two independent investigators used a standardized data extraction form to identify the articles chosen for full review. Results: Nine of 406 citations met inclusion criteria. Four CAPEPs were computer games, 7 only studied children, and 4 focused on urban populations. One study each showed that the intervention reduced the number of hospitalizations, acute care visits, or rescue inhaler use. Two studies reported lung function improvements. Four studies showed improvement in asthma knowledge, and 5 studies reported improvements in symptoms. Conclusions: Although interactive CAPEPs may improve patient asthma knowledge and symptoms, their effect on objective clinical outcomes is less consistent. C1 Baylor Coll Med, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Bussey-Smith, KL (reprint author), 1 Baylor Plaza,BCM 285,Suite 672E, Houston, TX 77030 USA. EM kristinb@bcm.edu NR 25 TC 40 Z9 40 U1 0 U2 6 PU AMER COLL ALLERGY ASTHMA IMMUNOLOGY PI ARLINGTON HTS PA 85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA SN 1081-1206 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD JUN PY 2007 VL 98 IS 6 BP 507 EP 516 PG 10 WC Allergy; Immunology SC Allergy; Immunology GA 178BK UT WOS:000247196000003 PM 17601262 ER PT J AU Lovasi, GS Lemaitre, RN Siscovick, DS Dublin, S Bis, JC Lumley, T Heckbert, SR Smith, NL Psaty, BM AF Lovasi, Gina S. Lemaitre, Rozenn N. Siscovick, David S. Dublin, Sascha Bis, Joshua C. Lumley, Thomas Heckbert, Susan R. Smith, Nicholas L. Psaty, Bruce M. TI Amount of leisure-time physical activity and risk of nonfatal myocardial infarction SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE case-control studies; epidemiology; exercise; leisure activities; myocardial infarction ID CARDIOVASCULAR-DISEASE; DOSE-RESPONSE; OLDER-ADULTS; EXERCISE; WOMEN; MORTALITY; HEALTH; INFLAMMATION; PREVENTION; INTENSITY AB Purpose: To investigate the shape of the relation between amount of leisure-time physical activity (LTPA) and myocardial infarction (MI) risk. Methods: Data were from a case-control study in a Washington State health maintenance organization, 1986 to 2002. Participants had no prior cardiovascular disease and good self-reported health before selection. Telephone interviews asked 697 nonfatal MI cases and 3,397 control subjects about 26 types of LTPA. Models adjusted for age, sex, year, treated hypertension, family history of heart disease, smoking, alcohol, aspirin, race, retirement, income, and education. Results: Some LTPA was reported by 90% of control subjects and 84% of cases. Compared with no LTPA, participation in LTPA was associated with lower risk of MI (adjusted odds ratio [OR] = 0.67, 95% confidence interval [CI]: 0.52, 0.86). Among active participants, LTPA time was associated with risk of MI (OR = 0.66 for high versus low quartile, 95% CI: 0.51, 0.86). Risk of MI decreased with increasing total or nonstrenuous LTPA time up to the median, beyond which we could not detect an association between LTPA time and MI risk. Conclusions: Time engaged in LTPA, even nonstrenuous LTPA, was associated with lower risk of MI, and the shape of this relationship was nonlinear. C1 Columbia Univ, Inst Social & Econ Res & Policy, New York, NY 10027 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Lovasi, GS (reprint author), Columbia Univ, Inst Social & Econ Res & Policy, 820 Int Affairs Bldg,Mail Code 3355,420 W 118th S, New York, NY 10027 USA. EM gl2225@columbia.edu RI Lovasi, Gina/C-2781-2009 OI Lovasi, Gina/0000-0003-2613-9599 FU NHLBI NIH HHS [R01-HL043201, R01-HL068639, T32 HL007902, T32-HL07902]; NIA NIH HHS [R01-AG09556] NR 31 TC 12 Z9 13 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD JUN PY 2007 VL 17 IS 6 BP 410 EP 416 DI 10.1016/j.annepidem.2006.10.012 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 178YU UT WOS:000247257100002 PM 17321755 ER PT J AU Slater, MS Komanapalli, CB Tripathy, U Ravichandran, PS Ungerleider, RM AF Slater, Matthew S. Komanapalli, Christopher B. Tripathy, Uttam Ravichandran, Pasala S. Ungerleider, Ross M. TI Treatment of endocarditis: a decade of experience SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT 53rd Annual Meeting of the Southern-Thoracic-Surgical-Association CY NOV 08-11, 2006 CL Tucson, AZ SP SE Thorac Surg Assoc ID PROSTHETIC VALVE ENDOCARDITIS; INFECTIVE ENDOCARDITIS; SURGICAL-MANAGEMENT; CLINICAL-FEATURES; EARLY PREDICTORS; MORTALITY; DIAGNOSIS; SURGERY; DEATH AB Background. Endocarditis represents a small proportion of cardiovascular disease but is associated with high mortality. Previous studies have reported a range of outcomes, and determinants of mortality remain poorly defined. Methods. The goal of this retrospective study was to identify independent variables for early and late mortality in 364 consecutive patients with endocarditis over a 10-year period. Results. The mean age of patients was 48.2 years, 35% had a history intravenous drug use, 19.8% were reoperative, and 93% had native valve endocarditis. Fever (68%) and fatigue (36%) were the most common presenting symptoms, and congestive heart failure (52%), embolization (45%), and uncontrolled sepsis (36%) were the most common indications for surgery. Overall survival at discharge, 1, 5, and 10 years was 87%, 76%, 55%, and 31%, respectively. Survival at discharge, 5, and 10 years was 91%, 69%, and 41% for surgical patients and 85%, 60%, and 31% for medically treated patients, respectively. Surgery was associated with improved short-term and long-term survival ( p < 0.0.01). Independent predictors of early death were hemodynamic instability ( p = 0.013) and age older than 55 years ( p < 0.025). Medical treatment ( p = 0.005), age older than 55 years ( p = 0.032), institution ( p < 0.001), New York Heart Association functional class III or IV ( p = 0.002), and hemodynamic instability ( p = 0.044) were predictive of late death. Conclusions. Short-term and long-term mortality from endocarditis remains high, although surgically treated patients had improved survival. Differing outcomes from two geographically similar institutions highlight the limitations of extrapolating risk factors between disparate patient populations. C1 Oregon Hlth & Sci Univ, Div Cardiothorac Surg, Dept Surg, Portland, OR 97239 USA. Portland VA Med Ctr, Dept Surg, Div Cardiothorac Surg, Portland, OR USA. RP Slater, MS (reprint author), Oregon Hlth & Sci Univ, Div Cardiothorac Surg, Dept Surg, 3181 SW Sam Jackson Pk Rd L353, Portland, OR 97239 USA. EM slaterm@ohsu.edu NR 15 TC 8 Z9 9 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD JUN PY 2007 VL 83 IS 6 BP 2074 EP 2080 DI 10.1016/j.athoracsur.2007.01.051 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 172GD UT WOS:000246791200023 PM 17532400 ER PT J AU Ikonomidis, JS Hilton, EJ Payne, K Harrell, A Finklea, L Clark, L Reeves, S Stroud, RE Leonardi, A Crawford, FA Spinale, FG AF Ikonomidis, John S. Hilton, Ebony J. Payne, Kimberly Harrell, April Finklea, Laura Clark, Leslie Reeves, Scott Stroud, Robert E. Leonardi, Amy Crawford, Fred A., Jr. Spinale, Francis G. TI Selective endothelin-A receptor inhibition after cardiac surgery: A safety and feasibility study SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT 53rd Annual Meeting of the Southern-Thoracic-Surgical-Association CY NOV 08-11, 2006 CL Tucson, AZ SP SE Thorac Surg Assoc ID CONGESTIVE-HEART-FAILURE; CARDIOPULMONARY BYPASS; POSTOPERATIVE RECOVERY; ANTAGONIST; BLOCKADE; REPERFUSION; PROGRESSION; TEZOSENTAN; ISCHEMIA; MYOCYTES AB Background. Increased synthesis and release of the bioactive peptide endothelin has been shown to change hemodynamics and postoperative recovery after cardiac surgery. However, the clinical effects of selective interruption of endothelin signaling have not been studied. Because the endothelin-A (ET-A) receptor subtype is the primary cardiovascular effector for endothelin, this study used the ET-A receptor antagonist sitaxsentan sodium (TBC11251Na) to evaluate: (1) dose-dependent changes in pulmonary artery pressure (PAP) and pulmonary (PVRI) and systemic (SVRI) vascular resistance index in patients undergoing on-pump coronary revascularization; and (2) whether ET-RA administration was associated with increased adverse events. Methods. Patients (n = 44, age, 62 +/- 1 years) were randomized to receive vehicle (n = 9) or different bolus infusions of ET-A receptor antagonist: 0.1 (n = 9), 0.5 (n = 9) 1.0 (n = 9), and 2.0 mg/kg (n = 8) at separation from cardiopulmonary bypass (CPB). Adverse events were tabulated until hospital discharge. Results were expressed as changes from a composite baseline value, or from time 0 due to a high degree of intrapatient measurement variability in the postoperative period. Results. PAP increased by 27% +/- 13% from baseline (19 +/- 1 mm Hg) in the vehicle group at 6 hours post-CPB (p < 0.05). PAP fell from this post-CPB vehicle value in a dose-dependent manner with the ET-A receptor antagonist; with a significant reduction observed at 2 mg/kg (7% +/- 8% increase from baseline, p < 0.05). PVRI was reduced by 28.6% +/- 16% from baseline (249 +/- 22 dyn.s.cm(-5).m(-2)) in the 2 mg/kg ET-A receptor antagonist group at 30 minutes post-CPB and remained reduced up to 6 hours post-CPB (p < 0.05). SVRI was reduced from baseline (2770 +/- 106 dyn.s.cm(-5).m(-2)) by 51% +/- 6% in the 2.0 mg/kg ET-A receptor antagonist group at 30 minutes post-CPB (p < 0.05) and remained reduced up to 6 hours post-CPB. A total of 203 adverse events were tabulated in the postoperative period and were equally distributed across the five treatment groups, with no direct attributions to ET-A receptor antagonist treatment. Conclusions. This unique study demonstrates that heightened endothelin-A receptor activation contributes to hemodynamic changes in patients after CPB. Selective inhibition of the endothelin receptor system can be successfully and safely performed in patients undergoing cardiac surgery and thereby reveals a potential, and clinically relevant therapeutic target. C1 Med Univ S Carolina, Div Cardiothorac Surg, Cardiothorac Surg Lab, Charleston, SC 29425 USA. Ralph J Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Ikonomidis, JS (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Cardiothorac Surg Lab, Suite 409CSB,96 Jonathan Lucas St, Charleston, SC 29425 USA. EM ikonomij@musc.edu FU NHLBI NIH HHS [HL057952, HL056603] NR 26 TC 13 Z9 15 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD JUN PY 2007 VL 83 IS 6 BP 2153 EP 2161 DI 10.1016/j.athoracsur.2007.02.087 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 172GD UT WOS:000246791200036 PM 17532415 ER PT J AU McNeil, MR Sung, JE Yang, D Pratt, SR Fossett, TRD Doyle, PJ Pavelko, S AF McNeil, Malcolm R. Sung, Jee Eun Yang, Dorothy Pratt, Sheila R. Fossett, Tepanta R. D. Doyle, Patrick J. Pavelko, Stacey TI Comparing connected language elicitation procedures in persons with aphasia: Concurrent validation of the Story Retell Procedure SO APHASIOLOGY LA English DT Article; Proceedings Paper CT 36th Clinical Aphasiology Conference CY 2006 CL Ghent, BELGIUM ID LEXICAL DIVERSITY; RELIABILITY; ADULTS AB Background: The Story Retell Procedure (SRP) (Doyle et al., 1998) is a well-described method for eliciting connected language samples in persons with aphasia (PWA). However, the stimuli and task demands of the SRP are fundamentally different from commonly employed picture description, narrative, and procedural description tasks reported in the aphasia literature. As such, the extent to which measures of linguistic performance derived from the SRP may be associated with those obtained from picture description, narrative, and procedural description tasks is unknown. Aims: To assess the concurrent validity of linguistic performance measures obtained from the SRP with those obtained from picture description, narrative, and procedural description tasks by examining the correlations and the magnitude differences across the linguistic variables among the elicitation tasks. Secondarily, we examined the relationship of the percentage of information units per minute (%IU/Min) to other linguistic variables within the SRP and across the other elicitation tasks. Methods and Procedures: This study compared the SRP to six different, frequently used sampling procedures (three sets of picture descriptions, one fairytale generation, one set of narratives, and one set of procedural description tasks) from which the same five verbal productivity, four information content, two grammatical, and two verbal disruption measures were computed. Language samples were elicited from 20 PWA, spanning the aphasia comprehension severity range. Tests of association and difference were calculated for each measure between the SRP and the other sampling methods. Outcomes & Results: Significant and strong associations were obtained between the SRP and the other elicitation tasks for most linguistic measures. The SRP produced either no significant or significantly greater instances of the dependent variable except for the type-token ratio, which yielded a significantly lower value than the other sampling procedures. Conclusions: The findings are interpreted as support for the concurrent validity of the SRP and as evidence that a single form of the SRP will yield a language sample that is generally equivalent in distribution to other sampling procedures, and one that is generally greater in quantity to those typically used to assess connected spoken language in PWA. Additionally, it was found that the %IU/Min metric predicted highly the information content linguistic measures on the SRP as well as on the other elicitation procedures. However, it did not predict well measures of verbal productivity, grammaticality, or verbal disruptions. C1 Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP McNeil, MR (reprint author), Univ Pittsburgh, Dept Commun Sci & Disorders, 4033 Forbes Tower, Pittsburgh, PA 15260 USA. EM mcneil@pitt.edu RI Pratt, Sheila/H-7139-2013 NR 19 TC 13 Z9 13 U1 1 U2 8 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0268-7038 J9 APHASIOLOGY JI Aphasiology PD JUN-AUG PY 2007 VL 21 IS 6-8 BP 775 EP 790 DI 10.1080/02687030701189980 PG 16 WC Clinical Neurology SC Neurosciences & Neurology GA 179XN UT WOS:000247323900020 ER PT J AU Chamlin, SL Lai, JS Cella, D Frieden, IJ Williams, ML Mancini, AJ Chren, MM AF Chamlin, Sarah L. Lai, Jin-Shei Cella, David Frieden, Ilona J. Williams, Mary L. Mancini, Anthony J. Chren, Mary-Margaret TI Childhood Atopic Dermatitis Impact Scale - Reliability, discriminative and concurrent validity, and responsiveness SO ARCHIVES OF DERMATOLOGY LA English DT Article ID QUALITY-OF-LIFE; EUROPEAN TASK-FORCE; INITIAL VALIDATION; SLEEP DISTURBANCE; CONSENSUS REPORT; SCORAD INDEX; CHILDREN; ECZEMA; FAMILIES AB Objective: To evaluate the test-retest reliability, discriminative and concurrent validity, and responsiveness of the Childhood Atopic Dermatitis Impact Scale (CADIS), a quality-of-life scale with 5 domains. Design: Prospective, longitudinal study. Setting: Two academic pediatric dermatology practices. Patients: A total of 301 parents of children younger than 6 years with atopic dermatitis. Main Outcome Measures: Participants completed the CADIS, sociodemographic items, and other clinical questions at enrollment and at a 4-week follow-up. In addition, 41 participants completed the CADIS again 48 hours after baseline. Disease severity was measured using the Severity Scoring of Atopic Dermatitis (SCORAD) index for all children. Results: Of 301 enrolled participants, 270 (90%) completed the enrollment materials and 228 (84%) of these completed the 4-week follow-up materials. Thirty-four (83%) of the 41 participants completed the 48-hour materials. Intraclass correlation coefficients of CADIS scores at enrollment and at 48 hours ranged from 0.89 to 0.95. Correlations between CADIS scores and the SCORAD index scores (range, 0.42-0.72) demonstrated that more severe atopic dermatitis is associated with worse quality of life. Scores from all 5 domains of the CADIS significantly differentiated patients at each severity level as measured by the SCORAD index (P <.001). Participants who rated their children as "improved" at the 4-week follow-up had significantly better CADIS scores than those who rated their children as having the "same" or "worse" skin disease (P <.05). Conclusions: These data confirm the test-retest reliability, concurrent validity, and discriminative validity of the CADIS. In addition, responsiveness evaluation demonstrates that the CADIS accurately measures change in patients whose disease improves. C1 Childrens Mem Hosp, Div Pediat Dermatol, Chicago, IL 60614 USA. Evanston NW Healthcare, Ctr Outcomes Res & Educ, Evanston, IL USA. NW Feinberg Sch Med, Evanston, IL USA. Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Serv Dermatol, San Francisco, CA USA. RP Chamlin, SL (reprint author), 2300 Childrens Plaza,Box 107, Chicago, IL 60614 USA. EM schamlin@childrensmemorial.org OI Frieden, Ilona/0000-0001-7305-5940 NR 17 TC 22 Z9 23 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD JUN PY 2007 VL 143 IS 6 BP 768 EP 772 DI 10.1001/archderm.143.6.768 PG 5 WC Dermatology SC Dermatology GA 178FU UT WOS:000247207400013 PM 17576944 ER PT J AU Mendez, MF Shapira, JS McMurtray, A Licht, E Miller, BL AF Mendez, Mario F. Shapira, Jill S. McMurtray, Aaron Licht, Eliot Miller, Bruce L. TI Accuracy of the clinical evaluation for frontotemporal dementia SO ARCHIVES OF NEUROLOGY LA English DT Article ID FRONTAL-LOBE DEMENTIA; ALZHEIMERS-DISEASE; PICKS-DISEASE; WORK GROUP; DEGENERATION; DIAGNOSIS; FEATURES; CRITERIA; PREVALENCE; CONSENSUS AB Background: Without a definitive clinical test, the early diagnosis of frontotemporal dementia ( FTD) can be difficult. Objective: To evaluate the accuracy of the clinical evaluation for FTD. Design: Retrospective assessment of consensus criteria for FTD, neuropsychological measures, magnetic resonance images, and single- photon emission computed tomography/ positron emission tomography ( SPECT/ PET) scans at baseline compared with a standard of subsequent clinical diagnosis after follow- up and reevaluation to year 2. Setting: University hospital. Patients: A total of 134 patients referred for clinical evaluation of suspected FTD. These patients had 1 or more core or supportive features of FTD in the absence of another etiology on initial assessment. Main Outcome Measures: Sensitivities, specificities, and predictive values of consensus criteria for FTD, magnetic resonance images, and SPECT/ PET scans at initial assessment. Results: The sensitivities and specificities for the diagnosis of FTD were 36.5% and 100.0% for consensus criteria, 63.5% and 70.4% formagneticresonanceimages, and 90.5% and 74.6% for SPECT/ PET scans, respectively. With a previous prevalence of nearly 50% for FTD, the positive predictive value was greatest for consensus criteria ( 100.0%), and the negative predictive value was greatest for SPECT/ PET ( 89.8%). The initial neuropsychological results did not distinguish FTD, but the pattern of progression ( worse naming and executive functions and preserved constructional ability) helped establish the diagnosis at year 2. Conclusions: Consensus criteria for FTD and neuropsychological measures lacked sensitivity for FTD; however, neuroimaging, particularly functional brain studies, greatly increased the sensitivity of detecting FTD. The clinical diagnosis of FTD needs to combine neuropsychiatric features with SPECT or PET findings while following the changes on neuropsychological tests. C1 VA Greater Los Angeles Healthcare, Neurobev Unit 116AF, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. Univ Hawaii, Dept Neurol, Honolulu, HI 96822 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare, Neurobev Unit 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu FU NIA NIH HHS [AG19724-01, P01 AG019724] NR 36 TC 91 Z9 99 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD JUN PY 2007 VL 64 IS 6 BP 830 EP 835 DI 10.1001/archneur.64.6.830 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 177HF UT WOS:000247143500007 PM 17562930 ER PT J AU Dicianno, BE Tovey, E AF Dicianno, Brad E. Tovey, Elyn TI Power mobility device provision: Understanding medicare guidelines and advocating for clients SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE insurance; medicare; public policy; rehabilitation; wheelchairs AB The Centers for Medicare and Medicaid (CMS) issued a new national coverage determination (NCD) for mobility assistive equipment (MAE) including wheelchairs in May 2005. CMS then issued a Final Rule in April 2006 that outlined significant changes required for documentation for prescribing MAE. Other insurance providers have since adopted and sometimes modified the NCD criteria and have begun to apply these criteria according to their own interpretations because some of the criteria are vague. In this report, we introduce a case example to show the components of the CMS NCD criteria, what was intended but poorly described in the language, how insurance providers may misinterpret or alter the criteria, and how clinicians can act as advocates. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Lab, Ctr Excellence Wheelchairs & Asocciated Rehabil E, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Med Phys, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Rehabil Inst Rehabil & Res, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Ctr Assist Technol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Med Ctr, Dept Phys Therapy, Pittsburgh, PA 15260 USA. RP Dicianno, BE (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Lab, Ctr Excellence Wheelchairs & Asocciated Rehabil E, 7180 Highland Dr,Bldg 4,2nd Fl E,151R1-H, Pittsburgh, PA 15206 USA. EM diciannob@herlpitt.org OI Dicianno, Brad/0000-0003-0738-0192 NR 26 TC 9 Z9 9 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUN PY 2007 VL 88 IS 6 BP 807 EP 816 DI 10.1016/j.apmr.2007.03.024 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 177AK UT WOS:000247125800021 PM 17532908 ER PT J AU Qiao, M Kisgati, M Cholewa, JM Zhu, WF Smart, EJ Sulistio, MS Asmis, R AF Qiao, Mu Kisgati, Marta Cholewa, Jill M. Zhu, Weifei Smart, Eric J. Sulistio, Melanie S. Asmis, Reto TI Increased expression of glutathione reductase in macrophages decreases atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Article DE atherosclerosis; glutathione; macrophage; oxidized low-density lipoprotein; oxidative stress ID OXIDATIVE MODIFICATION HYPOTHESIS; INDUCED CELL INJURY; ATHEROGENESIS; CDNA; GENE; GLUTAREDOXIN; DYSFUNCTION; MECHANISMS; APOPTOSIS; SEQUENCE AB Objective-Thiol oxidative stress leads to macrophage dysfunction and cell injury, and has been implicated in the development of atherosclerotic lesions. We investigated if strengthening the glutathione-dependent antioxidant system in macrophages by overexpressing glutathione reductase (GR) decreases the severity of atherosclerosis. Methods and Results-Bone marrow cells infected with retroviral vectors expressing either enhanced green fluorescent protein (EGFP) or an EGFP-fusion protein of cytosolic GR (GR(cyto)-EGFP) or mitochondrial GR (GR(mito)-EGFP) were transplanted into low-density lipoprotein receptor-deficient mice. Five weeks after bone marrow transplantation, animals were challenged with a Western diet for 10 weeks. No differences in either plasma cholesterol and triglyceride levels or peritoneal macrophage content were observed. However, mice reconstituted with either GR(cyto)-EGFP or GR(mito)-EGFP-expressing bone marrow had lesion areas (P<0.009) that were 32% smaller than recipients of EGFP-expressing bone marrow. In cultured macrophages, adenovirus-mediated overexpression of GR(cyto)-EGFP or GR(mito)-EGFP protected cells from mitochondrial hyperpolarization induced by oxidized low-density lipoprotein. Conclusion-This study provides direct evidence that the glutathione-dependent antioxidant system in macrophages plays a critical role in atherogenesis, and suggests that thiol oxidative stress-induced mitochondrial dysfunction contributes to macrophage injury in atherosclerotic lesions. C1 Univ Texas, Hlth Sci Ctr, Div Nephrol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Kenezy Gyula Hosp, Dept Lab Med, Debrecen, Hungary. Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY USA. Univ Kentucky, Dept Pediat, Lexington, KY USA. Univ Texas, SW Med Ctr, Dallas, TX 75230 USA. Univ Texas, Hlth Sci Ctr, Div Cardiol, San Antonio, TX USA. RP Asmis, R (reprint author), Univ Texas, Hlth Sci Ctr, Div Nephrol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM asmis@uthscsa.edu FU NHLBI NIH HHS [HL-70963] NR 32 TC 31 Z9 32 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-5642 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD JUN PY 2007 VL 27 IS 6 BP 1375 EP 1382 DI 10.1161/ATVBAHA.107.142109 PG 8 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 171DH UT WOS:000246714600022 PM 17363688 ER PT J AU Simpson, R Koester, H LoPresti, E AF Simpson, Richard Koester, Heidi LoPresti, Ed TI Selecting an appropriate scan rate: The ".65 rule" SO ASSISTIVE TECHNOLOGY LA English DT Article DE assessment; row-column scanning; physical impairment; assistive technology; computer access AB Investigators have discovered that the ratio between a user's reaction time and an appropriate scan rate for that user is approximately.65, which we refer to as "the.65 rule." As part of a larger effort to develop software that automatically adapts the configuration of switch access software, data were collected comparing subject performance with a scan rate chosen using the .65 rule and a scan rate chosen by the user. Analysis of the data indicates that for many people, the .65 rule produces a scan rate that is approximately the same as the average switch press time plus 2 standard deviations. Further analysis demonstrates a relationship between the coefficient of variation (the standard deviation divided by the mean) and error rate. If accurate information is available about the mean, standard deviation, and distribution of a client's switch press time, a scan rate can be chosen that will yield a specific error level. If a rigorous statistical approach is impractical, the .65 rule will generally yield a usable scan rate based on mean press time alone. C1 Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. Koester Performance Res, Ann Arbor, MI USA. AT Sci, Pittsburgh, PA USA. RP Simpson, R (reprint author), Forbes Tower,Suite 5044,Sennott & Atwoods St, Pittsburgh, PA 15260 USA. EM ris20@pitt.edu RI Simpson, Richard/G-5683-2015 OI Simpson, Richard/0000-0002-6306-9393 FU NICHD NIH HHS [1 R43 HD045015-01] NR 7 TC 4 Z9 4 U1 0 U2 0 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PD SUM PY 2007 VL 19 IS 2 BP 51 EP 58 PG 8 WC Rehabilitation SC Rehabilitation GA 190PR UT WOS:000248071800001 PM 17727073 ER PT J AU Chaves, ES Cooper, RA Collins, DM Karmarkar, A Cooper, R AF Chaves, Eliana S. Cooper, Rory A. Collins, Diane M. Karmarkar, Amol Cooper, Rosemarie TI Review of the use of physical restraints and lap belts with wheelchair users SO ASSISTIVE TECHNOLOGY LA English DT Review DE seat belts; lap belts; restraints; wheelchair falls; wheelchair transportation ID NURSING-HOME RESIDENTS; UNITED-STATES; SEAT-BELT; FALLS; ACCIDENTS; PREDICTORS; FACILITIES; LEGRESTS; INJURIES; TIPS AB Wheelchair-related physical restraints, lap belts, and other alternatives are intended to provide safe and adequate seating and mobility for individuals using wheelchairs. Physical restraints and lap belts are also helpful for positioning people in their wheelchairs to reduce the risk of injury during wheelchair tips and falls. However, when used improperly or in ways other than intended, injury or even death can result. Although widely prescribed, little evidence is available to direct professionals on the appropriate use of these restraints and lap belts and for whom these restraints are indicated. The purpose of this study was to conduct a review of available literature from 1966-2006 to identify the risks and benefits associated with lap belts while seated in wheelchairs. Twenty-five studies that met the inclusion criteria were reviewed. Nine studies reported the frequency of asphyxial deaths caused by physical restraints, nine studies reported the long-term complication and indirect adverse effects of physical restraints and lap-belt use, and seven studies reported the benefits of physical restraints and lap belts with individuals using wheelchairs. Despite the weak evidence, the results suggest a considerable number of deaths from asphyxia caused by the use of physical restraints occurred each year in the U.S. The majority of the deaths occurred in nursing homes, followed by hospitals, and then the home of the person. Most deaths occurred while persons were restrained in wheelchairs or beds. Based on that, caution needs to be exercised when using restraints or positioning belts. In addition, other seating and environment alternatives should be explored prior to using restraints or positioning belts, such as power wheelchair seating options. Positioning belts may reduce risk of falls from wheelchairs and should be given careful consideration, but caution should be exercised if the individual cannot open the latch independently. Also, the duration of use of the physical restraint should be limited. Therefore, several factors should be considered when devising a better quality of physical-restraint services provided by health care professionals. These efforts can lead to improved safety and quality of life for individuals who use wheelchairs. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rahabil Sci & Technol, Pittsburgh, PA 15260 USA. RP Cooper, R (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, HD 151 R1,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu RI Karmarkar, Amol/E-6030-2011 OI Karmarkar, Amol/0000-0001-8355-1585 NR 45 TC 7 Z9 7 U1 1 U2 7 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PD SUM PY 2007 VL 19 IS 2 BP 94 EP 107 PG 14 WC Rehabilitation SC Rehabilitation GA 190PR UT WOS:000248071800004 PM 17727076 ER PT J AU Glahn, DC Lovallo, WR Fox, PT AF Glahn, David C. Lovallo, William R. Fox, Peter T. TI Reduced amygdala activation in young adults at high risk of alcoholism: Studies from the Oklahoma family health patterns project SO BIOLOGICAL PSYCHIATRY LA English DT Article DE alcoholism; amygdala; behavioral disinhibition; fMRI; risk factors ID DECISION-MAKING; USE DISORDERS; SUBSTANCE USE; HISTORY; CORTEX; ABUSE; RECOGNITION; POPULATION; ALLOSTASIS; CORTISOL AB Background: Risk of alcoholism is higher in those with a positive family history (FH+) and in those showing behavioral disinhibition, possibly reflecting altered limbic system function. Methods: We performed functional magnetic resonance imaging (fMRI) in 17 nonabusing young adults, 9 with FH+ and high in disinhibition versus 8 with a negative family history (FH-) and low in disinhibition. We probed limbic system reactivity with a recognition task using faces expressing fear versus geometric objects. Results: Subjects with FH- had robust activation to the faces in the region of the right and left amygdalar complexes (p's <.05), while subjects with FH+ had no such activation (p's >.46). The blood oxygenation level-dependent (BOLD) signal in the region of the amygdala was correlated with scores on the self-report measure of temperament in the combined groups (r =.51, p <.04). Conclusions: Behaviorally disinhibited temperament, found in many with FH+, may be associated with amygdalar hyporesponsiveness and a failure to avoid risky decisions, increasing the person's liability for alcohol abuse. C1 Vet Affairs Med Ctr, Behav Sci Labs, Oklahoma City, OK 73104 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78285 USA. Univ Texas, Hlth Sci Ctr, Res Imaging Ctr, San Antonio, TX 78285 USA. RP Lovallo, WR (reprint author), Vet Affairs Med Ctr, Behav Sci Labs, 151A,921 NE 13th St, Oklahoma City, OK 73104 USA. EM bill@mindbody1.org RI Fox, Peter/B-4725-2010 OI Fox, Peter/0000-0002-0465-2028 FU NCRR NIH HHS [M01 RR014467, M01 RR001346, M01-RR-01346, RR14467]; NIAAA NIH HHS [AA12207, R01 AA012207, R01 AA012207-03] NR 31 TC 67 Z9 67 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD JUN 1 PY 2007 VL 61 IS 11 BP 1306 EP 1309 DI 10.1016/j.biopsych.2006.09.041 PG 4 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 172UK UT WOS:000246829700011 PM 17306772 ER PT J AU Zeber, JE Copeland, LA McCarthy, JF Bauer, MS Kilbourne, AM AF Zeber, J. E. Copeland, L. A. McCarthy, J. F. Bauer, M. S. Kilbourne, A. M. TI Self-reported access to medical and psychiatric care in patients with bipolar disorder SO BIPOLAR DISORDERS LA English DT Meeting Abstract CT International Conference on Bipolar Disorder CY JUN 07-09, 2007 CL Pittsburgh, PA SP ICBD DE access; treatment barriers; veterans C1 [Zeber, J. E.; Copeland, L. A.] S Texas Vet Hlth Care Syst Verdict, San Antonio, TX USA. [Zeber, J. E.; Copeland, L. A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX USA. [McCarthy, J. F.; Kilbourne, A. M.] Univ Michigan, Va Ann Arbor Healthcare Syst, Serious Menatal Illness Treatment Res & Educ Ctr, Ann Arbor, MI USA. [McCarthy, J. F.; Kilbourne, A. M.] Univ Michigan, Dept Psychiat, Ann Arbor, MI USA. [Bauer, M. S.] Brown Univ, Dept Psychiat, Providence, RI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD JUN PY 2007 VL 9 SU 1 BP 12 EP 12 PG 1 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 264JQ UT WOS:000253284000033 ER PT J AU Abulseoud, OA Hellemann, G Frye, MA Altshuler, LL Keck, PE Mcelroy, SL Suppes, T Nolen, WA Kupka, RW Grunze, H Leverich, GS Post, RM AF Abulseoud, O. A. Hellemann, G. Frye, M. A. Altshuler, L. L. Keck, P. E., Jr. Mcelroy, S. L. Suppes, T. Nolen, W. A. Kupka, R. W. Grunze, H. Leverich, G. S. Post, R. M. TI Mood stabilizer and subsequent need for adjunctive antidepressant: naturalistic follow up of the SFBN SO BIPOLAR DISORDERS LA English DT Meeting Abstract CT 7th International Conference on Bipolar Disorder CY JUN 07-09, 2007 CL Pittsburgh, PA SP ICBD DE bipolar; depression; antidepressant; mood stabilizer C1 [Abulseoud, O. A.; Hellemann, G.; Frye, M. A.; Altshuler, L. L.] Univ Calif Los Angeles, Los Angeles, CA USA. [Abulseoud, O. A.; Hellemann, G.; Altshuler, L. L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Frye, M. A.] Mayo Coll Med, Rochester, MN USA. [Mcelroy, S. L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Suppes, T.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Nolen, W. A.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [Kupka, R. W.] Altrech Inst Mental Hlth Care, Utrecht, Netherlands. [Grunze, H.] LMU Munioh, Munich, Germany. [Leverich, G. S.; Post, R. M.] Natl Inst Hlth, NIMH, Bethesda, MD USA. [Post, R. M.] Penn State Coll Med, Hershey, PA USA. RI Nolen, Willem/E-9006-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD JUN PY 2007 VL 9 SU 1 BP 13 EP 13 PG 1 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 264JQ UT WOS:000253284000034 ER PT J AU Copeland, LA Zeber, JE Salloum, IM Pincus, HA Fine, MJ Kilbourne, AM AF Copeland, L. A. Zeber, J. E. Salloum, I. M. Pincus, H. A. Fine, M. J. Kilbourne, A. M. TI Treatment adherence and illness insight in veterans with bipolar disorder SO BIPOLAR DISORDERS LA English DT Meeting Abstract CT International Conference on Bipolar Disorder CY JUN 07-09, 2007 CL Pittsburgh, PA SP ICBD DE bipolar disorder; illness insight; patient acceptance of healthcare; patient non-adherence; veterans C1 [Copeland, L. A.; Zeber, J. E.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Salloum, I. M.] Univ Texas Hlth Sci Ctr San Antonio, VERDICT, San Antonio, TX 78229 USA. [Salloum, I. M.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Pincus, H. A.] Columbia Univ, Dept Psychiat, New York Presbyterian Hosp, New York, NY USA. [Fine, M. J.] Ctr Hlth Equ Res & Promot, VA Pittsburg Hlthcare Syst, Pittsburgh, PA USA. [Fine, M. J.] Univ Pittsburgh, Div Gen Internal Med, Dept Med, Pittsburgh, PA USA. [Kilbourne, A. M.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Kilbourne, A. M.] Serious Mental Illness Treatment Res & Educ Ctr, VA Ann Arbor Hlthcare Syst, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD JUN PY 2007 VL 9 SU 1 BP 29 EP 30 PG 2 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 264JQ UT WOS:000253284000081 ER PT J AU Kelly, DI Suppes, T Keck, PE McElroy, SL Altshuler, LL Frye, MA Nolen, WA Kupka, RW Grunze, H Leverich, GS Mintz, J Luckenbaugh, DA Fischer, EG Post, RM AF Kelly, D. I. Suppes, T. Keck, P. E., Jr. McElroy, S. L. Altshuler, L. L. Frye, M. A. Nolen, W. A. Kupka, R. W. Grunze, H. Leverich, G. S. Mintz, J. Luckenbaugh, D. A. Fischer, E. G. Post, R. M. TI Quetiapine for the continuation treatment of bipolar depression: naturalistic prospective case series from the Stanley Bipolar Treatment Network SO BIPOLAR DISORDERS LA English DT Meeting Abstract CT 7th International Conference on Bipolar Disorder CY JUN 07-09, 2007 CL Pittsburgh, PA SP ICBD DE bipolar disorder; bipolar depression; cycling; quetiapine C1 [Kelly, D. I.; Suppes, T.; Fischer, E. G.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Keck, P. E., Jr.; McElroy, S. L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Keck, P. E., Jr.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA. [Altshuler, L. L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Altshuler, L. L.] Univ Calif Los Angeles, Los Angeles, CA USA. [Frye, M. A.] Mayo Coll Med, Rochester, MN USA. [Nolen, W. A.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [Kupka, R. W.] Altrech Inst Med Hlth Care, Utrecht, Netherlands. [Grunze, H.] Ludwig Maximilians Univ Munchen, Munich, Germany. [Leverich, G. S.; Luckenbaugh, D. A.] NIMH, NIH, Bethesda, MD 20892 USA. [Post, R. M.] Penn State Coll Med, Hershey, PA USA. RI Nolen, Willem/E-9006-2014 NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD JUN PY 2007 VL 9 SU 1 BP 57 EP 57 PG 1 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 264JQ UT WOS:000253284000157 ER PT J AU Kilbourne, AM Bauer, MS Nossek, A Drill, L Cooley, S Post, EP AF Kilbourne, A. M. Bauer, M. S. Nossek, A. Drill, L. Cooley, S. Post, E. P. TI Improving medical outcomes in patients with bipolar disorder: a randomized, controlled trial SO BIPOLAR DISORDERS LA English DT Meeting Abstract CT 7th International Conference on Bipolar Disorder CY JUN 07-09, 2007 CL Pittsburgh, PA SP ICBD DE general medical comorbidity; cardiovascular disease; metabolic syndrome; chronic care model C1 [Kilbourne, A. M.; Post, E. P.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Kilbourne, A. M.; Post, E. P.] VA Ann Arbor Serious Mental Illness Treatment Res, Ann Arbor, MI USA. [Bauer, M. S.] VA Providence Med Ctr, Providence, RI USA. [Bauer, M. S.] Brown Univ, Providence, RI 02912 USA. [Nossek, A.; Drill, L.; Cooley, S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Cooley, S.] Western Psychiat Inst & Clin, Pittsburgh, PA USA. [Post, E. P.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD JUN PY 2007 VL 9 SU 1 BP 59 EP 59 PG 1 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 264JQ UT WOS:000253284000162 ER PT J AU Nery, FG Stanley, JA Chen, HH Hatch, JP Nicoletti, MA Monkul, ES Lafer, B Soares, JC AF Nery, F. G. Stanley, J. A. Chen, H. H. Hatch, J. P. Nicoletti, M. A. Monkul, E. S. Lafer, B. Soares, J. C. TI Glutamatergic abnormalities in the left dorsolateral prefrontal cortex of patients with bipolar disorder and comorbid alcohol/drug use disorders: a proton spectroscopy study SO BIPOLAR DISORDERS LA English DT Meeting Abstract CT International Conference on Bipolar Disorder CY JUN 07-09, 2007 CL Pittsburgh, PA SP ICBD DE bipolar disorder; substance-related disorders; magnetic resonance spectroscopy C1 [Nery, F. G.; Nicoletti, M. A.; Monkul, E. S.; Soares, J. C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Nery, F. G.; Nicoletti, M. A.; Monkul, E. S.; Soares, J. C.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Nery, F. G.; Lafer, B.] Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. [Stanley, J. A.] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA. [Chen, H. H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Hatch, J. P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Orthodont, San Antonio, TX 78229 USA. RI Lafer, Beny/C-1055-2012; Lafer, Beny/F-9390-2015 OI Lafer, Beny/0000-0002-6132-9999; Lafer, Beny/0000-0002-6132-9999 NR 0 TC 0 Z9 0 U1 1 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD JUN PY 2007 VL 9 SU 1 BP 82 EP 83 PG 2 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 264JQ UT WOS:000253284000230 ER PT J AU Quinones, MP Ahmadi, S Nery, FG Torres, V Estrada, C Olvera, R Hatch, JP Vipraio, G Pliszka, S Soares, JC AF Quinones, M. P. Ahmadi, S. Nery, F. G. Torres, V. Estrada, C. Olvera, R. Hatch, J. P. Vipraio, G. Pliszka, S. Soares, J. C. TI Reduction in the availability of the neurotrophic factor Insulin Growth Factor (IGF)-1, but not brain derived neurotrophic factor (BDNF), in individuals with mood disorder may result from synergistic effects of disease-specific processes and normal age-associated reduction in circulating levels SO BIPOLAR DISORDERS LA English DT Meeting Abstract CT 7th International Conference on Bipolar Disorder CY JUN 07-09, 2007 CL Pittsburgh, PA SP ICBD DE growth factors; biomarkers; children and adult bipolar disorder C1 [Quinones, M. P.; Ahmadi, S.; Estrada, C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Quinones, M. P.; Nery, F. G.; Estrada, C.; Olvera, R.; Pliszka, S.; Soares, J. C.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Quinones, M. P.; Torres, V.; Olvera, R.; Pliszka, S.; Soares, J. C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Nery, F. G.; Olvera, R.; Hatch, J. P.; Vipraio, G.; Pliszka, S.; Soares, J. C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, Div Mood & Anxiety Disorders, MOOD CNS Program, San Antonio, TX 78229 USA. [Nery, F. G.] Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. [Hatch, J. P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Orthodont, San Antonio, TX 78229 USA. [Soares, J. C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD JUN PY 2007 VL 9 SU 1 BP 87 EP 88 PG 2 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 264JQ UT WOS:000253284000243 ER PT J AU Quinones, MP Torres, V Nery, FG Ahmadi, S Estrada, C Olvera, R Hatch, JP Vipraio, G Pliszka, S Soares, JC AF Quinones, M. P. Torres, V. Nery, F. G. Ahmadi, S. Estrada, C. Olvera, R. Hatch, J. P. Vipraio, G. Pliszka, S. Soares, J. C. TI Differential involvement of inflammatory markers in adult and pediatric bipolar disorder SO BIPOLAR DISORDERS LA English DT Meeting Abstract CT 7th International Conference on Bipolar Disorder CY JUN 07-09, 2007 CL Pittsburgh, PA SP ICBD DE inflammation; biomarkers; children and adult bipolar disorder C1 [Quinones, M. P.; Ahmadi, S.; Estrada, C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Quinones, M. P.; Nery, F. G.; Estrada, C.; Olvera, R.; Pliszka, S.; Soares, J. C.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Quinones, M. P.; Torres, V.; Nery, F. G.; Olvera, R.; Pliszka, S.; Soares, J. C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. Univ Sao Paulo, Dept Psychiat, Sao Paulo, Brazil. [Soares, J. C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Hatch, J. P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Orthodont, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD JUN PY 2007 VL 9 SU 1 BP 87 EP 87 PG 1 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 264JQ UT WOS:000253284000242 ER PT J AU Zeber, JE Copeland, LA Good, CB Fine, MJ Bauer, MS Kilbourne, AM AF Zeber, J. E. Copeland, L. A. Good, C. B. Fine, M. J. Bauer, M. S. Kilbourne, A. M. TI Therapeutic alliance perceptions and medication adherence in patients with bipolar disorder SO BIPOLAR DISORDERS LA English DT Meeting Abstract CT International Conference on Bipolar Disorder CY JUN 07-09, 2007 CL Pittsburgh, PA SP ICBD DE therapeutic alliance; medication adherence; treatment barriers; ethnicity; veterans C1 [Zeber, J. E.; Copeland, L. A.] Univ Texas Hlth Sci Ctr San Antonio, VERDICT, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Zeber, J. E.; Copeland, L. A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Good, C. B.; Fine, M. J.] Univ Pittsburgh, Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Good, C. B.; Fine, M. J.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Bauer, M. S.] Brown Univ, Dept Psychiat, Providence, RI 02912 USA. [Kilbourne, A. M.] Univ Michigan, Serious Mental Illness Treatment Res & Educ Ctr, VA Ann ARbor Healthcare Syst, Ann Arbor, MI 48109 USA. [Kilbourne, A. M.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD JUN PY 2007 VL 9 SU 1 BP 113 EP 113 PG 1 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 264JQ UT WOS:000253284000314 ER PT J AU Frey, BN Stanley, JA Nery, FG Monkul, ES Nicoletti, MA Chen, HH Hatch, JP Caetano, SC Ortiz, O Kapczinski, F Soares, JC AF Frey, Benicio N. Stanley, Jeffrey A. Nery, Fabiano G. Monkul, E. Serap Nicoletti, Mark A. Chen, Hua-Hsuan Hatch, John P. Caetano, Sheila C. Ortiz, Oswaldo Kapczinski, Flavio Soares, Jair C. TI Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medication-free individuals with bipolar disorder: an in vivo H-1 MRS study SO BIPOLAR DISORDERS LA English DT Article; Proceedings Paper CT International Conference on Bipolar Disorder CY JUN 07-09, 2007 CL Pittsburgh, PA SP ICBD DE bipolar disorder; brain imaging dorsolateral; prefrontal cortex; magnetic resonance spectroscopy ID MAGNETIC-RESONANCE-SPECTROSCOPY; N-ACETYL-ASPARTATE; BRAIN PHOSPHORUS-METABOLISM; MITOCHONDRIAL DYSFUNCTION; ACUTE MANIA; NEUROPSYCHIATRIC DISORDERS; CREATINE-KINASE; FRONTAL LOBES; RATING-SCALE; LITHIUM AB Objectives: While the pathophysiology of bipolar disorder (BD) remains to be elucidated, postmortem and neuroimaging studies have suggested that abnormalities in the dorsolateral prefrontal cortex (DLPFC) are implicated. We compared the levels of specific brain chemicals of interest measured with proton magnetic resonance spectroscopy (H-1 MRS) in medication-free BD subjects and age- and gender-matched healthy controls. We hypothesized that BD subjects would present abnormal cellular metabolism within the DLPFC, as reflected by lower N-acetyl-aspartate (NAA) and creatine + phosphocreatine (Cr + PCr). Methods: Thirty-two medication-free BD subjects (33.8 +/- 10.2 years) and 32 matched controls ( 33.8 +/- 9.0 years) underwent a short echo-time (TE 30 ms) H-1 MRS. An 8-cm(3) single voxel was placed in the left DLPFC, and individual concentrations of NAA, Cr + PCr, choline-containing compounds (GPC + PC), myo-inositol, and glutamate were obtained, using the water signal as an internal reference. Results: BD subjects had lower Cr + PCr [F-(1,F-62) 5.85; p = 0.018; one-way analysis of variance (ANOVA)] and lower GPC + PC [F-(1,F-62) 5.79; p = 0.019; one-way ANOVA] levels in the left DLPFC. No significant differences were observed for other brain metabolites. Conclusions: These findings provide further evidence that the pathophysiology of BD involves impairment in the DLPFC. Our findings can be interpreted as evidence for reduced cellular energy and phospholipid metabolism, consistent with the hypothesis of mitochondrial dysfunction in BD. C1 [Frey, Benicio N.; Nery, Fabiano G.; Monkul, E. Serap; Nicoletti, Mark A.; Hatch, John P.; Caetano, Sheila C.; Soares, Jair C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, MOOD CNS Program, Div Mood & Anxiety Disorders, San Antonio, TX 78229 USA. [Frey, Benicio N.; Kapczinski, Flavio] Univ Fed Rio Grande do Sul, ICBS, Dept Biochem, BR-90046900 Porto Alegre, RS, Brazil. [Frey, Benicio N.; Kapczinski, Flavio] Hosp Clin Porto Alegre, Bipolar Disorders Program, Porto Alegre, RS, Brazil. [Stanley, Jeffrey A.; Caetano, Sheila C.] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA. [Nery, Fabiano G.] Univ Sao Paulo, Sch Med, Inst Psychiat, Dept Psychiat, Sao Paulo, Brazil. [Monkul, E. Serap] Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. [Nicoletti, Mark A.; Ortiz, Oswaldo; Soares, Jair C.] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Div, S Texas Vet Hlth Care Syst, Psychiat Serv, San Antonio, TX 78229 USA. [Chen, Hua-Hsuan; Soares, Jair C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. RP Frey, BN (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, MOOD CNS Program, Div Mood & Anxiety Disorders, 3939 Med Dr,Suite 100, San Antonio, TX 78229 USA. EM benicio.frey@gmail.com RI Kapczinski, Flavio/D-3175-2013; Caetano, Sheila/H-5010-2012; Kapczinski, Flavio/J-5803-2014 OI Caetano, Sheila/0000-0001-8403-7078; FU NCRR NIH HHS [M01-RR-01346, RR020571]; NIMH NIH HHS [MH 01736, MH 068662, MH 068766] NR 60 TC 60 Z9 63 U1 0 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD JUN PY 2007 VL 9 SU 1 BP 119 EP 127 DI 10.1111/j.1399-5618.2007.00454.x PG 9 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 264JQ UT WOS:000253284000324 PM 17543030 ER PT J AU Bearden, CE Glahn, DC Caetano, S Olvera, RL Fonseca, M Najt, P Hunter, K Pliszka, SR Soares, JC AF Bearden, Carrie E. Glahn, David C. Caetano, Sheila Olvera, Rene L. Fonseca, Manoela Najt, Pablo Hunter, Kristina Pliszka, Steve R. Soares, Jair C. TI Evidence for disruption in prefrontal cortical functions in juvenile bipolar disorder SO BIPOLAR DISORDERS LA English DT Article; Proceedings Paper CT International Conference on Bipolar Disorder CY JUN 07-09, 2007 CL Pittsburgh, PA SP ICBD DE ADHD; cognition; development; executive function; juvenile mania; pediatric mood disorder; working memory ID WORKING-MEMORY; ADOLESCENT BIPOLARITY; EUTHYMIC PATIENTS; COMORBID ANXIETY; RATING-SCALE; I DISORDER; CHILDREN; MANIA; ADHD; SCHIZOPHRENIA AB Objectives: Systematic parsing of executive function processes is critical for the development of more specific models of neurobiological processes mediating disturbed cognition in youth with bipolar disorder (BPD). Methods: A sample of 33 children and adolescents with bipolar I disorder (BPD I) (mean age 12.1 +/- 3.0 years, 39% female) and 44 demographically matched healthy participants (mean age 12.9 +/- 2.8 years, 50% female) completed a neurocognitive battery including measures aimed at detection of disruption in prefrontal cortical circuitry (i.e., working memory, set shifting, and rule attainment). Results: Compared to healthy controls, BPD I children exhibited significant deficits in spatial working memory, visual sequencing and scanning, verbal fluency and abstract problem solving, particularly when a memory component was involved. In our spatial delayed response task, memory set size was parametrically varied; the performance pattern in BPD I children suggested deficits in short-term memory encoding and/or storage, rather than capacity limitations in spatial working memory. Earlier age at onset of illness and antipsychotic medication usage were associated with poorer performance on speeded information-processing tasks; however, severity of mood symptomatology and comorbidity with disruptive behavior disorders were not associated with task performance. Conclusions: These results suggest impairment in measures of prefrontal cortical function in juvenile BPD I that are similar to those seen in the adult form of the illness, and implicate both the ventral and dorsolateral prefrontal cortex as loci of pathology in juvenile BPD. As these deficits were not associated with clinical state or comorbidity with other disorders, they may reflect trait-related impairments, a hypothesis that will be pursued further in longitudinal studies. C1 [Bearden, Carrie E.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Glahn, David C.; Caetano, Sheila; Fonseca, Manoela; Najt, Pablo; Hunter, Kristina; Soares, Jair C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78229 USA. [Caetano, Sheila] Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo, Brazil. [Olvera, Rene L.; Pliszka, Steve R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, Div Child & Adolescent Psychiat, San Antonio, TX 78229 USA. [Fonseca, Manoela] Univ Fed Rio Grande do Sul, Sch Med, Psychiat Res Unit, Porto Alegre, RS, Brazil. [Najt, Pablo; Soares, Jair C.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Bearden, CE (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, 300 Bldg Med Plaza,Suite 2265, Los Angeles, CA 90095 USA. EM cbearden@mednet.ucla.edu RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 FU NCRR NIH HHS [M01-RR-01346, RR-020571]; NIMH NIH HHS [K23 MH 074644-01, K23 MH068280, K23 MH074644, K23 MH074644-01, MH-01736, MH-68662, MH-69774] NR 55 TC 32 Z9 33 U1 3 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD JUN PY 2007 VL 9 SU 1 BP 145 EP 159 DI 10.1111/j.1399-5618.2007.00453.x PG 15 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 264JQ UT WOS:000253284000327 PM 17543033 ER PT J AU Huang, AJ Ettinger, B Ensrud, K Vittinghoff, E Cummings, SR AF Huang, A. J. Ettinger, B. Ensrud, K. Vittinghoff, E. Cummings, S. R. TI The effect of ultra low-dose transdermal estradiol on bone turnover depends on endogenous estradiol levels SO BONE LA English DT Meeting Abstract CT 17th Scientific Meeting of the International-Bone-and-Mineral-Society CY JUN 24-29, 2007 CL Montreal, CANADA SP Int Bone & Mineral Soc C1 San Francisco VA Med Ctr, San Francisco, CA USA. Kaiser Permanente, Div Res, Oakland, CA USA. Vet Affairs Med Ctr, Minneapolis, MN USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 J9 BONE JI Bone PD JUN PY 2007 VL 40 IS 6 SU 2 BP S134 EP S135 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 181GV UT WOS:000247426100067 ER PT J AU Thannickal, TC Lai, YY Siegel, JM AF Thannickal, Thomas C. Lai, Yuan-Yang Siegel, Jerome M. TI Hypocretin (orexin) cell loss in Parkinson's disease SO BRAIN LA English DT Article DE Parkinson; narcolepsy; sleep; hypocretin; orexin; melanin concentrating hormone ID EXCESSIVE DAYTIME SLEEPINESS; BEHAVIOR DISORDER; REM-SLEEP; HUMAN NARCOLEPSY; KNOCKOUT MICE; LEWY BODIES; NEURONS; HYPOTHALAMUS; WAKEFULNESS; PATHOLOGY AB It has recently been reported that Parkinson's disease (PD) is preceded and accompanied by daytime sleep attacks, nocturnal insomnia, REM sleep behaviour disorder, hallucinations and depression, symptoms which are frequently as troublesome as the motor symptoms of PD. All these symptoms are present in narcolepsy, which is linked to a selective loss of hypocretin (Hcrt) neurons. In this study, the Hcrt system was examined to determine if Hcrt cells are damaged in PD. The hypothalamus of I I PD (mean age 79 +/- 4) and 5 normal (mean age 77 3) brains was examined. Sections were immunostained for H crt- 1, melanin concentrating hormone (MCH) and alpha synuclein and glial fibrillary acidic protein (GFAP).The substantia nigra of 10 PD brains and 7 normal brains were used for a study of neuromelanin pigmented cell loss. The severity of PD was assessed using the Hoehn and Yahr scale and the level of neuropathology was assessed using the Braak staging criteria. Cell number, distribution and size were determined with stereologic techniques on a one in eight series. We found an increasing loss of hypocretin cells with disease progression. Similarly, there was an increased loss of MCH cells with disease severity. Hcrt and MCH cells were lost throughout the anterior to posterior extent of their hypothalamic distributions. The percentage loss of Hcrt cells was minimal in stage 1 (23%) and was maximal in stage V (62%). Similarly, the percentage loss of MCH cells was lowest in stage 1 (12%) and was highest in stage V (74%). There was a significant increase (P = 0.0006, t = 4.25, df = 15) in the size of neuromelanin containing cells in PD patients, but no difference in the size of surviving Hcrt (P = 0.18, t = 1.39, df = 14) and MCH (P = 0.28, t = 1.39, df = 14) cells relative to controls. In summary, we found that PD is characterized by a massive loss of Hcrt neurons.Thus, the loss of Hcrt cells may be a cause of the narcolepsy-like symptoms of PD and may be ameliorated by treatments aimed at reversing the Hcrt deficit. We also saw a substantial loss of hypothalamic MCH neurons. The losses of Hcrt and MCH neurons are significantly correlated with the clinical stage of PD, not disease duration, whereas the loss of neuromelanin cells is significantly correlated only with disease duration. The significant correlations that we found between the loss of Hcrt and MCH neurons and the clinical stage of PD, in contrast to the lack of a relationship of similar strength between loss of neuromelanin containing cells and the clinical symptoms of PD, suggests a previously unappreciated relationship between hypothalamic dysfunction and the time course of the overall clinical picture of PD. C1 Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA. Vet Adm Greater Los Angeles Healthcare Syst, Neurobiol Res 151A3, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA. RP Siegel, JM (reprint author), Univ Calif Los Angeles, VAGLAHS, Neurobiol Res 151A3, 16111 Plummer St, Sepulveda, CA 91343 USA. EM jsiegel@ucla.edu FU NHLBI NIH HHS [HL41370]; NIMH NIH HHS [MH64109]; NINDS NIH HHS [NS14610, NS42566] NR 59 TC 222 Z9 230 U1 3 U2 13 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD JUN PY 2007 VL 130 BP 1586 EP 1595 DI 10.1093/brain/awm097 PN 6 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 183IA UT WOS:000247565300015 PM 17491094 ER PT J AU Griffith, HR Okonkwo, OC den Hollander, JA Belue, K Lanza, S Harrell, LE Brockington, JC Clark, DG Marson, DC AF Griffith, H. Randall Okonkwo, Ozioma C. den Hollander, Jan A. Belue, Katherine Lanza, Sara Harrell, Lindy E. Brockington, John C. Clark, David G. Marson, Daniel C. TI Brain Proton MRS is Correlated with Financial Abilities in Patients with Alzheimer's Disease SO BRAIN IMAGING AND BEHAVIOR LA English DT Article DE Financial abilities; Alzheimer's disease; Cingulate gyrus; Brain metabolism; Magnetic resonance spectroscopy AB Persons with Alzheimer's disease (AD) demonstrate frank impairments in the performance of everyday functional abilities. However, the neuroanatomic and neuro-metabolic correlates of these functional deficits in mild AD are largely unknown. Using 3-Tesla proton magnetic resonance spectroscopy ((1)H-MRS) of the posterior cingulate gyrus in 14 patients with mild AD and 14 healthy adult controls, we sought to determine the brain metabolic correlates of financial impairments in mild AD. Both N-acetylaspartate (NAA) and choline-containing compounds (Cho) were found to be abnormal in mild AD. In AD patients, NAA showed a positive correlation with financial abilities, while Cho showed a possible negative correlation with financial abilities. These findings suggest that metabolic abnormalities of posterior cortical paralimbic regions may reflect the underlying neuropathological processes that are instrumental in the degradation of financial abilities in mild AD. Proton MRS could offer a means to track brain changes associated with functional change in mild AD. C1 [Griffith, H. Randall; Okonkwo, Ozioma C.] Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA. [Griffith, H. Randall; Belue, Katherine; Lanza, Sara; Harrell, Lindy E.; Brockington, John C.; Clark, David G.; Marson, Daniel C.] Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA. [den Hollander, Jan A.] Univ Alabama, Dept Med Cardiol, Birmingham, AL USA. [Harrell, Lindy E.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Griffith, HR (reprint author), Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA. EM rlgriffith@uabmc.edu FU National Institute on Aging [1P50 AG16582-01]; Alzheimer's of Central Alabama [1R01 AG021927-01] FX This research was supported by grants from the National Institute on Aging (Alzheimer's Disease Research Center; 1P50 AG16582-01: Harrell, PI), (1R01 AG021927-01: Marson, PI) and grants from Alzheimer's of Central Alabama. NR 34 TC 4 Z9 4 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1931-7557 J9 BRAIN IMAGING BEHAV JI Brain Imaging Behav. PD JUN PY 2007 VL 1 IS 1-2 BP 23 EP 29 DI 10.1007/s11682-007-9002-3 PG 7 WC Neuroimaging SC Neurosciences & Neurology GA V07KX UT WOS:000207261200004 ER PT J AU Chopra, V Choksi, PU Cavusoglu, E AF Chopra, Vineet Choksi, Palak U. Cavusoglu, Erdal TI Beyond lipid lowering: The anti-hypertensive role of statins SO CARDIOVASCULAR DRUGS AND THERAPY LA English DT Review DE cholesterol; blood pressure lowering; endothelium; statins; pleiotropic; review ID ENDOTHELIAL NITRIC-OXIDE; COA REDUCTASE INHIBITORS; ACUTE CORONARY SYNDROMES; SMOOTH-MUSCLE-CELLS; BLOOD-PRESSURE; ATHEROSCLEROTIC PLAQUES; CARDIOVASCULAR-DISEASE; HYPERTENSIVE PATIENTS; CHOLESTEROL LEVELS; SUPEROXIDE ANION AB Introduction The management of the hypercholesterolemic patient has evolved tremendously with the introduction of the HMG-CoA Reductase inhibitors, a class of drugs better known as the statins. Statins modify cholesterol metabolism by inhibiting the rate-limiting enzyme of cholesterol biosynthesis, producing greater decreases in plasma cholesterol levels than previously realized with hypolipidemic therapy. With the advent of the classic statin-megatrials such as the Scandinavian Simvastatin Survival Study (4S), WOSCOPS, CARE, and the more recent Heart Protection Study (HPS), the role of statins in both the primary and secondary prevention and ultimate risk reduction of patients with coronary disease has been firmly established. Discussion With an increase in use and popularity, a number of beneficial actions of the statins unrelated to their cholesterol-lowering ability have been reported. These effects have generated greater interest in the possible additional roles and indications for the use of these drugs. Of central focus in this paper is the cholesterol-independent benefit of this group of agents on the cardiovascular system, particularly on the lowering of systemic blood pressure. A number of hypotheses have been proposed for this action and these shall be reviewed within this paper. Conclusion We explore recent data that suggests that statins may provide substantial reduction of blood pressure in the hypertensive, hypercholesterolemic patient independent of their lipid-lowering effect. In addition, we review several notable publications that postulate unique mechanisms for this action and benefit. We also present plausible explanations as to why some of the larger statin trials did not report similar such findings. C1 Bronx Vet Affairs Med Ctr, Div Internal Med, Bronx, NY USA. SUNY, Downstate Med Ctr, Div Cardiol, Brooklyn, NY USA. Mt Sinai Sch Med, Bronx, NY USA. RP Chopra, V (reprint author), Bronx Vet Affairs Med Ctr, Div Internal Med, Bronx, NY USA. EM vineet.chopra@sbcglobal.net NR 51 TC 20 Z9 21 U1 0 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0920-3206 EI 1573-7241 J9 CARDIOVASC DRUG THER JI Cardiovasc. Drugs Ther. PD JUN PY 2007 VL 21 IS 3 BP 161 EP 169 DI 10.1007/s10557-007-6025-3 PG 9 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 171WE UT WOS:000246765300005 PM 17468937 ER PT J AU Hariharan, S Welsh, CH AF Hariharan, Sujatha Welsh, Carolyn H. TI Shortness of breath and hypoxemia after chemotherapy with carboplatin and gemcitabine SO CHEST LA English DT Editorial Material ID OBLITERANS ORGANIZING PNEUMONIA; PULMONARY TOXICITY C1 Denver Vet Affairs Med Ctr, Div Pulm Sci & Crit Care Med, Dept Med, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Div Med Oncol, Aurora, CO USA. RP Welsh, CH (reprint author), Denver Vet Affairs Med Ctr, Div Pulm Sci & Crit Care Med, Dept Med, 1055 Clermont St, Denver, CO 80220 USA. EM Carolyn.Welsh@med.va.gov NR 10 TC 2 Z9 2 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD JUN PY 2007 VL 131 IS 6 BP 1978 EP 1981 DI 10.1378/chest.06-1464 PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 180CD UT WOS:000247336600056 PM 17565034 ER PT J AU El-Serag, HB Richardson, P Pilgrim, P Gilger, MA AF El-Serag, Hashem B. Richardson, Peter Pilgrim, Petra Gilger, Mark A. TI Determinants of gastroesophageal reflux disease in adults with a history of childhood gastroesophageal reflux disease SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID FOLLOW-UP; HIATAL-HERNIA; SYMPTOMS; CHILDREN; RISK; OBESITY; WOMEN AB Background & Aims: We conducted a nested case-control study to examine the prevalence and risk factors for current gastroesophageal reflux disease (GERD) symptoms in young adults with a history of childhood GERD. Methods: We identified a cohort of individuals diagnosed with GERD in childhood during 1995-1996, and controls without childhood GERD. Patients with neurodevelopmental disorders, tracheoesophageal anomalies, or cystic fibrosis were excluded. A computer-assisted telephone interview was conducted during 2004-2005. We calculated the prevalence of GERD symptoms, and examined the potential determinants of symptoms in unadjusted and adjusted logistic regression analyses. Results: A total of 113 cases completed the questionnaires (participation rate, 70.6%). The mean age of participants was 18 years, and their mean age at the time of childhood GERD diagnosis was 10 years. At least weekly heartburn or regurgitation was reported in 52 (46%) participants, 94% of whom were taking proton pump inhibitors, H2RA, or antacids. On the other hand, 33 controls were identified (44% participation rate) in whom weekly heartburn or regurgitation was reported in 30%. GERD was significantly more frequent in females using oral contraceptive pills (76.5%) as compared with females not on oral contraceptive pills (47.9%), or males (33.3%) (P = .008). Weight, height, nonsteroidal anti-inflammatory drug use, race, family history of GERD, education level, employment status, tobacco smoking, alcohol, or coffee drinking were not associated significantly with adulthood GERD. Conclusions: Frequent GERD symptoms requiring antisecretory therapy are present in approximately half of young adults with a history of childhood GERD. The use of oral contraceptives is a risk factor for GERD symptoms in these individuals. C1 Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX 77030 USA. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA. Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Houston Vet Affairs Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu FU NIDDK NIH HHS [DK 56338] NR 15 TC 16 Z9 17 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD JUN PY 2007 VL 5 IS 6 BP 696 EP 701 DI 10.1016/j.cgh.2007.02.033 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 176JR UT WOS:000247081500013 PM 17544996 ER PT J AU Williams, PH Cobb, BL Namjou, B Scofield, RH Sawalha, AH Harley, JB AF Williams, Pamela H. Cobb, Beth L. Namjou, Bahram Scofield, R. Hal Sawalha, Amr H. Harley, John B. TI Horizons in Sjogren's syndrome genetics SO CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY LA English DT Review DE Sjogren's syndrome; genetics; HLA; histocompatibility ID VASOACTIVE-INTESTINAL-PEPTIDE; BINDING LECTIN GENE; NOD MOUSE MODEL; SYSTEMIC-LUPUS-ERYTHEMATOSUS; HEPATITIS-C VIRUS; SALIVARY-GLANDS; AUTOANTIBODY PRODUCTION; AUTOIMMUNE-DISEASES; JAPANESE PATIENTS; CLASS-II AB Sjogren's syndrome (SS) is a complex polygenic autoimmune disorder. A few major genetic effects have been identified. Historically, HLA and non-HLA genetic associations have been reported. Recently, the HLA region continued to reveal association findings. A new susceptibility region has been suggested by a study of a D6S349 microsatellite marker. Among non-HLA studies, recent association of immunoglobulin K chain allotype KM1 with anti-La autoantibodies in primary Sjogren's syndrome confirms findings in a study from two decades ago. Meanwhile, mouse models have been employed to study the genetic contribution to salivary lymphadenitis or dry eyes and mouth. Gene transfer exploration in mouse models shows promise. The authors review the HLA and non-HLA association studies and the mouse model work that has been reported. Newly developed genomic capacity will provide, in the future, a much closer approximation of the true picture of the genetic architecture of Sjogren's syndrome. C1 Oklahoma Med Res Fdn, Arthritis & Immunol Program, Oklahoma City, OK 73104 USA. Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Harley, JB (reprint author), Oklahoma Med Res Fdn, Arthritis & Immunol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM john-harley@omrf.ouhsc.edu FU NCRR NIH HHS [P20-RR015577, P20 RR015577, RR020143, P20 RR020143]; NIAID NIH HHS [R01 AI024717, AI24717, R01 AI031584, R37 AI024717, AI31584]; NIAMS NIH HHS [N01AR12253, P01 AR049084, P30 AR053483, R01 AR042460, P50 AR048940, AR048940, AR049084, AR42460]; NIDCR NIH HHS [R01 DE015223, DE015223] NR 76 TC 10 Z9 10 U1 0 U2 3 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1080-0549 J9 CLIN REV ALLERG IMMU JI Clin. Rev. Allergy Immunol. PD JUN PY 2007 VL 32 IS 3 BP 201 EP 209 DI 10.1007/s12016-007-8002-9 PG 9 WC Allergy; Immunology SC Allergy; Immunology GA 234HF UT WOS:000251150600002 PM 17963047 ER PT J AU Yang, M Barner, JC Worchel, J AF Yang, Min Barner, Jamie C. Worchel, Jason TI Factors related to antipsychotic oversupply among central Texas veterans SO CLINICAL THERAPEUTICS LA English DT Article DE adherence; oversupply; medication possession ratio; antipsychotic; medication utilization ID MEDICATION COMPLIANCE; ELDERLY-PATIENTS; HOSPITAL DISCHARGE; SUBSTANCE-ABUSE; DRUG ADHERENCE; MENTALLY-ILL; SCHIZOPHRENIA; NONCOMPLIANCE; PRESCRIPTION; POPULATION AB Background: There have been many studies of underadherence to antipsychotics, but antipsychotic overadherence, or medication oversupply, in which patients receive more prescription medications than are needed, has been overlooked. Both underadherence and oversupply can have an important impact on clinical outcomes. Objectives: This study examined adherence (based on the medication possession ratio [MPR]) among patients treated with antipsychotics in the Central Texas Veterans Health Care System (CTVHCS) and investigated factors associated with their adherence status. Methods: Data from September 1995 to October 2002 were extracted from the computerized patient record system of the CTVHCS for continuously enrolled adult outpatients receiving antipsychotic monotherapy and filling at least 2 prescriptions within a year of the index date. Patients' prescription records were tracked for up to 12 months. Underadherence was defined as an MPR <0.8, good adherence as an MPR from 0.8 to 1.2, and oversupply as an MPR >1.2. Results: Of 3268 eligible patients, 49.9% had good adherence, 42.6% were underadherent, and 7.6% had medication oversupply. The overall mean (SD) MPR was 0.83 (0.33). Multinomial logistic regression analysis revealed that compared with patients with good adherence, underadherent patients were significantly more likely to be nonwhite (P < 0.001), younger (P < 0.01), and receiving chlorpromazine therapy (P < 0.05), and were less likely to be receiving fluphenazine (P < 0.01), olanzapine (P < 0.05), or risperidone (P < 0.05). Patients with medication oversupply were significantly more likely to be receiving olanzapine (P < 0.001), quetiapine (P < 0.01), or risperidone (P < 0.05) than those with good adherence. Conclusions: Although half of adult outpatients receiving antipsychotic monotherapy in the CTVHCS were adherent to their treatment regimens, a large proportion were underadherent, and a small proportion had medication oversupply. Patients receiving second-generation antipsychotics were more likely to be adherent and were more likely to have medication oversupply than patients receiving first-generation antipsychotics. C1 Univ Texas, Coll Pharm, Austin, TX 78712 USA. US Dept Vet Affairs, Cent Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Yang, M (reprint author), QualityMetric Inc, 640 George Washington Highway,Suite 201, Lincoln, RI 02865 USA. EM myang@qualitymetric.com NR 50 TC 11 Z9 11 U1 1 U2 1 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD JUN PY 2007 VL 29 IS 6 BP 1214 EP 1225 DI 10.1016/j.clinthera.2007.06.013 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 193SF UT WOS:000248293900020 PM 17692735 ER PT J AU Alexander, JA Copeland, LA Metzger, ME AF Alexander, Jeffrey A. Copeland, Laurel A. Metzger, Maureen E. TI Explaining differences in operating costs among poison control centers: An exploratory study SO CLINICAL TOXICOLOGY LA English DT Article DE poison control centers; costs and cost analyses; health resources AB Objectives. To explore the effects of population, staffing, location, and funding on cost per human poison exposure call; and organizational characteristics differentiating higher- and lower-cost centers. Methods. Data from 65 poison control centers (2001) were analyzed with linear multiple regression; qualitative data from 10 centers were compared. Results. The most important predictor of expenses per call was 24-hour coverage by Specialists in Poison Information ($15.70 of $40.53/call). Other factors increasing total expenses included northeast location and more health educator FTEs. Qualitative information revealed that more complex organizational forms, including multiple reporting and accountability relationships, characterized higher-cost centers. Surprisingly, having a wider range of reported activities (less specialization) was more common among lower-cost centers. Conclusions. Wide variability in cost per call suggests that inefficiencies exist. While elimination of inefficient poison control centers could reduce costs, the loss of training and collaborative opportunities, and preparedness for public health emergencies and bio-terrorism events, might mitigate against such restructuring. C1 Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, Dept Vet Affairs,VERDICT Program, San Antonio, TX 78284 USA. RP Alexander, JA (reprint author), Univ Michigan, Sch Publ Hlth, 1420 Washington Hts, Ann Arbor, MI 48109 USA. EM jalexand@sph.umich.edu OI Copeland, Laurel/0000-0002-9478-0209 NR 13 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1556-3650 EI 1556-9519 J9 CLIN TOXICOL JI Clin. Toxicol. PD JUN-AUG PY 2007 VL 45 IS 5 BP 440 EP 450 DI 10.1080/15563650601117921 PG 11 WC Toxicology SC Toxicology GA 185SV UT WOS:000247731600002 PM 17503241 ER PT J AU Lara-Castro, C Fu, Y Chung, BH Garvey, WT AF Lara-Castro, Cristina Fu, Yuchang Chung, B. Hong Garvey, W. Timothy TI Adiponectin and the metabolic syndrome: mechanisms med ating risk for metabolic and cardiovascular disease SO CURRENT OPINION IN LIPIDOLOGY LA English DT Review DE adipocytes; adiponectin; cardiovascular disease; insulin resistance; lipids ID MOLECULAR-WEIGHT ADIPONECTIN; CORONARY-HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; TYPE-2 DIABETES-MELLITUS; PROMOTES ADIPOCYTE DIFFERENTIATION; MONOCYTE-DERIVED MACROPHAGES; PLASMA-PROTEIN ADIPONECTIN; ADIPOSE-SPECIFIC PROTEIN; RECEPTOR-GAMMA AGONISTS; INSULIN-RESISTANCE AB Purpose of review Adiponectin is secreted exclusively by adipocytes, aggregates in multimeric forms, and circulates at high concentrations in blood. This review summarizes recent studies highlighting cellular effects of adiponectin and its role in human lipid metabolism and atherosclerosis. Recent findings Adiponectin is an important autocrine/paracrine factor in adipose tissue that modulates differentiation of preadipocytes and favors formation of mature adipocytes. It also functions as an endocrine factor, influencing whole-body metabolism via effects on target organs. Adiponectin multimers exert differential biologic effects, with the high-molecular-weight multimer associated with favorable metabolic effects (i.e. greater insulin sensitivity, reduced visceral adipose mass, reduced plasma triglycerides, and increased HDL-cholesterol). Adiponectin influences plasma lipoprotein levels by altering the levels and activity of key enzymes (lipoprotein lipase and hepatic lipase) responsible for the catabolism of triglyceride-rich lipoproteins and HDL. It thus influences atherosclerosis by affecting the balance of atherogenic and antiatherogenic lipoproteins in plasma, and by modulating cellular processes involved in foam cell formation. Summary Recent studies emphasize the role played by adiponectin in the homeostasis of adipose tissue and in the pathogenesis of the metabolic syndrome, type 2 diabetes, and atherosclerosis. These pleiotropic effects make it an attractive therapeutic target for obesity-related conditions. C1 Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Lara-Castro, C (reprint author), Univ Alabama, Dept Nutr Sci, 1675 Univ Blvd, Birmingham, AL 35294 USA. EM garveyt@uab.edu NR 99 TC 147 Z9 160 U1 2 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0957-9672 J9 CURR OPIN LIPIDOL JI Curr. Opin. Lipidology PD JUN PY 2007 VL 18 IS 3 BP 263 EP 270 DI 10.1097/MOL.0b013e32814a645f PG 8 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Peripheral Vascular Disease SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Cardiovascular System & Cardiology GA 176LJ UT WOS:000247086300006 PM 17495599 ER PT J AU Hirschmann, JV AF Hirschmann, Jan V. TI Antimicrobial therapy for skin infections SO CUTIS LA English DT Article ID SOFT-TISSUE INFECTIONS; RESISTANT STAPHYLOCOCCUS-AUREUS; FINE-NEEDLE ASPIRATION; LONG-TERM EFFICACY; VENOUS LEG ULCERS; ATOPIC-DERMATITIS; DOUBLE-BLIND; CUTANEOUS CELLULITIS; ANAEROBIC BACTERIOLOGY; RECURRENT ERYSIPELAS AB The most common skin infections are caused by Staphylococcus aureus, group A streptococci (Streptococcus pyogenes), or the normal skin flora. An antistaphylococcal oral antibiotic is the preferred treatment for nonbullous and bullous impetigo, and a therapeutic agent that is effective against both S aureus and streptococci is appropriate for most cases of cellulitis. For furuncles, carbuncles, cutaneous abscesses, and inflamed epidermal cysts, the most important therapy is incision and drainage, and in most cases there is no need for antimicrobial therapy. Patients with venous ulcers and atopic eczema do not benefit from systemic antimicrobial therapy unless obvious infection is present, as indicated by clinical features such as fever, cellulitis, and lymphangitis. C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98195 USA. RP Hirschmann, JV (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. NR 86 TC 7 Z9 7 U1 2 U2 3 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 0011-4162 J9 CUTIS JI Cutis PD JUN PY 2007 VL 79 IS 6 SU S BP 26 EP 36 PG 11 WC Dermatology SC Dermatology GA 187XR UT WOS:000247883100003 PM 17649855 ER PT J AU Hirschmann, JV AF Hirschmann, Jan V. TI Antimicrobial prophylaxis in Dermatologic surgery SO CUTIS LA English DT Article ID ELECTIVE COLORECTAL SURGERY; INFECTIVE ENDOCARDITIS; SKIN SURGERY; ANTIBIOTIC-PROPHYLAXIS; CUTANEOUS ABSCESSES; BACTERIAL-ENDOCARDITIS; TRANSIENT BACTEREMIA; DENTAL EXTRACTIONS; DOUBLE-BLIND; PREVENTION AB Antimicrobial prophylaxis is rarely appropriate for dermatologic surgery. Dermatologic procedures seldom cause bacteremia, and they have been implicated as a cause in only an extremely small number of cases of endocarditis or infections of vascular grafts or orthopedic prostheses. Accordingly, systemic prophylactic antibiotics are not indicated in patients undergoing dermatologic surgery who have valvular heart disease, vascular grafts, or orthopedic prostheses. Because wound infections following dermatologic surgery are uncommon, usually mild, and generally easily treatable, systemic antimicrobial prophylaxis is not indicated to prevent postoperative wound infections either. Topical antibiotic ointments for that purpose are ineffective. Whether prophylactic antivirals are helpful in preventing herpes simplex infections after facial resurfacing is uncertain. C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98195 USA. RP Hirschmann, JV (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. NR 55 TC 6 Z9 7 U1 0 U2 0 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 0011-4162 J9 CUTIS JI Cutis PD JUN PY 2007 VL 79 IS 6 SU S BP 43 EP 51 PG 9 WC Dermatology SC Dermatology GA 187XR UT WOS:000247883100005 PM 17649857 ER PT J AU Tong, J Boyko, EJ Utzschneider, KM McNeely, MJ Hayashi, T Carr, DB Wallace, TM Zraika, S Gerchman, F Leonetti, DL Fujimoto, WY Kahn, SE AF Tong, J. Boyko, E. J. Utzschneider, K. M. McNeely, M. J. Hayashi, T. Carr, D. B. Wallace, T. M. Zraika, S. Gerchman, F. Leonetti, D. L. Fujimoto, W. Y. Kahn, S. E. TI Intra-abdominal fat accumulation predicts the development of the metabolic syndrome in non-diabetic Japanese-Americans SO DIABETOLOGIA LA English DT Article DE Asians; epidemiology; insulin resistance; metabolic syndrome; visceral adiposity ID VISCERAL ADIPOSITY; HYPERINSULINEMIA; DISEASE; RISK AB Aims/hypothesis Intra-abdominal fat (IAF) is an important risk factor for CHD and type 2 diabetes, and in cross-sectional studies is associated with the metabolic syndrome (MetS). Our aim was to determine whether IAF accumulation predicts the future development of MetS in non-diabetic Japanese-Americans. Subjects and methods We conducted a prospective study of 457 Japanese-American men and women (mean +/- SD: age 51.5 +/- 12.0 years, BMI 23.9 +/- 3.1 kg/m(2)) without diabetes or MetS at baseline. Of these, 408 completed a 5-year follow-up and 366 completed a 10-year follow-up. BMI, waist circumference, IAF and subcutaneous fat (SCF) areas by computed tomography, blood pressure, fasting plasma glucose, insulin, triacylglycerol and HDL-cholesterol were measured at baseline and at 5- and 10-year follow-up. MetS was defined using National Cholesterol Education Program Adult Treatment Panel III criteria. Results Incidence of MetS was 15.3% at 5 years and 17.8% at 10 years. A change of 1 SD in IAF area was associated with a 2.1-fold increase in the odds of MetS at 10 years (odds ratio = 2.08, 95% CI 1.41-3.07) after adjusting for age, sex, baseline IAF and the presence of each individual MetS criteria at baseline. This association was independent of changes in fasting insulin and SCF areas. Conclusion We conclude that IAF accumulation over time independently predicts the development of MetS and thus may play an important role in the development of MetS in Japanese-Americans. C1 VA Puget Sound Hlth Care Syst 151, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst 151, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. Osaka City Univ, Dept Prevent Med & Environm Hlth, Osaka 558, Japan. Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. RP Tong, J (reprint author), VA Puget Sound Hlth Care Syst 151, Div Metab Endocrinol & Nutr, Dept Med, 1660 S Columbian Way, Seattle, WA 98108 USA. EM tongj@u.washington.edu RI Hayashi, Tomoshige/N-8508-2015 OI Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X FU NIDDK NIH HHS [DK 02860, DK 55460] NR 12 TC 38 Z9 43 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD JUN PY 2007 VL 50 IS 6 BP 1156 EP 1160 DI 10.1007/s00125-007-0651-y PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 164YT UT WOS:000246271600006 PM 17387445 ER PT J AU Wu, Y Zhao, WD Zhao, JB Pan, JP Wu, QQ Zhang, YF Bauman, WA Cardozo, CP AF Wu, Yong Zhao, Weidong Zhao, Jingbo Pan, Jiangping Wu, Qiaqia Zhang, Yuanfei Bauman, William A. Cardozo, Christopher P. TI Identification of androgen response elements in the insulin-like growth factor I upstream promoter SO ENDOCRINOLOGY LA English DT Article ID STEROID-HORMONE RECEPTORS; IGF-I; GENE-EXPRESSION; DNA-BINDING; GLUCOCORTICOID-RECEPTORS; DEOXYRIBONUCLEIC-ACID; ANABOLIC-STEROIDS; DEPENDENT MANNER; PROBASIN GENE; MESSENGER-RNA AB Testosterone stimulates the expression of IGF-I in cells and tissues that include prostate, muscle and muscle satellite cells, and the uterus. Here, the molecular mechanisms of this effect of testosterone were explored. Testosterone increased IGF-I mRNA levels in HepG2 and LNCaP cells and stimulated the activity of reporter genes controlled by 1.6 kb of the upstream promoter of the human IGF- I gene. An androgen-responsive region that was located between -1320 and -1420 bases upstream of the first codon was identified by truncation studies. The androgen- responsive region was found to contain two sequences resembling known androgen receptor (AR)binding sites from the Pem1 gene. Reporter genes incorporating these sequences were strongly stimulated by androgens. Each of the androgen-responsive elements (AREs) bound recombinant AR-DNA-binding domain in gel-shift experiments; binding was greatly enhanced by sequences flanking the apparent AR-binding half-sites. Testosterone induced recruitment of AR to sequences of genomic DNA containing these AREs. The two AREs were activated 5-fold more by AR than glucocorticoid receptor. Collectively, these findings indicate the presence of two AREs within the IGF-I upstream promoter that act in cis to activate IGF-I expression. These AREs seem likely to contribute to the up-regulation of the IGF-I gene in prostate tissues, HepG2 cells, and potentially other tissues. C1 James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Dept Vet Affairs, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. RP Cardozo, CP (reprint author), James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Dept Vet Affairs, Room 1E-02, Bronx, NY 10468 USA. EM Chris.Cardozo@mssm.edu FU NIDDK NIH HHS [DK 60598] NR 48 TC 51 Z9 52 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD JUN PY 2007 VL 148 IS 6 BP 2984 EP 2993 DI 10.1210/en.2006-1653 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 169DH UT WOS:000246572400050 PM 17363459 ER PT J AU Niquet, J Auvin, S Archie, M Seo, DW Allen, S Sankar, R Wasterlain, CG AF Niquet, Jerome Auvin, Stephane Archie, Mark Seo, Dae-Won Allen, Suni Sankar, Raman Wasterlain, Claude G. TI Status epilepticus triggers caspase-3 activation and necrosis in the immature rat brain SO EPILEPSIA LA English DT Article DE hippocampus; electron microscopy; programmed cell death ID PILOCARPINE STATUS EPILEPTICUS; NEURONAL NECROSIS; NEURODEGENERATION AB The mode and mechanism of neuronal death induced by status epilepticus (SE) in the immature brain have not been fully characterized. In this study, we analyzed the contribution of neuronal necrosis and caspase-3 activation to CA1 damage following lithium-pilocarpine SE in P14 rat pups. By electron microscopy, many CA1 neurons displayed evidence of early necrosis 6 hours following SE, and the full ultrastructural features of necrosis at 24-72 hours. Caspase-3 was activated in injured (acidophilic) neurons 24 hours following SE, raising the possibility that they died by caspase-dependent "programmed" necrosis. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Epilepsy Res Lab 151, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90024 USA. Lille Univ Hosp, Pediat Neurol Dept, Lille, France. Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea. RP Niquet, J (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Epilepsy Res Lab 151, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jniquet@ucla.edu OI Auvin, Stephane/0000-0003-3874-9749 FU NINDS NIH HHS [NS046516, R01 NS13515] NR 13 TC 26 Z9 28 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD JUN PY 2007 VL 48 IS 6 BP 1203 EP 1206 DI 10.1111/j.1528-1167.2007.01102.x PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 176ZZ UT WOS:000247124700024 PM 17441993 ER PT J AU Zeber, JE Copeland, LA Amuan, M Cramer, JA Pugh, MJV AF Zeber, John E. Copeland, Laurel A. Amuan, Megan Cramer, Joyce A. Pugh, Mary Jo V. TI The role of comorbid psychiatric conditions in health status in epilepsy SO EPILEPSY & BEHAVIOR LA English DT Article DE epilepsy; comorbid psychiatric conditions; health status; veterans ID QUALITY-OF-LIFE; PSYCHOGENIC NONEPILEPTIC SEIZURES; VETERANS-AFFAIRS; OLDER-ADULTS; ADMINISTRATIVE DATA; RESISTANT EPILEPSY; MENTAL-ILLNESS; DISORDERS; DEPRESSION; PREVALENCE AB Comorbid psychiatric conditions are highly prevalent in patients with epilepsy, yet the long-term implications across multiple mental health conditions are poorly understood. We examined the association between psychiatric diagnoses and self-reported health status in veterans with epilepsy. ANCOVA models were used to derive adjusted SF-36V scores for individuals with epilepsy alone (N = 7379) or with additional psychiatric conditions (N = 6320): depression, schizophrenia, bipolar disorder, anxiety disorder, substance abuse, and posttraumatic stress disorder (PTSD). Compared with patients with epilepsy alone, scores of veterans with comorbid psychiatric diagnoses averaged 21% lower across all domains. Role Limitation scales exhibited the greatest decrement across domains. A PTSD diagnosis consistently corresponded to lower scores, followed by depression. Schizophrenia contributed the least detriment to perceived health status. Comorbid psychiatric conditions impart significant emotional and physical burdens, requiring timely recognition and treatment of these disorders. Patients with epilepsy are uniquely at risk for high physical-psychiatric comorbidity profiles, with concomitant losses in perceived health status. Published by Elsevier Inc. C1 S Texas Vet Hlth Care Syst, Audie L Murphy Div, VERDICT Ctr 11C6, HSR&D Verdict, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. Edith Nourse Rogers Mem Vet Adm Hosp, CHQOER, Bedford, MA 01730 USA. Yale Univ, Sch Med, New Haven, CT USA. Univ Texas, Hlth Sci Ctr, Dept Internal Med, San Antonio, TX USA. RP Zeber, JE (reprint author), S Texas Vet Hlth Care Syst, Audie L Murphy Div, VERDICT Ctr 11C6, HSR&D Verdict, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM zeber@uthscsa.edu OI Pugh, Mary Jo/0000-0003-4196-7763; Copeland, Laurel/0000-0002-9478-0209 NR 67 TC 30 Z9 31 U1 4 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 EI 1525-5069 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD JUN PY 2007 VL 10 IS 4 BP 539 EP 546 DI 10.1016/j.yebeh.2007.02.008 PG 8 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA 178JL UT WOS:000247216900004 PM 17416208 ER PT J AU Artinian, NT Warnecke, RB Kelly, KM Weiner, J Lurie, N Flack, JM Mattei, J Eschbach, K Long, JA Furumoto-Dawson, A Hankin, JR DeGraffinreid, C AF Artinian, Nancy T. Warnecke, Richard B. Kelly, Kimberly M. Weiner, Janet Lurie, Nicole Flack, John M. Mattei, Josiemer Eschbach, Karl Long, Judith A. Furumoto-Dawson, Alice Hankin, Janet R. DeGraffinreid, Cecilia TI Advancing the science of health disparities research SO ETHNICITY & DISEASE LA English DT Article DE Centers for Population Health and Health Disparities; health policy; population health; community-based participatory research; underserved populations ID RESIDENTIAL SEGREGATION; SOCIAL-ISOLATION; HEART-DISEASE; UNITED-STATES; CANCER; ENVIRONMENTS; MULTILEVEL; MECHANISMS; MORTALITY; PARADOX AB Research to eliminate health disparities in the United States is best approached from the perspective of population health. The objectives of this paper are to: a) describe how ongoing research at the eight national Centers for Population Health and Health Disparities (CPHHD) is using a population health perspective and a community-based approach to advance the field of health disparities research; and b) to discuss potential implications of such research for health policies that target some of the determinants of population health. C1 Wayne State Univ, Coll Nursing, Detroit, MI 48202 USA. Wayne State Univ, Natl Ctr Populat Hlth & Hlth Dispar, Detroit, MI 48202 USA. Univ Illinois, Ctr Canc, Chicago, IL USA. Ohio State Univ, Columbus, OH 43210 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RAND, Ctr Publ Hlth, Ctr Domest & Int Hlth Secur, Philadelphia, PA USA. Wayne State Univ, Sch Med, Dept Internal Med, Detroit, MI 48202 USA. Tufts Univ, Friedman Sch Nutr Sci & Policy, Medford, MA 02155 USA. Univ Texas, Med Branch, Dept Internal Med Geriatr, Galveston, TX 77550 USA. Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. Univ Penn, Dept Internal Med, Philadelphia, PA 19104 USA. Univ Chicago, Ctr Interdisciplinary Hlth Dispar Res, Inst Mind & Biol, Chicago, IL 60637 USA. Wayne State Univ, Dept Sociol, Detroit, MI 48202 USA. Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. RP Artinian, NT (reprint author), Wayne State Univ, Coll Nursing, 5557 Cass Ave, Detroit, MI 48202 USA. EM n.artinian@wayne.edu RI Mattei, Josiemer/H-1800-2016 OI Mattei, Josiemer/0000-0001-5424-8245; Weiner, Janet/0000-0001-5810-5807 FU NCI NIH HHS [1P50 CA 106743-01, 1P50 CA195641, 1P59 CA105632, 5P50 CA105631, P50 CA105631, P50 CA105632, P50 CA106743]; NHLBI NIH HHS [T32 HL069772]; NIA NIH HHS [5P01 AG023394-3, P01 AG023394]; NIEHS NIH HHS [5P50 ES012382, 5P50 ES12383, P50 ES012382, P50 ES012383, P50 ES012395] NR 31 TC 4 Z9 4 U1 0 U2 2 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X J9 ETHNIC DIS JI Ethn. Dis. PD SUM PY 2007 VL 17 IS 3 BP 427 EP 433 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 204TI UT WOS:000249066500002 PM 17985493 ER PT J AU Pott, GB Sailer, CA Porat, R Peskind, RL Fuchs, AC Angel, JB Skolnik, PR Jacobson, MA Giordano, MF LeBeaut, A Grint, PC Dinarello, CA Shapiro, L AF Pott, Gregory B. Sailer, Carrie A. Porat, Reuven Peskind, Robert L. Fuchs, Amy C. Angel, Jonathan B. Skolnik, Paul R. Jacobson, Mark A. Giordano, Michael F. LeBeaut, Alexandre Grint, Paul C. Dinarello, Charles A. Shapiro, Leland TI Effect of a four-week course of interleukin-10 on cytokine production in a placebo-controlled study of HIV-1-infected subjects SO EUROPEAN CYTOKINE NETWORK LA English DT Article DE HIV-1; interleukin-10; pro-inflammatory cytokines; whole blood; ex vivo ID HUMAN-IMMUNODEFICIENCY-VIRUS; NECROSIS-FACTOR-ALPHA; BLOOD MONONUCLEAR-CELLS; INFECTED U1 CELLS; IN-VITRO; CONTROLLED-TRIAL; TNF-ALPHA; MONOCYTE/MACROPHAGE LINEAGE; RECEPTOR ANTAGONIST; HIV-1 EXPRESSION AB Interleukin (IL)-10 suppresses synthesis of the pro-inflammatory cytokines tumor necrosis factor (TNF)alpha, IL-1 beta, and interferon (IFN)gamma. Since pro-inflammatory cytokines have been implicated in the production of human immunodeficiency virus type I (HIV-1), cytokine synthesis in whole blood cultures were determined during a 4-week course of subcutaneous IL-10 injections in 33 HIV-1-infected patients. Patients were randomized into four groups: placebo (nine), IL-10 at 1 mu g/kg/day (nine), IL-10 at 4 mu g/kg/day (six) and IL-10 at 8 mu g/kg three times per week (nine). Whole blood was obtained at the beginning and conclusion of the study and was stimulated for 24 hours with the combination of IL-18 plus lipopolysaccharide. TNF alpha production in stimulated whole blood was reduced three and six hours after the first injection of IL-10 compared to subjects injected with the placebo. After four weeks of treatment, production of IFN gamma was suppressed in a greater number of patients in the IL-10 treatment groups compared to subjects in the placebo group. Similarly, IL-1 beta production was lower in the IL-10 treatment groups compared to subjects receiving placebo. In contrast, after four weeks of IL-10, circulating levels of the anti-inflammatory TNF soluble receptor p55 increased dose-dependently compared to placebo subjects. Patient heterogeneity and small sample size presented difficulties in establishing statistical significance. Although the cytokine changes in our study did not demonstrate statistically significant changes, the data nevertheless reveal that four weeks of IL-10 therapy in HIV-1 infected subjects produced the anticipated suppression of pro-inflammatory cytokines. C1 Univ Colorado, Div Infect Dis, Dept Med, Denver, CO 80262 USA. Hlth Sci Ctr, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. Ischlov Hosp, Tel Aviv Soursky Med, Dept Med, Tel Aviv, Israel. Drexel Univ, Coll Med, Philadelphia, PA 19104 USA. Univ Ottawa, Ottawa, ON, Canada. Boston Univ, Med Ctr, Ctr HIV AIDS Care & Res, Boston, MA 02215 USA. Univ Calif San Francisco, Posit Hlth Program, San Francisco, CA USA. San Francisco Gen Hosp, Med Serv, San Francisco, CA 94110 USA. Cornell Univ, Coll Med, New York, NY USA. Schering Plough Res Inst, Kenilworth, NJ USA. RP Shapiro, L (reprint author), Univ Colorado, Div Infect Dis, Dept Med, 4200 E 9th Ave,Box B168, Denver, CO 80262 USA. EM leland.shapiro@uchsc.edu FU NCRR NIH HHS [M01RR00083]; NIAID NIH HHS [AI 15614] NR 38 TC 4 Z9 5 U1 0 U2 1 PU JOHN LIBBEY EUROTEXT LTD PI MONTROUGE PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE SN 1148-5493 J9 EUR CYTOKINE NETW JI Eur. Cytokine Netw. PD JUN PY 2007 VL 18 IS 2 BP 49 EP 58 DI 10.1684/ecn.2007.0094 PG 10 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA 199RV UT WOS:000248713800001 PM 17594937 ER PT J AU Alexander, JJ Jacob, A Vezina, P Sekine, H Gilkeson, GS Quigg, RJ AF Alexander, Jessy J. Jacob, Alexander Vezina, Paul Sekine, Hideharu Gilkeson, Gary S. Quigg, Richard J. TI Absence of functional alternative complement pathway alleviates lupus cerebritis SO EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE apoptosis; brain; complement factor B; extracellular matrix; MRL/lpr mice ID CENTRAL-NERVOUS-SYSTEM; INTERCELLULAR-ADHESION MOLECULE-1; ANTIGEN-SPECIFIC LYMPHOCYTES; ENDOTHELIAL GROWTH-FACTOR; BLOOD-BRAIN-BARRIER; FACTOR-B; NEUROPSYCHIATRIC LUPUS; MEDIATED APOPTOSIS; AUTOIMMUNE MICE; GENE-EXPRESSION AB The complement inhibitor, Crry, which blocks both the classical and alternative pathways, alleviates CNS disease in the lupus model, MRLIMpJ-Tnfrsf6lpr (MRL/Ipr) mice. To understand the role of the alternative pathway, we studied mice deficient in a key alternative pathway protein, complement factor B (M). Immune deposits (IgG and C3) were reduced in the brains of MRL/lpr fB-deficient (fB(-/-)MRL/lpr) compared to fBsufficient (MRL/Ipr) mice, indicating reduced complement activation. Reduced neutrophil infiltration (22% of MRL/1pr mice) and apoptosis (caspase-3 activity was reduced to 33% of MRL/Ipr mice) in these mice indicates that the absence of the alternative pathway was neuroprotective. Furthermore, expression of phospho (p)-Akt (0.16 +/- 0.02 vs. 0.35 +/- 0.13, p < 0.03) was increased, while expression of p-PTEN (0.40 +/- 0.06 vs. 0.11 +/- 0.07, p < 0.05) was decreased in fB(-/-)MRL/lpr mice compared to their MRL/1pr counterparts. The expression of fibronectin, laminin and collagen I-V was significantly decreased in fB(-/-)MRL/Ipr mice compared to MRL/lpr mice, indicating that in the lupus setting, tissue integrity was maintained in the absence of the alternative pathway. Absence of fB reduced behavioral alterations in MRL/lpr mice. Our results suggest that in lupus, the alternative pathway may be the key mechanism through which complement activation occurs in brain, and therefore it might serve as a therapeutic target for lupus cerebritis. C1 Univ Chicago, Dept Med, Chicago, IL 60637 USA. Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA. Med Univ SC, Ralph H Johnson VA Med Ctr, Dept Med, Med Res Serv, Charleston, SC USA. RP Alexander, JJ (reprint author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC5100, Chicago, IL 60637 USA. EM jalexand@medicine.bsd.uchicago.edu FU NIDDK NIH HHS [R01DK055357] NR 55 TC 25 Z9 27 U1 1 U2 2 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY SN 0014-2980 J9 EUR J IMMUNOL JI Eur. J. Immunol. PD JUN PY 2007 VL 37 IS 6 BP 1691 EP 1701 DI 10.1002/eji.2006366381 PG 11 WC Immunology SC Immunology GA 179HF UT WOS:000247279600028 PM 17523212 ER PT J AU Cook-Easterwood, J Middaugh, LD Griffin, WC Khan, I Tyor, WR AF Cook-Easterwood, Jennifer Middaugh, Lawrence D. Griffin, William C., III Khan, Irfan Tyor, William R. TI Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis SO EXPERIMENTAL NEUROLOGY LA English DT Article DE HIV; encephalitis; highly active antiretroviral therapy; cognition; neuronal abnormalities; TNF-alpha; SCID mice ID HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; CEREBROSPINAL-FLUID; DEMENTIA COMPLEX; ALPHA PRODUCTION; MURINE MODEL; MOUSE MODEL; BRAIN; NEUROPATHOGENESIS; QUANTITATION AB Our objective was to determine if highly active antiretroviral therapy (HAART), previously shown to ameliorate several pathological features of HIV encephalitis (HIVE) in a SCID mouse model, would also reduce additional established pathological features of HIV. cognitive dysfunction, TNF-alpha, production, and reduced MAP-2 expression. SCID mice with HIVE and control mice inoculated with uninfected monocytes were administered HAART or saline. The HIV pathological features evaluated included astrogliosis, viral load, neuronal apoptosis, MAP-2 expression, mouse TNF-alpha mRNA production and learning acquisition and retention. HAART reduced the HIV-induced viral load, and the astro- and microgliosis as previously observed-, this effect was extended to HIV-induced increases in TNF-alpha mRNA production. In contrast, although HIV produced the cognitive deficits previously observed and also decreased MAP-2 expression in the area surrounding the injected HIV-infected human monocytes, HAART did not attenuate these effects. Interestingly, there was no neuronal apoptosis evident at the time point reflecting the above pathology. The results of this study combined with previous reports indicate that HAART reduces TNF-alpha. mRNA, viral load and astrogliosis; however, HAART does not improve HIV-induced cognitive dysfunction or MAP-2 decreases. These results suggest that viral load, astrogliosis, TNF-alpha and apoptosis are not prominent in the pathogenesis of early functional deficits related to decreased MAP-2 expression or cognitive dysfunction in HIVE in SCID mice. (c) 2007 Elsevier Inc. All rights reserved. C1 Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Ralph H Johnson VAMC, Serv Neurol, Charleston, SC 29401 USA. RP Tyor, WR (reprint author), Med Univ S Carolina, Dept Neurosci, 96 Jonathan Lucas St,Suite 309, Charleston, SC 29425 USA. FU BLRD VA [I01 BX001506]; NIMH NIH HHS [R01 MH62697-05, R01 MH062697, R01 MH062697-04] NR 34 TC 19 Z9 20 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD JUN PY 2007 VL 205 IS 2 BP 506 EP 512 DI 10.1016/j.expneurol.2007.03.007 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 176TQ UT WOS:000247108200020 PM 17442303 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Time trends of ulcer mortality in Europe SO GASTROENTEROLOGY LA English DT Article ID PERFORATED PEPTIC-ULCER; LAST 150 YEARS; HELICOBACTER-PYLORI; SEX-DISTRIBUTION; DUODENAL-ULCER; AGE-INCIDENCE; DISEASE; ENGLAND; ADMISSIONS; INFECTION AB Background & Aims: The aim of the present study was to follow the time trends of ulcer disease in a representative sample of European countries and assess whether the most recent behavior of peptic ulcer still fits the overall pattern governed by an underlying birth-cohort phenomenon. Methods: Mortality data from 6 countries between 1921 and 2004 were analyzed, including Denmark, France, Germany, The Netherlands, Spain, and Switzerland. The age-specific death rates of gastric and duodenal ulcers from each individual country were plotted as period-age and cohort-age contours. Results: The data from the past 50-80 years show striking similarities among the 6 European countries. In all countries alike, the risk of dying from gastric and duodenal ulcer increased among consecutive generations born during the second half of the 19th century until shortly before the turn of the century, and then decreased in all subsequent generations. The time trends of gastric ulcer preceded those of duodenal ulcer by 10-30 years. The increase in nonsteroidal anti-inflammatory drug consumption or introduction of potent antisecretory medications have not affected the long-term downward trends of ulcer mortality. The birth-cohort pattern has continued to influence the temporal variations of peptic ulcer until most recently. Conclusions: The unique shape of the birth-cohort patterns of gastric and duodenal ulcers and their identical appearance in countries with different health care systems and varying political and socioeconomic histories reflect the overriding influence of Helicobacter pylori infection. C1 Portland VA Med Ctr, Div Gastroenterol, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Div Gastroenterol, Portland, OR USA. EM sonnenbe@ohsu.edu NR 31 TC 48 Z9 52 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JUN PY 2007 VL 132 IS 7 BP 2320 EP 2327 DI 10.1053/j.gastro.2007.03.108 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 177IN UT WOS:000247146900013 PM 17570207 ER PT J AU El-Serag, HB Rudolph, L AF El-Serag, Hashem B. Rudolph, Lenhard TI Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis SO GASTROENTEROLOGY LA English DT Review ID CHRONIC HEPATITIS-C; NONALCOHOLIC FATTY LIVER; VIRUS-RELATED CIRRHOSIS; NF-KAPPA-B; POPULATION-BASED COHORT; ORAL-CONTRACEPTIVE USE; HFE C282Y MUTATIONS; UNITED-STATES; GENETIC EPIDEMIOLOGY; TELOMERE DYSFUNCTION AB Primary liver cancer, which consists predominantly of hepatocellular carcinoma (HCC), is the fifth most common cancer worldwide and the third most common cause of cancer mortality. HCC has several interesting epidemiologic features including dynamic temporal trends; marked variations among geographic regions, racial and ethnic groups, and between men and women; and the presence of several well-documented environmental potentially preventable risk factors. Moreover, there is a growing understanding on the molecular mechanisms inducing hepatocarcinogenesis, which almost never occurs in healthy liver, but the cancer risk increases sharply in response to chronic liver injury at the cirrhosis stage. A detailed understanding of epidemiologic factors and molecular mechanisms associated with HCC ultimately could improve our current concepts for screening and treatment of this disease. C1 Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Ctr Qual Care & Utilizat Studies, Houston, TX USA. Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-3000 Hannover, Germany. RP El-Serag, HB (reprint author), Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. EM Rudolph.Lenhard@MH-Hannover.de OI Rudolph, Karl Lenhard/0000-0002-4839-2862 NR 183 TC 2515 Z9 2669 U1 60 U2 398 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JUN PY 2007 VL 132 IS 7 BP 2557 EP 2576 DI 10.1053/j.gastro.2007.04.061 PG 20 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 177IN UT WOS:000247146900032 PM 17570226 ER PT J AU Lieberman, D AF Lieberman, David TI Colorectal cancer screening in primary care SO GASTROENTEROLOGY LA English DT Editorial Material ID FECAL OCCULT BLOOD; ASYMPTOMATIC ADULTS; COLONOSCOPY; NEOPLASIA; SIGMOIDOSCOPY; POPULATION; RISK C1 Oregon Hlth & Sci Univ, Div Gastroenterol, Portland VA Med Ctr, Portland, OR 97239 USA. RP Lieberman, D (reprint author), Oregon Hlth & Sci Univ, Div Gastroenterol, Portland VA Med Ctr, P3-GI,1037 SW Vet Hosp Rd, Portland, OR 97239 USA. EM lieberma@ohsu.edu NR 16 TC 11 Z9 14 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JUN PY 2007 VL 132 IS 7 BP 2591 EP 2594 DI 10.1016/j.gastro.2007.04.026 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 177IN UT WOS:000247146900042 PM 17570229 ER PT J AU Krasinskas, AM Raina, A Khalid, A Tublin, M Yadav, D AF Krasinskas, Alyssa M. Raina, Amit Khalid, Asif Tublin, Mitchell Yadav, Dhiraj TI Autoimmune pancreatitis SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA LA English DT Article ID PRIMARY SCLEROSING CHOLANGITIS; IDIOPATHIC CHRONIC-PANCREATITIS; SERUM IGG4 CONCENTRATIONS; FINE-NEEDLE-ASPIRATION; DIAGNOSTIC-CRITERIA; RETROPERITONEAL FIBROSIS; SJOGRENS-SYNDROME; STEROID-THERAPY; CLINICOPATHOLOGICAL FEATURES; EXTRAPANCREATIC LESIONS AB Autoimmune pancreatitis (AIP) is a benign, IgG4-related, fibroinflammatory form of chronic pancreatitis that can mimic pancreatic ductal adenocarcinoma both clinically and radiographically. Laboratory studies typically demonstrate elevated serum IgG4 levels and imaging studies reveal a diffusely or focally enlarged pancreas with associated diffuse or focal narrowing of the pancreatic duct. The pathologic features include periductal lymphoplasmacytic inflammation, obliterative phlebitis, and abundant IgG4-positive plasma cells. The treatment of choice for AIP is steroid therapy. Diagnostic criteria for All? have been proposed that incorporate histologic, radiographic, serologic, and clinical information. C1 Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, UPMC Shadyside, Dept Med, Pittsburgh, PA 15213 USA. VA Pittsburgh Hlth Care, Pittsburgh, PA 15213 USA. Univ Pittsburgh, UPMC, Dept Radiol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, UPMC, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15237 USA. RP Krasinskas, AM (reprint author), Univ Pittsburgh, Med Ctr, Dept Pathol, 200 Lothrop St,A610, Pittsburgh, PA 15213 USA. EM krasinskasam@upmc.edu NR 88 TC 19 Z9 22 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8553 J9 GASTROENTEROL CLIN N JI Gastroenterol. Clin. North Am. PD JUN PY 2007 VL 36 IS 2 BP 239 EP + DI 10.1016/j.gtc.2007.03.015 PG 20 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 182WS UT WOS:000247535300003 PM 17533077 ER PT J AU Jani, N Moser, AJ Khalid, A AF Jani, Niraj Moser, A. James Khalid, Asif TI Pancreatic endocrine tumors SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA LA English DT Article ID ISLET-CELL TUMORS; SOMATOSTATIN-RECEPTOR SCINTIGRAPHY; ZOLLINGER-ELLISON-SYNDROME; PHASE HELICAL CT; NEUROENDOCRINE TUMORS; INTRAOPERATIVE ULTRASONOGRAPHY; PREOPERATIVE LOCALIZATION; ENDOSCOPIC ULTRASOUND; PROGNOSTIC-FACTORS; NEOPLASIA TYPE-1 AB Incidental, nonfunctional pancreatic endocrine tumors (PET) are observed with increasing frequency. Most are insulinomas. Endoscopic ultrasound with fine-needle aspiration plays a significant role in the localization and tissue diagnosis of PET. Establishing PET behavior as aggressive or indolent remains challenging especially preoperatively. Newer techniques including DNA and micro-RNA analysis may play a role in this arena. Small benign PET may be enucleated or removed laparascopically. Surgery is the mainstay of treating advanced disease including those with metastases and Zollinger-Ellison syndrome. The management of multiple endocrine neoplasia type I continues to be a challenge, including treating symptoms, targeted resections, and close observation. Diagnosis, management, and prognostication of PET are under evolution and a number of changes in these fronts are anticipated. C1 Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA 15213 USA. VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. RP Khalid, A (reprint author), Univ Pittsburgh, Med Ctr, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. EM khalida@upmc.edu NR 68 TC 13 Z9 14 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8553 J9 GASTROENTEROL CLIN N JI Gastroenterol. Clin. North Am. PD JUN PY 2007 VL 36 IS 2 BP 431 EP + DI 10.1016/i.gtc.2007.03.002 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 182WS UT WOS:000247535300014 PM 17533088 ER PT J AU Leung, JW Lee, JG Rojany, M Wilson, R Leung, FW AF Leung, Joseph W. Lee, John G. Rojany, Micha Wilson, Robert Leung, Felix W. TI Development of a novel ERCP mechanical simulator SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID GASTROENTEROLOGY FELLOWS; TRAINER AB Background: There is a paucity of objective methods for evaluating trainee performance and comparing ERCP accessories. Objective: Use of a mechanical ERCP simulator to evaluate trainee performance and to compare ERCP accessories via procedure time. Design: Pilot study using a mechanical simulator. Setting: Hands-on ERCP practice workshops. Subjects: Endoscopists at various levels of ERCP experience. Method: Validation studies are described to show that the simulator permits participants with varying ERCP experience to demonstrate their skill levels and offers novel training applications in ERCP courses. The time required for completing a simulated stent placement procedure, simulated fluoroscopy time, and participant expectations were recorded in different settings. Participants' expectations were compared before and after training to determine whether the simulator was a credible adjunct to ERCP training. Results: Significantly shorter procedure times were recorded for the same accessories used by participants with more ERCP experience than those with less experience and for the same group of participants when using accessories with I design compared with another. The mean total credibility score showed a significant increase after simulator practice. Limitations: In vitro practice by using a mechanical simulator, results may not translate directly to the clinical setting. How the objective procedure times measured during practice can complement assessment of trainee competence or define usefulness of different accessories is unknown but deserves to be explored in future studies. Conclusions: The procedure times can categorize participants according to their ERCP experience and separate accessories according to their ease of use. An increase in credibility score validates participants' endorsement of such practice as a credible adjunct to ERCP training. C1 Sacramento VA Med Ctr, Gastroenterol Sect, Vet Affairs No Calif Healthcare Syst, Mather, CA 95655 USA. Univ Calif Davis, Davis Med Ctr, Div Gastroenterol, Sacramento, CA USA. Univ Calif Irvine, Med Ctr, Comprehens Digest Dis Ctr, Irvine, CA USA. Sepulveda Ambulatory Care Ctr & Nursing Home, Res & Med Serv, Sepulveda, CA USA. Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RP Leung, JW (reprint author), Sacramento VA Med Ctr, Gastroenterol Sect, Vet Affairs No Calif Healthcare Syst, 10535 Hosp Way, Mather, CA 95655 USA. NR 14 TC 19 Z9 19 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JUN PY 2007 VL 65 IS 7 BP 1056 EP 1062 DI 10.1016/j.gie.2006.11.018 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 178JF UT WOS:000247216300021 PM 17531642 ER PT J AU Yu, CE Seltman, H Peskind, ER Galloway, N Zhou, PX Rosenthal, E Wijsman, EM Tsuang, DW Devlin, B Schellenberg, GD AF Yu, Chang-En Seltman, Howard Peskind, Elaine R. Galloway, Nichole Zhou, Peter X. Rosenthal, Elisabeth Wijsman, Ellen M. Tsuang, Debby W. Devlin, Bernie Schellenberg, Gerard D. TI Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: Patterns of linkage disequilibrium and disease/marker association SO GENOMICS LA English DT Article DE molecular haplotyping; apolipoprotein E; selection; linkage disequilibrium; genetic association; Alzheimer disease ID APOLIPOPROTEIN-E GENE; REGULATORY REGION; PHENOTYPIC ASSOCIATIONS; PROMOTER POLYMORPHISMS; CLADISTIC-ANALYSIS; LIPID-METABOLISM; RISK; EXPRESSION; HAPLOTYPES; GENOTYPE AB The epsilon(4) allele of APOE confers a two- to fourfold increased risk for late-onset Alzheimer's disease (LOAD), but LOAD pathology does not all fit neatly around APOE. It is conceivable that genetic variation proximate to APOE contributes to LOAD risk. Therefore, we investigated the degree of linkage disequilibrium (LD) for a comprehensive set of 50 SNPs in and surrounding APOE using a substantial Caucasian sample of 1100 chromosomes. SNPs in APOE were further molecularly haplotyped to determine their phases. One set of SNPs in TOMM40, roughly 15 kb upstream of APOE, showed intriguing LD with the epsilon(4) allele and was strongly associated with the risk for developing LOAD. However, when all the SNPs were entered into a logit model, only the effect of APOE epsilon(4) remained significant. These observations diminish the possibility that loci in the TOMM40 gene may have a major effect on the risk for LOAD in Caucasians. (c) 2007 Elsevier Inc. All rights reserved. C1 Vet Affairs Puget Sound Hlth care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA. Vet Affairs Puget Sound Hlth care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA. Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. Univ Washington, Sch Med, Dept Neurol, Div Neurogenet, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA. RP Yu, CE (reprint author), Vet Affairs Puget Sound Hlth care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. EM changeyu@u.washington.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894; Seltman, Howard/0000-0002-7543-3578; Wijsman, Ellen/0000-0002-2725-6669 FU NIA NIH HHS [P50 AG005136, AG05136, AG21544, AG24486, P50 AG005136-21, P50 AG005136-23, R01 AG021544, R01 AG021544-05, R21 AG024486, R21 AG024486-01, R21 AG024486-02, U24 AG021886]; NIMH NIH HHS [MH57881, R01 MH057881, R37 MH057881] NR 50 TC 75 Z9 78 U1 1 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0888-7543 J9 GENOMICS JI Genomics PD JUN PY 2007 VL 89 IS 6 BP 655 EP 665 DI 10.1016/j.ygeno.2007.02.002 PG 11 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 171YC UT WOS:000246770300001 PM 17434289 ER PT J AU Kraus, CA Kunik, ME Stanley, MA AF Kraus, Cynthia A. Kunik, Mark E. Stanley, Melinda A. TI Use of cognitive behavioral therapy in late-life psychiatric disorders SO GERIATRICS LA English DT Article DE cognitive behavioral therapy; anxiety; depression; psychosocial interventions ID CHRONIC BREATHING DISORDERS; OLDER-ADULTS; ANXIETY DISORDERS; PRIMARY-CARE; DEPRESSION; PREVALENCE; HEALTH AB With prevalence rates approaching 10% for anxiety disorders and 6% for major depression, anxiety and depression have a significant impact on adults in later life. Cognitive behavioral therapy (CBT) is a psychosocial intervention for anxiety and depression that can serve as a useful alternative or adjunct to pharmacologic intervention for older adults. Older adults often prefer nonmedical treatment and need to limit use of medications in conjunction with serious medical illness. This article presents a basic description of CBT in light of special considerations for older patients. The principles of CBT can be integrated into primary care interactions. Assessment instruments for anxiety and depressive disorders are mentioned, in addition to referral sources. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77211 USA. Baylor Coll Med, Div Psychol, Houston, TX 77030 USA. Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, McIngvale Family Chair Obsess Compuls Disorder Re, Houston, TX 77030 USA. RP Kraus, CA (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, 152 MED-VAMC 152, Houston, TX 77211 USA. NR 21 TC 10 Z9 10 U1 0 U2 1 PU ADVANSTAR COMMUNICATIONS PI DULUTH PA 131 W FIRST ST, DULUTH, MN 55802 USA SN 0016-867X J9 GERIATRICS JI Geriatrics PD JUN PY 2007 VL 62 IS 6 BP 21 EP 26 PG 6 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 182XP UT WOS:000247537600009 PM 17547480 ER PT J AU Wieland, D Hedrick, S AF Wieland, Darryl Hedrick, Susan TI Leading the way to quality long-term care: Lessons from the past, strategies for the future SO GERONTOLOGIST LA English DT Editorial Material C1 [Wieland, Darryl] Palmetto Hlth Richland Hosp, Geriatr Serv, Columbia, SC USA. [Hedrick, Susan] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. RP Wieland, D (reprint author), Palmetto Hlth Richland Hosp, Geriatr Serv, Columbia, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD JUN PY 2007 VL 47 IS 3 BP 355 EP 355 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 272CR UT WOS:000253837100008 ER PT J AU Kinosian, B Stallard, E Wieland, D AF Kinosian, Bruce Stallard, Eric Wieland, Darryl TI Projected use of long-term-care services by enrolled veterans SO GERONTOLOGIST LA English DT Article DE projection models; nursing home utilization; home- and community-based service utilization; Veterans Health Administration; National Long-Term Care Survey AB Purpose: The purpose of this article is to describe the projected use for long-term-care services through 2012. Design and Methods: We constructed a static-component projection model using age, function, and other covariates. We obtained enrollee projections from the Veterans Health Administration (VHA) and combined these with nursing home and community long-term-care service use rates from the 1999 National Long-Term Care Survey and the 2000 National Health Interview Survey. Results: Over the next decade, the number of oldest veterans (aged 85+) will double, and VHA-enrolled veterans aged 85 and older will increase sevenfold. This will result in a 20-25% increase in use for both nursing home and home- and community-based services. VHA currently concentrates 90% of its long-term-care resources on nursing home care. However, among those who receive long-term care from all formal sources, 56% receive care in the community. Age and marital status are significant predictors of use of either type of formal long-term-care service for any given level of disability. VHA's experience with the mandatory nursing home benefit suggests that even when the cost to the veteran is near zero, only 60-65% of eligibles will choose VHA-provided care. Assisted living represents nearly 15% of care provided during the past decade to individuals in nursing homes, and approximately 19% of veterans using nursing homes have disability levels comparable to those of men supported in assisted living. Implications: As most of the increased projected use for long-term care will be for home- and community-based services, VHA will need to expand those resources. Use of VHA resources to leverage community services may offer new opportunities to enhance community-based long-term care. C1 [Kinosian, Bruce] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Kinosian, Bruce] Univ Penn, Philadelphia, PA 19104 USA. [Wieland, Darryl] Univ S Carolina, Columbia, SC 29208 USA. [Stallard, Eric] Duke Univ, Ctr Demog Studies, Durham, NC 27706 USA. RP Kinosian, B (reprint author), Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, 38th & Woodland Ave, Philadelphia, PA 19104 USA. EM brucek@mail.med.upenn.edu FU NIA NIH HHS [P01AG17937, U01AG07198] NR 9 TC 17 Z9 17 U1 3 U2 7 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD JUN PY 2007 VL 47 IS 3 BP 356 EP 364 PG 9 WC Gerontology SC Geriatrics & Gerontology GA 272CR UT WOS:000253837100009 PM 17565100 ER PT J AU Hedrick, S Guihan, M Chapko, M Manheim, L Sullivan, J Thomas, M Barry, S Zhou, A AF Hedrick, Susan Guihan, Marylou Chapko, Michael Manheim, Larry Sullivan, Jean Thomas, Mark Barry, Sarah Zhou, Andrew TI Characteristics of residents and providers in the assisted living pilot program SO GERONTOLOGIST LA English DT Article DE assisted living facilities; group homes; long-term care; Department of Veterans Affairs ID NURSING-HOMES; CARE; FACILITIES; SERVICES; OREGON AB Purpose: The number of residents in assisted living has rapidly increased, although these facilities still primarily serve people who can pay out of pocket. The U.S. Department of Veterans Affairs was authorized to provide this level of care for the first time in the Assisted Living Pilot Program (ALPP). We describe the residents and providers, comparing them across three facility types and other populations, to assess the characteristics and feasibility of this new approach. Design and Methods: We assessed ALPP residents and providers across seven Veterans Affairs Medical Centers. We obtained information from medical records, assessment tools, and a provider survey. Results: We report here on 743 residents placed from 2002 to 2004. The Department of Veterans Affairs contracted with 58 adult family homes, 56 assisted living facilities, and 46 residential care facilities. The average ALPP resident was a 70-year-old unmarried White man referred from an inpatient hospital and living in a private residence prior to placement. Adult family homes enrolled residents requiring greater levels of assistance with activities of daily living than other facility types Assisted living facilities were less likely than adult family homes to admit residents with functional disabilities and less likely than either adult family homes or adult residential care facilities to admit residents with certain care needs. Implications: ALPP placed residents with a wide range of characteristics in community facilities that varied widely in size and services. This information can help determine the role of this type of care in and outside of the Department of Veterans Affairs. C1 [Hedrick, Susan; Chapko, Michael; Sullivan, Jean; Barry, Sarah; Zhou, Andrew] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98101 USA. [Guihan, Marylou; Manheim, Larry; Thomas, Mark] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Midwest Ctr Hlth Serv & Policy Res, Hines, IL 60141 USA. RP Hedrick, S (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM susan.hedrick@med.va.gov NR 30 TC 12 Z9 12 U1 2 U2 5 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD JUN PY 2007 VL 47 IS 3 BP 365 EP 377 PG 13 WC Gerontology SC Geriatrics & Gerontology GA 272CR UT WOS:000253837100010 PM 17565101 ER PT J AU Hawes, C Fries, BE James, ML Guihan, M AF Hawes, Catherine Fries, Brant E. James, Mary L. Guihan, Marylou TI Prospects and pitfalls: Use of the RAI-HIC assessment by the Department of Veterans Affairs for home care clients SO GERONTOLOGIST LA English DT Article DE Minimum Data Set; MDS-HC; home health ID MINIMUM DATA SET; RESIDENT ASSESSMENT INSTRUMENT; LIVING ELDERLY-PATIENTS; ART. NO. 7; NURSING-HOMES; OLDER-PEOPLE; MDS-HC; RUG-III; COMMUNITY; SYSTEM AB Purpose: The U.S. Department of Veterans Affairs has adopted two functional assessment systems that guide care planning: one for nursing home residents (the Resident Assessment Instrument [RAI]) and a compatible one for home care clients (RAI-HC). The purpose of this article is to describe the RAI-HC (often referred to as the Minimum Data Set-Home Care or MDS-HC) and its uses and offer lessons learned from implementation experiences in other settings. Design and Methods: We reviewed implementation challenges associated both with the RAI and the RAI-HC in the United States, Canada, and other adopter countries, and drew on these to suggest lessons for the Department of Veterans Affairs as well as other entities implementing the RAI-HC. Results: Beyond its clinical utility, there are a number of evidence-based uses for the assessment system. The resident-level data can be aggregated and analyzed, and scales identify clinical conditions and risk for various types of negative outcomes. In addition, the data can be used for other programmatic and research purposes, such as determining eligibility, setting payment rates for contract care, and evaluating clinical interventions. At the same time, there are a number of implementation challenges the Department of Veterans Affairs and other organizations may face. Implications: Policy makers and program managers in any setting, including state long-term-care programs, who wish to implement an assessment system must anticipate and address a variety of implementation problems with a clear and consistent message from key leadership, adequate training and clinical support for assessors, and appropriate planning and resources for data systems. C1 [Hawes, Catherine] Texas A&M Univ Syst, Hlth Sci Ctr, Dept Hlth Policy & Management, Sch Rural Publ Hlth, College Stn, TX 77843 USA. [Fries, Brant E.; James, Mary L.] Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA. [Fries, Brant E.] Ann Arbor Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Ann Arbor, MI USA. [Guihan, Marylou] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA. [Guihan, Marylou] Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Chicago, IL 60611 USA. RP Hawes, C (reprint author), Texas A&M Univ Syst, Hlth Sci Ctr, Dept Hlth Policy & Management, Sch Rural Publ Hlth, Mail Stop 1266, College Stn, TX 77843 USA. EM hawes@srph.tamhsc.edu NR 56 TC 12 Z9 13 U1 3 U2 9 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD JUN PY 2007 VL 47 IS 3 BP 378 EP 387 PG 10 WC Gerontology SC Geriatrics & Gerontology GA 272CR UT WOS:000253837100011 PM 17565102 ER PT J AU El-Serag, HB Ergun, GA Pandolfino, J Fitzgerald, S Tran, T Kramer, JR AF El-Serag, Hashem B. Ergun, Gulchin A. Pandolfino, John Fitzgerald, Stephanie Tran, Thomas Kramer, Jennifer R. TI Obesity increases oesophageal acid exposure SO GUT LA English DT Article ID GASTROESOPHAGEAL-REFLUX DISEASE; BODY-MASS INDEX; PH-METRY; INTRAABDOMINAL PRESSURE; INTRAGASTRIC PRESSURE; SPHINCTER PRESSURE; RISK; RESISTANCE; DIAGNOSIS; ASCITES AB Background: Obesity has been associated with gastro-oesophageal reflux disease (GERD); however, the mechanism by which obesity may cause GERD is unclear. Aim: To examine the association between oesophageal acid exposure and total body or abdominal anthropometric measures. Methods: A cross-sectional study of consecutive patients undergoing 24 h pH-metry was conducted. Standardised measurements of body weight and height as well as waist and hip circumference were obtained. The association between several parameters of oesophageal acid exposures and anthropometric measures were examined in univariate and multivariate analyses. Results: 206 patients (63% women) with a mean age of 51.4 years who were not on acid-suppressing drugs were enrolled. A body mass index (BMI) of > 30 kg/m(2) (compared with BMI, 25 kg/m(2)) was associated with a significant increase in acid reflux episodes, long reflux episodes (> 5 min), time with pH < 4, and a calculated summary score. These significant associations have affected total, postprandial, upright and supine pH measurements. Waist circumference was also associated with oesophageal acid exposure, but was not as significant or consistent as BMI. When adjusted for waist circumference by including it in the same model, the association between BMI > 30 kg/m(2) and measures of oesophageal acid exposure became attenuated for all, and not significant for some, thus indicating that waist circumference may mediate a large part of the effect of obesity on oesophageal acid exposure. Conclusions: Obesity increases the risk of GERD, at least partly, by increasing oesophageal acid exposure. Waist circumference partly explains the association between obesity and oesophageal acid exposure. C1 Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu NR 28 TC 137 Z9 143 U1 2 U2 3 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 J9 GUT JI Gut PD JUN PY 2007 VL 56 IS 6 BP 749 EP 755 DI 10.1136/gut.2006.100263 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 170WI UT WOS:000246696500005 PM 17127706 ER PT J AU Malfertheiner, P Megraud, F O'Morain, C Bazzoli, F El-Omar, E Graham, D Hunt, R Rokkas, T Vakil, N Kuipers, EJ AF Malfertheiner, P. Megraud, F. O'Morain, C. Bazzoli, F. El-Omar, E. Graham, D. Hunt, R. Rokkas, T. Vakil, N. Kuipers, E. J. CA EHSG Study Grp TI Current concepts in the management of Helicobacter pylori infection: the maastricht III consensus report SO GUT LA English DT Article ID GASTROESOPHAGEAL-REFLUX DISEASE; RANDOMIZED CONTROLLED-TRIAL; C-13-UREA BREATH TEST; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; IDIOPATHIC THROMBOCYTOPENIC PURPURA; PREVENT GASTRIC-CANCER; IRON-DEFICIENCY ANEMIA; PROTON PUMP INHIBITORS; LOW-DOSE ASPIRIN; B-CELL LYMPHOMA AB Background: Guidelines on the management of Helicobacter pylori, which cover indications for management and treatment strategies, were produced in 2000. Aims: To update the guidelines at the European Helicobacter Study Group (EHSG) Third Maastricht Consensus Conference, with emphasis on the potential of H pylori eradication for the prevention of gastric cancer. Results: Eradication of H pylori infection is recommended in (a) patients with gastroduodenal diseases such as peptic ulcer disease and low grade gastric, mucosa associated lymphoid tissue (MALT) lymphoma; (b) patients with atrophic gastritis; (c) first degree relatives of patients with gastric cancer; (d) patients with unexplained iron deficiency anaemia; and (e) patients with chronic idiopathic thrombocytopenic purpura. Recurrent abdominal pain in children is not an indication for a "test and treat'' strategy if other causes are excluded. Eradication of H pylori infection (a) does not cause gastro-oesophageal reflux disease (GORD) or exacerbate GORD, and (b) may prevent peptic ulcer in patients who are naive users of non-steroidal antiinflammatory drugs (NSAIDs). H pylori eradication is less effective than proton pump inhibitor (PPI) treatment in preventing ulcer recurrence in long term NSAID users. In primary care a test and treat strategy using a non-invasive test is recommended in adult patients with persistent dyspepsia under the age of 45. The urea breath test, stool antigen tests, and serological kits with a high accuracy are non-invasive tests which should be used for the diagnosis of H pylori infection. Triple therapy using a PPI with clarithromycin and amoxicillin or metronidazole given twice daily remains the recommended first choice treatment. Bismuth-containing quadruple therapy, if available, is also a first choice treatment option. Rescue treatment should be based on antimicrobial susceptibility. Conclusion: The global burden of gastric cancer is considerable but varies geographically. Eradication of H pylori infection has the potential to reduce the risk of gastric cancer development. C1 Univ Magdeburg, Fak Med, Zentrum Innere Med, Klin Gastroenterol Hepatol & Infektiol, D-39120 Magdeburg, Germany. INSERM, U853, Bordeaux, France. Univ Dublin Trinity Coll, Adelaide & Meath Hosp, Dublin, Ireland. Univ Bologna, Bologna, Italy. Univ Aberdeen, Aberdeen AB9 1FX, Scotland. VA Med Ctr, Houston, TX USA. McMaster Univ, Hamilton, ON, Canada. Henry Dunant Hosp, Athens, Greece. Univ Wisconsin, Sch Med, Milwaukee, WI 53201 USA. Erasmus Univ, Med Ctr, Rotterdam, Netherlands. RP Malfertheiner, P (reprint author), Univ Magdeburg, Fak Med, Zentrum Innere Med, Klin Gastroenterol Hepatol & Infektiol, Leipziger Str 44, D-39120 Magdeburg, Germany. EM peter.malfertheiner@medizin.uni-magdeburg.de RI Machado, Jose Carlos/C-5907-2009 OI Machado, Jose Carlos/0000-0003-4741-8415 NR 100 TC 1115 Z9 1263 U1 6 U2 93 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 J9 GUT JI Gut PD JUN PY 2007 VL 56 IS 6 BP 772 EP 781 DI 10.1136/gut.2006.101634 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 170WI UT WOS:000246696500010 PM 17170018 ER PT J AU Roodman, GD Kurihara, N Hiruma, Y AF Roodman, G. D. Kurihara, N. Hiruma, Y. TI New agents targeting myeloma bone disease SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL LA English DT Meeting Abstract CT 11th International Myeloma Workshop/4th International Workshop on Wladenestroms Macroglobulinemia CY JUN 25-30, 2007 CL Kos Isl, GREECE C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA STRADA NUOVA 134, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOL-HEMATOL J JI Haematol-Hematol. J. PD JUN PY 2007 VL 92 IS 6 SU 2 BP 20 EP 20 PG 1 WC Hematology SC Hematology GA 181GS UT WOS:000247425800020 ER PT J AU Yano, EM Soban, LM Parkerton, PH Etzioni, DA AF Yano, Elizabeth M. Soban, Lynn M. Parkerton, Patricia H. Etzioni, David A. TI Primary care practice organization influences colorectal cancer screening performance SO HEALTH SERVICES RESEARCH LA English DT Article DE primary health care; colorectal cancer; prevention; quality of health care; veterans ID CLINICAL PREVENTIVE SERVICES; MEDICAL GROUP PRACTICES; FECAL OCCULT BLOOD; MANAGED CARE; DELIVERY SYSTEMS; QUALITY; PHYSICIANS; BARRIERS; GUIDELINES; FRAMEWORK AB Objective. To identify primary care practice characteristics associated with colorectal cancer (CRC) screening performance, controlling for patient-level factors. Data Sources/Study Setting. Primary care director survey (1999-2000) of 155 VA primary care clinics linked with 38,818 eligible patients' sociodemographics, utilization, and CRC screening experience using centralized administrative and chart-review data (2001). Study Design. Practices were characterized by degrees of centralization (e.g., authority over operations, staffing, outside-practice influence); resources (e.g., sufficiency of nonphysician staffing, space, clinical support arrangements); and complexity (e.g., facility size, academic status, managed care penetration), adjusting for patient-level covariates and contextual factors. Data Collection/Extraction Methods. Chart-based evidence of CRC screening through direct colonoscopy, sigmoidoscopy, or consecutive fecal occult blood tests, eliminating cases with documented histories of CRC, polyps, or inflammatory bowel disease. Principal Findings. After adjusting for sociodemographic characteristics and health care utilization, patients were significantly more likely to be screened for CRC if their primary care practices had greater autonomy over the internal structure of care delivery (p <.04), more clinical support arrangements (p <.03), and smaller size (p <.001). Conclusions. Deficits in primary care clinical support arrangements and local autonomy over operational management and referral procedures are associated with significantly lower CRC screening performance. Competition with hospital resource demands may impinge on the degree of internal organization of their affiliated primary care practices. C1 VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda VA Ambulatory Care Ctr, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA USA. Univ Minnesota, Dept Colorectal Canc Surg, Minneapolis, MN USA. RP Yano, EM (reprint author), VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda VA Ambulatory Care Ctr, 16111 Plummer St, Sepulveda, CA 91343 USA. NR 46 TC 41 Z9 44 U1 1 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD JUN PY 2007 VL 42 IS 3 BP 1130 EP 1149 DI 10.1111/j.1475-6773.2006.00643.x PN 1 PG 20 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 163ZG UT WOS:000246201400013 PM 17489907 ER PT J AU Wertheimer, AM Polyak, SJ Leistikow, R Rosen, HR AF Wertheimer, Anne M. Polyak, Stephen J. Leistikow, Rachel Rosen, Hugo R. TI Engulfment of apoptotic cells expressing HCV proteins leads to differential chemokine expression and STAT signaling in human dendritic cells SO HEPATOLOGY LA English DT Article ID HEPATITIS-C-VIRUS; NONSTRUCTURAL 5A PROTEIN; GENE-EXPRESSION; LIVER-DISEASE; FUNCTIONAL-ANALYSIS; T-CELLS; INFECTION; INTERLEUKIN-8; INTERFERON; REPLICATION AB In the majority of cases, infection with hepatitis C virus (HCV) becomes chronic and is often associated with impaired innate and adaptive immune responses. The mechanisms underlying viral persistence and lack of protective immunity are poorly understood. Considering that dendritic cells (DCs) play critical roles in initiating and modulating immune responses, we explored the effect of HCV proteins on DC gene and protein expression, phenotype, and function. Human DCs were generated following plastic adherence of monocytes and culture with granulocyte-macrophage colony stimulating factor and interleukin-4 (IL-4) from normal subjects. Autologous nonadherent peripheral blood mononuclear cells were infected with vaccinia constructs expressing various HCV proteins (core-E1, WA, NS5B) or an irrelevant protein beta-galactosidase (beta-gal) as the control, induced to undergo apoptosis, then co-cultured with DCs. Between 2% and 10% of the genes probed in a cDNA nylon array were differentially regulated within DCs that had engulfed HCV proteins. In particular, the presence of intracellular NS5A led to increased transcriptional and protein expression of IL-8 (CXCL-8), a chemokine with proinflammatory and anti-interferon properties, and impaired interferon induction of signal transducers and activators of transcription 1 (STAT1) serine and tyrosine and STAT2 tyrosine phosphorylation. Conclusion: These data provide novel mechanisms by which HCV subverts antiviral host immunity. C1 Portland VA Med Ctr, Dept Med, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. Vaccine & Gene Therapy Inst, Beaverton, OR USA. Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. Univ Colorado, Grad Program Microbiol, Denver, CO 80202 USA. Univ Colorado, Div Gastroenterol & Hepatol, Denver, CO 80202 USA. Univ Colorado, Integrated Program Immunol, Denver, CO 80202 USA. Univ Colorado, Hepatitis C Ctr, Denver, CO 80202 USA. Univ Washington, Dept Microbiol, Seattle, WA 98195 USA. Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA. RP Rosen, HR (reprint author), Univ Colorado, UCHSC GI Div, 4200 E 9th Ave B-158, Denver, CO 80202 USA. EM hugo.rosen@uchsc.edu RI Polyak, Stephen/B-5743-2011 FU NCRR NIH HHS [5M01 RR 000334]; NIAID NIH HHS [U19 AI066328-030002, U19 AI066328]; NIDDK NIH HHS [R01 DK 060590, DK 62187] NR 49 TC 15 Z9 15 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD JUN PY 2007 VL 45 IS 6 BP 1422 EP 1432 DI 10.1002/hep.21637 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 175KC UT WOS:000247011500014 PM 17538964 ER PT J AU Luks, AM Henderson, WR Swenson, ER AF Luks, Andrew M. Henderson, William R., Jr. Swenson, Erik R. TI Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia SO HIGH ALTITUDE MEDICINE & BIOLOGY LA English DT Article DE acute mountain sickness; high altitude; montelukast; leukotriene receptor blockade; leukotrienes; urinary leukotriene E-4 ID HIGH-ALTITUDE; E(4) LEVELS; MONTELUKAST; MODERATE; E-4 AB Luks, Andrew M., William R. Henderson, Jr., and Erik R. Swenson. Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia. High Alt. Med. Biol. 8:131-138, 2007.-Previous research has demonstrated that blood and urine concentrations of various leukotrienes are elevated with acute hypoxic exposure. Some of these studies have suggested that leukotrienes may be mediators in the pathogenesis of acute mountain sickness (AMS). We conducted a randomized, double-blind study to determine if AMS symptoms correlated with the increase in leukotriene synthesis and if prophylactic leukotriene receptor blockade would prevent the development of AMS in a simulated high altitude exposure. Three male and five female subjects completed two normobaric hypoxia chamber exposures (average F 102 12.4 +/- 0.09%), receiving montelukast 10 mg daily for 4 days prior to one session and placebo for 4 days prior to the other session. There were no differences in Lake Louise AMS scores, time spent in the chamber, average oxygen saturation, and average heart rate during the montelukast and placebo sessions. Headache scores were higher during treatment with montelukast than during treatment with placebo. Compared to preexposure values, urinary leukotriene E-4 concentrations were unchanged during the hypoxic chamber exposure following treatment with placebo or montelukast. Urinary leukotriene E-4 excretion during the hypoxic exposure did not differ between the two sessions. A 4-day course of leukotriene receptor blockade does not prevent symptoms of AMS. These results suggest that leukotrienes do not play a causal role in the pathophysiology of AMS. C1 Univ Washington, Div Pulm & Crit Care, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Ctr Allergy & Inflammat, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA. RP Luks, AM (reprint author), Univ Washington, Div Pulm & Crit Care, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, 1959 NE Pacific St,Box 356522, Seattle, WA 98195 USA. EM aluks@u.washington.edu NR 13 TC 3 Z9 3 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1527-0297 J9 HIGH ALT MED BIOL JI High Alt. Med. Biol. PD SUM PY 2007 VL 8 IS 2 BP 131 EP 138 DI 10.1089/ham.2007.1052 PG 8 WC Biophysics; Public, Environmental & Occupational Health; Sport Sciences SC Biophysics; Public, Environmental & Occupational Health; Sport Sciences GA 182YF UT WOS:000247539200006 PM 17584007 ER PT J AU Rogers, J Kochunov, P Lancaster, J Shelledy, W Glahn, D Blangero, J Fox, P AF Rogers, Jeffrey Kochunov, Peter Lancaster, Jack Shelledy, Wendy Glahn, David Blangero, John Fox, Peter TI Heritability of brain volume, surface area and shape: An MRI study in an extended pedigree of baboons SO HUMAN BRAIN MAPPING LA English DT Article DE brain size; gray matter volume; cerebral surface area; primate; regional heritability; voxel based morphometry ID BIPOLAR DISORDER; LINKAGE ANALYSIS; ANATOMICAL MRI; TRAIT LOCI; SIZE; SCHIZOPHRENIA; MORPHOMETRY; EVOLUTION; GENETICS; INTELLIGENCE AB To evaluate baboons (Papio hamadryas) as a primate model for the study of the genetic control of brain size and internal structure, we performed high resolution (< 500 mu m) magnetic resonance imaging on 109 pedigreed baboons. Quantitative genetic analysis of these MR images using a variance components approach indicates that native (untransformed) brain volume exhibits significant heritability among these baboons (h(2) = 0.52, P = 0.0049), with age and sex also accounting for substantial variation. Using global spatial normalization, we transformed all images to a standard population-specific reference, and recalculated the heritability of brain volume. The transformed images generated heritability estimates of h(2) = 0.82 (P = 0.00022) for total brain volume, h(2) = 0.86 (P = 0.0006) for cerebral volume, h(2) = 0.73 (P = 0.0069) for exposed surface area of the cerebrum and h(2) = 0.67 (P = 0.01) for gray matter volume. Regional differences in the genetic effects on brain structure were calculated using a voxel-based morphometry (VBM) approach. This analysis of regional variation shows that some areas of motor cortex and the superior temporal gyrus show relatively high heritability while other regions (e.g. superior parietal cortex) exhibit lower heritability. The general pattern of regional differences is similar to that observed in previous studies of humans. The present study demonstrates that there is substantial genetic variation underlying individual variation in brain size and structure among Papio baboons, and that broad patterns of genetic influence on variation in brain structure may be similar in baboons and humans. C1 SW Fdn Biomed Res, Dept Genet, San Antonio, TX 78227 USA. SW Natl Primate Res Ctr, San Antonio, TX 78227 USA. Univ Texas, Hlth Sci Ctr, Res Imaging Ctr, San Antonio, TX 78285 USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX USA. RP Rogers, J (reprint author), SW Fdn Biomed Res, Dept Genet, 7620 NW Loop 410, San Antonio, TX 78227 USA. EM jrogers@darwin.sfbr.org RI Lancaster, Jack/F-2994-2010; Kochunov, Peter/E-4711-2010; Fox, Peter/B-4725-2010 OI Fox, Peter/0000-0002-0465-2028 FU NCRR NIH HHS [P51-RR013986]; NIMH NIH HHS [R01MH078111, R37MH059490] NR 42 TC 51 Z9 51 U1 0 U2 6 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1065-9471 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD JUN PY 2007 VL 28 IS 6 BP 576 EP 583 DI 10.1002/hbm.20407 PG 8 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 169YV UT WOS:000246628900012 PM 17437285 ER PT J AU Matsunaga, J Lo, M Bulach, DM Zuerner, RL Adler, B Haake, DA AF Matsunaga, James Lo, Miranda Bulach, Dieter M. Zuerner, Richard L. Adler, Ben Haake, David A. TI Response of Leptospira interrogans to physiologic osmolarity: Relevance in signaling the environment-to-host transition SO INFECTION AND IMMUNITY LA English DT Article ID SURFACE-EXPOSED LIPOPROTEIN; OSMOTIC-STRESS RESPONSE; OUTER-MEMBRANE PROTEINS; PATHOGENIC LEPTOSPIRA; GENE-EXPRESSION; SEROVAR LAI; MOLECULAR CHARACTERIZATION; MAMMALIAN INFECTION; ESCHERICHIA-COLI; CYCLIC-AMP AB Transmission of pathogenic Leptospira between mammalian hosts usually involves dissemination via soil or water contaminated by the urine of carrier animals. The ability of Leptospira to adapt to the diverse conditions found inside and outside the host is reflected in its relatively large genome size and high percentage of signal transduction genes. An exception is Leptospira borgpetersenii serovar Hardjo, which is transmitted by direct contact and appears to have lost genes necessary for survival outside the mammalian host. Invasion of host tissues by Leptospira interrogans involves a transition from a low osmolar environment outside the host to a higher physiologic osmolar environment within the host. Expression of the lipoprotein LigA and LigB adhesins is strongly induced by an upshift in osmolarity to the level found in mammalian host tissues. These data suggest that Leptospira utilizes changes in osmolarity to regulate virulence characteristics. To better understand how L. interrogans serovar Copenhageni adapts to osmolar conditions that correspond with invasion of a mammalian host, we quantified alterations in transcript levels using whole-genome microarrays. Overnight exposure in leptospiral culture medium supplemented with sodium chloride to physiologic osmolarity significantly altered the transcript levels of 6% of L. interrogans genes. Repressed genes were significantly more likely to be absent or pseudogenes in L. borgpetersenii, suggesting that osmolarity is relevant in studying the adaptation of L. interrogans to host conditions. Genes induced by physiologic osmolarity encoded a higher than expected number of proteins involved in signal transduction. Further, genes predicted to encode lipoproteins and those coregulated by temperature were overrepresented among both salt-induced and salt-repressed genes. In contrast, leptospiral homologues of hyperosmotic or general stress genes were not induced at physiologic osmolarity. These findings suggest that physiologic osmolarity is an important signal for regulation of gene expression by pathogenic leptospires during transition from ambient conditions to the host tissue environment. C1 VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Monash Univ, Australian Bacterial Pathogenesis Program, Clayton, Vic 3800, Australia. Monash Univ, Victorian Bioinformat Consortium, Clayton, Vic 3800, Australia. USDA ARS, Natl Anim Dis Ctr, Ames, IA 50010 USA. Monash Univ, Australian Res Council Ctr Excellence Struct & Fu, Clayton, Vic 3800, Australia. Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. RP Matsunaga, J (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv, Mail Code 151, Los Angeles, CA 90073 USA. EM jamesm@ucla.edu RI Bulach, Dieter/D-5793-2011 OI Bulach, Dieter/0000-0001-9823-6078 FU NIAID NIH HHS [R01 AI034431-10A1, AI 34431, R01 AI034431, R21 AI034431, R29 AI034431] NR 62 TC 63 Z9 64 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD JUN PY 2007 VL 75 IS 6 BP 2864 EP 2874 DI 10.1128/IAI.01619-06 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 172SN UT WOS:000246824500024 PM 17371863 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Similar geographic variations in mortality from peptic ulcer and inflammatory bowel disease SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE Crohn's disease; death rates; duodenal ulcer; epidemiology; enteric infections; etiology of ulcerative colitis; gastric ulcer; mortality; time trends ID HELICOBACTER-PYLORI INFECTION; DUODENAL-ULCER; CROHNS-DISEASE; UNITED-STATES; RISK-FACTORS; TIME TRENDS; COLITIS; PREVALENCE; PERIOD AB Background: The epidemiology of peptic ulcer and inflammatory bowel disease shows many similar patterns. The aim of the present study was to compare the geographic distribution of mortality from peptic ulcer with that from inflammatory bowel disease. \ Methods: Mortality data from 27 countries between 1991 and 2004 were analyzed. The relationships between the geographic distributions of mortality from gastric ulcer, duodenal ulcer, Crohn's disease, and ulcerative colitis were compared using least-squares linear regression analyses. Results: The study revealed a 20- to 30-fold variation in mortality from peptic ulcer and a 60-fold variation in mortality from inflammatory bowel disease among different countries. Mortality from peptic ulcer and inflammatory bowel disease tended to be more common in northern European countries and rare in most countries in Asia and South America. The similar variations of all 4 diseases resulted in the correlations among their geographic distributions being statistically significant. Conclusions: The similarities in the geographic distributions of gastric ulcer, duodenal ulcer, Crohn's disease, and ulcerative colitis indicate that all 4 diseases may share a common set of risk factors. C1 Portland VA Med Ctr, Portland, OR 97207 USA. Oregon Hlth & Sci Univ, Portland, OR USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM sonnenbe@ohsu.edu NR 33 TC 4 Z9 5 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JUN PY 2007 VL 13 IS 6 BP 763 EP 768 DI 10.1002/ibd.20111 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 173SX UT WOS:000246893900013 PM 17260352 ER PT J AU Phan, BAP Chu, BC Polissar, N Hatsukami, TS Yuan, C Zhao, XQ AF Phan, Binh An P. Chu, Baocheng Polissar, Nayak Hatsukami, Thomas S. Yuan, Chun Zhao, Xue-Qiao TI Association of high-density lipoprotein levels and carotid atherosclerotic plaque characteristics by magnetic resonance imaging SO INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING LA English DT Article DE atherosclerosis; high-density lipoprotein; magnetic resonance imaging; carotid arteries ID IN-VIVO; HIGH-RESOLUTION; CHOLESTEROL; DISEASE; SIMVASTATIN; PREVENTION; REGRESSION; LESIONS; MILANO; MRI AB A low level of high-density lipoprotein cholesterol (HDL-C) is a risk factor for atherosclerotic disease. Magnetic resonance imaging (MRI) can provide detailed information on carotid atherosclerotic plaque size and composition. The purpose of this study was to correlate HDL levels with carotid plaque burden and composition by MRI. Thirty-four patients with coronary artery disease (CAD) receiving simvastatin plus niacin or placebo for both drugs for three years were randomly selected to undergo MRI of carotid arteries. Atherosclerotic plaque wall volumes (WVs) and plaque components including lipid rich/necrotic core (LR/NC), calcium, fibrous tissue, and loose matrix were measured. Mean WV or atherosclerotic burden was significantly associated with total HDL-C levels (r = -0.39, P = 0.02), HDL2 (r = -0.36, P = 0.03), HDL3 (r = -0.34, P = 0.04), and LDL/HDL ratio (r = 0.42, P = 0.02). Plaque lipid composition or LR/NC was significantly associated with HDL3 (r = -0.68, P = 0.02). Patients with low HDL levels (<= 35 mg/dL) had increased WV (97 +/- 23 vs. 81 +/- 19 mm(3), P = 0.05) compared with patients with HDL levels > 35 mg/dL. Among CAD patients, low HDL-C levels were significantly associated with increased carotid atherosclerotic plaque burden and lipid content by MRI. C1 Univ Washington, Div Cardiol, Dept Med, Seattle, WA 98103 USA. Washington Univ, Dept Radiol, Seattle, WA USA. Mt Whisper Light Stat Consulting, Seattle, WA USA. Washington Univ, Dept Surg, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Phan, BAP (reprint author), Univ Washington, Div Cardiol, Dept Med, 1914 N 34th St,Suite 105, Seattle, WA 98103 USA. EM bapp@u.washington.edu NR 23 TC 20 Z9 24 U1 2 U2 5 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1569-5794 J9 INT J CARDIOVAS IMAG JI Int. J. Cardiovasc. Imaging PD JUN PY 2007 VL 23 IS 3 BP 337 EP 342 DI 10.1007/s10554-006-9175-7 PG 6 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 166PZ UT WOS:000246392600006 PM 17086362 ER PT J AU Chen, PJ Kales, HC Weintraub, D Blow, FC Jiang, L Ignacio, RV Mellow, AM AF Chen, Peijun Kales, Helen C. Weintraub, Daniel Blow, Frederic C. Jiang, Lan Ignacio, Rosalinda V. Mellow, Alan M. TI Depression in veterans with Parkinson's disease: frequency, co-morbidity, and healthcare utilization SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article; Proceedings Paper CT 18th Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 03-06, 2005 CL San Diego, CA SP Amer Assoc Geriatr Psychiat DE depression; Parkinson's disease; frequency; co-morbidity; healthcare utilization ID NONMOTOR SYMPTOMS; DEMENTIA; PREVALENCE; PSYCHOSIS; LIFE AB Objective To determine the frequency of depression in Parkinson's disease (PD) in routine clinical care, and to examine its association with co-morbid psychiatric and medical conditions and healthcare utilization. Methods Depression diagnoses and healthcare utilization data for all male veterans with PD age 55 or older seen in fiscal year 2002 (n = 41,162) were analyzed using Department of Veterans Affairs (VA) national databases. Frequencies of co-morbid disorders and healthcare utilization were determined for depressed and non-depressed patients; associations with depression were examined using multivariate logistic regression models. Results A depression diagnosis was recorded for 18.5% of PD, patients, including major depression in 3.9%. Depression decreased in frequency and severity with increasing age. In multivariate logistic regression models, depressed patients had significantly greater psychiatric and medical co-morbidity, including dementia, psychosis, stroke, congestive heart failure, diabetes, and chronic obstructive pulmonary disease than non-depressed patients (all p < 0.01). Depressed PD patients were also significantly more likely to have medical (OR = 1.34, 95% CI = 1.25-1.44) and psychiatric hospitalizations (OR = 2.14, 95% CI = 1.83-2.51), and had more outpatient visits (p < 0.01), than non-depressed PD) patients in adjusted models. Conclusion Depression in PD in non-tertiary care settings may not be as common or as severe as that seen in specialty care, though these findings also may reflect under-recognition or diagnostic imprecision. The occurrence of depression in PD is associated with greater psychiatric and medical co-morbidity, and greater healthcare utilization. These findings suggest that screening for depression in PD is important and should be embedded in a comprehensive psychiatric, neuropsychological, and medical evaluation. Copyright (c) 2006 John Wiley & Sons, Ltd. C1 Univ Michigan, Dept Psychiat, Div Geriatr Psychiat, Ann Arbor, MI 48109 USA. VA Natl Serious Mental Illness Treatment Res & Ev, Ann Arbor, MI USA. VA Ann Arbor Healthcare Syst, Geriatr Res Educ & Clin Ctr, Ann Arbor, MI USA. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Parkinsons Dis & Mental Illness Res Educ & Clin C, PADRECC, Philadelphia, PA USA. Philadelphia VA Med Ctr, MIRECC, Philadelphia, PA USA. VISN 11 Mental Hlth Serv Line, Dept Vet Affairs, Ann Arbor, MI USA. RP Chen, PJ (reprint author), Cleveland VA Med Ctr, Psychiat Serv 116A B, 10000 Brecksville Rd, Brecksville, OH 44141 USA. EM Peijun.chen@med.va.gov FU NIMH NIH HHS [K23 MH067894, K23 MH067894-04] NR 33 TC 18 Z9 20 U1 3 U2 6 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD JUN PY 2007 VL 22 IS 6 BP 543 EP 548 DI 10.1002/gps.1712 PG 6 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 181OO UT WOS:000247446200005 PM 17133656 ER PT J AU Faison, WE Schultz, SK Aerssens, J Alvidrez, J Anand, R Farrer, LA Jarvik, L Manly, J Mcrae, T Murphy, GM Olin, JT Regier, D Son, M Mintzer, JE AF Faison, Warachal E. Schultz, Susan K. Aerssens, Jeroen Alvidrez, Jennifer Anand, Ravi Farrer, Lindsay A. Jarvik, Lissy Manly, Jennifer McRae, Thomas Murphy, Greer M., Jr. Olin, Jason T. Regier, Darrel Son, Mary Mintzer, Jacobo E. TI Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article DE dementia; Alzheimer's disease; genetics; minority issues and cross-cultural psychiatry; social and political issues ID CANCER SCREENING TRIAL; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; PROSTATE-SPECIFIC ANTIGEN; AFRICAN-AMERICAN ELDERS; CLINICAL-TRIALS; RECRUITMENT EXPERIENCE; RACIAL-DIFFERENCES; COGNITIVE DECLINE; DIVERSE ELDERS; READING LEVEL AB Objective: Despite numerous clinical trials, it is unknown whether ethnicity affects treatment response to cognitive enhancers in Alzheimer's disease (AD). There is convincing evidence of ethnic and genetic variability in drug metabolism. This article reviews the available data on ethnicity in clinical trials for AD to answer two questions: (1) what are the challenges to diagnose and treat AD across different ethnic groups, and (2) are there differences in response to pharmacologic interventions for AD across these different ethnic groups? Method: Available data from Alzheimer's Disease Cooperative Study (ADCS) randomized controlled clinical trials and from randomized controlled industry-sponsored trials for four cognitive enhancers (donepezil, galantamine, rivastigmine and sabeluzole) were pooled to assess the numbers of non-Caucasian participants. Results: The participation of ethnic minority subjects in clinical trials for AD was dependent on the funding source, although Caucasian participants were over-represented and non-Caucasian participants were under-represented in the clinical trials. Because of the low participation rate of ethnic minorities, there were insufficient data to assess any differences in treatment outcome among different ethnic groups. Strategies to improve diversity in clinical trials are discussed. Conclusion: Greater participation of ethnically diverse participants in clinical trials for AD would generate additional information on possible differences in metabolism, treatment response, adverse events to therapeutic agents, and could foster the investigation of genetic variability among ethnic groups. C1 Med Univ S Carolina, Alzheimers Res & Clin Programs, Dept Neurosci, N Charleston, SC 29406 USA. Univ Iowa, Coll Med, Iowa City, IA USA. Janssen Pharmaceut NV, Johnson & Johnson Pharmaceut Res & Dev, Dept Internal Med, Beerse, Belgium. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Anand Pharma Consulting, Oberwil, Switzerland. Boston Univ, Sch Med, Genet Program, Boston, MA 02215 USA. Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. VA Greater Los Angeles Hlth Care Syst, Dept Vet Affairs, Los Angeles, CA USA. Columbia Univ, Med Ctr, New York, NY USA. Pfizer Inc, Alzheimers Dis Management Team, New York, NY USA. NYU, Sch Med, New York, NY USA. Stanford Univ, Sch Med, Neurosci Res Labs, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. Forest Res Inst, Jersey, NJ USA. Amer Psychiat Assoc, Div Res, Arlington, VA USA. APIRE, Arlington, VA USA. Mt Sinai Sch Med, Alzheimer Dis Res Ctr, Bronx, NY USA. James J Peters VA Med Ctr, Bronx, NY USA. Med Univ S Carolina, Dept Neurosci, Div Translat Res, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Faison, WE (reprint author), Med Univ S Carolina, Alzheimers Res & Clin Programs, Dept Neurosci, 5900 Core Rd,Suite 203, N Charleston, SC 29406 USA. EM faison@musc.edu OI Farrer, Lindsay/0000-0001-5533-4225 NR 95 TC 25 Z9 25 U1 2 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD JUN PY 2007 VL 19 IS 3 BP 539 EP 558 DI 10.1017/S104161020700511X PG 20 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA 175AQ UT WOS:000246984800016 PM 17451614 ER PT J AU Peluso, MAM Hatch, JP Glahn, DC Monkul, ES Sanches, M Najt, P Bowden, CL Barratt, ES Soares, JC AF Peluso, M. A. M. Hatch, J. P. Glahn, D. C. Monkul, E. S. Sanches, M. Najt, P. Bowden, C. L. Barratt, E. S. Soares, J. C. TI Trait impulsivity in patients with mood disorders SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE impulsivity; bipolar disorder; unipolar disorder; depression; mood ID BIPOLAR DISORDER; SUICIDE; HISTORY; SCALE AB Background: Impulsivity is a key component of the manic behavior of bipolar disorder and is reported to occur in bipolar patients as a stable characteristic, i.e. a trait. Nevertheless, impulsivity has not been widely studied in depressed bipolar patients. We assessed impulsivity in depressed and euthymic bipolar and unipolar patients and healthy controls. We hypothesized that bipolar subjects would have higher levels of trait impulsivity than the comparison groups. Methods: Twenty-four depressed bipolar, 24 depressed unipolar, 12 euthymic bipolar, and 10 euthymic unipolar patients, as well as 51 healthy subjects were evaluated with the Barratt Impulsiveness Scale (BIS). Analysis of covariance with age and sex as covariates was used to compare mean group differences. Results: Depressed bipolar, euthymic bipolar, and depressed unipolar patients did not differ, and showed greater impulsivity than healthy controls on all of the BIS scales. Euthymic unipolar patients scored higher than healthy controls only on motor impulsivity. Limitations: Higher number of past substance abusers in the bipolar groups, and no control for anxiety and personality disorders, as well as small sample sizes, limit the reach of this study. Conclusions: This study replicates prior findings of stable trait impulsivity in bipolar disorder patients, and extends them, confirming that this trait can be demonstrated in depressed patients, as well as manic and euthymic ones. Trait impulsivity may be the result of repeated mood episodes or be present prior to their onset, either way it would influence the clinical presentation of bipolar disorder. (c) 2006 Elsevier B.V. All rights reserved. C1 UTHSCSA, Dept Psychiat, San Antonio, TX USA. Univ Sao Paulo, Dept Psychiat, Sect Psychiat Epidemiol, Sao Paulo, Brazil. UTHSCSA, Dept Orthodont, San Antonio, TX USA. Dokuz Eylul Univ, Dept Psychiat, Izmir, Turkey. Univ Fed Sao Paulo, Dept Psychiat, Sao Paulo, Brazil. Univ Texas, Med Branch, Dept Psychiat, Galveston, TX 77555 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. UTHSCSA, Dept Radiol, San Antonio, TX USA. RP Peluso, MAM (reprint author), Univ Sao Paulo, Inst Psychiat, Rua Dr Ovidio Pires Campos,785-3 Andar, BR-05403010 Sao Paulo, SP, Brazil. EM mampeluso@hotmail.com FU NCRR NIH HHS [M01-RR-01346]; NIMH NIH HHS [MH068662, MH01736] NR 18 TC 106 Z9 107 U1 0 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JUN PY 2007 VL 100 IS 1-3 BP 227 EP 231 DI 10.1016/j.jad.2006.09.037 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 185IK UT WOS:000247704400027 PM 17097740 ER PT J AU Bamman, MM Petrella, JK Kim, JS Mayhew, DL Cross, JM AF Bamman, Marcas M. Petrella, John K. Kim, Jeong-su Mayhew, David L. Cross, James M. TI Cluster analysis tests the importance of myogenic gene expression during myofiber hypertrophy in humans SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE muscle growth; myogenin; insulin-like growth factor I; muscle fiber ID GROWTH-FACTOR-I; MUSCLE SATELLITE CELLS; HUMAN SKELETAL-MUSCLE; MESSENGER-RNA EXPRESSION; IGF-I; RESISTANCE EXERCISE; MOLECULAR RESPONSES; TIME-COURSE; OLDER MEN; NITRIC-OXIDE AB We applied K-means cluster analysis to test the hypothesis that muscle-specific factors known to modulate protein synthesis and satellite cell activity would be differentially expressed during progressive resistance training (PRT, 16 wk) in 66 human subjects experiencing extreme, modest, and failed myofiber hypertrophy. Muscle mRNA expression of IGF-I isoform Ea (IGF-IEa), mechanogrowth factor (MGF, IGF-IEc), myogenin, and MyoD were assessed in muscle biopsies collected at baseline (T1) and 24 h after the first (T2) and last (T3) loading bouts from previously untrained subjects clustered as extreme responders (Xtr, n = 17), modest responders (Mod, n = 32), and nonresponders (Non, n = 17) based on mean myofiber hypertrophy. Myofiber growth averaged 2,475 mu m(2) in Xtr, 1, 111 mu m(2) in Mod, and - 16 mu m(2) in Non. Main training effects revealed increases in all transcripts (46-83%, P < 0.005). For the entire cohort, IGF-IEa. MGF, and myogenin mRNAs were upregulated by T2 (P < 0.05), while MyoD did not increase significantly until T3 (P < 0.001). Within clusters, MGF and myogenin upregulation was robust in Xtr (126% and 65%) and Mod (73% and 41%) vs. no changes in Non. While significant in all clusters by T3, IGF-IEa increased most in Xtr (105%) and least in Non (44%). Although MyoD expression increased overall, no changes within clusters were detected. We reveal for the first time that MGF and myogenin transcripts are differentially expressed in subjects experiencing varying degrees of PRT-mediated myofiber hypertrophy. The data strongly suggest the load-mediated induction of these genes may initiate important actions necessary to promote myofiber growth during PRT, while the role of MyoD is less clear. C1 Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA. Univ Alabama, Dept Surg, Birmingham, AL 35294 USA. Univ Alabama, Med Sci Training Program, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Birmingham, AL USA. RP Bamman, MM (reprint author), Univ Alabama, Vet Affairs Med Ctr, Dept Physiol & Biophys, Core Muscle Res Lab, GRECC-11G,1530 3rd Ave S, Birmingham, AL 35294 USA. EM mbamman@uab.edu FU NCRR NIH HHS [M01-RR-00032]; NIA NIH HHS [R01-AG-017896] NR 49 TC 77 Z9 78 U1 0 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD JUN PY 2007 VL 102 IS 6 BP 2232 EP 2239 DI 10.1152/japplphysiol.00024.2007 PG 8 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 195KJ UT WOS:000248410800023 PM 17395765 ER PT J AU Mangat, S Agarwal, S Rosendorff, C AF Mangat, Simardeep Agarwal, Sanjay Rosendorff, Clive TI Do statins lower blood pressure? SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS LA English DT Review DE statins; hypertension; blood pressure ID NITRIC-OXIDE SYNTHASE; COA REDUCTASE INHIBITORS; LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; PLACEBO-CONTROLLED TRIAL; TYPE-2 DIABETIC-PATIENTS; CHOLESTEROL REDUCTION; HYPERTENSIVE PATIENTS; ENDOTHELIAL-CELLS; OXIDIZED LDL AB Hypercholesterolemia is present in many patients with hypertension and adds a significant component of cardiovascular risk. The 3-hydroxy-3 methyl-glutaryl-coenzyme A reductase inhibitors (statins) lower low-density lipoprotein cholesterol but also inhibit many of the structural and functional components of the arteriosclerotic process. Structural effects include reductions in vascular smooth muscle hypertrophy and proliferation, fibrin deposition, and collagen cross-linking. Among the functional effects are improvements in endothelial function, reduction in inflammatory cytokines and reactive oxygen species, and down-regulation of angiotensin 11 and endothelin receptors. These would be expected to reduce blood pressure in patients with hypertension; 14 studies have shown statin-induced decrease in blood pressure, but I I studies showed no effect. Many of the studies had no placebo controls, were of short duration, or had small sample sizes, or combinations of these. Despite predictions made on the basis of. the vasoprotective actions of statins, the blood-pressure-lowering effects of statins are at best modest. C1 James J Peters VA Med Ctr, Dept Med 111, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Med, New York, NY USA. James J Peters VA Med Ctr, Bronx, NY USA. RP Rosendorff, C (reprint author), James J Peters VA Med Ctr, Dept Med 111, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM clive.rosendorff@med.va.gov NR 67 TC 13 Z9 13 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1074-2484 J9 J CARDIOVASC PHARM T JI J. Cardiovasc. Pharmacol. Ther. PD JUN PY 2007 VL 12 IS 2 BP 112 EP 123 DI 10.1177/107424807300380 PG 12 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 176VF UT WOS:000247112300004 PM 17562781 ER PT J AU Song, YL Liu, CX Finegold, SM AF Song, Yuli Liu, Chengxu Finegold, Sydney M. TI Peptoniphilus gorbachii sp nov., Peptoniphilus olsenii sp nov., and Anaerococcus murdochii sp nov isolated from clinical specimens of human origin SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID POSITIVE ANAEROBIC COCCI; GENUS PEPTOSTREPTOCOCCUS; PROPOSAL; IDENTIFICATION; MEMBERS; MAGNUS AB Three groups of previously unknown gram-positive, anaerobic, coccus-shaped bacteria were characterized using phenotypic and molecular taxonomic methods. Phenotypic and genotypic data demonstrate that these organisms are distinct, and each group represents a previously unknown subline within Clostridium cluster XIII. Two groups are most closely related to Peptoniphilus harei in the genus Peptoniphilus, and the other group is most closely related to Anaerococcus lactolyticus in the genus Anaerococcus. Based on the findings, three novel species, Peptoniphilus gorbachii sp. nov., Peptoniphilus olsenii sp. nov., and Anaerococcus murdochii sp. nov., are proposed. The type strains of Peptoniphilas gorbachii sp. nov., Peptoniphilus olsenii sp. nov., and Anaerococcus murdochii sp. nov. are WAL 10418(T) (= CCUG 53341(T) = ATCC BAA-1383(T)), WAL 12922(T) (= CCUG 53342(T) (=) ATCC BAA-1384(T)), and WAL 17230(T) (= CCUG 53340(T) = ATCC BAA-1385(T)), respectively. C1 W Los Angeles Vet Affairs Med Ctr, Res Serv, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Infect Dis Sect, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA USA. RP Song, YL (reprint author), W Los Angeles Vet Affairs Med Ctr, Res Serv, Bldg 304,Rm E3-227,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM yulis1@yahoo.com NR 20 TC 32 Z9 32 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JUN PY 2007 VL 45 IS 6 BP 1746 EP 1752 DI 10.1128/JCM.00213-07 PG 7 WC Microbiology SC Microbiology GA 179JT UT WOS:000247286500012 PM 17428937 ER PT J AU Grand, RBG Hwang, S Han, J George, T Brody, AL AF Grand, Risa B. Gershon Hwang, Sun Han, Juliette George, Tony Brody, Arthur L. TI Short-term naturalistic treatment outcomes in cigarette smokers with substance abuse and/or mental illness SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT 12th Annual Meeting of the Society-for-Research-on-Nicotine-and-Tobacco CY FEB 15-18, 2006 CL Orlando, FL SP Soc Res Nicotine & Tobacco ID METHADONE-MAINTENANCE TREATMENT; POSTTRAUMATIC-STRESS-DISORDER; BUPROPION SUSTAINED-RELEASE; PLACEBO-CONTROLLED TRIAL; NICOTINE PATCH THERAPY; OF-VETERANS-AFFAIRS; SMOKING-CESSATION; MAJOR DEPRESSION; UNITED-STATES; EPIDEMIOLOGIC SURVEY AB Objective: The majority of cigarette smokers have a lifetime diagnosis of substance abuse and/or mental illness, and treatment outcomes for smokers with these comorbidities are generally reported to be worse than for smokers without comorbidities. We sought to examine the effect of specific substance abuse/mental illness diagnoses compared to one another on treatment outcomes. Method: A retrospective chart review of naturalistic treatment for nicotine dependence was performed on male smokers (N = 231) who enrolled in the Greater Los Angeles Veterans Affairs Mental Health Clinic Smoking Cessation Program (Los Angeles, Calif.) over a 1.5-year period (January 2004 to June 2005). Subjects in this program, who were diagnosed with nicotine dependence on the basis of a DSM-lV-based interview and a Fagerstrom Test for Nicotine Dependence score of ! 3, underwent comprehensive treatment for nicotine dependence (including, but not limited to, group psychotherapy, nicotine replacement therapy, and bupropion hydrochloride). Quitting smoking was defined as a report of at least I week of abstinence and an exhaled carbon monoxide less than or equal to 8 parts per million at the final clinic visit. Results: Of the total group, 36.4% (84/231) quit smoking at the end of treatment. Quit rates were affected by the presence of specific diagnoses, with smokers with a history of alcohol abuse/dependence or schizophrenia/schizoaffective disorder having poorer response rates than smokers without such diagnoses. Other substance abuse and mental illness diagnoses did not affect quit rates. Conclusion: Lower quit rates among patients with alcohol abuse/dependence or schizophrenia/schizoaffective disorder may be due to the severity of these conditions and suggest that specialized treatment is needed for these populations of smokers. Smokers with most comorbid diagnoses are successfully treated with standard treatment methods. C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. Yale Univ, Sch Med, New Haven, CT USA. RP Brody, AL (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. EM abrody@ucla.edu NR 73 TC 20 Z9 21 U1 1 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JUN PY 2007 VL 68 IS 6 BP 892 EP 898 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 183FT UT WOS:000247558800011 ER PT J AU Cully, JA Graham, DP Stanley, MA Kunik, ME AF Cully, Jeffrey A. Graham, David P. Stanley, Melinda A. Kunik, Mark E. TI Depressed and anxious COPD patients: Predictors of psychotherapy engagement from a clinical trial SO JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS LA English DT Article DE engagement in mental health treatment; anxiety; depression; chronic obstructive pulmonary disease ID PRIMARY-CARE PATIENTS; QUALITY-OF-LIFE; MAJOR DEPRESSION; ANXIETY; INTERVENTION; ATTITUDES; SYMPTOMS; DISEASE AB This study examined patient-level factors associated with engagement in mental health treatment in a sample of medically ill patients with clinically significant symptoms of depression and/or anxiety. A total of 248 patients was enlisted from a randomized controlled trial of cognitive-behavioral therapy for depression and anxiety in patients with chronic obstructive pulmonary disease (COPD). Logistic regression analysis was used to predict mental health engagement, defined as attending at least one intervention session. Results indicated that patient-perceived mastery over COPD was negatively related to mental health engagement. Further, mastery was the only significant predictor of mental health engagement after controlling for patient demographic characteristics, severity of COPD, depression, and anxiety. To improve engagement for medically ill patients with comorbid mental health difficulties, clinicians should explore patients' attitudes about their mental health within the context of their perceived ability to cope with their medical disease. C1 Michael E Debakey Vet Affairs Med Ctr, Vet Affairs HSR&D Ctr Excellence, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Vet Affairs S Cent Mental Illness Res Educ & Clin, Houston, TX USA. RP Cully, JA (reprint author), Michael E Debakey Vet Affairs Med Ctr, Vet Affairs HSR&D Ctr Excellence, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe 152, Houston, TX 77030 USA. EM jcully@bcm.edu RI Graham, David /J-1158-2014 NR 16 TC 4 Z9 4 U1 1 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9583 J9 J CLIN PSYCHOL MED S JI J. Clin. Psychol. Med. Settings PD JUN PY 2007 VL 14 IS 2 BP 160 EP 164 DI 10.1007/s10880-007-9060-0 PG 5 WC Psychology, Clinical SC Psychology GA 201EO UT WOS:000248814500009 ER PT J AU Taylor, JG Baker, SB AF Taylor, John G. Baker, Stanley B. TI Psychosocial and moral development of PTSD-diagnosed combat veterans SO JOURNAL OF COUNSELING AND DEVELOPMENT LA English DT Article AB Two related studies were conducted in order to investigate whether psychosocial and moral development appeared to have been disrupted and arrested in veterans diagnosed as having posttraumatic stress disorder (PTSD). Study 1 was devoted to developing a measure of late adolescence, early adulthood, and adulthood stages of psychosocial development. In Study 2, a sample of 32 PTSD-diagnosed and 32 PTSD-free veterans participated. The PTSD-diagnosed participants presented evidence of arrested psychosocial and moral development. C1 US Dept Vet Affairs, Vocat Rehabil & Employment, Jacksonville, NC 28540 USA. N Carolina State Univ, Counselor Educ Program, Raleigh, NC 27695 USA. RP Taylor, JG (reprint author), US Dept Vet Affairs, Vocat Rehabil & Employment, Box 4360 MCAS, Jacksonville, NC 28540 USA. EM ADJJTAYL2@vba.va.gov NR 26 TC 2 Z9 2 U1 1 U2 1 PU AMER COUNSELING ASSOC PI ALEXANDRIA PA 5999 STEVENSON AVE, ALEXANDRIA, VA 22304-3300 USA SN 0748-9633 J9 J COUNS DEV JI J. Couns. Dev. PD SUM PY 2007 VL 85 IS 3 BP 364 EP 369 PG 6 WC Psychology, Applied SC Psychology GA 181RF UT WOS:000247453100012 ER PT J AU Kougias, P El Sayed, HF Zhou, W Lin, PH AF Kougias, Panagiotis El Sayed, Hosam F. Zhou, Wei Lin, Peter H. TI Management of chronic mesenteric ischemia. The role of endovascular therapy SO JOURNAL OF ENDOVASCULAR THERAPY LA English DT Article DE mesenteric ischemia; endovascular therapy; surgical intervention; review ID PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; DRUG-ELUTING STENTS; INTESTINAL ISCHEMIA; OCCLUSIVE DISEASE; SURGICAL-TREATMENT; VISCERAL ISCHEMIA; ARTERY BYPASS; LATE OUTCOMES; FOLLOW-UP; REVASCULARIZATION AB Chronic mesenteric ischemia is an uncommon disorder manifested most commonly as abdominal pain. Surgical revascularization has traditionally been the treatment of choice. Endovascular management of this entity was originally attempted as an alternative for high-risk patients. Improvements in stent technology, refinement in technique, and increased efficiency of antiplatelet regimens have, over time, increased the popularity of this minimally invasive approach. We present a review of the available series on endovascular treatment of chronic mesenteric ischemia, with emphasis on short- and long-term outcome and morbidity and mortality results. Principles of operative technique and controversial issues and topics of interest are also discussed. C1 Baylor Coll Med, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, Houston, TX USA. RP Kougias, P (reprint author), Houston VAMC, Michael E DeBakey Dept Surg, 2002 Holcombe Blvd 112, Houston, TX 77030 USA. EM pkougias@bcm.tmc.edu NR 48 TC 22 Z9 24 U1 0 U2 0 PU ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS PI LAWRENCE PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA SN 1526-6028 J9 J ENDOVASC THER JI J. Endovascular Ther. PD JUN PY 2007 VL 14 IS 3 BP 395 EP 405 DI 10.1583/07-2102.1 PG 11 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 188KV UT WOS:000247919700018 PM 17723025 ER PT J AU Campbell, DG Felker, BL Liu, CF Yano, EM Kirchner, JE Chan, D Rubenstein, LV Chaney, EF AF Campbell, Duncan G. Felker, Bradford L. Liu, Chuan-Fen Yano, Elizabeth M. Kirchner, JoAnn E. Chan, Domin Rubenstein, Lisa V. Chaney, Edmund F. TI Prevalence of depression-PTSD comorbidity: Implications for clinical practice guidelines and primary care-based interventions SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT National Annual Meeting of the US Department of Veterans Affairs Health Services Research and Development Service CY FEB, 2005 CL Baltimore, MD DE depression; PTSD; primary care; clinical practice guidelines ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; LATE-LIFE DEPRESSION; MAJOR DEPRESSION; SUICIDAL-BEHAVIOR; FUNCTIONAL STATUS; VETERANS HEALTH; SOCIAL SUPPORT; COMMUNITY; ASSOCIATION AB BACKGROUND: Compared to those with depression alone, depressed patients with posttraumatic stress disorder ( PTSD) experience more severe psychiatric symptomatology and factors that complicate treatment. OBJECTIVE: To estimate PTSD prevalence among depressed military veteran primary care patients and compare demographic/illness characteristics of PTSD screen-positive depressed patients (MDD-PTSD+) to those with depression alone (MDD). DESIGN: Cross-sectional comparison of MDD patients versus MDD-PTSD+ patients. PARTICIPANTS: Six hundred seventy-seven randomly sampled depressed patients with at least 1 primary care visit in the previous 12 months. Participants composed the baseline sample of a group randomized trial of collaborative care for depression in 10 VA primary care practices in 5 states. MEASUREMENTS: The Patient Health Questionnaire-9 assessed MDD. Probable PTSD was defined as a Primary Care PTSD Screen >= 3. Regression-based techniques compared MDD and MDD-PTSD+ patients on demographic/illness characteristics. RESULTS: Thirty-six percent of depressed patients screened positive for PTSD. Adjusting for sociodemographic differences and physical illness comorbidity, MDD-PTSD+ patients reported more severe depression (P <. 001), lower social support (P <. 001), more frequent outpatient health care visits (P <. 001), and were more likely to report suicidal ideation (P <. 001) than MDD patients. No differences were observed in alcohol consumption, self-reported general health, and physical illness comorbidity. CONCLUSIONS: PTSD is more common among depressed primary care patients than previously thought. Comorbid PTSD among depressed patients is associated with increased illness burden, poorer prognosis, and delayed response to depression treatment. Providers should consider recommending psychotherapeutic interventions for depressed patients with PTSD. C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Dept Vet Affairs, Seattle, WA USA. Univ Montana, Dept Psychol, Missoula, MT 59812 USA. VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Dept Vet Affairs, Seattle, WA USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA. VA Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Hlth Serv Res & Dev Ctr Excellence, Sepulveda, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. Cent Arkansas Vet Healthcare Syst, Dept Vet Affairs, Hlth Serv Res & Dev, N Little Rock, AR USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. RAND Corp, Hlth Program, Santa Monica, CA 90406 USA. RP Campbell, DG (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Dept Vet Affairs, Seattle, WA USA. EM Duncan.Campbell@umontana.edu NR 58 TC 138 Z9 138 U1 2 U2 15 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2007 VL 22 IS 6 BP 711 EP 718 DI 10.1007/s11606-006-0101-4 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 169AA UT WOS:000246563900001 PM 17503104 ER PT J AU Crothers, K Goulet, JL Rodriguez-Barradas, MC Gibert, CL Butt, AA Braithwaite, RS Peck, R Justice, AC AF Crothers, Kristina Goulet, Joseph L. Rodriguez-Barradas, Maria C. Gibert, Cynthia L. Butt, Adeel A. Braithwaite, R. Scott Peck, Robin Justice, Amy C. TI Decreased awareness of current smoking among health care providers of HIV-positive compared to HIV-negative veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE tobacco; detection of smoking; HIV; smoking cessation ID HUMAN-IMMUNODEFICIENCY-VIRUS; CIGARETTE-SMOKING; ANTIRETROVIRAL THERAPY; BACTERIAL PNEUMONIA; INFECTED PERSONS; RANDOMIZED-TRIAL; MORTALITY-RATES; TOBACCO USE; DISEASE; DEATH AB BACKGROUND: Cigarette smoking is an important risk factor for morbidity and mortality in HIV-positive patients on combination antiretroviral therapy. OBJECTIVE: To determine whether awareness of smoking differs between HIV and non-HIV providers, and to identify factors associated with failure to recognize current smoking. DESIGN: Observational study. PARTICIPANTS: 801 HIV-positive and 602 HIV-negative patients, 72 HIV and 71 non-HIV providers enrolled in the Veterans Aging Cohort 5 Site Study. MEASUREMENTS: Data sources included patient and provider questionnaires; electronic medical records; and the national administrative VA database. We calculated sensitivity, specificity, and measures of agreement between patient-and provider-reported smoking, and examined factors associated with failure to recognize current smoking using logistic regression. RESULTS: Whereas most providers were correct when they identified a patient as a current smoker (specificity >= 90%), HIV providers missed current smoking more often (sensitivity 65% for HIV vs. 82% for non-HIV). Kappa scores for current smoking were significantly lower for HIV compared to non- HIV providers (0.55 vs. 0.75, p <.001). In models adjusted for age, gender, race, and other differences, patient HIV status and provider specialty in infectious diseases were independent predictors of a provider's failure to recognize current smoking. Comorbid illnesses, cough/dyspnea, degree of immune competence and HIV viral suppression did not impact recognition of current smoking. Only 39% of HIV providers reported confidence in their ability to influence smoking cessation compared to 62% of non-HIV providers (p=. 049). CONCLUSIONS: Interventions to increase HIV provider awareness of current smoking and skills to influence smoking cessation are needed. Efforts should also target patient populations with smoking-related comorbid diseases who would especially benefit from smoking cessation. C1 Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA. Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA. VA Connecticut Healthcare Syst, West Haven, CT USA. Michael A DeBakey VA Med Ctr, Med Serv, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. George Washington Univ, Washington, DC 20052 USA. VA Med Ctr, Med Serv, Washington, DC USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Dept Internal Med, Pittsburgh, PA USA. RP Justice, AC (reprint author), Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA. EM amy.justice2@va.gov OI Goulet, Joseph/0000-0002-0842-804X; Crothers, Kristina/0000-0001-9702-0371 FU NCRR NIH HHS [K12 RR0117594-01]; NIAAA NIH HHS [3U01 AA 13566, U01 AA013566]; NIDA NIH HHS [K23 DA016175, K23 DA016175-01A1]; PHS HHS [K23 G00826] NR 31 TC 31 Z9 31 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2007 VL 22 IS 6 BP 749 EP 754 DI 10.1007/s11606-007-0158-8 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 169AA UT WOS:000246563900006 PM 17503106 ER PT J AU Kressin, NR Wang, F Long, J Bokhour, BG Orner, MB Rothendler, J Clark, C Reddy, S Kozak, W Kroupa, LP Berlowitz, DR AF Kressin, Nancy R. Wang, Fei Long, Judith Bokhour, Barbara G. Orner, Michelle B. Rothendler, James Clark, Christine Reddy, Surekha Kozak, Waldemar Kroupa, Laura P. Berlowitz, Dan R. TI Hypertensive patients' race, health beliefs, process of care, and medication adherence SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE physician-patient relations; patient compliance; attitude to health ID ANTIHYPERTENSIVE THERAPY; RACIAL-DIFFERENCES; VALIDATION; DISPARITIES; AWARENESS; MORTALITY; GENDER AB BACKGROUND: African Americans have higher rates of hypertension and worse blood pressure (BP) control than Whites, and poorer medication adherence may contribute to this phenomenon. We explored associations among patients' race, self-reported experiences with clinicians, attitudes and beliefs about hypertension, and ultimately, medication adherence, among a sample with no racial disparities in BP control, to determine what lessons we could learn from patients and providers in this setting. METHODS: We recruited 793 White and African-American (58%) patients previously diagnosed with hypertension from 3 VA medical centers to participate in survey assessments of each of the above dimensions, subsequent to a primary care clinic visit. RESULTS: African-American patients' providers were significantly more active in advising and counseling about hypertension care and medication adherence. African-American patients indicated greater knowledge or heightened awareness of the importance of controlling their BP, but there were no race differences on a summary adherence measure. In multivariate models modeling medication adherence, race was not significant, but having been told to split one's pills, believing one's BP continues to be high, and having one's provider discuss things to do to make it easier to take BP medications were each significantly associated with worse adherence, whereas having more confidence in one's ability to take BP medications as prescribed was associated with better adherence (all p's <=. 02). CONCLUSION: When both physicians and patients take BP management seriously, disparities in BP adherence and control may be reduced. C1 Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, VA Hlth Serv Res & Dev, Natl Ctr Excellence, Bedford, England. Boston Univ, Sch Med, Div Gen Internal Med, Boston, MA 02215 USA. Boston Univ, Sch Publ Hlth, Hlth Policy & Management Dept, Boston, MA 02215 USA. Philadelphia VAMC, CHERP, Philadelphia, PA USA. Univ Penn, Sch Med, Dept Internal Med, Philadelphia, PA 19104 USA. Jesse Brown VAMC, Chicago, IL USA. Univ Illinois, Chicago, IL 60680 USA. St Louis VAMC, St Louis, MO USA. St Louis Univ, St Louis, MO 63103 USA. RP Kressin, NR (reprint author), Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, VA Hlth Serv Res & Dev, Natl Ctr Excellence, Bedford, England. EM nkressin@bu.edu OI Bokhour, Barbara/0000-0001-8238-0745; Kressin, Nancy/0000-0003-2767-4286 NR 27 TC 52 Z9 52 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2007 VL 22 IS 6 BP 768 EP 774 DI 10.1007/s11606-007-0165-9 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 169AA UT WOS:000246563900009 PM 17364243 ER PT J AU Tsui, JI Saitz, R Cheng, DM Nunes, D Libman, H Alperen, JK Samet, JH AF Tsui, Judith I. Saitz, Richard Cheng, Debbie M. Nunes, David Libman, Howard Alperen, Julie K. Samet, Jeffrey H. TI Awareness of hepatitis C diagnosis is associated with less alcohol use among persons co-infected with HIV SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 29th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 27-29, 2006 CL Los Angeles, CA SP Soc Gen Internal Med DE alcohol; hepatitis C; HIV; awareness of diagnosis ID INJECTION-DRUG USERS; MINI-MENTAL-STATE; VIRUS-INFECTION; CAGE QUESTIONNAIRE; CONSUMPTION; ABUSE; RISK AB BACKGROUND AND OBJECTIVE: It is unknown whether testing HIV-infected individuals for hepatitis C virus (HCV) and informing them of their HCV status impacts subsequent alcohol use. We hypothesized that HIV-infected individuals with current or past alcohol problems who reported being told they had HCV were more likely to 1) abstain from alcohol and 2) not drink unhealthy amounts compared to individuals who had not been told. DESIGN, PARTICIPANTS, AND MEASUREMENTS: Data from a prospective, observational cohort study (HIV-Longitudinal Interrelationships of Viruses and Ethanol) were used to assess the association between awareness of having HCV at baseline and subsequent abstinence and not drinking unhealthy amounts as reported at 6-month follow-up intervals. General estimating equations logistic regression was used to account for the correlation from using repeated observations from the same subject over time. We adjusted for age, sex, race, homelessness, injection drug use, depressive symptoms, and having abnormal liver tests. RESULTS: Participants who reported being told they had HCV were more likely to report abstaining from alcohol (AOR=1.60; 95% CI: 1.13 to 2.27) and not drinking unhealthy amounts (AOR=1.46; 95% CI: 1.01 to 2.11). CONCLUSIONS: Among patients infected with HIV who had a history of alcohol problems, reporting being told one had HCV was associated with greater abstinence from alcohol and less unhealthy amounts of drinking. C1 San Francisco VA Med Ctr, Gen Internal Med Sect 111A1, San Francisco, CA 94121 USA. Boston Med Ctr, Sect Gen Inernal Med, CARE Unit, Boston, MA USA. Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. Boston Univ, Dept Biostat, Boston, MA 02215 USA. Boston Univ, Boston Med Ctr, Sch Med, Dept Med,Sect Gastroenterol, Boston, MA 02215 USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Gen Med & Primary Care, Boston, MA USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Infect Dis, Boston, MA USA. Boston Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02215 USA. RP Tsui, JI (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect 111A1, 4150 Clemont St, San Francisco, CA 94121 USA. EM Judith.Tsui@ucsf.edu OI Samet, Jeffrey/0000-0002-0897-3400; /0000-0002-2535-1427 FU NCRR NIH HHS [M01 RR000533-385634, KL2 RR024130, KL2 RR024130-01, M01 RR000533, M01 RR001032, M01 RR00533, M01 RR01032]; NIAAA NIH HHS [K24 AA015674, K24 AA015674-01A1, R01 AA010870, R01 AA010870-05, R01 AA011785, R01 AA011785-04, R01 AA013216, R01 AA013216-05, R01-AA10870, R01-AA11785, R01-AA13766] NR 20 TC 12 Z9 12 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2007 VL 22 IS 6 BP 822 EP 825 DI 10.1007/s11606-007-0147-y PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 169AA UT WOS:000246563900018 PM 17503108 ER PT J AU Koya, DL Egede, LE AF Koya, Deepika L. Egede, Leonard E. TI Association between length of residence and cardiovascular disease risk factors among an ethnically diverse group of United States immigrants SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE length of residence; cardiovascular disease; immigrants; race; ethnicity ID CIGARETTE-SMOKING; MORTALITY; HEALTH; ACCULTURATION; HISPANICS; PARADOX; US; RACE/ETHNICITY; BEHAVIORS; NATIVITY AB BACKGROUND: Although differences in cardiovascular disease (CVD) risk factors between immigrants and nonimmigrants have been examined previously, the effect of acculturation on CVD risk factors in immigrants has been less well studied. OBJECTIVE: To determine the association between length of U.S. residence (proxy for acculturation) and major CVD risk factors. METHODS: Data on 5,230 immigrant adults from the 2002 National Health Interview Survey (NHIS) was analyzed. Primary independent variable was length of U.S. residence < 10, 10 to < 15, and >= 15 years. Main outcome measures included obesity, hypertension, diabetes, hyperlipidemia, smoking, and physical inactivity. Multiple logistic regression was used to assess the association between length of residence and odds of multiple CVD risk factors adjusting for confounders. SAS-callable SUDAAN was used for statistical analysis. RESULTS: Among the patients, 55.4% were obese, 17.3% had hypertension, 15.9% had hyperlipidemia, 6.6% had diabetes, 79.3% were physically inactive, and 14.3% were smokers. Using < 10 years as reference, those with length of residence >= 15 years were more likely to be obese (OR 1.31, 95% CI 1.03-1.65), have hyperlipidemia (OR 1.59, 95% CI 1.14-2.22), and be smokers (OR 1.39, 95% CI 1.04-1.85). Length of residence >= 15 years was associated with decreased odds of sedentary lifestyle (OR 0.63, 95% CI 0.47-0.84). Length of residence >= 15 years was not associated with odds of having diabetes (OR 1.40, 95% CI 0.78-2.51) or hypertension (OR 1.21, 95% CI 0.86-1.71). CONCLUSIONS: Among immigrants from diverse ethnic backgrounds, longer length of residence in the United States is associated with increased odds of obesity, hyperlipidemia, and cigarette smoking even after adjusting for relevant confounding factors. C1 Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA. Med Univ S Carolina, Ctr Hlth Disparities Res, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston VA TREP, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Dept Med, Div Gen Internal Med, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA. EM egedel@musc.edu FU PHS HHS [D55HP05159] NR 29 TC 108 Z9 109 U1 1 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2007 VL 22 IS 6 BP 841 EP 846 DI 10.1007/s11606-007-0163-y PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 169AA UT WOS:000246563900022 PM 17503110 ER PT J AU Burgess, D van Ryn, M Dovidio, J Saha, S AF Burgess, Diana van Ryn, Michelle Dovidio, John Saha, Somnath TI Reducing racial bias among health care providers: Lessons from social-cognitive psychology SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Review DE provider behavior; disparities; race; ethnicity; social cognition ID MEDICAL-STUDENTS; PATIENT SATISFACTION; IN-GROUP; PHYSICIAN COMMUNICATION; STEREOTYPE ACTIVATION; CULTURAL COMPETENCE; RACE BIAS; EMPATHY; PREJUDICE; ATTITUDES AB The paper sets forth a set of evidence-based recommendations for interventions to combat unintentional bias among health care providers, drawing upon theory and research in social cognitive psychology. Our primary aim is to provide a framework that outlines strategies and skills, which can be taught to medical trainees and practicing physicians, to prevent unconscious racial attitudes and stereotypes from negatively influencing the course and outcomes of clinical encounters. These strategies and skills are designed to: 1) enhance internal motivation to reduce bias, while avoiding external pressure; 2) increase understanding about the psychological basis of bias; 3) enhance providers' confidence in their ability to successfully interact with socially dissimilar patients; 4) enhance emotional regulation skills; and 5) improve the ability to build partnerships with patients. We emphasize the need for programs to provide a nonthreatening environment in which to practice new skills and the need to avoid making providers ashamed of having racial, ethnic, or cultural stereotypes. These recommendations are also intended to provide a springboard for research on interventions to reduce unintentional racial bias in health care. C1 Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55417 USA. Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. Univ Minnesota, Dept Family Med & Community Hlth, Minneapolis, MN 55455 USA. Yale Univ, Dept Psychol, New Haven, CT 06520 USA. Oregon Hlth & Sci Univ, Sect Gen Internal Med, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. RP Burgess, D (reprint author), Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, 1 Vet Dr, Minneapolis, MN 55417 USA. EM Diana.Burgess@va.gov RI VAN RYN, MICHELLE/B-1664-2010; Burgess, Diana/A-1946-2016 NR 114 TC 121 Z9 122 U1 10 U2 30 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2007 VL 22 IS 6 BP 882 EP 887 DI 10.1007/s11606-007-0160-1 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 169AA UT WOS:000246563900029 PM 17503111 ER PT J AU Nithipongvanitch, R Ittarat, W Velez, JM Zhao, R Clair, DKS Oberley, TD AF Nithipongvanitch, Rarnaneeya Ittarat, Wanida Velez, Joyce M. Zhao, Rui St. Clair, Daret K. Oberley, Terry D. TI Evidence for p53 as guardian of the cardiomyocyte mitochondrial genome following acute adriamycin treatment SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY LA English DT Article DE apoptosis; cardiomyopathy; doxorubicin; mitochondrial DNA; oxidative stress ID INDUCED RENAL CARCINOGENESIS; BASE EXCISION-REPAIR; INDUCED APOPTOSIS; IN-VIVO; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; DNA; CELLS; DOXORUBICIN; TISSUES AB The present study is an initial analysis of whether p53 may function as guardian of the cardiomyocyte mitochondrial genome, with mitochondrial p53 localization proposed to be involved in both mitochondrial DNA (mtDNA) repair and apoptosis. Subcellular distribution, protein levels, and possible function(s) of p53 protein in the response of cardiomyocytes to adriamycin (ADR) were analyzed. Levels and subcellular localization of proteins were determined by Western blot and immunogold ultrastructural analysis techniques. Here we demonstrate that stress caused by ADR induced upregulation of p53 protein in cardiomyocyte mitochondria and nuclei between 3 and 24 hr. Increased expression of PUMA and Bax proteins, pro-apoptotic targets of p53, was documented following ADR treatment and was accompanied by increased levels of apoptotic markers, with elevation of cytosolic cytochrome c at 24 hr and subsequent caspase-3 cleavage at 3 days. Mitochondrial p53 levels correlated with mtDNA oxidative damage. Loss of p53 in knockout mouse heart resulted in a significant increase in mtDNA vulnerability to damage following ADR treatment. Our results suggest that mitochondrial p53 could participate in mtDNA repair as a first response to oxidative damage of cardiomyocyte mtDNA and demonstrate an increase of apoptotic markers as a result of mitochondrial/nuclear p53 localization. C1 William S Middleton Mem Vet Adm Med Ctr, Dept Pathol & Lab Med, Madison, WI 53705 USA. Univ Kentucky, Dept Toxicol, Lexington, KY USA. Mahidol Univ, Fac Med Technol, Bangkok 10700, Thailand. Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI USA. RP Oberley, TD (reprint author), William S Middleton Mem Vet Adm Med Ctr, Dept Pathol & Lab Med, Room A-35,2500 Overlook Terrace, Madison, WI 53705 USA. EM dstcl00@pop.uky.edu; toberley@wisc.edu FU NCI NIH HHS [CA-94853] NR 44 TC 40 Z9 40 U1 1 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0022-1554 EI 1551-5044 J9 J HISTOCHEM CYTOCHEM JI J. Histochem. Cytochem. PD JUN PY 2007 VL 55 IS 6 BP 629 EP 639 DI 10.1369/jhc.6A7146.2007 PG 11 WC Cell Biology SC Cell Biology GA 170CW UT WOS:000246640500010 PM 17312011 ER PT J AU Aujesky, D Perrier, A Roy, PM Stone, RA Cornuz, J Meyer, G Obrosky, DS Fine, MJ AF Aujesky, D. Perrier, A. Roy, P.-M. Stone, R. A. Cornuz, J. Meyer, G. Obrosky, D. S. Fine, M. J. TI Validation of a clinical prognostic model to identify low-risk patients with pulmonary embolism SO JOURNAL OF INTERNAL MEDICINE LA English DT Article DE mortality; prognostic model; pulmonary embolism; validation ID MOLECULAR-WEIGHT HEPARIN; RIGHT-VENTRICULAR DYSFUNCTION; HELICAL COMPUTED-TOMOGRAPHY; OUTPATIENT TREATMENT; CONTROLLED-TRIALS; PREDICTION RULE; MANAGEMENT; METAANALYSIS; GUIDELINES; THROMBOSIS AB Objective. To validate the Pulmonary Embolism Severity Index (PESI), a clinical prognostic model which identifies low-risk patients with pulmonary embolism (PE). Design. Validation study using prospectively collected data. Setting. A total of 119 European hospitals. Subjects. A total of 899 patients diagnosed with PE. Intervention. The PESI uses 11 clinical factors to stratify patients with PE into five classes (I-V) of increasing risk of mortality. We calculated the PESI risk class for each patient and the proportion of patients classified as low-risk (classes I and II). The outcomes were overall and PE-specific mortality for low-risk patients at 3 months after presentation. We calculated the sensitivity, specificity and predictive values to predict overall and PE-specific mortality and the discriminatory power using the area under the receiver operating characteristic curve. Results. Overall and PE-specific mortality was 6.5% (58/899) and 2.3% (21/899) respectively. Forty-seven per cent of patients (426/899) were classified as low-risk. Low-risk patients had an overall mortality of only 1.2% (5/426) and a PE-specific mortality of 0.7% (3/426). The sensitivity was 91 [95% confidence interval (CI): 81-97%] and the negative predictive value was 99% (95% CI: 97-100%) for overall mortality. The sensitivity was 86% (95% CI: 64-97%) and the negative predictive value was 99% (95% CI: 98-100%) for PE-specific mortality. The areas under the receiver operating characteristic curve for overall and PE-specific mortality were 0.80 (95% CI: 0.75-0.86) and 0.77 (95% CI: 0.68-0.86) respectively. Conclusions. This validation study confirms that the PESI reliably identifies low-risk patients with PE who are potential candidates for less costly outpatient treatment. C1 Univ Lausanne, Univ Outpatient Clin, Div Gen Internal Med, CH-1015 Lausanne, Switzerland. Univ Lausanne, Clin Epidemiol Ctr, CH-1015 Lausanne, Switzerland. Univ Geneva, Div Gen Internal Med, CH-1211 Geneva, Switzerland. Univ Angers, Dept Emergency Med, Angers, France. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15260 USA. VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Hop Europeen Georges Pompidou, Dept Resp & Crit Care Med, Paris, France. Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA. RP Aujesky, D (reprint author), CHU Vaudois, Serv Med Interne, BH 10-622, CH-1011 Lausanne, Switzerland. EM drahomir.aujesky@chuv.ch RI Perrier, Arnaud/M-2263-2014 FU NIAID NIH HHS [K24AI01769] NR 31 TC 69 Z9 70 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0954-6820 J9 J INTERN MED JI J. Intern. Med. PD JUN PY 2007 VL 261 IS 6 BP 597 EP 604 DI 10.1111/j.1365-2796.2007.01785.x PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 172KO UT WOS:000246803400008 PM 17547715 ER PT J AU Chren, MM Sahay, AP Bertenthal, DS Sen, S Landefeld, CS AF Chren, Mary-Margaret Sahay, Anju P. Bertenthal, Daniel S. Sen, Saunak Landefeld, C. Seth TI Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID MOHS MICROGRAPHIC SURGERY; NONMELANOMA SKIN-CANCER; TREATMENT MODALITIES; SURGICAL EXCISION; FACE; QUESTIONNAIRE; MEDICARE AB Quality of life is an important treatment outcome for conditions that are rarely fatal, such as cutaneous basal cell carcinoma and squamous cell carcinoma (typically called nonmelanoma skin cancer (NMSC)). The purpose of this study was to compare quality-of-life outcomes of treatments for NMSC. We performed a prospective cohort study of 633 consecutive patients with NMSC diagnosed in 1999 and 2000 and followed for 2 years after treatment at a university-based private practice or a Veterans Affairs clinic. The main outcome was tumor-related quality of life 1 to 2 years after therapy, measured with the 16-item version of Skindex, a validated measure. Skindex scores vary from 0 (best) to 100 (worst) in three domains: Symptoms, Emotions, and Function. Treatments were electrodessication and curettage (ED&C) in 21%, surgical excision in 40%, and Mohs surgery in 39%. Five hundred and eight patients (80%) responded after treatment. Patients treated with excision or Mohs surgery improved in all quality-of-life domains, but quality of life did not improve after ED&C. There was no difference in the amount of improvement after excision or Mohs surgery. For example, mean Skindex Symptom scores improved 9.7 (95% Cl: 6.9, 12.5) after excision, 10.2 (7.4, 12.9) after Mohs surgery, and 3.4 (-0.9, 7.6) after ED&C. We conclude that, for NMSC, quality-of-life outcomes were similar after excision and Mohs surgery, and both therapies had better outcomes than ED&C. C1 Univ Calif San Francisco, San Francisco VAMC, Dermatol Serv, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Vet Affairs, San Francisco, CA 94121 USA. Vet Affairs Med Ctr, Hlth Serv Res Enhancement Award Program, REAP, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. Univ Calif San Francisco, Geriatr & Extended Care Serv, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. RP Chren, MM (reprint author), Univ Calif San Francisco, San Francisco VAMC, Dermatol Serv, 151R,4150 Clement St, San Francisco, CA 94121 USA. EM chrenm@derm.ucsf.edu FU NIAMS NIH HHS [K02 AR 02203-01] NR 29 TC 46 Z9 46 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD JUN PY 2007 VL 127 IS 6 BP 1351 EP 1357 DI 10.1038/sj.jid.5700740 PG 7 WC Dermatology SC Dermatology GA 169UT UT WOS:000246618300013 PM 17301830 ER PT J AU Bohnen, NI Kaufer, DI Hendrickson, R Constantine, GM Mathis, CA Moore, RY AF Bohnen, N. I. Kaufer, D. I. Hendrickson, R. Constantine, G. M. Mathis, C. A. Moore, R. Y. TI Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY LA English DT Article ID ALZHEIMER AB Aim: To investigate the relationship between ratings of depressive symptoms and in vivo cortical acetylcholinesterase (AChE) activity in subjects with Parkinson's disease (PD) and parkinsonian dementia (PDem). Methods: Subjects (with PD, n = 18, including subjects with PDem, n = 6, and normal controls, n = 10) underwent [C-11] methyl-4-piperidinyl propionate AChE positron emission tomography imaging and clinical assessment including the Cornell Scale for Depression in Dementia (CSDD). Results: Subjects with PD and PDem had higher scores on the CSDD compared with normal controls: 7.3 (5.4) and 2.8 (2.6), respectively (F = 6.9, p = 0.01). Pooled analysis demonstrated a significant inverse correlation between cortical AChE activity and CSDD scores: R = 20.5, p = 0.007. This correlation remained significant after controlling for Mini-Mental State Examination scores. Conclusion: Depressive symptomatology is associated with cortical cholinergic denervation in PD that tends to be more prominent when dementia is present. C1 Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Math & Stat, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Bohnen, NI (reprint author), Univ Michigan, Med Ctr, Dept Radiol, Div Nucl Med,Univ Hosp, B1 G505,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA. EM nbohnen@umich.edu RI Mathis, Chester/A-8607-2009 FU NIA NIH HHS [AG-05133] NR 18 TC 48 Z9 49 U1 1 U2 3 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-3050 J9 J NEUROL NEUROSUR PS JI J. Neurol. Neurosurg. Psychiatry PD JUN PY 2007 VL 78 IS 6 BP 641 EP 643 DI 10.1136/jnnp.2006.100073 PG 3 WC Clinical Neurology; Psychiatry; Surgery SC Neurosciences & Neurology; Psychiatry; Surgery GA 169LO UT WOS:000246593900024 PM 17507447 ER PT J AU Morasco, BJ Gfeller, JD Elder, KA AF Morasco, Benjamin J. Gfeller, Jeffrey D. Elder, Katherine A. TI The utility of the NEO-PI-R validity scales to detect response distortion: A comparison with the MMPI-2 SO JOURNAL OF PERSONALITY ASSESSMENT LA English DT Article ID PERSONALITY-INVENTORY; SOCIAL DESIRABILITY; PSYCHOPATHOLOGY; METAANALYSIS; DISORDER; RATINGS; STYLE AB In this psychometric study, we compared the recently developed Validity Scales from the Revised NEO Personality Inventory (NEO PI-R; Costa & McCrae, 1992b) with the MMPI-2 (Butcher, Dahstrom, Graham, Tellegen, & Kaemmer, 1989) Validity Scales. We collected data from clients (n = 74) who completed comprehensive psychological evaluations at a university-based outpatient mental health clinic. Correlations between the Validity Scales of the NEO-PI-R and MMPI-2 were significant and in the expected directions. The relationships provide support for convergent and discriminant validity of the NEO-PI-R Validity Scales. The percent agreement of invalid responding on the two measures was high, although the diagnostic agreement was modest (kappa=.22-33). Finally, clients who responded in an invalid manner on the NEO-PI-R Validity Scales produced significantly different clinical profiles on the NEO-PI-R and MMPI-2 than clients with valid protocols. These results provide additional support for the clinical utility of the NEO-PI-R Validity Scales as indicators of response bias. C1 Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. St Louis Univ, Dept Psychol, St Louis, MO 63103 USA. St Louis Univ, Dept Psychiat, St Louis, MO 63103 USA. Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA. RP Morasco, BJ (reprint author), Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, 3710 SW US Vet Hosp Rd P3MHDC, Portland, OR 97239 USA. EM benjamin.morasco@va.gov NR 37 TC 5 Z9 5 U1 2 U2 8 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 0022-3891 J9 J PERS ASSESS JI J. Pers. Assess. PD JUN PY 2007 VL 88 IS 3 BP 276 EP 283 PG 8 WC Psychology, Clinical; Psychology, Social SC Psychology GA 176XZ UT WOS:000247119500003 PM 17518549 ER PT J AU Simon, WA Herrmann, M Klein, T Shin, JM Huber, R Senn-Bilfinger, J Postius, S AF Simon, W. A. Herrmann, M. Klein, T. Shin, J. M. Huber, R. Senn-Bilfinger, J. Postius, S. TI Soraprazan: Setting new standards in inhibition of gastric acid secretion SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID GASTROESOPHAGEAL-REFLUX DISEASE; PROTON PUMP INHIBITORS; K+-COMPETITIVE INHIBITOR; H,K-ATPASE; PANTOPRAZOLE; SCH-28080; MEMBRANES; BINDING; MUCOSA; ION AB After treatment of millions of patients suffering from gastroesophageal reflux disease (GERD) and other acid-related ailments with proton pump inhibitors, there are still unmet medical needs such as rapid and reliable pain relief, especially for nocturnal acid breakthrough. In this work, we introduce and characterize the biochemistry and pharmacology of the potassium-competitive acid blocker (P-CAB) soraprazan, a novel, reversible, and fast-acting inhibitor of gastric H,K-ATPase. Inhibitory and binding properties of soraprazan were analyzed together with its mode of action, its selectivity, and its in vivo potency. This P-CAB has an IC50 of 0.1 mu M if measured with ion leaky vesicles and of 0.19 mu M in isolated gastric glands. With a K-i of 6.4 nM, a K-d of 26.4 nM, and a B-max of 2.89 nmol/mg, this compound is a highly potent and reversible inhibitor of the H,K-ATPase. Soraprazan shows immediate inhibition of acid secretion in various in vitro models and in vivo and was found to be more than 2000-fold selective for H,K-ATPase over Na,K- and Ca-ATPases. Soraprazan is superior to esomeprazole in terms of onset of action and the extent and duration of pH elevation in vivo in the dog. Rapid and consistent inhibition of acid secretion by soraprazan renders the P-CABs a promising group of compounds for therapy of GERD. C1 ALTANA Pharma AG, Dept Biochem Gastroenterol, D-78467 Constance, Germany. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Herrmann, M (reprint author), ALTANA Pharma AG, Dept Biochem Gastroenterol, Ryk Gulden Str 2, D-78467 Constance, Germany. EM michael.herrmann@altanapharma.com NR 41 TC 33 Z9 35 U1 0 U2 1 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 EI 1521-0103 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD JUN PY 2007 VL 321 IS 3 BP 866 EP 874 DI 10.1124/jpet.107.120428 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 167LJ UT WOS:000246452900006 PM 17369284 ER PT J AU Meredith, CW Jaffe, C Yanasak, E Cherrier, M Saxon, AJ AF Meredith, Charles W. Jaffe, Craig Yanasak, Elisia Cherrier, Monique Saxon, Andrew J. TI An open-label pilot study of risperidone in the treatment of methamphetamine dependence SO JOURNAL OF PSYCHOACTIVE DRUGS LA English DT Article DE amphetamine; methamphetamine; neuropsychology; risperidone; stimulant; treatment ID BRIEF SYMPTOM INVENTORY; DOPAMINE TRANSPORTER; ABSTINENT METHAMPHETAMINE; INDUCED REINSTATEMENT; COCAINE DEPENDENCE; STIMULANT ABUSE; D-AMPHETAMINE; DRUG-SEEKING; STRESS; TRIAL AB Psychopharmacological treatments for methamphetamine (MA) dependence have questionable efficacy. Open-label risperidone was evaluated in veterans seeking MA dependence treatment. Participants (N = 11) received four weeks of risperidone. They provided weekly self-reports of substance use, urine drug screens, and adverse effects. Neuropsychological assessments and psychiatric symptomatology (Brief Symptom Inventory; BSI) were measured at baseline and follow-up. The eight completers had an average risperidone dose of 3.6mg/day and decreased days of MA use during the trial from a mean of 13.0 (SD = 6.5) in the 30 days prior to starting risperidone to a mean of 0.125 (SD = 0.4; t = 5.7, p =.001). When measured over time, fine motor function (Grooved Peg Board Dominant Hand) was the only neuropsychological domain to improve significantly. No other domain changed significantly from baseline to follow-up among study completers. BSI data were converted to demographically corrected T-scores utilizing appropriate normative data (mean = 50, SD = 10). BSI somatization T-scores declined from a mean of 59.0 (SD = 8.4) to 51.8 (SD = 8.3; t = 2.7, p <.05), and positive symptom distress declined from a mean of 52.8 (SD = 8.0) to 41.7 (SD = 8.6; t = 3.0, p <.05), Risperidone was well tolerated and associated with decreased MA use. C1 VA Puget Sound Hlth Care Syst, Med Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Addict Psychiat Residency Program, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Addict Patient Care Line, Seattle, WA USA. RP Meredith, CW (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA. EM cwmeredi@u.washington.edu NR 44 TC 17 Z9 19 U1 2 U2 4 PU HAIGHT-ASHBURY PUBL PI SAN FRANCISCO PA 409 CLAYTON ST, SAN FRANCISCO, CA 94117 USA SN 0279-1072 J9 J PSYCHOACTIVE DRUGS JI J. Psychoact. Drugs PD JUN PY 2007 VL 39 IS 2 BP 167 EP 172 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 191OF UT WOS:000248140000007 PM 17703711 ER PT J AU Schumacher, HR Taylor, W Joseph-Ridge, N Perez-Ruiz, F Chen, LX Schlesinger, N Khanna, D Furst, DE Becker, MA Dalbeth, N Edwards, NL AF Schumacher, H. Ralph Taylor, William Joseph-Ridge, Nancy Perez-Ruiz, Fernando Chen, Lan X. Schlesinger, Naomi Khanna, Dinesh Furst, Daniel E. Becker, Michael A. Dalbeth, Nicola Edwards, N. Lawrence TI Outcome evaluations in gout SO JOURNAL OF RHEUMATOLOGY LA English DT Article; Proceedings Paper CT 8th International Consensus Conference on Outcome Measures in Rheumatology Clinical Trails (OMERACT 8) CY MAY 10-14, 2006 CL St Julians Bay, MALTA DE gout; outcomes; OMERACT; uric acid ID RHEUMATOID-ARTHRITIS; CLINICAL-TRIALS; FACT TRIAL; ALLOPURINOL; FEBUXOSTAT; REDUCTION AB Methods to measure outcomes in gout still require consensus and validation. This Special Interest Group was assembled to identify domains of interest and is now evaluating a series of outcomes for features of acute gouty arthritis and chronic gout. To accomplish this, working groups have been formed and domains identified. Delphi methodology has been used to address gouty flares as an outcome of greatest interest. Studies addressing other outcome measures were reported at the OMERACT 8 meeting and validation has begun on some outcomes. There has been progress on developing a definition of a flare, and validating reproducibility of some chrome gout outcome measures in some domains, such as tophus size and patient perceptions. Use of these outcomes as well as a health-related quality of life measure are being studied in clinical trials. Pain on a Likert scale appears to be a valid outcome in acute gout. Final validation of these outcomes has not yet been achieved. In summary, the unique problems of evaluating outcomes in gout are finally being addressed. While no measures are available for use yet, an agenda has been developed. C1 VA Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Vet Affairs Med Ctr, Sch Med, Philadelphia, PA 19104 USA. RP Schumacher, HR (reprint author), VA Med Ctr, 151K,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM schumacr@mail.med.upenn.edu RI PEREZ-RUIZ, FERNANDO/E-4844-2012 OI Perez-Ruiz, Fernando/0000-0002-5268-1894 NR 17 TC 21 Z9 21 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD JUN PY 2007 VL 34 IS 6 BP 1381 EP 1385 PG 5 WC Rheumatology SC Rheumatology GA 176WW UT WOS:000247116600029 PM 17552064 ER PT J AU Baucom, B Eldridge, K Jones, J Sevier, M Clements, M Markman, H Stanley, S Sayers, SL Sher, T Christensen, A AF Baucom, Brian Eldridge, Kathleen Jones, Janice Sevier, Mia Clements, Mari Markman, Howard Stanley, Scott Sayers, Steven L. Sher, Tamara Christensen, Andrew TI Relative contributions of relationship distress and depression to communication patterns in couples SO JOURNAL OF SOCIAL AND CLINICAL PSYCHOLOGY LA English DT Article ID MARITAL INTERACTION; SELF-REPORT; SEQUENTIAL INTERACTIONS; CONFLICT; WOMEN; BEHAVIOR; THERAPY; CONSISTENCY; ADJUSTMENT; OTHERS AB Researchers have long been interested in the relationship between marital distress and depression. Empirical findings from investigations into the relative contributions of marital distress and depression to marital communication have been inconsistent, and some communication behaviors, such as the demand/withdraw interaction pattern, have yet to be examined. The ability of depression to predict major types of communication (positive communication, negative communication, problem-solving, and demand/withdraw) was analyzed after controlling for the shared variance between marital distress and depression. Across two studies of couples beginning therapy and one study of couples beginning an enhancement program, results failed to provide support for a unique contribution of depression to couples' communication behaviors. C1 Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. Univ Denver, Denver, CO 80208 USA. Univ Penn, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. IIT, Chicago, IL 60616 USA. RP Baucom, B (reprint author), Univ Calif Los Angeles, Dept Psychol, 1285 Franz Hall,Box 951563, Los Angeles, CA 90095 USA. EM bbaucom@ucla.edu FU NICHD NIH HHS [R01 HD047564, R01 HD048780, R01 HD048780-02, R01 HD053314] NR 57 TC 6 Z9 6 U1 5 U2 8 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0736-7236 J9 J SOC CLIN PSYCHOL JI J. Soc. Clin. Psychol. PD JUN PY 2007 VL 26 IS 6 BP 689 EP 707 DI 10.1521/jscp.2007.26.6.689 PG 19 WC Psychology, Clinical; Psychology, Social SC Psychology GA 181AI UT WOS:000247408700003 PM 19343103 ER PT J AU Heinzerling, KG Kral, AH Flynn, NM Anderson, RL Scott, A Gilbert, ML Asch, SM Bluthenthal, RN AF Heinzerling, Keith G. Kral, Alex H. Flynn, Neil M. Anderson, Rachel L. Scott, Andrea Gilbert, Mary L. Asch, Steven M. Bluthenthal, Ricky N. TI Human immunodeficiency virus and hepatitis C virus testing services at syringe exchange programs: Availability and outcomes SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE HIV testing; hepatitis C virus; syringe exchange programs; injection drug use ID INJECTION-DRUG USERS; HIV RISK; SEROCONVERSION; INFECTION; PREVALENCE; STRATEGIES; CLIENTS; CITIES; NEEDLE; COHORT AB We described the availability and outcomes of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) testing services at syringe exchange programs throughout California, using interviews with 24 syringe exchange Program directors and 560 syringe exchange clients. Both HIV and HCV testing services were available in 62% of programs, 21% had HIV testing only, and 17% had neither. Programs administered by health care/social service providers were more likely than independent syringe exchange programs to have HIV and HCV testing services available. Among clients of programs with testing available, clients of illegal programs were significantly less likely than clients of legal programs to have used syringe exchange HIN and HCV testing services. The availability of HIV and HCV testing services at syringe exchange programs varies, and the use of existing testing services by clients is not universal. Efforts to increase both the availability of HIV and HCV testing services at syringe exchange programs and the use of existing testing services are needed. (C) 2007 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Integrated Subst Abuse Program, Los Angeles, CA 90095 USA. VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RTI Int, San Francisco, CA USA. Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA. Univ Calif Davis, Dept Internal Med, Div Infect Dis, Sacramento, CA 95817 USA. RAND Corp, Hlth Program, Santa Monica, CA USA. RAND Corp, Drug Policy Res Ctr, Santa Monica, CA USA. Calif State Univ Dominguez Hills, Urban Community Res Ctr, Dominiguez Hills, CA USA. RP Heinzerling, KG (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, 10880 Wilshire Blvd,Suite 540,Box 957087, Los Angeles, CA 90095 USA. EM heinzk@ucla.edu OI Bluthenthal, Ricky/0000-0003-3491-1702 FU NIDA NIH HHS [R01 DA14210]; PHS HHS [R06/CCR918667] NR 23 TC 4 Z9 4 U1 2 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD JUN PY 2007 VL 32 IS 4 BP 423 EP 429 DI 10.1016/j.jsat.2006.11.002 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 169EP UT WOS:000246575800012 PM 17481466 ER PT J AU Diem, SJ Blackwell, TL Stone, KL Yaffe, K Cauley, JA Whooley, MA Ensrud, KE AF Diem, Susan J. Blackwell, Terri L. Stone, Katie L. Yaffe, Kristine Cauley, Jane A. Whooley, Mary A. Ensrud, Kristine E. CA Study Osteoporotic Fractures TI Depressive symptoms and rates of bone loss at the hip in older women SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT 28th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 15-19, 2006 CL Philadelphia, PA SP Amer Soc Bone & Mineral Res DE depression; bone mineral density; osteoporosis ID MINERAL DENSITY; MAJOR DEPRESSION; LOSS INCREASE; RISK-FACTORS; AGE; OSTEOPOROSIS; SEROTONIN; COMMUNITY; FRACTURE; MEN AB Objectives: To ascertain whether depressive symptoms are associated with increased rates of bone loss at the hip. Design: Population-based prospective cohort study. Setting: Four clinical centers in the United States. Participants: Four thousand one hundred seventy-seven community-dwelling women, aged 69 and older, enrolled in the Study of Osteoporotic Fractures. Measurements: Depressive symptoms were assessed using the Geriatric Depression Scale (GDS). Subjects were categorized as depressed if their GDS score was 6 or greater at the fourth examination. Bone mineral density (BMD) at the hip was measured using dual-energy x-ray absorptiometry at the fourth and sixth examinations (average 4.4 years between examinations). Use of antidepressant medications was assessed by interview and verified from medication containers at the fourth and sixth examinations of the Study of Osteoporotic Fractures. A computerized dictionary was used to categorize type of medication. Results: In age-adjusted models, mean total hip BMD decreased 0.69%/year in 3,977 women with a GDS score of less than 6, compared with 0.96%/year in 200 women with a GDS score of 6 or greater (P <.01). Results were not substantially altered when adjusted for potential confounders and when users of antidepressants were excluded from the analysis. Conclusion: Depression, as defined by a GDS score of 6 or greater, was associated with an increased rate of bone loss at the hip in this cohort of older women. Clinicians should be aware of a possible increased rate of bone loss in older, depressed women. C1 Univ Minnesota, Epidemiol Clin Res Ctr, Dept Med, Div Epidemiol & Community Hlth, Minneapolis, MN 55415 USA. Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA. RP Diem, SJ (reprint author), Univ Minnesota, Epidemiol Clin Res Ctr, Dept Med, Div Epidemiol & Community Hlth, 1100 Washington Ave S,Suite 201, Minneapolis, MN 55415 USA. EM sdiem@umn.edu RI Diem, Susan/B-6479-2013; Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408 FU NIA NIH HHS [AG05394, AG08415, AG05407]; NIAMS NIH HHS [AR35582, AR35583, AR35584] NR 44 TC 42 Z9 43 U1 1 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2007 VL 55 IS 6 BP 824 EP 831 DI 10.1111/j.1532-5415.2007.01194.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 172HI UT WOS:000246794400003 PM 17537081 ER PT J AU Sun, BC Hoffman, JR Mangione, CM Mower, WR AF Sun, Benjamin C. Hoffman, Jerome R. Mangione, Carol M. Mower, William R. TI Older age predicts short-term, serious events after syncope SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE syncope; prognosis; risk predictors ID RISK STRATIFICATION; UNEXPLAINED SYNCOPE; EMERGENCY; SCORE AB Objectives: To assess the relationship between age and 14-day serious events after an emergency department (ED) visit for syncope. Design: One-year prospective cohort study. Setting: Single academic ED. Participants: Adult patients with an ED complaint of syncope or near-syncope. Measurements: Treating physicians prospectively recorded the presence or absence of potential risk factors for serious clinical events. Patients were contacted by telephone at 14 days for a structured interview. A three-physician panel reviewed ED charts, hospital records, and telephone interview forms to identify predefined events. The primary outcome included any 14-day predefined event. A secondary outcome included any 14-day predefined event that was first diagnosed after the initial ED visit. Age was analyzed in 20-year intervals. Multivariate logistic regression controlled for baseline demographic, comorbidity, and electrocardiogram data. Results: Of 592 eligible patients, 477 (81%) provided informed consent. Follow-up was successfully obtained for 463 (97%) patients. The age range was 18 to 96, and 47% of patients were aged 60 and older. There were 80 (17%) patients who had a 14-day event, including 18 (4%) with a delayed diagnosis. Compared with patients aged 18 to 39, the adjusted odds ratio (OR) of a serious outcome was 2.7 (95% confidence interval (CI)=0.9-8.4) for patient aged 40 to 59, 3.8 (95% CI=1.3-12) for patients aged 60 to 79, and 3.8 (95% CI=1.2-12) for patients aged 80 and older. Conclusion: Age of 60 and older is strongly associated with short-term serious events after an ED visit for syncope. C1 W Los Angeles Vet Affairs Med Ctr, Off 3214A, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Ctr Emergency Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. RP Sun, BC (reprint author), W Los Angeles Vet Affairs Med Ctr, Off 3214A, Dept Med, Mail Stop 111,Bldg 500,Wing 3E,11301 Wilshire Blv, Los Angeles, CA 90073 USA. EM bsun@post.harvard.edu FU NIA NIH HHS [K12 AG001004, AG02004] NR 15 TC 20 Z9 20 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2007 VL 55 IS 6 BP 907 EP 912 DI 10.1111/j.1532-5415.2007.01188.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 172HI UT WOS:000246794400014 PM 17537092 ER PT J AU Balkovetz, DF AF Balkovetz, Daniel F. TI Opening pandora's box in the tight junction SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID MEMBRANE-PROTEINS; EXPRESSION; CYCLOSPORINE; CELLS; CLAUDIN-2 C1 Univ Alabama, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. Univ Alabama, Dept Med, Birmingham, AL 35233 USA. Univ Alabama, Dept Cell Biol, Birmingham, AL 35233 USA. Univ Alabama, Dept Microbiol, Birmingham, AL 35233 USA. RP Balkovetz, DF (reprint author), 668 LHRB,1530 3rd Ave S, Birmingham, AL 35294 USA. NR 13 TC 3 Z9 4 U1 0 U2 0 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JUN PY 2007 VL 18 IS 6 BP 1624 EP 1625 DI 10.1681/ASN.2007040403 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 174OV UT WOS:000246952700002 PM 17513323 ER PT J AU Johansen, KL AF Johansen, Kirsten L. TI Exercise in the end-stage renal disease population SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID QUALITY-OF-LIFE; MAINTENANCE HEMODIALYSIS-PATIENTS; RANDOMIZED CONTROLLED-TRIAL; DIALYSIS PATIENTS; REVERSE EPIDEMIOLOGY; PHYSICAL PERFORMANCE; PERITONEAL-DIALYSIS; SKELETAL-MUSCLE; CARDIOVASCULAR COMPLICATIONS; REHABILITATION PROGRAMS AB Many of the known benefits of exercise in the general population are of particular relevance to the ESRD population. In addition, the poor physical functioning that is experienced by patients who are on dialysis is potentially addressable through exercise interventions. The study of exercise in the ESRD population dates back almost 30 yr, and numerous interventions, including aerobic training, resistance exercise training, and combined training programs, have reported beneficial effects. Recently, interventions during hemodialysis sessions have become more popular and have been shown to be safe. The risks of exercise in this population have not been rigorously studied, but there have been no reports of serious injury as a result of participation in an exercise training program. It is time that we incorporate exercise into the routine care of patients who are on dialysis, but identification of an optimal training regimen or regimens, according to patient characteristics or needs, is still needed to facilitate implementation of exercise programs. C1 San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA. EM kirsten.johansen@ucsf.edu NR 90 TC 110 Z9 117 U1 5 U2 13 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JUN PY 2007 VL 18 IS 6 BP 1845 EP 1854 DI 10.1681/ASN.2007010009 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 174OV UT WOS:000246952700028 PM 17442789 ER PT J AU Dunn, NJ Rehm, LP Schillaci, J Souchek, J Mehta, P Ashton, CM Yanasak, E Hamilton, JD AF Dunn, Nancy Jo Rehm, Lynn P. Schillaci, Jeanne Souchek, Julianne Mehta, Paras Ashton, Carol M. Yanasak, Elisia Hamilton, Joseph D. TI A randomized trial of self-management and psychoeducational group therapies for comorbid chronic posttraumatic stress disorder and depressive disorder SO JOURNAL OF TRAUMATIC STRESS LA English DT Article; Proceedings Paper CT 33rd Annual Meeting of the Society-for-Psychotherapy-Research CY JUN 25, 2002 CL Santa Barbara, CA SP Soc Psychotherapy Res ID COLLABORATIVE RESEARCH-PROGRAM; COGNITIVE THERAPY; RATING SCALE; CLINICIAN; VETERANS AB The authors randomized 101 male veterans with chronic combat-related posttraumatic stress disorder (PTSD) and depressive disorder to an evidence-based depression treatment (self-management therapy; n = 51) or active-control therapy (n = 50). Main outcome measures for efficacy, using intention-to-treat analyses, were subjective and objective PTSD and depression scales at pretest, posttest, and 3-, 6-, and 12-month follow-up. Other measures included treatment compliance, satisfaction, treatment-targeted constructs, functioning, service utilization, and costs. Self-management therapy modestly greater improvement on depression symptoms at treatment completion disappeared on follow-up. No other differences on symptoms or functioning appeared, although psychiatric outpatient utilization and overall outpatient costs were lower with self-management therapy. Despite success in other depressed populations, self-management therapy produced no clinically significant effect in depression with chronic PTSD. C1 Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. Ctr Qual Care & Utilizat Studies, Houston, TX USA. Vet Affairs S Cent Mental Illness Res Educ & Clin, MIRECC, Houston, TX USA. Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Univ Houston, Dept Psychol, Houston, TX USA. VeriCare, San Diego, CA USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Vet Affairs Puget Sound Hlth Care Syst, Tacoma, WA USA. RP Dunn, NJ (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd,Mental Hlth Care Line 116MHCL-, Houston, TX 77030 USA. EM ndunn@bcm.tmc.edu RI Mehta, Paras/G-3180-2010 OI Mehta, Paras/0000-0002-7378-3179 NR 36 TC 29 Z9 30 U1 0 U2 3 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD JUN PY 2007 VL 20 IS 3 BP 221 EP 237 DI 10.1002/jts.20214 PG 17 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 186RF UT WOS:000247795100001 PM 17598141 ER PT J AU Simpson, TL Kaysen, D Bowen, S MacPherson, LM Chawla, N Blume, A Marlatt, GA Larimer, M AF Simpson, T. L. Kaysen, D. Bowen, S. MacPherson, L. M. Chawla, N. Blume, A. Marlatt, G. A. Larimer, M. TI PTSD symptoms, substance use, and Vipassana meditation among incarcerated individuals SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; EXPERIENTIAL AVOIDANCE; ALCOHOL DEPENDENCE; ABUSE; WOMEN; THERAPY; COMORBIDITY; RECIDIVISM; PREVALENCE; REDUCTION AB The present study evaluated whether Posttraumatic Stress Disorder (PTSD) symptom severity was associated with participation and treatment outcomes comparing a Vipassana meditation course to treatment a; usual in an incarcerated sample. This study utilizes secondary data. The original study demonstrated that Vipassana meditation is associated with reductions in substance use. The present study found that PTSD symptom severity did not differ significantly between those who did and did not volunteer to take the course. Participation in the Vipassana course was associated with significantly greater reductions in substance use than treatment as usual, regardless of PTSD symptom severity levels. These results suggest that Vipassana meditation is worthy of further study for those with comorbid P TSD and substance use problems. C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Psychol, Seattle, WA 98195 USA. Univ N Carolina, Dept Psychol, Charlotte, NC 28223 USA. RP Simpson, TL (reprint author), 1660 S Columbian Way ATC-116-S, Seattle, WA 98108 USA. EM tracey.simpson@va.gov FU NIAAA NIH HHS [1 R21 AA13054-01] NR 51 TC 39 Z9 42 U1 3 U2 13 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD JUN PY 2007 VL 20 IS 3 BP 239 EP 249 DI 10.1002/jts.20209 PG 11 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 186RF UT WOS:000247795100002 PM 17597132 ER PT J AU Garzotto, M AF Garzotto, Mark TI Determining D sing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: A prospective study - Editorial comment SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Urol, Portland, OR 97201 USA. RP Garzotto, M (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Urol, Portland, OR 97201 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JUN PY 2007 VL 177 IS 6 BP 2135 EP 2135 DI 10.1016/j.juro.2007.01.261 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 170BJ UT WOS:000246635800026 ER PT J AU Komers, R Lindsley, JN Oyama, TT Cohen, DM Anderson, S AF Komers, Radko Lindsley, Jessie N. Oyama, Terry T. Cohen, David M. Anderson, Sharon TI Renal p38 MAP kinase activity in experimental diabetes SO LABORATORY INVESTIGATION LA English DT Article DE diabetic nephropathy; hyperglycemia; p38 mitogen-activated protein kinase; proteinuria; signaling ID ACTIVATED PROTEIN-KINASE; ANGIOTENSINOGEN GENE-EXPRESSION; PROXIMAL TUBULAR CELLS; SIGNAL-TRANSDUCTION PATHWAYS; HUMAN MESANGIAL CELLS; SMOOTH-MUSCLE-CELLS; HIGH GLUCOSE; INDEPENDENT ACTIVATION; ACTIN CYTOSKELETON; MESSENGER-RNA AB Renal cell activity of p38 mitogen-activated protein kinase (p38) is increased in the diabetic milieu. p38 mediates signals relevant for the development of diabetic nephropathy (DN). However, renal p38 in Type 1 diabetes in vivo, particularly in conditions reflecting the differences in metabolic control, and its activity in advanced stages of DN, has received less attention. We examined the p38 pathway in renal cortex of rats with streptozotocin diabetes (4 weeks) with poor (DS), moderate (DM), and intensive (DII) metabolic control, achieved by varying doses of insulin therapy. Renal p38 was also studied in 12-month diabetic rats with established nephropathy (DM12) and compared with age-matched controls. p38 activity (in vitro kinase assay and expression of phosphorylated (active) p38 (P-p38)) was increased in DM and DS rats, as compared with non-diabetic controls, and attenuated by intensive insulin treatment. In all groups, P-p38 was predominantly localized in macula densa cells. Diabetic rats also demonstrated P-p38 immunoreactivity in the distal tubule and glomeruli. Enhanced p38 activity in DS and DM rats was not associated with increases in expression of active mitogen-activated protein kinase 3/6, an activator of p38, but paralleled with increased expression of scaffolding protein transforming growth factor-beta-activated protein kinase 1-binding protein 1. Expression of mitogen-activated protein phosphatase-1 (MKP-1), one of the phosphatases involved in inactivation of mitogen-activated protein kinase signaling, was increased in all diabetic groups, irrespective of metabolic control. Renal p38 activation was also detectable in D12 rats with established albuminuria and glomerulosclerosis. In summary, renal cortical p38 activity was increased in diabetic rats at early and advanced stages of nephropathy, as compared with non-diabetic animals, and attenuated by improved metabolic control. p38 activation in diabetes is likely to occur via multiple pathways and cannot be explained by downregulation of MKP-1. C1 Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA. Inst Clin & Expt Med, Ctr Diabet, Prague, Czech Republic. Portland VA Med Ctr, Med Serv, Portland, OR USA. RP Komers, R (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, PP262,3314 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM komersr@ohsu.edu FU NIDDK NIH HHS [DK-52494, DK 063231] NR 40 TC 26 Z9 30 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JUN PY 2007 VL 87 IS 6 BP 548 EP 558 DI 10.1038/labinvest.3700549 PG 11 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 168ZA UT WOS:000246561300004 PM 17401436 ER PT J AU Ioannou, GN AF Ioannou, George N. TI Towards a better liver transplant allocation system - Reply SO LIVER TRANSPLANTATION LA English DT Letter C1 Univ Washington, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Ioannou, GN (reprint author), Univ Washington, Seattle, WA 98195 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1527-6465 J9 LIVER TRANSPLANT JI Liver Transplant. PD JUN PY 2007 VL 13 IS 6 BP 937 EP 937 DI 10.1002/lt.21145 PG 1 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA 174ZS UT WOS:000246982200030 ER PT J AU Singh, M Rihal, CS Lennon, RJ Spertus, J Rumsfeld, JS Holmes, DR AF Singh, Mandeep Rihal, Charanjit S. Lennon, Ryan J. Spertus, John Rumsfeld, John S. Holmes, David R., Jr. TI Bedside estimation of risk from percutaneous coronary intervention: The new Mayo Clinic risk scores. SO MAYO CLINIC PROCEEDINGS LA English DT Article ID IN-HOSPITAL MORTALITY; OPERATOR VOLUME; COMPLICATIONS; MODELS; STRATIFICATION; PREDICTION; VALIDATION; EXPERIENCE AB Objective: To derive risk models for percutaneous coronary intervention (PCI) outcomes from clinical and laboratory variables available before the procedure so they can be used for preprocedure risk stratification. Patients and Methods: Using the Mayo Clinic registry, we analyzed 9035 PCIs on 7640 unique patients from January 1, 2000, through April 30, 2005. We included only the first PCI per patient (n=7457). Logistic regression was used to model the calculated risk score and major procedural complications. Separate risk models were made for mortality and major adverse cardiovascular events (MACE) derived solely from baseline and laboratory characteristics. Final risk scores for procedural death, defined as any death during the index hospitalization, and MACE contained the same 7 variables (age, myocardial infarction :524 hours, preprocedural shock, serum creatinine level, left ventricular ejection fraction, congestive heart failure, and peripheral artery disease). Results: Models had adequate goodness of fit, and areas under the receiver operating characteristic curve were 0.74 and 0.89 for MACE and procedural death, respectively, indicating excellent overall discrimination. The model was robust across many subgroups, including those undergoing elective PCI, those having diabetes mellitus, and elderly patients. Bootstrap analysis Indicated that the model was not overfit to the available data set. Conclusions: Before coronary angiography is performed, a risk-scoring system based on 7 variables can be used conveniently to predict cardiovascular complications after PCI. This model may be useful for providing patients with individualized, evidence-based estimates of procedural risk as part of the informed consent process. C1 Mayo Clin & Mayo Fdn, Coll Med, Div Cardiovasc Dis, Rochester, MN 55905 USA. Mayo Clin & Mayo Fdn, Coll Med, Div Biostat, Rochester, MN 55905 USA. Mid Amer Heart Inst, Kansas City, MO USA. Denver VA Med Ctr, Div Cardiovasc, Denver, CO USA. RP Singh, M (reprint author), Mayo Clin & Mayo Fdn, Coll Med, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA. EM singh.mandeep@mayo.edu NR 18 TC 64 Z9 64 U1 0 U2 7 PU MAYO CLINIC PROCEEDINGS PI ROCHESTER PA 660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905 USA SN 0025-6196 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD JUN PY 2007 VL 82 IS 6 BP 701 EP 708 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 174XT UT WOS:000246976900010 PM 17550750 ER PT J AU Min, LC Wenger, NS Fung, C Chang, JT Ganz, DA Higashi, T Kamberg, CJ MacLean, CH Roth, CP Solomon, DH Young, RT Reuben, DB AF Min, Lillian C. Wenger, Neil S. Fung, Constance Chang, John T. Ganz, David A. Higashi, Takahiro Kamberg, Caren J. MacLean, Catherine H. Roth, Carol P. Solomon, David H. Young, Roy T. Reuben, David B. TI Multimorbidity is associated with better quality of care among vulnerable elders SO MEDICAL CARE LA English DT Article DE multimorbidity; comorbidity; vulnerable elders; quality of care; quality indicators ID OLDER PATIENTS; MEDICAL CONDITIONS; FUNCTIONAL STATUS; BLOOD-PRESSURE; WOMENS HEALTH; MORTALITY; COMMUNITY; PEOPLE; COMORBIDITY; POPULATION AB Background: Older patients with multiple chronic conditions may be at higher risk of receiving poorer overall quality of care compared with those with single or no chronic conditions. Possible reasons include competing guidelines for individual conditions, burden of numerous recommendations, and difficulty implementing treatments for multiple conditions. Objectives: We sought to determine whether coexisting combinations of 8 common chronic conditions (hypertension, coronary artery disease, chronic obstructive pulmonary disease, osteoarthritis, diabetes mellitus, depression, osteoporosis, and having atrial fibrillation or congestive heart failure) are associated with overall quality of care among vulnerable older patients. Materials and Methods: Using an observational cohort study, we enrolled 372 community-dwel ling persons 65 years of age or older who were at increased risk for death or functional decline within 2 years. We included (1) a comprehensive measure (% of quality indicators satisfied) of quality of medical and geriatric care that accounted for patient preference and appropriateness in light of limited life expectancy and advanced dementia, and (2) a measure of multimorbidity, either as a simple count of conditions or as a combination of specific conditions. Results: Multimorbidity was associated with greaer overall quality scores: mean proportion of quality indicators satisfied increased from 47% for elders with none of the prespecified conditions to 59% for those with 5 or 6 conditions (P < 0.0001), after controlling for number of office visits. Patients with greater multimorbidity also received care that was better than would be expected based on the specific set of quality indicators they triggered. Conclusions: Among older persons at increased risk of death or functional decline, multimorbidity results in better, rather than worse, quality of care. C1 Univ Calif Los Angeles, Dept Geriatr Med, David Geffen Sch Med, Los Angeles, CA 90095 USA. RAND Hlth, Santa Monica, CA USA. Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. Univ Calif Los Angeles, STAR Program, Los Angeles, CA 90095 USA. Kyoto Univ, Dept Epidemiol & Healthcare Res, Kyoto, Japan. RP Min, LC (reprint author), Univ Calif Los Angeles, Dept Geriatr Med, David Geffen Sch Med, 10945 Conte Ave,Suite 2339 Box 951687, Los Angeles, CA 90095 USA. EM lmin@mednet.ucla.edu FU BHP HRSA HHS [PE-19001]; NIA NIH HHS [AG10415] NR 50 TC 86 Z9 86 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JUN PY 2007 VL 45 IS 6 BP 480 EP 488 DI 10.1097/MLR.0b013e318030fff9 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 176JJ UT WOS:000247080700002 PM 17515774 ER PT J AU Bryson, CL Au, DH Young, B McDonell, MB Fihn, SD AF Bryson, Chris L. Au, David H. Young, Bessie McDonell, Mary B. Fihn, Stephan D. TI A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp) SO MEDICAL CARE LA English DT Article DE drug; compliance; adherence; validity; methods; pharmacy ID PHARMACY RECORDS; MEDICATION ADHERENCE; THERAPY; PERSISTENCE; VALIDATION AB Background: There are many measures of refill adherence available, but few have been designed or validated for use with repeated measures designs and short observation periods. Objective: To design a refill-based adherence algorithm suitable for short observation periods, and compare it to 2 reference measures. Methods: A single composite algorithm incorporating information on both medication gaps and oversupply was created. Electronic Veterans Affairs pharmacy data, clinical data, and laboratory data from routine clinical care were used to compare the new measure, ReComp, with standard reference measures of medication gaps (MEDOUT) and adherence or oversupply (MEDSUM) in 3 different repeated measures medication adherence-response analyses. These analyses examined the change in low density lipoprotein (LDL) with simvastatin use, blood pressure with antihypertensive use, and heart rate with P-blocker use for 30- and 90-day intervals. Measures were compared by regression based correlations (R-2 values) and graphical comparisons of average medication adherence-response curves. Results: In each analysis, ReComp yielded a significantly higher R-2 value and more expected adherence-response curve regardless of the length of the observation interval. For the 30-day intervals, the highest correlations were observed in the LDL-simvastatin analysis (ReComp R-2 = 0.231; [95% CI, 0.222-0.239]; MEDSUM R 2 = 0.054; [95% CI, 0.049-0.059]; MEDOUT R 2 = 0.053; [95% CI, 0.048-0.058]). Conclusions: ReComp is better suited to shorter observation intervals with repeated measures than previously used measures. C1 VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev NW Ctr Excellence, Seattle, WA 98101 USA. VA Puget Sound Hlth Care Syst, Epidemol Res & Informat Ctr, Seattle, WA 98101 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Bryson, CL (reprint author), VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev NW Ctr Excellence, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM cbryson@u.washington.edu NR 17 TC 64 Z9 64 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JUN PY 2007 VL 45 IS 6 BP 497 EP 504 DI 10.1097/MLR.0b013e3180329368 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 176JJ UT WOS:000247080700004 PM 17515776 ER PT J AU Pumbwe, L Chang, A Smith, RL Wexler, HM AF Pumbwe, Lilian Chang, Abraham Smith, Rachel L. Wexler, Hannah M. TI BmeRABC5 is a multidrug efflux system that can confer metronidazole resistance in Bacteroides fragilis SO MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE LA English DT Article ID TRANSCRIPTIONAL REPRESSOR; PUMP; SUSCEPTIBILITY; STRAINS AB The RND-family efflux pump gene bmeB5 was previously shown to be overexpressed in metronidazole-resistant laboratory mutants of Bacteroides fragilis. In the present study, we characterized the bmeABC5 genes and an upstream putative TetR-family regulator gene (bmeR5). bmeR5 (645 bp) was located 51 bp upstream of bmeA5 and encoded a 24.9-kDa protein. Deletant strains lacking bmeB5 or bmeR5 were constructed from a wild-type B. fragilis strain ADB77. Strain antimicrobial susceptibility was determined and gene expression was quantified. bmeR5 was overexpressed in Escherichia coli using a 6 x-His tag system; BmeR5-HiS(6) was isolated from inclusion bodies and its binding to bmeABC5 promoter regions was determined. BmeR5-HiS(6) bound specifically to the bmeR5-bmeC5 intergenic region (IT1). Deletion of bmeR5 (ADB77 Delta bmeR5) resulted in a significant (p < 0.05) increase in expression of bmeA5, bmeB5, and bmeC5, and > two-fold increase in minimum inhibitory concentrations (MICs) of ampicillin, cefoxitin, cefoperazone, ciprofloxacin, imipenem, metronidazole, ethidium bromide, and sodium dodecyl sulfate (SDS). MICs were reduced by the efflux pump inhibitor carbonyl cyanide m-chlorophenyl hydrazone (CCCP). The MICs of ampicillin, cefoperazone, metronidazole, and SDS were reduced by approximately two-fold in ADB77 Delta bmeB5. A multidrug (metronidazole)-resistant, nim-negative B. fragilis clinical isolate overexpressed bmeABC5 genes, had a G -> T point mutation in IT1, and significantly reduced binding to BmeR5-HiS(6). These data demonstrate that BmeR5 is a local repressor of bmeABC5 expression and that mutations in IT1 can lead to a derepression and resistance to multiple antimicrobial agents, including metronidazole. C1 Wadsworth Anaerobe Lab, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. RP Pumbwe, L (reprint author), Wadsworth Anaerobe Lab, Bldg 304,Room E3-226,GLAVAHCS 691-151J, Los Angeles, CA 90073 USA. EM lilskil@ucla.edu NR 15 TC 20 Z9 20 U1 1 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1076-6294 J9 MICROB DRUG RESIST JI Microb. Drug Resist.-Mechan. Epidemiol. Dis. PD SUM PY 2007 VL 13 IS 2 BP 96 EP 101 DI 10.1089/mdr.2007.719 PG 6 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 194SD UT WOS:000248363200004 PM 17650960 ER PT J AU Hazra, S Batra, RK Tai, HH Sharma, S Cui, XY Dubinett, SM AF Hazra, Saswati Batra, Raj K. Tai, Hsin H. Sharma, Sherven Cui, Xiaoyan Dubinett, Steven M. TI Pioglitazone and rosiglitazone decrease prostaglandin E-2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase SO MOLECULAR PHARMACOLOGY LA English DT Article ID ACTIVATED-RECEPTOR-GAMMA; CYCLOOXYGENASE-2 EXPRESSION; COLORECTAL-CANCER; COX-2 INHIBITION; TUMOR-SUPPRESSOR; GENE-EXPRESSION; THIAZOLIDINEDIONE; INFLAMMATION; CARCINOMA; PULMONARY AB Lung cancer cells elaborate the immunosuppressive and anti-apoptotic mediator prostaglandin E 2 (PGE 2), a product of cyclooxygenase-2 (COX-2) enzyme activity. Because peroxisome proliferator-activated receptor (PPAR) gamma ligands, such as thiazolidinediones (TZDs), inhibit lung cancer cell growth, we examined the effect of the TZDs pioglitazone and rosiglitazone on PGE 2 levels in non -small-cell lung cancer (NSCLC) A427 and A549 cells. Both TZDs inhibited PGE 2 production in NSCLC cells via a COX-2 independent pathway. To define the mechanism underlying COX-2 independent suppression of PGE 2 production, we focused on other enzymes responsible for the synthesis and degradation of PGE (2). The expression of none of the three prostaglandin synthases (microsomal PGES1, PGES2 and cystosolic PGES) was down-regulated by the TZDs. It is noteworthy that 15-hydroxyprostaglandin dehydrogenase (15-PGDH), an enzyme that produces biologically inactive 15-ketoprostaglandins from active PGE 2, was induced by TZDs. The TZD-mediated suppression of PGE 2 concentration was significantly inhibited by small interfering RNA to 15-PGDH. Studies using dominant-negative PPAR gamma overexpression or 2-chloro-5-nitrobenzanilide (GW9662; a PPAR gamma antagonist) revealed that the suppressive effect of the TZDs on PGE 2 is PPAR gamma-independent. Together, these findings indicate that it is possible to use a clinically available pharmacological intervention to suppress tumor-derived PGE 2 by enhancing catabolism rather than blocking synthesis. C1 Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, UCLA Lung Canc Res Program, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY USA. RP Hazra, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, UCLA Lung Canc Res Program, 37-131 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM shazra@mednet.ucla.edu OI Batra, Raj K./0000-0002-1126-543X FU NCI NIH HHS [R01-CA111851, P50-CA90388] NR 38 TC 58 Z9 59 U1 1 U2 2 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0026-895X J9 MOL PHARMACOL JI Mol. Pharmacol. PD JUN PY 2007 VL 71 IS 6 BP 1715 EP 1720 DI 10.1124/mol.106.033357 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 174YT UT WOS:000246979500029 PM 17412838 ER PT J AU Omer, HA Hussein, MR AF Omer, Hyder A. Hussein, Mahmoud R. TI Primary renal lymphoma SO NEPHROLOGY LA English DT Article ID KIDNEY C1 King Khalid Univ, Coll Med, Dept Med, Nephrol Sect,Assir Cent Hosp, Abha, Saudi Arabia. Assuit Univ Hosp, Dept Pathol, Assiut, Egypt. Univ Wisconsin, Sch Med, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Omer, HA (reprint author), King Khalid Univ, Coll Med, Dept Med, Nephrol Sect,Assir Cent Hosp, Abha, Saudi Arabia. NR 3 TC 7 Z9 8 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1320-5358 J9 NEPHROLOGY JI Nephrology PD JUN PY 2007 VL 12 IS 3 BP 314 EP 315 DI 10.1111/j.1440-1797.2007.00783.x PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 173QX UT WOS:000246888700017 PM 17498130 ER PT J AU Zhao, Z Xiang, ZM Haroutunian, V Buxbaum, JD Stetka, B Pasinetti, GM AF Zhao, Zhong Xiang, Zhongmin Haroutunian, Vahram Buxbaum, Joseph D. Stetka, Breton Pasinetti, Giulio Maria TI Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease SO NEUROBIOLOGY OF AGING LA English DT Article DE IDE; MCI; CDR; beta-amyloid ID MILD COGNITIVE IMPAIRMENT; AMYLOID BETA-PROTEIN; EXTRACELLULAR LEVELS; A-BETA; DEGRADATION; BRAIN; MECHANISMS; OLIGOMERS; PEPTIDE AB In this study we report that the mem brane-bound, but not cytosolic insulin degrading enzyme (IDE) protein concentration and IDE activity are significantly decreased in the hippocampal formation of cases affected by mild cognitive impairment (MCI) which are at high risk to develop Alzheimer's disease (AD), relative to normal neurological controls. Membrane-bound IDE protein concentrations and activity in the hippocampal formation continued to decrease during the conversion from MCI to mild-severe AD. This selective decrease in hippocampal membrane-bound, but not cytosolic, IDE concentration and activity was tissue specific since no changes in either membrane-bound or cytosolic IDE were found in the occipital cortex of the same cases examined. Most interestingly, the decreased hippocampal membrane-bound IDE protein activity negatively correlated with brain beta-amyloid (A beta)X-42 content in MCI and in AD brain. The study tentatively suggests that interventions aimed at promoting membrane-bound IDE activities in the brain of MCI cases may help to prevent the onset and possibly the progression into AD through mechanisms involving the clearance of monomeric A beta from the brain. (c) 2006 Elsevier Inc. All rights reserved. C1 Mt Sinai Sch Med, Neuroinflammat Res Labs, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA. Bronx Vet Affairs Med Ctr, GRECC, Bronx, NY 10468 USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Neuroinflammat Res Labs, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu OI Buxbaum, Joseph/0000-0001-8898-8313 FU NIA NIH HHS [AG13799, AG14239, AG14766] NR 18 TC 68 Z9 73 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUN PY 2007 VL 28 IS 6 BP 824 EP 830 DI 10.1016/j.neurobiolaging.2006.05.001 PG 7 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 164SB UT WOS:000246253300003 PM 16769157 ER PT J AU Wong, HK Muftuoglu, M Beck, G Imam, SZ Bohr, VA Wilson, DM AF Wong, Heng-Kuan Muftuoglu, Meltem Beck, Gad Imam, Syed Z. Bohr, Vilhelm A. Wilson, David M., III TI Cockayne syndrome B protein stimulates apurinic endonuclease 1 activity and protects against agents that introduce base excision repair intermediates SO NUCLEIC ACIDS RESEARCH LA English DT Article ID RNA-POLYMERASE-II; TRANSCRIPTION-COUPLED REPAIR; HUMAN APURINIC ENDONUCLEASE; ABASIC SITE RECOGNITION; STRAND BREAK REPAIR; CSB GENE-PRODUCT; DNA-REPAIR; XERODERMA-PIGMENTOSUM; POLY(ADP-RIBOSE) POLYMERASE; MAJOR HUMAN AB The Cockayne syndrome B (CSB) protein-defective in a majority of patients suffering from the rare autosomal disorder CS-is a member of the SWI2/SNF2 family with roles in DNA repair and transcription. We demonstrate herein that purified recombinant CSB and the major human apurinic/apyrimidinic (AP) endonuclease, APE1, physically and functionally interact. CSB stimulates the AP site incision activity of APE1 on normal (i.e. fully paired) and bubble AP-DNA substrates, with the latter being more pronounced ( =up to 6-fold). This activation is ATP-independent, and specific for the human CSB and full-length APE1 protein, as no CSB-dependent stimulation was observed with Escherichia coli endonuclease IV or an N-terminal truncated APE1 fragment. CSB and APE1 were also found in a common protein complex in human cell extracts, and recombinant CSB, when added back to CSB-deficient whole cell extracts, resulted in increased total AP site incision capacity. Moreover, human fibroblasts defective in CSB were found to be hypersensitive to both methyl methanesulfonate (MMS) and 5-hydroxymethyl 20-deoxyuridine, agents that introduce base excision repair (BER) DNA substrates/intermediates. C1 NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA. Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA. RP Wilson, DM (reprint author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA. EM wilsonda@grc.nia.nih.gov FU Intramural NIH HHS NR 81 TC 63 Z9 66 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD JUN PY 2007 VL 35 IS 12 BP 4103 EP 4113 DI 10.1093/nar/gkm404 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 186ZS UT WOS:000247817700022 PM 17567611 ER PT J AU Lata, PF Elliott, ME AF Lata, Paul F. Elliott, Mary E. TI Patient assessment in the diagnosis, prevention, and treatment of osteoporosis SO NUTRITION IN CLINICAL PRACTICE LA English DT Review ID BONE-MINERAL DENSITY; FRACTURE INTERVENTION TRIAL; X-RAY ABSORPTIOMETRY; VITAMIN-D STATUS; SEROTONIN-REUPTAKE INHIBITORS; POPULATION-BASED COHORT; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURE; HIP FRACTURE; BIOCHEMICAL MARKERS AB Assessment of the patient with osteoporosis includes history and physical examination, laboratory testing, and imaging studies. Information gathered during this assessment assists clinicians in targeting strategies to prevent fractures. The medical history should contain items such as personal and family history of fractures, lifestyle, intake of substances such as vitamin D, calcium, corticosteroids, and other medications. The physical examination can reveal relevant information such as height loss and risk of falls. Bone mineral density (BMD), most commonly determined by dual-energy x-ray absorptiometry, best predicts fracture risk in patients without previous fracture. BMD testing is most efficient in women over 65 years old but is also helpful for men and women with risk factors. Serial BMD tests can identify individuals losing bone mass, but clinicians should be aware of what constitutes a significant change. Laboratory testing can detect other risk factors and can provide clues to etiology. Selection of laboratory tests should be individualized, as there is no consensus regarding which tests are optimal. Biochemical markers of bone turnover have a potential role in fracture risk assessment and in gauging response to therapy, but are not widely used at present. Clinicians should be aware of problems with vitamin D measurement, including seasonal variation, variability among laboratories, and the desirable therapeutic range. Careful assessment of the osteoporotic patient is essential in developing a comprehensive plan that reduces fracture risk and improves quality of life. C1 Bay Area Med Ctr, Case Management Serv, Marinette, WI 54143 USA. Univ Wisconsin, Sch Pharm, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Lata, PF (reprint author), Bay Area Med Ctr, Case Management Serv, 3100 Shore Dr, Marinette, WI 54143 USA. EM plata@bamc.org NR 133 TC 8 Z9 8 U1 0 U2 2 PU AMER SOC PARENTERAL & ENTERAL NUTRITION PI SILVER SPRING PA 8630 FENTON STREET SUITE 412, SILVER SPRING, MD 20910 USA SN 0884-5336 J9 NUTR CLIN PRACT JI Nutr. Clin. Pract. PD JUN PY 2007 VL 22 IS 3 BP 261 EP 275 DI 10.1177/0115426507022003261 PG 15 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 217CT UT WOS:000249926700003 PM 17507727 ER PT J AU Friedlander, AH Cohen, SN AF Friedlander, Arthur H. Cohen, Stanley N. TI Panoramic radiographic atheromas portend adverse vascular events SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY LA English DT Article ID CORONARY-ARTERY-DISEASE; INTIMA-MEDIA THICKNESS; CAROTID-ARTERY; RISK-FACTORS; ATHEROSCLEROSIS; CALCIFICATION; PLAQUES; STROKE; EXTENT; HEART AB Objective. This study sought to determine if calcified carotid artery atheromas (CCAA) imaged on panoramic radiographs portend an adverse vascular event. Study design. Medical records of 46 males (mean age 66) with a CCAA (Group 1) were reviewed for preimaging vascular risks and for cerebrovascular events subsequent to the radiograph. Matched controls (age, gender, ethnicity, and vascular risks) treated at the same hospital but never radiographed were identified (Group 2) and matched to their cohort. The medical records of Group 2 individuals were re-reviewed for development of vascular events occurring after the date of their cohort's radiograph. Results. Twenty adverse vascular events (myocardial infarct, stroke, revascularization procedure, transient ischemic attack, angina requiring hospitalization) occurred in twelve Group 1 patients and 6 events occurred in five Group 2 patients (P = 0.006). Conclusion. The incidental finding of a CCAA portends significant risk of a future, adverse vascular event. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA. Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA. EM arthur.friedlander@med.va.gov NR 28 TC 30 Z9 32 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1079-2104 J9 ORAL SURG ORAL MED O JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. PD JUN PY 2007 VL 103 IS 6 BP 830 EP 835 DI 10.1016/j.tripleo.2006.07.016 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 191AX UT WOS:000248103300018 PM 17261373 ER PT J AU Dempsey, EC Cool, CD Littler, CM AF Dempsey, Edward C. Cool, Carlyne D. Littler, Cassana M. TI Lung disease and PKCs SO PHARMACOLOGICAL RESEARCH LA English DT Review DE pulmonary vasculature; airway; alveolar; interstitial; injury; inflammation; cancer; contraction; proliferation; apoptosis; migration; PKC-alpha; PKC-beta; PKC-delta; PKC-epsilon; PKC-theta; PKC-eta; PKC-zeta; PKC-iota; human; knockout mice ID PROTEIN-KINASE-C; SMOOTH-MUSCLE-CELLS; BRONCHIAL EPITHELIAL-CELLS; FIBROBLAST COLLAGEN-SYNTHESIS; ENDOTHELIAL PROGENITOR CELLS; KAPPA-B ACTIVATION; GROWTH-FACTOR-BETA; GENE-EXPRESSION; PULMONARY-FIBROSIS; CANCER CELLS AB The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified. (C) 2007 Elsevier Ltd. All rights reserved. C1 Univ Colorado, Hlth Sci Ctr, Cardiovasc Pulm Res Lab, Denver, CO 80262 USA. Denver VA Med Ctr, Med Serv, Pulm & Crit Care Sect, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA. Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80220 USA. RP Dempsey, EC (reprint author), Univ Colorado, Hlth Sci Ctr, Cardiovasc Pulm Res Lab, B-133,4200 E 9th Ave, Denver, CO 80262 USA. EM edward.dempsey@uchsc.edu FU NHLBI NIH HHS [R0-1 HL078927, HL14985]; NIDDK NIH HHS [5 T35 DK07496-18] NR 112 TC 50 Z9 53 U1 0 U2 1 PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-6618 J9 PHARMACOL RES JI Pharmacol. Res. PD JUN PY 2007 VL 55 IS 6 BP 545 EP 559 DI 10.1016/j.phrs.2007.04.010 PG 15 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 191VP UT WOS:000248160400009 PM 17582782 ER PT J AU Benator, DA Weiner, MH Burman, WJ Vernon, AA Zhao, ZA Khan, AE Jones, BE Sandman, L Engle, M Silva-Trigo, C Hsyu, PH Becker, MI Peloquin, CA AF Benator, Debra A. Weiner, Marc H. Burman, William J. Vernon, Andrew A. Zhao, Zhen A. Khan, Awal E. Jones, Brenda E. Sandman, Laurie Engle, Melissa Silva-Trigo, Claudia Hsyu, Poe H. Becker, Mark I. Peloquin, Charles A. CA Tuberculosis Trials Consortium TI Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection SO PHARMACOTHERAPY LA English DT Article; Proceedings Paper CT 100th International Conference of the American-Thoracic-Society CY MAY 21-26, 2004 CL Orlando, FL SP Amer Thorac Soc DE tuberculosis; human immunodeficiency virus; HIV; nelfinavir; rifabutin; isoniazid; drug interactions; cytochrome P450; pharmacokinetics ID ACQUIRED RIFAMYCIN RESISTANCE; PHARMACOKINETICS; HIV; PLASMA; M8 AB Study Objective. To characterize the bidirectional interaction between twice-daily nelfinavir and twice-weekly rifabutin and isoniazid in patients with tuberculosis and human immunodeficiency virus (HIV) infection. Design. Prospective cohort study. Setting. Three clinical research centers. Patients. Seven patients with HIV-related tuberculosis. Intervention. Rifabutin 300 mg and isoniazid 15 mg/kg (maximum dose 900 mg) twice/week were administered for at least 2 weeks during the continuation phase of tuberculosis treatment. Antiretroviral therapy with nelfinavir 1250 mg twice/day and two nucleoside reverse transcriptase inhibitors was then added. Measurements and Main Results. Patients underwent blood sampling for pharmacokinetic analysis during the continuation phase of tuberculosis therapy and after a median of 21, days after the addition of antiretroviral treatment. When rifabutin was coadministered with nelfinavir, its area under the concentration-time curve from 0-21 hours (AUC(0-21)) increased 22% (geometric mean 5.01 mu g.hr/ml [90% confidence interval (CI) 3.25-7.711 with nelfinavir vs 4.10 mu g.hr/ml [90% CI 3.18-5.27] without nelfinavir; geometric mean ratio 1.22 [90% CI 0.78-1.921). Also, the AUCO-21 for the active metabolite, desacetylrifabutin, increased significantly (geometric mean ratio 3.46, 90% CI 1.84-6.47, p=0.009). in the presence of rifabutin, the pharmacokinetic parameters of nelfinavir and its principal metabolite M8 were similar to those of patients not taking rifabutin. No drug interaction between nelfinavir and isoniazid was detected. Conclusions. Coadministration of rifabutin and isoniazid without dosage adjustment during twice-weekly tuberculosis therapy with nelfinavir-based antiretroviral therapy resulted in rifabutin exposures within the acceptable ranges for safety and efficacy. Therefore, this combination is an appropriate option for the simultaneous treatment of tuberculosis and HIV infection when tuberculosis therapy is given twice weekly. C1 Vet Affairs Med Ctr, Div Infect Dis, Washington, DC 20422 USA. George Washington Univ, Med Ctr, Washington, DC 20037 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Natl Jewish Med & Res Ctr, Denver, CO USA. Ctr Dis Control & Prevent, Atlanta, GA USA. Univ So Calif, Los Angeles Cty Med Ctr, Los Angeles, CA 90033 USA. NYU, Sch Med, New York, NY USA. Agouron Pharmaceut Inc, La Jolla, CA USA. RP Benator, DA (reprint author), Vet Affairs Med Ctr, Div Infect Dis, 151 B,50 Irving St NW, Washington, DC 20422 USA. EM debra.benator@med.va.gov FU NCRR NIH HHS [M01-RR-01346] NR 28 TC 10 Z9 11 U1 2 U2 7 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD JUN PY 2007 VL 27 IS 6 BP 793 EP 800 DI 10.1592/phco.27.6.793 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 172OF UT WOS:000246812900003 PM 17542762 ER PT J AU Valdiserri, RO AF Valdiserri, Ronald O. TI Late HIV diagnosis: Bad medicine and worse public health SO PLOS MEDICINE LA English DT Editorial Material ID PERSONS AWARE; UNITED-STATES; PREVENTION; INFECTION; UNAWARE; VIRUS C1 US Dept Vet Affairs, Washington, DC USA. RP Valdiserri, RO (reprint author), US Dept Vet Affairs, Washington, DC USA. EM R.Valdiserri@va.gov NR 14 TC 19 Z9 19 U1 2 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD JUN PY 2007 VL 4 IS 6 BP 975 EP 976 AR e200 DI 10.1371/journal.pmed.0040200 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 182AA UT WOS:000247476300005 PM 17564489 ER PT J AU Cusack, KJ Grubaugh, AL Yim, E Knapp, RG Robins, CS Frueh, BC AF Cusack, Karen J. Grubaugh, Anouk L. Yim, Eunsil Knapp, Rebecca G. Robins, Cynthia S. Frueh, B. Christopher TI Are there racial differences in the experience of harmful or traumatic events within psychiatric settings? SO PSYCHIATRIC QUARTERLY LA English DT Article DE psychiatric patients; hospital; racial differences; trauma ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-ILLNESS; PSYCHOMETRIC PROPERTIES; SPECIAL SECTION; PTSD CHECKLIST; CARE; RESTRAINT; SECLUSION; RACE; SCHIZOPHRENIA AB The current study examined racial differences in the reported frequency and distress associated with potentially harmful or traumatic experiences occurring within psychiatric settings. One hundred and forty-two (109 African-American; 32 Caucasian) randomly selected adult consumers recruited from a community psychosocial day program completed a battery of self-report measures to assess experiences in the psychiatric setting, lifetime trauma exposure, PTSD severity, and were the subject of a chart review. A subset of participants (20%) also completed a qualitative interview exploring their perceptions of events occurring in psychiatric settings. Few racial differences were noted in the reported frequency or distress associated with particular events in the psychiatric setting. However, we found differential patterns of association between adverse psychiatric events and lifetime trauma history, and racial differences in diagnosis and medications prescribed by the mental health center. These racial differences merit further attention to better understand their meaning and to improve mental health services provided to both African-Americans and Caucasian public-sector psychiatric patients. C1 Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA. Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. Med Univ S Carolina, Charleston, SC USA. Westat Corp, Rockville, MD USA. Univ Hawaii, Dept Psychol, Hilo, HI USA. RP Cusack, KJ (reprint author), Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, 725 Martin Luther King,CB 7590, Chapel Hill, NC 27599 USA. EM kcusack@schsr.unc.edu FU NIMH NIH HHS [MH01660, MH65517] NR 42 TC 5 Z9 5 U1 2 U2 5 PU KLUWER ACADEMIC-HUMAN SCIENCES PRESS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA SN 0033-2720 J9 PSYCHIAT QUART JI Psychiatr. Q. PD JUN PY 2007 VL 78 IS 2 BP 101 EP 115 DI 10.1007/s11126-006-9031-x PG 15 WC Psychiatry SC Psychiatry GA 157ZH UT WOS:000245759700003 PM 17345158 ER PT J AU Zeber, JE McCarthy, JF Bauer, MS Kilbourne, AM AF Zeber, John E. McCarthy, John F. Bauer, Mark S. Kilbourne, Amy M. TI Datapoints: Self-reported access to general medical and psychiatric care among veterans with bipolar disorder SO PSYCHIATRIC SERVICES LA English DT Editorial Material C1 [Zeber, John E.] S Texas Vet Hlth Care Syst, Vet Affairs Hlth Serv Res & Dev Serv, San Antonio, TX 78229 USA. [McCarthy, John F.; Kilbourne, Amy M.] VA HSR&D, Serious Ment Illness Treatment Evaluat & Res Ctr, Ann Arbor, MI USA. [Bauer, Mark S.] VA Med Ctr, Providence, RI USA. RP Zeber, JE (reprint author), S Texas Vet Hlth Care Syst, Vet Affairs Hlth Serv Res & Dev Serv, 7400 Merton Minter Blvd 11C6, San Antonio, TX 78229 USA. EM zeber@uthscsa.edu NR 3 TC 5 Z9 5 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JUN PY 2007 VL 58 IS 6 BP 740 EP 740 DI 10.1176/appi.ps.58.6.740 PG 1 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 265LJ UT WOS:000253360100002 PM 17535932 ER PT J AU Senior, AC Kunik, ME Rhoades, HM Novy, DM Wilson, NL Stanley, MA AF Senior, Ashley C. Kunik, Mark E. Rhoades, Howard M. Novy, Diane M. Wilson, Nancy L. Stanley, Melinda A. TI Utility of telephone assessments in an older adult population SO PSYCHOLOGY AND AGING LA English DT Article DE telephone assessments; anxiety and depression; older adults ID MULTITRAIT-MULTIMETHOD MATRIX; GENERALIZED ANXIETY DISORDER; BECK DEPRESSION INVENTORY; FACE-TO-FACE; PRIMARY-CARE; VALIDATION; INTERVIEW; OUTCOMES; IMPACT; SCALE AB Telephone assessments are commonly used in mental health research and may be especially beneficial in older populations. The current study assessed the psychometric properties of the Penn State Worry Questionnaire (T. J. Meyer, M. L. Miller, R. L. Metzger, & T. D. Borkovec, 1990) and the Beck Depression Inventory-II (A. T. Beck, R. A. Steer, & G. K. Brown, 1996), when administered over the telephone in an older adult population. Results indicate no differences in mean symptom level or internal consistency across two modes of administration. Correlations between the in-person and telephone-administered measures and diagnostic categories suggest adequate validity of the telephone-administered measures. With this demonstrated evidence, the telephone assessment method can be applied in a variety of research and clinical settings. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX 77030 USA. Univ Houston, Dept Psychol, Houston, TX 77004 USA. Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Houston, TX 77225 USA. RP Stanley, MA (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM mstanley@bcm.tmc.edu FU PHS HHS [53932] NR 43 TC 18 Z9 18 U1 20 U2 21 PU AMER PSYCHOLOGICAL ASSOC/EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0882-7974 J9 PSYCHOL AGING JI Psychol. Aging PD JUN PY 2007 VL 22 IS 2 BP 392 EP 397 DI 10.1037/0882-7974.22.2.392 PG 6 WC Gerontology; Psychology, Developmental SC Geriatrics & Gerontology; Psychology GA 176KI UT WOS:000247083500019 PM 17563195 ER PT J AU Murphy, MR Escamilla, MI Blackwell, PH Lucke, KT Miner-Williams, D Shaw, V Lewis, SL AF Murphy, Margaret R. Escamilla, Monica I. Blackwell, Paula H. Lucke, Kathy T. Miner-Williams, Denise Shaw, Virginia Lewis, Sharon L. TI Focus on research methods - Assessment of caregivers' willingness to participate in an intervention research study SO RESEARCH IN NURSING & HEALTH LA English DT Article DE recruitment; retention; caregivers; Alzheimer's disease; qualitative research ID FAMILY CAREGIVERS; CLINICAL-RESEARCH; RECRUITMENT; RETENTION; DEMENTIA; ISSUES; ADULTS AB The purpose of the study was to identify factors that influenced family caregivers' decisions to participate in an intervention research study. In interviews conducted before and after the intervention, caregivers (n=21) described reasons for participation. A focused content analysis was used to examine responses. Themes that emerged included: (a) caregivers recognized a need for help; (b) expectations and motivations toward change; (c) recognition of self worth as caregivers; (d) timeliness of recruitment strategies; (e) support of research staff affected recruitment; and (f) caregivers recognized the benefits of participation. These findings support the importance of many different strategies for effective recruitment of caregivers in future studies. Copyright (c) 2007 Wiley Periodicals, Inc. C1 S Texas Vet Hlth Care Syst, GRECC 182, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Sch Nursing, San Antonio, TX 78285 USA. Univ Texas, Med Branch, Galveston, TX 77550 USA. Univ Texas, Hlth Sci Ctr, Sch Med, San Antonio, TX USA. RP Lewis, SL (reprint author), S Texas Vet Hlth Care Syst, GRECC 182, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. NR 24 TC 20 Z9 20 U1 1 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0160-6891 J9 RES NURS HEALTH JI Res. Nurs. Health PD JUN PY 2007 VL 30 IS 3 BP 347 EP 355 DI 10.1002/nur.20186 PG 9 WC Nursing SC Nursing GA 174JW UT WOS:000246939200011 PM 17514708 ER PT J AU Hoo, GWS AF Hoo, Guy W. Soo TI Hospital at home: The right place for the right patient SO RESPIRATORY CARE LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; OBSTRUCTIVE PULMONARY-DISEASE; ACUTE EXACERBATIONS; CARE; OUTCOMES; COPD C1 Univ Calif Los Angeles, Pulm & Crit Care Sect, W Los Angeles Vet Affairs Med Ctr, Vet Affairs Greater Los Angeles Healthcare Syst,G, Los Angeles, CA 90073 USA. RP Hoo, GWS (reprint author), Univ Calif Los Angeles, Pulm & Crit Care Sect, W Los Angeles Vet Affairs Med Ctr, Vet Affairs Greater Los Angeles Healthcare Syst,G, 11301 Wilshire Blvd 111Q, Los Angeles, CA 90073 USA. EM guy.soohoo@va.gov NR 18 TC 0 Z9 0 U1 0 U2 1 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD JUN PY 2007 VL 52 IS 6 BP 710 EP 712 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 179KX UT WOS:000247289500001 PM 17521459 ER PT J AU Lopez-Meraz, ML Martinez, A Rocha, L AF Lopez-Meraz, Maria Leonor Martinez, Adrian Rocha, Luisa TI Effect of 8-OH-DPAT on electrographic activity during the kainic acid-induced status epilepticus in rats SO SEIZURE-EUROPEAN JOURNAL OF EPILEPSY LA English DT Article DE 8-OH-DPAT; 5-HT1A receptor; kainic acid; status epilepticus; EEG activity; hippocampus; frontal cortex ID SUSTAINING STATUS EPILEPTICUS; RECEPTOR ACTIVATION; INDUCED SEIZURES; LIMBIC SEIZURES; 5-HT1A RECEPTOR; DENTATE GYRUS; CA1 NEURONS; SEROTONIN; HIPPOCAMPUS; STIMULATION AB The effect of 8-OH-DPAT, a 5-HT1A receptor agonist, on electrographic activity during the kainic acid (KA)-induced status epilepticus (SE) was evaluated in mate Wistar rats. Electrographic (EEG) recordings from the ventral hippocampus and the frontal cortex along with behavioral changes were evaluated in animals that received KA administration (10 mg/kg, i.p.) 20 min after saline solution (control group) or 8-OH-DPAT (1 mg/kg, s.c.) injection. Rats pretreated with 8-OH-DPAT presented augmented latency for wet dog shakes (71%), generalized seizures (54%) and behavioral SE (31%). 8-OH-DPAT delayed occurrence of the first KA-induced paroxystic spikes (70%), increased latency to the EEG SE (39%) and decreased spike frequency (35-43%) recorded from the frontal cortex, and increased the time necessary for the high voltage EEG activity synchronization of the hippocampus and the frontal cortex (125%). However, EEG ictal activity recorded in hippocampus was not modified after 8-OH-DPAT pretreatment. These results indicate that 8-OH-DPAT reduces the EEG activity associated with the KA-induced SE in the frontal cortex, but not the hippocampus, and suggest an inhibitory effect in the propagation of epileptic seizures during the KA-induced SE. (c) 2007 Published by Elsevier Ltd on behalf of British Epilepsy Association. C1 Ctr Invest & Estudios Avanzaods Sede Sur, Dept Farmacobiol, Mexico City, DF, Mexico. Inst Nacl Psiquiat Ramon de la Fuente Muniz, Direcc Invest Neurociencias, Mexico City, DF, Mexico. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Epilepsy Res Lab, Los Angeles, CA USA. RP Lopez-Meraz, ML (reprint author), VA Greater Los Angeles Healthcare Syst, Epilepsy Res Lab 151, 11301 Wilshire Blvd,Bldg 114,Room 139, Los Angeles, CA 90073 USA. EM lopezmerazml@ucla.edu NR 40 TC 7 Z9 7 U1 0 U2 2 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1059-1311 J9 SEIZURE-EUR J EPILEP JI Seizure PD JUN PY 2007 VL 16 IS 4 BP 365 EP 370 DI 10.1016/j.seizure.2007.02.009 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 167KE UT WOS:000246449800012 PM 17391992 ER PT J AU Freytes, CO AF Freytes, Cesar O. TI Thromboembolic complications related to central venous access catheters in cancer patients SO SEMINARS IN THROMBOSIS AND HEMOSTASIS LA English DT Article DE indwelling catheters; central venous catheterization; neoplasm; venous thrombosis; thrombolytic therapy ID DEEP-VEIN THROMBOSIS; FACTOR-V-LEIDEN; UPPER-EXTREMITY; DOUBLE-BLIND; RISK-FACTORS; INFECTIOUS COMPLICATIONS; PROSPECTIVE TRIAL; DEVICES; PROPHYLAXIS; PREVENTION AB Recent well-designed, prospective, controlled trials have demonstrated a lower incidence of catheter-related deep vein thrombosis (CRDVT) compared with earlier studies but this complication remains an important limitation to the delivery of drugs and supportive care to cancer patients. Prophylaxis of CRDVT with antithrombotic agents was not supported by recent prospective randomized trials, and its routine use is not recommended. Larger studies will be required to determine if cancer patients at particularly high risk for CRDVT can benefit from prophylaxis with antithrombotic agents. There are no prospective controlled studies to guide the therapy of CRDVT but treatment with anticoagulants remains the mainstay of therapy. Although recently published guidelines might help standardize the therapy of patients with CRDVT, prospective controlled studies are needed to determine the optimal therapy of this important complication of central venous catheters in cancer patients. C1 Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. RP Freytes, CO (reprint author), Mail Code 7880,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM freytes@uthscsa.edu NR 74 TC 7 Z9 8 U1 0 U2 0 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0094-6176 J9 SEMIN THROMB HEMOST JI Semin. Thromb. Hemost. PD JUN PY 2007 VL 33 IS 4 BP 389 EP 396 DI 10.1055/s-2007-976174 PG 8 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 174TT UT WOS:000246966400012 PM 17525896 ER PT J AU Szymusiak, R Gvilia, I McGinty, D AF Szymusiak, Ronald Gvilia, Irma McGinty, Dennis TI Hypothalamic control of sleep SO SLEEP MEDICINE LA English DT Article DE hypothalamus ID VENTROLATERAL PREOPTIC NUCLEUS; EYE-MOVEMENT SLEEP; WAKING DISCHARGE PATTERNS; BASAL FOREBRAIN NEURONS; FOS PROTEIN EXPRESSION; LATERAL HYPOTHALAMUS; C-FOS; GALANINERGIC NEURONS; PROMOTING NEURONS; NERVOUS-SYSTEM AB A sleep-promoting function for the rostral hypothalamus was initially inferred from the presence of chronic insomnia following damage to this brain region. Subsequently, it was determined that a unique feature of the preoptic hypothalamus and adjacent basal forebrain is the presence of neurons that are activated during sleep compared to waking. Preoptic area "sleep-active" neurons have been identified by single and multiple-unit recordings and by the presence of the protein product of the c-Fos gene in the neurons of sleeping animals. Sleep-active neurons are located in several subregions of the preoptic area, occurring with high density in the ventrolateral preoptic area (vlPOA) and the median preoptic nucleus (MnPN). Neurons in the vlPOA contain the inhibitory neuromodulator, galanin, and the inhibitory neurotransmitter, GABA. A majority of MnPN neurons activated during sleep contain GABA. Anatomical tracer studies reveal projections from the vlPOA and MnPN to multiple arousal-regulatory systems in the posterior and lateral hypothalamus and the rostral brainstem. Cumulative evidence indicates that preoptic area neurons function to promote sleep onset and sleep maintenance by inhibitory modulation of multiple arousal systems. Recent studies suggest a role for preoptic area neurons in the homeostatic aspects of the regulation of both rapid eye movement (REM) and non-REM (NREM) sleep and as a potential target for endogenous somnongens, such as cytokines and adenosine. (c) 2007 Elsevier B.V. All rights reserved. C1 VA Greater Los Angeles Healthcare Syst, Res Serv, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Psychol, Los Angeles, CA 90024 USA. I Beritashvili Inst Physiol, Thilisi, GA USA. RP Szymusiak, R (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv, 16111 Plummer St, Sepulveda, CA 91343 USA. EM rszym@ucla.edu FU NHLBI NIH HHS [HL60296]; NIMH NIH HHS [MH63323] NR 72 TC 83 Z9 89 U1 4 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1389-9457 J9 SLEEP MED JI Sleep Med. PD JUN PY 2007 VL 8 IS 4 BP 291 EP 301 DI 10.1016/j.sleep.2007.03.013 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA 178OU UT WOS:000247230800002 PM 17468047 ER PT J AU Spagnoletti, CL Rubio, DM McNeil, MA AF Spagnoletti, Carla L. Rubio, Doris M. McNeil, Melissa A. TI Internal medicine residents' preparedness to care for reproductive-age and pregnant women SO TEACHING AND LEARNING IN MEDICINE LA English DT Article ID HEALTH CURRICULUM; INFERTILITY; COMPETENCES; ATTITUDES; SKILLS; NEED AB Background. Research that addresses whether residents are prepared to deliver preconception care and manage medical conditions in pregnant and postpartum women has beet? scarce since the publication of women's health competency guidelines for internists in 1997. Purpose: To investigate current attitudes, training, and perceived preparedness in these areas and to explore relationships between resident characteristics and preparedness. Methods: A 62-item questionnaire was given to 105 internal medicine residents and recent graduates at two affiliated residency programs. Results: Eighty-five surveys were returned. Most respondents reported that they had minimal training and were unprepared in these areas but felt that learning these topics is important. Perceived preparedness correlated strongly with relevant didactic and clinical training but was not associated with gender, residency track, or career plan. Conclusions: In light of published competency guidelines, internal medicine training programs should consider adding or increasing curricular content to improve residents' perceived preparedness to deliver care to reproductive-age and pregnant women. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. RP Spagnoletti, CL (reprint author), 9W 923 Montefiore Hosp,200 Lothrup St, Pittsburgh, PA 15213 USA. EM spangloletticl@upmc.edu NR 23 TC 6 Z9 6 U1 1 U2 1 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 1040-1334 J9 TEACH LEARN MED JI Teach. Learn. Med. PD SUM PY 2007 VL 19 IS 3 BP 257 EP 263 PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 187LV UT WOS:000247850100008 PM 17594221 ER PT J AU Mavropoulos, JC Partin, AW Amling, CL Terris, MK Kane, CJ Aronson, WJ Presti, JC Mangold, LA Freedland, SJ AF Mavropoulos, John C. Partin, Alan W. Amling, Christopher L. Terris, Martha K. Kane, Christopher J. Aronson, William J. Presti, Joseph C., Jr. Mangold, Leslie A. Freedland, Stephen J. TI Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? SO UROLOGY LA English DT Article ID RADICAL PROSTATECTOMY; ANDROGEN RECEPTOR; WHITE PATIENTS; TUMOR VOLUME; CANCER; HYPERPLASIA; PROGRESSION; SPECIMENS; PREDICTOR; AGE AB Objectives To determine whether elevated serum prostate-specific antigen (PSA) values in black men are due, at least partially, to larger prostate size among black men. Methods The study population consisted of two cohorts: (1) 1410 men undergoing radical prostatectomy between 1988 and 2005 at five equal-access medical centers comprising the Shared Equal Access Regional Cancer Hospital (SEARCH) Database; and (2) 9601 men undergoing radical prostatectomy between 1988 and 2004 at the Johns Hopkins Hospital. We evaluated the association between race and serum PSA value and prostate weight using multivariable linear regression while adjusting for demographic and clinicopathologic cancer characteristics. Results In both cohorts, black men had higher serum PSA values (P <= 0.001). After adjusting for either demographic characteristics or demographic and cancer-specific characteristics, there were no significant associations between race and prostate size in either cohort. After adjusting for multiple demographic, clinical, and pathologic cancer-specific characteristics, black men had 15% higher serum PSA values relative to white men in both the SEARCH (P = 0.001) and Hopkins cohorts (P <0.001). Conclusions In this study of patients undergoing radical prostatectomy in two very different practice settings, black men in both cohorts had higher serum PSA values relative to white men, despite adjustment for demographic and cancer-specific characteristics, including prostate weight. The lack of significant association between race and prostate size suggests that alternative reasons are needed to explain higher serum PSA values in black men. C1 Duke Univ, Med Ctr, Div Urol Surg, Duke Prostate Ctr,Sch Med, Durham, NC 27710 USA. Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA. Duke Univ, Sch Med, Duke Prostate Ctr, Dept Surg, Durham, NC 27710 USA. Vet Adm Med Ctr, Urol Sect, Dept Surg, Durham, NC USA. Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD USA. Univ Alabama, Dept Urol, Birmingham, AL USA. Med Coll Georgia, Dept Surg, Vet Adm Med Ctr, Urol Sect, Augusta, GA 30912 USA. USN, San Diego Hosp, Dept Urol, San Diego, CA 92152 USA. Vet Adm Med Ctr, Urol Sect, Dept Surg, San Francisco, CA 94121 USA. Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA. Vet Adm Greater Los Angeles Healthcare Syst, Urol Sect, Dept Surg, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. Vet Adm Med Ctr, Urol Sect, Dept Surg, Palo Alto, CA 94304 USA. RP Freedland, SJ (reprint author), Duke Univ, Med Ctr, Div Urol Surg, Duke Prostate Ctr,Sch Med, Box 2626, Durham, NC 27710 USA. EM steve.freedland@duke.edu OI Terris, Martha/0000-0002-3843-7270 FU NCI NIH HHS [P50CA58236, P50 CA058236, P50 CA092131, P50 CA092131-01A1, P50 CA92131-01A1, R01 CA100938, R01 CA100938-05, R01CA100938] NR 20 TC 11 Z9 12 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD JUN PY 2007 VL 69 IS 6 BP 1138 EP 1142 DI 10.1016/j.urology.2007.01.102 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 188KC UT WOS:000247917800027 PM 17572202 ER PT J AU Tsokas, P Ma, T Iyengar, R Landau, EM Blitzer, RD AF Tsokas, Panayiotis Ma, Tao Iyengar, Ravi Landau, Emmanuel M. Blitzer, Robert D. TI Mitogen-activated protein kinase upregulates the dendritic translation machinery in long-term potentiation by controlling the mammalian target of rapamycin pathway SO JOURNAL OF NEUROSCIENCE LA English DT Article DE mammalian target of rapamycin; mitogen-activated protein kinase; dendrites; ERK; hippocampus; LTP; protein synthesis; synaptic plasticity ID CYTOPLASMIC POLYADENYLATION ELEMENT; MESSENGER-RNA TRANSLATION; HIPPOCAMPAL CA1 REGION; RIBOSOMAL S6 KINASE; SYNAPTIC PLASTICITY; LATE-PHASE; SIGNALING PATHWAY; TUBEROUS SCLEROSIS; PYRAMIDAL CELLS; PHOSPHATIDYLINOSITOL 3-KINASE AB Protein synthesis is required for persistent forms of synaptic plasticity, including long-term potentiation (LTP). A key regulator of LTP-related protein synthesis is mammalian target of rapamycin (mTOR), which is thought to modulate translational capacity by facilitating the synthesis of particular components of the protein synthesis machinery. Recently, extracellularly regulated kinase (ERK) also was shown to mediate plasticity-related translation, an effect that may involve regulation of the mTOR pathway. We studied the interaction between the mTOR and ERK pathways in hippocampal LTP induced at CA3 -CA1synapses by high-frequency synaptic stimulation (HFS). Within minutes after HFS, the expression of multiple translational proteins, the synthesis of which is under the control of mTOR, increased in area CA1 stratum radiatum. This upregulation was detected in pyramidal cell dendrites and was blocked by inhibitors of the ERK pathway. In addition, ERK mediated the stimulation of mTOR by HFS. The possibility that ERK regulates mTOR by acting at a component further upstream in the phosphatidylinositide 3-kinase (PI3K) -mTOR pathway was tested by probing the phosphorylation of p90-S6 kinase, phosphoinositide-dependent kinase 1 (PDK1), and Akt. ERK inhibitors blocked HFS-induced phosphorylation of all three proteins at sites implicated in the regulation of mTOR. Moreover, a component of basal and HFS-induced ERK activity depended on PI3K, indicating that mTOR-mediated protein synthesis in LTP requires coincident and mutually dependent activity in the PI3K and ERK pathways. The role of ERK in regulating PDK1 and Akt, with their extensive effects on cellular function, has important implications for the coordinated response of the neuron to LTP-inducing stimulation. C1 Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. Bronx Vet Adm Med Ctr, Psychiat Serv, Bronx, NY 10463 USA. RP Blitzer, RD (reprint author), Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, Box 1215,1 Gustave Levy Pl, New York, NY 10029 USA. EM robert.blitzer@mssm.edu FU NIDA NIH HHS [DA015863]; NIGMS NIH HHS [GM54508] NR 82 TC 110 Z9 110 U1 1 U2 8 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD MAY 30 PY 2007 VL 27 IS 22 BP 5885 EP 5894 DI 10.1523/JNEUROSCI.4548-06.2007 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 175YA UT WOS:000247048700008 PM 17537959 ER PT J AU Horan, WP Ventura, J Mintz, J Kopelowicz, A Wirshing, D Christian-Herman, J Foy, D Liberman, RP AF Horan, William P. Ventura, Joseph Mintz, Jim Kopelowicz, Alex Wirshing, Donna Christian-Herman, Jennifer Foy, David Liberman, Robert P. TI Stress and coping responses to a natural disaster in people with schizophrenia SO PSYCHIATRY RESEARCH LA English DT Article DE schizophrenia; bipolar disorder; stress; disaster; coping; methodology ID RECENT-ONSET SCHIZOPHRENIA; SEVERE MENTAL-ILLNESS; DAILY-LIFE STRESS; EVENT SCALE; BIPOLAR DISORDER; SOCIAL SUPPORT; IMPACT; EARTHQUAKE; SURVIVORS; RELAPSE AB Investigations of how individuals with schizophrenia differ from non-patients in their responses to stressful life events are subject to the criticism that any between-group differences might merely reflect differences in the types of stressful events that each group experiences. This report presents new analyses of data collected from schizophrenia patients (n=96), bipolar disorder patients (n=18), and healthy controls (n= 18) immediately after the Northridge Earthquake that struck Southern California in 1994, a natural experiment that confronted all groups with the same stressful event. Participants completed the, Impact of Events Scale (IES; [Horowitz, M.J., Wilner, N., Alvarez, W., 1979. Impact of Events Scale. A measure of subjective stress. Psychosomatic Medicine 41, 209-218]) at I week and 5 weeks post-earthquake. At the 5-week follow-up, measures of coping, social support, and self-esteem were also completed. Both patient groups reported higher IES avoidance symptoms than controls immediately after the earthquake. The schizophrenia group also reported lower approach coping, self-esteem, and social support than controls, with the bipolar group reporting intermediate levels. Within the schizophrenia group, higher levels of avoidance coping predicted higher residual stress symptoms at follow-up. Results support the validity of prior reports of altered responses to stressful life events in schizophrenia and demonstrate the clinical relevance of individual differences in coping among affected individuals. (C) 2006 Elsevier Ireland Ltd. All rights reserved. C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. W Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. San Fernando Mental Hlth Ctr, Los Angeles, CA USA. Pepperdine Univ, Los Angeles, CA USA. RP Horan, WP (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 300 UCLA Med Plaza,Room 2240, Los Angeles, CA 90095 USA. EM horan@ucla.edu OI kopelowicz, alex/0000-0002-1728-4105 NR 45 TC 25 Z9 27 U1 3 U2 8 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD MAY 30 PY 2007 VL 151 IS 1-2 BP 77 EP 86 DI 10.1016/j.psychres.2006.10.009 PG 10 WC Psychiatry SC Psychiatry GA 185WF UT WOS:000247740400009 PM 17382405 ER PT J AU Ahmad, H Jones, PG Buchanan, DM Ho, PM Decker, C Spertus, JA AF Ahmad, Homaa Jones, Philip G. Buchanan, Donna M. Ho, P. M. Decker, Carole Spertus, John A. TI Medication use post acute myocardial infarction: A latent class analysis SO CIRCULATION LA English DT Meeting Abstract CT 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 09-11, 2007 CL Washington, DC C1 St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. Denver VA Med Ctr, Denver, CO USA. Univ Missouri, Mid Amer Heart Inst, Kansas City, MO 64110 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 29 PY 2007 VL 115 IS 21 BP E587 EP E587 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 172LA UT WOS:000246804600185 ER PT J AU Helfrich, CD Sharp, ND Pineros, SL Lowy, E McDermott, KA Sales, AE Larsen, GC Fihn, SD AF Helfrich, Christian D. Sharp, Nancy D. Pineros, Sandra L. Lowy, Elliott McDermott, Kelly A. Sales, Anne E. Larsen, Greg C. Fihn, Stephan D. TI How veterans health administration facilities have changed practices to improve care for patients with acute coronary syndromes SO CIRCULATION LA English DT Meeting Abstract CT 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 09-11, 2007 CL Washington, DC C1 VA Puget Sound Healthcare Syst, Seattle, WA USA. Univ Alberta, Edmonton, AB T6G 2M7, Canada. VA Med Ctr, Portland, OR USA. RI Sales, Anne/D-9678-2012 NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 29 PY 2007 VL 115 IS 21 BP E591 EP E591 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 172LA UT WOS:000246804600200 ER PT J AU Ho, PM Magid, DJ Shetterly, SM Olson, KO Peterson, PN Masoudi, FA Rumsfeld, JS AF Ho, P. Michael Magid, David J. Shetterly, Susan M. Olson, Kari O. Peterson, Pamela N. Masoudi, Frederick A. Rumsfeld, John S. TI The importance of therapy intensification and medication non-adherence for blood pressure control in patients with coronary artery disease SO CIRCULATION LA English DT Meeting Abstract CT 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 09-11, 2007 CL Washington, DC C1 Denver VA Med Ctr, Denver, CO USA. Kaiser Permanente, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 29 PY 2007 VL 115 IS 21 BP E580 EP E580 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 172LA UT WOS:000246804600151 ER PT J AU Ho, PM Fihn, SD Wang, L Bryson, CL Lowy, E Maynard, C Magid, DJ Peterson, ED Rumsfeld, JS AF Ho, P. Michael Fihn, Stephan D. Wang, Li Bryson, Chris L. Lowy, Elliott Maynard, Charles Magid, David J. Peterson, Eric D. Rumsfeld, John S. TI The impact of clopidogrel use on long-term outcomes following stent implantation for acute coronary syndrome in the VHA SO CIRCULATION LA English DT Meeting Abstract CT 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 09-11, 2007 CL Washington, DC C1 Denver VA Med Ctr, Denver, CO USA. Puget Sound VA Healthcare Syst, Seattle, WA USA. Kaiser Pemanente Colorado, Denver, CO USA. Duke Clin Res Inst, Durham, NC USA. RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 29 PY 2007 VL 115 IS 21 BP E573 EP E573 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 172LA UT WOS:000246804600121 ER PT J AU Larsen, GC McFalls, E Rumsfeld, JS Pineros, SL Wang, L Zoble, RG Tenney, S Bradley, M Morris, K Steinberg, S Shaikh, M Fihn, SD AF Larsen, Greg C. McFalls, Edward Rumsfeld, John S. Pineros, Sandra L. Wang, Li Zoble, Robert G. Tenney, Scott Bradley, Mark Morris, Kenneth Steinberg, Sidney Shaikh, Muhammed Fihn, Stephan D. TI Is quality of care for unstable angina comparable to that for acute myocardial infarction in the veterans health administration? SO CIRCULATION LA English DT Meeting Abstract CT 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 09-11, 2007 CL Washington, DC C1 VA Med Ctr, Portland, OR USA. VA Med Ctr, Minneapolis, MN USA. VA Med Ctr, Denver, CO USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. James A Haley Vet Hosp, Tampa, FL 33612 USA. VA Med Ctr, Sheridan, WY USA. VA Med Ctr, Roseburg, OR USA. VA Med Ctr, Durham, NC USA. WG Bill Hefner VA Med Ctr, Salisbury, NC USA. VA Med Ctr, Fargo, ND USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 29 PY 2007 VL 115 IS 21 BP E598 EP E599 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 172LA UT WOS:000246804600235 ER PT J AU Lichtman, JH Wang, YF Curtis, JP Allen, NB Watanabe, E Shaw, LJ Rumsfeld, JS Krumholz, HM AF Lichtman, Judith H. Wang, Yongfei Curtis, Jeptha P. Allen, Norrina B. Watanabe, Emi Shaw, Leslee J. Rumsfeld, John S. Krumholz, Harlan M. TI Conventional risk factors are highest for minority women presenting with myocardial infarction: Results from the ACC-NCDR registry SO CIRCULATION LA English DT Meeting Abstract CT 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 09-11, 2007 CL Washington, DC C1 Yale Univ, Sch Med, New Haven, CT USA. Emory Univ, Sch Med, Atlanta, GA USA. Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 29 PY 2007 VL 115 IS 21 BP E554 EP E554 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 172LA UT WOS:000246804600037 ER PT J AU Lichtman, JH Wang, YF Curtis, JP Watanabe, E Allen, NB Shaw, LJ Rumsfeld, JS Krumholz, HM AF Lichtman, Judith H. Wang, Yongfei Curtis, Jeptha P. Watanabe, Emi Allen, Norrina B. Shaw, Leslee J. Rumsfeld, John S. Krumholz, Harlan M. TI Young women undergoing elective PCI procedures have higher complication rates than similarly aged men: Results from the ACC-NCDR registry SO CIRCULATION LA English DT Meeting Abstract CT 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 09-11, 2007 CL Washington, DC C1 Yale Univ, Sch Med, New Haven, CT USA. Emory Univ, Sch Med, Atlanta, GA 30322 USA. Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 29 PY 2007 VL 115 IS 21 BP E578 EP E578 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 172LA UT WOS:000246804600141 ER PT J AU Luther, SA Magid, DJ Ho, PM Brand, DW Peterson, PN Ross, C Rumsfeld, JS Frederick, MA AF Luther, Stacie A. Magid, David J. Ho, P. Michael Brand, David W. Peterson, Pamela N. Ross, Colleen Rumsfeld, John S. Frederick, Masoudi A. TI Sex differences in evaluation and treatment after exercise stress testing SO CIRCULATION LA English DT Meeting Abstract CT 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 09-11, 2007 CL Washington, DC C1 Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. Kaiser Permanente, Denver, CO USA. Denver VA Med Ctr, Denver, CO USA. Denver Hlth Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 29 PY 2007 VL 115 IS 21 BP E587 EP E587 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 172LA UT WOS:000246804600182 ER PT J AU Pineros, SL Rumsfeld, JS Larsen, GC Wang, L McFalls, E Zoble, RG Tenney, S Bradley, M Steinberg, S Shaikh, M Morris, K Fihn, SD AF Pineros, Sandra L. Rumsfeld, John S. Larsen, Greg C. Wang, Li McFalls, Edward Zoble, Robert G. Tenney, Scott Bradley, Mark Steinberg, Sidney Shaikh, Muhammed Morris, Kenneth Fihn, Stephan D. TI Outcomes of acute coronary syndrome patients who report in-hospital depressive symptoms in veterans health administration SO CIRCULATION LA English DT Meeting Abstract CT 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 09-11, 2007 CL Washington, DC C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. VA Med Ctr, Denver, CO USA. VA Med Ctr, Portland, OR USA. VA Med Ctr, Minneapolis, MN USA. James A Haley Vet Hosp, Tampa, FL USA. VA Med Ctr, Sheridan, WY USA. VA Med Ctr, Roseburg, OR USA. WG Bill Hefner VA Med Ctr, Salisbury, NC USA. VA Med Ctr, Fargo, ND USA. VA Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 29 PY 2007 VL 115 IS 21 BP E595 EP E595 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 172LA UT WOS:000246804600220 ER PT J AU Wang, TY Xiao, L Alexander, KP Kosiborod, MN Rumsfeld, JS Spertus, JA Peterson, ED AF Wang, Tracy Y. Xiao, Lan Alexander, Karen P. Kosiborod, Mikhail N. Rumsfeld, John S. Spertus, John A. Peterson, Eric D. TI Trends in antiplatelet therapy use following discharge among acute myocardial infarction patients with in-hospital bleeding SO CIRCULATION LA English DT Meeting Abstract CT 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 09-11, 2007 CL Washington, DC C1 Duke Univ, Med Ctr, Durham, NC 27706 USA. Duke Clin Res Inst, Durham, NC USA. St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. Denver VA Med Ctr, Denver, CO USA. Univ Missouri, Mid Amer Heart Inst, Kansas City, MO 64110 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 29 PY 2007 VL 115 IS 21 BP E575 EP E575 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 172LA UT WOS:000246804600128 ER PT J AU Weintraub, WS Zhang, ZF Kolm, P Jurkovitz, C Hartigan, P Culler, S Becker, E Lewis, C Veledar, E Bowen, J Dunbar, SB Deaton, C Kaufman, S Maron, D Teo, K O'Rourke, R Goeree, R Barnett, P Spertus, J Boden, WE AF Weintraub, William S. Zhang, Zefeng Kolm, Paul Jurkovitz, Claudine Hartigan, Pamela Culler, Steven Becker, Edmund Lewis, Cheryl Veledar, Emir Bowen, Jim Dunbar, Sandra B. Deaton, Christi Kaufman, Stanley Maron, David Teo, Koon O'Rourke, Robert Goeree, Ron Barnett, Paul Spertus, John Boden, William E. TI Quality-of-life and economic outcomes in the Clinical Outcomes Utilizing Percutaneous coronary Revascularization and Aggressive Guideline-driven Drug Evaluation (COURAGE) trial SO CIRCULATION LA English DT Meeting Abstract CT 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 09-11, 2007 CL Washington, DC C1 Christiana Care Hlth Syst, Newark, DE USA. W Haven Vet Affairs Med Ctr, West Haven, CT USA. Emory Univ, Atlanta, GA 30322 USA. Univ Manchester, Manchester, Lancs, England. Epimetrics, San Francisco, CA USA. Vanderbilt Univ, Nashville, TN USA. McMaster Univ, Hamilton, ON, Canada. Vet Adm Med Ctr, San Antonio, TX USA. Vet Adm Med Ctr, Palo Alto, CA 94304 USA. Mid Amer Heart Inst, Kansas City, MO USA. Kaleida Hlth Syst, Buffalo, NY USA. RI Deaton, Christi/F-6485-2010; Veledar, Emir/K-2808-2012 OI Veledar, Emir/0000-0002-3831-5433 NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 29 PY 2007 VL 115 IS 21 BP E551 EP E551 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 172LA UT WOS:000246804600022 ER PT J AU Welch, VL Parashar, S Reid, KJ Lichtman, JH Ahmad, H Spertus, JA Rumsfeld, JS Vaccarino, V AF Welch, Verna L. Parashar, Susmita Reid, Kimberly J. Lichtman, Judith H. Ahmad, Homaa Spertus, John A. Rumsfeld, John S. Vaccarino, Viola TI Depression partially explains worse quality-of-life outcomes of women versus men following acute myocardial infarction SO CIRCULATION LA English DT Meeting Abstract CT 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 09-11, 2007 CL Washington, DC C1 Morehouse Sch Med, Atlanta, GA 30310 USA. Emory Univ, Atlanta, GA 30322 USA. St Lukes Hlth Syst, Mid Amer Heart Inst, Kansas City, MO USA. Yale Univ, New Haven, CT USA. Univ Missouri, Mid Amer Heart Inst, Kansas City, MO 64110 USA. Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 29 PY 2007 VL 115 IS 21 BP E553 EP E553 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 172LA UT WOS:000246804600031 ER PT J AU Lyketsos, CG AF Lyketsos, C. G. CA ADAPT Res Grp TI Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial SO NEUROLOGY LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; REPLACEMENT THERAPY; CACHE COUNTY; DOUBLE-BLIND; DEMENTIA; MEMORY; ROFECOXIB; PLACEBO AB Objective: To evaluate the efficacy and safety of naproxen and celecoxib for the primary prevention of Alzheimer disease ( AD). Methods: Randomized, placebo-controlled, double-masked clinical trial conducted at six US dementia research clinics. Volunteers aged 70+ years, with cognitive screening scores above designated cut-offs and a family history of AD, were randomly assigned to celecoxib 200 mg BID, naproxen sodium 220 mg BID, or placebo. Enrollment began in early 2001. The main outcome measure was diagnosis of AD after randomization. Results: On December 17, 2004, treatments were suspended. Events while on treatment yielded hazard ratios vs placebo of 1.99 (95% CI 0.80 to 4.97; p = 0.14) for celecoxib and 2.35 (0.95 to 5.77; p = 0.06) for naproxen. Imperfect screening measures led to enrollment of 7 individuals with dementia and 46 others with milder cognitive syndromes. Their (prevalent) illness was detected at enrollment and diagnosed within 6 months following randomization. Secondary analyses that excluded the 7 cases of prevalent dementia showed increased hazard ratios for AD with both treatments. Neither treatment produced a notable effect on the incidence of milder cognitive syndromes. Conclusions: These results do not support the hypothesis that celecoxib or naproxen prevent Alzheimer dementia, at least within the early years after initiation of treatment. Masked long-term follow-up of these participants will be essential. C1 Johns Hopkins Bayview, Dept Psychiat, Baltimore, MD 21224 USA. Johns Hopkins Sch Med, Baltimore, MD USA. Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Boston Univ, Sch Med, Boston, MA 02215 USA. Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. Sun Hlth Res Inst, Sun City, AZ USA. RP Lyketsos, CG (reprint author), Johns Hopkins Bayview, Dept Psychiat, 5300 Alpha Commons Dr,4th Floor, Baltimore, MD 21224 USA. NR 40 TC 141 Z9 143 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD MAY 22 PY 2007 VL 68 IS 21 BP 1800 EP 1808 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 170LI UT WOS:000246664500007 ER PT J AU Asch, DA Armstrong, K AF Asch, David A. Armstrong, Katrina TI Aggregating and partitioning populations in health care disparities research: Differences in perspective SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article AB Health and health care are distributed unevenly across individuals and populations, and identifying these disparities is the first step toward remedying them. We reveal how conceptual and statistical challenges make even the identification of disparities difficult. These difficulties arise because the social, biologic, and environmental causes of disparities are intertwined, leading to statistical confounding. These difficulties arise also because the same data can be analyzed to examine care from the perspective of the patient, or from the perspective of organizations such as health systems or jurisdictions, and these alternative perspectives can yield contradictory results. The result is that health care disparities can be challenging to interpret unless the analytic and policy perspective is clear. C1 Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. RP Asch, DA (reprint author), Univ Penn, Leonard Davis Inst Hlth Econ, 3641 Locust Walk, Philadelphia, PA 19104 USA. EM asch@wharton.upenn.edu OI Asch, David/0000-0002-7970-286X NR 9 TC 10 Z9 10 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2007 VL 25 IS 15 BP 2117 EP 2121 DI 10.1200/JCO.2006.09.3336 PG 5 WC Oncology SC Oncology GA 172KW UT WOS:000246804200027 PM 17513818 ER PT J AU Rubin, BP Heinrich, MC Corless, CL AF Rubin, Brian P. Heinrich, Michael C. Corless, Christopher L. TI Gastrointestinal stromal tumour SO LANCET LA English DT Review ID C-KIT GENE; RECEPTOR TYROSINE KINASE; TERM-FOLLOW-UP; AUTONOMIC NERVE TUMORS; OF-FUNCTION MUTATIONS; BONE-SARCOMA-GROUP; EORTC-SOFT-TISSUE; GERMLINE MUTATION; IMATINIB MESYLATE; INTERSTITIAL-CELLS AB Gastrointestinal stromal tumours are the most common mesenchymal neoplasm of the gastrointestinal tract and are highly resistant to conventional chemotherapy and radiotherapy. Such tumours usually have activating mutations in either KIT (75-80%) or PDGFRA (5-10%), two closely related receptor tyrosine kinases. These mutations lead to ligand-independent activation and signal transduction mediated by constitutively activated KIT or PDGFRA. Targeting these activated proteins with imatinib mesylate, a small-molecule kinase inhibitor, has proven useful in the treatment of recurrent or metastatic gastrointestinal stromal tumours and is now being tested as an adjuvant or neoadjuvant. However, resistance to imatinib is a growing problem and other targeted therapeutics such as sunitinib are available. The important interplay between the molecular genetics of gastrontestinal stromal turnout and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumours. C1 Cleveland Clin Fdn, Dept Anat Pathol, Taussig Canc Ctr, Cleveland, OH 44195 USA. Cleveland Clin Fdn, Dept Mol Genet, Taussig Canc Ctr, Cleveland, OH 44195 USA. Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA. Oregon Hlth & Sci Univ, Inst Canc, Dept Pathol, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Inst Canc, Dept Med, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Inst Canc, Dept Cell & Dev Biol, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. RP Rubin, BP (reprint author), Cleveland Clin Fdn, Dept Anat Pathol, Taussig Canc Ctr, 9500 Euclid Ave, Cleveland, OH 44195 USA. EM rubinb2@ccf.org NR 135 TC 267 Z9 302 U1 2 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD MAY 20 PY 2007 VL 369 IS 9574 BP 1731 EP 1741 DI 10.1016/S0140-6736(07)60780-6 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 169ZT UT WOS:000246631300029 PM 17512858 ER PT J AU Harel, O Zhou, XH AF Harel, Ofer Zhou, Xiao-Hua TI Multiple imputation for the comparison of two screening tests in two-phase Alzheimer studies SO STATISTICS IN MEDICINE LA English DT Article DE missing data; multiple imputation; verification bias; two-phase studies ID CORRELATED BINARY PROPORTIONS; CONFIDENCE-INTERVALS; BINOMIAL PROPORTIONS; VERIFICATION BIAS; DIAGNOSTIC-TESTS; PAIRED DATA; DIFFERENCE; DISTRIBUTIONS; SELECTION; DEMENTIA AB Two-phase designs are common in epidemiological studies of dementia, and especially in Alzheimer research. In the first phase, all subjects are screened using a common screening test(s), while in the second phase, only a subset of these subjects is tested using a more definitive verification assessment, i.e. golden standard test. When comparing the accuracy of two screening tests in a two-phase study of dementia, inferences are commonly made using only the verified sample. It is well documented that in that case, there is a risk for bias, called verification bias. When the two screening tests have only two values (e.g. positive and negative) and we are trying to estimate the differences in sensitivities and specificities of the tests, one is actually estimating a confidence interval for differences of binomial proportions. Estimating this difference is not trivial even with complete data. It is well documented that it is a tricky task. In this paper, we suggest ways to apply imputation procedures in order to correct the verification bias. This procedure allows us to use well-established complete-data methods to deal with the difficulty of the estimation of the difference of two binomial proportions in addition to dealing with incomplete data. We compare different methods of estimation and evaluate the use of multiple imputation in this case. Our simulation results show that the use of multiple imputation is superior to other commonly used methods. We demonstrate our finding using Alzheimer data. Copyright (C) 2006 John Wiley & Sons, Ltd. C1 Univ Connecticut, Dept Stat, Storrs, CT 06269 USA. VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98108 USA. Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. RP Harel, O (reprint author), Univ Connecticut, Dept Stat, 215 Glenbrook Rd,Unit 4120, Storrs, CT 06269 USA. EM oharel@stat.uconn.edu FU NIMH NIH HHS [K01 MH087219] NR 29 TC 10 Z9 10 U1 0 U2 1 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0277-6715 J9 STAT MED JI Stat. Med. PD MAY 20 PY 2007 VL 26 IS 11 BP 2370 EP 2388 DI 10.1002/sim.2715 PG 19 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 163LN UT WOS:000246161400006 PM 17054089 ER PT J AU Liang, HY Van Remmen, H Frohlich, V Lechleiter, J Richardson, A Ran, QT AF Liang, Hanyu Van Remmen, Holly Frohlich, Victoria Lechleiter, James Richardson, Arlan Ran, Qitao TI Gpx4 protects mitochondrial ATP generation against oxidative damage SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE glutathione peroxidase 4; mitochondria; oxidative stress; ATP production; transgenic mice ID HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; HYPOGLYCEMIA-INDUCED APOPTOSIS; PERMEABILITY TRANSITION; HYDROGEN-PEROXIDE; CYTOCHROME-C; CELLS; CARDIOLIPIN; OXYGEN; STRESS; INJURY AB Mitochondrial ATP production can be impaired by oxidative stress. Glutathione peroxidase 4 (Gpx4) is an antioxidant defense enzyme found in mitochondria as well as other subcellular organelles that directly detoxifies membrane lipid hydroperoxides. To determine if Gpx4 protects ATP production in vivo, we compared mitochondrial ATP production between wild-type mice and Gpx4 transgenic mice using a diquat model. Diquat (50 mg/kg) significantly decreased mitochondrial ATP synthesis in livers of wild-type mice; however, no decrease in mitochondrial ATP synthesis was detected in Gpx4 transgenic mice after diquat. We observed no differences in activities of mitochondrial respiratory chain complexes between Gpx4 transgenic mice and wild-type mice. However, compared to wild-type mice, diquat-induced loss of mitochondrial membrane potential was attenuated in Gpx4 transgenic mice. Therefore, our results indicate that decreased ATP production under oxidative stress is primarily due to reduced mitochondrial membrane potential and overexpression of Gpx4 maintains mitochondrial membrane potential under oxidative stress. (c) 2007 Published by Elsevier Inc. C1 Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA. Univ Texas, Hlth Sci Ctr, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Ran, QT (reprint author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM ran@uthscsa.edu RI Liang, Hanyu/A-1066-2010 FU NIA NIH HHS [P01AG020591, 1P30-AG13319, P01 AG19316] NR 39 TC 42 Z9 50 U1 0 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD MAY 18 PY 2007 VL 356 IS 4 BP 893 EP 898 DI 10.1016/j.bbrc.2007.03.045 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 158ZD UT WOS:000245833500011 PM 17395155 ER PT J AU El-Serag, HB Lau, M AF El-Serag, H. B. Lau, M. TI Temporal trends in new and recurrent oesophageal strictures in a Medicare population SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID GASTROESOPHAGEAL-REFLUX-DISEASE; PROTON PUMP INHIBITORS; BARRETTS-ESOPHAGUS; CONCEPTUAL-FRAMEWORK; OMEPRAZOLE; DYSPLASIA; THERAPY AB Background The widespread use of proton pump inhibitors for gastro-oesophageal reflux disease could result in a decline in new as well as recurrent gastro-oesophageal reflux disease-related oesophageal strictures. The temporal trends of strictures have not been examined in population-based studies. Methods To examine the temporal trends in strictures, we calculated the age-adjusted incidence rates of new oesophageal strictures with or without oesophageal dilation in a sample of Medicare beneficiaries between 1992 and 2000. We also examined recurrent dilations recorded at least 3 months after a new stricture or the preceding recurrent stricture. Results The age-adjusted rates for strictures accompanied with dilation declined by approximately 11% from 215 per million to 192 per million. New oesophageal strictures with dilation declined as a proportion of all upper endoscopies procedures (from 2.6% to 1.9%). Recurrent dilation within 1 year declined dramatically from 16% (9.5% CI: 12.5 - 20.3) in 1992 to 8% ( 95% CI: 4.43 - 10.62) in 2000. In multivariable proportional hazards model, there was a 30% risk reduction of recurrent oesophageal strictures. Conclusions This population-based study indicates that the incidence of new as well as recurrent oesophageal strictures has been declining. In the face of rising incidence of other gastro-oesophageal reflux disease-related complications, it is important to understand the explanation of the present observations. C1 Houston Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Houston Vet Affairs Med Ctr, Gastroenterol Sect, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu NR 15 TC 12 Z9 12 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD MAY 15 PY 2007 VL 25 IS 10 BP 1223 EP 1229 DI 10.1111/j.1365-2036.2007.03310.x PG 7 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 160JX UT WOS:000245937800009 PM 17451568 ER PT J AU Bennett, KM Hernandez, AF Chen, AY Mulgund, J Newby, L Rumsfeld, JS Hochman, JS Hoekstra, JW Ohman, EM Gibler, WB Roe, MT Peterson, ED AF Bennett, Kyla M. Hernandez, Adrian F. Chen, Anita Y. Mulgund, Jyotsna Newby, L. Kristin Rumsfeld, John S. Hochman, Judith S. Hoekstra, James W. Ohman, E. Magnus Gibler, W. Brian Roe, Matthew T. Peterson, Eric D. TI Heart failure with preserved left ventricular systolic function among patients with non-ST-segment elevation acute coronary syndromes SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENTS; NATIONAL-REGISTRY; CLINICAL-EVIDENCE; GUIDELINE UPDATE; VALIANT REGISTRY; DYSFUNCTION; MORBIDITY; MANAGEMENT; MORTALITY AB Previous studies of non-ST-segment elevation acute coronary syndromes (NSTE ACSs) complicated by heart failure (HF) have focused primarily on patients with left ventricular systolic dysfunction defined by an ejection fraction (EF) <40%. Little is known about HF with preserved systolic function (EF >= 40%) in the NSTE ACS population. We identified high-risk patients with NSTE ACS (ischemic electrocardiographic changes and/or positive cardiac markers) from the CRUSADE quality improvement initiative who had an EF recorded and who had information on HF status. Management and outcomes were analyzed and compared based on the presence or absence of HF and whether left ventricular EF was >= 40%. Of 94,558 patients with NSTE ACS, 21,561 (22.8%) presented with signs of HF, and most had HF with preserved systolic function (n = 11,860,'55%). Mortality rates were 10.7% for HF/systolic dysfunction, 5.8% for HF/preserved systolic function, 5.7% for no HF/systolic dysfunction, and 1.5% for no HF/preserved systolic function. Use of guideline-recommended medical therapies and interventions was frequently significantly lower in those with HF regardless of EF compared with those without HF, except for use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. In conclusion, NSTE ACS complicated by HF with preserved systolic function is common and associated with a 2.3-fold higher mortality compared with NSTE ACS without HF or systolic dysfunction. Guideline-recommended therapies and interventions are under-utilized in patients with NSTE ACS and HF, with and without preserved systolic function, compared with those without HF. (c) 2007 Elsevier Inc. All rights reserved. C1 Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27706 USA. Wake Forest Univ, Winston Salem, NC 27109 USA. Univ Colorado, Hlth Sci Ctr, Denver VA Med Ctr, Denver, CO 80202 USA. NYU, Sch Med, New York, NY USA. Univ Cincinnati, Sch Med, Cincinnati, OH 45221 USA. RP Hernandez, AF (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27706 USA. EM herna014@mc.duke.edu RI Hernandez, Adrian F./A-7818-2016 OI Hernandez, Adrian F./0000-0003-3387-9616; Hochman, Judith/0000-0002-5889-5981 NR 24 TC 10 Z9 13 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD MAY 15 PY 2007 VL 99 IS 10 BP 1351 EP 1356 DI 10.1016/j.amjcard.2006.12.057 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 171DU UT WOS:000246715900001 PM 17493458 ER PT J AU Cavusoglu, E Ruwende, C Eng, C Chopra, V Yanamadala, S Clark, LT Pinsky, DJ Marmur, JD AF Cavusoglu, Erdal Ruwende, Cyril Eng, Calvin Chopra, Vineet Yanamadala, Sunitha Clark, Luther T. Pinsky, David J. Marmur, Jonathan D. TI Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID CHRONIC HEART-FAILURE; CARDIAC MORTALITY; PROGNOSTIC VALUE; CHEST-PAIN; ASSOCIATION; ADIPONECTIN; DISEASE; RISK AB Baseline plasma myeloperoxidase (MPO) levels have been shown to independently predict the early risk of myocardial infarction (MI) in patients presenting with chest pain. In addition, baseline MPO levels have been demonstrated to predict the development of adverse cardiac events up to 6 months after an acute coronary syndrome (ACS). However, in contrast to other biomarkers, there are no data about the long-term independent predictive value of baseline MPO values in patients with ACS. The present study investigated the long-term prognostic significance of baseline MPO levels in a well-characterized cohort of 193 men with ACS who were referred for coronary angiography at a Veterans Administration Medical Center. All patients were followed prospectively for the development of death and MI, and follow-up data were available for all patients at 24 months. After controlling for different baseline clinical, laboratory, and angiographic variables, baseline plasma MPO values were a strong and independent predictor of MI at 24 months by multivariate analysis. Using the median MPO value of the entire cohort of patients (i.e., 20.34 ng/ml) as a prespecified cutoff, the MI-free survival at 24 months for the group whose baseline MPO values were <= 20.34 ng/ml was 88% compared with 74% in those whose values were > 20.34 ng/ml (p = 0.0249 by log-rank test). In conclusion, these data demonstrate that baseline MPO levels independently predict MI at 2 years in patients with ACS. (c) 2007 Elsevier Inc. All rights reserved. C1 Suny Downstate Med Ctr, Div Cardiol, Dept Med, Brooklyn, NY 11203 USA. Bronx Vet Affairs Med Ctr, Dept Med, Bronx, NY USA. Univ Michigan, Dept Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA. RP Cavusoglu, E (reprint author), Suny Downstate Med Ctr, Div Cardiol, Dept Med, Brooklyn, NY 11203 USA. EM ecavusoglu@aol.com NR 17 TC 72 Z9 84 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD MAY 15 PY 2007 VL 99 IS 10 BP 1364 EP 1368 DI 10.1016/j.amjcard.2006.12.060 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 171DU UT WOS:000246715900004 PM 17493461 ER PT J AU McClure, MM Barch, DM Romero, MJ Minzenberg, MJ Triebwasser, J Harvey, PD Siever, LJ AF McClure, Margaret M. Barch, Deanna M. Romero, Michelle J. Minzenberg, Michael J. Triebwasser, Joseph Harvey, Philip D. Siever, Larry J. TI The effects of guanfacine on context processing abnormalities in Schizotypal personality disorder SO BIOLOGICAL PSYCHIATRY LA English DT Article DE cognition; guanfacine; pharmacology; schizophrenia; Schizotypal; working memory ID SCHIZOPHRENIA; DEFICITS; DYSFUNCTION; COGNITION; DOPAMINE; CORTEX AB Background: The signature of impaired cognition in people with schizotypal personality disorder (SPD) maybe centrally related to working memory impairments. Guanfacine, an alpha(2A) agonist that acts post-synaptically in the prefrontal cortex (PFC), has shown potential for reducing working memory limitations in other populations. This study examined the potential of guanfacine for improving context processing, a feature of working memory, in SPD. Methods: 29 individuals with SPD entered into a 4-week, randomized parallel-design, double-blind, placebo-controlled trial of guanfacine treatment, followed by a 4-week open-label extension. A modified version of the AX-Continuous Performance Test (AX-CPT) was administered. On this task, evidence of intact context processing includes few BX errors (false cue, correct probe) and higher levels of AY errors (correct cue, false probe). Results: At the end of double-blind treatment, participants treated with guanfacine demonstrated a significant reduction in BX errors and a small but significant increase in AY errors, a pattern that was not seen in the participants treated with placebo. Conclusions: SPD participants improved in their context processing toward a normal response bias, making fewer BX and more AY errors, after being treated with guanfacine. C1 Bronx Vet Adm Med Ctr, VA VISN 3 MIRECC, Bronx, NY 10468 USA. Washington Univ, Dept Psychol, St Louis, MO 63130 USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. Univ Calif Davis, Sch Med, Dept Psychiat, Sacramento, CA 95817 USA. James J Peters Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. RP McClure, MM (reprint author), Bronx Vet Adm Med Ctr, VA VISN 3 MIRECC, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM margaret.mcnamara@mssm.edu RI Barch, Deanna/G-8638-2013 FU NCRR NIH HHS [M01-RR-00071]; NIMH NIH HHS [MH 56140, MH 63116] NR 18 TC 22 Z9 23 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 15 PY 2007 VL 61 IS 10 BP 1157 EP 1160 DI 10.1016/j.biopsych.2006.06.034 PG 4 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 165VV UT WOS:000246335100007 PM 16950221 ER PT J AU Mostaghel, EA Page, ST Lin, DW Fazli, L Coleman, IM True, LD Knudsen, B Hess, DL Nelson, CC Matsumoto, AM Bremner, WJ Gleave, ME Nelson, PS AF Mostaghel, Elahe A. Page, Stephanie T. Lin, Daniel W. Fazli, Ladan Coleman, Ilsa M. True, Lawrence D. Knudsen, Beatrice Hess, David L. Nelson, Colleen C. Matsumoto, Alvin M. Bremner, Witham J. Gleave, Martin E. Nelson, Peter S. TI Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer SO CANCER RESEARCH LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; DEPRIVATION THERAPY; HORMONAL-THERAPY; RESPONSIVE GENES; RECEPTOR; TISSUE; PROGRESSION; CELLS; ANTIANDROGENS; MICROARRAYS AB Androgen deprivation therapy (ADT) remains the primary treatment for advanced prostate cancer. The efficacy of ADT has not been rigorously evaluated by demonstrating suppression of prostatic androgen activity at the target tissue and molecular level. We determined the efficacy and consistency of medical castration in suppressing prostatic androgen levels and androgen-regulated gene expression. Androgen levels and androgen-regulated gene expression (by microarray profiling, quantitative reverse transcription-PCR, and immunohistochemistry) were measured in prostate samples from a clinical trial of short-term castration (1 month) using the gonadotropin-releasing hormone antagonist, Acyline, versus placebo in healthy men. To assess the effects of long-term ADT, gene expression measurements were evaluated at baseline and after 3, 6, and 9 months of neoadjuvant ADT in prostatectomy samples from men with localized prostate cancer. Medical castration reduced tissue androgens by 75% and reduced the expression of several androgen-regulated genes (NDRG1, FKBP5, and TMPRSS2). However, many androgen-responsive genes, including the androgen receptor (A-R) and prostate-specific antigen (PSA), were not suppressed after short-term castration or after 9 months of neoadjuvant ADT. Significant heterogeneity in PSA and AR protein expression was observed in prostate cancer samples at each time point of ADT. Medical castration based on serum testosterone levels cannot be equated with androgen ablation in the prostate microenvironment. Standard androgen deprivation does not consistently suppress androgen-dependent gene expression. Suboptimal suppression of tumoral androgen activity may lead to adaptive cellular changes allowing prostate cancer cell survival in a low androgen environment. Optimal clinical efficacy will require testing of novel approaches targeting complete suppression of systemic and intracrine contributions to the prostatic androgen microenvironment. C1 Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Vancouver Gen Hosp, Vancouver, BC, Canada. Oregon Natl Primate Res Ctr, Beaverton, OR USA. RP Nelson, PS (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,MS D4-100, Seattle, WA 98109 USA. EM pnelson@fhcrc.org FU NCI NIH HHS [P50CA97186, T32 CA09515-21, K23 CA122820-01]; NCRR NIH HHS [RR0163]; NIA NIH HHS [K23 AG027238, K23 AG027238-01A1, K23AG027238-01A1]; NICHD NIH HHS [U54 HD42454]; NIDDK NIH HHS [DK65083, DK65204] NR 49 TC 300 Z9 305 U1 0 U2 9 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD MAY 15 PY 2007 VL 67 IS 10 BP 5033 EP 5041 DI 10.1158/0008-5472.CAN-06-3332 PG 9 WC Oncology SC Oncology GA 172BG UT WOS:000246778500059 PM 17510436 ER PT J AU Fan, J Li, Y Levy, RM Fan, JJ Hackam, DJ Vodovotz, Y Yang, H Tracey, KJ Billiar, TR Wilson, MA AF Fan, Jie Li, Yuehua Levy, Ryan M. Fan, Janet J. Hackam, David J. Vodovotz, Yoram Yang, Huan Tracey, Kevin J. Billiar, Timothy R. Wilson, Mark A. TI Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: Role of HMGB1-TLR4 signaling SO JOURNAL OF IMMUNOLOGY LA English DT Article ID MOBILITY GROUP BOX-1; TOLL-LIKE RECEPTOR-4; NF-KAPPA-B; MEDIATES HEPATIC-INJURY; END-PRODUCTS RAGE; PROTEIN-KINASE-C; NADPH OXIDASE; CUTTING EDGE; SYSTEMIC INFLAMMATION; LUNG INFLAMMATION AB Hemorrhagic shock/resuscitation (HS/R)-induced generation of reactive oxygen species (ROS) plays an important role in posthemorrhage inflammation and tissue injury. We have recently reported that HS/R-activated neutrophils (PMN), through release of ROS, serve an important signaling function in mediating alveolar macrophage priming and lung inflammation. PMN NAD(P)H oxiclase has been thought to be an important source of ROS following HS/R. TLR4 sits at the interface of microbial and sterile inflammation by mediating responses to both bacterial endotoxin and multiple endogenous ligands, including high-mo bility group box 1 (HMGB1). Recent studies have implicated HMGB1 as an early mediator of inflammation after HS/R and organ ischemia/ reperfusion. In the present study, we tested the hypothesis that HS/R activates NAD(P)H oxidase in PMN through HMGB1/TLR4 signaling. We demonstrated that HS/R induced PMN NAD(P)H oxidase activation, in the form of phosphorylation of p47(phox)subunit of NAD(P)H oxidase, in wild-type mice; this induction was significantly diminished in TLR4-mutant C3H/HeJ mice. HMGB1 levels in lungs, liver, and serum were increased as early as 2 h after HS/R. Neutralizing Ab to HMGB1 prevented HS/R-induced phosphorylation of p47(phox) in PMN. In addition, in vitro stimulation of PMN with recombinant HMGB1 caused TLR4-dependent activation of NAD(P)H oxidase as well as increased ROS production through both MyD88-IRAK4-p38 MAPK and MyD88-IRAK4-Akt signaling pathways. Thus, PMN NAD(P)H oxidase activation, induced by HS/R and as mediated by HMGBI/TLR4 signaling, is an important mechanism responsible for PMN-mediated inflammation and organ injury after hemorrhage. The Journal of Immunology, 2007, 178: 6573-6580. C1 Vet Affairs Pittsburgh Healthcare Syst, Dept Surg, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA. Childrens Hosp Pittsburgh, Div Pediat Surg, Pittsburgh, PA 15213 USA. NYU, Sch Med, N Shore Univ Hosp, Lab Biomed Sci, Manhasset, NY 11030 USA. RP Fan, J (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Dept Surg, CHERP Bldg 25 151C-U,Univ Dr C, Pittsburgh, PA 15240 USA. EM jif7@pitt.edu OI Tracey, Kevin J/0000-0003-1884-6314 FU NHLBI NIH HHS [R01-HL-079669]; NIGMS NIH HHS [P50-GM-53789] NR 62 TC 166 Z9 181 U1 3 U2 14 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD MAY 15 PY 2007 VL 178 IS 10 BP 6573 EP 6580 PG 8 WC Immunology SC Immunology GA 165EG UT WOS:000246286200066 PM 17475888 ER PT J AU White, D Moore, S Waring, S Cook, K Lai, E AF White, Donna Moore, Suzanne Waring, Stephen Cook, Karon Lai, Eugene TI Identifying incident cases of parkinsonism among veterans using a tertiary medical center SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; secondary; veterans; incidence; vital status; ICD-9 CM ID QUALITY-OF-LIFE; DISEASE; PREVALENCE; PRISONERS; SPAIN; WAR AB To better understand the impact of incident Parkinson's disease (PD) on the Veteran's Health Administration (VHA) and to develop methods applicable to future epidemiological research, we performed a medical record review study at a tertiary referral VHA medical center. Searching the local data base, we identified 782 veterans with diagnostic codes for PD or secondary parkinsonism (SP) between 1998 and 2000. Based on structured medical record review, a movement disorders specialist confirmed diagnoses for incident parkinsonism cases. Among the 782, 191 incident parkinsonism cases were identified (100 PD, 75 SP, and 16 Parkinson's Plus). Incident PD cases were older at diagnosis (74.5 vs. 70.4 yr; P < 0.05) and more likely to be white (81% vs. 62; P < 0.07) than incident SP cases. Diagnostic codes were insufficient to distinguish between incident PD and SP (positive predictive value, 57% and 39%, respectively), and VHA sources failed to identify 21% of confirmed deaths among the incident PD cohort by November 2004. Although the large number of incident cases identified suggests PD is an important cause of disability among elderly VHA users, observed limitations of VHA sources for identifying incident PD cases and determining their vital status should be considered when designing future studies. (C) 2007 Movement Disorder Society. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. Michael E DeBakey Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Houston, TX USA. Univ Texas, Hlth Sci Ctr, Dept Epidemiol, Houston, TX USA. Univ Washington, Seattle, WA 98195 USA. RP Lai, E (reprint author), 2002 Holcombe Blvd, Houston, TX 77030 USA. EM elai@bcm.edu NR 29 TC 3 Z9 3 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD MAY 15 PY 2007 VL 22 IS 7 BP 915 EP 923 DI 10.1002/mds.21353 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 174BU UT WOS:000246917000002 PM 17415798 ER PT J AU Cook, DB O'Connor, PJ Lange, G Steffener, J AF Cook, Dane B. O'Connor, Patrick J. Lange, Gudrun Steffener, Jason TI Functional neuroimaging correlates of mental fatigue induced by cognition among chronic fatigue syndrome patients and controls SO NEUROIMAGE LA English DT Article ID VERBAL WORKING-MEMORY; BECK DEPRESSION INVENTORY; VISUAL ANALOG SCALES; HUMAN BRAIN; FMRI; TASK; COMPONENTS; SYSTEM; MRI; EPIDEMIOLOGY AB The neural mechanisms underlying feelings of fatigue are poorly understood. The primary purpose of the study was to use functional magnetic resonance imaging (fMRI) to determine the association between feelings of mental fatigue and blood oxygen level dependent (BOLD) brain responses during a mentally fatiguing cognitive task. Healthy, non-fatigued controls and chronic fatigue syndrome (CFS) patients were included to determine the influence of chronic levels of fatigue on brain responses. We hypothesized that mental fatigue would be significantly related to brain activity during a fatiguing cognitive task but not during either a non-fatiguing motor (finger tapping) or cognitive (auditory monitoring) task. Patients (n = 9) and controls (n = 11) completed a finger tapping task, a simple auditory monitoring task and a challenging working memory task, designed to induce mental fatigue, while undergoing fMRI. Fatigue was measured prior to scanning and following each task during fMRI data collection. Results showed that mental fatigue was significantly related to brain activity during the fatiguing cognitive task but not the finger tapping or simple auditory monitoring tasks. Significant (p <= 50.005) positive relationships were found for cerebellar, temporal, cingulate and frontal regions. A significant (p=0.001) negative relationship was found for the left posterior parietal cortex. CFS participants did not differ from controls for either finger tapping or auditory monitoring tasks, but exhibited significantly greater activity, in several cortical and subcortical regions during the fatiguing cognitive task. Our results suggest an association between subjective feelings of mental fatigue and brain responses during fatiguing cognition. (C) 2007 Elsevier Inc. All rights reserved. C1 Univ Wisconsin, Dept Kinesiol, Unit Gym 2, Madison, WI 53706 USA. William S Middleton Mem Vet Adm Med Ctr, Dept Vet Affairs, Madison, WI 53706 USA. Univ Georgia, Dept Kinesiol, Athens, GA 30602 USA. New Jersey Hlth Care Syst, Dept Vet Affairs, E Orange, NJ 07018 USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Radiol, Newark, NJ 07103 USA. Columbia Univ, Cognit Neurosci Div, Taub Inst Res Alzheimers Dis Aging Brain, New York, NY 10032 USA. RP Cook, DB (reprint author), Univ Wisconsin, Dept Kinesiol, Unit Gym 2, 2000 Observ Dr, Madison, WI 53706 USA. EM dcook@education.wisc.edu NR 61 TC 107 Z9 109 U1 11 U2 33 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD MAY 15 PY 2007 VL 36 IS 1 BP 108 EP 122 DI 10.1016/j.neuroimage.2007.02.033 PG 15 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 168YI UT WOS:000246559500011 PM 17408973 ER PT J AU Ilvesaro, JM Merrell, MA Swain, TM Davidson, J Zayzafoon, M Harris, KW Selander, KS AF Ilvesaro, Joanna M. Merrell, Melinda A. Swain, Telisha Millender Davidson, Jennifer Zayzafoon, Majd Harris, Kevin W. Selander, Katri S. TI Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro SO PROSTATE LA English DT Article DE toll-like receptor 9; prostate cancer; invasion; matrix metalloproteinase-13 ID EPITHELIAL-CELLS; CPG-OLIGODEOXYNUCLEOTIDES; SUBCELLULAR-LOCALIZATION; HELICOBACTER-PYLORI; DENDRITIC CELLS; EXPRESSION; TLR9; ACTIVATION; RECOGNITION; ESTROGEN AB BACKGROUND. Toll-like receptor 9 (TLR9) recognizes microbial DNA. In addition to immune cells, TLR9 expression has been detected in various cancer cells. We showed recently that TLR9 agonistic CpG-oligonucleotides (CpG-ODNs) induce matrix metalloproteinase-13 (MMP-13)-mediated invasion in TLR9-expressing (TLR9(+)) breast cancer cells. We investigated here TLR9 expression and function in human prostate cancer (CaP) cells. METHODS. TLR9 expression was detected with Western blotting and immunohistochemistry. Invasion was studied with Matrigel-assays. MMP-13 was assayed with ELISA. RESULTS. Human CaP cell lines and clinical samples exhibit various levels of TLR9 expression. Treatment of TLR9+, but not TLR9(-) CaP cells with CpG-ODNs or bacterial DNA increased their invasion, which was inhibited with chloroquine. CpG-ODN-treatment also increased MMP-13 activity and neutralizing anti-MMP-13 antibody prevented CpG-ODNinduced invasion in TLR9+ Cap cells. Estradiol up-regulated TLR9 expression in LnCaP cells. CONCLUSIONS. TLR9-mediated invasion may represent a novel mechanism through which infections promote prostate cancer. C1 UAB, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA. UAB, Dept Pathol, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Selander, KS (reprint author), UAB, Dept Med, Div Hematol Oncol, WTI T558,1824 6th Ave S, Birmingham, AL 35294 USA. EM Katri.Selander@ccc.uab.edu NR 47 TC 101 Z9 110 U1 2 U2 6 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-4137 J9 PROSTATE JI Prostate PD MAY 15 PY 2007 VL 67 IS 7 BP 774 EP 781 DI 10.1002/pros.20562 PG 8 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 161NM UT WOS:000246022200010 PM 17373717 ER PT J AU Mercaldo, ND Lau, KF Zhou, XH AF Mercaldo, Nathaniel D. Lau, Kit F. Zhou, Xiao H. TI Confidence intervals for predictive values with an emphasis to case-control studies SO STATISTICS IN MEDICINE LA English DT Article DE predictive values; confidence intervals; diagnostic tests; Alzheimer's disease; breast cancer ID ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; BREAST-CANCER; ASSOCIATION; PREVALENCE; ALLELE AB The accuracy of a binary-scale diagnostic test can be represented by sensitivity (Se), specificity (Sp) and positive and negative predictive values (PPV and NPV). Although Se and Sp measure the intrinsic accuracy of a diagnostic test that does not depend on the prevalence rate, they do not provide information on the diagnostic accuracy of a particular patient. To obtain this information we need to use PPV and NPV. Since PPV and NPV are functions of both the accuracy of the test and the prevalence of the disease, constructing their confidence intervals for a particular patient is not straightforward. In this paper, a novel method for the estimation of PPV and NPV, as well as their confidence intervals, is developed. For both predictive values, standard, adjusted and their logit transformed-based confidence intervals are compared using coverage probabilities and interval lengths in a simulation study. These methods are then applied to two case-control studies: a diagnostic test assessing the ability of the e4 allele of the apolipoprotein E gene (ApoE.e4) on distinguishing patients with late-onset Alzheimer's disease (AD) and a prognostic test assessing the predictive ability of a 70-gene signature on breast cancer metastasis. Copyright (c) 2006 John Wiley & Sons, Ltd. C1 Univ Washington, Dept Biostat, Seattle, WA 98027 USA. Celera Diagnost, Alameda, CA USA. VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA USA. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, Seattle, WA 98027 USA. EM azhou@u.washington.edu NR 16 TC 31 Z9 31 U1 2 U2 7 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0277-6715 J9 STAT MED JI Stat. Med. PD MAY 10 PY 2007 VL 26 IS 10 BP 2170 EP 2183 DI 10.1002/sim.2677 PG 14 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 160TM UT WOS:000245965200003 PM 16927452 ER PT J AU Giordano, TP Henderson, L Landgren, O Chiao, EY Kramer, JR El-Serag, H Engels, EA AF Giordano, Thomas P. Henderson, Louise Landgren, Ola Chiao, Elizabeth Y. Kramer, Jennifer R. El-Serag, Hashem Engels, Eric A. TI Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID ADMINISTRATION MEDICAL SYSTEM; THYROID-CANCER; UNITED-STATES; WALDENSTROM MACROGLOBULINEMIA; MONOCLONAL GAMMOPATHY; INFECTION; PREVALENCE; CRYOGLOBULINEMIA; ASCERTAINMENT; REGRESSION AB Context Hepatitis C virus (HCV) infection causes liver cancer and cirrhosis and may also increase the risk of other tumors, particularly hematopoietic malignancies and thyroid cancer. Previous studies have been too small to adequately assess these risks. Objective To test the hypothesis that HCV infection is associated with increased risk for hematological malignancies, related lymphoproliferative disorders, and thyroid cancer. Design, Setting, and Patients A retrospective cohort study of users of US Veterans Affairs health care facilities from 1997-2004, which included 146 394 patients infected with HCV who had at least 2 visits with a diagnostic code for HCV infection, and 572 293 patients uninfected with HCV. To assemble the HCV-uninfected cohort, we randomly selected up to 4 patients per patient infected with HCV from all veterans who matched on age, sex, and baseline visit date and type (inpatient or outpatient). Individuals with human immunodeficiency virus were excluded. Main Outcome Measures Risks of hematopoietic malignancies, related lymphoproliferative precursor diseases, and thyroid cancer, adjusting for selection factors, race, era of military service, and use of medical services. Results The mean (SD) age of the patients was 52 (8) years, and 97% were men. Risks for non-Hodgkin lymphoma (n = 1359), Waldenstrom macroglobulinemia (n = 165), and cryoglobulinemia (n = 551) were increased with HCV infection (adjusted hazard ratio [ HR], 1.28; 95% confidence interval [ CI], 1.12-1.45; adjusted HR, 2.76; 95% CI, 2.01-3.79; and adjusted HR, 3.98; 95% CI, 3.36-4.72; respectively). We found no significantly increased risk for other hematological malignancies. Although thyroiditis risk was slightly increased, risk for thyroid cancer (n = 320) was not (adjusted HR, 0.72; 95% CI, 0.52-0.99). Adjusted P values for non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, cryoglobulinemia, and thyroiditis were all < .0038, the Bonferroni threshold for statistical significance considering multiple comparisons. Conclusions Hepatitis C virus infection confers a 20% to 30% increased risk of non-Hodgkin lymphoma overall, and a 3-fold higher risk of Waldenstrom macroglobulinemia, a low-grade lymphoma. Risks were also increased for cryoglobulinemia. These results support an etiological role for HCV in causing lymphoproliferation and causing non-Hodgkin lymphoma. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. NCI, NIH, Rockville, MD USA. RP Giordano, TP (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, VA152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM tpg@bcm.tmc.edu FU Intramural NIH HHS; NCI NIH HHS [K23CA124318]; NIMH NIH HHS [K23MH67505] NR 27 TC 168 Z9 175 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 9 PY 2007 VL 297 IS 18 BP 2010 EP 2017 DI 10.1001/jama.297.18.2010 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 165JM UT WOS:000246301800023 PM 17488966 ER PT J AU Miampamba, M Million, M Yuan, PQ Larauche, M Tache, Y AF Miampamba, Marcel Million, Mulugeta Yuan, Pu-Qing Larauche, Muriel Tache, Yvette TI Water avoidance stress activates colonic myenteric neurons in female rats SO NEUROREPORT LA English DT Article DE colonic motor function; Fos; myenteric neurons; peripheral choline acetyltransferase; stress ID CORTICOTROPIN-RELEASING-FACTOR; IRRITABLE-BOWEL-SYNDROME; ENTERIC NERVOUS-SYSTEM; C-FOS EXPRESSION; PARAVENTRICULAR NUCLEUS; GASTROINTESTINAL-TRACT; CONSCIOUS RATS; MOTOR RESPONSE; CRF1 RECEPTOR; SPINAL-CORD AB Stress stimulates colonic motor function and plays a role in functional bowel disorders, prevalently in women. We examined, in conscious female rats, the influence of water avoidance stress for 60 min on colonic myenteric neuron activity using immunohistochemical detection of Fos as a marker of neuronal activity. In control rats, Fos immunoreactive nuclei were rare in proximal and distal colon and no defecation was observed. Water avoidance stimulated fecal pellet output, which was associated with Fos expression in myenteric ganglia of proximal and distal colon including in a population of peripheral choline acetyltransferase-immunoreactive neurons. Atropine blocked fecal pellet output but not Fos expression in myenteric ganglia. These results indicate that psychological stress stimulates the activity of colonic cholinergic myenteric neurons. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Div Digest Dis, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth,Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, CURE Digest Dis Res Ctr, David Geffen Sch Med, Los Angeles, CA 90024 USA. RP Miampamba, M (reprint author), VA Greater Los Angeles Healthcare Syst, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM marcel.miampamba@ferring.com; ytache@mednet.ucla.edu OI Larauche, Muriel/0000-0003-3320-3675 FU NIAMS NIH HHS [P50 AR 049550]; NIDDK NIH HHS [DK 41301, R01 DK 33061] NR 25 TC 17 Z9 17 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0959-4965 J9 NEUROREPORT JI Neuroreport PD MAY 7 PY 2007 VL 18 IS 7 BP 679 EP 682 DI 10.1097/WNR.0b013e3280bef7f8 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 159HK UT WOS:000245856000012 PM 17426598 ER PT J AU Nolen, WA Kupka, RW Hellemann, G Frye, MA Altshuler, LL Leverich, GS Suppes, T Keck, PE McElroy, S Grunze, H Mintz, J Post, RM AF Nolen, W. A. Kupka, R. W. Hellemann, G. Frye, M. A. Altshuler, L. L. Leverich, G. S. Suppes, T. Keck, P. E., Jr. McElroy, S. Grunze, H. Mintz, J. Post, R. M. TI Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study SO ACTA PSYCHIATRICA SCANDINAVICA LA English DT Article DE bipolar disorder; bipolar depression; tranylcypromine; lamotrigine; lithium; anticonvulsant ID MOOD STABILIZERS; MAINTENANCE TREATMENT; VENLAFAXINE; DISORDER; MANIA; ANTIDEPRESSANTS; IMIPRAMINE; SERTRALINE; BUPROPION; CROSSOVER AB Objective: To compare the efficacy and tolerability of tranylcypromine vs. lamotrigine in bipolar depression not responding to conventional antidepressants. Method: Bipolar depressed patients received open randomized treatment with tranylcypromine or lamotrigine as add-on to a mood stabilizer during 10 weeks. In a second treatment phase, non-responding patients could receive the opposite drug. Outcome criteria were response (measured with CGI-BP and IDS-C), switch into mania, and completion of the study. Results: Only 20 of 70 planned patients were randomized, due to problems with recruitment, and 19 patients received any medication. During the first treatment phase 5/8 patients (62.5%) responded to tranylcypromine without switch into mania, compared with 4/11 patients (36.4%) on lamotrigine with two switches (statistically not significant). Over both treatment phases, 8/10 patients (80%) receiving tranylcypromine completed the study vs. 5/13 (38.5%) on lamotrigine (likelihood 0.02). Conclusions: There still appears to be a role for tranylcypromine in the treatment of refractory bipolar depression. Larger controlled studies are demanded. C1 Univ Groningen, Dept Psychiat, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands. Altrecht Inst Mental Hlth Care, Utrecht, Netherlands. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA. W Los Angeles VA Med Ctr, Los Angeles, CA USA. NIMH, Dept Hlth & Human Serv, Biol Psychiat Branch, NIH, Bethesda, MD 20892 USA. Univ Texas, SW Med Ctr, Dallas, TX USA. Univ Cincinnati, Coll Med, Dept Psychiat, Psychopharmacol Res Program, Cincinnati, OH USA. Univ Munich, Munich, Germany. RP Nolen, WA (reprint author), Univ Groningen, Dept Psychiat, Univ Med Ctr Groningen, POB 30-001, NL-9700 RB Groningen, Netherlands. EM w.a.nolen@med.umcg.nl RI Nolen, Willem/E-9006-2014 OI Grunze, Heinz/0000-0003-4712-8979 NR 23 TC 30 Z9 31 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0001-690X J9 ACTA PSYCHIAT SCAND JI Acta Psychiatr. Scand. PD MAY PY 2007 VL 115 IS 5 BP 360 EP 365 DI 10.1111/j.1600-0447.2007.00993.x PG 6 WC Psychiatry SC Psychiatry GA 152VM UT WOS:000245390100004 PM 17430413 ER PT J AU Tyrka, AR Wier, LM Anderson, GM Wilkinson, CW Price, LH Carpenter, LL AF Tyrka, A. R. Wier, L. M. Anderson, G. M. Wilkinson, C. W. Price, L. H. Carpenter, L. L. TI Temperament and response to the trier social stress test SO ACTA PSYCHIATRICA SCANDINAVICA LA English DT Article DE Cortisol; adrenocorticotropic hormone; stress; temperament; personality; inhibition ID TRIDIMENSIONAL PERSONALITY QUESTIONNAIRE; CORTICOTROPIN-RELEASING FACTOR; BEHAVIORAL-INHIBITION; PSYCHOBIOLOGICAL MODEL; FEARFUL TEMPERAMENT; CORTISOL RESPONSES; SALIVARY CORTISOL; MAJOR DEPRESSION; PHYSICAL ABUSE; RHESUS-MONKEYS AB Objective: The personality characteristics behavioural inhibition and neuroticism have been associated with mood and anxiety disorders and, in some studies, hypothalamic-pituitary-adrenal (HPA) axis hyperactivity. We recently reported that low levels of Novelty Seeking were associated with elevated plasma cortisol responses to the dexamethasone/corticotropin-releasing hormone (Dex/CRH) test in healthy adults with no psychiatric disorder. The present study tested the association between temperament and HPA axis function in the same group of subjects using a standardized psychosocial neuroendocrine stress test. Method: Subjects completed diagnostic interviews, questionnaires, and the Trier Social Stress Test (TSST). Results: Novelty Seeking was inversely associated with plasma cortisol concentrations at baseline and throughout the TSST, but was not related to adrenocorticotropic hormone (ACTH) levels. Conclusion: Results of this study extend our previous finding in the Dex/CRH test to a psychosocial stress test. Future investigations are needed to replicate these findings and further elucidate how temperament and personality are linked to HPA function. C1 Butler Hosp, Mood Disorders Res Program, Providence, RI 02906 USA. Butler Hosp, Lab Clin Neurosci, Providence, RI 02906 USA. Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI USA. Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA. VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Tyrka, AR (reprint author), Butler Hosp, Mood Disorders Res Program, 345 Blackstone Blvd, Providence, RI 02906 USA. EM audrey_tyrka@brown.edu RI Tyrka, Audrey/L-2504-2014 FU NIMH NIH HHS [R01 MH068767, K23 MH067947, 1 K23 MH067947] NR 50 TC 33 Z9 34 U1 5 U2 13 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0001-690X J9 ACTA PSYCHIAT SCAND JI Acta Psychiatr. Scand. PD MAY PY 2007 VL 115 IS 5 BP 395 EP 402 DI 10.1111/j.1600-0447.2006.00941.x PG 8 WC Psychiatry SC Psychiatry GA 152VM UT WOS:000245390100009 PM 17430418 ER PT J AU Graham, J Bennett, IM Holmes, WC Gross, R AF Graham, Joseph Bennett, Ian M. Holmes, William C. Gross, Robert TI Medication beliefs as mediators of the health literacy-antiretroviral adherence relationship in HIV-infected individuals SO AIDS AND BEHAVIOR LA English DT Article DE HIV-1; antiretroviral therapy; adherence; health literacy ID VIRAL LOAD; THERAPY; KNOWLEDGE; CARE; ASSOCIATION; PATTERNS; OUTCOMES; ADULTS; SKILLS; AIDS AB Identifying modifiable barriers to antiretroviral adherence remains an important aim. We hypothesized that mistaken beliefs regarding taking HIV medications mediated the relation between low literacy and poor adherence. We studied 87 HIV-infected individuals on standard antiretroviral regimens for >= 3 months. Adherence was assessed using pharmacy refill records. Medication beliefs, including an individual's norm for acceptable adherence, were measured using questions developed by expert panel. Literacy was associated with < 95% adherence (64% for < 9th grade level vs. 40% for < 9th grade level). Participants with < 95% adherence had a lower threshold of acceptable adherence than those with >= 95% adherence [80% adherence (interquartile range 70-90%) vs. 90% adherence (interquartile range 80-90%)]. However, the effect was independent of literacy. No other beliefs assessed were associated with adherence. Although the beliefs assessed do not mediate the relation between literacy and adherence, we identified low adherence norms as a potentially modifiable belief associated with adherence. C1 Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. Univ Penn, Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. RP Gross, R (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 804 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rgross@cceb.med.upenn.edu OI Bennett, Ian/0000-0002-7139-9456 FU AHRQ HHS [HS10399]; NIAID NIH HHS [P30-AI45008, U01-AI32783]; NICHD NIH HHS [K23 HD048915, K23 HD048915-03]; NIMH NIH HHS [MH-01854] NR 28 TC 31 Z9 32 U1 1 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS behav. PD MAY PY 2007 VL 11 IS 3 BP 385 EP 392 DI 10.1007/s10461-006-9164-9 PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 153TP UT WOS:000245458400004 PM 17053858 ER PT J AU Durazzo, TC Gazdzinski, S Meyerhoff, DJ AF Durazzo, Timothy C. Gazdzinski, Stefan Meyerhoff, Dieter J. TI The neurobiological and neurocognitive consequences of chronic cigarette smoking in alcohol use disorders SO ALCOHOL AND ALCOHOLISM LA English DT Review ID CEREBRAL-BLOOD-FLOW; ALZHEIMERS-DISEASE; NEUROPSYCHIATRIC DISORDERS; BRAIN ATROPHY; COGNITIVE PERFORMANCE; ABSTINENT ALCOHOLICS; POSTURAL STABILITY; COCAINE DEPENDENCE; GLUCOSE-METABOLISM; MAJOR DEPRESSION AB A vast body of research attests to the adverse effects of chronic smoking on cardiac, pulmonary, and vascular function as well as the increased risk for various forms of cancer. However, comparatively little is known about the effects of chronic smoking on human brain function. Although smoking rates have decreased in the developed world, they remain high in individuals with alcohol use disorders. Despite the high prevalence of comorbid chronic smoking in alcohol use disorders, very few studies have addressed the potential neurobiological or neurocognitive effects of chronic smoking in alcohol use disorders. Here, we briefly review the existing literature on the neurobiological and neurocognitive consequences of chronic cigarette smoking and summarize our neuroimaging and neurocognitive studies on the effects of comorbid chronic excessive alcohol consumption and cigarette smoking in treatment-seeking and treatment-naive populations. Our research suggests comorbid chronic cigarette smoking modulates magnetic resonance-detectable brain injury and neurocognition in alcohol use disorders and that neurobiological recovery in our abstinent alcoholics is adversely affected by chronic smoking. Consideration of the potential separate effects and interactions of chronic smoking and alcohol consumption may foster a better understanding of specific mechanisms and neurocognitive consequences of brain injury in alcoholism and of brain recovery during sustained abstinence from alcohol. The material presented also contributes to ongoing discussions about treatment strategies for comorbid alcoholism and cigarette smoking and will hopefully stimulate further research into the neurobiological and neurocognitive consequences of chronic smoking in alcoholism and other substance use disorders. C1 Dept Vet Affairs Med Ctr, Ctr Neuroimaging Neurodegenerat Dis, San Francisco, CA USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. RP Durazzo, TC (reprint author), San Francisco Vet Adm Med Ctr, Ctr Imaging Neurodegenerat Dis, 114M,4150 Clement St, San Francisco, CA 94121 USA. EM timothy.durazzo@ucsf.edu FU NIAAA NIH HHS [R01 AA10788, P01 AA11493] NR 107 TC 55 Z9 58 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0735-0414 J9 ALCOHOL ALCOHOLISM JI Alcohol Alcohol. PD MAY-JUN PY 2007 VL 42 IS 3 BP 174 EP 185 DI 10.1093/alcalc/agm020 PG 12 WC Substance Abuse SC Substance Abuse GA 185QN UT WOS:000247725600003 PM 17526627 ER PT J AU Shaib, YH El-Serag, HB Nooka, AK Thomas, M Brown, TD Patt, YZ Hassan, MM AF Shaib, Yasser H. El-Serag, Hashem B. Nooka, Ajay K. Thomas, Melanie Brown, Thomas D. Patt, Yehuda Z. Hassan, Manal M. TI Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A hospital-based case-control study SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID HEPATITIS-C VIRUS; POLYMERASE CHAIN-REACTION; UNITED-STATES; RNA SEQUENCES; B SURFACE; LIVER; CANCER; EPIDEMIOLOGY; INFECTION; CARCINOMA AB BACKGROUND: The risk factors for cholangiocarcinoma are poorly defined in the United States. We evaluated hepatitis C virus (HCV), hepatitis B virus (HBV), and liver cirrhosis as risk factors for intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC). METHODS: A case-control study in which cases were cholangiocarcinoma patients referred to the M.D. Anderson Cancer Center between 1992 and 2002 and controls were healthy individuals. Information about liver diseases, family history, diabetes, smoking, and alcohol consumption were collected on both groups. Blood from all participants was tested for HBV and HCV markers. RESULTS: We identified 246 cases (83 ICC and 163 ECC) and matched them to 236 controls. Compared with controls, ICC patients had a higher prevalence of anti-HCV antibodies (6.0% vs 0.8%, P = 0.01), anti-HBc (9.6% vs 0%, P < 0.0001), and heavy alcohol consumption (21.7% vs 3.8%, P < 0.0001). The adjusted odds ratio and 95% confidence interval (CI) were 7.9 (95% CI 1.3-84.5), 28.6 (95% CI 3.9-1,268.1), and 5.9 (95% CI 2.1-17.4), respectively. Only heavy alcohol consumption was higher in patients with ECC than in controls (17.8% vs 3.8%, P = 0.003). The prevalence of diabetes and smoking were not significantly different between cases (ICC or ECC) and controls. The prevalence of cirrhosis was higher in patients with ICC than those with ECC (24.1% vs 4.9%, P < 0.0001). CONCLUSIONS: Liver cirrhosis and chronic HCV infection are possible risk factors for ICC but not ECC. Heavy alcohol consumption is a risk factor for both ICC and ECC. C1 MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX USA. Houston Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Univ New Mexico, Ctr Canc, Sect Gastrintestinal Oncol, Albuquerque, NM 87131 USA. RP Hassan, MM (reprint author), MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA. NR 16 TC 131 Z9 140 U1 2 U2 10 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAY PY 2007 VL 102 IS 5 BP 1016 EP 1021 DI 10.1111/j.1572-0241.2007.01104.x PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 163TS UT WOS:000246186700017 PM 17324130 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Time trends of ulcer mortality in non-European countries SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Review ID PEPTIC-ULCER; DISEASE; EPIDEMIOLOGY; RATES; PATTERNS AB AIMS: The aim of the present study was to follow the time trends of mortality from gastric and duodenal ulcer in countries outside Europe and compare them with previous reports of ulcer mortality from Europe and North America. METHODS: Mortality data from eight different countries were analyzed, including Argentina, Australia, Chile, Hong Kong, Japan, Mexico, Singapore, and Taiwan. The age-standardized death rates of individual countries were followed from 1971 to 2004. Japan and Australia had mortality data for more than 50 yr that provided the opportunity to conduct a birth-cohort analysis. RESULTS: The data from all countries were characterized by a decline in gastric and duodenal ulcer mortality. Except for Hong Kong, mortality from gastric ulcer was higher than mortality from duodenal ulcer. In Japan and Australia, mortality from gastric and duodenal ulcer displayed time trends that were consistent with an underlying birth-cohort phenomenon. The risk of dying from gastric and duodenal ulcer increased in consecutive generations born between the mid- and the end of the nineteenth century and decreased in all subsequent generations. The peak mortality from gastric ulcer occurred among generations born in 1875, whereas peak mortality from duodenal ulcer occurred among generations born 10-20 yr later. CONCLUSIONS: The ubiquitous decline in ulcer mortality in countries from different parts of the world is likely to be associated with a worldwide decline in the occurrence of H. pylori infection. The events accompanying the receding infection in developed countries must have similarly affected populations exposed to increasing standards of hygiene. C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Portland, OR USA. NR 19 TC 22 Z9 23 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAY PY 2007 VL 102 IS 5 BP 1101 EP 1107 DI 10.1111/j.1572-0241.2007.01157.x PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 163TS UT WOS:000246186700029 PM 17355419 ER PT J AU Rosendoff, C Beeri, MS Silverman, JM AF Rosendoff, Clive Beeri, Michal S. Silverman, Jeremy M. TI Cardiovascular risk factors for Alzheimer's disease SO AMERICAN JOURNAL OF GERIATRIC CARDIOLOGY LA English DT Review ID ADVANCED GLYCATION ENDPRODUCTS; ELDERLY JAPANESE POPULATION; TOTAL CHOLESTEROL LEVELS; SYSTOLIC BLOOD-PRESSURE; AMYLOID-BETA PEPTIDE; E EPSILON-4 ALLELE; COGNITIVE FUNCTION; APOLIPOPROTEIN-E; TOTAL HOMOCYSTEINE; DIABETES-MELLITUS AB There is now sizable literature on the association between traditional cardiovascular risk factors and Alzheimer's disease (AD). Based on epidemiologic studies, both cross-sectional and' longitudinal, there are statistically significant correlations between the prevalence of AD and diabetes, hypercholesterolemia, hypertension, hyperhomocysteinemia, dietary saturated fats, cholesterol, antioxidants, alcohol consumption, smoking, physical activity, the presence of atrial fibrillation, atherosclerotic disease, and the plasma concentration of some hemostatic factors. Most of the cardiovascular risk factors found to be associated with AD are age-dependent, and the prevalence of AD increases with age. Therefore, the association could simply be attributed to aging. On the other hand, the common pathogenetic mechanisms for the generation of both atherosclerotic disease and AD, such as inflammation and the generation of free radicals, suggest a causal link. If this is the case, the identification of modifiable risk factors for dementia becomes a research priority,and early intervention aimed at reducing those cardiovascular risk factors a therapeutic imperative. C1 James J Peters VA Med Ctr, Dept Med 111, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Med, New York, NY USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Rosendoff, C (reprint author), James J Peters VA Med Ctr, Dept Med 111, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM clive.rosendorff@va.gov NR 86 TC 78 Z9 83 U1 1 U2 7 PU LE JACQ LTD PI DARIEN PA 3 PARKLANDS DRIVE, DARIEN, CT 06820 USA SN 1076-7460 J9 AM J GERIATR CARDIOL JI Am. J. Geriatr. Cardiol. PD MAY-JUN PY 2007 VL 16 IS 3 BP 143 EP 149 DI 10.1111/j.1076-7460.2007.06696.x PG 7 WC Cardiac & Cardiovascular Systems; Geriatrics & Gerontology SC Cardiovascular System & Cardiology; Geriatrics & Gerontology GA 164LN UT WOS:000246235300003 PM 17483665 ER PT J AU Chodosh, J Kado, DM Seeman, TE Karlamangla, AS AF Chodosh, Joshua Kado, Deborah M. Seeman, Teresa E. Karlamangla, Arun S. TI Depressive symptoms as a predictor of cognitive decline: MacArthur studies of successful aging SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE depression; dementia; distress; cognitive decline ID MENTAL STATUS QUESTIONNAIRE; ALZHEIMERS-DISEASE; OLDER PERSONS; INFLAMMATORY MARKERS; RISK-FACTOR; FOLLOW-UP; COMMUNITY; DEMENTIA; IMPAIRMENT; ASSOCIATION AB Objective: The prevalence of dementia continues to rise, and yet, there are few known modifiable risk factors. Depression, as a treatable condition, may be important in the development of dementia. Our objective was to examine the association between depressive symptoms and longitudinal cognitive changes in older adults who were high-functioning at baseline. Methods: The authors analyzed data from a community-based cohort (aged 70-79 at baseline), who, at study entry, scored 7 or more (out of 9) on the Short Portable Mental Status Questionnaire (SPMSQ). Depressive symptoms were assessed at baseline using the depression subscale of the Hopkins Symptom Check List. Cognitive performance was measured at baseline and at seven-year follow up by the SPMSQ and by summary scores from standard tests of naming, construction, spatial recognition, abstraction, and delayed recall. Results: After adjusting for potential confounders, including age, education, and chronic health conditions such as diabetes, heart attack, stroke, and hypertension, a higher number of baseline depressive symptoms were strongly associated with greater seven-year decline in cognitive performance and with higher odds of incident cognitive impairment, i.e., decline in SPMSQ score to <= 6 (adjusted odds ratio per quartile of depressive symptoms score: 1.34, 95% confidence interval: 1.10-1.68). Conclusions: Depressive symptomatology independently predicts cognitive decline and incident cognitive impairment in previously high-functioning older persons. C1 VA Greater Los Angeles Hlth Syst, HSR&D COE, Los Angeles, CA 90073 USA. VA Greater Los Angeles Hlth Syst, GRECC, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90024 USA. RP Chodosh, J (reprint author), VA Greater Los Angeles Hlth Syst, HSR&D COE, 11G,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jchodosh@mednet.ucla.edu OI Chodosh, Joshua/0000-0001-7784-4306 FU NIA NIH HHS [1K12AG01004, AG-17056, AG-17265] NR 51 TC 68 Z9 69 U1 5 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAY PY 2007 VL 15 IS 5 BP 406 EP 415 DI 10.1097/01.JGP.0b013e31802c0c63 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 165IZ UT WOS:000246299600006 PM 17353297 ER PT J AU McFarland, LV Beneda, HW Clarridge, JE Raugi, GJ AF McFarland, Lynne V. Beneda, Henry W. Clarridge, Jill E. Raugi, Gregory J. TI Implications of the changing face of Clostridium difficile disease for health care practitioners SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Review ID ANTIBIOTIC-ASSOCIATED DIARRHEA; BINARY-TOXIN GENES; PROTON PUMP INHIBITORS; INFECTION-CONTROL; RISK-FACTORS; NOSOCOMIAL TRANSMISSION; HOSPITALIZED-PATIENTS; ENVIRONMENTAL CONTAMINATION; INTRAVENOUS IMMUNOGLOBULIN; PIPERACILLIN-TAZOBACTAM AB Recent reported outbreaks of Clostridium difficile-associated disease in Canada have changed the profile of C difficile infections. Historically C difficile disease was thought of mainly as a nosocomial disease associated with broad-spectrum antibiotics, and the disease was usually riot life threatening. The ernergence of an epidemic strain, BI/NAPI/027, which produces a binary toxin in addition to the 2 classic C difficile toxins A and B and is resistant to some fluoroquinolones, was associated with large numbers of cases with high rates of mortality Recently, C difficile has been reported more frequently in non hospital-based settings, such as community-acquired cases. The C difficile disease is also being reported in populations once considered of low risk (children and young healthy women). In addition, poor response to metronidazole treatment is increasing, Faced with an increasing incidence of C difficile infections and the changing profile of patients who become infected, this paper will reexamine the current concepts on the epidemiology and treatment of C difficile-associated disease, present new hypotheses for risk factors, examine the role of spores in the transmission of C difficile, and provide recommendations that may enhance infection control practices. C1 VA Puget Sound Hlth Care Syst, Dept Hlth Serv Res & Dev, Seattle, WA 98101 USA. Univ Washington, Dept Med Chem, Seattle, WA 98195 USA. Univ Washington, Sch Pharm, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Dept Infect Control, Seattle, WA 98101 USA. VA Puget Sound Hlth Care Syst, Lab Serv, Seattle, WA 98101 USA. Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. Vet Adm Puget Sound Hlth Care Syst, Dermatol Sect, Primary & Specialty Serv, Seattle, WA USA. Univ Washington, Div Dermatol, Dept Med, Seattle, WA 98195 USA. RP McFarland, LV (reprint author), VA Puget Sound Hlth Care Syst, Dept Hlth Serv Res & Dev, S152,1100 Olive Way 1400, Seattle, WA 98101 USA. EM Lynne.McFarland@va.gov NR 171 TC 64 Z9 65 U1 2 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAY PY 2007 VL 35 IS 4 BP 237 EP 253 DI 10.1016/j.ajic.2006.06.004 PG 17 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 168BY UT WOS:000246498500006 PM 17482995 ER PT J AU Wyatt, C Konduri, V Eng, J Rohatgi, R AF Wyatt, Christina Konduri, Vinaya Eng, John Rohatgi, Rajeev TI Reporting of estimated GFR in the primary care clinic SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE glomerular filtration rate; chronic kidney disease; angiotensin-converting enzyme inhibitor; angiotensin receptor blocker; blood pressure control ID CHRONIC RENAL-INSUFFICIENCY; CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; QUALITY-OF-CARE; CONVERTING-ENZYME INHIBITOR; CARDIOVASCULAR EVENTS; SERUM CREATININE; CKD; NEPHROPATHY; DEFINITION AB Background: Because serum creatinine is an insensitive measure of kidney dysfunction, guidelines have advocated routine use of estimated glomerular filtration rate (eGFR) to identify patients with chronic kidney disease (CKD). Patients with early (stage 3) CKD remain undiagnosed in primary care clinics; therefore, we hypothesized that routine reporting of eGFR in outpatient clinics would improve the recognition and treatment of CKD. Methods: A retrospective review of primary care patients was undertaken at the Bronx Veterans Affairs Medical Center, Bronx, New York, before and after the institution of routine eGFR reporting. We evaluated the achievement of diagnostic and therapeutic treatment goals based on the Kidney Disease Outcomes Quality Initiative guidelines (documentation of CKD, urinalysis assessment, blood pressure < 130/80 mm Hg, and renin-angiotensin system blockade) for patients with stage 3 CKD during each period. Results: Overall, patients with diabetes with early-stage CKD achieved superior treatment rates than similar patients without diabetes. Routine reporting of eGFR improved the documentation and identification of CKD by almost 50%, although absolute improvement was modest. Use of renin-angiotensin system blockers improved minimally, as did blood pressure control. Patients with documented CKD achieved treatment goals more frequently than patients without documented CKD. Conclusion: Routine reporting of eGFR alone modestly improved the identification of patients with CKD without a clinically significant effect on care. For Modification of Diet in Renal Disease Study calculation of eGFR reporting to effect improvements in CKD care, it will be necessary to pair eGFR reporting with provider education to identify these patients and treat them effectively. C1 CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. Highland Hosp, Dept Med, Rochester, NY 14620 USA. Bronx Vet Affairs Med Ctr, Dept Med, Bronx, NY USA. RP Rohatgi, R (reprint author), CUNY Mt Sinai Sch Med, Dept Med, Box 1243,1 Gustave L Levy Pl, New York, NY 10029 USA. EM rajeev.rohatgi@mssm.edu NR 27 TC 46 Z9 47 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAY PY 2007 VL 49 IS 5 BP 634 EP 641 DI 10.1053/j.ajkd.2007.02.258 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 197QG UT WOS:000248570100011 PM 17472845 ER PT J AU Aspinall, SL Metlay, JP Maselli, JH Gonzales, R AF Aspinall, Sherrie L. Metlay, Joshua P. Maselli, Judith H. Gonzales, Ralph TI Impact of hospital formularies on fluoroquinolone prescribing in emergency departments SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article; Proceedings Paper CT 43rd Annual Meeting of the Infectious-Diseases-Society-of-America CY OCT 06-09, 2005 CL San Francisco, CA SP Infect Dis Soc Amer ID COMMUNITY-ACQUIRED PNEUMONIA; RESISTANT STREPTOCOCCUS-PNEUMONIAE; RESPIRATORY-TRACT INFECTIONS; UNITED-STATES; RISK-FACTORS; CLOSTRIDIUM-DIFFICILE; EDUCATIONAL-METHODS; ANTIBIOTIC-THERAPY; MANAGEMENT; MORTALITY AB Objective: To examine factors associated with fluoroquinolone prescribing among adults receiving antibiotics for acute respiratory tract infections (ARIs) in emergency departments. Study Design: Cross-sectional. Methods: We analyzed data from 8 Department of Veterans Affairs medical centers and 7 nonfederal US hospitals. At each hospital, we randomly sampled 200 ARI visits with International Classification of Diseases, Ninth Revision discharge diagnoses for nonspecific upper respiratory infections, acute bronchitis, pharyngitis, sinusitis, and pneumonia between November 1, 2003, and February 29, 2004. Patient and provider factors associated with each visit were extracted from medical records. System characteristics were obtained by surveying pharmacy directors. Multivariate logistic regression was used to evaluate independent predictors of fluoroquinolone prescribing. Results: Fluoroquinolones accounted for 14% of these prescriptions. At hospitals with at least 1 unrestricted fluoroquinolone on formulary (n = 12) , the average fluoroquinolone prescription rate was 17%, compared with a 6% prescription rate at hospitals were fluoroquinolone access was restricted by the hospital formulary (n = 3) (P < .0001). Factors associated with increased fluoroquinolone prescription rates were hospital admission (odds ratio [OR] = 1.8; 95% confidence interval [CI] = 1.1, 3.1) and the diagnoses of acute bronchitis (OR = 2.3; 95% CI = 1.3, 4.2), acute exacerbations of chronic bronchitis (OR = 2.6; 95% CI = 1.2, 5.6), and pneumonia (OR = 6.4; 95% CI = 3.3. 12.4). Restricted hospital status was associated with decreased fluoroquinolones accounted for 14% of the antibiotic prescriptions. Conclusions: Hospital formulary policies represent a potentially important target for influencing out-patient drug prescribing in emergency departments. C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA. RP Aspinall, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot 151C U, Univ Dr C, Pittsburgh, PA 15240 USA. EM sherrie.aspinall@va.gov FU AHRQ HHS [R01-HS13915] NR 32 TC 5 Z9 5 U1 0 U2 0 PU AMER MED PUBLISHING, M W C COMPANY PI JAMESBURG PA 241 FORSGATE DR, STE 102, JAMESBURG, NJ 08831 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD MAY PY 2007 VL 13 IS 5 BP 241 EP 248 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 169AI UT WOS:000246564700005 PM 17488189 ER PT J AU Phillips-Edwards, A Collins-Smith, R Del Rio, GC Brown, C Wu, L Singh, H AF Phillips-Edwards, Althea Collins-Smith, Ruth Del Rio, Gustavo Camacho Brown, Carmen Wu, Louis Singh, Hardeep TI 'ALLHAT' and innovations in nursing SO AMERICAN JOURNAL OF NURSING LA English DT Editorial Material ID BLOOD-PRESSURE-MEASUREMENT; LIPID-LOWERING TREATMENT; ATTACK TRIAL ALLHAT; PRIMARY-CARE; SPHYGMOMANOMETERS; SUBCOMMITTEE; HYPERTENSION; COMMITTEE C1 Michael E DeBakey Vet Affairs Med Ctr, Primary Care Sect, Houston, TX USA. Michael E DeBakey Vet Affairs Med Ctr, Gen Med Sect, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Phillips-Edwards, A (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Primary Care Sect, Houston, TX USA. EM Phillips-Edwards.Althea@houston.med.va.gov NR 23 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-936X J9 AM J NURS JI Am. J. Nurs. PD MAY PY 2007 VL 107 IS 5 BP 72C EP + PG 5 WC Nursing SC Nursing GA 166NC UT WOS:000246384700031 ER PT J AU Chang, DS Barack, BM Lee, MH Lee, HY AF Chang, Donald S. Barack, Bruce M. Lee, Margaret H. Lee, Hsin-Yi TI Congenitally corrected transposition of the great arteries: Imaging with 16-MDCT SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE angiography; cardiac imaging; cardiovascular disease; congenital; CT ID ANATOMY; ADULT; VENTRICLE C1 VA Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Imaging Serv, Los Angeles, CA 90073 USA. Olive View UCLA Med Ctr, Dept Radiol, Sylmar, CA 91342 USA. RP Chang, DS (reprint author), VA Greater Los Angeles Healthcare Syst, Div Cardiol, 11301 Wilshire Blvd 111E, Los Angeles, CA 90073 USA. EM dchang@ucla.edu NR 9 TC 6 Z9 6 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAY PY 2007 VL 188 IS 5 BP W428 EP W430 DI 10.2214/AJR.05.0636 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 161KE UT WOS:000246013000052 PM 17449738 ER PT J AU Gutierrez, AJ Freitas, AD Modarresi, S Masih, S AF Gutierrez, A. J. Freitas, A. D. Modarresi, S. Masih, S. TI Radiologic-Orthopedic Correlation of Laymen Terms for Sports Injuries SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Meeting Abstract C1 [Gutierrez, A. J.] Univ Calif Los Angeles, Med Ctr, Dept Radiol, Los Angeles, CA 90024 USA. [Freitas, A. D.; Modarresi, S.; Masih, S.] Vet Adm Greater Los Angeles, Dept Radiol, Los Angeles, CA USA. EM agut95@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAY PY 2007 VL 188 IS 5 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA V04XA UT WOS:000207089900625 ER PT J AU Larsen, LH Meiselman, S Iyengar, G Klipfel, N Chantra, PK Palmer, S AF Larsen, Hovanessian L. Meiselman, S. Iyengar, G. Klipfel, N. Chantra, P. K. Palmer, S. TI Granulomatous Mastitis: An Update of Clinical, Imaging, and Pathological Features Reported in a Large Series of 35 Cases SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Meeting Abstract C1 [Larsen, Hovanessian L.; Meiselman, S.; Iyengar, G.; Klipfel, N.; Palmer, S.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Chantra, P. K.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. EM lhovanes@usc.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAY PY 2007 VL 188 IS 5 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA V04XA UT WOS:000207089900288 ER PT J AU Lee, EW Masih, S Alex, FD Modarresi, S AF Lee, E. W. Masih, S. Alex, F. D. Modarresi, S. TI MRI and CT Diagnosis of Previously Missed Occult Fractures SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Meeting Abstract C1 [Lee, E. W.] Univ Calif Los Angeles, Med Ctr, Dept Radiol, Los Angeles, CA 90024 USA. [Masih, S.; Alex, F. D.; Modarresi, S.] Vet Adm Greater Los Angeles, Dept Radiol, Los Angeles, CA USA. EM EdwardLee@mednet.ucla.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAY PY 2007 VL 188 IS 5 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA V04XA UT WOS:000207089900628 ER PT J AU Lee, EW Modarresi, S Masih, S Freitas, AD AF Lee, E. W. Modarresi, S. Masih, S. Freitas, A. D. TI MRI and CT Evaluation of Shoulder Pain and Weakness Caused by Nerve Compression SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Meeting Abstract C1 [Lee, E. W.] Univ Calif Los Angeles, Med Ctr, Dept Radiol, Los Angeles, CA 90024 USA. [Modarresi, S.; Masih, S.; Freitas, A. D.] Vet Adm Greater Los Angeles, Dept Radiol, Los Angeles, CA USA. EM EdwardLee@mednet.ucla.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAY PY 2007 VL 188 IS 5 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA V04XA UT WOS:000207089900589 ER PT J AU Matin, A Masih, S Freitas, AD Modarresi, S Learch, TJ AF Matin, A. Masih, S. Freitas, A. D. Modarresi, S. Learch, T. J. TI MRI Pictorial Review of Bursal Anatomy and Pathology SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Meeting Abstract C1 [Matin, A.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. [Learch, T. J.] Univ So Calif, Univ Hosp, Los Angeles, CA USA. [Masih, S.; Freitas, A. D.; Modarresi, S.] Vet Adm Greater Los Angeles, Los Angeles, CA USA. EM amatin@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAY PY 2007 VL 188 IS 5 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA V04XA UT WOS:000207089900541 ER PT J AU Butt, AA Tsevat, J Ahmad, J Shakil, AO Mrus, JM AF Butt, Adeel A. Tsevat, Joel Ahmad, Jawad Shakil, A. Obaid Mrus, Joseph M. TI Biochemical and virologic parameters in patients co-infected with hepatitis C and HIV versus patients with hepatitis C mono-infection SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article ID IMMUNODEFICIENCY-VIRUS-INFECTION; ALPHA-2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA-2A; LIVER-DISEASE; VIREMIA; COINFECTION; DIAGNOSIS; MORTALITY; GENOTYPE; IMPACT AB Background. Previous studies of patients with hepatitis C virus (HCV) infection looking at the effect of human immunodeficiency virus (HIV) co-infection on biochemical parameters and HCV RNA level have shown conflicting results. Accurate characterization of the effect of HIV is important for evaluation and treatment of HCV in co-infected persons. Methods: We studied 315 HCV mono-infected and 75 HCV-HIV coinfected subjects to determine the effect of HIV on biochemical parameters and HCV RNA and to determine the predictors of elevated serum alanine aminotransferase (ALT) levels and HCV RNA levels. Results: The co-infected subjects were more likely to be African-American (55% vs 26%, P < 0.0005), have used injection drugs (68% vs 60%, P = 0.02), have detectable HCV RNA (84% vs 70.5%, P = 0.018), have HCV RNA levels > 6 log(10) IU/mL (60% vs 38%, P = 0.001), and have lower mean serum ALT levels (50.4 IU/mL vs 73.7 IU/mL, P = 0.006). In multivariable analyses, the following factors predicted an ALT level > 50 IU/mL: log,0 HCV RNA (OR, 1.15; 95% CI, 1.00 to 1.32); HIV co-infection (OR, 0.48; 95% CI, 0.25 to 0.89); and having ever been treated for HCV (OR, 1.92; 95% CI, 1.16 to 3.18). The only significant predictor of HCV RNA level > 6 log,0 IU/mL was HIV co-infection (OR, 2.75; 95% CI, 1.46 to 5.15). Significant predictors of having a detectable HCV RNA level were female sex (OR, 3.81; 95% CI, 1.18 to 12.25); HIV co-infection (2.45; 95% CI, 1.14 to 5.26); and ever being treated for HCV (OR, 1.96; 95% CI, 1.10 to 3.48). Conclusions: HCV-HIV co-infected persons have higher HCV RNA levels but lower serum ALT levels than HCV mono-infected patients. Criteria for performing liver biopsy and treating HCV infection in co-infected patients may need to be revisited. C1 Univ Pittsburgh, Med Ctr, Div Infect Dis, VA Pittsburgh Healthcare Syst,Ctr Hlth Equ Res &, Pittsburgh, PA 15213 USA. Vet Healthcare Syst Ohio, Cincinnati, OH USA. Univ Cincinnati, Med Ctr, Dept Internal Med, Cincinnati, OH 45267 USA. Univ Cincinnati, Med Ctr, Inst Study Hlth, Cincinnati, OH 45267 USA. Univ Pittsburgh, Med Ctr, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. RP Butt, AA (reprint author), Univ Pittsburgh, Med Ctr, Div Infect Dis, VA Pittsburgh Healthcare Syst,Ctr Hlth Equ Res &, 3601 5th Ave,Suite 3A,Falk Med Bldg, Pittsburgh, PA 15213 USA. EM butta@dom.pitt.edu FU AHRQ HHS [1-R03-HS13220-01]; NCCIH NIH HHS [1-R01-AT01147, K24 AT001676]; NIAID NIH HHS [U01-AI-25897]; NIDA NIH HHS [1-K23-DA016175-01A1] NR 18 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-9629 J9 AM J MED SCI JI Am. J. Med. Sci. PD MAY PY 2007 VL 333 IS 5 BP 271 EP 275 DI 10.1097/MAJ.0b013e31805341f0 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 173VS UT WOS:000246901200003 PM 17505167 ER PT J AU Akoad, M Francis, F Wagener, M Cacciarelli, TV AF Akoad, Mohamed Francis, Fadi Wagener, Marilyn Cacciarelli, Thomas V. TI The impact of recipient disease severity on outcome with the use of extended criteria donors in liver transplantation. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT Annual American Transplant Congress CY MAY 05-09, 2007 CL San Francisco, CA C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2007 VL 7 SU 2 MA 84 BP 168 EP 168 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 166HQ UT WOS:000246370200085 ER PT J AU Streblow, D Kreklywich, C Moses, A Andoh, T Nelson, J Orloff, SL AF Streblow, Daniel Kreklywich, Crai Moses, Ashlee Andoh, Takeshi Nelson, Jay Orloff, Susan L. TI Activation of tissue repair/angiogenesis genes during CMV-accelerated transplant vascular sclerosis in rat cardiac allografts. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT Annual American Transplant Congress CY MAY 05-09, 2007 CL San Francisco, CA C1 Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Portland, OR USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2007 VL 7 SU 2 MA 642 BP 315 EP 315 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 166HQ UT WOS:000246370201078 ER PT J AU Akoad, M Francis, F Wagener, MM Cacciarelli, TV AF Akoad, Mohamed Francis, Fadi Wagener, Marilyn M. Cacciarelli, Thomas V. TI The adverse impact of orthotopic liver retransplantation (re-OLT) and hepatitis C virus infection on graft survival: A single center experience. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT Annual American Transplant Congress CY MAY 05-09, 2007 CL San Francisco, CA C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2007 VL 7 SU 2 MA 1575 BP 552 EP 552 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 166HQ UT WOS:000246370202440 ER PT J AU Randhawa, IS Junaid, I Klaustermeyer, WB AF Randhawa, Inderpal Singh Junaid, Imran Klaustermeyer, William B. TI Allergen immunotherapy in a patient with human immunodeficiency virus: effect on T-cell activation and viral replication SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Article ID PLACEBO-CONTROLLED TRIAL; ANTIRETROVIRAL THERAPY; INFLUENZA IMMUNIZATION; CHILDREN; HIV AB Background: Allergen immunotherapy is a major therapeutic modality in the treatment of allergic rhinitis. However, with T-cell activation potential, its role in patients with human immunodeficiency virus (HIV) was theoretically limited. Objective: To report the results of allergen immunotherapy in a patient with HIV treated with highly active antiretroviral therapy (HAART). Methods: A 44-year-old man with a history of HIV did not respond to medical therapy for allergic rhinitis. His HIV status was well controlled with HAART. Owing to the severity of his allergic rhinitis symptoms, he accepted the risk of allergy immunotherapy despite the unknown effect of immunotherapy in patients with HIV. Results: After 6 weeks of weekly immunotherapy injections, his viral load remained undetectable and his CD4 cell count changed from 540 to 570 cells/mu L. After 16 weeks of weekly immunotherapy, his viral load increased to 10,900 copies/mL, and his CD4 cell count increased to 665 cells/mu L. After 24 weeks of weekly immunotherapy, his viral load returned to an undetectable level, and his CD4 cell count stabilized at 356 cells/mu L. Despite his notable change in HIV status, he continues to receive the same HAART. He currently continues en route to maintenance immunotherapy. Conclusions: The effect of allergen immunotherapy on HIV infection has not been previously reported. A concern remains that any form of immunotherapy may negatively affect HIV disease progression. This case illustrates that weekly allergen immunotherapy may have induced limited T-cell proliferation and a modest increase in RNA viral load, which resolved with continuation of HAART. C1 Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Randhawa, IS (reprint author), Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd,Suite 111R, Los Angeles, CA 90073 USA. EM docrandhawa@yahoo.com NR 11 TC 10 Z9 11 U1 0 U2 0 PU AMER COLL ALLERGY ASTHMA IMMUNOLOGY PI ARLINGTON HTS PA 85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA SN 1081-1206 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD MAY PY 2007 VL 98 IS 5 BP 495 EP 497 PG 3 WC Allergy; Immunology SC Allergy; Immunology GA 170GQ UT WOS:000246651200014 PM 17521037 ER PT J AU Parchman, ML Pugh, JA Romero, RL Bowers, KW AF Parchman, Michael L. Pugh, Jacqueline A. Romero, Raquel L. Bowers, Krista W. TI Competing demands or clinical inertia: The case of elevated glycosylated hemoglobin SO ANNALS OF FAMILY MEDICINE LA English DT Article; Proceedings Paper CT 33rd Annual Meeting of the North-American-Primary-Care-Research-Group CY OCT 15-18, 2005 CL Quebec City, CANADA SP N Amer Primary Care Res Grp DE diabetes mellitus, type 2; hemoglobin A, glycosylated; ambulatory care; primary care; health care delivery; health services research; quality of care; practice-based research networks; office visits ID PRIMARY-CARE PHYSICIANS; DIABETES-MELLITUS; GLYCEMIC CONTROL; MANAGEMENT; RISK; AMERICANS; DISEASES; THERAPY; ADULTS AB PURPOSE This study aimed to examine the contribution of competing demands to changes in hypoglycemic medications and to return appointment intervals for patients with type 2 diabetes and an elevated glycosylated hemoglobin (A(1c)) level. METHODS We observed 211 primary care encounters by adult patients with type 2 diabetes in 20 primary care clinics and documented changes in hypoglycemic medications. Competing demands were assessed from length of encounter, number of concerns patients raised, and number of topics brought up by the clinician. Days to the next scheduled appointment were obtained at patient checkout. Recent A,, values and dates were determined from the chart. RESULTS Among patients with an A,, level greater than 7%, each additional patient concern was associated with a 49% (95% confidence interval, 35%-60%) reduction in the likelihood of a change in medication, independent of length of the encounter and most recent level of A,,. Among patients with an A,, level greater than 7% and no change in medication, for every additional minute of encounter length, the time to the next scheduled appointment decreased by 2.8 days (P = .001). Similarly, for each additional 1% increase in A,, level, the time to the next scheduled appointment decreased by 8.6 days (P = .001). CONCLUSIONS The concept of clinical inertia is limited and does not fully characterize the complexity of primary care encounters. Competing demands is a principle for constructing models of primary care encounters that are more congruent with reality and should be considered in the design of interventions to improve chronic disease outcomes in primary care settings. C1 S Texas Vet Hlth Care Syst, VERDICT Hlth Serv Res Ctr, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Family & Community Med, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. RP Parchman, ML (reprint author), S Texas Vet Hlth Care Syst, VERDICT 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM parchman@uthscsa.edu OI Parchman, Michael/0000-0001-7129-2889; Pugh, Jacqueline/0000-0003-4933-141X FU AHRQ HHS [K08 HS013008-02] NR 29 TC 117 Z9 118 U1 0 U2 4 PU ANNALS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672, UNITED STATES SN 1544-1709 J9 ANN FAM MED JI Ann. Fam. Med. PD MAY-JUN PY 2007 VL 5 IS 3 BP 196 EP 201 DI 10.1370/afm.679 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 183FK UT WOS:000247557900002 PM 17548846 ER PT J AU Lynn, J Baily, MA Bottrell, M Jennings, B Levine, RJ Davidoff, F Casarett, D Corrigan, J Fox, E Wynia, MK Agich, GJ O'Kane, M Speroff, T Schyve, P Batalden, P Tunis, S Berlinger, N Cronenwett, L Fitzmaurice, JM Dubler, NN James, B AF Lynn, Joanne Baily, Mary Ann Bottrell, Melissa Jennings, Bruce Levine, Robert J. Davidoff, Frank Casarett, David Corrigan, Janet Fox, Ellen Wynia, Matthew K. Agich, George J. O'Kane, Margaret Speroff, Theodore Schyve, Paul Batalden, Paul Tunis, Sean Berlinger, Nancy Cronenwett, Linda Fitzmaurice, J. Michael Dubler, Nancy Neveloff James, Brent TI The ethics of using quality improvement methods in health care SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID CLINICAL-RESEARCH; SERVICES RESEARCH; UNITED-STATES; DELIVERY; IMPACT AB Quality improvement (QI) activities can improve health care but must be conducted ethically. The Hastings Center convened leaders and scholars to address ethical requirements for QI and their relationship to regulations protecting human subjects of research. The group defined QI as systematic, data-guided activities designed to bring about immediate improvements in health care delivery in particular settings and concluded that Ql is an intrinsic part of normal health care operations. Both clinicians and patients have an ethical responsibility to participate in QI, provided that it complies with specified ethical requirements. Most QI activities are not human subjects research and should not undergo review by an institutional review board; rather, appropriately calibrated supervision of QI activities should be part of professional supervision of clinical practice. The group formulated a framework that would use key characteristics of a project and its context to categorize it as QI, human subjects research, or both, with the potential of a customized institutional review board process for the overlap category. The group recommended a period of innovation and evaluation to refine the framework for ethical conduct of QI and to integrate that framework into clinical practice. C1 Hastings Ctr, Garrison, NY 10524 USA. RAND Corp, Washington, DC USA. Vet Hlth Adm, Natl Qual Forum, Washington, DC USA. Natl Comm Qual Assurance, Washington, DC USA. Montefiore Med Ctr, Bronx, NY 10467 USA. Vet Hlth Adm, Seattle, WA USA. Yale Univ, New Haven, CT USA. Inst Healthcare Improvement, Cambridge, MA USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. Amer Med Assoc, Chicago, IL 60610 USA. Joint Commiss Accreditat Healthcare Org, Oak Brook Terrace, IL USA. Bowling Green State Univ, Bowling Green, OH 43403 USA. Vanderbilt Univ, Ctr Med, Nashville, TN 37232 USA. Dartmouth Coll Sch Med, Hanover, NH USA. Hlth Tech, San Francisco, CA USA. Univ N Carolina, Chapel Hill, NC USA. Agcy Hlth Care Policy & Res, Rockville, MD USA. Intermt Inst Hlth Care Delivery Res, Salt Lake City, UT USA. RP Baily, MA (reprint author), Hastings Ctr, 21 Malcolm Gordan Rd, Garrison, NY 10524 USA. EM bailym@thehastingscenter.org FU AHRQ HHS [1R13HS13369] NR 32 TC 124 Z9 125 U1 3 U2 9 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 1 PY 2007 VL 146 IS 9 BP 666 EP 673 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 162EV UT WOS:000246070500006 PM 17438310 ER PT J AU Shrank, W Avorn, J Rolon, C Shekelle, P AF Shrank, William Avorn, Jerry Rolon, Cony Shekelle, Paul TI Effect of content and format of prescription drug labels on readability, understanding, and medication use: A systematic review SO ANNALS OF PHARMACOTHERAPY LA English DT Review DE patient information; prescription drug label ID PHYSICIAN-PATIENT COMMUNICATION; THE-COUNTER MEDICATIONS; INFORMATION LEAFLETS; DECISION-MAKING; ANTIRETROVIRAL THERAPY; PHARMACOLOGICAL CARE; ELDERLY PATIENTS; GENERAL-PRACTICE; AMBULATORY-CARE; HEALTH LITERACY AB OBJECTIVE: To evaluate the evidence regarding the optimal content and format of prescription labels that might improve readability, understanding, and medication use. DATA SOURCES: We performed a systematic review of randomized controlled trials, observational studies, and systematic reviews from MEDLINE and the Cochrane Database (1990-June 2005), supplemented by reference mining and reference lists from a technical expert panel. STUDY SELECTION: We selected studies that focused on the content of physician-patient communication about medications and the content and format of prescription drug labels. DATA EXTRACTION: Two reviewers extracted and synthesized information about study design, populations, and outcomes. DATA SYNTHESIS: Of 2009 articles screened, 36 that addressed the content of physician-patient communication about medications and 69 that were related to the content or format of medication labels met review criteria. Findings showed that patients request information about a drug's indication, expected benefits, duration of therapy, and a thorough list of potential adverse effects. The evidence about label format supports the use of larger fonts, lists, headers, and white space, using simple language and logical organization to improve readability and comprehension. Evidence was not sufficient to support the use of pictographic icons, Little evidence linked label design or content to measurable health outcomes, adherence, or safety. CONCLUSIONS: Evidence suggests that specific content and format of prescription drug labels facilitate communication with and comprehension by patients. Efforts to improve the labels should be guided by such evidence, although additional study assessing the influence of label design on medication-taking behavior and health outcomes is needed. Several policy options exist to require minimal standards to optimize medical therapy, particularly in light of the new Medicare prescription drug benefit. C1 Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA. So Calif EPC RAND, Santa Monica, CA USA. Greater Los Angeles Vet Affairs Healthcare Syst, Div Gen Internal Med, Santa Monica, CA USA. RP Shrank, W (reprint author), 1620 Tremont St,Suite 3030, Boston, MA 02120 USA. EM wshrank@partners.org NR 136 TC 58 Z9 60 U1 3 U2 17 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD MAY PY 2007 VL 41 IS 5 BP 783 EP 801 DI 10.1345/aph.1H582 PG 19 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 165CG UT WOS:000246280800008 PM 17426075 ER PT J AU Hu, G Taylor, AB McAlister-Henn, L Hart, PJ AF Hu, Gang Taylor, Alexander B. McAlister-Henn, Lee Hart, P. John TI Crystal structure of the yeast nicotinamidase Pnc1p SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Article DE Nicotinamidase; Sir2p; X-ray crystallography; kinetic analyses; NAD(+); multiple isomorphous replacement; multiwavelength anomalous diffraction ID LIFE-SPAN EXTENSION; N-CARBAMOYLSARCOSINE AMIDOHYDROLASE; DEPENDENT ISOCITRATE DEHYDROGENASE; NAD(+) SALVAGE PATHWAY; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; MYCOBACTERIUM-TUBERCULOSIS; GENE; SIR2; PYRAZINAMIDE AB The yeast nicotinamidase Pnc1p acts in transcriptional silencing by reducing levels of nicotinamide, an inhibitor of the historic deacetylase Sir2p. The Pnc1p structure was determined at 2.9 A resolution using MAD and MIRAS phasing methods after inadvertent crystallization during the pursuit of the structure of histidine-tagged yeast isocitrate dehydrogenase (IDH). Pnc1p displays a cluster of surface histidine residues likely responsible for its co-fractionation with IDH from Ni2+-coupled chromatography resins. Researchers expressing histidine-tagged proteins in yeast should be aware of the propensity of Pnc1p to crystallize, even when overwhelmed in concentration by the protein of interest. The protein assembles into extended helical arrays interwoven to form an unusually robust, yet porous superstructure. Comparison of the Pnc1p structure with those of three homologous bacterial proteins reveals a common core fold punctuated by amino acid insertions unique to each protein. These insertions mediate the self-interactions that define the distinct higher order oligomeric states attained by these molecules. Pnc1p also acts on pyrazinamide, a substrate analog converted by the nicotinamidase from Mycobacterium tuberculosis into a product toxic to that organism. However, we find no evidence for detrimental effects of the drug on yeast cell growth. (c) 2007 Elsevier Inc. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Xray Crystallog Core Lab, San Antonio, TX 78285 USA. Univ Texas, Hlth Sci Ctr, Geriatr Res Educ & Clin Ctr, Dept Vet Affairs,S Texas Vet Hlth Care Syst, San Antonio, TX 78285 USA. RP McAlister-Henn, L (reprint author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM henn@uthscsa.edu; pjhart@biochem.uthsesa.edu FU NIGMS NIH HHS [R01 GM051265, GM051265, R01 GM051265-12] NR 45 TC 19 Z9 22 U1 2 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD MAY 1 PY 2007 VL 461 IS 1 BP 66 EP 75 DI 10.1016/j.abb.2007.01.037 PG 10 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 165RS UT WOS:000246323800009 PM 17382284 ER PT J AU Belogrudov, GI AF Belogrudov, Grigory I. TI A 24-residue presequence localizes human factor B to mitochondria SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Article DE factor B; presequence; precursor; mitochondria; confocal microscopy; HEK293 cells ID COUPLING FACTOR-B; BOVINE FACTOR-B; OXIDATIVE-PHOSPHORYLATION; ATP SYNTHESIS; PURIFICATION; TRANSLATION; SEQUENCES; SIGNAL; EXPORT AB We reported previously that the human factor B precursor is a 215-amino acid polypeptide, the first 40 amino acid residues of which function as a mitochondrial targeting presequence [G.I. Belogrudov, Y. Hatefi, J. Biol. Chem. 277 (2002) 6097-6103]. Confocal microscopy of live HEK293 cells, transiently transfected with factor B constructs tagged at the C-terminus with green fluorescent protein (GFP) revealed that either a 40- or 25-residue presequence localized factor B to mitochondria. Indirect immunofluorescent labeling of fixed, permeabilized HEK293 cells that were transiently transfected with a construct lacking a presequence, showed diffuse, intracellular staining that was consistent with targeting of ectopically expressed factor B to cellular compartments distinct from the mitochondria. Mutants in which either Met(-25) or both Met(-25)/Met(-24) residues of the presequence were deleted exhibited decreased or undetectable levels, respectively, of the GFP-tagged factor B. The factor B presequence alone was shown to target a reporter polypeptide GFP to mitochondria. Our studies, therefore, demonstrate that a 24-residue presequence is sufficient to localize factor B to mitochondria, and suggest that the human factor B precursor is a 199-amino acid polypeptide. (c) 2007 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Belogrudov, GI (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 113,Rm 324, Los Angeles, CA 90073 USA. EM gbelo@ucla.edu FU NIGMS NIH HHS [R01 GM066085] NR 21 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD MAY 1 PY 2007 VL 461 IS 1 BP 95 EP 103 DI 10.1016/j.abb.2007.01.032 PG 9 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 165RS UT WOS:000246323800012 PM 17359931 ER PT J AU Marra, DE Pourrabbani, S Fincher, EF Moy, RL AF Marra, Diego E. Pourrabbani, Shahram Fincher, Edgar F. Moy, Ronald L. TI Fractional photothermolysis for the treatment of adult colloid milium SO ARCHIVES OF DERMATOLOGY LA English DT Article C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Dept Internal Med, Los Angeles, CA USA. RP Moy, RL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 100 UCLA Med Plaza,Suite 590, Los Angeles, CA 90024 USA. EM rmoy@ucla.edu NR 11 TC 21 Z9 23 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD MAY PY 2007 VL 143 IS 5 BP 572 EP 574 DI 10.1001/archderm.143.5.572 PG 3 WC Dermatology SC Dermatology GA 167UF UT WOS:000246477300002 PM 17515508 ER PT J AU Primack, BA Switzer, GE Dalton, MA AF Primack, Brian A. Switzer, Galen E. Dalton, Madeline A. TI Improving measurement of normative beliefs involving smoking among adolescents SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID CIGARETTE-SMOKING; PSYCHOSOCIAL PREDICTORS; POPULAR FILMS; HIGH-SCHOOL; TOBACCO USE; PREVALENCE; INTENTIONS; INITIATION; BEHAVIORS; PROMOTION AB Objectives: To identify different components of smoking normative beliefs and determine if each component is independently associated with 2 clinically relevant measures of smoking in adolescents. Design: Cross-sectional survey. Setting: One large suburban high school. Participants: A total of 1211 high school students aged 14 to 18 years. Outcome Measures: Current smoking and susceptibility to smoking. Results: Of the 1138 students with data on current smoking, 216 (19.0%) reported current smoking, and 342 (38.3%) of the 893 nonsmoking students with susceptibility data were susceptible to future smoking. Factor analysis identified 3 normative belief constructs, labeled "perceived prevalence of smoking," "perceived popularity of smoking among elite/successful elements of society," and "disapproval of smoking by parents/peers." On average, students believed that 56% of people in the United States smoke cigarettes; 27.7% believed that wealthy people smoke more than poor people. Multiple logistic regression showed that each of the 3 constructs was independently associated with current smoking (adjusted odds ratios, 1.05 [95% confidence interval {CI}, 1.02-1.08], 1.12 [95% Cl, 1.02-1.23], and 0.66 [95% CI, 0.59-0.75], respectively), even after controlling for covariates. Students' perceptions of smoking among the successful/elite and disapproval by parents/peers were independently associated with susceptibility to future smoking (adjusted odds ratios, 1.20 [95% Cl, 1.11-1.29] and 0.87 [95% Cl, 0.79-0.96], respectively). Conclusions: Adolescents' normative beliefs about smoking are multidimensional and include at least 3 distinct components, each of which was independently related to smoking outcomes. These distinct components should be considered in the design and evaluation of programs related to prevention and cessation of adolescent smoking. C1 Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Med, Div Gen Internal Med, Dept Med, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Med, Div Adolescent Med, Dept Pediat, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Ctr Hlth Equ & Promot, Pittsburgh, PA USA. Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pediat, Hanover, NH 03756 USA. Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Community Hlth Res Program,Hood Ctr Children & Fa, Hanover, NH 03756 USA. RP Primack, BA (reprint author), Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, 230 Kee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM bprimack@pitt.edu FU NCI NIH HHS [K07 CA114315, K07 CA114315-01A1, K07-CA114315] NR 35 TC 29 Z9 29 U1 2 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD MAY PY 2007 VL 161 IS 5 BP 434 EP 439 DI 10.1001/archpedi.161.5.434 PG 6 WC Pediatrics SC Pediatrics GA 164VP UT WOS:000246263200001 PM 17485617 ER PT J AU Villa-Bellosta, R Bogaert, YE Levi, M Sorribas, V AF Villa-Bellosta, Ricardo Bogaert, Yolanda E. Levi, Moshe Sorribas, Victor TI Characterization of phosphate transport in rat vascular smooth muscle cells - Implications for vascular calcification SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Article DE vascular calcification; phosphate transport; VSMC; Pit1; Pit2 ID CHRONIC KIDNEY-DISEASE; APE LEUKEMIA-VIRUS; IN-VITRO; COTRANSPORTER; EXPRESSION; PIT-1; DETERMINANTS; MECHANISMS; RECEPTORS; PROTEINS AB Objective - Hyperphosphatemia and inorganic phosphate (Pi) transport by vascular smooth muscle cells (VSMCs) have been implicated in the pathogenesis of vascular calcification. The aim of this work has been to characterize Pi transport in VSMCs. Methods and Results - Primary cultures of VSMCs express both high affinity Na-dependent and Na-independent components of Pi transport. Under physiological conditions both transport systems are saturated, show similar activity, and are inhibited by increasing pH. The Na-dependent transport is also weakly inhibited by phosphonoformic acid (PFA) (3.9 mmol/L IC50 at 0.05 mmol/L Pi). Real-time polymerase chain reaction shows that Pit1 and Pit2 are expressed to the same degree, and no other Pi transporters are significantly expressed. When expressed in Xenopus oocytes they are strictly Na-dependent, with high affinities for Pi, and are inhibited by increasing pH, but only weakly inhibited by PFA. We have used RNA interference to demonstrate that Pit1 and Pit2 are the transporters responsible for Na-dependent Pi transport in VSMCs. Conclusions - Taken together these novel findings suggest new roles of Pi transport in the pathogenesis of VC and have implications as potential future clinical targets. C1 Univ Zaragoza, Mol Toxicol Lab, Fac Vet, E-50013 Zaragoza, Spain. Denver VAMC, Dept Med, Div Renal Dis & Hypertens, Denver, CO USA. Denver VAMC, Dept Physiol & Biophys, Div Renal Dis & Hypertens, Denver, CO USA. Univ Colorado, Denver, CO 80202 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. RP Sorribas, V (reprint author), Univ Zaragoza, Mol Toxicol Lab, Fac Vet, Calle Miguel Servet 177, E-50013 Zaragoza, Spain. EM sorribas@unizar.es OI Levi, Moshe/0000-0002-6225-946X; Sorribas, Victor/0000-0003-3457-323X FU NIDDK NIH HHS [1 R01 DK066029-01] NR 30 TC 60 Z9 64 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-5642 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD MAY PY 2007 VL 27 IS 5 BP 1030 EP 1036 DI 10.1161/ATVBAHA.106.132266 PG 7 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 158RE UT WOS:000245810400010 PM 17322102 ER PT J AU Game, BA He, L Jarido, V Nareika, A Jaffa, AA Lopes-Virella, MF Huang, Y AF Game, Bryan A. He, Lin Jarido, Veronica Nareika, Alena Jaffa, Ayad A. Lopes-Virella, Maria F. Huang, Yan TI Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice SO ATHEROSCLEROSIS LA English DT Article; Proceedings Paper CT 65th Annual Meeting of the American-Diabetes-Association CY JUN 10-14, 2005 CL San Diego, CA SP Amer Diabet Assoc DE diabetes mellitus; peroxisome proliferator-activated receptor; thiazolidinediones; connective tissue growth factor; arteriosclerosis ID SMOOTH-MUSCLE-CELLS; ANTIDIABETIC DRUGS; GAMMA; TROGLITAZONE; MECHANISMS; APOPTOSIS; DISEASE; LESIONS; BETA AB Connective tissue growth factor (CTGF) is expressed in atherosclerotic plaques. It is generally recognized that CTGF contributes to atherosclerosis by stimulating vascular smooth muscle cell (VSMC) proliferation and extracellular matrix production during the development of atherosclerosis. Recent studies indicate that CTGF may also contribute to plaque destabilization as it induces apoptosis and stimulates MMP-2 expression in VSMCs. Thiazolidinediones (TZDs), a new class of insulin sensitizing drugs for type 2 diabetes, inhibit atherosclerosis. However, their effect on CTGF expression in atherosclerotic plaques remains unknown. In this study, male LDL receptor-deficient mice were fed high-fat diet for 4 months to induce the formation of atherosclerotic plaques and then given the high-fat diet with or without pioglitazone for the next 3 months. At the end of the 7-month study, CTGF expression in aortic atherosclerotic lesions was examined. Results showed that CTGF expression was increased in mice fed the high-fat diet by seven-fold as compared to that in mice fed normal chow, but the treatment with pioglitazone significantly inhibited the high-fat diet-induced CTGF expression. To verify these in vivo observations, in vitro studies using human aortic SMC were conducted. Quantitative real-time PCR and Western blot showed that pioglitazone inhibited TGF-beta-stimulated CTGF expression. In conclusion, the present study has demonstrated that pioglitazone inhibits CTGF expression in mouse advanced atherosclerotic plaques and in cultured human SMCs, and hence unveiled a possible mechanism potentially involved in the inhibition of atherosclerosis by TZD. (c) 2006 Elsevier Ireland Ltd. All rights reserved. C1 Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA. Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. RP Huang, Y (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St,Room 531, Charleston, SC 29403 USA. EM huangyan@musc.edu NR 27 TC 22 Z9 29 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD MAY PY 2007 VL 192 IS 1 BP 85 EP 91 DI 10.1016/j.atherosclerosis.2006.06.025 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 170IB UT WOS:000246655400011 PM 16901490 ER PT J AU Berka, C Levendowski, DJ Lumicao, MN Yau, A Davis, G Zivkovic, VT Olmstead, RE Tremoulet, PD Craven, PL AF Berka, Chris Levendowski, Daniel J. Lumicao, Michelle N. Yau, Alan Davis, Gene Zivkovic, Vladimir T. Olmstead, Richard E. Tremoulet, Patrice D. Craven, Patrick L. TI EEG correlates of task engagement and mental workload in vigilance, learning, and memory tasks SO AVIATION SPACE AND ENVIRONMENTAL MEDICINE LA English DT Article DE cognition; neuroergonomics; military operations; brain monitoring; human-computer interface; neurophysiology; psychophysiology ID SLEEP-APNEA PATIENTS; ADAPTIVE AUTOMATION; WORKING-MEMORY; SYSTEM; PERFORMANCE; ALERTNESS; COMPONENT; SPECTRUM; INDEXES AB Introduction: The ability to continuously and unobtrusively monitor levels of task engagement and mental workload in an operational environment could be useful in identifying more accurate and efficient methods for humans to interact with technology. This information could also be used to optimize the design of safer, more efficient work environments that increase motivation and productivity. Methods: The present study explored the feasibility of monitoring electroencephalographic (EEG) indices of engagement and workload acquired unobtrusively and quantified during performance of cognitive tests. EEG was acquired from 80 healthy participants with a wireless sensor headset (F3-F4,C3-C4,Cz-POz,F3-Cz,Fz-C3,Fz-POz) during tasks including: multi-level forward/backward-digit-span, grid-recall, trails, mental-addition, 20-min 3-Choice Vigilance, and image-learning and memory tests. EEG metrics for engagement and workload were calculated for each 1-s of EEG. Results: Across participants, engagement but not workload decreased over the 20-min vigilance test. Engagement and workload were significantly increased during the encoding period of verbal and image-learning and memory tests when compared with the recognition/recall period. Workload but not engagement increased linearly as level of difficulty increased in forward and backward-digit-span, grid-recall, and mental-addition tests. EEG measures correlated with both subjective and objective performance metrics. Discussion: These data in combination with previous studies suggest that EEG engagement reflects information-gathering, visual processing, and allocation of attention. EEG workload increases with increasing working memory load and during problem solving, integration of information, analytical reasoning, and may be more reflective of executive functions. Inspection of EEG on a second-by-second timescale revealed associations between workload and engagement levels when aligned with specific task events providing preliminary evidence that second-by-second classifications reflect parameters of task performance. C1 Adv Brain Monitoring Inc, Carlsbad, CA 92008 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Lockheed Martin Adv Technol Labs, Cherry Hill, NJ USA. RP Berka, C (reprint author), Adv Brain Monitoring Inc, 2850 Pio Pico Dr,Suite A, Carlsbad, CA 92008 USA. EM chris@b-alert.com FU NHLBI NIH HHS [HL070484]; NIDA NIH HHS [DA019357] NR 56 TC 135 Z9 137 U1 6 U2 48 PU AEROSPACE MEDICAL ASSOC PI ALEXANDRIA PA 320 S HENRY ST, ALEXANDRIA, VA 22314-3579 USA SN 0095-6562 J9 AVIAT SPACE ENVIR MD JI Aviat. Space Environ. Med. PD MAY PY 2007 VL 78 IS 5 SU S BP B231 EP B244 PG 14 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Sport Sciences SC Public, Environmental & Occupational Health; General & Internal Medicine; Sport Sciences GA 167OK UT WOS:000246460800032 PM 17547324 ER PT J AU Brambilla, P MacDonald, AW Sassi, RB Johnson, MK Mallinger, AG Carter, CS Soares, JC AF Brambilla, Paolo MacDonald, Angus W., III Sassi, Roberto B. Johnson, Melissa K. Mallinger, Alan G. Carter, Cameron S. Soares, Jair C. TI Context processing performance in bipolar disorder patients SO BIPOLAR DISORDERS LA English DT Article DE attention; cognition; continuous performance test (CPT); executive functions; mood disorders; neuropsychology; working memory ID DORSOLATERAL PREFRONTAL CORTEX; COGNITIVE IMPAIRMENT; WORKING-MEMORY; I DISORDER; SCHIZOPHRENIC DEFICITS; DYSFUNCTION; MANIA; PSYCHOSIS; DISTURBANCES; SPECIFICITY AB Objectives: Context processing is the adaptive control of current behavior through the use of prior context information. It has been found to be impaired in schizophrenia. Some studies have indicated that, compared with patients with schizophrenia, those with bipolar disorder (BPD) display a similar but less severe neuropsychological pattern of impairment. However, this cognitive dimension has not yet been examined in BPD patients in the existing literature. Methods: An expectancy version of the AX continuous performance test (AX-CPT) was administered to 15 bipolar outpatients and 26 healthy controls. Patients with schizophrenia, in which context processing deficits are known to occur, were used as a reference group. Results: Bipolar patients showed a context processing deficit relative to healthy controls, although this was less severe and generalized than in schizophrenia patients. Conclusions: These findings suggest there are milder impairments in context processing in BPD compared with schizophrenia. However, the severity of possible context processing deficits in BPD may have been underestimated in our sample of mostly euthymic outpatients. C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders,MOOD CNS Program, San Antonio, TX 78229 USA. Univ Udine, Dept Pathol & Expt & Clin Med, Sect Psychiat, I-33100 Udine, Italy. Sci Inst IRCCS E Medea, Udine, Italy. Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo, Brazil. Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA USA. Univ Calif Davis, Dept Psychiat, Sacramento, CA 95817 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol,Audie L Murphy Div, S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. RP Soares, JC (reprint author), Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders,MOOD CNS Program, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM soares@uthscsa.edu RI brambilla, paolo/B-4184-2010; MacDonald, Angus/M-9855-2016 OI brambilla, paolo/0000-0002-4021-8456; MacDonald, Angus/0000-0003-4588-931X FU NCRR NIH HHS [RR 020571]; NIMH NIH HHS [MH 01736, MH 068662, MH 068766, MH 30915] NR 54 TC 21 Z9 21 U1 4 U2 8 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD MAY PY 2007 VL 9 IS 3 BP 230 EP 237 DI 10.1111/j.1399-5618.2007.00398.x PG 8 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 152WM UT WOS:000245392900005 PM 17430297 ER PT J AU Luciano, F Krajewska, M Ortiz-Rubio, P Krajewski, S Zhai, DY Faustin, B Bruey, JM Bailly-Maitre, B Lichtenstein, A Kolluri, SK Satterthwait, AC Zhang, XK Reed, JC AF Luciano, Frederic Krajewska, Maryla Ortiz-Rubio, Paulina Krajewski, Stan Zhai, Dayong Faustin, Benjamin Bruey, Jean-Marie Bailly-Maitre, Beatrice Lichtenstein, Alan Kolluri, Siva Kumar Satterthwait, Arnold C. Zhang, Xiao-Kun Reed, John C. TI Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma SO BLOOD LA English DT Article ID PRO-APOPTOTIC ACTIVITY; NEGATIVE REGULATOR; FAMILY PROTEIN; DEATH; BAX; ACTIVATION; BINDS; BFL-1/A1; APAF-1; MEMBER AB Defects in apoptosis mechanisms play important roles in malignancy and autoimmunity. Orphan nuclear receptor Nur77/ TR3 has been demonstrated to bind antiapoptotic protein Bcl-2 and convert it from a cytoprotective to a cytodestructive protein, representing a phenotypic conversion mechanism. Of the 6 antiapoptotic human Bcl-2 family members, we found that Nur77/TR3 binds strongest to Bcl-B, showing selective reactivity with Bcl-B, Bcl-2, and Bfl-1 but not Bcl-X-L, Mcl-1, or Bcl-W. Nur77 converts the phenotype of Bcl-B from antiapoptotic to proapoptotic. Bcl-B is prominently expressed in plasma cells and multiple myeloma. Endogenous Bcl-B associates with endogenous Nur77 in RPMI 8226 myeloma cells, where RNA interference experiments demonstrated dependence on Bcl-B for Nur77-induced apoptosis. Furthermore, a Nur77-mimicking peptide killed RPMI 8226 myeloma cells through a Bcl-B-dependent mechanism. Because Bcl-B is abundantly expressed in plasma cells and some myelomas, these findings raise the possibility of exploiting the Nur77/Bcl-B mechanism for apoptosis for eradication of autoimmune plasma cells or myeloma. C1 Burnham Inst Med Res, La Jolla, CA 92037 USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Reed, JC (reprint author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA. EM reedoffice@burnham.org FU NIGMS NIH HHS [R01 GM060554, GM 60554] NR 34 TC 51 Z9 52 U1 0 U2 6 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD MAY 1 PY 2007 VL 109 IS 9 BP 3849 EP 3855 DI 10.1182/blood-2006-11-056879 PG 7 WC Hematology SC Hematology GA 162MJ UT WOS:000246091400040 PM 17227826 ER PT J AU Leverenz, JB Yu, CE Montine, TJ Steinbart, E Bekris, LM Zabetian, C Kwong, LK Lee, VMY Schellenberg, GD Bird, TD AF Leverenz, J. B. Yu, C. E. Montine, T. J. Steinbart, E. Bekris, L. M. Zabetian, C. Kwong, L. K. Lee, V. M-Y. Schellenberg, G. D. Bird, T. D. TI A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology SO BRAIN LA English DT Article DE frontotemporal dementia; progranulin; tau; alpha synuclein; neurogenetics ID FRONTOTEMPORAL LOBAR DEGENERATION; DEMENTIA; GENE; CHROMOSOME-17; INCLUSIONS; ANTIBODIES; FAMILIES; MISSENSE; DISEASE; CELLS AB Mutations in the progranulin (GRN) gene have recently been reported as a cause of the frontotemporal dementia (FTD) syndrome. We performed a clinical, neuropathological and molecular genetic study of two families with FTD and the same novel mutation in GRN. Age of onset ranged from 35 to 75 years and all individuals progressed to a severe dementia syndrome with a mean disease duration of similar to 6-10 years. Variable clinical presentations included language impairment, behaviour change or parkinsonism. Seven total autopsies in the families (five in Family 1, two in Family 2) showed gross and microscopic evidence of neuronal loss in the neocortex, striatum, hippocampus and substantia nigra. All cases with material available for immunohistochemistry had cytoplasmic and intranuclear ubiquitin positive, tau negative inclusions that stained best with an antibody to the TDP43 protein. In addition, all but one had evidence of distinctive tau pathology. Two cases in Family I also had alpha-synuclein (SNCA) pathology, one with diffuse neocortical inclusions and neurites and unusual striatal cytoplasmic inclusions. Affected persons in both families had the same mutation in GRN (c.709-2A > G). A minigene construct showed that this mutation alters splicing of exon 7 and results in reduced mRNA message in brain. A single GRN mutation in these two families was associated with variable clinical presentations consistent with the FTD syndrome. All cases had ubiquitin/TDP43 immuno-positive inclusions and most had additional tau pathology. Two cases had SNCA pathology. These findings suggest a link between mutations in GRN and aggregation of tau, TDP43 and SNCA. C1 Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Ctr, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Geriatr Ctr, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA. Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA. RP Bird, TD (reprint author), 1660S Columbian Way S-182-GRECC, Seattle, WA 98108 USA. EM tomnroz@u.washington.edu OI Zabetian, Cyrus/0000-0002-7739-4306 FU NIA NIH HHS [AG17586, P50 AG 005 136-22] NR 31 TC 81 Z9 84 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD MAY PY 2007 VL 130 BP 1360 EP 1374 DI 10.1093/brain/awm069 PN 5 PG 15 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 165GW UT WOS:000246293400019 PM 17439980 ER PT J AU Alcantara, O Boldt, DH AF Alcantara, Orlando Boldt, David H. TI Iron deprivation blocks multilineage haematopoietic differentiation by inhibiting induction of p21(WAF1/CIP1) SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE iron; haematopoiesis; p21(WAF1/CIP1); CD34(+) cells ID CELL-CYCLE; LEUKEMIC-CELLS; EXPRESSION; INVITRO; GROWTH; DESFERRIOXAMINE; INVIVO; APOPTOSIS AB Iron is required for the differentiation of HL-60 cells along the monocyte lineage in vitro, reflecting a requirement for iron in the transcriptional induction of the p21(WAF1/CIP1) gene. To determine if the same requirement holds true for differentiation in other cell lineages and for primary human CD34(+) bone marrow precursor cells, we induced granulocyte differentiation by treating HL-60 cells with dimethyl sulphoxide, and erythroid or megakaryocytic differentiation by treating K562 cells with butyrate or phorbol myristate acetate, respectively. Nitro blue tetrazolium reduction, expression of haem, or expression of CD41 was used to assess granulocytic, erythroid, or megakaryocytic differentiation respectively. Purified CD34(+) cells were cultured with granulocyte/macrophage-colony stimulating factor and stem cell factor to induce myelomonocytic differentiation. Iron deprivation was induced by desferrioxamine. p21(WAF1/CIP1) antisense oligonucleotides were used to inhibit p21 expression. Iron deprivation blocked p21 induction as judged by real-time polymerase chain reaction assays. In addition, both iron deprivation and p21 antisense blocked CD34(+) cell differentiation. These observations were not explained by induction of widespread apoptosis under conditions of iron deprivation. We concluded that both iron and functional p21(WAF1/CIP1) are required for in vitro differentiation of human haematopoietic precursors along multiple cell lineages. C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Boldt, DH (reprint author), Univ Texas, Hlth Sci Ctr, 7703 Floyd Curl Dr,Mail Code 7880, San Antonio, TX 78229 USA. EM boldt@uthscsa.edu FU NCI NIH HHS [P30 CA54174.]; NIDDK NIH HHS [R01 DK5042] NR 21 TC 6 Z9 6 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0007-1048 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD MAY PY 2007 VL 137 IS 3 BP 252 EP 261 DI 10.1111/j.1365-2141.2007.06549.x PG 10 WC Hematology SC Hematology GA 152WR UT WOS:000245393400011 PM 17408467 ER PT J AU Kahana, A Marcet, MM Albert, DM Thliveris, AT AF Kahana, Alon Marcet, Marcus M. Albert, Daniel M. Thliveris, Andrew T. TI Drug-induced cicatrising granulomatous conjunctivitis SO BRITISH JOURNAL OF OPHTHALMOLOGY LA English DT Editorial Material C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53792 USA. Univ Wisconsin, Dept Ophthalmol & Visual Sci, William S Middleton Mem Vet Hosp, Madison, WI 53792 USA. RP Kahana, A (reprint author), Univ Wisconsin, Dept Ophthalmol & Visual Sci, 600 Highland Ave, Madison, WI 53792 USA. EM kahana@wisc.edu RI Marcet, Marcus/E-9876-2010 OI MARCET, Marcus/0000-0003-0433-4684; Kahana, Alon/0000-0002-5667-2274 NR 6 TC 1 Z9 2 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0007-1161 J9 BRIT J OPHTHALMOL JI Br. J. Ophthalmol. PD MAY PY 2007 VL 91 IS 5 BP 691 EP 692 DI 10.1136/bjo.2006.099085 PG 6 WC Ophthalmology SC Ophthalmology GA 158XW UT WOS:000245829900034 PM 17446509 ER PT J AU Knight, SJ Latini, DM Hart, SL Sadetsky, N Kane, CJ DuChane, J Carroll, PR AF Knight, Sara J. Latini, David M. Hart, Stacey L. Sadetsky, Natalia Kane, Christopher J. DuChane, Janeen Carroll, Peter R. CA CaPSURE Investigators TI Education predicts quality of life among men with prostate cancer cared for in the department of veterans affairs - A longitudinal quality of life analysis from CaPSURE SO CANCER LA English DT Article DE prostate cancer; education; health related quality of life; socioeconomic status; disparities; VA health care system ID LOW-INCOME PATIENTS; SYSTEM; LITERACY; DATABASE AB BACKGROUND. Previous findings have suggested that patient educational attainment is related to cancer stage at presentation and treatment for localized prostate cancer, but there is little information on education and quality of life outcomes. Patient education level and quality of life were examined among men diagnosed with prostate cancer and cared for within an equal-access health care system, the Department of Veterans Affairs Veterans Health Administration (VA). METHODS. Participants were 248 men with prostate cancer cared for in the VA and enrolled in CaPSURE. Repeated-measures analysis of variance was used to examine quality of life over time according to education level, controlling for age, ethnicity, income, site of clinical care, and year of diagnosis. RESULTS. Patients with lower levels of education tended to be younger, nonwhite, and have lower incomes. Controlling for age, ethnicity, income, year of diagnosis, and site, men with less formal education, compared with those with more, had worse functioning in the physical (P = .0248), role physical (P = .0048), role emotional (P = .0089), vitality (P = .0034), mental health (P = .0054), social function (P = .0056), and general health (P = .0002) domains and worse urinary (P = .003) and sexual (P = .0467) side effects. CONCLUSIONS. Men with less education experienced worse health-related quality of life across a wide range of domains and greater urinary and sexual symptoms than their peers who had more education. Clinicians should be aware that, even within an equal access to health care system, men with less education are vulnerable, having greater difficulty functioning in their daily lives after their prostate cancer treatment. C1 San Francisco VA Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA. Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. TAP Pharmaceut Prod Inc, Lake Forest, IL USA. RP Knight, SJ (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM sara.knight@ucsf.edu RI Hart, Stacey/E-4819-2011 OI Latini, David/0000-0002-6161-4861 FU PHS HHS [P50 C89520] NR 25 TC 38 Z9 38 U1 0 U2 9 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER JI Cancer PD MAY 1 PY 2007 VL 109 IS 9 BP 1769 EP 1776 DI 10.1002/cncr.22597 PG 8 WC Oncology SC Oncology GA 160JP UT WOS:000245937000011 PM 17380491 ER PT J AU Ioannou, GN Weiss, NS Kowdley, KV AF Ioannou, George N. Weiss, Noel S. Kowdley, Kris V. TI Relationship between transferrin-iron saturation, alcohol consumption, and the incidence of cirrhosis and liver cancer SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID C VIRUS-INFECTION; HEPATITIS-C; HEREDITARY HEMOCHROMATOSIS; HEPATOCELLULAR-CARCINOMA; LIPID-PEROXIDATION; UNITED-STATES; BINDING CAPACITY; OVERLOAD; PREVALENCE; INJURY AB Background & Aims: Excessive alcohol consumption and iron overload might act in synergy to promote hepatic fibrogenesis and carcinogenesis. We examined the relation between baseline serum transferrin-iron saturation (TS) and the incidence of hospitalizations or deaths related to cirrhosis and liver cancer as well as the influence of alcohol consumption on this relationship. Methods: Participants included 8767 persons aged 25-74 years without evidence of cirrhosis at entry into the study or during the first 5 years of follow-up who were subsequently followed for a mean of 13.3 years as part of the first National Health and Nutrition Examination Survey. Results: During 116,656 person-years of follow-up, 115 participants were hospitalized for or died of cirrhosis and 4 more of liver cancer. Compared with persons with low TS (< 40%) and low alcohol consumption (<= 1 drink/day) who had an incidence of cirrhosis/liver cancer of 70/100,000 person-years, the incidence was increased in persons with elevated TS (>= 40%) and low alcohol consumption (154/100,000; adjusted hazard ratio, 2.2; 95% confidence interval, 1.3-3.8) and in persons with low TS and elevated (> 1 drink/day) alcohol consumption (198/100,000; adjusted hazard ratio, 2.9; 95% confidence interval, 1.7-5.0). The incidence of cirrhosis/liver cancer was particularly high among persons with both elevated TS and elevated alcohol consumption (480/100,000; adjusted hazard ratio, 6.8; 95% confidence interval, 3.6-12.9), exceeding the rate predicted by the addition of the separate attributable risks associated with drinking and elevated serum TS. Conclusions: Elevated serum TS is associated with an increased incidence of cirrhosis or liver cancer particularly in the presence of elevated alcohol consumption. C1 Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, Seattle, WA 98108 USA. Univ Washington, Med Ctr, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, S-111-GI,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU NIDDK NIH HHS [DK 02957, DK063996] NR 31 TC 11 Z9 11 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAY PY 2007 VL 5 IS 5 BP 624 EP 629 DI 10.1016/j.cgh.2007.01.008 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 165SV UT WOS:000246326800020 PM 17478349 ER PT J AU Kestenbaum, B Rudser, KD Shlipak, MG Fried, LF Newman, AB Katz, R Sarnak, MJ Seliger, S Stehman-Breen, C Prineas, R Siscovick, DS AF Kestenbaum, Bryan Rudser, Kyle D. Shlipak, Michael G. Fried, Linda F. Newman, Anne B. Katz, Ronit Sarnak, Mark J. Seliger, Stephen Stehman-Breen, Catherine Prineas, Ronald Siscovick, David S. TI Kidney function, electrocardiographic findings, and cardiovascular events among older adults SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID GLOMERULAR-FILTRATION-RATE; CONGESTIVE-HEART-FAILURE; QT INTERVAL PROLONGATION; CORONARY-ARTERY-DISEASE; STAGE RENAL-DISEASE; QRS DURATION; CORRECTED QT; CYSTATIN-C; FOLLOW-UP; HEMODIALYSIS AB Chronic kidney disease (CKD) is associated with cardiovascular (CV) disease and mortality. It is not known whether cardiac rhythm disturbances are more prevalent among individuals with CKD or whether resting electrocardiogram findings predict future CV events in the CKD setting. Data were obtained from the Cardiovascular Health Study, a community-based study of adults aged >= 65 yr. After exclusions for prevalent heart disease, atrial fibrillation, implantable pacemaker, or antiarrhythmic medication use, 3238 participants were analyzed. CKD was defined by an estimated GFR <60 ml/min per 1.73 m(2). Outcomes were adjudicated incident heart failure (HF), incident coronary heart disease (CHD), and mortality. Participants with CKD had longer PR and corrected QT intervals compared with those without CKD; however, differences in electrocardiographic markers were explained by traditional CV risk factors and CV medication use. After adjustment for known risk factors, each 10-ms increase in the QRS interval was associated with a 15% greater risk for incident HF (95% confidence interval [CI] 1.04 to 1.27), a 13% greater risk for CHD (95% CI 1.04 to 1.24), and a 17% greater risk for mortality (95% CI 1.09, 1.25) among CKD participants. Each 5% increase in QTI was associated with a 42% (95% CI 1.23 to 1.65), 22% (95% CI 1.07 to 1.40), and 10% (95% CI 0.98 to 1.22) greater risk for HF, CHD, and mortality, respectively. Associations seemed stronger for participants with CKD; however, no significant interactions were detected. Resting electrocardiographic abnormalities are common in CKD and independently predict future clinical CV events in this setting. C1 Univ Washington, Harborview Med Ctr, Div Nephrol, Seattle, WA 98104 USA. Univ Washington, Dept Biostat, Seattle, WA 98104 USA. Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98104 USA. Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98104 USA. Collaborat Hlth Studies Coordinating Ctr, Seattle, WA USA. Univ Calif San Francisco, Gen Internal Med Sect, Vet Affairs Med Ctr, San Francisco, CA 94143 USA. Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. Tufts New Englans Med Ctr, Dept Med, Boston, MA USA. Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. Amgen Inc, Thousand Oaks, CA 91320 USA. Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Epidemiol Sect, Winston Salem, NC 27103 USA. RP Kestenbaum, B (reprint author), Univ Washington, Harborview Med Ctr, Div Nephrol, Room 10EH11,Box 359764, Seattle, WA 98104 USA. EM brk@u.washington.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU NHLBI NIH HHS [N01 HC-55222, N01 HC-15103, N01-HC-35129, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, U01 HL080295]; NIDDK NIH HHS [K23 DK63274-01] NR 32 TC 13 Z9 14 U1 0 U2 0 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD MAY PY 2007 VL 2 IS 3 BP 501 EP 508 DI 10.2215/CJN.04231206 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 161XB UT WOS:000246049100016 PM 17699457 ER PT J AU Zivkovic, SA Medsger, TA AF Zivkovic, Sasa A. Medsger, Thomas A., Jr. TI Myasthenia gravis and scleroderma: Two cases and a review of the literature SO CLINICAL NEUROLOGY AND NEUROSURGERY LA English DT Review DE myasthenia gravis; scleroderma; systemic sclerosis; localized scleroderma; D-penicillamine ID PROGRESSIVE SYSTEMIC-SCLEROSIS; MORPHEA LOCALIZED SCLERODERMA; D-PENICILLAMINE; CLASSIFICATION; PATHOGENESIS; DISORDERS; DISEASES; COUNTY; LUPUS AB Myasthenia gravis is uncommon in patients with scleroderma, and when diagnosed is usually associated with previous use of D-penicillamine. Clinically, both myasthenia and scleroderma may present with fatigue, weakness and bulbar symptoms, so one of diagnoses may be delayed. We report two new cases and review clinical features of 12 other reported cases of co-existing scleroderma and myasthenia gravis, unrelated to previous D-penicillamine therapy. Co-occurrence of myasthenia and scleroderma was reported almost exclusively (13/14) in women with a mean latency of 7.03 years. Most patients (10/11) had seropositive generalized myasthenia, and there were no cases with exclusively ocular symptoms. Three patients with pre-existing myasthenia were safely treated with D-penicillamine. Myasthenia and scleroderma occur in the context of an underlying autoimmune diathesis, but their co-occurrence could be underreported as the recognition of either disorder may be delayed by overlapping clinical symptoms. Our findings also suggest that D-penicillamine may be cautiously used in selected patients with pre-existing scleroderma and myasthenia, when potential benefits outweigh the risk of possible myasthenia exacerbation. (c) 2007 Elsevier B.V. All rights reserved. C1 Univ Pittsburgh, Dept Neurol, Sch Med, PUH F875, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Dept Med, Div Rheumatol & Clin Immunol, Pittsburgh, PA 15213 USA. RP Zivkovic, SA (reprint author), Univ Pittsburgh, Dept Neurol, Sch Med, PUH F875, 200 Lothrop St, Pittsburgh, PA 15213 USA. EM zivkovics@upmc.edu NR 30 TC 6 Z9 6 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0303-8467 J9 CLIN NEUROL NEUROSUR JI Clin. Neurol. Neurosurg. PD MAY PY 2007 VL 109 IS 4 BP 388 EP 391 DI 10.1016/j.clineuro.2007.01.006 PG 4 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 159RN UT WOS:000245884100017 PM 17280777 ER PT J AU Schelleman, H Chen, Z Kealey, C Whitehead, AS Christie, J Price, M Brensinger, CM Newcomb, CW Thorn, CF Samaha, FF Kimmel, SE AF Schelleman, H. Chen, Z. Kealey, C. Whitehead, A. S. Christie, J. Price, M. Brensinger, C. M. Newcomb, C. W. Thorn, C. F. Samaha, F. F. Kimmel, S. E. TI Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Article ID VKORC1 GENE; INTERETHNIC VARIABILITY; ORAL ANTICOAGULANTS; REQUIREMENT; POPULATION; HAPLOTYPES; POLYMORPHISMS AB The objective of this study was to determine whether two vitamin K epoxide reductase complex 1 ( VKORC1) polymorphisms contribute to the variability in warfarin response, particularly in African Americans. The effect of the VKORC1 1173C/T and -1639G/A polymorphisms was examined in a prospective cohort study of 338 warfarin users. Subjects carrying an 1173T allele had a lower warfarin maintenance dose compared with subjects with the CC genotype in African Americans ( -12.10 mg/week +/- 4.93; P = 0.02) and Caucasians ( -14.41 mg/week +/- 3.28; P<0.001). Before reaching maintenance dose, only Caucasians with the T allele had significantly increased risk of international normalized ratio 43 ( odds ratio 3.10; 95% confidence interval: 1.73-5.55) compared with Caucasians with the CC genotype. Polymorphisms in the VKORC1 gene are associated with warfarin maintenance dose requirements among both African Americans and Caucasians. However, these polymorphisms may not be as useful in predicting over-anticoagulation among African Americans. C1 Univ Penn, Dept Biostat & Epidemiol, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Dept Pharmacol, Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Ctr Pharmacogenet, Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Dept Med, Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Vet Affairs Med Ctr, Sch Med, Philadelphia, PA 19104 USA. RP Kimmel, SE (reprint author), Univ Penn, Dept Biostat & Epidemiol, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. EM skimmel@cceb.med.upenn.edu FU NCRR NIH HHS [P20RR020741]; NHLBI NIH HHS [R01HL066176] NR 21 TC 83 Z9 85 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0009-9236 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD MAY PY 2007 VL 81 IS 5 BP 742 EP 747 DI 10.1038/sj.clpt.6100144 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 160DT UT WOS:000245921500023 PM 17329985 ER PT J AU Yueh, B Collins, MP Souza, PE Heagerty, PJ Liu, CF Boyko, EJ Loovis, CF Fausti, SA Hedrick, SC AF Yueh, Bevan Collins, Margaret P. Souza, Pamela E. Heagerty, Patrick J. Liu, Chuan-Fen Boyko, Edward J. Loovis, Carl F. Fausti, Stephen A. Hedrick, Susan C. TI Screening for Auditory Impairment - Which Hearing Assessment Test (SAI-WHAT): RCT design and baseline characteristics SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE hearing loss; screening; rehabilitation of hearing impaired; hearing aids; patient compliance; treatment effectiveness; randomized controlled trials; depression; quality of life; patient outcome assessment ID QUALITY-OF-LIFE; RANDOMIZED TRIAL; ELDERLY PEOPLE; HEALTH-STATUS; OLDER-ADULTS; PRIMARY-CARE; VALIDATION; AMPLIFICATION; HANDICAP; AIDS AB Background: Effective screening programs should not merely detect presence of disease, but also lead to long-term benefit. We describe the rationale and design of the first randomized clinical trial to study the long-term effects of routine screening for hearing loss. We also describe the baseline characteristics of the randomized cohort. Methods: We randomized 2305 veterans age 50 years or older to a control arm without screening, or to screening with: physiologic testing (AudioScope), a self-administered questionnaire (Hearing Handicap Inventory for the Elderly-Screening version [HHIE-S]), or both tests. The primary outcome measure will be hearing aid use one year after screening. We will also study a number of secondary outcomes, including appointments made with and visits to an audiologist, cases of aidable hearing loss, hearing aids dispensed, self-rated communication ability, and hearing-related quality of life. Results: Baseline demographic and health status measures were evenly distributed across the screening arms. The percentage of patients who screened positive for hearing loss was 18.6%, 59.2%, and 63.6% for the AudioScope, HHIE-S, and combined screening arms, respectively. C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. Portland VA Med Ctr, Natl Ctr Rehabiliatat & Auditory Res, Portland, OR USA. Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. Univ Washington, Dept Speech & Hearing Sci, Seattle, WA 98195 USA. Univ Washington, Dept Internal Med, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Yueh, B (reprint author), VA Puget Sound Hlth Care Syst, Surg Serv 1120TO, 1660 S Columbian Way, Seattle, WA 98108 USA. EM byueh@u.washington.edu OI Yueh, Bevan/0000-0003-1380-1053; Boyko, Edward/0000-0002-3695-192X NR 53 TC 6 Z9 8 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAY PY 2007 VL 28 IS 3 BP 303 EP 315 DI 10.1016/j.cct.2006.08.008 PG 13 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 152DA UT WOS:000245339800010 PM 17030153 ER PT J AU de Aguilar-Nascimento, JE Kudsk, KA AF de Aguilar-Nascimento, Jose Eduardo Kudsk, Kenneth A. TI Use of small-bore feeding tubes: successes and failures SO CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE LA English DT Article DE enteral nutrition; feeding tube placement; pneumothorax ID CRITICALLY-ILL PATIENTS; INADVERTENT INTRACRANIAL PLACEMENT; INTENSIVE-CARE-UNIT; NASOGASTRIC TUBE; ENTERAL NUTRITION; SEPTIC MORBIDITY; ESPEN GUIDELINES; ABDOMINAL-TRAUMA; HEAD-INJURIES; METAANALYSIS AB Purpose of review Early enteral nutrition is the preferred option for feeding patients who cannot meet their nutrient requirements orally. This article reviews complications associated with small-bore feeding tube insertion and potential methods to promote safe gastric or postpyloric placement. We review the available bedside methods to check the position of the feeding tube and identify inadvertent misplacements. Recent findings Airway misplacement rates of small feeding tubes are considerable. Bedside methods (auscultation, pH, aspirate appearance, air bubbling, external length of the tube, etc.) to confirm the position of a newly inserted small-bore feeding tube have limited scientific basis. Radiographic confirmation therefore continues to be the most accurate method to ascertain tube position. Fluoroscopic and endoscopic methods are reliable but costly and are not available in many hospitals. Rigid protocols to place feeding tubes along with new emerging technology such as CO2 colorimetric paper and tubes coupled with signaling devices are promising candidates to substitute for the blind placement method. Summary The risk of misplacement with blind bedside methods for small-bore feeding tube insertion requires a change in hospital protocols. C1 Univ Fed Mato Grosso, Dept Surg, Cuiaba, Brazil. William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI 53705 USA. Univ Wisconsin, Dept Surg, Madison, WI 53706 USA. RP de Aguilar-Nascimento, JE (reprint author), Rua Estevao Mendonca 81 Apto 801, BR-78043300 Cuiaba, MT, Brazil. EM aguilar@terra.com.br NR 50 TC 9 Z9 9 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1363-1950 J9 CURR OPIN CLIN NUTR JI Curr. Opin. Clin. Nutr. Metab. Care PD MAY PY 2007 VL 10 IS 3 BP 291 EP 296 DI 10.1097/MCO.0b013e3280d64a1d PG 6 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 165CJ UT WOS:000246281100005 PM 17414497 ER PT J AU Kisgati, M Asmis, R AF Kisgati, Marta Asmis, Reto TI Generation of retroviruses for the overexpression of cytosolic and mitochondrial glutathione reductase in macrophages in vivo SO CYTOTECHNOLOGY LA English DT Article DE retrovirus; gene Transfer; glutathione Reductase; macrophage; atherosclerosis ID LOW-DENSITY LIPOPROTEIN; INDUCED CELL INJURY; GENE-TRANSFER; HEMATOPOIETIC PROGENITOR; APOLIPOPROTEIN-E; LESION FORMATION; DEFICIENT MICE; STEM-CELLS; ATHEROSCLEROSIS; EXPRESSION AB Retroviral gene transfer and bone marrow transplantation has been used by many investigators to study the role of macrophage proteins in different mouse models of human disease. While this approach is faster and less expensive than generating transgenic mice with macrophage-specific promoters and applicable to a wider array of mouse models, it has been hampered by two major drawbacks: labor-intensive cloning procedures involved in generating retroviral vectors for each gene of interest and low viral titers. Here we describe the construction of a MSCV-based retroviral vector that can serve as an acceptor vector for commercially available Cre-lox-compatible donor vectors. Using this new retroviral vector in combination with a FACS approach to enhance viral titers, we generated high-titer retroviruses carrying either EGFP-tagged cytosolic or EGFP-tagged mitochondria-targeted glutathione reductase. We show that the introduction of these constructs via retroviral gene transfer and bone marrow transplantation into atherosclerosis-prone LDL receptor-null mice results in the long-term increase in macrophage glutathione reductase activity. C1 Univ Texas, Hlth Sci Ctr, Div Nephrol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. Kenezy Gyula Hosp, Dept Lab Med, Debrecen, Hungary. RP Asmis, R (reprint author), Univ Texas, Hlth Sci Ctr, Div Nephrol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM asmis@uthscsa.edu FU NHLBI NIH HHS [R01 HL070963] NR 32 TC 0 Z9 1 U1 0 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0920-9069 J9 CYTOTECHNOLOGY JI Cytotechnology PD MAY PY 2007 VL 54 IS 1 BP 5 EP 14 DI 10.1007/s10616-007-9046-7 PG 10 WC Biotechnology & Applied Microbiology; Cell Biology SC Biotechnology & Applied Microbiology; Cell Biology GA 179ET UT WOS:000247273100002 PM 19003013 ER PT J AU Nurgalieva, Z Lowrey, A El-Serag, HB AF Nurgalieva, Zhannat Lowrey, Angus El-Serag, Hashem B. TI The use of cytokeratin stain to distinguish Barrett's esophagus from contiguous tissues: A systematic review SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Barrett's esophagus; markers; cardiac; intestinal metaplasia; cytokeratins; microarray ID GASTROESOPHAGEAL-REFLUX-DISEASE; GASTRIC INTESTINAL METAPLASIA; DISTAL ESOPHAGUS; IMMUNOREACTIVITY PATTERNS; ESOPHAGOGASTRIC JUNCTION; EXPRESSION; CARDIA; ADENOCARCINOMA; EPITHELIUM; DIAGNOSIS AB Our objective was to systematically review the existing literature regarding the use of cytokeratin (CK) stain in differentiating Barrett's esophagus (BE) from tissues of the gastric cardia, corpus, or antrum, with or without intestinal metaplasia (IM). Pubmed was searched for full publications in English (1983-2005) addressing the use of CK for differentiation of BE from contiguous tissues. Information was collected on the study sample, blinding, the methods used for CK staining, and for defining and applying the gold standard tests. Test characteristics were obtained or calculated. Sixteen studies (containing 46 comparisons) met the inclusion and exclusion criteria. Immunostaining for CK 7 and 20 was generally highly specific in distinguishing long-segment BE from antrum IM, fundus IM, or noncardiac gastric IM; 27 comparisons showed statistically significant differences. However, only 8 of 15 comparisons (6 of 12 studies) reported significant differences in CK staining patterns between BE and gastric cardia IM with a high sensitivity (89%-100%) and specificity (83%-100%) for long-segment BE and lower estimates for short-segment BE, while the other seven comparisons showed no significant differences and a very low sensitivity. Examination by a blinded pathologist was reported in five of six positive studies and in only one of six of the negative studies. In addition, variation in the patient populations, use of surgical resection versus endoscopic biopsies, and biopsy sampling technique in endoscopic studies may have accounted for these differences. Finally, two studies did not find significant differences in CK staining patterns between BE and normal cardiac mucosa. In conclusions, CK immunostaining has not performed well in differentiating BE, especially short-segment BE, from cardia IM. There seems to be a spectrum bias where the accuracy varies with different tested populations. CK immunostaining distinguished well between BE and IM in noncardiac segments of the stomach; however, these comparisons are not clinically relevant. C1 Baylor Coll Med, Houston Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA. Baylor Coll Med, Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu FU NIDDK NIH HHS [R21 DK067366-02] NR 40 TC 14 Z9 17 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD MAY PY 2007 VL 52 IS 5 BP 1345 EP 1354 DI 10.1007/s10620-006-9399-3 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 158VL UT WOS:000245823100035 PM 17373588 ER PT J AU Movahed, MR Ebrahimi, R AF Movahed, Mohammad-Reza Ebrahimi, Ramin TI The prevalence of valvular abnormalities in patients who were referred for echocardiographic examination with a primary diagnosis of "Heart murmur" SO ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES LA English DT Article DE echocardiography; murmur; valvular heart disease; valvular abnormalities; mitral regurgitation; mitral stenosis; aortic regurgitation; aortic stenosis ID SYSTOLIC MURMURS; DOPPLER ECHOCARDIOGRAPHY; AORTIC REGURGITATION; AUSCULTATION AB Introduction: The prevalence of valvular abnormality and innocent murmur in patients who are referred for echocardiographic evaluation with the diagnosis of "murmur" is not known. The goal of this study was to evaluate the prevalence of valvular abnormalities in such patients. Methods: We retrospectively reviewed the echocardiograms that were referred with the primary ordering diagnosis of "murmur," for the presence of valvular abnormalities. For comparison, we used other documented primary reasons for echocardiographic referral, such as chest pain, shortness of breath, etc. Results: In this cohort, 7,684 echocardiogram reports documented primary diagnostic reasons for echocardiographic referral. A total of 3,460 echocardiogram reports (45%) were coded "murmur" as the primary reason for the study referral. There was a higher prevalence of female patient referrals for heart murmur evaluation (61.8% vs. 38.2%). Although, patients with murmur had a higher prevalence of valvular abnormalities, compared to other reasons for echocardiographic examination, the prevalence of valvular abnormality was less than 50% (48.6% vs. 35.5%) in both groups. Despite the higher number of female patients referred with the diagnosis of murmur, the percentage of abnormal valves was lower in women (45.6% vs. 53.4% in men). Conclusion: The prevalence of valvular abnormalities in patients who were referred with the diagnosis of murmur for echocardiographic examination was less than 50%, with a lesser degree found in women. Routine utilization of echocardiography for evaluation of all murmurs may be unwarranted. C1 Univ Arizona, Coronary Care Unit, Sarver Heart Ctr, Dept Med,Sect Cardiol, Tucson, AZ 85724 USA. Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90024 USA. Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. RP Movahed, MR (reprint author), Univ Arizona, Coronary Care Unit, Sarver Heart Ctr, Dept Med,Sect Cardiol, 1501 N Campbell Ave, Tucson, AZ 85724 USA. EM rmovahed@email.arizona.edu NR 19 TC 6 Z9 6 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0742-2822 J9 ECHOCARDIOGR-J CARD JI Echocardiography-J. Cardiovasc. Ultrasound Allied Tech. PD MAY PY 2007 VL 24 IS 5 BP 447 EP 451 DI 10.1111/j.1540-8175.2007.00425.x PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 160KT UT WOS:000245940100001 PM 17456061 ER PT J AU Salinsky, M Storzbach, D Oken, B Spencer, D AF Salinsky, Martin Storzbach, Daniel Oken, Barry Spencer, David TI Topiramate effects on the EEG and alertness in healthy volunteers: A different profile of antiepileptic drug neurotoxicity SO EPILEPSY & BEHAVIOR LA English DT Article; Proceedings Paper CT 59th Annual Meeting of the American-Epilepsy-Society/American-Clinical-Neurophysiology-Society CY DEC 02-06, 2005 CL Washington, DC SP Amer Epilepsy Soc, Amer Clin Neurophysiol Soc DE antiepileptic drugs; electroencephalogram; cognition; neurotoxicity; gabapentin; topiramate ID COGNITIVE PERFORMANCE; DOUBLE-BLIND; CARBAMAZEPINE; EPILEPSY; GABAPENTIN; PHENYTOIN; LAMOTRIGINE; ADULTS; ABILITIES; THERAPY AB Objective. Previous quantitative EEG (QEEG) studies of carbamazepine (CBZ), oxcarbazepine (OXC), and phenytoin (PHT) revealed a pattern of EEG slowing and an increase in drowsiness on the awake maintenance task (AMT). EEG slowing has been shown to correlate with negative effects on cognitive tests. Topiramate (TPM) is a novel AED with relatively large negative effects on cognitive function. We tested the hypothesis that TPM would induce significant slowing of EEG background rhythms and an increase in AMT drowsiness. Methods. Forty healthy volunteers were randomized to TPM, gabapentin (GBP), or placebo. Doses were escalated as tolerated to a maximum of 400 mg/day for TPM or 3600 mg/day for GBP, over a 10-week period, followed by a minimum 2-week plateau period. Volunteers underwent an EEG, cognitive tests, and the AMT prior to starting an AED and again 12 weeks later. The EEG was captured using a structured recording protocol and quantified using the fast Fourier transform. Four target measures were derived from the averaged occipital electrodes (peak frequency of the dominant posterior rhythm, median frequency, percentage theta, and percentage delta). Test re-test changes for all measures were scored against similar test retest distributions previously obtained from untreated healthy volunteers. Results. TPM produced no significant change in any of the four target EEG measures or on the AMT, even though several target cognitive tests revealed moderate or greater negative effects. There were also no significant changes in the placebo group. GBP slowed the peak and median frequency EEG measures and increased the percentage of theta and delta activity. Neither TPM, GBP, nor placebo caused a significant increase in drowsiness on the AMT. Conclusions. TPM has a unique neurotoxicity profile. It has no effect on EEG background measures or on the AMT, but induces moderate to large negative changes in many cognitive test scores. This profile differs from those of CBZ, OXC, PHT, and GBP. (C) 2007 Elsevier Inc. All rights reserved. C1 Oregon Hlth & Sci Univ, Epilepsy Ctr, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. RP Salinsky, M (reprint author), Oregon Hlth & Sci Univ, Epilepsy Ctr, 3181 SW Sam Jackson Pk Rd,CDW-3, Portland, OR 97201 USA. EM Salinsky@OHSU.edu NR 43 TC 9 Z9 10 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD MAY PY 2007 VL 10 IS 3 BP 463 EP 469 DI 10.1016/j.yebeh.2006.12.011 PG 7 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA 165RD UT WOS:000246322200018 PM 17337249 ER PT J AU Sawalha, AH Jeffries, M AF Sawalha, Amr H. Jeffries, Matlock TI Defective DNA methylation and CD70 overexpression in CD4(+) T cells in MRL/lpr lupus-prone mice SO EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE CD70; DNA methylation; lupus; mouse ID SYNGENEIC MICE; ERYTHEMATOSUS; ACTIVATION; DISEASE; CD27; DEMETHYLATION; 5-AZACYTIDINE; MECHANISMS; EXPRESSION; INHIBITORS AB We have determined that abnormal DNA methylation in T cells coincides with the development of autoimmunity, using a mouse model that exhibits an age-dependent lupus-like disease (MRL/1pr mice). Splenic CD4(+) T cells were isolated from these mice at 5 and 16 wk of age (before and after autoimmunity is established) and the expression of DNA methyltransferase 1 (Dnmt1) and the methylation-sensitive gene Tnfsf7 (CD70) was measured. Bisulfite DNA sequencing was used to monitor the methylation status of the Tnfsf7 gene. We found that Dnmt1 steady-state mRNA levels were significantly lower in 16-wk-old MRL/1pr mice, which had established autoimmunity, compared to the 5-wk-old MRL/1pr mice. Furthermore, the expression of CD70 was higher in MRL/1pr mice at 16 wk. CD70 was overexpressed in MRL/1pr mice compared to age- and sexmatched MRL+/+ controls. Bisulfite DNA sequencing of the Tnfsf7 gene in MRL/1pr mice revealed that at 16 wk, CG pairs were hypomethylated compared to 5-wk-old mice, and that Tnfsf7 from MRL/lpr mice was hypomethylated at 16 wk relative to age-matched MRL+/+ controls. Our data indicate that decreased expression of Dnmt1 and the corresponding T cell DNA hypomethylation correlate with the development of age-dependent autoimmunity in MRL/lpr mice. C1 US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. Oklahoma Med Res Fdn, Arthritis & Immunol Program, Oklahoma City, OK 73104 USA. RP Sawalha, AH (reprint author), 825 NE 13th St MS 24, Oklahoma City, OK 73104 USA. EM amr-sawalha@omrf.ouhsc.edu OI Jeffries, Matlock/0000-0001-9516-4312 FU NCRR NIH HHS [P20-RR015577]; NIAMS NIH HHS [P30 AR053483] NR 25 TC 37 Z9 40 U1 0 U2 0 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY SN 0014-2980 J9 EUR J IMMUNOL JI Eur. J. Immunol. PD MAY PY 2007 VL 37 IS 5 BP 1407 EP 1413 DI 10.1002/eji.200636872 PG 7 WC Immunology SC Immunology GA 168XY UT WOS:000246558500029 PM 17429846 ER PT J AU Meeran, SM Katiyar, SK AF Meeran, Syed M. Katiyar, Santosh K. TI Grape seed proanthocyanidins promote apoptosis in human epidermoid carcinoma A431 cells through alterations in Cdki-Cdk-cyclin cascade, and caspase-3 activation via loss of mitochondrial membrane potential SO EXPERIMENTAL DERMATOLOGY LA English DT Article DE apoptosis; cell cycle; grape seed proanthocyanidins; skin cancer ID DEPENDENT KINASE INHIBITORS; CYTOCHROME-C RELEASE; NF-KAPPA-B; POLYPHENOLIC FRACTION; INK4 INHIBITORS; SKIN-CANCER; GROWTH; BCL-2; KERATINOCYTES; INDUCTION AB Dietary grape seed proanthocyanidins (GSPs) prevent photocarcinogenesis in mice. Here, we report that in vitro treatment of human epidermoid carcinoma A431 cells with GSPs inhibited cellular proliferation (13-89%) and induced cell death (1-48%) in a dose (5-100 mu g/ml)- and time (24, 48 and 72 h)-dependent manner. GSP-induced inhibition of cell proliferation was associated with an increase in G1-phase arrest at 24 h, which was mediated through the inhibition of cyclin-dependent kinases (Cdk) Cdk2, Cdk4, Cdk6 and cyclins D1, D2 and E and simultaneous increase in protein expression of cyclin-dependent kinase inhibitors (Cdki), Cip1/p21 and Kip1/p27, and enhanced binding of Cdki-Cdk. The treatment of A431 cells with GSPs (20-80 mu g/ml) resulted in a dose-dependent increase in apoptotic cell death (26-58%), which was associated with an increased protein expression of proapoptotic Bax, decreased expression of antiapoptotic Bcl-2 and Bcl-xl, loss of mitochondrial membrane potential, and cleavage of caspase-9, caspase-3 and PARP. Pretreatment with the pan-caspase inhibitor (z-VAD-fmk) blocked the GSP-induced apoptosis in A431 cells suggesting that GSP-induced apoptosis is associated primarily with the caspase-3-dependent pathway. Together, our study suggests that GSPs possess chemotherapeutic potential against human epidermoid carcinoma cells in vitro, further in vivo mechanistic studies are required to verify the chemotherapeutic effect of GSPs in skin cancers. C1 Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU NCI NIH HHS [CA 104428]; NIAMS NIH HHS [AR 050948-01] NR 41 TC 40 Z9 47 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0906-6705 J9 EXP DERMATOL JI Exp. Dermatol. PD MAY PY 2007 VL 16 IS 5 BP 405 EP 415 DI 10.1111/j.1600-0625.2007.00542.x PG 11 WC Dermatology SC Dermatology GA 155VC UT WOS:000245605500003 PM 17437483 ER PT J AU Novgorodov, AS El-Alwani, M Bielawski, J Obeid, LM Gudz, TI AF Novgorodov, Alexander S. El-Alwani, Mazen Bielawski, Jacek Obeid, Lina M. Gudz, Tatyana I. TI Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration SO FASEB JOURNAL LA English DT Article DE brain development; S1P2 receptor; FTY720; directional guidance cue ID PROTEIN-COUPLED RECEPTORS; SPHINGOSINE 1-PHOSPHATE RECEPTOR; RHO FAMILY GTPASES; CELL-MIGRATION; AXON GUIDANCE; PROLIFERATION; MECHANISMS; FTY720; LYSOPHOSPHOLIPIDS; ANGIOGENESIS AB Sphingosine-1-phosphate (S1P) acts as an extracellular ligand for a family of G-protein coupled receptors that are crucial in cell migration. S1P5 is exclusively expressed in oligodendrocytes and oligodendrocyte precursor cells (OPCs), which migrate considerable distances during brain development. The current studies suggest a physiological role for S1P and S1P5 in regulation of OPC migration. mRNA expression levels of S1P2 and S1P5 are comparable in OPCs, but S1P binding specifically to the S1P5 receptor blocked OPC migration (IC50 = 29 nM). Thus, knocking down S1P5 using siRNA prevented the S1P-induced decrease in OPC migration, whereas knocking down S1P2 did not have any effect. S1P-induced modulation of OPC migration was insensitive to pertussis toxin, suggesting that S1P5-initiated signaling is not mediated by the G alpha(i)-protein coupled pathway. Furthermore, S1P5 appears to engage the G alpha(12/13) protein coupled Rho/ROCK signaling pathway to impede OPC migration. To modulate OPC motility, extracellular S1P could be derived from the export of intracellular S1P generated in response to glutamate treatment of OPCs. These studies suggest that S1P could be a part of the neuron-oligodendroglial communication network regulating OPC migration and may provide directional guidance cues for migrating OPCs in the developing brain. C1 Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA. Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Gudz, TI (reprint author), Med Univ S Carolina, Dept Neurosci, 114 Doughty St, Charleston, SC 29425 USA. EM gudz@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCRR NIH HHS [P20 RR 17677-04]; NIGMS NIH HHS [GM062887] NR 66 TC 82 Z9 86 U1 2 U2 5 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAY PY 2007 VL 21 IS 7 BP 1503 EP 1514 DI 10.1096/fj.06-7420com PG 12 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 162VG UT WOS:000246117000025 PM 17255471 ER PT J AU Lieberman, D Nadel, M Smith, RA Atkin, W Duggirala, SB Fletcher, R Glick, SN Johnson, CD Levin, TR Pope, JB Potter, MB Ransohoff, D Rex, D Schoen, R Schroy, P Winawer, S AF Lieberman, David Nadel, Marion Smith, Robert A. Atkin, Wendy Duggirala, Subash B. Fletcher, Robert Glick, Seth N. Johnson, C. Daniel Levin, Theodore R. Pope, John B. Potter, Michael B. Ransohoff, David Rex, Douglas Schoen, Robert Schroy, Paul Winawer, Sidney TI Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID FLEXIBLE SIGMOIDOSCOPY; ASA CLASSIFICATION; ADENOMA DETECTION; CT COLONOGRAPHY; AVERAGE-RISK; SURVEILLANCE; POLYPECTOMY; GUIDELINES; SOCIETY; UPDATE AB Background: Standardized reporting systems for diagnostic and screening tests facilitate quality improvement programs and clear communication among health care providers. Although colonoscopy is commonly used for screening, diagnosis, and therapy, no standardized reporting system for this procedure currently exists. The Quality Assurance Task Group of the National Colorectal Cancer Roundtable developed a reporting and data system for colonoscopy based on continuous quality improvement indicators. Design: The Task Group systematically reviewed quality indicators recommended by the Multi-Society Task Force on Colorectal Cancer and developed consensus-based terminology for reporting and data systems to capture these data elements. The Task Group included experts in several disciplines: gastroenterology, primary care, diagnostic imaging, and health care delivery. Results and Conclusions: The standardized colonoscopy reporting and data system provides a tool that can be used for efforts in continuous quality improvement within and across practices that use colonoscopy. C1 Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. Amer Canc Soc, Atlanta, GA 30329 USA. Ctr Medicare Serv, Chron Care Policy Grp, Baltimore, MD USA. Ctr Medicaid Serv, Chron Care Policy Grp, Baltimore, MD USA. Harvard Univ, Sch Med, Dept Ambulatory Care, Boston, MA USA. Harvard Univ, Sch Med, Dept Prevent Epidemiol & Social Med, Boston, MA USA. Univ Penn, Penn Presbyterian Med Ctr, Dept Med Imaging, Philadelphia, PA 19104 USA. Mayo Clin, Dept Radiol, Rochester, MN USA. Kaiser Permanente Med Ctr, Dept Gastroenterol, Walnut Creek, CA USA. Louisiana State Univ, Hlth Sci Ctr, Dept Family Med, Shreveport, LA 71105 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ N Carolina, Dept Med, Chapel Hill, NC USA. Indiana Univ, Sch Med, Div Gastroenterol, Indianapolis, IN USA. Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA. Boston Univ, Sch Med, Gastroenterol Sect, Boston, MA 02118 USA. Mem Sloan Kettering Canc Ctr, Dept Med, Serv Gastroenterol & Nutr, New York, NY 10021 USA. St Marks Hosp, Canc Res UK, Colorectal Canc Unit, Harrow, Middx, England. Oregon Hlth & Sci Univ, Div Gastroenterol, Portland, OR 97239 USA. RP Lieberman, D (reprint author), Oregon Hlth & Sci Univ, Div Gastroenterol, Portland VA Med Ctr, P3-GI,POB 1034, Portland, OR 97239 USA. OI Atkin, Wendy/0000-0001-9073-9658 NR 32 TC 159 Z9 160 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2007 VL 65 IS 6 BP 757 EP 766 DI 10.1016/j.gie.2006.12.055 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 164EW UT WOS:000246217300003 PM 17466195 ER PT J AU Horowitz, RE Naritoku, WY AF Horowitz, Richard E. Naritoku, Wesley Y. TI The autopsy as a performance measure and teaching tool SO HUMAN PATHOLOGY LA English DT Article DE autopsy; medical student education; pathology resident training; performance measurement ID ACCURACY AB A survey of pathology training programs about current operations and attitudes revealed that the autopsy is underused in medical student and pathology resident teaching, is inadequately reported, often does not have a dedicated faculty, is not championed by pathologists or clinicians, is not valued as a performance measure, and is barely used as a resource for medical research. The autopsy can be reestablished as a teaching too] and performance measure, but this will require that the autopsy be recognized as a credible and valuable medical procedure. The autopsy must then be funded; and new sources of both volume and funding, such as incorporating autopsies into payment schedules, into clinical trials, and in pay-for-performance initiatives, must be solicited. Once there is reimbursement for autopsies, pathologists, clinicians, and health care administrators will embrace the autopsy as a new source of revenue and as a valid measure of physician, hospital, and health system performance. Pathologists and the pathology specialty societies must take the lead in the reestablishment of the autopsy and must, at the same time, encourage innovations such as centralization, greater use of Pathology Assistants, and application of molecular techniques. New tools for using the autopsy in medical student teaching should be embraced, and the role of the autopsy in pathology residency programs must be reevaluated. (c) 2007 Elsevier Inc. All rights reserved. C1 Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA. W Los Angeles Vet Affairs Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90073 USA. RP Horowitz, RE (reprint author), VA Hlth Care Ctr, Mail Code 691-113, Los Angeles, CA 90073 USA. EM rehorwtz@ucla.edu NR 16 TC 23 Z9 23 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0046-8177 J9 HUM PATHOL JI Hum. Pathol. PD MAY PY 2007 VL 38 IS 5 BP 688 EP 695 DI 10.1016/j.humpath.2007.01.001 PG 8 WC Pathology SC Pathology GA 162UJ UT WOS:000246114700002 PM 17376512 ER PT J AU Nyby, MD Abedi, K Smutko, V Eslami, P Tuck, ML AF Nyby, Michael D. Abedi, Karolin Smutko, Victoria Eslami, Pirooz Tuck, Michael L. TI Vascular angiotensin type 1 receptor expression is associated with vascular dysfunction, oxidative stress and inflammation in fructose-fed rats SO HYPERTENSION RESEARCH LA English DT Article DE angiotensin; hypertension; oxidative stress; vascular; insulin resistance ID CONVERTING ENZYME-INHIBITOR; NITRIC-OXIDE SYNTHASE; AORTIC SMOOTH-MUSCLE; INSULIN-RESISTANCE; HYPERINSULINEMIC RATS; BLOOD-PRESSURE; HYPERTENSION; IMPROVEMENT; SYSTEM; MECHANISMS AB This study determined whether or not oxidative stress and vascular dysfunction in fructose-induced hyper-insulinernic rats are associated with activation of the vascular renin-angiotensin system (RAS). Four groups of rats were used. CONT rats were fed normal rat chow, CONT+CAP were fed normal rat chow and given 500 mg/L captopril in their drinking water, fructose-fed rats (FFR) were fed a high-fructose diet and FFR+CAP were fed the high-fructose diet plus captopril in water. After 8 weeks, the vascular reactivity of mesenteric artery segments was measured. Blood was analyzed for insulin, glucose, hydrogen peroxide and 8-isoprostane. Aortic and heart tissue were used for subjected to quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis. Systolic blood pressure was significantly higher in FFR (p<0.05), and captopril treatment inhibited the blood pressure increase. Mesenteric artery dose-response curves to acetylcholine were shifted to the right in FFR (p<0.05) and were normal in FFR+CAP. Plasma insulin (p<0.05), hydrogen peroxide (p<0.02) and 8-isoprostane (p<0.05) were increased in FFR. Captopril treatment reducd hydrogen peroxide and 8-isoprostane concentrations. Aortic tissue mRNA expression levels were increased for angiotensin-converting enzyme (ACE, p<0.05), angiotensin type 1 receptor (AT1R, p<0.02), NOX4 (p<0.02) and VCAM-1 (p<0.05) in FFR aortic samples. Captopril treatment reduced AT1R, NOX4 and VCAM-1 expression in FFR to levels not different from CONT. Similar changes in heart tissue mRNA expression for angiotensinogen, AT1R and NOX4 were also observed. These results demonstrate that vascular RAS is upregulated in FFR and support the hypothesis that vascular RAS mediates vascular dysfunction and vascular oxidative stress in FFR. C1 VA Greater Los Angles Healthcare Syst, Dept Med, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RP Nyby, MD (reprint author), VA Greater Los Angles Healthcare Syst, Dept Med, Sepulveda 111E,16111 Plummer St, Sepulveda, CA 91343 USA. EM mnyby@ucla.edu NR 25 TC 49 Z9 52 U1 0 U2 2 PU JAPANESE SOC HYPERTENSION CENT ACADEMIC SOC, PUBL OFFICE PI TOYONAKA PA SENRI ASAHI HANKYU BLDG, 13TH FLOOR, 1-5-3 SHINSENRIHIGASHI-MACHI, TOYONAKA, 560-0082, JAPAN SN 0916-9636 J9 HYPERTENS RES JI Hypertens. Res. PD MAY PY 2007 VL 30 IS 5 BP 451 EP 457 DI 10.1291/hypres.30.451 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 189GQ UT WOS:000247977800010 PM 17587757 ER PT J AU Choy, HA Kelley, MM Chen, TL Moller, AK Matsunaga, J Haake, DA AF Choy, Henry A. Kelley, Melissa M. Chen, Tammy L. Moller, Annette K. Matsunaga, James Haake, David A. TI Physiological osmotic induction of Leptospira interrogans adhesion: LigA and LigB bind extracellular matrix proteins and fibrinogen SO INFECTION AND IMMUNITY LA English DT Article ID LYME-DISEASE SPIROCHETE; TANDEM BETA-ZIPPER; FIBRONECTIN-BINDING; STAPHYLOCOCCUS-AUREUS; BORRELIA-BURGDORFERI; GENE-EXPRESSION; MAMMALIAN-CELLS; HOST-CELLS; IDENTIFICATION; BBK32 AB Transmission of leptospirosis occurs through contact of mucous membranes and abraded skin with freshwater contaminated by pathogenic Leptospira spp. Exposure to physiological osmolarity induces leptospires to express high levels of the Lig surface proteins containing imperfect immunoglobulin-like repeats that are shared or differ between LigA and LigB. We report that osmotic induction of Lig is accompanied by 1.6- to 2.5-fold increases in leptospiral adhesion to immobilized extracellular matrix and plasma proteins, including collagens I and IV, laminin, and especially fibronectin and fibrinogen. Recombinant LigA-unique and LigB-unique repeat proteins bind to these same host ligands. We found that the avidity of LigB in binding fibronectin is comparable to that of the Staphylococcus aureus FnBPA D repeats. Both LigA- and LigB-unique repeats interact with the amino-terminal fibrin- and gelatin-binding domains of fibronectin, which are also recognized by fibronectin-binding proteins mediating the adhesion of other microbial pathogens. In contrast, repeats common to both LigA and LigB do not bind these host proteins, and nonrepeat sequences in the carboxyterminal domain of LigB show only weak interaction with fibronectin and fibrinogen. A functional role for the binding activity of LigA and LigB is suggested by the ability of the recombinants to inhibit leptospiral adhesion to fibronectin by 28% and 21%, respectively. The binding of LigA and LigB; to multiple ligands present in different tissues suggests that these adhesins may be involved in the initial colonization and dissemination stages of leptospirosis. The characterization of the Lig adhesin function should aid the design of Lig-based vaccines and serodiagnostic tests. C1 VA Greater LA Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. RP Choy, HA (reprint author), VA Greater LA Healthcare Syst, Div Infect Dis, Bldg 113,Room 225,111F, Los Angeles, CA 90073 USA. EM hachoy@ucla.edu FU NIAID NIH HHS [AI-34431, R01 AI034431, R01 AI034431-10A1, R21 AI034431, R29 AI034431] NR 68 TC 143 Z9 148 U1 0 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD MAY PY 2007 VL 75 IS 5 BP 2441 EP 2450 DI 10.1128/IAI.01635-06 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 165YY UT WOS:000246345000042 PM 17296754 ER PT J AU Kaz, A Kim, YH Dzieciatkowskil, S Lynch, H Watson, P Washington, MK Lin, L Grady, WM AF Kaz, Andrew Kim, Young-Ho Dzieciatkowskil, Slavomir Lynch, Henry Watson, Patrice Washington, Mary Kay Lin, Li Grady, William M. TI Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE Lynch syndrome; HNPCC; DNA methylation; colon cancer; adenoma ID NONPOLYPOSIS COLORECTAL-CANCER; CPG ISLAND METHYLATION; MISMATCH REPAIR DEFICIENCY; HMLH1 PROMOTER; COLON-CANCER; MICROSATELLITE INSTABILITY; BREAST-CANCER; WILD-TYPE; SOMATIC INACTIVATION; MOLECULAR ANALYSIS AB Colorectal cancer (CRC) forms through a series of histologic steps that are accompanied by mutations and epigenetic alterations, which is called the polyp-cancer sequence. The role of epigenetic alterations, such as aberrant DNA methylation, in the polyp-cancer sequence in sporadic CRC and particularly in hereditary colon cancer is not well understood. Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14(ARF) in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a "second hit" mechanism in CRC and to characterize the role of DNA methylation in the polyp phase of the Lynch syndrome. We found MLH1 and p14(ARF) are methylated in 53 and 60% of the Lynch syndrome adenomas and in 4 and 20% of sporadic adenomas, whereas CDKN2A/p16 and MGMT are methylated in 6 and 14% of the Lynch syndrome adenomas versus 50 and 64% of sporadic adenomas. Therefore, the frequency and pattern of gene methylation varies between the Lynch syndrome and sporadic colon adenomas, implying differences in the molecular pathogenesis of the tumors. MLH1 methylation in the Lynch syndrome adenomas suggests gene methylation might have a role in the initiation of these neoplasms. (c) 2007 Wiley-Liss, Inc. C1 Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. Fred Hutchinson Canc Res Ctr, Publ Hlth Sci Div, Seattle, WA 98109 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Samsung Med Ctr, Dept Med, Seoul, South Korea. Sungkyunkwan Univ, Sch Med, Dept Med, Seoul, South Korea. Creighton Univ, Sch Med, Dept Prevent Med, Omaha, NE 68178 USA. Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA. VA Puget Sound Healthcare Syst, R&D Serv, Seattle, WA USA. RP Grady, WM (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D4-100, Seattle, WA 98109 USA. EM wgrady@fhcrc.org NR 53 TC 21 Z9 21 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD MAY 1 PY 2007 VL 120 IS 9 BP 1922 EP 1929 DI 10.1002/ijc.22544 PG 8 WC Oncology SC Oncology GA 146ZA UT WOS:000244972000012 PM 17278092 ER PT J AU Tennstedt, SL Fitzgerald, MP Nager, CW Xu, Y Zimmern, P Kraus, S Goode, PS Kusek, JW Borello-France, D Mallett, V AF Tennstedt, Sharon L. Fitzgerald, Mary Pat Nager, Charles W. Xu, Yan Zimmern, Philippe Kraus, Stephen Goode, Patricia S. Kusek, John W. Borello-France, Diane Mallett, Veronica CA Urinary Incontinence Treatment TI Quality of life in women with stress urinary incontinence SO INTERNATIONAL UROGYNECOLOGY JOURNAL LA English DT Article DE quality of life; urinary incontinence ID UROGENITAL DISTRESS INVENTORY; PELVIC ORGAN PROLAPSE; IMPACT QUESTIONNAIRE; DYSFUNCTION; PREVALENCE; INSTRUMENT; WHITE; URGE AB The objective of this study was to identify clinical and demographic factors associated with incontinence-related quality of life (QoL) in 655 women with stress urinary incontinence who elected surgical treatment. The following factors were examined for their association with QoL as measured with the Incontinence Impact Questionnaire (IIQ): number of incontinence (UI) episodes/day; self-reported type of UI symptoms (stress and urge); sexual function as measured by the Prolapse/Urinary Incontinence Sexual Questionnaire; symptom bother as measured by the Urogenital Distress Inventory; as well as other clinical and sociodemographic factors. A stepwise least-squares regression analysis was used to identify factors significantly associated with QoL. Lower QoL was related to the greater frequency of stress UI symptoms, increasing severity, greater symptom bother, prior UI surgery or treatment, and sexual dysfunction (if sexually active). Health and sociodemographic factors associated with lower incontinence-related QoL included current tobacco use, younger age, lower socioeconomic status, and Hispanic ethnicity. C1 New England Res Inst, Watertown, MA 02472 USA. Loyola Univ, Med Ctr, Maywood, IL 60153 USA. Univ Calif San Diego, Med Ctr, San Diego, CA 92103 USA. Univ Texas, SW Med Ctr, Dallas, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Birmingham VA Med Ctr, Birmingham, AL USA. Univ Alabama, Birmingham, AL USA. NIDDKD, NIH, Bethesda, MD 20892 USA. Duquesne Univ, Pittsburgh, PA 15219 USA. Univ Tennessee, Knoxville, TN USA. RP Tennstedt, SL (reprint author), New England Res Inst, 9 Galen St, Watertown, MA 02472 USA. EM stennstedt@neriscience.com FU NIDDK NIH HHS [U01 DK 60401, U01 DK, U01 DK 58225, U01 DK 58229, U01 DK 58231, U01 DK 58234, U01 DK 60379, U01 DK 60380, U01 DK 60393, U01 DK 60395, U01 DK 60397] NR 22 TC 38 Z9 40 U1 2 U2 5 PU SPRINGER LONDON LTD PI ARTINGTON PA ASHBOURNE HOUSE, THE GUILDWAY, OLD PORTSMOUTH ROAD, ARTINGTON GU3 1LP, GUILDFORD, ENGLAND SN 0937-3462 J9 INT UROGYNECOL J JI Int. Urogynecol. J. PD MAY PY 2007 VL 18 IS 5 BP 543 EP 549 DI 10.1007/s00192-006-0188-5 PG 7 WC Obstetrics & Gynecology; Urology & Nephrology SC Obstetrics & Gynecology; Urology & Nephrology GA 153TK UT WOS:000245457900011 PM 17036169 ER PT J AU Anastos, K Lu, DL Shi, QH Tien, PC Kaplan, RC Hessol, NA Cole, S Vigen, C Cohen, M Young, M Justman, J AF Anastos, Kathryn Lu, Dalian Shi, Qiuhu Tien, Phyllis C. Kaplan, Robert C. Hessol, Nancy A. Cole, Steven Vigen, Cheryl Cohen, Mardge Young, Mary Justman, Jessica TI Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE high-density lipoprotein; highly active antiretroviral therapy; lipids; low-density lipoprotein; women ID DENSITY-LIPOPROTEIN CHOLESTEROL; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; WOMENS INTERAGENCY HIV; HIGH BLOOD CHOLESTEROL; ADULT TREATMENT PANEL; PLASMA-CONCENTRATIONS; PROTEASE INHIBITORS; INFECTED PATIENTS; INSULIN SENSITIVITY; DIABETES-MELLITUS AB Background: The effects of HIV infection, highly active antiretroviral therapy (HAART), and specific antiretroviral agents on lipoproteins in women are not well described. Methods: In a cross-sectional substudy of the Women's Interagency HIV Study with 623 HIV-negative and 1556 HIV-positive women (636 untreated, 419 on non-protease inhibitor [PI] HAART, and 501 on PI-containing HAART), we performed multivariate analyses of associations among fasting lipoprotein levels, HIV infection, and HAART. Results: Untreated HIV-positive women had lower high-density lipoprotein cholesterol (HDL-C and higher triglycerides (TGs) but not lower low-density lipoprotein cholesterol (LDL-C) than HIV-negative women and were the most likely to have unfavorable HDL-C by National Cholesterol Education Program (NCEP) guidelines. PI HAART users had higher LDL-C than untreated HIV-infected women (107 vs. 100 mg/dL, P = 0.0006) and were the most likely to have unfavorable LDL-C and TGs by NCEP guidelines. HIV-negative women and non-PI HAART users had similar HDL-C levels (55 and 53 mg/dL, respectively), which were higher than those in untreated HIV-infected women and PI HAART users (42 and 49 mg/dL, respectively; P < 0.001 for all). Lamivudinc, didanosine, nevirapine, and efavirenz were independently associated with higher HDL-C (P < 0.001 for all). Ritonavir, indinavir/ritonavir, and nelfinavir were associated with higher LDL-C (P < 0.01 for all). Stavudine, abacavir, and all ritonavir- containing regimens were associated with higher TGs (P < 0.05 for all), and tenofovir was associated with lower TGs (P = 0.009). Conclusions: A dyslipidemic pattern was associated with HIV infection itself, was more severe in users of PI-containing HAART, but was not present in women taking non-PI HAART. C1 Montefiore Med Ctr, Womens Interagcy HIV Study, Bronx, NY 10467 USA. Albert Einstein Coll Med, Bronx, NY 10467 USA. Data Solut LLC, Bronx, NY USA. New York Med Coll, Valhalla, NY 10595 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. Univ So Calif, Los Angeles, CA USA. Cook Cty Hosp, Chicago, IL 60612 USA. Georgetown Univ, Med Ctr, Washington, DC 20007 USA. Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. RP Anastos, K (reprint author), Montefiore Med Ctr, Womens Interagcy HIV Study, 3311 Bainbridge Ave, Bronx, NY 10467 USA. EM kanastos@montefiore.org RI Kaplan, Robert/A-2526-2011 FU NCRR NIH HHS [M01-RR-00079, M01-RR-00083]; NIAID NIH HHS [U01-AI-31834, AI-51519, N01-AI-35161, U01-AI-34989, U01-AI-34993, U01-AI-34994, U01-AI-35004, U01-AI-42590]; NICHD NIH HHS [U01-HD-32632]; NIDDK NIH HHS [DK-54615] NR 55 TC 64 Z9 66 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAY 1 PY 2007 VL 45 IS 1 BP 34 EP 42 DI 10.1097/QAI.0b013e318042d5fe PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 160TA UT WOS:000245964000006 PM 17460470 ER PT J AU Pole, N Neylan, TC Otte, C Metzler, TJ Best, SR Henn-Haase, C Marmar, CR AF Pole, Nnamdi Neylan, Thomas C. Otte, Christian Metzler, Thomas J. Best, Suzanne R. Henn-Haase, Clare Marmar, Charles R. TI Associations between childhood trauma and emotion-modulated psychophysiological responses to startling sounds: A study of police cadets SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE childhood trauma; startle; police stress; psychophysiology ID POSTTRAUMATIC-STRESS-DISORDER; SEXUALLY ABUSED GIRLS; ACOUSTIC STARTLE; NEUROENDOCRINE ACTIVITY; MATERNAL-DEPRIVATION; VIETNAM VETERANS; WOMEN; SYMPTOMS; PSYCHOPATHOLOGY; MALTREATMENT AB Childhood trauma may confer risk for adult psychopathology by altering emotional and physiological responses to subsequent stressors. Few studies have distinguished effects of childhood trauma from effects of current Axis I psychopathology on adult psychophysiological reactivity. The authors exposed 90 psychiatrically healthy police cadets to startling sounds under increasing threat of shock while assessing their eyeblink electromyogram (EMG), skin conductance (SC), and heart rate responses. When compared with those who did not endorse early trauma (n = 65), cadets reporting childhood trauma (n = 25) reported less positive emotion and showed greater SC responses across all threat levels. They also showed threat-dependent elevations in reported negative emotions and EMG responses. Results suggest that childhood trauma may lead to long-lasting alterations in emotional and psychophysiological reactivity even in the absence of current Axis I psychopathology. C1 Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Pole, N (reprint author), Univ Michigan, Dept Psychol, 2260 E Hall,530 Church St, Ann Arbor, MI 48109 USA. EM nnamdi@umich.edu FU NIMH NIH HHS [R01-MH056350-06] NR 49 TC 30 Z9 31 U1 1 U2 7 PU AMER PSYCHOLOGICAL ASSOC/EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD MAY PY 2007 VL 116 IS 2 BP 352 EP 361 DI 10.1037/0021-843X.116.2.352 PG 10 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA 168DL UT WOS:000246502900012 PM 17516767 ER PT J AU Peden, DB Bush, RK AF Peden, David B. Bush, Robert K. TI Advances in environmental and occupational disorders 2006 SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE hygiene hypothesis; endotoxin; dendritic cell; Toll receptors; air pollution; allergens; fungi; occupational; indoor exposures; exposure reduction ID HUMAN DENDRITIC CELLS; AIRWAY INFLAMMATION; ENDOTOXIN EXPOSURE; HYGIENE HYPOTHESIS; BIRTH COHORT; ASTHMA; ALLERGEN; IGE; SENSITIZATION; DISEASE AB In 2006, there continued to be significant contributions to the Journal in the area of environmental and occupational allergy. In addition to very strong clinical observations, there were a number of studies that examined the effect of environmental agents on cellular and molecular processes in allergy, and molecular approaches were also used in investigations of allergen structure and biology. The Journal also received a number of very strong epidemiologic studies examining several aspects of environmental and occupational allergy. Thus, this particular area of our specialty thrives as a result of clinical, mechanistic, epidemiologic, and translational observations. This article reviews a number of these papers presented in the journal in 2006. C1 Univ N Carolina, Sch Med, Div Pediat Immunol & Infect Dis, Chapel Hill, NC 27599 USA. Univ N Carolina, Sch Med, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA. Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA. Univ Wisconsin, Sch Med & Publ Hlth, Sect Allergy Immunol Pulm Crit Care & Sleep Med, Madison, WI 53706 USA. RP Peden, DB (reprint author), Univ N Carolina, Sch Med, Div Pediat Immunol & Infect Dis, CB 7310,104 Mason Farm Rd, Chapel Hill, NC 27599 USA. EM David_Peden@med.unc.edu NR 61 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD MAY PY 2007 VL 119 IS 5 BP 1127 EP 1132 DI 10.1016/j.jaci.2007.03.030 PG 6 WC Allergy; Immunology SC Allergy; Immunology GA 167CB UT WOS:000246427200012 PM 17472812 ER PT J AU Venkatesan, B Mahimainathan, L Das, F Ghosh-Choudhury, N Choudhury, GG AF Venkatesan, Balachandar Mahimainathan, Lenin Das, Falguni Ghosh-Choudhury, Nandini Choudhury, Goutam Ghosh TI Downregulation of catalase by reactive oxygen species via PI 3 kinase/Akt signaling in mesangial cells SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Article ID AKT/PROTEIN KINASE-B; TRANSCRIPTION FACTOR FOXO3A; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR PTEN; SMOOTH-MUSCLE-CELLS; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASE; LIFE-SPAN; C-FOS AB Reactive oxygen species (ROS) contribute to many glomerular diseases by targeting mesangial cells. ROS have been shown to regulate expression of many antioxidant enzymes including catalase. The mechanism by which the expression of catalase protein is regulated by ROS is not precisely known. Here we report that increased intracellular ROS level by hydrogen peroxide (H2O2) reduced the expression of catalase. H2O2 increased phosphorylation of Akt kinase in a dose-dependent and sustained manner with a concomitant increase in the phosphorylation of FoxOI transcription factor. Further analysis revealed that H2O2 promoted rapid activation of phosphatidylinositol (PI) 3 kinase. The PI 3 kinase inhibitor Ly294002 and expression of tumor suppressor protein PTEN inhibited Akt kinase activity, resulting in the attenuation of FoxOI phosphorylation and preventing the downregulating effect of H2O2 on catalase protein level. Dominant negative Akt attenuated the inhibitory effect of H2O2 on expression of catalase. Constitutively active FoxOI increased the expression of catalase. However, dominant negative FoxOI inhibited catalase protein level. Catalase transcription was reduced by H2O2 treatment. Furthermore, expression of dominant negative Akt and constitutively active FoxOI increased catalase transcription, respectively. These results demonstrate that ROS downregulate the expression of catalase in mesangial cells by PI3 kinase/Akt signaling via FoxOI as a target. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Choudhury, GG (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu OI /0000-0001-5077-3552 FU NIAMS NIH HHS [R01 AR52425]; NIDDK NIH HHS [R01 DK50190, R01 DK55815] NR 51 TC 49 Z9 52 U1 0 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9541 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD MAY PY 2007 VL 211 IS 2 BP 457 EP 467 DI 10.1002/jcp.20953 PG 11 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 152ET UT WOS:000245344500021 PM 17186497 ER PT J AU Amory, JK Wang, C Swerdloff, RS Anawalt, BD Matsumoto, AM Bremner, WJ Walker, SE Haberer, LJ Clark, RV AF Amory, John K. Wang, Christina Swerdloff, Ronald S. Anawalt, Bradley D. Matsumoto, Alvin M. Bremner, William J. Walker, Susan E. Haberer, Lynda J. Clark, Richard V. TI The effect of 5 alpha reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID BENIGN PROSTATIC HYPERPLASIA; DUAL 5-ALPHA-REDUCTASE INHIBITOR; PLACEBO-CONTROLLED TRIAL; STEROID 5-ALPHA-REDUCTASE; SPERM CONCENTRATION; DIHYDROTESTOSTERONE; EFFICACY; SAFETY; TESTOSTERONE; TYPE-1 AB Context: Dutasteride and finasteride are 5 alpha-reductase inhibitors (5ARIs) that dramatically reduce serum levels of dihydrotestosterone (DHT). Objective: Because androgens are essential for fertility, we sought to determine the impact of 5ARI administration on serum testosterone (T), DHT, and spermatogenesis. Design, Setting, Subjects, and Intervention: We conducted a randomized, double-blinded, placebo-controlled trial in 99 healthy men randomly assigned to receive dutasteride (D; 0.5 mg) (n = 33), finasteride (F; 5 mg) (n = 34), or placebo (n = 32) once daily for 1 yr. Main Outcome Measures: Blood and semen samples were collected at baseline and 26 and 52 wk of treatment and 24 wk after treatment and were assessed for T, DHT, and semen parameters. Results: D and F significantly (P < 0.001) suppressed serum DHT, compared with placebo (D, 94%; F, 73%) and transiently increased serum T. In both treatment groups, total sperm count, compared with baseline, was significantly decreased at 26 wk (D, -28.6%; F, -34.3%) but not at 52 wk (D, -24.9%; F, -16.2%) or the 24-wk follow-up (D, -23.3%; F, -6.2%). At 52 wk, semen volume was decreased (D, -29.7%; F, -14.5%, significantly for D) as was sperm concentration (D, -13.2%; F, -7.4%, neither significant). There was a significant reduction of -6 to 12% in sperm motility during treatment with both D and F and at follow-up. Neither treatment had any effect on sperm morphology. Conclusions: This study demonstrates that the decrease in DHT induced by 5ARIs is associated with mild decreases in semen parameters that appear reversible after discontinuation. C1 Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Geriatr Res Educ & Clin Ctr, Seattle, WA 98195 USA. GlaxoSmithKline Res & Dev Ltd, Dept Clin Pharmacol, Res Triangle Pk, NC 27709 USA. Univ Calif Los Angeles, Harbor Med Ctr, Dept Med, Torrance, CA 90509 USA. Univ Calif Los Angeles, Harbor Med Ctr, Gen Clin Res Ctr, Torrance, CA 90509 USA. RP Clark, RV (reprint author), Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 42 TC 89 Z9 92 U1 0 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAY PY 2007 VL 92 IS 5 BP 1659 EP 1665 DI 10.1210/jc.2006-2203 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 164GI UT WOS:000246221200017 PM 17299062 ER PT J AU Croda, J Ramos, JGR Matsunaga, J Queiroz, A Homma, A Riley, LW Haake, DA Reis, MG Ko, AI AF Croda, Julio Ramos, Joao G. R. Matsunaga, James Queiroz, Adriano Homma, Akira Riley, Lee W. Haake, David A. Reis, Mitermayer G. Ko, Albert I. TI Leptospira immunoglobulin-like proteins as a serodiagnostic marker for acute leptospirosis SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID LINKED IMMUNOSORBENT ASSAYS; HUMAN IMMUNE-RESPONSE; POLYMERASE-CHAIN-REACTION; OUTER-MEMBRANE PROTEIN; URBAN EPIDEMIC; BOVINE LEPTOSPIROSIS; RAPID SERODIAGNOSIS; DIPSTICK ASSAY; M ANTIBODIES; IGM-ELISA AB There is an urgent need for improved diagnosis of leptospirosis, an emerging infectious disease which imparts a large disease burden in developing countries. We evaluated the use of Leptospira immunoglobulin (Ig)-like (Lig) proteins as a serodiagnostic marker for leptospirosis. Lig proteins have bacterial immunoglobulin-like (Big) tandem repeat domains, a moiety found in virulence factors in other pathogens. Sera from patients identified during urban outbreaks in Brazil reacted strongly with immunoblots of a recombinant fragment comprised of the second to sixth Big domains of LigB from L. interrogans serovar Copenhageni, the principal agent for transmission in this setting. Furthermore, the sera recognized an analogous LigB fragment derived from L. kirschneri serovar Grippotyphosa, a pathogenic serovar which is not endemic to the study area. The immunoblot assay detected anti-LigB IgM antibodies in sera from 92% (95% confidence interval, 85 to 96%) of patients during acute-phase leptospirosis. The assay had a sensitivity of 81% for sera from patients with less than 7 days of illness. Anti-LigB antibodies were found in sera from 57% of the patients who did not have detectable anti-whole-Leptospira responses as detected by IgM enzyme-linked immunosorbent assay and microagglutination test. The specificities of the assay were 93 to 100% and 90 to 97% among sera from healthy individuals and patients with diseases that have clinical presentations that overlap with those of leptospirosis, respectively. These findings indicate that the antibody response to this putative virulence determinant is a sensitive and specific marker for acute infection. The use of this marker may aid the prompt and timely diagnosis required to reduce the high mortality associated with severe forms of the disease. C1 Brazilian Minist Hlth, Oswaldo Cruz Fdn, Goncalo Moniz Res Ctr, Salvador, BA, Brazil. Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Brazilian Minist Hlth, Oswaldo Cruz Fdn, Biomanguinhos, Rio De Janeiro, Brazil. Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. Cornell Univ, Weill Med Coll, Div Int Med & Infect Dis, Ithaca, NY USA. RP Ko, AI (reprint author), Fdn OSwaldo Cruz MS, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao 121, BR-40295001 Salvador, BA, Brazil. EM aik2001@med.cornell.edu RI Ko, Albert/P-2343-2015 OI Ko, Albert/0000-0001-9023-2339 FU FIC NIH HHS [D43 TW000905, D43 TW000919, TW-00905, TW-00919]; NIAID NIH HHS [AI-034431, AI-052473, R01 AI034431, R01 AI034431-10A1, R01 AI052473, R21 AI034431, R29 AI034431] NR 63 TC 52 Z9 54 U1 1 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAY PY 2007 VL 45 IS 5 BP 1528 EP 1534 DI 10.1128/JCM.02344-06 PG 7 WC Microbiology SC Microbiology GA 169OA UT WOS:000246600300023 PM 17360842 ER PT J AU Marder, SR West, B Lau, GS Pultz, JA Pikalov, A Marcus, RN Gutierrez-Esteinou, R Crandall, DT AF Marder, Stephen R. West, Britt Lau, Gina S. Pultz, Joseph A. Pikalov, Andrei Marcus, Ronald N. Gutierrez-Esteinou, Rolando Crandall, David T. TI Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: A post Hoc analysis of 4 randomized, placebo-controlled clinical trials SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID DOUBLE-BLIND; INTRAMUSCULAR HALOPERIDOL; SCHIZOAFFECTIVE DISORDER; PHARMACOLOGICAL MANAGEMENT; PARTIAL AGONIST; SHORT-TERM; OLANZAPINE; EFFICACY; ZIPRASIDONE; RISPERIDONE AB Objective: Patients with acute schizophrenia who are agitated typically manifest worse overall symptomatology and are generally more challenging to treat than nonagitated patients. In order to determine whether baseline agitation level influences treatment response, the effects of oral aripiprazole in acute patients with schizophrenia experiencing either higher or lower levels of agitation were examined. Method: A post hoc analysis of pooled data from the first 4 or 6 weeks of 4 randomized, double-blind, placebo-controlled aripiprazole trials was conducted. Patients with a DSM-IV diagnosis of acute schizophrenia randomly assigned to treatment with either aripiprazole 10, 15, 20, or 30 mg/day (N = 790) or placebo (N = 397) were divided into groups experiencing higher or lower agitation at baseline. Higher agitation was defined as a baseline Positive and Negative Syndrome Scale (PANSS)-Excited Component (PEC) score of >= 14 and a score of >= 4 on at least 1 PEC item (excitement, hostility, tension, uncooperativeness, or poor impulse control). Analysis of covariance was used to evaluate PANSS total, Clinical Global Impressions-Improvement scale (CGI-I), and PEC scores between aripiprazole and placebo within the higher and lower agitation groups. Results: In both the higher and lower agitation groups, aripiprazole treatment produced significantly lower PANSS total, CGI-I, and PEC scores at weeks 2 to 6, compared with placebo (p < .05 for each measure). Percentage of concomitant benzodiazepine use was similar at end point for aripiprazole and placebo, and adverse events were generally mild across groups. Conclusions: Aripiprazole significantly improved the core symptoms of acute schizophrenia regardless of baseline agitation level. In particular, agitation symptoms were significantly decreased in patients with higher baseline agitation. Improvements appeared to be independent of benzodiazepine use or excessive sedation effects. These results suggest that oral aripiprazole is an effective and safe treatment option for patients with acute schizophrenia who manifest agitation symptoms. C1 Univ Calif Los Angeles, Semel Inst Neurosci, Los Angeles, CA USA. Bristol Myers Squibb, Columbia, SC USA. Bristol Myers Squibb, Los Angeles, CA USA. Otsuka Amer Pharmaceut Inc, Princeton, NJ USA. Bristol Myers Squibb, Lawrenceville, NJ USA. Bristol Myers Squibb, Plainsboro, NJ USA. RP Marder, SR (reprint author), Univ Calif Los Angeles, VA Greater LA Healthcare Syst, Bldg 210,Rm 130,11301 Wilshire Blvd, Los Angeles, CA USA. EM marder@ucla.edu NR 35 TC 15 Z9 18 U1 1 U2 1 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD MAY PY 2007 VL 68 IS 5 BP 662 EP 668 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 171MO UT WOS:000246740300021 PM 17503974 ER PT J AU Pierre, JM Peloian, JH Wirshing, DA Wirshing, WC Marder, SR AF Pierre, Joseph M. Peloian, John H. Wirshing, Donna A. Wirshing, William C. Marder, Stephen R. TI A randomized, double-blind, placebo-controlled trial on modafinil for negative symptoms in schizophrenia SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID DEFICIT SYNDROME; RATING-SCALE; FATIGUE; CLOZAPINE; EFFICACY; AUGMENTATION; MEDICATIONS; SOMNOLENCE; NARCOLEPSY; OLANZAPINE AB Objective: Negative symptoms are core features of schizophrenia that are functionally debilitating, associated with poor outcomes, and resistant to existing pharmacotherapies. We performed a randomized, double-blind, placebo-controlled study of modafinil, a medication approved for the treatment of excessive daytime sleepiness, to explore its efficacy as an adjunctive therapy for negative symptoms in schizophrenia. Method: Twenty subjects with DSM-IV schizophrenia or schizoaffective disorder were randomly assigned to double-blind treatment with modafinil or placebo for 8 weeks. The study ran from March 2002 through March 2006. Outcome measures included the Scale for the Assessment of Negative Symptoms (SANS), Brief Psychiatric Rating Scale (BPRS), Clinical Global Impressions (CGI) scale, Quality of Life Interview, neurocognitive assessments (California Verbal Learning Test, Degraded Performance-Continuous Performance Test, Trail-Making Test B), and somatic measures (sleep, weight, side effects). Results: Modafinil treatment was associated with a greater rate (CGI-Improvement [CGI-I] score <= 3, 7/10 vs. 1/10) and degree (mean CGI-I score, 3.2 vs. 4.1) of global improvement at study endpoint compared with placebo. However, modafinil did not significantly improve global negative symptoms as measured by the total SANS or SANS individual global items. Modafinil did not significantly worsen psychopathology (according to the BPRS), compared with placebo, and was well tolerated. Conclusions: Although no effect on negative symptoms was found, adjunctive therapy with modafinil may result in global improvements in patients with schizophrenia who have prominent negative symptoms. C1 Vet Adm Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. RP Pierre, JM (reprint author), 11301 Wilshire Blvd,Bldg 210 B-151H, Los Angeles, CA 90073 USA. EM drjoe@ucla.edu NR 52 TC 35 Z9 35 U1 1 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD MAY PY 2007 VL 68 IS 5 BP 705 EP 710 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 171MO UT WOS:000246740300026 PM 17503979 ER PT J AU Zhang, XY Tan, YL Zhou, DF Cao, LY Wu, GY Haile, CN Kosten, TA Kosten, TR AF Zhang, Xiang Yang Tan, Yun Long Zhou, Dong Feng Cao, Lian Yuan Wu, Gui Ying Haile, Colin N. Kosten, Theresa A. Kosten, Thomas R. TI Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenia patients with tardive dyskinesia SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID VITAMIN-E TREATMENT; MANGANESE SUPEROXIDE-DISMUTASE; INDUCED OROFACIAL DYSKINESIA; FREE-RADICAL PATHOLOGY; OXIDATIVE STRESS; POLYMORPHISM; INVOLVEMENT; PLASMA AB Background: Free radical-mediated pathology has been implicated in the development of tardive dyskinesia (TD). Antioxidant defense system alterations and increased lipid peroxidation have been postulated as a possible mechanism for neuronal damage associated with TD. However, the relationship between antioxidant enzymes, lipid peroxidation products, and the severity of TD symptoms has not been determined within a single patient group. Method: Plasma levels of malondialdehyde (MDA), a marker of lipid peroxidation, superoxide dismutase, glutathione peroxidase, and catalase were examined in 80 patients with schizophrenia (DSM-IV criteria) and TD (Schooler-Kane criteria) and 45 schizophrenia patients without TD. Results were compared to those of 50 age-, sex-, and smoking status-matched controls. Tardive dyskinesia severity was assessed using the Abnormal Involuntary Movement Scale, and patient psychopathology was assessed using the Positive and Negative Syndrome Scale. Results: Patients with TD had lower plasma superoxide dismutase, glutathione peroxidase, and catalase levels but higher MDA levels than those without TD. In the patients with TD, MDA levels were positively correlated with Abnormal Involuntary Movement Scale total score and with Positive and Negative Syndrome Scale negative subscore. Superoxide dismutase and catalase activities were inversely correlated with MDA levels. Conclusions: Our data support the hypothesis that oxidative stress is involved in the pathophysiology of TD. These data also suggest a relationship between oxidative stress and the severity of dyskinesia in TD patients. Increased lipid peroxidation may likely be a result of decreased endogenous antioxidant enzyme activities in TD. C1 Baylor Coll Med, VA Med Ctr, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Peking Univ, Inst Mental Hlth, Beijing, Peoples R China. Beijing Hui Long Guan Hosp, Ctr Biol Psychiat, Beijing, Peoples R China. RP Zhang, XY (reprint author), Baylor Coll Med, VA Med Ctr, Dept Psychiat & Behav Sci, Res Bldg 109,room 130,2002 Holcombe Blvd, Houston, TX 77030 USA. EM xyzhang@bcm.edu FU NIDA NIH HHS [P50-DA18827, K05-DA0454] NR 36 TC 45 Z9 46 U1 2 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD MAY PY 2007 VL 68 IS 5 BP 754 EP 760 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 171MO UT WOS:000246740300032 PM 17503985 ER PT J AU Grande, D Asch, DA Armstrong, K AF Grande, David Asch, David A. Armstrong, Katrina TI Do doctors vote? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE professionalism; social science; community health; health policy ID MEDICAL PROFESSIONALISM; PUBLIC ROLES AB Background: Organizational leaders and scholars have issued calls for the medical profession to refocus its efforts on fulfilling the core tenets of professionalism. A key element of professionalism is participation in community affairs. Objective: To measure physician voting rates as an indicator of civic participation. Design: Cross-sectional survey of a subgroup of physicians from a nationally representative household survey of civilian, noninstitutionalized adult citizens. Participants: A total of 350,870 participants in the Current Population Survey (CPS) November Voter Supplement from 1996-2002, including 1,274 physicians and 1,886 lawyers; 414,989 participants in the CPS survey from 1976-1982, including 2,033 health professionals. Measurements: Multivariate logistic regression models were used to compare adjusted physician voting rates in the 1996-2002 congressional and presidential elections with those of lawyers and the general population and to compare voting rates of health professionals in 1996-2002 with those in 1976-1992. Results: After multivariate adjustment for characteristics known to be associated with voting rates, physicians were less likely to vote than the general population in 1998 (odds ratio 0.76; 95% confidence interval [CI] 0.59-0.99), 2000 (odds ratio 0.64; 95% CI 0.44-0.93), and 2002 (odds ratio 0.62; 95% CI 0.48-0.80) but not 1996 (odds ratio 0.83; 95% CI 0.59-1.17). Lawyers voted at higher rates than the general population and doctors in all four elections (P <.001). The pooled adjusted odds ratio for physician voting across the four elections was 0.70 (CI 0.61-0.81). No substantial changes in voting rates for health professionals were observed between 1976-1982 and 1996-2002. Conclusions: Physicians have lower adjusted voting rates than lawyers and the general population, suggesting reduced civic participation. C1 Univ Penn, Robert Wood Johnson Hlth & Soc Scholars Program, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. RP Grande, D (reprint author), Univ Penn, Robert Wood Johnson Hlth & Soc Scholars Program, 3641 Locust Walk, Philadelphia, PA 19104 USA. EM dgrande@wharton.upenn.edu OI Asch, David/0000-0002-7970-286X NR 35 TC 8 Z9 8 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2007 VL 22 IS 5 BP 585 EP 589 DI 10.1007/s11606-007-0105-8 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 158YL UT WOS:000245831500005 PM 17443365 ER PT J AU Steinman, MA Chren, MM Landefeld, CS AF Steinman, Michael A. Chren, Mary-Margaret Landefeld, C. Seth TI What's in a name? Use of brand versus generic drug names in United States outpatient practice SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE drug labeling; drug industry; prescriptions; drug; drugs; generic; names; prescription fees; ambulatory care ID TRADE NAMES; POTENTIAL SAVINGS; SUBSTITUTION; INFORMATION; PHYSICIAN; MEDICAID; BENEFIT AB Background: The use of brand rather than generic names for medications can increase health care costs. However, little is known at a national level about how often physicians refer to drugs using their brand or generic names. Objective: To evaluate how often physicians refer to drugs using brand or generic terminology. Design and Participants: We used data from the 2003 National Ambulatory Medical Care Survey (NAMCS), a nationally representative survey of 25,288 community-based outpatient visits in the United States. After each visit, patient medications were recorded on a survey encounter form by the treating physician or transcribed from office notes. Measurements: Our main outcome measure was the frequency with which medications were recorded on the encounter form using their brand or generic names. Results: For 20 commonly used drugs, the median frequency of brand name use was 98% (interquartile range, 81-100%). Among 12 medications with no generic competition at the time of the survey, the median frequency of brand name use was 100% (range 92-100%). Among 8 medications with generic competition at the time of the survey ("multisource" drugs), the median frequency of brand name use was 79% (range 0-98%; P < .001 for difference between drugs with and without generic competition). Conclusions: Physicians refer to most medications by their brand names, including drugs with generic formulations. This may lead to higher health care costs by promoting the use of brand-name products when generic alternatives are available. C1 San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. San Francisco VA Med Ctr, Dept Dermatol, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94121 USA. RP Steinman, MA (reprint author), San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. EM mike.steinman@ucsf.edu FU NIA NIH HHS [Z01 AG000912, K07 AG000912]; NIAMS NIH HHS [AR02203, K02 AR002203] NR 19 TC 28 Z9 28 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2007 VL 22 IS 5 BP 645 EP 648 DI 10.1007/s11606-006-0074-3 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 158YL UT WOS:000245831500014 PM 17443372 ER PT J AU Egede, LE AF Egede, Leonard E. TI Failure to recognize depression in primary care: Issues and challenges SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID INTERNATIONAL PRIMARY-CARE; LATE-LIFE DEPRESSION; COLLABORATIVE CARE; MAJOR DEPRESSION; MENTAL-DISORDERS; GENERAL-PRACTICE; ANTIDEPRESSANT TREATMENT; COST-EFFECTIVENESS; RANDOMIZED-TRIAL; FOLLOW-UP C1 Charleston VA TREP, Ralph H Johnson VA Med Ctr, Charleston, SC USA. Med Univ S Carolina, Ctr Hlth Dispar Res, Div Gen Internal Med, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Charleston VA TREP, Ralph H Johnson VA Med Ctr, Charleston, SC USA. EM egedel@musc.edu NR 43 TC 27 Z9 27 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2007 VL 22 IS 5 BP 701 EP 703 DI 10.1007/s11606-007-0170-z PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 158YL UT WOS:000245831500025 PM 17370030 ER PT J AU Cordasco, KM Eisenman, DP Glik, DC Golden, JF Asch, SM AF Cordasco, Kristina M. Eisenman, David P. Glik, Deborah C. Golden, Joya F. Asch, Steven M. TI "They blew the levee": Distrust of authorities among hurricane Katrina evacuees SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Hurricane Katrina; disaster planning; trust; qualitative research ID RISK COMMUNICATION; AFRICAN-AMERICANS; TRUST; TRUSTWORTHINESS; BIOTERRORISM; CHALLENGES; PHYSICIANS; ANTHRAX; LESSONS C1 Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA 90024 USA. VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Cordasco, KM (reprint author), Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, 911 Broxton Ave,3rd Floor, Los Angeles, CA 90024 USA. EM kcordasco@mednet.ucla.edu FU ODCDC CDC HHS [K01 CD 000049-02] NR 28 TC 25 Z9 25 U1 0 U2 2 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD MAY PY 2007 VL 18 IS 2 BP 277 EP 282 DI 10.1353/hpu.2007.0028 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 163LY UT WOS:000246162500009 PM 17483557 ER PT J AU Williams, LH Raugi, GJ Dhaliwal, G Saint, S Lipsky, BA AF Williams, Lisa H. Raugi, Gregory J. Dhaliwal, Gurpreet Saint, Sanjay Lipsky, Benjamin A. TI "Are we there yet?" SO JOURNAL OF HOSPITAL MEDICINE LA English DT Editorial Material ID POPULATION-BASED COHORT; INFLAMMATORY MYOPATHIES; DERMATOMYOSITIS; POLYMYOSITIS; CANCER; MYOSITIS; MALIGNANCY; FEATURES C1 [Williams, Lisa H.; Raugi, Gregory J.; Lipsky, Benjamin A.] VA Puget Sound Hlth Care Syst, Primary & Special Med Serv, Dept Pediat, Seattle, WA 98108 USA. [Williams, Lisa H.; Raugi, Gregory J.; Lipsky, Benjamin A.] Univ Washington, Sch Med, Seattle, WA USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Saint, Sanjay] Univ Michigan Hlth Syst, Ann Arbor Vet Affairs Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA. [Saint, Sanjay] Univ Michigan Hlth Syst, Patient Safety Enhancement Program, Ann Arbor, MI 48109 USA. RP Lipsky, BA (reprint author), VA Puget Sound Hlth Care Syst, Primary & Special Med Serv, Dept Pediat, S-111-GIMC,1660 S Columbian Way, Seattle, WA 98108 USA. EM Benjamin.Lipsky@med.va.gov OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 23 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD MAY-JUN PY 2007 VL 2 IS 3 BP 181 EP 188 DI 10.1002/jhm.210 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 292HP UT WOS:000255257400011 PM 17551950 ER PT J AU Mummidi, S Adams, LM VanCompernolle, SE Kalkonde, M Camargo, JF Kulkarni, H Bellinger, AS Bonello, G Tagoh, H Ahuja, SS Unutmaz, D Ahnja, SK AF Mummidi, Srinivas Adams, Lisa M. VanCompernolle, Scott E. Kalkonde, Mrunal Camargo, Jose F. Kulkarni, Hemant Bellinger, Adam S. Bonello, Gregory Tagoh, Hiromi Ahuja, Seema S. Unutmaz, Derya Ahnja, Sunil K. TI Production of specific mRNA transcripts, usage of an alternate promoter, and octamer-binding transcription factors influence the surface expression levels of the HIV cereceptor CCR5 on primary T cells SO JOURNAL OF IMMUNOLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; RECEPTOR 5 CCR5; DISEASE PROGRESSION; IN-VITRO; CHEMOKINE RECEPTORS; INTERLEUKIN-2 GENE; INFECTION; TYPE-1; CORECEPTOR; ENTRY AB Surface levels of CCR5 on memory CD4+ T cells influence HIV-1/AIDS susceptibility. Alternative promoter usage results in the generation of CCR5 mRNA isoforms that differ based on whether they contain or lack the untranslated exon 1. The impact of exon 1-containing transcripts on CCR5 surface expression is unknown. In this study, we show that the increased cell surface expression of CCR5 on primary T cells is associated with selective enrichment of exon 1-containing transcripts. The promoter that drives exon I-containing transcripts is highly active in primary human T cells but not in transformed T cell lines. The transcription factors Oct-1 and -2 inhibit and enhance, respectively, the expression of exon 1-containing transcripts and CCR5 surface levels. However, polymorphisms at homologous octamer-binding sites in the CCR5 promoter of nonhuman primates abrogate the binding of these transcription factors. These results identify exon 1-containing transcripts, and the cis-trans factors that regulate the expression levels of these mRNA isoforms as key parameters that affect CCR5 surface expression levels, and by extension, susceptibility to HIV/AIDS among humans, and possibly, the observed interspecies differences in susceptibility to lentiviral infection. The Journal of Immunology, 2007, 178: 5668-.5681. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. S Texas Vet Healthcare Syst, Vet Adm Ctr AIDS & HIV Infect, San Antonio, TX 78229 USA. Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA. Univ Leeds, St Jamess Univ Hosp, Mol Med Unit, Leeds, W Yorkshire, England. NYU, Sch Med, Dept Microbiol, Joan & Joel Smilow Res Ctr, New York, NY 10016 USA. RP Ahnja, SK (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM derya.unutmaz@med.nyu.edu; ahujas@uthscsa.edu RI Mummidi, Srinivas/C-1004-2008; Tagoh, Hiromi/B-2954-2009 OI Mummidi, Srinivas/0000-0002-4068-6380; Tagoh, Hiromi/0000-0001-9905-6992 FU NIAID NIH HHS [F32 AI 063975, AI 049131, AI 043279, AI 054206]; NIMH NIH HHS [MH 069270]; PHS HHS [NIH R37 046326] NR 57 TC 10 Z9 11 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2007 VL 178 IS 9 BP 5668 EP 5681 PG 14 WC Immunology SC Immunology GA 161YZ UT WOS:000246054400032 PM 17442950 ER PT J AU Reckamp, KL Figlin, RA Moldawer, N Pantuck, AJ Belldegrun, AS Burdick, MD Strieter, RM AF Reckamp, Karen L. Figlin, Robcrt A. Moldawer, Nancy Pantuck, Allan J. Belldegrun, Arie S. Burdick, Marie D. Strieter, Robert M. TI Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy SO JOURNAL OF IMMUNOTHERAPY LA English DT Article DE chemokines; renal cell carcinoma; cytokine therapy ID TUMOR-SUPPRESSOR GENE; PHASE-II TRIAL; T-CELLS; SUBCUTANEOUS INTERLEUKIN-2; CHEMOKINE RECEPTORS; DOSE INTERLEUKIN-2; BIOLOGICAL AXIS; RENCA TUMOR; CANCER; BEVACIZUMAB AB Chemokines play an important role in regulating tumor-mediated immunity, angiogenesis, and tumor cell inetastasis. The chemokine receptor, CXCR3, is expressed in various human tumors, including renal cell carcinoma (RCC). CXCR3 is also associated with antiangiogenic effects in multiple tumors, and we hypothesized that interleukin-2 (IL-2) treatment of patients with metastatic clear cell RCC could augment CXCR3 levels on circulating mononuclear cells and correlate to outcome. The kinetics of CXCR3 expression on circulating mononuclear cells and its ligands (CXCL9, CXCL10, and CXCL11) in plasma were evaluated in 20 patients with metastatic clear cell RCC during cycles I and 2 of high dose IL-2 therapy. Subpopulations of peripheral blood mononuclear cells (PBMCs) were studied by dual color flow cytometry. Angiogenic ligands were measured and an "angiogenic ratio" was calculated prehigh and posthigh dose IL-2. CXCR3 expression on PBMC at baseline was similar in patients with metastatic RCC and normal controls. PBMC CXCR3 expression increased during treatment, and peaked during cycle 2. Plasma from RCC patients displayed similar baseline levels of CXCR3 ligands to normal controls. however, the angiogenic ratio was significantly increased in patients with metastatic RCC at baseline. Plasma levels of CXCR3 ligands increased during treatment, resulting in a reversal in the angiogenic ratio to favor angiostatic chemokines. The CXCR3/CXCR3 ligand biologic axis and angiogenic ratio may be important biomarkers in clear cell RCC patients who are undergoing high dose IL-2 therapy. C1 City Hope Natl Med Ctr, Div Med Oncol & Therapeut Res, Duarte, CA 91010 USA. Beckman Res Inst, Duarte, CA USA. Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22901 USA. Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90024 USA. RP Reckamp, KL (reprint author), City Hope Natl Med Ctr, Div Med Oncol & Therapeut Res, 1500 E Duarte Rd,MOB 1001, Duarte, CA 91010 USA. EM kreckamp@coh.org OI Reckamp, Karen/0000-0002-9213-0325 FU NCI NIH HHS [CA87879, P50CA90388] NR 39 TC 18 Z9 19 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1524-9557 J9 J IMMUNOTHER JI J. Immunother. PD MAY-JUN PY 2007 VL 30 IS 4 BP 417 EP 424 DI 10.1097/CJI.0b013e31802e089a PG 8 WC Oncology; Immunology; Medicine, Research & Experimental SC Oncology; Immunology; Research & Experimental Medicine GA 161QE UT WOS:000246029600006 PM 17457216 ER PT J AU Korutla, L Degnan, R Wang, PJ Mackler, SA AF Korutla, Laxminarayana Degnan, Ryan Wang, Peijie Mackler, Scott A. TI NAC1, a cocaine-regulated POZ/BTB protein interacts with CoREST SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE coimmunoprecipitation; gene expression; homodimers; mammalian two-hybrids; nucleus accumbens; transcriptional repressor ID TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; GENE-EXPRESSION; BTB/POZ DOMAIN; DNA-BINDING; N-COR; REST; RECRUITMENT; ADDICTION; COMPLEXES AB In this report, CoREST was identified as a protein that interacts with NAC1. NAC1 is a cocaine-regulated Pox virus and Zinc finger/Bric-a-brac Tramtrack Broad complex (POZ/BTB) repressor protein, which mediates interactions among several other transcriptional regulators. In the present study, an interaction between NAC1 and CoREST was detected in neuro-2A cells and HEK293T cells. We found that the POZ/BTB domain is necessary and sufficient for interaction with CoREST. Surprisingly, only one of five mutations in the POZ/BTB domain that disrupts homodimer assembly interfered with NAC1 and CoREST interactions. These results indicate that POZ/BTB homodimer formation is not required for NAC1-CoREST interaction. CoREST demonstrated protein-protein interactions with both isoforms of NAC1, sNAC1, and lNAC1. Coimmunoprecipitation studies show that NAC1 and CoREST are physically bound together. To further support the results, a direct interaction was demonstrated in glutathione-S-transferase pull down assays. siRNA directed against NAC1 mRNA significantly reduced NAC1 protein expression and resulted in reversal of CoREST-mediated repression in cells. This interaction between NAC1 and CoREST was not found for other POZ/BTB proteins tested. Endogenous interaction was demonstrated in lysates from rat brain samples. This is the first report to demonstrate that a POZ/BTB protein interacts with CoREST. Taken together, the results indicate that CoREST may be part of the NAC1 repressor mechanism. C1 Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Mackler, SA (reprint author), Univ Penn, Sch Med, Dept Pharmacol, 67 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA. EM smackler@mail.med.upenn.edu FU NIDA NIH HHS [DA 11809] NR 23 TC 21 Z9 22 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD MAY PY 2007 VL 101 IS 3 BP 611 EP 618 DI 10.1111/j.1471-4159.2006.04387.x PG 8 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 158SA UT WOS:000245813600003 PM 17254023 ER PT J AU Bourguignon, LYW Gilad, E Peyrollier, K Brightman, A Swanson, RA AF Bourguignon, Lilly Y. W. Gilad, Eli Peyrollier, Karine Brightman, Amy Swanson, Raymond A. TI Hyaluronan-CD44 interaction stimulates Rac1 signaling and PKN gamma kinase activation leading to cytoskeleton function and cell migration in astrocytes SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE astrocyte; CD44; cytoskeleton; hyaluronan; migration; PKN gamma; Rac1 ID SPINAL-CORD-INJURY; FIBRILLARY ACIDIC PROTEIN; HYALURONIC-ACID; EXTRACELLULAR-MATRIX; TYROSINE PHOSPHORYLATION; REACTIVE ASTROCYTES; POTENTIAL EFFECTOR; NERVE REGENERATION; ADHESION MOLECULE; CD44 INTERACTION AB Both hyaluronan [HA, the major glycosaminoglycans in the extracellular matrix (ECM)] and CD44 (a primary HA receptor) are associated with astrocyte activation and tissue repair following central nervous system (CNS) injury. In this study we investigated the question of whether HA-CD44 interaction influences astrocyte signaling and migration. Our data indicated that HA binding to the cultured astrocytes stimulated Rac1 signaling and cytoskeleton-mediated migration. To determine the cellular and molecular basis of these events, we focused on PKN gamma, a Rac1-activated serine/threonine kinase in astrocytes. We determined that HA binding to astrocytes stimulated Rac1-dependent PKN gamma kinase activity which, in turn, up-regulated the phosphorylation of the cytoskeletal protein, cortactin, and attenuated the ability of cortactin to cross-link F-actin. Further analyses indicated that the N-terminal antiparallel coiled-coil (ACC) domains of PKN gamma interacted with Rac1, and transfection of astrocytes with PKN gamma-ACCcDNA inhibited PKN gamma activity. Over-expression of the PKN gamma-ACC domain also functions as a dominant-negative mutant to block HA/CD44-mediated PKN gamma activation of cortactin and astrocyte migration. Taken together, these findings strongly suggest that hyaluronan/CD44 interaction with Rac1-PKN gamma plays a pivotal role in cytoskeleton activation and astrocyte migration. These newly discovered HA/CD44-induced astrocyte function may provide important insight into novel therapeutic treatments for tissue repair following CNS injury. C1 Univ Calif San Francisco, Dept Med, Endocrine Unit, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Neurol, Endocrine Unit, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Bourguignon, LYW (reprint author), Univ Calif San Francisco, Dept Med, Endocrine Unit, San Francisco VA Med Ctr, 111 N,4150 Clement St, San Francisco, CA 94121 USA. EM lilly.bourguignon@ucsf.edu FU NCI NIH HHS [R01 CA66163, R01 CA78633]; NIAMS NIH HHS [P01 AR39448] NR 62 TC 48 Z9 53 U1 0 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD MAY PY 2007 VL 101 IS 4 BP 1002 EP 1017 DI 10.1111/j.1471-4159.2007.04485.x PG 16 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 161RB UT WOS:000246032000014 PM 17403031 ER PT J AU Vandenbark, A Burrows, G Offner, H Link, J AF Vandenbark, A. Burrows, G. Offner, H. Link, J. TI From EAE to an MS clinical trial: DR 2/MOG-35-55 recombinant T cell receptor ligand treats relapses of experimental encephalomyelitis in DR 2 transgenic mice SO JOURNAL OF NEUROLOGY LA English DT Meeting Abstract CT 17th Meeting of the European-Neurological-Society CY JUN 16-20, 2007 CL Rhodes, GREECE SP European Neurolog Soc C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU DR DIETRICH STEINKOPFF VERLAG PI DARMSTADT PA PO BOX 10 04 62, D-64204 DARMSTADT, GERMANY SN 0340-5354 J9 J NEUROL JI J. Neurol. PD MAY PY 2007 VL 254 SU 3 BP 163 EP 163 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 175SN UT WOS:000247034400624 ER PT J AU Wengreen, HJ Munger, RG Corcoran, CD Zandi, P Hayden, KM Fotuhi, M Skoog, I Norton, MC Tschanz, J Breitner, JCS Welsh-Bohmer, KA AF Wengreen, H. J. Munger, R. G. Corcoran, C. D. Zandi, P. Hayden, K. M. Fotuhi, M. Skoog, I. Norton, M. C. Tschanz, J. Breitner, J. C. S. Welsh-Bohmer, K. A. TI Antioxidant intake and cognitive function of elderly men and women: The cache county study SO JOURNAL OF NUTRITION HEALTH & AGING LA English DT Article DE antioxidants; cognition; elderly; dementia-prevention ID FOOD FREQUENCY QUESTIONNAIRE; SYSTEMIC OXIDATIVE STRESS; ALZHEIMERS-DISEASE; DIETARY-INTAKE; OLDER PERSONS; VITAMIN-E; DEMENTIA; POPULATION; DECLINE; RISK AB Objective: We prospectively examined associations between intakes of antioxidants (vitamins C, vitamin E, and carotene) and cognitive function and decline among elderly men and women of the Cache County Study on Memory and, Aging in Utah. Participants and Design: In 1995, 3831 residents 65 years of age or older completed a baseline survey that included a food frequency questionnaire and cognitive assessment. Cognitive function was assessed using an adapted version of the Modified Mini-Mental State examination (3MS) at baseline and at three subsequent follow-up interviews spanning approximately 7 years. Multivariable-mixed models were used to estimate antioxidant nutrient effects on average 3MS score over time. Results: Increasing quartiles of vitamin C intake alone and combined with vitamin E were associated with higher baseline average 3MS scores (p-trend = 0.013 and 0.02 respectively); this association appeared stronger for food sources compared to supplement or food and supplement sources combined. Study participants with lower levels of intake of vitamin C, vitamin E and carotene had a greater acceleration of the rate of 3MS decline over time compared to those with higher levels of intake. Conclusion: High antioxidant intake from food and supplement sources of vitamin C, vitamin E, and carotene may delay cognitive decline in the elderly. C1 Utah State Univ, Dept Nutr & Food Sci, Logan, UT 84322 USA. Utah State Univ, Ctr Epidemiol Res, Logan, UT 84322 USA. Johns Hopkins Univ, Dept Mental Hlth, Bloomberg Sch publ Hlth, Baltimore, MD 21215 USA. Duke Univ, Ctr Med, Dept Psychiat & Behav Sci, Durham, NC 27710 USA. Sinai Hosp, Div Neurol, Baltimore, MD 21215 USA. Johns Hopkins Univ, Sch Med, Baltimore, MD 21215 USA. Gothenburg Univ, Sahlgrenska Hosp, Sect Psuchiat, Inst Clin Neurosci, S-41124 Gothenburg, Sweden. Dept Family Consumer & Human Dev, Logan, UT 84322 USA. Ctr Epidemiol Res, Logan, UT 84322 USA. Dept Psychol, Logan, UT 84322 USA. Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Duke Univ, Dept Psychiat & Behav Sci, Durham, NC 27710 USA. RP Wengreen, HJ (reprint author), Utah State Univ, Dept Nutr & Food Sci, Logan, UT 84322 USA. RI Corcoran, Chris/F-2155-2010; Tschanz, JoAnn/E-5986-2010; Norton, Maria/E-6994-2013; Hayden, Kathleen/B-6442-2012 OI Hayden, Kathleen/0000-0002-7745-3513; Fotuhi, Majid/0000-0002-0980-1176 FU NIA NIH HHS [AG-11380] NR 42 TC 62 Z9 62 U1 2 U2 8 PU SERDI EDITION PI PARIS PA 320 RUE SAINT-HONORE, PARIS, 75001, FRANCE SN 1279-7707 J9 J NUTR HEALTH AGING JI J. Nutr. Health Aging PD MAY-JUN PY 2007 VL 11 IS 3 BP 230 EP 237 PG 8 WC Geriatrics & Gerontology; Nutrition & Dietetics SC Geriatrics & Gerontology; Nutrition & Dietetics GA 175ZR UT WOS:000247053000004 PM 17508099 ER PT J AU Katiyar, S Elmets, CA Katiyar, SK AF Katiyar, Suchitra Elmets, Craig A. Katiyar, Santosh K. TI Green tea and skin cancer: photoimmunology, angiogenesis and DNA repair SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY LA English DT Review DE green tea polyphenols; photocarcinogenesis; DNA repair; cyclobutane pyrimidine dimer; immunosuppression; contact hypersensitivity; angiogenesis; IL-10; IL-12 ID ULTRAVIOLET-B RADIATION; ANTIGEN-PRESENTING CELL; CONTACT HYPERSENSITIVITY; INDUCED IMMUNOSUPPRESSION; HAIRLESS MICE; T-CELLS; PREVENTS PHOTOCARCINOGENESIS; CYTOKINE PRODUCTION; IMMUNE SUPPRESSION; PYRIMIDINE DIMERS AB Human skin is constantly exposed to numerous noxious physical, chemical and environmental agents. Some of these agents directly or indirectly adversely affect the skin. Cutaneous overexposure to environmental solar ultraviolet (UV) radiation (290-400 nm) has a variety of adverse effects on human health, including the development of melanoma and nonmelanoma skin cancers. Therefore, there is a need to develop measures or strategies, and nutritional components are increasingly being explored for this purpose. The polyphenols present in green tea (Camellia sinensis) have been shown to have numerous health benefits, including protection from UV carcinogenesis. (-)-Epigallocatechin-3-gallate (EGCG) is the major and most photoprotective polyphenolic component of green tea. In this review article, we have discussed the most recent investigations and mechanistic studies that define and support the photoprotective efficacy of green tea polyphenols (GTPs) against UV carcinogenesis. The oral administration of GTPs in drinking water or the topical application of EGCG prevents UVB-induced skin tumor development in mice, and this prevention is mediated through: (a) the induction of immunoregulatory cytokine interleukin (IL) 12; (b) IL-12-dependent DNA repair following nucleotide excision repair mechanism; (c) the inhibition of UVinduced immunosuppression through IL-12-dependent DNA repair; (d) the inhibition of angiogenic factors; and (e) the stimulation of cytotoxic T cells in a tumor microenvironment. New mechanistic information strongly supports and explains the chemopreventive activity of GTPs against photocarcinogenesis. (c) 2007 Elsevier Inc. All rights reserved. C1 Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU NCI NIH HHS [CA089738, CA104428, CA105368]; NIAMS NIH HHS [AR050948-01]; NIEHS NIH HHS [ES11421] NR 68 TC 105 Z9 111 U1 1 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0955-2863 J9 J NUTR BIOCHEM JI J. Nutr. Biochem. PD MAY PY 2007 VL 18 IS 5 BP 287 EP 296 DI 10.1016/j.jnutbio.2006.08.004 PG 10 WC Biochemistry & Molecular Biology; Nutrition & Dietetics SC Biochemistry & Molecular Biology; Nutrition & Dietetics GA 164LY UT WOS:000246236500001 PM 17049833 ER PT J AU Kang, W Kudsk, KA AF Kang, Woodae Kudsk, Kenneth A. TI Is there evidence that the gut contributes to mucosal immunity in humans? SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Review ID ANTIBODY-FORMING-CELLS; POLYMERIC IMMUNOGLOBULIN-A; ESCHERICHIA-COLI VACCINE; UPPER RESPIRATORY-TRACT; MAJOR ABDOMINAL-TRAUMA; HUMAN PERIPHERAL-BLOOD; ILL ADULT PATIENTS; ORAL IMMUNIZATION; PARENTERAL-NUTRITION; ENTERAL NUTRITION AB Background: Our understanding of the common mucosal immune system derives from animal studies. Antigen-sensitized lymphocytes in the gut-associated lymphoid tissue (GALT) migrate via the blood to mucosal tissues to generate the mucosal-associated lymphoid tissue (MALT). In these sites, B cells differentiate into plasma cells and produce antigen-specific secretory IgA, the principal specific immune antiviral and antibacterial defense of moist mucosal surfaces. Responses to oral intake seem necessary to actively maintain this system in health. Experimentally, lack of enteral stimulation with parenteral feeding alters GALT and MALT size and function. These alterations disturb intestinal and extraintestinal mucosal immunity. Methods: This review is an overview of current and classical studies demonstrating the human mucosal immune system and interactions with nutrition. Results: Human evidence of the mucosal immune system exists, although most data are indirect. Gut stimulation after oral intake induces a generalized immune response in the human MALT through a mucosal-immune network. Examples include neonatal development of GALT influenced by enteral feeding, the presence of antigen-specific IgA and antigen-specific IgA-secreting plasma cells in distant mucosal effector sites such as the breast after gut luminal antigen exposure, and isolation of IgA-producing cells from circulating blood. Conclusions: It is unlikely that clinical studies will ever completely define the effect of route of feeding in all patient populations. This may be possible, however, if investigators understand, define and characterize nutrition-dependent immunologic mechanisms, allowing clinicians to examine clinical responses to nutrition in specific patient populations. This might allow generation of new approaches to protect mucosal immunity. C1 William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. Univ Wisconsin, Dept Surg, Madison, WI USA. RP Kudsk, KA (reprint author), 600 Highland Ave,H4-736 CSC, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu NR 77 TC 41 Z9 43 U1 0 U2 2 PU AMER SOC PARENTERAL & ENTERAL NUTRITION PI SILVER SPRING PA 8630 FENTON STREET SUITE 412, SILVER SPRING, MD 20910 USA SN 0148-6071 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD MAY-JUN PY 2007 VL 31 IS 3 BP 246 EP 258 DI 10.1177/0148607107031003246 PG 13 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 195XG UT WOS:000248445100015 PM 17463152 ER PT J AU Leverich, GS Post, RM Keck, PE Altshuler, LL Frye, MA Kupka, RW Nolen, WA Suppes, T McElroy, SL Grunze, H Denicoff, K Moravec, MKM Luckenbaugh, D AF Leverich, Gabriele S. Post, Robert M. Keck, Paul E., Jr. Altshuler, Lori L. Frye, Mark A. Kupka, Ralph W. Nolen, Willem A. Suppes, Trisha McElroy, Susan L. Grunze, Heinz Denicoff, Kirk Moravec, Maria K. M. Luckenbaugh, David TI The poor prognosis of childhood-onset bipolar disorder SO JOURNAL OF PEDIATRICS LA English DT Article ID SUBSTANCE USE DISORDERS; MENTAL-DISORDERS; CLINICAL-COURSE; I-DISORDER; NETWORK I; CHILDREN; ADOLESCENTS; ILLNESS; GUIDELINES; MANIA AB Objective We examined age of onset of bipolar disorder as a potential course-of-iflness modifier with the hypothesis that early onset will engender more severe illness. Study design A total of 480 carefully diagnosed adult outpatients with bipolar disorder (mean age, 42.5 +/- 11.6 years) were retrospectively rated for age of illness onset, time to first pharmacotherapy, and course of illness. Clinicians prospectively rated daily mood fluctuations over I year. Results Of the 480 patients, 14% experienced onset in childhood (12 years or younger); 36% in adolescence (13 to 18 years); 32% in early adulthood (19 to 29 years); and 19% in late adulthood (after 30 years). Childhood-onset bipolar illness was associated with long delays to first treatment, averaging more than 16 years. The patients with childhood or adolescent onset reported more episodes, more comorbidities, and rapid cycling retrospectively; prospectively, they demonstrated more severe mania, depression, and fewer days wen. Conclusions This study demonstrates that childhood onset of bipolar disorder is common and is associated with long delays to first treatment. Physicians and clinicians should be alert to a possible bipolar diagnosis in children in hopes of shortening the time to initiating treatment and perhaps ameliorating the otherwise adverse course of illness. C1 NIMH, DHHS, NIH, Biol Psychiat Branch,Dept Hlth & Human Serv, Bethesda, MD 20892 USA. Univ Cincinnati, Psychopharmacol Res Program, Dept Psychiat, Coll Med, Cincinnati, OH 45221 USA. Cincinnati VA Med Ctr, Ment Hlth Care Line & Gen Clin Res Ctr, Cincinnati, OH USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehv Sci, Los Angeles, CA USA. W Los Angeles VA Med Ctr, Los Angeles, CA USA. Altrecht Inst Ment Hlth Care, Utrecht, Netherlands. Univ Groningen Hosp, Dept Psychiat, Groningen, Netherlands. Univ Texas, SW Med Ctr, Dallas, TX USA. LMU, Psychiat Klin, Munich, Germany. RP Leverich, GS (reprint author), NIMH, DHHS, NIH, Biol Psychiat Branch,Dept Hlth & Human Serv, Bldg 10,Room 3S239,10 Ctr Dr,MSC-1272, Bethesda, MD 20892 USA. EM levericg@mail.nih.gov RI Nolen, Willem/E-9006-2014 OI Grunze, Heinz/0000-0003-4712-8979 NR 45 TC 120 Z9 121 U1 2 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD MAY PY 2007 VL 150 IS 5 BP 485 EP 490 DI 10.1016/j.jpeds.2006.10.070 PG 6 WC Pediatrics SC Pediatrics GA 164PH UT WOS:000246245600012 PM 17452221 ER PT J AU Doyle, SR Donovan, DM Kivlahan, DR AF Doyle, Suzanne R. Donovan, Dennis M. Kivlahan, Daniel R. TI The factor structure of the alcohol use disorders 14 identification test (AUDIT) SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID FIT INDEXES; DRINKING; NONNORMALITY; SENSITIVITY; EMERGENCY; VARIABLES; GOODNESS; PROJECT; SAMPLE; MODELS AB Objective: Past research assessing the factor structure of the Alcohol Use Disorders Identification Test (AUDIT) with various exploratory and confirmatory factor analytic techniques has identified one-, two-, and three-factor solutions. Because different factor analytic procedures may result in dissimilar findings, we examined the factor structure of the AUDIT using the same factor analytic technique on two new large clinical samples and on archival data from six samples studied in previous reports. Method: Responses to the AUDIT were obtained from participants who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), criteria for alcohol dependence in two large randomized clinical trials: the COMBINE (Combining Medications and Behavioral Interventions) Study (N= 1,337; 69% men) and Project MATCH (Matching Alcoholism Treatments to Client Heterogeneity; N= 1,711; 76% men). Supplementary analyses involved six correlation matrices of AUDIT data obtained from five previously published articles. Confirmatory factor analyses based on one-, two-, and three-factor models were conducted on the eight correlation matrices to assess the factor structure of the AUDIT. Results: Across samples, analyses supported a correlated, two-factor solution representing alcohol consumption and alcohol-related consequences. The three-factor solution fit the data equally well, but two factors (alcohol dependence and harmful alcohol use) were highly correlated. The one-factor solution did not provide a good fit to the data. Conclusions: These findings support a two-factor solution for the AUDIT (alcohol consumption and alcohol-related consequences). The results contradict the original three-factor design of the AUDIT and the prevalent use of the AUDIT as a one-factor screening instrument with a single cutoff score. C1 Univ Washington, Inst Alcohol & Drug Abuse, Seattle, WA 98105 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Exellence Subst Abuse Treatment & Educ, Seattle, WA USA. RP Doyle, SR (reprint author), Univ Washington, Inst Alcohol & Drug Abuse, 1107 NE 45th St,Suite 120, Seattle, WA 98105 USA. EM srdoyle@u.washington.edu FU NIAAA NIH HHS [U10 AA11777, U10 AA11721, U10 AA11776, U10 AA11756, U10 AA11799, U10 AA11768, U10 AA11787, U10 AA01179, U10 AA11773, U10 AA11727, U10 AA11783, U10 AA11715, U10 AA11716] NR 31 TC 27 Z9 29 U1 0 U2 5 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD MAY PY 2007 VL 68 IS 3 BP 474 EP 479 PG 6 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA 199RM UT WOS:000248712900019 PM 17446988 ER PT J AU Skolnick, AH Alexander, KP Chen, AY Roe, MT Pollack, CV Ohman, EM Rumsfeld, JS Gibler, WB Peterson, ED Cohen, DJ AF Skolnick, Adam H. Alexander, Karen P. Chen, Anita Y. Roe, Matthew T. Pollack, Charles V., Jr. Ohman, E. Magnus Rumsfeld, John S. Gibler, W. Brian Peterson, Eric D. Cohen, David J. TI Characteristics, management, and outcomes of 5,557 patients age >= 90 years with acute coronary syndromes - Results from the CRUSADE initiative SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID INFARCTION; PHYSICIAN AB Objectives The goal of this work was to explore the treatment and outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) age -90 years. Background The elderly are often excluded from clinical trials of NSTE-ACS and are underrepresented in clinical registries. Methods We used data from the CRUSADE registry to study 5,557 patients with NSTE-ACS age >= 90 years and compared their baseline characteristics, treatment patterns, and in-hospital outcomes with a cohort age 75 to 89 years (n = 46,270). Results Although both groups had much in common, compared with the younger elderly, the older elderly were less likely to be diabetic, smokers, or obese. Among patients without contraindications, the older elderly were less likely to receive glycoprotein IIb/IIIa inhibitors and statins during the first 24 h and were less likely to undergo cardiac catheterization within 48 h. The older elderly were more likely to die (12.0% vs. 7.8%) and experienced more frequent adverse events (26.8% vs. 21.3%) during the hospitalization -differences that persisted after adjustment for baseline patient and hospital characteristics. Increasing adherence to guideline-recommended therapies was associated with both increased bleeding and a graded reduction in risk-adjusted in-hospital mortality across both age groups. Conclusions In this large population of nonagenarians and centenarians with NSTE-ACS, increasing adherence to guideline-recommended therapies was associated with decreased mortality. These findings reinforce the importance of optimizing care patterns for even the oldest patients with NSTE-ACS, while examining novel approaches to reduce the risk of bleeding in this rapidly expanding patient population. C1 St Lukes Mid Amer Heart Inst, Kansas City, MO 64111 USA. Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA. Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. Univ Penn Hlth Syst, Penn Hosp, Philadelphia, PA USA. Univ Colorado, Denver VA Med Ctr, Denver, CO 80202 USA. Univ Cincinnati, Coll Med, Cincinnati, OH USA. RP Cohen, DJ (reprint author), St Lukes Mid Amer Heart Inst, 4401 Wornall Rd, Kansas City, MO 64111 USA. EM dcohen@saint-lukes.org NR 11 TC 73 Z9 79 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAY 1 PY 2007 VL 49 IS 17 BP 1790 EP 1797 DI 10.1016/j.jacc.2007.01.066 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 163CH UT WOS:000246135800007 PM 17466230 ER PT J AU Teal, CR Baham, DL Gor, BJ Jones, LA AF Teal, Cayla R. Baham, Danielle L. Gor, Beverly J. Jones, Lovell A. TI Is the MEDFICTS rapid dietary fat screener valid for premenopausal African-American women? SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Dietetic-Association CY OCT, 2004 CL Anaheim, CA SP Amer Dietet Assoc ID FOOD-FREQUENCY QUESTIONNAIRE; BREAST-CANCER RISK; INTERVENTION TRIAL; RANDOMIZED-TRIAL; FIBER; RELIABILITY; HORMONE; METAANALYSIS; VEGETABLES; ADHERENCE AB Objective To assess the predictive validity of the meats, eggs, dairy, fried foods, fat in baked goods, convenience foods, fats added at the table, and snacks (MEDFICTS) questionnaire, a rapid dietary fat screening instrument, when used with African-American women. Design A case series design was utilized to assess the validity of MEDFICTS compared to the Arizona Food Frequency Questionnaire. Subjects/setting Data for this study were collected from 184 healthy premenopausal African-American women who completed both the MEDFICTS and the Arizona Food Frequency Questionnaire during screening for eligibility in a nutrition intervention study. Statistical analyses performed Analyses of sensitivity, specificity, predictive values, and receiver operating characteristic analysis were used to examine the predictive validity of MEDFICTS. Covariates of correctly and incorrectly identified groups were examined with contingency table analysis and t tests. Results MEDFICTS was a statistically significant predictor of dietary fat consumption, but underestimated fat consumption of >= 30%. MEDFICTS' sensitivity to detect those consuming >= 30% fat was 57.3%, whereas its specificity (detection of those consuming < 30% dietary fat) was 66.0%. Positive and negative predictive values were 80.6% and 38.5%, respectively. A reduction in the threshold score resulted in increased sensitivity but decreased specificity. Women identified by MEDFICTS as consuming < 30% dietary fat but who were actually consuming 30% or more reported greater consumption of fats from foods classified as mixed foods. Conclusions Study findings suggest MEDFICTS underestimates fat consumption of >= 30%. The inclusion of a category to assess mixed foods could improve the sensitivity and specificity of MEDFICTS for predicting dietary fat consumption. These results demonstrate the need for population-based validation of dietary screening instruments. C1 Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Vet Affairs Hlth Serv Res & Dev Serv Ctr Excellen, Houston, TX USA. Univ Texas, MD Anderson Canc Ctr, Ctr Res Minor Hlth, Dept Hlth Dispar Res,Div Canc Prevent & Populat S, Houston, TX 77030 USA. RP Teal, CR (reprint author), Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Sect Hlth Serv Res, Dept Med, 2002 Holcombe 152, Houston, TX 77030 USA. EM cteal@bcm.tmc.edu FU NCCDPHP CDC HHS [K01# DP-000090]; NIMHD NIH HHS [P60 MD000503-02]; PHS HHS [U48 CCU619515] NR 35 TC 8 Z9 9 U1 0 U2 3 PU AMER DIETETIC ASSOC PI CHICAGO PA 216 W JACKSON BLVD #800, CHICAGO, IL 60606-6995 USA SN 0002-8223 J9 J AM DIET ASSOC JI J. Am. Diet. Assoc. PD MAY PY 2007 VL 107 IS 5 BP 773 EP 781 DI 10.1016/j.jada.2007.02.005 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 165UD UT WOS:000246330400018 PM 17467372 ER PT J AU Steinman, MA Landefeld, CS Rosenthal, GE Bertenthal, D Sen, S Kaboli, PJ AF Steinman, Michael A. Landefeld, C. Seth Rosenthal, Gary E. Bertenthal, Daniel Sen, Saunak Kaboli, Peter J. TI Does the number of coexisting chronic diseases affect the adverse association between polypharmacy and prescribing quality in older adults? Response SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID CARE C1 Univ Calif San Francisco, HSR & D Res Enhancement Award Program, San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94143 USA. Iowa City VA Med Ctr, Ctr Res Implementat Innovat Strategies Practice, Iowa City, IA USA. Univ Iowa, Div Gen Internal Med, Dept Internal Med, Carver Coll Med, Iowa City, IA USA. RP Steinman, MA (reprint author), Univ Calif San Francisco, HSR & D Res Enhancement Award Program, San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94143 USA. NR 3 TC 2 Z9 2 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2007 VL 55 IS 5 BP 803 EP 804 DI 10.1111/j.1532-5415.2007.01166.x PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 161RA UT WOS:000246031900028 ER PT J AU Shimazaki, M Martin, JL AF Shimazaki, Mark Martin, Jennifer L. TI Do herbal agents have a place in the treatment of sleep problems in long-term care? SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE alternative therapies; elderly; insomnia; sleep ID VALERIAN EXTRACT; DOUBLE-BLIND; PRIMARY INSOMNIA; HIP-FRACTURES; NURSING-HOME; MELATONIN; EFFICACY; FALLS; COMPLEMENTARY; TOLERABILITY AB Sleep disruption is common in the long-term care setting. This article discusses the available literature on 2 herbal approaches to sleep problems in long-term care. The largest body of evidence exists for the use of the dietary/herbal supplements valerian and melatonin. While these agents appear to have a modest positive effect on sleep quality among older adults, most studies were small in size and included only subjective assessments of sleep quality. In addition, it is unclear whether these agents pose risks to long-term care residents because of potential drug interactions. Additional research is needed before making conclusive recommendations about the use of these interventions for sleep in the long-term care setting. C1 Univ Calif Los Angeles, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Sepulveda, CA USA. RP Martin, JL (reprint author), VA Sepulveda GRECC, 11E,16111 Plummer St, North Hills, CA 91343 USA. EM Jennifer.martin@va.gov FU NCRR NIH HHS [P41 RR001209, P41 RR001209-200140]; NIA NIH HHS [P60 AG010415] NR 37 TC 7 Z9 7 U1 3 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD MAY PY 2007 VL 8 IS 4 BP 248 EP 252 DI 10.1016/j.jamda.2006.11.001 PG 5 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 170EF UT WOS:000246644300009 PM 17498609 ER PT J AU Al-Samarrai, NR Uman, GC Al-Samarrai, T Alessi, CA AF Al-Samarrai, Nahla R. Uman, Gwen C. Al-Samarrai, Teeb Alessi, Cathy A. TI Introducing a new incontinence management system for nursing home residents SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article ID URINARY-INCONTINENCE; INTERVENTION AB Objectives: To describe current practices of incontinence care in nursing homes (NHs) provided by certified nurse assistants (CNAs), and to evaluate the feasibility and acceptability of an integrated incontinence care product, the One Step Incontinence System (OSIS) in the NH setting. While the ultimate purpose of OSIS is to encourage more consistent skin cleansing and thus reduce perineal dermatitis and risk of pressure ulcers, this study reports an initial feasibility test of OSIS. Design: Controlled trial at two NH sites, with one ward at each site assigned to intervention with OSIS and one ward at each site assigned to a control condition with a box of wipes placed at the bedside (BW). Setting: Two NHs (one community and one Veterans Administration) in the Los Angeles area. Participants: 24 incontinent NH residents and 61 CNAs Intervention: OSIS integrates an adult brief and two cleansing/protective wipes into a single item byway of a waterproof pouch that is removed at the time of incontinence care. The OSIS briefs were placed on the intervention wards in the same location(s) and adjacent to regular adult briefs. Measurements: Structured observations of incontinence care episodes were performed by trained research staff at baseline on all wards, and at follow-up with either the intervention (OSIS) or control condition (BW) in place. Observations included resident location, thoroughness and duration of incontinence care, and materials used. In addition, CNAs' opinions of their preferred incontinence care materials and their experience using OSIS were obtained by self-administered survey. Results: Use of OSIS resulted in significantly greater frequency of use of cleansing wipes (97% of episodes) compared to the baseline (77% of episodes) and BW conditions (41% of episodes). In 59% of the observed episodes in the BW condition, the box of wipes was actually missing from the bedside, or completely absent from the patient's room and had to be replaced. The two wipes that were incorporated with OSIS were used for perineal skin cleansing immediately when providing incontinence care. There was a significant reduction in the percentage use of and number of cloth towels used during incontinence care with OSIS (53% of episodes, 0.8 towels) compared to baseline (67%, 1.1 towels) and BW conditions (82%, 1.2 towels; p=.002 and p=.012, respectively). CNAs were significantly less often interrupted by the need to find supplies during OSIS condition (13%) compared to baseline (23%) and BW (36%; p=.005). There were no significant differences between conditions in the thoroughness of observed cleansing. The average observed time for incontinence care from putting on gloves to fastening the clean adult brief (T1) and between uncovering the resident to fastening a clean adult brief M) decreased significantly within both groups (OSIS and BW) at follow-up (all p-values <.05), but there were no significant differences in T1 and T2 between groups at follow-up. CNAs were more likely to report that they felt that OSIS facilitated skin cleansing compared to the BW. Conclusion: We successfully implemented a trial of an innovative adult brief that encouraged skin cleansing during incontinence care. The system was easily and effectively incorporated into the nursing home, was used by CNAs whenever available (97% of the time), and was favored by CNAs. Patterns of incontinence care differed at follow-up with OSIS compared to BW, with fewer linens used, fewer wipes used, and less CNA interruption during care, which may result in greater privacy and comfort for residents. C1 Stat Plus Inc, Torrance, CA 90505 USA. Vet Adm Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Sepulveda, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Vital Res LLC, Los Angeles, CA USA. Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. RP Al-Samarrai, NR (reprint author), Stat Plus Inc, 5108 Newton St, Torrance, CA 90505 USA. EM nahla@statistics-plus.com FU NIA NIH HHS [1R43-AG020867, R43 AG020867, R43 AG020867-01A2] NR 27 TC 8 Z9 8 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD MAY PY 2007 VL 8 IS 4 BP 253 EP 261 DI 10.1016/j.jamda.2006.10.001 PG 9 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 170EF UT WOS:000246644300010 PM 17498610 ER PT J AU Rohit, M Levine, A Hinkin, C Abramyan, S Saxton, E Valdes-Sueiras, M Singer, E AF Rohit, Mona Levine, Andrew Hinkin, Charles Abramyan, Shogik Saxton, Ernestine Valdes-Sueiras, Miguel Singer, Elyse TI Education correction using years in school or reading grade-level equivalent? Comparing the accuracy of two methods in diagnosing HIV-associated neurocognitive impairment SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE HIV; dementia; neuropsychology; WRAT-3; education; reading ID NEUROPSYCHOLOGICAL TEST-PERFORMANCE; BOSTON NAMING TEST; AFRICAN-AMERICAN; NORMATIVE DATA; PREMORBID INTELLIGENCE; INFECTION; LITERACY AB Neuropsychological tests generally require adjustments for years of education when determining the presence of neurocognitive impairment. However, evidence indicates that educational quality, as assessed with reading tests, may be a better reflection of educational attainment among African Americans. Thus, African Americans with poor educational quality may be incorrectly classified with neuroconitive impairment based on neuropsychological tests. We compared the accuracy of neuropsychological test scores standardized using reading grade-equivalent versus years of education in predicting neurocognitive impairment among a sample of Whites and African-American adults who were HIV+. Participants were examined by a neurologist and classified with or without HIV-associated neurocognitive disorders according to accepted criteria. Participants were also classified as impaired versus not impaired based on their neuropsychological test scores standardized by 1) self-reported education or 2) WRAT-3 reading grade-level. Cross tabulation tables were used to determine agreement of the two methods in detecting impairment. Among African-Americans, standardized scores derived from reading scores had greater specificity than those derived from years of education (84. 1% vs. 77.3). Among the Whites, correction based on years of education had both greater specificity and sensitivity. The results suggest that reading tests may be a useful alternative for determining NCI among African Americans. C1 Univ Calif Los Angeles, Natl Neurol AIDS Bank, Dept Neurol, Los Angeles, CA 90025 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90025 USA. Vet Adm Greater Los Angeles Hlth Care Syst, Dept Psychiat, Los Angeles, CA USA. Charles R Drew Univ Med & Sci, Dept Neurol, Los Angeles, CA 90059 USA. RP Levine, A (reprint author), Univ Calif Los Angeles, Natl Neurol AIDS Bank, Dept Neurol, 11645 Wilshire Blvd,Suite 770, Los Angeles, CA 90025 USA. EM ajlevine@mednet.ucla.edu FU NINDS NIH HHS [R24 NS038841-10, NS-38841, R24 NS038841] NR 38 TC 11 Z9 11 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD MAY PY 2007 VL 13 IS 3 BP 462 EP 470 DI 10.1017/S1355617707070506 PG 9 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 162WZ UT WOS:000246121500011 PM 17445295 ER PT J AU Rapp, JH Wakil, L Sawhney, R Pan, XM Yenari, MA Glastonbury, C Coogan, S Wintermark, M AF Rapp, Joseph H. Wakil, Laura Sawhney, Rajiv Pan, Xian Mang Yenari, Midori A. Glastonbury, Christine Coogan, Sheila Wintermark, Max TI Subclinical embolization after carotid artery stenting: New lesions on diffusion-weighted magnetic resonance imaging occur postprocedure SO JOURNAL OF VASCULAR SURGERY LA English DT Article; Proceedings Paper CT 21st Annual Meeting of the Western-Vascular-Society CY SEP 16-19, 2006 CL La Jolla, CA SP Western Vasc Soc ID CEREBRAL PROTECTION; ENDARTERECTOMY; ANGIOPLASTY; ATHEROEMBOLI; INFARCTION; ISCHEMIA; DISEASE; BRAIN; SIZE; RISK AB Objectives: The reported rate of subclinical brain injury after carotid artery stenting (CAS) seen on diffusion-weighted magnetic resonance imaging (DWI) varies from 10% to > 40%. Data from transcranial Doppler after CAS indicate that embolization may continue for several days, suggesting that that at least some lesions seen on DWI occur postprocedure. Because DWI lesions appear hour of embolization, we used DWI to prospectively study patients before CAS, 1 hour after, and 48 hours after CAS to answer this question. Methods: The study participants were 48 male patients aged 59 to 83. All patients were examined by a neurologist before and after the procedure and had DWI preprocedure and 48 hours postprocedure. In addition, 23 patients had a DWI 1 hour post-CAS. Magnetic resonance imaging exams, including axial and coronal DWI and fluid-attenuated inversion recovery images, were read by two neuroradiologists blinded to the study timing. The embolic protection device was obtained from all patients, washed, and the contents examined under a digital microscope for fragments >= 60 mu m. Results: There were two periprocedural strokes and one transient ischemic attack (TIA), but no strokes or TlAs occurred during follow-up. In the 23 patients imaged 1 hour postprocedure, new lesions were found in two (9%), and 18 (78%) had new lesions at 48 hours (P <.001). For the entire study group, the incidence of new lesions at 48 hours was 67% (36/54). The median number of DWI lesions was four (range, 1 to 17). Every protection device examined had atherosclerotic debris, with a mean of 135 +/- 73 fragments (range, 18 to 310) sized > 60 mu m and a mean of eight fragments (range, 2 to 21) sized > 500 mu m. Findings on postprocedure DWI did not correlate with the degree of stenosis, size of angioplasty balloon, or number of inflations, nor with the number or size of fragments retrieved from the protection device. Conclusions: CAS can be performed with a very low incidence of clinically evident neurologic events; however, it is associated with embolization during and after the procedure. Protection devices effectively prevent clinical and subclinical events during the procedure. Significant embolization continues for at least 48 hours postprocedure, causing lesions on DWI when there is no mechanism for cerebral protection. These data correlate with transcranial Doppler reports of continued embolization after CAS and indicate that DWI should be done as late as possible to accurately assess the rate of subclinical brain injury with CAS procedures. C1 San Francisco VA Med Ctr, Vasc Surg Serv, San Francisco, CA USA. Univ Calif San Francisco, Div Vasc Surg, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Serv Radiol, San Francisco, CA USA. San Francisco VA Med Ctr, Serv Neurol, San Francisco, CA USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. Palo Alto VA Med Ctr, Vasc Surg Serv, Palo Alto, CA USA. Stanford Med Ctr, Div Vasc Surg, Stanford, CA USA. RP Rapp, JH (reprint author), San Francisco Dept Vet Affairs Med Ctr, Vasc Surg Serv, 4150 Clement St, San Francisco, CA USA. EM rappj@surgery.ucsf.edu OI GLASTONBURY, CHRISTINE/0000-0002-9611-1287; Wintermark, Max/0000-0002-6726-3951 NR 19 TC 63 Z9 67 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD MAY PY 2007 VL 45 IS 5 BP 867 EP 872 DI 10.1016/j.jvs.2006.12.058 PG 6 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 163CA UT WOS:000246135000001 PM 17376643 ER PT J AU Lombard, LE Steinhauer, KM AF Lombard, Lori E. Steinhauer, Kimberly M. TI A novel treatment for hypophonic voice: Twang therapy SO JOURNAL OF VOICE LA English DT Article DE Twang; hypophonia; voice therapy; epilarynx ID VOCAL FOLD PARALYSIS AB A hypophonic voice, characterized perceptually as weak and breathy, is associated with voice disorders such as vocal fold atrophy and unilateral vocal fold paralysis. Although voice therapy programs for hypophonia typically address the vocal folds or the sound source, twang voice quality was examined in this study as an alternative technique for increasing vocal power by altering the epilarynx or the sound filter. Objective: This study investigated the effect of twang production on physiologic, acoustic, anti perceived voice handicap measures in speakers with hypophonia. Design/Methods: This prospective pilot study compared the vocal outcomes of six participants with hypophonia at pre- and posttreatment time points. Outcome measures included mean airflow rate, intensity in dB sound pressure level (SPL), maximum phonation time, and self-report of voice handicap. Results: All subjects improved in at least three of the four vocal outcome measures. Wilcoxon signed-rank test of paired differences revealed significant differences between pre- and posttherapy group means for airflow rate, SPL, and Voice Handicap Index scores. Conclusion: The twang voice quality as a manipulation of the sound filter offers a clinical complement to traditional voice therapies that primarily address the sound source. C1 Indiana Univ, Indiana, PA 15705 USA. Univ Pittsburgh, Voice Ctr, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Commun Sci & Disorders, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Lombard, LE (reprint author), Indiana Univ, 203 Davis Hall, Indiana, PA 15705 USA. EM llombard@iup.edu NR 18 TC 6 Z9 6 U1 1 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0892-1997 J9 J VOICE JI J. Voice PD MAY PY 2007 VL 21 IS 3 BP 294 EP 299 DI 10.1016/j.jvoice.2005.12.006 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA 171AQ UT WOS:000246707700004 PM 16527452 ER PT J AU Spiegel, B AF Spiegel, Brennan TI Hot topics in gastroenterology: Differential diagnosis of dyspepsia, GERD, and IBS SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAY PY 2007 VL 16 IS 4 BP 571 EP 571 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 171DD UT WOS:000246714200039 ER PT J AU Moriarty, HJ Bunting-Perry, LK Robinson, JP Dowling-Castronovo, A AF Moriarty, Helene J. Bunting-Perry, Lisette K. Robinson, Joanne P. Dowling-Castronovo, Annemarie TI Cognitive, affective, and behavioral dimensions of the lower urinary tract symptom experience in men with Parkinson's disease SO JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING LA English DT Meeting Abstract C1 Univ Penn, Sch Nursing, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. SUNY New Jersey, Coll Nursing, Newark, NJ USA. EM hcincotta@msn.com; Lisette.bunting-Perry@med.va.gov; jprobins@nilgers.edu; a.dowling.castronovo@verizon.net NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1071-5754 J9 J WOUND OSTOMY CONT JI J. Wound Ostomy Cont. Nurs. PD MAY-JUN PY 2007 VL 34 IS 3 SU S BP S66 EP S67 PG 2 WC Nursing SC Nursing GA 171ZK UT WOS:000246773700182 ER PT J AU Robinson, JP Bunting-Perry, LK Moriarty, H Avi-Itzhak, T AF Robinson, Joanne P. Bunting-Perry, Lisette K. Moriarty, Helene Avi-Itzhak, Tamara TI An explanatory study of the lower urinary tract symptom experience and quality of life in men with Parkinson's disease SO JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING LA English DT Meeting Abstract C1 SUNY, Coll Nursing, Newark, NJ USA. Univ Penn, Sch Nursing, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. CUNY York Coll, Jamaica, NY 11451 USA. EM jprobins@rutgers.edu; Lisette.bunting-Perty@med.va.gov; helene.moriarty@med.va.gov; aviitzh@rci.rutgers.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1071-5754 J9 J WOUND OSTOMY CONT JI J. Wound Ostomy Cont. Nurs. PD MAY-JUN PY 2007 VL 34 IS 3 SU S BP S4 EP S4 PG 1 WC Nursing SC Nursing GA 171ZK UT WOS:000246773700005 ER PT J AU Boron, JB Turiano, NA Willis, SL Schaie, W AF Boron, Julie Blaskewicz Turiano, Nicholas A. Willis, Sherry L. Schaie, Warner TI Effects of cognitive training on change in accuracy in inductive reasoning ability SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES LA English DT Article ID OLD-AGE; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; LONGITUDINAL FINDINGS; MENTAL ROTATION; PERFORMANCE; ADULTS; HYPERTENSION; INTELLIGENCE; DECLINE AB We investigated cognitive training effects on accuracy and number of items attempted in inductive reasoning performance in a sample of 335 older participants (M = 72.78 years) from the Seattle Longitudinal Study. We assessed the impact of individual characteristics, including chronic disease. The reasoning training group showed significantly greater gain in accuracy and number of attempted items than did the comparison group; gain was primarily due to enhanced accuracy. Reasoning training effects involved a complex interaction of gender, prior cognitive status, and chronic disease. Women with prior decline on reasoning but no heart disease showed the greatest accuracy increase. In addition, stable reasoning-trained women with heart disease demonstrated significant accuracy gain. Comorbidity was associated with less change in accuracy. The results support the effectiveness of cognitive training on improving the accuracy of reasoning performance. C1 [Boron, Julie Blaskewicz] Georgia Inst Technol, Sch Psychol, Atlanta, GA 30332 USA. [Turiano, Nicholas A.] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Willis, Sherry L.; Schaie, Warner] Penn State Univ, Dept Human Dev & Family Studies, University Pk, PA 16802 USA. RP Boron, JB (reprint author), Georgia Inst Technol, Sch Psychol, 654 Cherry St, Atlanta, GA 30332 USA. EM julie.boron@psych.gatech.edu FU NIA NIH HHS [5 T32 AG00048-26, R37 AG024102, R37 AG08055, U01 AG014263] NR 40 TC 6 Z9 6 U1 2 U2 8 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5014 J9 J GERONTOL B-PSYCHOL JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci. PD MAY PY 2007 VL 62 IS 3 BP P179 EP P186 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology, Multidisciplinary SC Geriatrics & Gerontology; Psychology GA 272CH UT WOS:000253835800006 PM 17507586 ER PT J AU Lipschutz, JH Huber, WG Dahman, MH Thomas, D AF Lipschutz, Joshua H. Huber, Wilhain G. Dahman, Marc H. Thomas, Deanna TI Practical advance in obtaining an emergency airway via cricothyroidotomy SO MILITARY MEDICINE LA English DT Article AB By the time a cricothyroidotomy is deemed necessary, the patient is in critical need of an emergency airway before anoxic damage ensues. Two things are necessary for the delivery of the requisite oxygen. First, an airway must be rapidly established. Second, the airway must be large enough to facilitate ventilation. Present methods for emergency cricothyroidotomy include needle cricothyroidotomy, which suffers from difficulties in both establishment and ventilation. We describe here a practical and widely available method for establishing a timely effective airway that has been used successfully for five patients since 1992. C1 Lutheran Gen Hosp, Dept Trauma Serv, Park Ridge, IL 60068 USA. Thomas Family Dent, Hermittage, PA 16148 USA. Univ Penn, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Overland Pk Reg Trauma Ctr, Overland Pk, KS 66215 USA. NR 7 TC 3 Z9 3 U1 0 U2 0 PU ASSN MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD MAY PY 2007 VL 172 IS 5 BP 504 EP 506 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 167XC UT WOS:000246484800012 ER PT J AU Lee, SH Goswami, S Grudo, A Song, LZ Bandi, V Goodnight-White, S Green, L Hacken-Bitar, J Huh, J Bakaeen, F Coxson, HO Cogswell, S Storness-Bliss, C Corry, DB Kheradmand, F AF Lee, Seung-Hyo Goswami, Sangeeta Grudo, Ariel Song, Li-zhen Bandi, Venkata Goodnight-White, Sheila Green, Linda Hacken-Bitar, Joan Huh, Joseph Bakaeen, Faisal Coxson, Harvey O. Cogswell, Sebastian Storness-Bliss, Claudine Corry, David B. Kheradmand, Farrah TI Antielastin autoimmunity in tobacco smoking-induced emphysema SO NATURE MEDICINE LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; ELASTIN; AIRWAYS; HEALTH AB Chronic obstructive pulmonary disease and emphysema are common destructive inflammatory diseases that are leading causes of death worldwide. Here we show that emphysema is an autoimmune disease characterized by the presence of antielastin antibody and T-helper type 1 (T(H)1) responses, which correlate with emphysema severity. These findings link emphysema to adaptive immunity against a specific lung antigen and suggest the potential for autoimmune pathology of other elastin-rich tissues such as the arteries and skin of smokers. C1 Baylor Coll Med, Dept Med, Sect Pulm & Crit Care, Houston, TX 77030 USA. Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Dept Pathol, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Dept Radiol, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Dept Surg, Houston, TX 77030 USA. Baylor Coll Med, Dept Surg, Houston, TX 77030 USA. Vancouver Gen Hosp, Dept Radiol, Vancouver, BC V6Z 1Y6, Canada. RP Kheradmand, F (reprint author), Baylor Coll Med, Dept Med, Sect Pulm & Crit Care, Houston, TX 77030 USA. EM dcorry@bcm.tmc.edu; farrahk@bcm.tmc.edu RI Lee, Seung Hyo/C-1689-2011; Lee, Seung-Hyo/B-9922-2015; Coxson, Harvey/A-9861-2017 OI Lee, Seung-Hyo/0000-0003-0010-4072; Coxson, Harvey/0000-0001-5750-9711 NR 15 TC 272 Z9 304 U1 7 U2 14 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD MAY PY 2007 VL 13 IS 5 BP 567 EP 569 DI 10.1038/nm1583 PG 3 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 165JW UT WOS:000246302800023 PM 17450149 ER PT J AU Fuhr, PS Liu, L Kuyk, TK AF Fuhr, Patti S. Liu, Lei Kuyk, Thomas K. TI Relationships between feature search and mobility performance in persons with severe visual impairment SO OPTOMETRY AND VISION SCIENCE LA English DT Article DE low vision; mobility; visual rehabilitation; visual search ID EYE-MOVEMENTS; OLDER-ADULTS; LOW-VISION; MACULAR DEGENERATION; RETINITIS-PIGMENTOSA; TARGET ECCENTRICITY; FEATURE-INTEGRATION; AGE; CONJUNCTION; TASK AB Purpose. Because visual search requires both the ability to discriminate visual features and the ability to process information in a large field of view, the association between feature search and mobility of visually impaired (VI) subjects was studied. Methods. Forty-four subjects with severe visual impairment participated in the study. Feature search performance (2 x 2 deg square target amid 1 x 1 deg square distracters) was measured for 8- to 16- and 32-item set-sizes on 10 x 10, 20 x 20, and 40 x 40 deg fields. Mobility was evaluated on indoor high-density obstacle courses under photopic and mesopic illumination. Results. In feature search, VI subjects were slower and made more errors than normal subjects, but they searched in a parallel fashion. On the mobility task, VI subjects walked slower and made more obstacle contacts than age-matched normal controls. In VI subjects, performances on feature search and mobility tasks were significantly associated, with 37.5% to 66.9 of variations in the mobility measurements being accounted for by visual search speed. Conclusions. Feature search reaction time can be a good predictor of VI patients' mobility. C1 Univ Alabama, Birmingham VA Med Ctr, Birmingham, AL 35233 USA. Northrop Grumman Informat Technol, Brooks City Base, TX USA. RP Fuhr, PS (reprint author), Univ Alabama, Birmingham VA Med Ctr, 700 S 19th St 124, Birmingham, AL 35233 USA. EM patti.fuhr@va.gov NR 35 TC 9 Z9 9 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-5488 J9 OPTOMETRY VISION SCI JI Optom. Vis. Sci. PD MAY PY 2007 VL 84 IS 5 BP 393 EP 400 DI 10.1097/OPX.0b013e31804f5afb PG 8 WC Ophthalmology SC Ophthalmology GA 171IE UT WOS:000246728600004 PM 17502822 ER PT J AU Profit, J Zupancic, JAF Gould, JB Petersen, LA AF Profit, Jochen Zupancic, John A. F. Gould, Jeffrey B. Petersen, Laura A. TI Implementing pay-for-performance in the neonatal intensive care unit SO PEDIATRICS LA English DT Article DE pay-for-performance programs; quality improvement ID BIRTH-WEIGHT INFANTS; QUALITY-OF-CARE; MODERATELY PREMATURE-INFANTS; FINANCIAL INCENTIVES; MEDICAL-CARE; HEALTH-CARE; IMPROVEMENT; MORTALITY; RATES; EXPERIENCE AB Pay-for-performance initiatives in medicine are proliferating rapidly. Neonatal intensive care is a likely target for these efforts because of the high cost, available databases, and relative strength of evidence for at least some measures of quality. Pay-for-performance may improve patient care but requires valid measurements of quality to ensure that financial incentives truly support superior performance. Given the existing uncertainty with respect to both the effectiveness of pay-for-performance and the state of quality measurement science, experimentation with pay-for-performance initiatives should proceed with caution and in controlled settings. In this article, we describe approaches to measuring quality and implementing pay-for-performance in the NICU setting. C1 Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Texas Childrens Hosp, Sect Neonatol, Houston, TX 77030 USA. Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Houston, TX USA. Beth Israel Deaconess Med Ctr, Harvard Neonatal Perinatal Med Program, Boston, MA 02215 USA. Calif Perinatal Qual Care Collaborat, Palo Alto, CA USA. Stanford Univ, Perinatal Epidemiol & Hlth Outcomes Res Unit, Div Neonatol, Lucile Packard Childrens Hosp,Sch Med, Palo Alto, CA 94304 USA. RP Profit, J (reprint author), Houston Ctr Qual Care & Utilizat Studies, VA HSR&D 152,200 Holcombe Blvd, Houston, TX 77030 USA. EM profit@bcm.edu OI Zupancic, John/0000-0003-1734-7193 FU NICHD NIH HHS [K23 HD056298, K23 HD056298-01] NR 50 TC 22 Z9 22 U1 1 U2 3 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD MAY PY 2007 VL 119 IS 5 BP 975 EP 982 DI 10.1542/peds.2006-1565 PG 8 WC Pediatrics SC Pediatrics GA 163IM UT WOS:000246153300014 PM 17473099 ER PT J AU Walker, RH Danek, A AF Walker, R. H. Danek, A. TI Obsessive-compulsive disorders due to neuroacanthocytosis treated with citalopram SO PHARMACOPSYCHIATRY LA English DT Letter C1 James J Peters Vet Affairs Med Ctr, Dept Neurol 127, Bronx, NY 10468 USA. Mt Sinai Sch Med, New York, NY USA. Univ Munich, Neurol Klin & Poliklin, Munich, Germany. RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Dept Neurol 127, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM ruth.walker@mssm.edu RI Danek, Adrian/G-7339-2011 OI Danek, Adrian/0000-0001-8857-5383 NR 5 TC 0 Z9 0 U1 0 U2 0 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0176-3679 J9 PHARMACOPSYCHIATRY JI Pharmacopsychiatry PD MAY PY 2007 VL 40 IS 3 BP 132 EP 132 DI 10.1055/s-2007-980202 PG 1 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 176KA UT WOS:000247082500011 PM 17541893 ER PT J AU Fremont, AM Young, AS Chinman, M Pantoja, P Morton, S Koegel, P Sullivan, G Kanouse, D AF Fremont, Allen M. Young, Alexander S. Chinman, Matthew Pantoja, Philip Morton, Sally Koegel, Paul Sullivan, Greer Kanouse, David TI Differences in HIV care between patients with and without severe mental illness SO PSYCHIATRIC SERVICES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; MEDICAL-CARE; PSYCHIATRIC-DISORDERS; SERVICES UTILIZATION; ANCILLARY SERVICES; INFECTED ADULTS; CASE-MANAGEMENT; RISK-FACTORS; HEALTH-CARE AB Objective: This study explored how HIV care differs for infected persons with and without severe mental illness. Methods: Data were obtained through interviews with and chart review of 295 patients with severe mental illness and HIV from public mental health agencies in Los Angeles County and New York City. Data were compared with data from 1,294 HIV patients without severe mental illness from a separate national probability sample. Measures were difficulty obtaining care, whether patients recommend their HIV care provider, hospital problem score, functional health status, and disability days. Results: In Los Angeles, HIV patients with severe mental illness were more likely than those without severe mental illness to have difficulty obtaining care (p < .001); to not recommend their provider (10% versus 5%, p=. 007); and to have problematic hospital care (p=.001), poor health status (p=.001), and more disability days (p <.001). In New York City, HIV patients with severe mental illness were more likely than patients without severe mental illness to have difficulty obtaining care ( p=. 002) and not recommend their provider ( p=. 02). The relationship between severe mental illness and health status in Los Angeles and access in New York City became insignificant after adjustment for sociodemographic factors, drug use, and CD4 cell count. Further adjustment for higher case management rates among HIV patients with severe mental illness reduced disparities only in the West. Conclusions: Patients with severe mental illness experienced more problems with HIV care than patients without severe mental illness, although high case management rates for patients with severe mental illness may have offset some problems. C1 RAND Corp, Dept Hlth, Santa Monica, CA 90407 USA. Greater Los Angeles Vet Hlth Care Syst, Dept Med, Los Angeles, CA USA. Desert Pacific Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs, Los Angeles, CA USA. RTI Int, Res Triangle Pk, NC USA. Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA. RP Fremont, AM (reprint author), RAND Corp, Dept Hlth, 1776 Main St, Santa Monica, CA 90407 USA. EM fremont@rand.org RI Young, Alexander/A-1523-2009 OI Young, Alexander/0000-0002-9367-9213 FU NIMH NIH HHS [P50-MH-54623, R01-MH-55936-05] NR 58 TC 10 Z9 10 U1 5 U2 8 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAY PY 2007 VL 58 IS 5 BP 681 EP 688 DI 10.1176/appi.ps.58.5.681 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 161JC UT WOS:000246009700015 PM 17463350 ER PT J AU Bromley, E AF Bromley, Elizabeth TI Clinicians' concepts of the cognitive deficits of schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Editorial Material DE neurocognition; schizophrenia; prescribing ID PERFORMANCE; DISORDER; CARE AB Several compounds to improve cognition in schizophrenia are being studied in clinical trials, but little is known about how clinicians conceptualize the cognitive deficits of schizophrenia. In a pilot study, the author asked 40 psychiatrists 3 brief questions about the clinical presentation of cognitive deficits. Descriptions of cognitive deficits show high variability. Informants describe phenomenology like follow-through, attention, and emptiness as indicative of cognitive impairment. Informants' concepts of cognitive deficits overlap substantially with positive, negative, and thought disorder symptoms. Clinicians' concepts are complex and contextualized, in contrast to the discrete skills measured by neuropsychological tests. Results suggest that appropriate prescribing of cognition-enhancing medications may be challenging. C1 Univ Calif Los Angeles, Semel Inst Hlth Serv, Res Ctr, Los Angeles, CA 90024 USA. Fdn Psychocultural Res, Palisades, CA 90272 USA. W Los Angeles Vet Affairs Med Ctr, Vet Affairs Desert Pacific Mental Illness Res Edu, Los Angeles, CA 90073 USA. RP Bromley, E (reprint author), Univ Calif Los Angeles, Semel Inst Hlth Serv, Res Ctr, 10920 Wilshire Blvd,Suite 300, Los Angeles, CA 90024 USA. EM ebromley@ucla.edu NR 18 TC 9 Z9 10 U1 2 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAY PY 2007 VL 33 IS 3 BP 648 EP 651 DI 10.1093/schbul/sbm024 PG 4 WC Psychiatry SC Psychiatry GA 178SZ UT WOS:000247241700004 PM 17420175 ER PT J AU Swerdlow, NR Sprock, J Light, GA Cadenhead, K Calkins, ME Dobie, DJ Freedman, R Green, MF Greenwood, TA Gur, RE Mintz, J Olincy, A Nuechterlein, KH Radant, AD Schork, NJ Seidman, LJ Siever, LJ Silverman, JM Stone, WS Tsuang, DW Tsuang, MT Turetsky, BI Braff, DL AF Swerdlow, Neal R. Sprock, Joyce Light, Gregory A. Cadenhead, Kristin Calkins, Monica E. Dobie, Dorcas J. Freedman, Robert Green, Michael F. Greenwood, Tiffany A. Gur, Raquel E. Mintz, Jim Olincy, Ann Nuechterlein, Keith H. Radant, Allen D. Schork, Nicholas J. Seidman, Larry J. Siever, Larry J. Silverman, Jeremy M. Stone, William S. Tsuang, Debbie W. Tsuang, Ming T. Turetsky, Bruce I. Braff, David L. TI Multi-site studies of acoustic startle and prepulse inhibition in humans: Initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE endophenotype; prepulse inhibition; schizophrenia; sex differences; startle ID TOURETTES-SYNDROME; MENSTRUAL-CYCLE; GATING DEFICITS; REFLEX; HABITUATION; RAT; STIMULATION; MODULATION; NORMALS AB Background: Startle and its inhibition by weak lead stimuli ("prepulse inhibition": PPI) are studied to understand the neurobiology of information processing in patients and community comparison subjects (CCS). PPI has a strong genetic basis in infrahumans, and there is evidence for its heritability, stability and reliability in humans. PPI has gained increasing use as an endophenotype to identify vulnerability genes for brain disorders, including schizophrenia. Genetic studies now often employ multiple, geographically dispersed test sites to accommodate the need for large and complex study samples. Here, we assessed the feasibility of using PPI in multi-site studies. Methods: Within a 7-site investigation with multiple measures, the Consortium on the Genetics of Schizophrenia conducted a methodological study of acoustic startle and PPI in CCS. Methods were manualized, videotaped and standardized across sites with intensive in-person training sessions. Equipment was acquired and programmed at the "PPI site" (UCSD), and stringent quality assurance (QA) procedures were used. Testing was completed on 196 CCS over 2.5 years, with 5 primary startle dependent measures: eyeblink startle magnitude, habituation, peak latency, latency facilitation and PPI. Results: Analyses identified significant variability across sites in some but not all primary measures, and determined factors both within the testing process and subject characteristics that influenced a number of test measures. QA procedures also identified non-standardized practices with respect to testing methods and procedural "drift", which may be particularly relevant to multi-site studies using these measures. Conclusion: With thorough oversight and QA procedures, measures of acoustic startle PPI can be acquired reliably across multiple testing sites. Nonetheless, even among sites with substantial expertise in utilizing psychophysiological measures, multi-site studies using startle and PPI as dependent measures require careful attention to methodological procedures. (c) 2007 Elsevier B.V All rights reserved. C1 Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. Univ Calif Los Angeles, Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Psychiat,Massachussetts Mental Hlth Ctr,Publ, Boston, MA 02115 USA. Harvard Univ, Inst Psychiat Epidemiol & Genet, Boston, MA 02115 USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Swerdlow, NR (reprint author), Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. EM nswerdlow@ucsd.edu RI Greenwood, Tiffany/F-6356-2012; Tsuang, Debby/L-7234-2016 OI Greenwood, Tiffany/0000-0002-6080-6503; Tsuang, Debby/0000-0002-4716-1894 FU NIMH NIH HHS [R01 MH065571, K02 MH001436, K02 MH001436-07, K02 MH001436-08, K02 MH001436-09, K02 MH001436-10, R01 MH042228, R01 MH042228-17A1, R01 MH042228-18, R01 MH042228-19, R01 MH042228-20, R01 MH043518, R01 MH065554, R01 MH065558, R01 MH065562, R01 MH065571-01A1, R01 MH065571-02, R01 MH065571-03, R01 MH065571-04, R01 MH065578, R01 MH065588, R01 MH065707, R01 MH084071, R37 MH043518] NR 49 TC 45 Z9 48 U1 1 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD MAY PY 2007 VL 92 IS 1-3 BP 237 EP 251 DI 10.1016/j.schres.2007.01.012 PG 15 WC Psychiatry SC Psychiatry GA 167CZ UT WOS:000246429800028 PM 17346930 ER PT J AU Tregellas, JR Davalos, DB Rojas, DC Waldo, MC Gibson, L Wylie, K Du, YP Freedman, R AF Tregellas, Jason R. Davalos, Deana B. Rojas, Donald C. Waldo, Merilyne C. Gibson, Linzi Wylie, Korey Du, Yiping P. Freedman, Robert TI Increased hemodynamic response in the hippocampus, thalamus and prefrontal cortex during abnormal sensory gating in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; fMRI; sensory gating; hippocampus; thalamus; prefrontal cortex ID AUDITORY EVOKED-RESPONSES; DRUG-FREE PATIENTS; NEUROPHYSIOLOGICAL EVIDENCE; BRAIN; P50; INTERNEURONS; METAANALYSIS; ACTIVATION; SYMPTOMS; DEFICITS AB Objective: Deficits in sensory gating are a common feature of schizophrenia. Failure of inhibitory gating mechanisms, shown by poor suppression of evoked responses to repeated auditory stimuli, has been previously studied using EEG methods. These methods yield information about the temporal characteristics of sensory gating deficits, but do not identify brain regions involved in the process. Hence, the neuroanatomical substrates of poor sensory gating in schizophrenia remain largely unknown. This study used functional magnetic resonance imaging (fMRI) to investigate the functional neuroanatomy of sensory gating deficits in schizophrenia. Methods: Twelve patients with schizophrenia and 12 healthy comparison subjects were scanned at 3 Tesla while performing a sensory gating task developed for fMRI. P50 EEG evoked potential recordings from a paired-stimulus conditioning-test paradigm were obtained from the same subjects. Results: Compared to healthy comparison subjects, patients with schizophrenia exhibited greater activation in the hippocampus, thalamus, and dorsolateral prefrontal cortex (DLPFC) during the fMRI sensory gating task. No group difference was observed in the superior temporal gyrus. Schizophrenia subjects also showed decreased P50 suppression as measured with EEG. Hemodynamic response in the fMRI measure was positively correlated with test/conditioning ratios from the EEG sensory gating measure. Conclusions: Poor sensory gating in schizophrenia is associated with dysfunction of an apparent network of brain regions, including the hippocampus, thalamus and DLPFC. Greater activation of these regions is consistent with evidence for diminished inhibitory function in schizophrenia. (c) 2007 Elsevier B.V. All rights reserved. C1 Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. Denver VA Med Ctr, MIRECC, VISN19, Denver, CO USA. Colorado State Univ, Dept Psychol, Ft Collins, CO 80523 USA. RP Tregellas, JR (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Campus Box C268-71,4200 E 9th Ave, Denver, CO 80262 USA. EM Jason.Tregellas@UCHSC.edu RI Rojas, Don/F-4296-2012; Tregellas, Jason/J-3637-2015 OI Rojas, Don/0000-0001-6560-9616 FU NIMH NIH HHS [5 P50 MH068582, P50 MH044212, P50 MH044212-090001, P50 MH068582] NR 42 TC 83 Z9 87 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD MAY PY 2007 VL 92 IS 1-3 BP 262 EP 272 DI 10.1016/j.schres.2006.12.033 PG 11 WC Psychiatry SC Psychiatry GA 167CZ UT WOS:000246429800030 PM 17336502 ER PT J AU Basile, JN AF Basile, Jan N. TI Recognizing the link between CKD and CVD in the primary care setting: Accurate and early diagnosis for timely and appropriate intervention SO SOUTHERN MEDICAL JOURNAL LA English DT Review DE chronic kidney disease; diabetes; hypertension; cardiovascular disease; proteinuria; anemia ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; CARDIOVASCULAR-DISEASE; DIABETIC-NEPHROPATHY; BLOOD-PRESSURE; RENAL-DISEASE; RISK-FACTOR; NONDIABETIC INDIVIDUALS; SERUM CREATININE; PROTEINURIA AB Chronic kidney disease (CKD), which is becoming increasingly prevalent in the US and worldwide, eventually progresses to end-stage renal disease (ESRD), requiring renal replacement therapy. Diabetes and hypertension, the two leading causes of CKD, are themselves reaching near epidemic proportions. Hypertension can cause both the development and progression of CKD, and CKD is a significant risk factor for the development of cardiovascular disease. Indeed, CKD patients are more likely to die of cardiovascular complications than progress to ESRD. However, data indicate that early recognition and management of CKD can have a significant positive impact on disease outcome. This creates an important interventional opportunity for the primary care physician. This report describes the major risk factors and comorbidities associated with the development and progression of CKD and offers suggestions for timely diagnosis and management of CKD in the primary care setting. C1 Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Basile, JN (reprint author), Med Univ S Carolina, Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. EM Jan.Basile@med.va.gov NR 39 TC 7 Z9 8 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 J9 SOUTH MED J JI South.Med.J. PD MAY PY 2007 VL 100 IS 5 BP 499 EP 505 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 172AZ UT WOS:000246777800013 PM 17534087 ER PT J AU Levine, DA Kiefe, CI Howard, G Howard, VJ Williams, OD Allison, JJ AF Levine, Deborah A. Kiefe, Catarina I. Howard, George Howard, Virginia J. Williams, O. Dale Allison, Jeroan J. TI Reduced medication access - A marker for vulnerability in US stroke survivors SO STROKE LA English DT Article DE access to health care; secondary prevention; stroke ID CHRONICALLY ILL; ISCHEMIC-STROKE; RISK-FACTORS; CARE; HEALTH; COST; UNDERUSE; ADULTS; BENEFICIARIES; PREVALENCE AB Background and Purpose - Medication access is crucial to secondary stroke prevention. We assessed medication access and associated barriers to care across region and time in a national sample of US stroke survivors. Methods - Among all 5840 black or white stroke survivors aged >= 45 years responding to the National Health Interview Survey years 1997 to 2004, we examined inability to afford medications within the last 12 months across region ( Northeast, Midwest, West, South) and time. With logistic regression, we adjusted associations between medication inaffordability and region and time for age, sex, race, neurological disability, comorbidity, health status, insurance, income and out-of-pocket medical expenses. Results - In 2004, approximate to 76 000 US stroke survivors were unable to afford medications. Lower medication affordability was reported among stroke survivors who were <65 years old, black, female, had high comorbidity or low health status. Compared with stroke survivors able to afford medications, those unable more frequently reported lack of transportation ( 15% versus 3%; P<0.001), no health insurance ( 16% versus 3%; P<0.001), no usual place of care ( 6% versus 2%; P=0.001), income <$ 20 000 ( 66% versus 40%; P<0.001) and out-of-pocket medical expenses >=$ 2000 ( 35% versus 25%; P<0.001). From 1997 to 2004, inability to afford medications increased significantly from 8.1% to 12.7% ( P-trend=0.01) overall and increased in all US regions except the Northeast. Conclusions - We identified a vulnerable stroke survivor population with reduced medication access and increased barriers to medical care. Membership in this population has grown substantially from 1997 to 2004, potentially leading to increased recurrent stroke incidence. C1 Univ Alabama, Dept Med, Div Gen Internal Med, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Deep S Ctr Effectiveness Res, Birmingham, AL USA. Univ Alabama, Sch Publ Hlth, Dept Biostat, Tuscaloosa, AL 35487 USA. Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. RP Levine, DA (reprint author), Univ Alabama, Dept Med, Div Gen Internal Med, 1530 3rd Ave S,FOT 720, Birmingham, AL 35294 USA. EM dlevine@uab.edu OI Allison, Jeroan/0000-0003-4472-2112 FU NINDS NIH HHS [NS 041588, R01 NS041588, U01 NS041588] NR 47 TC 20 Z9 21 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAY PY 2007 VL 38 IS 5 BP 1557 EP 1564 DI 10.1161/STROKEAHA.106.478545 PG 8 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 160DM UT WOS:000245919500024 PM 17395861 ER PT J AU Lam, PPL Binker, LIC Lugea, A Pandol, SJ Gaisano, HY AF Lam, Patrick P. L. Binker, Laura I. Cosen Lugea, Aurelia Pandol, Stephen J. Gaisano, Herbert Y. TI Alcohol redirects CCK-mediated apical exocytosis to the acinar basolateral membrane in alcoholic pancreatitis SO TRAFFIC LA English DT Article DE alcoholic pancreatitis; cholecystokinin; exocytosis; Munc18c; SNARE proteins ID REGULATED EXOCYTOSIS; ENZYME-SECRETION; CELL; CHOLECYSTOKININ; FUSION; MUNC18C; MECHANISMS; MACHINERY; PROTEINS; SYNTAXIN AB The molecular mechanism of clinical alcohol-induced pancreatitis remains vague. We had reported that experimental high-dose cholecystokinin (CCK)-induced pancreatitis is in part because of excessive aberrant basolateral exocytosis. High-dose CCK caused Munc18c on basolateral plasma membrane (BPM) to dissociate from syntaxin (Syn)-4, activating Syn-4 to complex with plasma membrane (PM)-SNAP-23 and granule-VAMP to mediate basolateral exocytosis. We now hypothesize that alcohol could render the acinar cell BPM conducive to exocytosis by a similar mechanism. Weakly stimulating postprandial doses of alcohol (20-50 mm) inhibited postprandial low-dose CCK-stimulated secretion by blocking physiologic apical exocytosis and redirecting exocytosis to less-efficient basal PM (visualized by FM1-43 fluorescence imaging) and lateral PM sites (electron microscopy). Alcohol or low-dose CCK had no effect on PM-Munc18c, but alcohol preincubation enabled low-dose CCK to displace Munc18c from BPM, leading to SNARE complex assembly in the BPM. Similarly, alcohol diet-fed rats did not exhibit morphologic defects in the pancreas nor affected PM-Munc18c behavior, but subsequent intraperitoneal injections of low-dose CCK analog cerulein caused Munc18c displacement from BPM and cytosolic degradation, which contributed to pancreatitis. We conclude that alcohol induces BPM-Munc18c to become receptive to postprandial CCK-induced displacement into the cytosol, a process which facilitates SNARE complex assembly that in turn activates restricted BPM sites to become available for aberrant exocytosis into the interstitial space, where zymogen activation would take place and cause pancreatitis. C1 Univ Toronto, Dept Med, Univ Hlth Network, Toronto, ON M5S 1A8, Canada. Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada. Vet Affairs Greater Los Angeles Healthcare Syst, Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA 90073 USA. RP Gaisano, HY (reprint author), Univ Toronto, Dept Med, Univ Hlth Network, 100 Coll St, Toronto, ON M5S 1A8, Canada. EM herbert.gaisano@utoronto.ca FU NIAAA NIH HHS [P50 AA11999, R21 AA015579-01A1] NR 33 TC 23 Z9 23 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1398-9219 J9 TRAFFIC JI Traffic PD MAY PY 2007 VL 8 IS 5 BP 605 EP 617 DI 10.1111/j.1600-0854.2007.00557.x PG 13 WC Cell Biology SC Cell Biology GA 160MK UT WOS:000245945500013 PM 17451559 ER PT J AU King, CR Freedland, SJ Terris, MK Kane, CJ Amling, CL Aronson, WJ Presti, JC AF King, Christopher R. Freedland, Stephen J. Terris, Martha K. Kane, Christopher J. Amling, Christopher L. Aronson, William J. Presti, Joseph C., Jr. TI Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: A report from the SEARCH database SO UROLOGY LA English DT Article ID RADICAL PROSTATECTOMY; PSA VELOCITY; CANCER; RISK; HYPERPLASIA; RECURRENCE AB Objectives To test the validity of preoperative prostate-specific antigen velocity (PSAV) (the rate of PSA rise before diagnosis) as a predictor for relapse after radical prostatectomy, in the context of patient obesity as measured by body mass index (BMI). Methods The rates of biochemical relapse were examined among 215 patients who underwent radical prostatectomy between 1992 and 2005. Kaplan-Meier relapse rates as a function of preoperative PSAV 2 ng/mL/yr or less versus greater than 2 ng/mL/yr were compared in two groups: nonobese patients (normal to overweight, BMI less than 30 kg/m(2)) and obese patients (mild to severely obese, BMI 30 kg/m(2) or greater). Results A preoperative PSAV greater than 2 ng/mL/yr was associated with higher relapse rates after radical prostatectomy compared with a PSAV of 2 ng/mL/yr or less, with 5-year relapse-free survival rates of 60% versus 70%, respectively (P = 0.03). Prostate-specific antigen velocity was independently significant on multivariate analysis, along with biopsy Gleason score, percent positive cores, and BMI. In this study 24% of patients were obese. Prostate-specific antigen velocity greater than 2 ng/mL/yr was associated with higher relapse rates in nonobese patients (P = 0.01) but not in obese patients (P = 0.9). The two BMI groups did not differ with respect to any factors. Obese patients with slowly rising PSA (PSAV 2 ng/mL/yr or less) fared just as poorly as nonobese patients with rapidly rising PSA (PSAV greater than 2 ng/mL/yr). Obesity was independently associated with higher relapse rates. Conclusions Preoperative PSAV greater than 2 ng/mL/yr was associated with a higher risk of relapse after radical prostatectomy, but its clinical usefulness might be limited to nonobese patients. Obesity conferred higher relapse rates, regardless of other prognostic factors including preoperative PSAV. C1 Stanford Univ, Sch Med, Dept Radiat Oncol, Div Urol Oncol, Stanford, CA 94305 USA. Duke Univ, Sch Med, Div Urol Surg, Durham, NC 27706 USA. Duke Univ, Sch Med, Duke Prostate Ctr, Durham, NC 27706 USA. VA Med Ctr, Dept Surg, Urol Sect, Durham, NC USA. Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. VA Med Ctr, Dept Surg, Augusta, GA 30912 USA. Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA. VA Med Ctr, Dept Surg, Urol Sect, San Francisco, CA USA. Univ Alabama, Dept Urol, Birmingham, AL USA. USN, San Diego Hosp, Dept Urol, San Diego, CA 92152 USA. Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA. VA Med Ctr, Dept Surg, Urol Sect, Palo Alto, CA USA. RP King, CR (reprint author), Stanford Univ, Sch Med, Dept Radiat Oncol, Div Urol Oncol, 875 Blake Wilbur Dr, Stanford, CA 94305 USA. EM crking@stanford.edu OI Terris, Martha/0000-0002-3843-7270 NR 14 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD MAY PY 2007 VL 69 IS 5 BP 921 EP 926 DI 10.1016/j.urology.2007.01.056 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 191GK UT WOS:000248119400028 PM 17482935 ER PT J AU Spurgeon, SEF Mongoue-Tchokote, S Collins, L Priest, R Hsieh, YC Peters, LM Beer, TM Mori, M Garzotto, M AF Spurgeon, Stephen E. F. Mongoue-Tchokote, Solange Collins, Lauren Priest, Ryan Hsieh, Yi-Ching Peters, Laura M. Beer, Tornasz M. Mori, Motorni Garzotto, Mark TI Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy SO UROLOGY LA English DT Article ID NG/ML; SERUM; RISK; MEN; FLUCTUATIONS; ERA AB Objectives Prostate-specific antigen (PSA) kinetics have failed to predict for the presence of prostate cancer in screening populations in which many patients harbor subclinical disease. We hypothesized that the prebiopsy PSA doubling time (PSADT) and PSA velocity (PSAV) could predict for cancer detection in a referral Population with a suspicion of prostate cancer. Methods Data were collected from 1699 consecutive veterans with a PSA level of 10 ng/mL or less who underwent prostate biopsy. Logistic regression analysis was performed on the following: age, race, family history, digital rectal examination findings, PSA, PSA density, PSADT, PSAV, prostate Volume, and ultrasound lesions. Model building was accomplished with 70% of the data, and validation was done using the remaining 30%. These data were also analyzed using classification and regression tree analysis. Results Using logistic regression analysis (P <0.05) on the model building set, prostate cancer was associated with age (older than 70 years), PSA level (greater than 2.9 ng/mL), PSA density (more than 0.12 ng/mL/cm(3)), digital rectal examination findings, and the presence of a lesion on ultrasonography. A PSADT of 2 to 5 years was marginally associated with prostate cancer detection (odds ratio 1.6, 95% confidence interval 1.1 to 2.3), and a PSADT of less than 2 years or longer than 5 years and PSAV were not predictive. On classification and regression tree analysis, PSADT was not selected as a predictive factor. Furthermore, neither PSADT nor PSAV was predictive of Gleason score 7 or worse cancer. Conclusions In contrast to its prognostic value after the diagnosis of prostate cancer has been established, PSA kinetics offer little to clinical decision making as predictors of cancer or high-grade cancer in men with a PSA level of 10 ng/mL or less. C1 Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Div Renal Transplantat, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Biostat Shared Resource, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Urol Sect, Portland, OR 97201 USA. RP Garzotto, M (reprint author), Portland VA Med Ctr, Urol Sect, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM garzotto@ohsu.edu NR 15 TC 12 Z9 14 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD MAY PY 2007 VL 69 IS 5 BP 931 EP 935 DI 10.1016/j.urology.2007.01.075 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 191GK UT WOS:000248119400030 PM 17482937 ER PT J AU Fremont, AM Correa-de-Araujo, R Hayes, SN AF Fremont, Allen M. Correa-de-Araujo, Rosaly Hayes, Sharonne N. TI Gender disparities in managed care - It's time for action SO WOMENS HEALTH ISSUES LA English DT Editorial Material ID QUALITY-OF-CARE; HEALTH; WOMEN C1 RAND Corp, Santa Monica, CA 90407 USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. W Los Angeles VAMC, Los Angeles, CA USA. US Dept HHS, Off Secretary, Off Global Hlth Affairs, Rockville, MD USA. Mayo Clin, Coll Med, Womens Heart Clin, Rochester, MN USA. RP Fremont, AM (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90407 USA. EM fremont@rand.org OI Hayes, Sharonne/0000-0003-3129-362X NR 16 TC 13 Z9 13 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD MAY-JUN PY 2007 VL 17 IS 3 BP 116 EP 119 DI 10.1016/j.whi.2007.04.001 PG 4 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA 178ZZ UT WOS:000247260400001 PM 17512754 ER PT J AU Bird, CE Fremont, AM Bierman, AS Wickstrom, S Shah, M Rector, T Horstman, T Escarce, JJ AF Bird, Chloe E. Fremont, Allen M. Bierman, Arlene S. Wickstrom, Steve Shah, Mona Rector, Thomas Horstman, Thomas Escarce, Jose J. TI Does quality of care for cardiovascular disease and diabetes differ by gender for enrollees in managed care plans? SO WOMENS HEALTH ISSUES LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; UNITED-STATES; ETHNIC-GROUPS; DISPARITIES; TRENDS; IMPACT; RACE; SEX AB Purpose. To assess gender differences in the quality of care for cardiovascular disease and diabetes for enrollees in managed care plans. Methods. We obtained data from 10 commercial and 9 Medicare plans and calculated performance on 6 Health Employer Data and Information Set (HEDIS) measures of quality of care (P-blocker use after myocardial infarction [Ml], low-density lipoprotein cholesterol [LDL-C] check after a cardiac event, and in diabetics, whether glycosylated hemoglobin [HgbA1c], LDL cholesterol, nephropathy, and eyes were checked) and a 7th HEDIS-like measure (angiotensin-converting enzyme [ACE] inhibitor use for congestive heart failure). A smaller number of plans provided HEDIS scores on 4 additional measures that require medical chart abstraction (control of LDL-C after cardiac event, blood pressure control in hypertensive patients, and HgbAlc and LDL-C control in diabetics). We used logistic regression models to adjust for age, race/ethnicity, socioeconomic status, and plan. Main Findings. Adjusting for covariates, we found significant gender differences on 5 of 11 measures among Medicare enrollees, with 4 favoring men. Similarly, among commercial enrollees, we found significant gender differences for 8 of 11 measures, with 6 favoring men. The largest disparity was for control of LDL-C among diabetics, where women were 19% less likely to achieve control among Medicare enrollees (relative risk [RR] = 0.81; 95% confidence interval [CI] 0.64-0.99) and 16% less likely among commercial enrollees (RR = 0.84; 95%Cl = 0.73-0.95). Conclusion. Gender differences in the quality of cardiovascular and diabetic care were common and sometimes substantial among enrollees in Medicare and commercial health plans. Routine monitoring of such differences is both warranted and feasible. C1 RAND Corp, Santa Monica, CA 90407 USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. W Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. Univ Toronto, Toronto, ON, Canada. St Michaels Hosp, Toronto, ON M5B 1W8, Canada. Ingenix, Eden Prairie, MN USA. United Healthcare, St Louis Pk, MN USA. Minneapolis Vet Adm Med Ctr, Minneapolis, MN USA. Univ Minnesota, Minneapolis, MN 55455 USA. RP Bird, CE (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. EM Chloe_Bird@rand.org RI Bird, Chloe/C-7107-2008; Fremont, Allen/A-7752-2009 NR 22 TC 37 Z9 37 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD MAY-JUN PY 2007 VL 17 IS 3 BP 131 EP 138 DI 10.1016/j.whi.2007.03.001 PG 8 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA 178ZZ UT WOS:000247260400003 PM 17434752 ER PT J AU Grady, D Barrett-Connor, E AF Grady, Deborah Barrett-Connor, Elizabeth TI Postmenopausal hormone therapy - Symptoms should be treated with lowest effective dose of hormone therapy for the shortest time possible SO BRITISH MEDICAL JOURNAL LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; MILD COGNITIVE IMPAIRMENT; HEALTH INITIATIVE MEMORY; ESTROGEN PLUS PROGESTIN; WOMEN; DEMENTIA; DISEASE C1 Univ Calif San Francisco, San Francisco, CA 94115 USA. San Francisco VA Med Ctr, San Francisco, CA 94115 USA. Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, Div Epidemiol, La Jolla, CA 92093 USA. RP Grady, D (reprint author), Univ Calif San Francisco, San Francisco, CA 94115 USA. EM Deborah.Grady@ucsf.edu NR 9 TC 10 Z9 10 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0959-8146 J9 BRIT MED J JI Br. Med. J. PD APR 28 PY 2007 VL 334 IS 7599 BP 860 EP 861 DI 10.1136/bmj39185.380405.BE PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 164FB UT WOS:000246217800002 PM 17463421 ER PT J AU Cosen-Binker, LI Lam, PPL Binker, MG Reeve, J Pandol, S Gaisano, HY AF Cosen-Binker, Laura I. Lam, Patrick P. L. Binker, Marcelo G. Reeve, Joseph Pandol, Stephen Gaisano, Herbert Y. TI Alcohol/cholecystokinin-evoked pancreatic acinar basolateral exocytosis is mediated by protein kinase C alpha phosphorylation of Munc18c SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID KAPPA-B ACTIVATION; ALCOHOLIC PANCREATITIS; REGULATED EXOCYTOSIS; MEMBRANE-FUSION; PLASMA-MEMBRANE; PKC-DELTA; CELLS; CHOLECYSTOKININ; MECHANISMS; MACHINERY AB The pancreatic acinus is the functional unit of the exocrine pancreas whose role is to secrete zymogens into the gut lumen for food digestion via apical exocytosis. We previously reported that supramaximal CCK induced apical blockade and redirected exocytosis to ectopic sites on the basolateral plasma membrane (BPM) of this polarized cell, leading to pancreatitis. Basolateral exocytosis was mediated by protein kinase C phosphorylation of BPM Munc18c, causing its displacement into the cytosol and activation of BPM-bound Syntaxin-4 to form aSNARE complex. To mimic the conditions of alcoholic pancreatitis, we now examined whether 20 mM alcohol followed by submaximal CCK might mimic supramaximal CCK in inducing these pathologic exocytotic events. We show that a non-secretory but clinically relevant alcohol concentration (20 mM) inhibited submaximal CCK (50 pM)-stimulated amylase secretion by blocking apical exocytosis and redirecting exocytosis to less efficient BPM, indeed mimicking supramaximal CCK (10 nM) stimulation. We further demonstrate that basolateral exocytosis caused by both stimulation protocols is mediated by PKC alpha-induced phosphorylation of Munc18c: 1) PKC alpha is activated, which binds and induces phosphorylation of PM-Munc18c at a Thr site, and these events can be inhibited by PKC alpha blockade; 2) PKC alpha inhibition blocks Munc18c displacement from the BPM; 3) PKC alpha inhibition prevents basolateral exocytosis but does not rescue apical exocytosis. We conclude that 20 mM alcohol/submaximal CCK as well supramaximal CCK stimulation can trigger pathologic basolateral exocytosis in pancreatic acinar cells via PKC alpha-mediated activation of Munc18c, which enables Syntaxin-4 to become receptive in forming a SNARE complex in the BPM; and we further postulate this to be an underlying mechanism contributing to alcoholic pancreatitis. C1 Univ Toronto, Univ Hlth Network, Dept Med, Toronto, ON M5S 1A8, Canada. Univ Toronto, Univ Hlth Network, Dept Physiol, Toronto, ON M5S 1A8, Canada. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Gaisano, HY (reprint author), Univ Toronto, Univ Hlth Network, Dept Med, Rm 7226,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada. EM herbert.gaisano@utoronto.ca FU NIAAA NIH HHS [R21 AA015579-01A1] NR 35 TC 36 Z9 36 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 27 PY 2007 VL 282 IS 17 BP 13047 EP 13058 DI 10.1074/jbc.M611132200 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 160LR UT WOS:000245942800074 PM 17324928 ER PT J AU Samaha, FF AF Samaha, Frederick F. TI New international measuring stick for defining obesity in non-Europeans SO CIRCULATION LA English DT Editorial Material DE editorials; diabetes mellitus; epidemiology; myocardial infarction; obesity ID BODY-MASS INDEX; MORTALITY; ASIANS C1 Univ Penn, Philadelphia VA Med Ctr, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Div Cardiovasc Med, Dept Med, Philadelphia, PA 19104 USA. RP Samaha, FF (reprint author), Univ Penn, Philadelphia VA Med Ctr, Dept Med, 8th Floor MC 111C,3900 Woodland Ave, Philadelphia, PA 19104 USA. EM rick.samaha@va.gov NR 13 TC 9 Z9 9 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD APR 24 PY 2007 VL 115 IS 16 BP 2089 EP 2090 DI 10.1161/CIRCULATIONAHA.107.696260 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 160DN UT WOS:000245919600002 PM 17452616 ER PT J AU Scott, DR Marcus, EA Wen, Y Oh, J Sachs, G AF Scott, David R. Marcus, Elizabeth A. Wen, Yi Oh, Jane Sachs, George TI Gene expression in vivo shows that Helicobacter pylori colonizes an acidic niche on the gastric surface SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE acid acclimation; gastric pH; global transcriptome; microarray ID MUCUS-BICARBONATE BARRIER; UREASE ACTIVITY; GNOTOBIOTIC PIGLETS; VIRULENCE FACTORS; PH; SECRETION; MUCOSA; ADAPTATION; PROTON; ARGINASE AB Helicobacter pylori is a gastric-dwelling pathogen responsible, with acid secretion, for peptic ulcer and a 20-fold increase in the risk of gastric cancer. Several transcriptomes have been described after short-term exposure to acidity in vitro, but there are no data identifying the effects of chronic gastric exposure on bacterial gene expression. Comparison of the in vivo to the in vitro transcriptome at pH 7.4 identified several groups of genes of known function that increased expression >2-fold, and three of these respond both to acidity in vitro and to gastric infection. Almost all known acid acclimation genes are highly up-regulated. These include ureA, ureB, and rocF and the pH-gated urea channel, urel. There is also up-regulation of two groups of motility and chemotaxis genes and for pathogenicity island genes, especially cagA, a predictor for pathogenicity. Most of these genes interact with HP0166, the response element of the pH-sensing two-component histidine kinase, HP0165/HP0166, ArsRS. Based on the pH profile of survival of urel deletion mutants in vitro and their inability to survive in gastric acidity, the habitat of the organism at the gastric surface is acidic with a pH <= 4.0. Hence, the pH of the habitat of H. pylori on the surface of the stomach largely determines the regulation of these specific groups of genes. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90024 USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Ewha Womans Univ, Dongdaemun Hosp, Dept Internal Med, Seoul 110783, South Korea. RP Scott, DR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, 405 Hilgard Ave, Los Angeles, CA 90024 USA. EM dscott@ucla.edu; gsachs@ucla.edu NR 62 TC 71 Z9 78 U1 0 U2 2 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 24 PY 2007 VL 104 IS 17 BP 7235 EP 7240 DI 10.1073/pnas.0702300104 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 161OK UT WOS:000246024700063 PM 17438279 ER PT J AU Cowart, LA Hannun, YA AF Cowart, L. Ashley Hannun, Yusuf A. TI Selective substrate supply in the regulation of yeast de novo sphingolipid synthesis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID HEAT-STRESS RESPONSE; MEMBRANE H+-ATPASE; LONG-CHAIN BASES; SACCHAROMYCES-CEREVISIAE; SERINE PALMITOYLTRANSFERASE; PLASMA-MEMBRANE; INDUCE APOPTOSIS; FREE SPHINGOSINE; PALMITIC ACID; STEARIC-ACID AB The heat stress response of Saccharomyces cerevisiae is characterized by transient cell cycle arrest, altered gene expression, degradation of nutrient permeases, trehalose accumulation, and translation initiation of heat shock proteins. Importantly heat stress also induces de novo sphingolipid synthesis upon which many of these subprograms of the heat stress response depend. Despite extensive data addressing the roles for sphingolipids in heat stress, the mechanism( s) by which heat induces sphingolipid synthesis remains unknown. This study was undertaken to determine the events and/or factors required for heat stress-induced sphingolipid synthesis. Data presented indicate that heat does not directly alter the in vitro activity of serine palmitoyltransferase ( SPT), the enzyme responsible for initiating de novo sphingolipid synthesis. Moreover deletion of the small peptide Tsc3p, which is thought to maximize SPT activity, specifically reduced production of C-20 sphingolipid species by over 70% but did not significantly decrease overall sphingoid base production. In contrast, the fatty-acid synthase inhibitor cerulenin nearly completely blocked sphingoid base production after heat, indicating a requirement for endogenous fatty acids for heat-mediated sphingoid base synthesis. Consistent with this, genetic studies show that fatty acid import does not contribute to heat-induced de novo synthesis under normal conditions. Interestingly the absence of medium serine also ameliorated heat-induced sphingoid base production, indicating a requirement for exogenous serine for the response, and consistent with this finding, disruption of synthesis of endogenous serine did not affect heat-induced sphingolipid synthesis. Serine uptake assays indicated that heat increased serine uptake from medium by 100% during the first 10 min of heat stress. Moreover treatments that increase serine uptake in the absence of heat including acute medium acidification and glucose treatment also enhanced de novo sphingoid base synthesis equivalent to that induced by heat stress. These data agree with findings from mammalian systems that availability of substrates is a key determinant of flux through sphingolipid synthesis. Moreover data presented here indicate that SPT activity can be driven by several factors that increase serine uptake in the absence of heat. These findings may provide insights into the many systems in which de novo synthesis is increased in the absence of elevated in vitro SPT activity. C1 Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Hannun, YA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. EM hannun@musc.edu FU NIGMS NIH HHS [GM63265] NR 52 TC 41 Z9 41 U1 2 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 20 PY 2007 VL 282 IS 16 BP 12330 EP 12340 DI 10.1074/jbc.M700685200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 160LK UT WOS:000245941900075 PM 17322298 ER PT J AU Maciejewski, ML Perkins, M Li, YF Chapko, M Fortney, JC Liu, CF AF Maciejewski, Matthew L. Perkins, Mark Li, Yu-Fang Chapko, Michael Fortney, John C. Liu, Chuan-Fen TI Utilization and expenditures of veterans obtaining primary care in community clinics and VA medical centers: an observational cohort study SO BMC HEALTH SERVICES RESEARCH LA English DT Article ID OUTPATIENT CLINICS; PERFORMANCE-MEASURES; RISK ADJUSTMENT; DISTANCE; COSTS; SERVICES; ACCESS; BIAS AB Background: To compare VA inpatient and outpatient utilization and expenditures of veterans seeking primary care in community-based outpatient clinics (CBOCs) and VA medical centers (VAMCs) in fiscal years 2000 (FY00) and 2001. Methods: The sample included 25,092 patients who obtained primary care exclusively from 108 CBOCs in FY00, 26,936 patients who obtained primary care exclusively from 72 affiliated VAMCs in FY00, and 11,450 "crossover" patients who obtained primary care in CBOCs and VAMCs in FY00. VA utilization and expenditure data were drawn from the VA's system-wide cost accounting system. Veteran demographic characteristics and a 1999 Diagnostic Cost Group risk score were obtained from VA administrative files. Outpatient utilization ( primary care, specialty care, mental health, pharmacy, radiology and laboratory) and inpatient utilization were estimated using count data models and expenditures were estimated using one-part or two-part models. The second part of two-part models was estimated using generalized linear regressions. Results: CBOC patients had a slightly more primary care visits per year than VAMC patients ( p < 0.0001), but lower primary care costs (-$71, p < 0.0001). CBOC patients had lower odds of one or more specialty, mental health, ancillary visits and hospital stays per year, and fewer numbers of visits and stays if they had any and lower specialty, mental health, ancillary and inpatient expenditures ( all, p < 0.0001). As a result, CBOC patients had lower total outpatient and overall expenditures than VAMC patients ( p < 0.0001). Conclusion: CBOCs provided veterans improved access to primary care and other services, but expenditures were contained because CBOC patients who sought health care had fewer visits and hospital stays than comparable VAMC patients. These results suggest a more complex pattern of health care utilization and expenditures by CBOC patients than has been found in prior studies. This study also illustrates that CBOCs continue to be a critical primary care and mental health access point for veterans. C1 Durham VA Med Ctr, Dept Vet Affairs, Ctr Hlth Serv Res Primary Care, Durham, NC 27710 USA. Univ N Carolina, Sch Pharm, Div Pharmaceut Outcomes & Policy, Chapel Hill, NC USA. VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev, Seattle, WA USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Sch Nursing, Seattle, WA 98195 USA. Cent Arkansas Healthcare Syst, Ctr Mental Hlth & Outcomes Res, Hlth Serv Res & Dev, N Little Rock, AR USA. Univ Arkansas Med Sci, Coll Med, Dept Psychiat, Div Hlth Serv Res, Little Rock, AR 72205 USA. RP Maciejewski, ML (reprint author), Durham VA Med Ctr, Dept Vet Affairs, Ctr Hlth Serv Res Primary Care, Durham, NC 27710 USA. EM matt@email.unc.edu; mark.perkins@med.va.gov; yli@u.washington.edu; michael.chapko@med.va.gov; FortneyJohnC@uams.edu; fliu@u.washington.edu NR 21 TC 24 Z9 24 U1 3 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD APR 18 PY 2007 VL 7 AR 56 DI 10.1186/1472-6963-7-56 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 159WX UT WOS:000245899400001 PM 17442115 ER PT J AU O'Hearn, DJ Giraud, GD Sippel, JM Edwards, C Chan, B Holden, WE AF O'Hearn, Daniel J. Giraud, George D. Sippel, Jeffrey M. Edwards, Chad Chan, Benjamin Holden, William E. TI Exhaled nasal nitric oxide output is reduced in humans at night during the sleep period SO RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY LA English DT Article DE sleep; somnolence; nitric oxide; nose ID NATURAL SLEEP; L-NAME; GAS; AIR; VENTILATION; ABSORPTION; ROLES AB The physiologic function of nasal nitric oxide (NO) release is unknown. In prior experiments, topical N-G-nitro-L-arginine methyl ester (L-NAME) on nasal mucosa reduced exhaled nasal NO output and caused daytime sleepiness. We hypothesized that nasal NO output is reduced at night during the sleep period. We measured exhaled nasal NO concentration and minute ventilation and calculated nasal NO output in humans over 24 h. Daytime awake NO output was greater than NO output at night during sleep or transient wakefulness. Exhaled NO concentration decreased during sleep along with minute ventilation. A daytime voluntary reduction in minute ventilation also decreased nasal NO output but exhaled NO concentration increased. Nasal NO output was not changed by body position. We conclude that exhaled nasal NO output is decreased at night due to decreased mass flow of NO into nasal air in addition to decreased minute ventilation. Our findings suggest a role of nasal NO in sleep or in the physiologic processes accompanying sleep. (c) 2006 Elsevier B.V. All rights reserved. C1 Portland VA Med Ctr, Med Serv, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Portland, OR USA. RP O'Hearn, DJ (reprint author), Portland VA Med Ctr, Med Serv, P3-PULM,3710 SW,US Vet Hosp Rd, Portland, OR 97201 USA. EM ohearnd@ohsu.edu NR 42 TC 3 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9048 J9 RESP PHYSIOL NEUROBI JI Respir. Physiol. Neuro. PD APR 16 PY 2007 VL 156 IS 1 BP 94 EP 101 DI 10.1016/j.resp.2006.08.002 PG 8 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 147KI UT WOS:000245001500012 PM 16978930 ER PT J AU Abraham, NS El-Serag, HB Hartman, C Richardson, P Deswal, A AF Abraham, N. S. El-Serag, H. B. Hartman, C. Richardson, P. Deswal, A. TI Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID CARDIOVASCULAR THROMBOTIC EVENTS; UPPER GASTROINTESTINAL EVENTS; VETERANS-AFFAIRS; CYCLO-OXYGENASE-2 INHIBITORS; COX-2 INHIBITORS; CELECOXIB; ROFECOXIB; TOXICITY; OUTCOMES; PRESCRIPTION AB Aim To assess degree of cyclooxygenase-2 (COX-2) selectivity of a non-steroidal anti-inflammatory drug (NSAID) and risk of myocardial infarction (MI) or cerebrovascular accident (CVA). Methods Prescription fill data were linked to medical records of a merged VA-Medicare dataset. NSAIDs were categorized by Cox-2 selectivity. Incidence of CVA and MI within 180 days of index prescription was assessed using Cox-proportional hazards models adjusted for gender, race, cardiovascular and pharmacological risk factors and propensity for prescription of highly COX-2 selective NSAIDs. Results Of 384 322 patients (97.5% men and 85.4% white), 79.4% were prescribed a poorly selective, 16.4% a moderately selective and 4.2% a highly selective NSAID. There were 985 incident cases of MI and 586 cases of CVA in > 145 870 person-years. Highly selective agents had the highest rate of MI (12.3 per 1000 person-years; [95% CI: 12.2-12.3]) and CVA (8.1 per 1000 person-years; [95% CI: 8.0-8.2]). Periods without NSAID exposure were associated with lowest risk. In adjusted models, highly selective COX-2 selective NSAIDs were associated with a 61% increase in CVA and a 47% increase in MI, when compared with poorly selective NSAIDs. Conclusions The risk of MI and CVA increases with any NSAID. Highly COX-2 selective NSAIDs confer the greatest risk. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Abraham, NS (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM nabraham@bcm.tmc.edu NR 57 TC 54 Z9 56 U1 1 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD APR 15 PY 2007 VL 25 IS 8 BP 913 EP 924 DI 10.1111/j.j.1365-2036.2007.03292.x PG 12 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 151SQ UT WOS:000245311500007 PM 17402995 ER PT J AU Singla, I Zahid, M Good, CB Macioce, A Sonel, AF AF Singla, Ish Zahid, Maliha Good, Chester B. Macioce, Alanna Sonel, Ali F. TI Impact of blood transfusions in patients presenting with anemia and suspected acute coronary syndrome SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID MYOCARDIAL-INFARCTION; CLINICAL-OUTCOMES; HEMOGLOBIN LEVELS; CELL TRANSFUSION; TASK-FORCE; STRATEGIES; MORTALITY; THERAPY AB Anemia has been shown to predict adverse events in patients presenting with acute coronary syndromes and non-ST-elevation myocardial infarctions (MIs). Less is known about the value of blood transfusions in this setting. We sought to evaluate the impact of red blood cell transfusions on outcomes. Transfusion in anemic patients admitted with suspected acute coronary syndrome/non-ST-elevation MIs led to a significant increase in 30-day recurrent MI or death (odds ratio 3.05, 95% confidence interval 1.80 to 5.17, p < 0.001). This relation persisted after adjusting for significant univariate predictors: hypotension on presentation, pulmonary edema, and increased troponin-I levels (odds ratio 2.57, 95% confidence interval 1.41 to 4.69, p < 0.001). In conclusion, the risk versus benefit of transfusion in patients presenting with an acute coronary syndrome needs careful assessment. (c) 2007 Elsevier Inc. All rights reserved. C1 Univ Pittsburgh, Pittsburgh, PA 15260 USA. Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Ctr Healthy Equ & Res Promot, Pittsburgh, PA USA. RP Zahid, M (reprint author), Univ Pittsburgh, Pittsburgh, PA 15260 USA. EM maz7@pitt.edu NR 15 TC 31 Z9 33 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD APR 15 PY 2007 VL 99 IS 8 BP 1119 EP 1121 DI 10.1016/j.amjcard.2006.11.056 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 159ZH UT WOS:000245906000018 PM 17437739 ER PT J AU Olvera, RL Pliszka, SR Dierschke, NA Stanley, JA Nicoletti, MA Hatch, JR Li, J Soares, JC AF Olvera, Rene L. Pliszka, Steven R. Dierschke, Nicole A. Stanley, Jeffrey A. Nicoletti, Mark A. Hatch, John R. Li, John Soares, Jair C. TI A proton magnetic spectroscopy study of juvenile offenders with mood and impulse control disorders SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Wayne State Univ, Sch Med, Detroit, MI USA. Audie Murphy Div, S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Res Imaging Ctr, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 12 BP 4S EP 5S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100014 ER PT J AU Quinones, MR Ahmadi, S Nery, FG Estrada, C Olvera, R Hatch, JR Vipraio, G Pliszka, S Soares, JC AF Quinones, Marlon R. Ahmadi, Sara Nery, Fabiano G. Estrada, Carlos Olvera, Rene Hatch, John R. Vipraio, Gil Pliszka, Steve Soares, Jair C. TI Plasma TNF-RII as a new specific biomarker for the pathogenesis of bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 17-20, 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Audie L Murphy, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders,MOOD CNS Program, San Antonio, TX 78284 USA. Univ Sao Paulo, Sch Med, Sao Paulo, Brazil. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 16 BP 6S EP 6S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100018 ER PT J AU Quinones, MP Torres, V Nery, FG Ahmadi, S Estrada, C Olvera, R Hatch, JP Vipraio, G Pliszka, S Soares, JC AF Quinones, Marlon P. Torres, Victor Nery, Fabiano G. Ahmadi, Sara Estrada, Carlos Olvera, Rene Hatch, John P. Vipraio, Gil Pliszka, Steve Soares, Jair C. TI Differential involvement of inflammatory markers in adult and pediatric bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 17-20, 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Audie L Murphy, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders,MOOD CNS Program, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Sao Paulo, Brazil. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 27 BP 11S EP 11S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100029 ER PT J AU New, AS Hazlett, EA Newmark, RE Meyerson, D Goldstein, K Goodman, M Koenigsberg, H Trisdorfer, R Siever, LJ Buchsbaum, MS AF New, Antonia S. Hazlett, Erin A. Newmark, Randall E. Meyerson, David Goldstein, Kim Goodman, Marianne Koenigsberg, Harold Trisdorfer, Roanna Siever, Larry J. Buchsbaum, Monte S. TI Laboratory induced aggression: A PET study of borderline personality disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Mt Sinai Sch Med, New York, NY USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. Mt Sinai Sch Med, Neurosci PET Lab, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 35 BP 14S EP 14S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100037 ER PT J AU Frey, BN Walls-Bass, C Hatch, JP Nery, FG Nicoletti, MA Chen, HH Monkul, ES Matsuo, K Zunta, G Stanley, JA Escamilla, MA Soares, JC AF Frey, Benicio N. Walls-Bass, Consuelo Hatch, John P. Nery, Fabiano G. Nicoletti, Mark A. Chen, Hua H. Monkul, E. Serap Matsuo, Koji Zunta, Giovana Stanley, Jeffrey A. Escamilla, Michael A. Soares, Jair C. TI Effects of BDNF val66met polymorphism on brain neurochemistry in bipolar disorder patients: A 1H MRS study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 17-20, 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil. Hosp Clin Porto Alegre, Lab Psiquiatria Mol, Porto Alegre, RS, Brazil. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Sao Paulo, Brazil. Wayne State Univ, Sch Med, Detroit, MI USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 186 BP 59S EP 59S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100188 ER PT J AU Mezzomo, KM Rene, OL Caetan, SC Matsuo, K Hatch, JR Dierschke, N Nicoletti, M Fonseca, M Belardinelli, C Zunta, G Pliszka, SR Soares, JC AF Mezzomo, Kelin M. Rene, Olvera L. Caetan, Sheila C. Matsuo, Koji Hatch, John R. Dierschke, Nicole Nicoletti, Mark Fonseca, Manoela Belardinelli, Cecilia Zunta, Giovana Pliszka, Steven R. Soares, Jair C. TI White matter abnormalities in pediatric bipolar disorder - A voxel-based morphometry (VBM) study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 17-20, 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. Audie L Murphy, S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 299 BP 94S EP 94S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100300 ER PT J AU Dracheva, S Marcus, SM Siever, LJ Haroutunian, V AF Dracheva, Stella Marcus, Sue M. Siever, Larry J. Haroutunian, Vahrarn TI Increased serotonin 2C receptor mRNA editing in suicide: A possible psychiatric diagnosis-independent risk factor SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Bronx Vet Adm Med Ctr, Bronx, NY USA. Mt Sinai Sch Med, New York, NY USA. Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 302 BP 95S EP 95S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100303 ER PT J AU Quinones, MP Nery, FG Ahmadi, S Torres, V Estrada, C Olvera, R Hatch, JP Vipraio, G Pliszka, S Soares, JC AF Quinones, Marlon P. Nery, Fabiano G. Ahmadi, Sara Torres, Victor Estrada, Carlos Olvera, Rene Hatch, John P. Vipraio, Gil Pliszka, Steve Soares, Jair C. TI Plasma level of CC chemokine ligand (CCL)-22 and CCL5 as biomarkers in adult or pediatric mood disorders SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders,MOOD CNS Program, San Antonio, TX 78284 USA. Univ Sao Paulo, Sch Med, Sao Paulo, Brazil. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 306 BP 96S EP 97S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100307 ER PT J AU Koenigsberg, HW Provhovnik, I Lee, H Pizzarello, S New, AS Siever, LJ AF Koenigsberg, Harold W. Provhovnik, Isak Lee, Hedok Pizzarello, Scott New, Antonia S. Siever, Larry J. TI Neural correlates of the processing of negative and positive social scenes in borderline personality disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. James J Peters VA Med Ctr, Bronx, NY USA. James J Peters VA Med Ctr, Mirecc, Bronx, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 334 BP 104S EP 104S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100329 ER PT J AU Green, MF Horan, W Nuechterlein, KH Stone, W Seidman, L AF Green, Michael F. Horan, William Nuechterlein, Keith H. Stone, William Seidman, Larry TI Neurocognitive endophenotypes in schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Univ Calif Los Angeles, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Harvard Univ, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 354 BP 110S EP 110S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100349 ER PT J AU Yao, JK Matson, WR Reddy, RD Bogdanov, M Keshavan, MS AF Yao, Jeffrey K. Matson, Wayne R. Reddy, Ravinder D. Bogdanov, Mikhail Keshavan, Matcheri S. TI Evaluation of plasma metabolome in first-episode schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Vet Affairs Pittsburgh Hlth Syst, Med Res Serv, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA. Bedford Vet Affairs Med Ctr, Med Res Serv, Bedford, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 386 BP 119S EP 119S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100381 ER PT J AU Yao, JK Dougherty, GG van Kammen, DP Peters, JL Gurklis, JA AF Yao, Jeffrey K. Dougherty, George G. van Kammen, Daniel P. Peters, Jeffrey L. Gurklis, John A. TI Multivariate comparisons of CSF amino acids in healthy controls and schizophrenic patients SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Vet Affairs Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA. ACADIA Pharmaceut Inc, Clin Dev, San Diego, CA USA. Vet Affairs Pittsburgh Healthcare Syst, Behav Hlth Product Line, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 387 BP 120S EP 120S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100382 ER PT J AU Taylor, F Mellman, TA Gross, C Peskind, ER Raskind, MA AF Taylor, Fletcher Mellman, Thomas A. Gross, Christopher Peskind, Elaine R. Raskind, Murray A. TI Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma PTSD: A placebo controlled study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Univ Washington, Seattle, WA 98195 USA. Howard Univ, Dept Psychiat, Washington, DC 20059 USA. VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 428 BP 132S EP 132S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100423 ER PT J AU Tang, Y Anderson, GM Zabetian, CR Cubells, JF AF Tang, Yilang Anderson, George M. Zabetian, Cyrus R. Cubells, Joseph F. TI Genotypic and haplotypic associations of the DBH gene with plasma dopamine beta-hydroxylase activity in African Americans SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Emory Univ, Atlanta, GA 30322 USA. Yale Univ, Sch Med, VA Connecticut Healthcare Syst, New Haven, CT USA. Yale Univ, Ctr Child Study, New Haven, CT 06520 USA. Univ Washington, Sch Med, Geriatr Res Educ & Clin Ctr, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 439 BP 135S EP 135S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100434 ER PT J AU Peskind, ER Lil, G Petrie, EC Leverenz, J Raskind, MA Galasko, D AF Peskind, Elaine R. Lil, Gail Petrie, Eric C. Leverenz, James Raskind, Murray A. Galasko, Douglas TI Gender, age, and APOE genotype effects on CSF abeta-42 in cognitively normal adults SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. Univ Calif San Diego, Dept Neurol, San Diego, CA 92103 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 464 BP 143S EP 143S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100459 ER PT J AU Kaddurah-Daouk, R McEvoy, J Baillie, RA Yao, JK Doraiswamy, PM Krishnan, KRR AF Kaddurah-Daouk, Rima McEvoy, Joseph Baillie, Rebecca A. Yao, Jeffrey K. Doraiswamy, P. Murali Krishnan, K. Ranga R. TI Metabolomic mapping of schizophrenia and atypical antipsychotic effects SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Duke Univ, Med Ctr, Durham, NC USA. Lipom Technol, Sacramento, CA USA. Univ Pittsburgh, Med Ctr, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 535 BP 164S EP 164S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100530 ER PT J AU Nery, FG Monkul, ES Hatch, JP Fonseca, M Zunta, GB Frey, BN Bowden, CL Soares, JC AF Nery, Fabiano G. Monkul, E. Serap Hatch, John P. Fonseca, Manoela Zunta, Giovana B. Frey, Benicio N. Bowden, Charles L. Soares, Jair C. TI Cox-2 inhibitor (Celecoxib) as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX USA. Audie L Murphy Div, Psychiat Serv, South Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX USA. Univ Fed Rio Grande do Sul, ICBS, Dept Biochem, Porto Alegre, RS, Brazil. Hosp Clin, Bipolar Disorder Program, Porto Alegre, RS, Brazil. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 555 BP 171S EP 171S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100550 ER PT J AU Katsel, P Davis, KL Li, C Greenstein, E Haroutunian, V AF Katsel, Pavel Davis, Kenneth L. Li, Celeste Greenstein, Elizabeth Haroutunian, Vahram TI Ectopic cell cycle activity in the cingulate cortex of subjects with schizophrenia and myelin deficiency animal models SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Mt Sinai Med Ctr, New York, NY 10029 USA. James J Peters Vet Affairs Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 563 BP 173S EP 174S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100558 ER PT J AU Koenigsberg, HW Fan, J Ochsner, K Pizzarello, S New, AS Sievert, LJ AF Koenigsberg, Harold W. Fan, Jin Ochsner, Kevin Pizzarello, Scott New, Antonia S. Sievert, Larry J. TI Neural correlates of efforts to downregulate emotion in borderline personality disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. James J Peter VA Med Ctr, Bronx, NY USA. Columbia Univ, Dept Psychol, New York, NY 10027 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 642 BP 200S EP 200S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100637 ER PT J AU Nery, FG Stanley, JA Chen, HH Hatch, JP Nicoletti, MA Monkul, ES Lafer, B Soares, JC AF Nery, Fabiano G. Stanley, Jeffrey A. Chen, Hua-Hsuan Hatch, John P. Nicoletti, Mark A. Monkul, E. Serap Lafer, Beny Soares, Jair C. TI Low glutamate concentrations in the left dorsolateral prefrontal cortex of patients with bipolar disorder and comorbid alcoholism: A 1H spectroscopy study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. Wayne State Univ, Sch Med, Dept Psychiat & Behav Sci, Detroit, MI USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX USA. RI Lafer, Beny/C-1055-2012; Lafer, Beny/F-9390-2015 OI Lafer, Beny/0000-0002-6132-9999; Lafer, Beny/0000-0002-6132-9999 NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 725 BP 224S EP 224S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100720 ER PT J AU Nery, FG Matsuo, K Nicoletti, MA Dierschke, N Monkul, ES Fonseca, M Zunta, GB Hatch, JP Lafer, B Soares, JC AF Nery, Fabiano G. Matsuo, Koji Nicoletti, Mark A. Dierschke, Nicole Monkul, E. Serap Fonseca, Manoela Zunta, Giovana B. Hatch, John P. Lafer, Beny Soares, Jair C. TI Small gray and white matter volumes in bipolar disorder patients with comorbid alcoholism: An optimized voxel-based morphometry study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 17-20, 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. RI Lafer, Beny/C-1055-2012; Lafer, Beny/F-9390-2015 OI Lafer, Beny/0000-0002-6132-9999; Lafer, Beny/0000-0002-6132-9999 NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 726 BP 225S EP 225S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100721 ER PT J AU Nery, FG Chen, HH Hatch, JP Nicoletti, MA Mallinger, AG Soares, JC AF Nery, Fabiano G. Chen, Hua-Hsuan Hatch, John P. Nicoletti, Mark A. Mallinger, Alan G. Soares, Jair C. TI Orbitofrontal cortex volumes correlate with mood state in bipolar disorder: A structural MRI study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 17-20, 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX USA. NIMH, Mood & Anxiety Disorders Program, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 728 BP 225S EP 226S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100723 ER PT J AU Nery, FG Hatch, JP Monkul, ES Peluso, MA Fonseca, M Zunta, GB Bowden, CL Soares, JC AF Nery, Fabiano G. Hatch, John P. Monkul, E. Serap Peluso, Marco A. Fonseca, Manoela Zunta, Giovana B. Bowden, Charles L. Soares, Jair C. TI Association between impulsivity and alcoholism in bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 17-20, 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 727 BP 225S EP 225S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100722 ER PT J AU Nery, FG Glahn, DC Bearden, CE Monkul, ES Zunta, GB Fonseca, M Soares, JC AF Nery, Fabiano G. Glahn, David C. Bearden, Carrie E. Monkul, E. Serap Zunta, Giovana B. Fonseca, Manoela Soares, Jair C. TI Neurocognitive deficits in bipolar disorder with comorbid alcoholism SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 729 BP 226S EP 226S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100724 ER PT J AU Quinones, MP Nery, F Ahmadi, S Torres, V Estrada, C Olvera, R Hatch, JP Vipraio, G Pliszka, S Soares, J AF Quinones, Marlon P. Nery, Fabiano Ahmadi, Sara Torres, Victor Estrada, Carlos Olvera, Rene Hatch, John P. Vipraio, Gil Pliszka, Steve Soares, Jair TI Infectious agents and the pathogenesis of pediatric and adult mood disorders SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 UTHSCSA, San Antonio, TX USA. UTHSCSA, Dept Psychiat, Div Mood & Anxiety Disorders, MOOD CNS Program, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Sao Paulo, Brazil. S Texas Vet Hlth Care Syst, Audie L Murphy, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Dept Psychiat, Div Mood & Anxiety Disorders, MOOD CNS Program, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 733 BP 227S EP 228S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100728 ER PT J AU Quinones, MP Estrada, C Ahmadi, S Nery, FG Torres, V Olvera, R Hatch, JP Vipraio, G Pliszka, S Escamilla, MA Walss-Bass, C Soares, JC AF Quinones, Marion P. Estrada, Carlos Ahmadi, Sara Nery, Fabiano G. Torres, Victor Olvera, Rene Hatch, John P. Vipraio, Gil Pliszka, Steve Escamilla, Michael A. Walss-Bass, Consuelo Soares, Jair C. TI Reduction in the availability of the neurotrophic factor insulin growth factor (IGF)-1, but not brain derived neurotrophic factor (BDNF), in individuals with mood disorders may result from synergistic effects of disease-specific processes and normal age-associated reduction in circulating levels SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 UTHSCSA, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Audie L Murphy, San Antonio, TX USA. UTHSCSA, Dept Psychiat, Div Mood & Anxiety Disorders, MOOD CNS Program, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Sao Paulo, Brazil. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 734 BP 228S EP 228S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100729 ER PT J AU Leung, WW McClure, MM Siever, LJ Harvey, PD AF Leung, Winnie W. McClure, Margaret M. Siever, Larry J. Harvey, Philip D. TI COMT genotype and context processing in healthy and personality disorder individuals SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. Mt Sinai Sch Med, New York, NY USA. James J Peters Bronx VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 789 BP 245S EP 245S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100784 ER PT J AU Radant, AD Dobie, DJ Meichle, SR Calkins, ME Olincy, A Tsuang, DW AF Radant, Allen D. Dobie, Dorcas J. Meichle, Sean R. Calkins, Monica E. Olincy, Ann Tsuang, Debby W. CA Consortium Genet Schizophrenia TI Are smooth pursuit eye movements a practical schizophrenia endophenotype? Evidence from the multisite consortium on the genetics of schizophrenia (COGS) study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry CY 2007 CL San Diego, CA SP Soc Biol Psychiat C1 Univ Washington, Dept Psychiat, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 SU S MA 802 BP 249S EP 249S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 157DF UT WOS:000245698100797 ER PT J AU Raskind, MA Peskind, ER Hoff, DJ Hart, KL Holmes, HA Warren, D Shofer, J O'Connell, J Taylor, F Gross, C Rohde, K McFall, ME AF Raskind, Murray A. Peskind, Elaine R. Hoff, David J. Hart, Kimberly L. Holmes, Hollie A. Warren, Daniel Shofer, Jane O'Connell, James Taylor, Fletcher Gross, Christopher Rohde, Kirsten McFall, Miles E. TI A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder SO BIOLOGICAL PSYCHIATRY LA English DT Article DE adrenergic antagonist; military; nightmare; post-traumatic stress disorder; prazosin; sleep ID CORTICOTROPIN-RELEASING HORMONE; ALPHA-ADRENOCEPTOR ANTAGONISTS; VIETNAM VETERANS; QUALITY INDEX; PTSD; NOREPINEPHRINE; METHOXAMINE; RAT; YOHIMBINE; RESPONSES AB Background: Excessive brain responsiveness to norepinephrine appears to contribute to post-traumatic stress disorder (PTSD), particularly at night. Prazosin, a brain active alpha-1 adrenergic receptor antagonist, significantly reduced trauma nightmares and sleep disturbance in 10 Vietnam War combat veterans in a previous placebo-controlled crossover study. The current parallel group trial in a larger sample of veterans evaluated prazosin effects on trauma nightmares, sleep quality, global clinical status, dream characteristics, and comorbid depression. Methods: Forty veterans (mean age 56 +/- 9) with chronic PTSD and distressing trauma nightmares and sleep disturbance were randomized to evening prazosin (13.3 +/- 3 mg/day) or placebo for 8 weeks. Results: In the evaluable sample (n = 34), primary outcome measures demonstrated that prazosin was significantly superior to placebo for reducing trauma nightmares and improving sleep quality and global clinical status with large effect sizes. Prazosin shifted dream characteristics from those typical of trauma-related nightmares toward those typical of normal dreams. Blood pressure changes from baseline to end study did not differ significantly between prazosin and placebo. Conclusions: Prazosin is an effective and well-tolerated treatment for trauma nightmares, sleep disturbance and global clinical status in veterans with chronic PTSD. C1 Vet Affairs NW Network Mental Illness Res, Educ & Clin Ctr MIRECC, Seattle, WA USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Raskind, MA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-116, Seattle, WA 98108 USA. EM murray.raskind@med.va.gov FU NIMH NIH HHS [R01MH069867] NR 41 TC 214 Z9 220 U1 3 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2007 VL 61 IS 8 BP 928 EP 934 DI 10.1016/j.biopsych.2006.06.032 PG 7 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 156GP UT WOS:000245636400002 PM 17069768 ER PT J AU Meeran, SM Katiyar, S Elmets, CA Katiyar, SK AF Meeran, Syed M. Katiyar, Suchitra Elmets, Craig A. Katiyar, Santosh K. TI Interleukin-12 deficiency is permissive for angiogenesis in UV radiation-induced skin tumors SO CANCER RESEARCH LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; GREEN TEA POLYPHENOLS; IFN-GAMMA PRODUCTION; INDUCED IMMUNOSUPPRESSION; MOUSE SKIN; MATRIX METALLOPROTEINASES; CANCER-THERAPY; DNA-REPAIR; T-CELLS; IL-12 AB We have shown previously that endogenous deficiency of interleukin (IL)-12 promotes photocarcinogenesis in mice. To characterize the role of IL-12 deficiency in tumor angiogenesis, we developed IL-12p35 knockout (IL-12 KO) mice on a C3H/HeN background. IL-12 KO mice and their wild-type (WT) counterparts were subjected to a photocarcinogenesis protocol. When tumor yield was stabilized, samples of tumor and tumor-uninvolved UVB-exposed skin were collected and subjected to immunohistochemistry, gelatinolytic zymography, real-time PCR, and Western blot analysis of angiogenic factors. We found that the protein, mRNA expression and/or activity of the matrix metalloproteinases (MMP)-2, MMP-3, MNIP-7, and MMP-9, and basic fibroblast growth factor, which play crucial roles in tumor growth, were significantly higher in UVB-exposed skin and tumors of IL-12 KO mice compared with WT mice. With respect to the tumor vasculature, the expression of CD31-positive cells and the expression of vascular endothelial growth factor were higher in the tumors of IL-12 KO mice than WTs. The proliferative capacity of tumor cells of the IL-12 KO mice was significantly higher than their WT counterparts when determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and by analyzing the expression of cyclin D1. The level of the proinflammatory cytokine IL-6 and the expression of IL-23 in tumors of IL-12 KO mice were markedly higher than in the tumors of WT mice. IL-23 has been shown to promote tumor growth. Together, these data indicate for the first time that IL-12 deficiency promotes proangiogenic stimuli in UVB-induced skin tumors and suggest that endogenous enhancement of IL-12 levels maybe effective in the prevention and treatment of UV-induced skin cancers. C1 Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. Univ Alabama, Skin Dis Res Ctr, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU NCCIH NIH HHS [R01 AT002536-01A2, AT 002536, R01 AT002536]; NIAMS NIH HHS [P30 AR050948-030001, P30 AR050948, AR 050948-01] NR 40 TC 15 Z9 16 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2007 VL 67 IS 8 BP 3785 EP 3793 DI 10.1158/0008-5472.CAN-06-3134 PG 9 WC Oncology SC Oncology GA 158GL UT WOS:000245779600041 PM 17440092 ER PT J AU Chen, RY Westfall, AO Hardin, JM Miller-Hardwick, C Stringer, JSA Raper, JL Vermund, SH Gotuzzo, E Allison, J Saag, MS AF Chen, Ray Y. Westfall, Andrew O. Hardin, J. Michael Miller-Hardwick, Cassandra Stringer, Jeffrey S. A. Raper, James L. Vermund, Sten H. Gotuzzo, Eduardo Allison, Jeroan Saag, Michael S. TI Complete blood cell count as a surrogate CD4 cell marker for HIV monitoring in resource-limited settings SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE AIDS; CD4(+) cell count; complete blood cell count; decision tree; HIV; total lymphocyte count ID TOTAL LYMPHOCYTE COUNT; ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; AFRICAN PATIENTS; STAGING SYSTEM; DECISION-TREE; CONSTRAINED COUNTRIES; INFECTED INDIVIDUALS; RAPID DECLINES; HOMOSEXUAL-MEN AB Background: A total lymphocyte count (TLC) of 1200 cells/mL has been used as a surrogate for a CD4 count of 200 cells/mu L in resourcelimited settings with varying results. We developed a more effective method based on a decision tree algorithm to classify subjects. Methods: A decision tree was used to develop models with the variables TLC, hemoglobin, platelet count, gender, body mass index, and antiretroviral treatment status of subjects from the University of Alabama at Birmingham (UAB) observational database. Models were validated on data from the Birmingham Veterans Affairs Medical Center (BVAMC) and Zambia, with primary decision trees also generated from these data. Results: A total of 1189 patients from the UAB observational database were included. The UAB decision tree classified a CD4 count <= 200 cells/mu L as better than a TLC cut-point of 1200 cells/mL, based on the area under the curve of the receiver-operator characteristic curve (P < 0.0001). When applied to data from the BVAMC and Zambia, the UAB-based decision tree performed better than the TLC cut-point of 1200 cells/mL (BVAMC: P < 0.0001; Zambia: P = 0.0009) but worse than a decision tree based on local data (BVAMC: P <= 0.0001; Zambia: P < 0.0001). Conclusion: A decision tree algorithm based on local data identifies low CD4 cell counts better than one developed from a different population or a TLC cut-point of 1200 cells/mL. C1 Univ Alabama, HIV Outpatient Clin, Dept Med, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Univ Alabama, Dept Biostat, Sch Publ Hlth, Birmingham, AL 35294 USA. Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35294 USA. Univ Alabama, Dept Epidemiol, Sch Publ Hlth, Birmingham, AL 35294 USA. Hosp Cayetano Heredia, Dept Transmissible Dis, Lima, Peru. RP Saag, MS (reprint author), Univ Alabama, HIV Outpatient Clin, Dept Med, Community Care Bldg,Room 142,908 20th St, Birmingham, AL 35294 USA. EM msaag@uab.edu OI Chen, Ray/0000-0001-6344-1442; Allison, Jeroan/0000-0003-4472-2112; Vermund, Sten/0000-0001-7289-8698 FU NIAID NIH HHS [P30 AI 27767] NR 45 TC 9 Z9 9 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2007 VL 44 IS 5 BP 525 EP 530 DI 10.1097/QAI.0b013e318032385e PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 152YZ UT WOS:000245399700005 PM 17259910 ER PT J AU Louey, S Jonker, SS Giraud, GD Thornburg, KL AF Louey, Samantha Jonker, Sonnet S. Giraud, George D. Thornburg, Kent L. TI Placental insufficiency decreases cell cycle activity and terminal maturation in fetal sheep cardiomyocytes SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID INTRAUTERINE GROWTH RESTRICTION; CARDIAC MYOCYTES; POSTNATAL-GROWTH; BLOOD-FLOW; RAT-HEART; EMBOLIZATION; HYPERTROPHY; GESTATION; REGENERATION; HYPERPLASIA AB Umbilicoplacental embolization (UPE) in sheep has been used to investigate the effects of placental insufficiency on fetal development. However, its specific effects on the heart have been little studied. The aim of this study was to determine the effects of placental insufficiency, induced by UPE, on cardiomyocyte size, maturation and proliferation. Instrumented fetal sheep underwent UPE for either 10 or 20 days. Hearts were collected at 125 +/- 1 days (10 day group) or 136 +/- 1 days (20 day group) of gestation (term similar to 145 days). Cell size, maturational state (as measured by the proportion of binucleated myocytes) and cell cycle activity (as measured by positive staining of cells for Ki-67) were determined in dissociated cardiomyocytes. UPE fetuses were hypoxaemic, but mean arterial pressures were not different from controls. UPE fetuses were lighter than control fetuses (10 days: -21%, P < 0.05; 20 days: -27%, P < 0.01) and had smaller hearts, but heart weight was appropriate for body weight. Neither lengths nor widths were different between control and UPE cardiomyocytes at either age. Ten days of UPE did not significantly alter the proportion of binucleated myocytes or cell cycle activity in either ventricle. However, 20 days of UPE reduced cell cycle activity in both ventricles by similar to 70% (P < 0.05); the proportion of binucleated myocytes was also lower in UPE fetuses at this age (left ventricle: 31.1 +/- 12.0 versus 46.0 +/- 6.6%, P < 0.05; right ventricle: 29.4 +/- 12.3 versus 46.3 +/- 5.3%, P < 0.05). It is concluded that in the absence of fetal arterial hypertension, placental insufficiency is associated with substantially depressed growth of the heart through suppressed proliferation and maturation of cardiomyocytes. C1 Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Med Cardiovasc, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97207 USA. RP Louey, S (reprint author), Oregon Hlth & Sci Univ, Heart Res Ctr, L464,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM loueys@ohsu.edu OI Thornburg, Kent/0000-0002-5561-4785; Jonker, Sonnet/0000-0002-1097-2562 FU NICHD NIH HHS [P01 HD034430, P01HD34430] NR 34 TC 46 Z9 47 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3751 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD APR 15 PY 2007 VL 580 IS 2 BP 639 EP 648 DI 10.1113/jphysiol.2006.122200 PG 10 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 156KN UT WOS:000245646900026 PM 17234700 ER PT J AU Netscher, DT Baumholtz, MA AF Netscher, David T. Baumholtz, Michael A. TI Treatment of congenital upper extremity problems SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article AB Learning Objectives: After studying this article, the participant should be able to: 1. Describe the terminology and classification of congenital hand anomalies. 2. Describe the incidence and embryogenesis of some common congenital hand anomalies. 3. Discuss the general principles and goals for treatment of congenital hand anomalies. 4. Describe the management of five of the more common congenital hand anomalies (syndactyly, short digits, thumb duplication, hypoplastic thumb, and radial dysplasia). Summary: Congenital hand anomalies can cause substantial emotional and functional problems. This article reviews the etiology, classification, and management of some of the more common hand anomalies. A general approach to the patient and the goals of treatment are reviewed, as is the approach to five specific congenital hand anomalies: syndactyly, short digits, thumb duplication, hypoplastic thumb, and radial dysplasia. C1 Baylor Coll Med, Div Plast Surg, Houston, TX 77030 USA. Dept Vet Affairs Med Ctr, Plast Surg Sect, Houston, TX USA. RP Netscher, DT (reprint author), Baylor Coll Med, Div Plast Surg, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD APR 15 PY 2007 VL 119 IS 5 BP 1611 EP 1612 DI 10.1097/01.prs.0000258535.31613.43 PG 2 WC Surgery SC Surgery GA 157IH UT WOS:000245711700028 ER PT J AU Fu, RW Harris, EL Helfand, M Nelson, HD AF Fu, Rongwei Harris, Emily L. Helfand, Mark Nelson, Heidi D. TI Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: A meta-analytic approach SO STATISTICS IN MEDICINE LA English DT Article; Proceedings Paper CT 10th Biennial Symposium on Statistical Methods CY 2007 CL Washington, DC SP CDC, ATSDR, Washington Statist Soc, Rutgers Univ, Ctr Discrete Math & Comp Sci, SAG, Statist Advisory Grp DE penetrance; BRCA mutations; meta-analysis; breast cancer risk; prevalence; family history ID OVARIAN-CANCER; FAMILY-HISTORY; JEWISH WOMEN; FOUNDER MUTATIONS; ASHKENAZI WOMEN; COMMON BRCA1; CASE SERIES; POPULATION; PENETRANCE; PREVALENCE AB Estimates of penetrance (or risk) of breast cancer among BRCA mutation carriers in published studies are heterogeneous, prohibiting direct combined estimates. Estimates of prevalence of hRCA mutations are more homogeneous and could allow combined estimates of prevalence. We propose a combined estimator of penetrance from combined estimates of the prevalence of BRCA mutations in women with and without breast cancer and from the probability of breast cancer by using Bayes' Theorem. The relative risk of having breast cancer with positive family history and the prevalence of positive family history contribute to the combined estimate of penetrance if family history is present. The combined estimate incorporates variation in estimates from different resources. The method is illustrated by using data from Ashkenazi Jewish women unselected for family history and for those with family history. Risks of breast cancer conferred by BRCA1 and BRCA2 mutations are estimated to be 8.39 per cent (6.56, 10.68 per cent) and 2.66 per cent (1.85, 3.82 per cent) by 40 years old, and 47.45 per cent (37.39, 57.72 per cent) and 31.85 per cent (23.72, 41.26 per cent) by 75 years old, respectively. For those with family history, risks of breast cancer conferred by BRCA mutations appear to be higher. Copyright (c) 2007 John Wiley & Sons, Ltd. C1 Oregon Hlth & Sci Univ, Oregon Evidence Based Pract Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. Kaiser Permanente Ctr Hlth Res, Portland, OR USA. Portland VA Med Ctr, Portland, OR USA. Providence Hlth & Serv, Portland, OR USA. RP Fu, RW (reprint author), Oregon Hlth & Sci Univ, Oregon Evidence Based Pract Ctr, 3181 SW Sam Jackson Pk Rd,CB669, Portland, OR 97239 USA. EM fur@ohsu.edu FU PHS HHS [290-02-0024] NR 40 TC 6 Z9 6 U1 0 U2 2 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0277-6715 J9 STAT MED JI Stat. Med. PD APR 15 PY 2007 VL 26 IS 8 BP 1775 EP 1787 DI 10.1002/sim.2811 PG 13 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 149JI UT WOS:000245142800011 PM 17243094 ER PT J AU Riley, DE Jeon, JS Krieger, JN AF Riley, Donald E. Jeon, Joon Seong Krieger, John N. TI Simple repeat evolution includes dramatic primary sequence changes that conserve folding potential SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE short tandem repeats; STR replacements; secondary structure preservation; simple repeats; microsatellites; evolution; non-coding sequences; UTRs ID SHORT TANDEM REPEATS; MESSENGER-RNA; ALLELE SIZE; MICROSATELLITES; HYBRIDIZATION; REPLACEMENTS; CONSTRAINTS; PREDICTION; MULTIPLE; ELEMENTS AB We previously demonstrated that many "weak-folding" simple repeats were replaced during evolution by alternative weak-folding repeats. This suggested repeat selection at the level of higher order structure potential. Here, we demonstrate similar phenomena for "strong-folding" simple repeats in non-coding DNA. The Rabgap1 gene's 3' UTR contained the self-complementary repeat (AT)n in Homo sapiens but, in Mus musculus, this site was occupied by the complementary repeats (GT)n and (AC)n. Similarly, primate Plag1 UTRs contained various (GT)n-(AC)n palindromes but in rodents, this site was occupied by (AT)n, preserving folding potential more than primary sequence. The Znf516, Senp1, Rock2, and other UTRs exhibited similar replacements. In the Bnc2 UTR, (AT)n was replaced by sequences that evolved with approximate symmetry about a central axis, a pattern difficult to explain without invoking selection to preserve secondary structure. These observations reflect a predictable evolutionary pattern for some common non-coding genomic sequences. (c) 2007 Elsevier Inc. All rights reserved. C1 VA Puget Sound Healthcare Syst, Dept Res, Seattle, WA 98012 USA. Univ Washington, Dept Urol, Seattle, WA 98195 USA. Inje Univ, Iksan Paik Hosp, Dept Urol, Koyang Si 411706, Kyunggi Do, South Korea. RP Riley, DE (reprint author), VA Puget Sound Healthcare Syst, Dept Res, Room 517,Bldg 1,1660 S Columbian Way, Seattle, WA 98012 USA. EM dri@u.washington.edu FU NIDDK NIH HHS [R01 DK38955] NR 25 TC 8 Z9 8 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD APR 13 PY 2007 VL 355 IS 3 BP 619 EP 625 DI 10.1016/j.bbrc.2007.01.200 PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 147KG UT WOS:000245001300004 PM 17320822 ER PT J AU Scremin, OU Li, MG Scremin, AME AF Scremin, O. U. Li, M. G. Scremin, A. M. E. TI Cortical contusion induces trans-hemispheric reorganization of blood flow maps SO BRAIN RESEARCH LA English DT Article DE cerebrovascular circulation; brain injury; cerebral ischemia; functional imaging ID BRAIN-INJURY; RAT SMI; MODULATION; MECHANISMS; CORTEX AB Cerebral blood flow (CBF), a surrogate of neural activity in the identification of brain regions involved in specific functions, has been used in this report to trace the compensatory enhancement of activity in non-traumatized areas of the brain following a focal lesion. We have previously shown activation of CBF in the cortex contralateral to a focal contusion, 24 h after the event. The present report extends the characterization of this trans-hemispheric cortical blood flow activation by studying its time course and regional distribution from 4 days to 4 weeks post-trauma. Adult male Sprague-Dawley rats received a cortical impact through a 6.3 mm craniotomy under halothane anesthesia. CBF was measured with the quantitative autoradio graphic C-14-lodoantipyrine technique, in conscious animals, 4 days, 2 weeks and 4 weeks post-trauma. CBF was severely decreased at the site of impact where necrosis developed later, and it remained depressed in the surrounding areas throughout the observation period. Trans-hemispheric CBF enhancement was maximal at 4 days and it returned to control levels 28 days post-trauma. This phenomenon was present in all cortical regions symmetrical to the impact zone, but also in auditory, visual, entorhinal and insular cortex. These results suggest that the participation of the contralateral cortex in the recovery from unilateral brain trauma is not limited to the regions homologous to those that received the impact. The time course of CBF changes was found to be consistent with the recovery of motor function in this model. (c) 2007 Elsevier B.V. All rights reserved. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA. RP Scremin, OU (reprint author), VA Greater Los Angeles Healthcare Syst, Bldg 15,Room 319,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM oscremin@ucla.edu NR 20 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD APR 13 PY 2007 VL 1141 BP 235 EP 241 DI 10.1016/j.brainres.2007.01.006 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 154FG UT WOS:000245491700026 PM 17275796 ER PT J AU Baran, Y Salas, A Senkal, CE Gunduz, U Bielawski, J Obeid, LM Ogretmen, B AF Baran, Yusuf Salas, Arelis Senkal, Can E. Gunduz, Ufuk Bielawski, Jacek Obeid, Lina M. Ogretmen, Besim TI Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID CHRONIC MYELOGENOUS LEUKEMIA; LONGEVITY ASSURANCE GENE-1; HUMAN ACID CERAMIDASE; SPHINGOSINE 1-PHOSPHATE; TYROSINE KINASE; DIHYDROCERAMIDE SYNTHASE; FAMILY-MEMBERS; CANCER-THERAPY; HUMAN HEAD; PROTEIN AB In this study, mechanisms of resistance to imatinib-induced apoptosis in human K562 cells were examined. Continuous exposure to stepwise increasing concentrations of imatinib resulted in the selection of K562/IMA-0.2 and -1 cells, which expressed similar to 2.3- and 19-fold resistance, respectively. Measurement of endogenous ceramides by high performance liquid chromatography/mass spectroscopy showed that treatment with imatinib increased the generation of ceramide, mainly C-18-ceramide, which is generated by the human longevity assurance gene 1 (hLASS1), in sensitive, but not in resistant cells. Inhibition of hLASS1 by small interfering RNA partially prevented imatinib-induced cell death in sensitive cells. In reciprocal experiments, overexpression of hLASS1, and not hLASS6, in drug-resistant cells caused a marked increase in imatinib-induced C-18-ceramide generation, and enhanced apoptosis. Interestingly, there were no defects in the levels of mRNA and enzyme activity levels of hLASS1 for ceramide generation in K562/IMA-1 cells. However, expression levels of sphingosine kinase-1 (SK1) and generation of sphingosine 1-phosphate (S1P) were increased significantly in K562/IMA-1 cells, channeling sphingoid bases to the sphingosine kinase pathway. The partial inhibition of SK1 expression by small interference RNA modulated S1P levels and increased sensitivity to imatinib-induced apoptosis in resistant cells. On the other hand, forced expression of SK1 in K562 cells increased the ratio between total S1P/C-18-ceramide levels similar to 6-fold and prevented apoptosis significantly in response to imatinib. Additional data indicated a role for SK1/S1P signaling in the up-regulation of the Bcr-Abl expression at the post-transcriptional level, which suggested a possible mechanism for resistance to imatinib-mediated apoptosis. In conclusion, these data suggest a role for endogenous C-18-ceramide synthesis mainly via hLASS1 in imatinib-induced apoptosis in sensitive cells, whereas in resistant cells, alterations of the balance between the levels of ceramide and S1P by overexpression of SK1 result in resistance to imatinib-induced apoptosis. C1 Med Univ S Carolina, Div Gen Internal Med, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA. Med Univ S Carolina, Hollings Canc Ctr, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Middle E Tech Univ, Dept Biol, TR-06531 Ankara, Turkey. RP Ogretmen, B (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Hollings Canc Ctr, 173 Ashley Ave, Charleston, SC 29425 USA. EM ogretmen@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [CA097132, CA88932]; NIDCR NIH HHS [DE01657] NR 56 TC 126 Z9 131 U1 2 U2 21 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 13 PY 2007 VL 282 IS 15 BP 10922 EP 10934 DI 10.1074/jbc.M610157200 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 160LG UT WOS:000245941500012 PM 17303574 ER PT J AU Copeland, LA Mortensen, EM Zeber, JE Pugh, MJ Restrepo, MI Dalack, GW AF Copeland, Laurel A. Mortensen, Eric M. Zeber, John E. Pugh, Mary Jo Restrepo, Marcos I. Dalack, Gregory W. TI Pulmonary disease among inpatient decedents: Impact of schizophrenia SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY LA English DT Review DE health services; mortality; respiratcry disorders; schizophrenia; veterans ID PLACEBO-CONTROLLED TRIAL; OF-VETERANS-AFFAIRS; MENTAL-ILLNESS; OLDER PATIENTS; INFLUENZA VACCINATION; PSYCHOTIC DISORDERS; TARDIVE-DYSKINESIA; SMOKING-CESSATION; MEDICAL-SERVICES; HEALTH-STATUS AB Objectives: Determine the risk associated with schizophrenia for common pulmonary illness (pneumonia and chronic obstructive pulmonary disorder (COPD)) during the last year of life. Methods: Inpatient decedents in Veterans (VA) hospitals in 2002 (N=27,798) were identified. Logistic regression modeled diagnosis of pulmonary illness in either the final year or final admission as a function of schizophrenia, smoking history and other covariates. Results: Among decedents, 943 (3%) had schizophrenia, 3% were women, most were white (76%) or African-American (18%), and average age at death was 72.4 years (SD 11.5). Three-fifths received VA outpatient care in the year prior to death. Among those with schizophrenia, only twofifths had outpatient care. Pneumonia was more common among schizophrenia patients (3 8% vs 3 1 %) as was COPD (46% vs 3 8%), In models controlling for history of smoking and other covariates, schizophrenia was a risk factor for pulmonary disease in the last year of life (OR= 1.9, 95% CI 1.6-2.2) but less so for final-stay pulmonary disease (OR= 1.5, 95% CI 1.3-1.7). Conclusions: VA inpatient decedents with schizophrenia were at increased risk for pneumonia and COPD, independent of smoking indicators. Clinicians treating schizophrenia patients need to be especially alert to potential comorbid medical conditions and ensure vulnerable patients receive appropriate care. Published by Elsevier Inc. C1 S Texas Vet Hlth Care Syst VERDICT, HSR&D, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. VA Ann Arbor Healthcare Syst, Dept Psychiat, Ann Arbor, MI 48105 USA. Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Copeland, LA (reprint author), S Texas Vet Hlth Care Syst VERDICT, HSR&D, 7400 Merton Minter,11c6, San Antonio, TX 78229 USA. EM copelandl@uthsesa.edu RI Restrepo, Marcos/H-4442-2014 OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563; Copeland, Laurel/0000-0002-9478-0209 NR 50 TC 24 Z9 24 U1 2 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0278-5846 J9 PROG NEURO-PSYCHOPH JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry PD APR 13 PY 2007 VL 31 IS 3 BP 720 EP 726 DI 10.1016/j.pnpbp.2007.01.008 PG 7 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 163NH UT WOS:000246166100019 PM 17292522 ER PT J AU Boden, WE O'Rourke, RA Teo, KK Hartigan, PM Maron, DJ Kostuk, WJ Knudtson, M Dada, M Casperson, P Harris, CL Chaitman, BR Shaw, L Gosselin, G Nawaz, S Title, LM Gau, G Blaustein, AS Booth, DC Bates, ER Spertus, JA Berman, DS Mancini, GBJ Weintraub, WS Boden, W O'Rourke, R Teo, K Hartigan, P Weintraub, W Maron, D Mancini, J Weintraub, W Boden, W O'Rourke, R Teo, K Hartigan, P Knudtson, M Maron, D Bates, E Blaustein, A Booth, D Carere, R Ellis, S Gosselin, G Gau, G Jacobs, A King, S Kostuk, W Harris, C Spertus, J Peduzzi, P Ryan, T Turnbull, B Feldman, T Bonow, R Haskell, W Diehr, P Lachenbruch, P Waters, D Johnstone, D Cohen, L Cantin, B Hager, W Samaha, F Januzzi, J Arrighi, J Chaitman, B Weintraub, W Hartigan, P O'Rourke, R Boden, W Barnett, P Spertus, J Goeree, R Maron, D Boden, W O'Rourke, R Teo, K Weintraub, W Peduzzi, P Antonelli, M Smith, J Kilstrom, R Hunter, B O'Neil, S Economou, T Nabors, J Kossack, A Sather, M Harris, C Gagne, W Fye, C Marottoli, R Allore, H Beckwith, D Farrell, W Feldman, R Mehta, R Neiderman, J Perry, E Kasl, S Zeman, M O'Leary, T Huang, G Boden, W Dada, M Potter, K Rivera, T O'Rourke, R Casperson, P O'Shea, A Teo, K Woodcock, G Weintraub, W Barnett, P Goeree, R O'Brien, B Mancini, GBJ Yeoh, E Ladenson, J Thompson, V Chaitman, B Bertran, T Berman, D Gerlach, J Littman, R Shaw, L Calfas, K Sallis, J O'Rourke, R Baker, P Bolton, J Blaustein, A Rowe, C Morris, K Hoffman, S Sedlis, S Keary, M Duvernoy, C Majors, C Shockey, M Zoble, R Fernandez, I Lehmann, K Sorley, A Abel, M Sheldon, M Wagoner, K Murphy, E Avalos, K Rossen, J Schneider, K Molavi, B Garza, L Barton, P Mavromatis, K Forghani, Z Smith, R Mitchell, C Ramanathan, K Touchstone, T Kostuk, W Sridhar, K Carr, S Wiseman, D Nawaz, S Dion, C Gosselin, G Theberge, J Cuso, M Title, L Simon, P Carroll, L Courtney-Cox, K Cohen, E Hsu, E Dzavik, V Lan, J Knudtson, M Lundberg, D Natarajan, M Cappelli, G Kutryk, M DiMarco, A Strauss, B Fung, A Chow, J Marr, D Fitzgerald, F Carere, R Nacario, T Tymchak, W Harris, L Lazzam, C Carter, A Palisaitis, D Mercure, C Bell, M Peterson, M Vicari, R Carroll, M Bates, E Luciano, A Mahrer, P Reyes, S Saucedo, J Vanwieren, D O'Keefe, J Kennedy, P Jacobs, A Berger, C Mayo, S Miller, J Arnold, T Kiernan, F Murphy, D Kugelmass, A Pangilinan, R Schwartz, R Caufield, L Hansen, D Mitchell, C Carhart, R Pennella, A Ellis, S Stevenson, C Krone, R Humphrey, J Appleton, C Wisbey, J Stillabower, M Davidson, M Mathien, J AF Boden, William E. O'Rourke, Robert A. Teo, Koon K. Hartigan, Pamela M. Maron, David J. Kostuk, William J. Knudtson, Merril Dada, Marcin Casperson, Paul Harris, Crystal L. Chaitman, Bernard R. Shaw, Leslee Gosselin, Gilbert Nawaz, Shah Title, Lawrence M. Gau, Gerald Blaustein, Alvin S. Booth, David C. Bates, Eric R. Spertus, John A. Berman, Daniel S. Mancini, G. B. John Weintraub, William S. Boden, W. O'Rourke, R. Teo, K. Hartigan, P. Weintraub, W. Maron, D. Mancini, J. Weintraub, W. Boden, W. O'Rourke, R. Teo, K. Hartigan, P. Knudtson, M. Maron, D. Bates, E. Blaustein, A. Booth, D. Carere, R. Ellis, S. Gosselin, G. Gau, G. Jacobs, A. King, S., III Kostuk, W. Harris, C. Spertus, J. Peduzzi, P. Ryan, T. Turnbull, B. Feldman, T. Bonow, R. Haskell, W. Diehr, P. Lachenbruch, P. Waters, D. Johnstone, D. Cohen, L. Cantin, B. Hager, W. Samaha, F. Januzzi, J. Arrighi, J. Chaitman, B. Weintraub, W. Hartigan, P. O'Rourke, R. Boden, W. Barnett, P. Spertus, J. Goeree, R. Maron, D. Boden, W. O'Rourke, R. Teo, K. Weintraub, W. Peduzzi, P. Antonelli, M. Smith, J. Kilstrom, R. Hunter, B. O'Neil, S. Economou, T. Nabors, J. Kossack, A. Sather, M. Harris, C. Gagne, W. Fye, C. Marottoli, R. Allore, H. Beckwith, D. Farrell, W. Feldman, R. Mehta, R. Neiderman, J. Perry, E. Kasl, S. Zeman, M. O'Leary, T. Huang, G. Boden, W. Dada, M. Potter, K. Rivera, T. O'Rourke, R. Casperson, P. O'Shea, A. Teo, K. Woodcock, G. Weintraub, W. Barnett, P. Goeree, R. O'Brien, B. Mancini, G. B. J. Yeoh, E. Ladenson, J. Thompson, V. Chaitman, B. Bertran, T. Berman, D. Gerlach, J. Littman, R. Shaw, L. Calfas, K. Sallis, J. O'Rourke, R. Baker, P. Bolton, J. Blaustein, A. Rowe, C. Morris, K. Hoffman, S. Sedlis, S. Keary, M. Duvernoy, C. Majors, C. Shockey, M. Zoble, R. Fernandez, I. Lehmann, K. Sorley, A. Abel, M. Sheldon, M. Wagoner, K. Murphy, E. Avalos, K. Rossen, J. Schneider, K. Molavi, B. Garza, L. Barton, P. Mavromatis, K. Forghani, Z. Smith, R. Mitchell, C. Ramanathan, K. Touchstone, T. Kostuk, W. Sridhar, K. Carr, S. Wiseman, D. Nawaz, S. Dion, C. Gosselin, G. Theberge, J. Cuso, M. Title, L. Simon, P. Carroll, L. Courtney-Cox, K. Cohen, E. Hsu, E. Dzavik, V. Lan, J. Knudtson, M. Lundberg, D. Natarajan, M. Cappelli, G. Kutryk, M. DiMarco, A. Strauss, B. Fung, A. Chow, J. Marr, D. Fitzgerald, F. Carere, R. Nacario, T. Tymchak, W. Harris, L. Lazzam, C. Carter, A. Palisaitis, D. Mercure, C. Bell, M. Peterson, M. Vicari, R. Carroll, M. Bates, E. Luciano, A. Mahrer, P. Reyes, S. Saucedo, J. vanWieren, D. O'Keefe, J. Kennedy, P. Jacobs, A. Berger, C. Mayo, S. Miller, J. Arnold, T. Kiernan, F. Murphy, D. Kugelmass, A. Pangilinan, R. Schwartz, R. Caufield, L. Hansen, D. Mitchell, C. Carhart, R. Pennella, A. Ellis, S. Stevenson, C. Krone, R. Humphrey, J. Appleton, C. Wisbey, J. Stillabower, M. Davidson, M. Mathien, J. CA COURAGE Trial Res Grp TI Optimal medical therapy with or without PCI for stable coronary disease SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID EVALUATION COURAGE TRIAL; BARE-METAL STENTS; OUTCOMES UTILIZING REVASCULARIZATION; RANDOMIZED CLINICAL-TRIALS; SIROLIMUS-ELUTING STENTS; MYOCARDIAL-INFARCTION; ARTERY-DISEASE; CARDIOVASCULAR EVENTS; HEART-DISEASE; RITA-2 TRIAL AB Background: In patients with stable coronary artery disease, it remains unclear whether an initial management strategy of percutaneous coronary intervention (PCI) with intensive pharmacologic therapy and lifestyle intervention (optimal medical therapy) is superior to optimal medical therapy alone in reducing the risk of cardiovascular events. Methods: We conducted a randomized trial involving 2287 patients who had objective evidence of myocardial ischemia and significant coronary artery disease at 50 U.S. and Canadian centers. Between 1999 and 2004, we assigned 1149 patients to undergo PCI with optimal medical therapy (PCI group) and 1138 to receive optimal medical therapy alone (medical-therapy group). The primary outcome was death from any cause and nonfatal myocardial infarction during a follow-up period of 2.5 to 7.0 years (median, 4.6). Results: There were 211 primary events in the PCI group and 202 events in the medical-therapy group. The 4.6-year cumulative primary-event rates were 19.0% in the PCI group and 18.5% in the medical-therapy group (hazard ratio for the PCI group, 1.05; 95% confidence interval [CI], 0.87 to 1.27; P=0.62). There were no significant differences between the PCI group and the medical-therapy group in the composite of death, myocardial infarction, and stroke (20.0% vs. 19.5%; hazard ratio, 1.05; 95% CI, 0.87 to 1.27; P=0.62); hospitalization for acute coronary syndrome (12.4% vs. 11.8%; hazard ratio, 1.07; 95% CI, 0.84 to 1.37; P=0.56); or myocardial infarction (13.2% vs. 12.3%; hazard ratio, 1.13; 95% CI, 0.89 to 1.43; P=0.33). Conclusions: As an initial management strategy in patients with stable coronary artery disease, PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events when added to optimal medical therapy. C1 SUNY Buffalo, Buffalo Gen Hosp, Div Cardiol, Buffalo, NY 14203 USA. Western New York Vet Affairs VA Healthcare Networ, Buffalo, NY USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. McMaster Univ, Med Ctr, Hamilton, ON, Canada. VA Connecticut Healthcare Syst, Cooperat Studies Program Coordinating Ctr, West Haven, CT USA. Vanderbilt Univ, Med Ctr, Nashville, TN USA. London Hlth Sci Ctr, London, ON, Canada. Foothills Prov Gen Hosp, Calgary, AB T2N 2T9, Canada. Hartford Hosp, Hartford, CT 06115 USA. VA Cooperat Studies Program Clin Res Pharm Coordi, Albuquerque, NM USA. St Louis Univ, St Louis, MO 63103 USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada. Sudbury Reg Hosp, Sudbury, ON, Canada. Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada. Mayo Clin, Rochester, MN USA. Houston VA Med Ctr, Houston, TX USA. Lexington VA Med Ctr, Lexington, KY USA. Univ Michigan, Med Ctr, Ann Arbor, MI USA. St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. Vancouver Hosp & Hlth Sci Ctr, Vancouver, BC V5Z 1M9, Canada. Christiana Care Hlth Syst, Newark, DE USA. RP Boden, WE (reprint author), SUNY Buffalo, Buffalo Gen Hosp, Div Cardiol, 100 High St, Buffalo, NY 14203 USA. EM wboden@kaleidahealth.org NR 51 TC 1847 Z9 1969 U1 10 U2 67 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 12 PY 2007 VL 356 IS 15 BP 1503 EP 1516 DI 10.1056/NEJMoa070829 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 156CA UT WOS:000245624400004 PM 17387127 ER PT J AU Rivier, J Gulyas, J Kunitake, K DiGruccio, M Cantle, JP Perrin, MH Donaldson, C Vaughan, J Million, M Gourcerol, G Adelson, DW Rivier, C Tache, Y Vale, W AF Rivier, Jean Gulyas, Jozsef Kunitake, Koichi DiGruccio, Michael Cantle, Jeffrey P. Perrin, Marilyn H. Donaldson, Cindy Vaughan, Joan Million, Mulugeta Gourcerol, Guillaume Adelson, David W. Rivier, Catherine Tache, Yvette Vale, Wylie TI Stressin(1)-A, a potent corticotropin releasing factor receptor 1 (CRF1)-selective peptide agonist SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID I-(I+3) GLU-LYS; FACTOR CRF; COMPETITIVE ANTAGONISTS; UROCORTIN-II; ASTRESSIN ANALOGS; STRESS; RAT; MICE; ADAPTATIONS; SUBTYPE-1 AB The potencies and selectivity of peptide CRF antagonists is increased through structural constraints, suggesting that the resulting ligands assume distinct conformations when interacting with CRF1 and CRF2 receptors. To develop selective CRF receptor agonists, we have scanned the sequence -Gln-Ala-His-Ser-Asn-Arg- (residues 30-35 of [DPhe(12),Nle(21,38)]Ac-hCRF(4-41)) with an i-(i+3) bridge consisting of the Glu(i)-Xaa-Xbb-Lys(i+3) scaffold, where residues i = 30, 31, and 32. When i = 31, stressin(1)-A, a potent CRF1 receptor-selective agonist was generated. In vitro, stressin(1)-A was equipotent to h/rCRF to release ACTH. Astressin(1)-A showed a low nanomolar affinity for CRF1 receptor (K-i = 1.7 nM) and greater than 100-fold selectivity versus CRF2 receptor (K-i = 222 nM). Stressin(1)-A released slightly less ACTH than oCRF in adult adrenal-intact male rats, with increased duration of action. Stressin(1)-A, injected intraperitoneally in rats, induced fecal pellet output (a CRF1 receptor-mediated response) and did not influence gastric emptying and blood pressure (CRF2 receptor-mediated responses). C1 Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA. CURE, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Ctr Neurovisceral Sci Womens Hlth, VA Greater Los Angeles Healthcare Syst, Dept Med,Div Digest Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA. RP Rivier, J (reprint author), Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA. EM jrivier@salk.edu OI DiGruccio, Michael/0000-0002-9375-2425; Adelson, David/0000-0002-4623-6030 FU NIDDK NIH HHS [DK 057238, DK 068155, DK026741, P01 DK026741, P01 DK026741-280010, P30 DK041301, P30 DK041301-199006, R01 DK057238, DK 041301, R01 DK057238-08, R21 DK068155, R21 DK068155-02] NR 34 TC 30 Z9 31 U1 0 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 J9 J MED CHEM JI J. Med. Chem. PD APR 5 PY 2007 VL 50 IS 7 BP 1668 EP 1674 DI 10.1021/jm0613875 PG 7 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 150ZV UT WOS:000245259000026 PM 17335188 ER PT J AU Shekelle, P AF Shekelle, Paul TI Medicare's hospital compare performance measures and mortality rates SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID QUALITY; CARE C1 Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RP Shekelle, P (reprint author), Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. EM paul.shekelle@va.gov NR 8 TC 1 Z9 1 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 4 PY 2007 VL 297 IS 13 BP 1430 EP 1431 DI 10.1001/jama.297.13.1430-b PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 153AM UT WOS:000245404100014 PM 17405965 ER PT J AU Werner, RM Bradlow, ET AF Werner, Rachel M. Bradlow, Eric T. TI Medicare's hospital compare performance measures and mortality rates - Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID QUALITY; CARE C1 Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA. Univ Penn, Dept Mkt, Philadelphia, PA 19104 USA. RP Werner, RM (reprint author), Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA. EM rwerner@mail.med.upenn.edu NR 3 TC 0 Z9 0 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 4 PY 2007 VL 297 IS 13 BP 1431 EP 1431 DI 10.1001/jama.297.13.1431 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 153AM UT WOS:000245404100015 ER PT J AU Margaretten, ME Kohlwes, J Moore, D Bent, S AF Margaretten, Mary E. Kohlwes, Jeffrey Moore, Dan Bent, Stephen TI Does this adult patient have septic arthritis? SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID SYNOVIAL-FLUID LEUKOCYTOSIS; BACTERIAL ARTHRITIS; INFECTIOUS ARTHRITIS; CLINICAL-FEATURES; JOINT DISEASE; LACTIC-ACID; RHEUMATOID-ARTHRITIS; GONOCOCCAL ARTHRITIS; ACUTE MONOARTHRITIS; RISK-FACTORS AB Context In patients who present with an acutely painful and swollen joint, prompt identification and treatment of septic arthritis can substantially reduce morbidity and mortality. Objective To review the accuracy and precision of the clinical evaluation for the diagnosis of nongonococcal bacterial arthritis. Data Sources Structured PubMed and EMBASE searches ( 1966 through January 2007), limited to human, English-language articles and using the following Medical Subject Headings terms: arthritis, infectious, physical examination, medical history taking, diagnostic tests, and sensitivity and specificity. Study Selection Studies were included if they contained original data on the accuracy or precision of historical items, physical examination, serum, or synovial fluid laboratory data for diagnosing septic arthritis. Data Extraction Three authors independently abstracted data from the included studies. Data Synthesis Fourteen studies involving 6242 patients, of whom 653 met the gold standard for the diagnosis of septic arthritis, satisfied all inclusion criteria. Two studies examined risk factors and found that age, diabetes mellitus, rheumatoid arthritis, joint surgery, hip or knee prosthesis, skin infection, and human immunodeficiency virus type 1 infection significantly increase the probability of septic arthritis. Joint pain ( sensitivity, 85%; 95% confidence interval [CI], 78%-90%), a history of joint swelling ( sensitivity, 78%; 95% CI, 71%-85%), and fever ( sensitivity, 57%; 95% CI, 52%-62%) are the only findings that occur in more than 50% of patients. Sweats ( sensitivity, 27%; 95% CI, 20%-34%) and rigors ( sensitivity, 19%; 95% CI, 15%-24%) are less common findings in septic arthritis. Of all laboratory findings readily available to the clinician, the 2 most powerful were the synovial fluid white blood cell (WBC) count and percentage of polymorphonuclear cells from arthrocentesis. The summary likelihood ratio (LR) increased as the synovial fluid WBC count increased ( for counts < 25 000/mu L: LR, 0.32; 95% CI, 0.23-0.43; for counts >= 25 000/ mu L: LR, 2.9; 95% CI, 2.5-3.4; for counts > 50 000/ mu L: LR, 7.7; 95% CI, 5.7-11.0; and for counts > 100 000/ mu L: LR, 28.0; 95% CI, 12.0-66.0). On the same synovial fluid sample, a polymorphonuclear cell count of at least 90% suggests septic arthritis with an LR of 3.4 ( 95% CI, 2.8-4.2), while a polymorphonuclear cell count of less than 90% lowers the likelihood ( LR, 0.34; 95% CI, 0.25-0.47). Conclusions Clinical findings identify patients with peripheral, monoarticular arthritis who might have septic arthritis. However, the synovial WBC and percentage of polymorphonuclear cells from arthrocentesis are required to assess the likelihood of septic arthritis before the Gram stain and culture test results are known. C1 Univ Calif San Francisco, Div Rheumatol, Dept Med, Prime Program, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Margaretten, ME (reprint author), Univ Calif San Francisco, Div Rheumatol, Dept Med, Prime Program, U-384,533 Parnassus Ave, San Francisco, CA 94143 USA. EM mary.margaretten@ucsf.edu FU PHS HHS [1 K08 ATO1338-01] NR 58 TC 136 Z9 143 U1 2 U2 14 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 4 PY 2007 VL 297 IS 13 BP 1478 EP 1488 DI 10.1001/jama.297.13.1478 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 153AM UT WOS:000245404100024 PM 17405973 ER PT J AU Petersen, LA AF Petersen, Laura A. TI Does pay-for-performance improve the quality of health care? Response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Petersen, LA (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. NR 2 TC 0 Z9 0 U1 1 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 3 PY 2007 VL 146 IS 7 BP 538 EP 539 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 153VB UT WOS:000245463200013 ER PT J AU Watnick, S AF Watnick, Suzanne TI Pregnancy and contraceptive counseling of women with chronic kidney disease and kidney transplants SO ADVANCES IN CHRONIC KIDNEY DISEASE LA English DT Article DE chronic kidney disease; kidney transplantation; pregnancy; dialysis; counseling ID RENAL-DISEASE; DIALYSIS PATIENTS; REPRODUCTIVE ISSUES; INSUFFICIENCY; MANAGEMENT; RECIPIENTS; DEVICE AB Women with kidney disease of childbearing age should expect proactive counseling regarding pregnancy and contraception. Discussions should include the impact of pregnancy on their kidney disease and the impact of kidney disease on maternal and fetal outcomes. However, nephrologists rarely discuss sexual dysfunction, infertility, menstrual irregularities, and contraception with their premenopausal women patients. This review will consider pregnancy-related issues to discuss when counseling women with all stages of chronic kidney disease. Issues related to contraception in women on dialysis, women with functioning kidney transplants, and those with chronic kidney disease will also be reviewed. (c) 2007 by the National Kidney Foundation, Inc. C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, VA Dialysis Unit, Portland, OR 97201 USA. RP Watnick, S (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, VA Dialysis Unit, 3710 SW US Vet Hosp Rd, Portland, OR 97201 USA. EM watnicks@ohsu.edu NR 42 TC 20 Z9 21 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1548-5595 J9 ADV CHRONIC KIDNEY D JI Adv. Chronic Kidney Dis. PD APR PY 2007 VL 14 IS 2 BP 126 EP 131 DI 10.1053/j.ackd.2007.01.003 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 156PI UT WOS:000245661000005 PM 17395115 ER PT J AU Chamberlain, CK Cornell, JE Saunders, MJ Hatch, JP Shinkai, RS Yeh, CK AF Chamberlain, Cheryl K. Cornell, John E. Saunders, Michele J. Hatch, John P. Shinkai, Rosemary S. Yeh, Chih-Ko TI Intra-oral tactile sensation and aging in a community-based population SO AGING CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article ID SENSITIVITY; AGE; VIBROTACTILE; ADULTS; YOUNG; TOUCH AB Background and aims: Intra-oral sensory function plays an important role in swallowing and food intake, yet the impact of aging on oral tactile perception is uncertain. This study examined the effects of age, ethnicity, and gender on tactile perception at specific intra-oral sites in a community-based sample of 372 Mexican-Americans (MAs) and European-Americans (EAs). Methods: Four levels of air-pressure were delivered to sites on the anterior and posterior thirds of the tongue and on the velum. Intensity judgments for suprathreshold air puffs were obtained with a direct scaling procedure. Data were analyzed by mixed model multivariate repeated measures ANOVA. Results: Mean judgments of intensity, slopes of intensity functions and intraclass correlation coefficients (ICCs) for intensity judgments, indicated that stimuli delivered to the anterior tongue elicited significantly larger and more consistent responding than at the other sites. MAs produced lower mean stimulus intensity judgments for all sites compared to EAs. No significant age-, gender- or ethnic group-related differences were found at any of the sites for the slopes of the intensity functions or for ICCs. Conclusions: Stimuli are judged more intense at the anterior tongue compared to the posterior tongue or velum and EAs gave higher estimates of intensity than did MAs. However, there are no age-, gender-, or ethnic group-related differences for the repeatability of intensity judgments or the slopes of intensity functions. Intra-oral tactile perception seems to be preserved during aging. C1 S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin 182, Audie L Murphy Div, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Dent Diagnost Sci, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX 78284 USA. Pontificia Univ Catolica Rio Grande do Sul, Dept Prosthodont, Porto Alegre, RS, Brazil. RP Yeh, CK (reprint author), S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin 182, Audie L Murphy Div, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM Yeh@uthscsa.edu RI Shinkai, Rosemary/I-3510-2013 OI Shinkai, Rosemary/0000-0002-4107-5661 FU NIDCR NIH HHS [DE10756] NR 28 TC 1 Z9 1 U1 0 U2 1 PU EDITRICE KURTIS S R L PI MILAN PA VIA LUIGI ZOJA 30, 20153 MILAN, ITALY SN 1594-0667 J9 AGING CLIN EXP RES JI Aging Clin. Exp. Res. PD APR PY 2007 VL 19 IS 2 BP 85 EP 90 PG 6 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 163XH UT WOS:000246196000001 PM 17446717 ER PT J AU Yaffe, K AF Yaffe, Kristine TI Metabolic syndrome and cognitive disorders - Is the sum greater than its parts? SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Review DE metabolic syndrome; cognition; dementia; insulin resistance; inflammation ID TYPE-2 DIABETES-MELLITUS; C-REACTIVE PROTEIN; ALZHEIMER-DISEASE; OLDER WOMEN; ELDERLY-WOMEN; RISK; INFLAMMATION; DEMENTIA; OBESITY; LEPTIN AB Given the anticipated exponential increase in both the incidence and prevalence of dementia, it is critical to identify preventative strategies and improved treatments for this disorder. The metabolic syndrome is comprised of 5 cardiovascular risk factors that include abdominal obesity, hypertriglyceridemia, low high-density lipoprotein levels, hypertension, and hyperglycemia. The prevalence of the metabolic syndrome, similar to that for cognitive disorders, increases dramatically with age. Several possible mechanisms may explain an association between the metabolic syndrome and cognitive decline including microvascular and macrovascular disease, inflammation, adiposity, and insulin resistance. Although some of the individual components of the metabolic syndrome have been linked to risk of developing dementia and cognitive impairment, few studies have looked at the components of the metabolic syndrome as a whole. We found, in 3 separate studies involving elders of different ethnicities, that the metabolic syndrome is a risk factor for accelerated cognitive aging. This was especially true for elders with the metabolic syndrome and with elevated serum level of inflammation. If metabolic syndrome is associated with increased risk of developing cognitive impairment, regardless of mechanism, then early identification and treatment of these individuals might offer avenues for disease course modification. C1 Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat, Box 181,4150 Clemnent St, San Francisco, CA 94121 USA. EM Kristine.yaffe@ucsf.edu FU NIDDK NIH HHS [DK070713] NR 39 TC 89 Z9 93 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD APR-JUN PY 2007 VL 21 IS 2 BP 167 EP 171 DI 10.1097/WAD.0b013e318065bfd6 PG 5 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 177AO UT WOS:000247126200017 PM 17545744 ER PT J AU Bartzokis, G Lu, PH Mintz, J AF Bartzokis, George Lu, Po H. Mintz, Jim TI Human brain myelination and amyloid beta deposition in Alzheimer's disease SO ALZHEIMERS & DEMENTIA LA English DT Article DE myelin; oligodendrocyte; white matter; amyloid; iron; Alzheimer's disease; PIB; degeneration; dementia; aging; medications; treatment; prevention ID PITTSBURGH COMPOUND-B; WHITE-MATTER DAMAGE; NEURODEGENERATIVE DISORDERS; IN-VIVO; PARKINSONS-DISEASE; COGNITIVE DECLINE; TRANSGENIC MICE; MR EVALUATION; DOWN-SYNDROME; IRON STORES AB We hypothesized that myelin breakdown in vulnerable late-myelinating regions releases oligodendrocyte- and myelin-associated iron that promotes amyloid beta (A beta) oligornerization, its associated toxicity, and the deposition of oligomerized A beta and iron in neuritic plaques observed in Alzheimer's disease (AD). The model was tested by using published maps of cortical myelination from 1901 and recent in vivo imaging maps of A beta deposits in humans. The data show that in AD, radiolabeled ligands detect A beta deposition in a distribution that matches the map of late-myelinating regions. Furthermore, the strikingly lower ability of this imaging ligand to bind A beta in animal models is consistent with the much lower levels of myelin and associated iron levels in rodents when compared with humans. The hypotheses derived from the "myelin model" are testable with current imaging methods and have important implications for therapeutic interventions that should be expanded to include novel targets such as oligodendrocytes, myelin, and brain iron. (c) 2007 The Alzheimer's Association. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Brain Mapping, Dept Neurol,Lab Neuroimaging, Los Angeles, CA USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. RP Bartzokis, G (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA USA. EM gbar@ucla.edu RI Bartzokis, George/K-2409-2013 FU NIA NIH HHS [P50 AG016570, P50 AG016570-06, R01 AG027342]; NIMH NIH HHS [R01 MH066029, R01 MH066029-01A2] NR 55 TC 49 Z9 51 U1 2 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD APR PY 2007 VL 3 IS 2 BP 122 EP 125 DI 10.1016/j.jalz.2007.01.019 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 212FV UT WOS:000249579900007 PM 18596894 ER PT J AU Patel, P White, DL Deswal, A AF Patel, Parag White, Donna L. Deswal, Anita TI Translation of clinical trial results into practice: Temporal patterns of beta-blocker utilization for heart failure at hospital discharge and during ambulatory follow-up SO AMERICAN HEART JOURNAL LA English DT Article ID CARDIAC-INSUFFICIENCY BISOPROLOL; RANDOMIZED-TRIAL; MANAGEMENT; CARVEDILOL; OUTCOMES; THERAPY; MORTALITY; SURVIVAL; PROGRAM; TRENDS AB Background Underutilization of beta-blockers in heart failure (HF) has been widely reported at hospital discharge and in the ambulatory setting. We examined recent temporal patterns of beta-blocker utilization in HF with systolic dysfunction at hospital discharge and over 2-year follow-up. Methods Annual trends of beta-blocker use were examined in a clinical database of patients with ejection fraction <= 40% discharged after HF hospitalization in 1998-2004 (n = 735). More detailed data on beta-blocker use at discharge and over 2-year follow-up were abstracted for 200 consecutive patients each in 1999-2001 and 2003-2004. Results Annual rates of p-blocker use at discharge increased steadily by 10% per year from 1998-2004 (P < .001), with no sharp increase noted in any single year after publication of clinical trials or guidelines. Use among patients without contraindications increased markedly from 1999-2001 to 2003-2004 at hospital discharge (38.7% vs 82.6%, P <.001) and 2-year follow-up (53.0% vs 84.5%, P <.001). The increase was significant in all examined subgroups. Although > 50% of patients remained on low doses of beta-blockers, a 9 eater proportion trended to reach target doses at 2 years in the later period (25.6% vs 12.5%, P =.13). Conclusions Substantial increase in beta-blocker utilization in HIF with systolic dysfunction occurred from 1998 to 2004, demonstrating that high rates of p-blocker use are being achieved at hospital discharge and maintained in the ambulatory setting after discharge. However, the time lag in translation of scientific evidence into maximal use of beneficial therapy in practice remains a target for quality improvement. C1 Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. Michael E DeBakey Vet Affairs Med Ctr, Sect Cardiol, Houston, TX USA. Baylor Coll Med, Winters Ctr Heart Failure Res, Houston, TX 77030 USA. RP Deswal, A (reprint author), VA Med Ctr, 111B,2002 Holcombe Blvd, Houston, TX 77030 USA. EM adeswol@bcm.tmc.edu NR 21 TC 13 Z9 13 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD APR PY 2007 VL 153 IS 4 BP 515 EP 522 DI 10.1016/j.ahj.2007.01.037 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 158IE UT WOS:000245784200011 PM 17383287 ER PT J AU Bagheri, R Schutta, M Cumaranatunge, RG Wolfe, ML Terembula, K Hoffman, B Schwartz, S Kimmel, SE Farouk, S Iqbal, N Reilly, MP AF Bagheri, Roshanak Schutta, Mark Cumaranatunge, Reshmaal Gomes Wolfe, Megan L. Terembula, Karen Hoffman, Barry Schwartz, Stan Kimmel, Stephen E. Farouk, Samira Iqbal, Nayyar Reilly, Muredach P. TI Value of electrocardiographic and ankle-brachial index abnormalities for prediction of coronary atherosclerosis in asymptomatic subjects with type 2 diabetes mellitus SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ELECTRON-BEAM TOMOGRAPHY; CARDIOVASCULAR RISK-FACTORS; ARTERY CALCIUM; COMPUTED-TOMOGRAPHY; OLDER ADULTS; QT INTERVAL; DISEASE; CALCIFICATION; EVENTS; GUIDELINES AB Type 2 diabetes mellitus (DM) is associated with increased cardiovascular risk, in part due to accelerated subclinical atherosclerosis. Electrocardiographic (ECG) and ankle-brachial index (ABI) abnormalities are used to screen for cardiovascular risk in the clinic. However, their capacity to identify patients with type 2 DM with nonobstructive subclinical atherosclerosis is unknown. Associations of ECG and ABI abnormalities with coronary artery calcium (CAC), a measure of coronary atherosclerosis, were examined using multivariable ordinal regression modeling in 589 asymptomatic patients with type 2 DM. Sensitivity, specificity, and positive and negative predictive values were determined. CAC was prevalent (44% CAC >100; 32% CAC >75th percentile score) despite normal electrocardiograms (64%) and ABIs (97%) in most subjects. Neither ECG nor ABI changes predicted CAC after adjusting for age, gender, and race. ECG abnormalities were neither sensitive nor specific for detection of CAC > 100, > 400, or > 75th percentile (sensitivities 0.43, 0.45, and 0.34; specificities 0.69, 0.66, and 0.63, respectively). ABI abnormalities were not sensitive (0.03, 0.04, and 0.03) but had high specificity (0.98, 0.98, and 0.98). In subjects with normal electrocardiograms and ABIs, extensive CAC was remarkably prevalent (CAC > 100 in 24%). In conclusion, ECG and ABI abnormalities failed to detect patients with subclinical coronary atherosclerosis and therefore may be of limited value in identifying many asymptomatic patients with type 2 DM at increased risk of cardiovascular disease. (c) 2007 Elsevier Inc. All rights reserved. C1 Univ Penn, Sch Med, Cardiovasc Inst, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. Univ Connecticut, Hlth Ctr, Div Cardiol, Farmington, CT USA. RP Reilly, MP (reprint author), Univ Penn, Sch Med, Cardiovasc Inst, Philadelphia, PA 19104 USA. EM muredach@spirit.gcrc.upenn.edu FU NCRR NIH HHS [M01-RR00040]; NHLBI NIH HHS [R01-HL73278-01]; NIDDK NIH HHS [R01-DK071224-01A1, DK19525] NR 29 TC 12 Z9 12 U1 1 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD APR 1 PY 2007 VL 99 IS 7 BP 951 EP 955 DI 10.1016/j.amjcard.2006.11.040 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 156LQ UT WOS:000245649900015 PM 17398190 ER PT J AU Pietrzak, RH Morasco, BJ Blanco, C Grant, BF Petry, NM AF Pietrzak, Robert H. Morasco, Benjamin J. Blanco, Carlos Grant, Bridget F. Petry, Nancy M. TI Gambling level and psychiatric and medical disorders in older adults: Results from the national epidemiologic survey on alcohol and related conditions SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article; Proceedings Paper CT Summer Training on Aging Research Topics in Mental Health Conference CY AUG 05-07, 2005 CL San Diego, CA DE older adults; problem gambling; pathological gambling; recreational gambling; health; substance abuse; epidemiology ID INTERVIEW SCHEDULE AUDADIS; GENERAL-POPULATION SAMPLE; QUALITY-OF-LIFE; DSM-IV ALCOHOL; UNITED-STATES; PATHOLOGICAL GAMBLERS; PERSONALITY-DISORDERS; RHEUMATOID-ARTHRITIS; SOCIAL ACTIVITY; FAMILY-HISTORY AB Objective: This study examined the association between gambling level and psychiatric and medical disorders in a nationally representative sample of older adults. Method: Data on 10,563 U. S. older adults (age 60 or older) were analyzed from the National Epidemiologic Survey on Alcohol and Related Conditions. Results: A total 28.74% of older adults were lifetime recreational gamblers and 0.85% were lifetime disordered gamblers. Compared with older adults without a history of regular gambling, recreational gamblers had significantly elevated rates of alcohol (30.1% versus 12.8%), nicotine (16.9% versus 8.0%), mood (12.6% versus 11.0%), anxiety (15.0% versus 11.6%), and personality disorders (11.3% versus 7.3%) and obesity (25.6% versus 20.8%), but were less likely to have past-year diagnoses of arteriosclerosis (4.7% versus 6.0%) or cirrhosis (0.2% versus 0.4%). Disordered gamblers were significantly more likely than older adults without a history of regular gambling to have alcohol (53.2% versus 12.8%), nicotine (43.2% versus 8.0%), drug (4.6% versus 0.7%), mood (39.5% versus 11.0%), anxiety (34.5% versus 11.6%), and personality (43.0% versus 7.3%) disorders, and to have past-year diagnoses of arthritis (60.2% versus 44.3%) or angina (22.7% versus 8.8%). These results remained significant even after controlling for demographic, psychiatric, and behavioral risk factors. Conclusions: Lifetime recreational gamblers were more likely than nonregular gamblers to have psychiatric disorders but were less likely to have some medical conditions. Lifetime disordered gamblers had a range of lifetime psychiatric disorders and were more likely than nonregular gamblers to have past-year diagnoses of angina and arthritis. C1 Univ Connecticut, Ctr Hlth, Dept Psychiat, Farmington, CT 06030 USA. Portland VA Med Ctr, Div Behav Hlth & Clin Neurosci, Portland, OR USA. Columbia Univ, Dept Psychiat, New York, NY USA. NIAAA, Lab Epidemiol & Biometry, Div Intramural Clin & Biol Res, NIH, Bethesda, MD USA. RP Petry, NM (reprint author), Univ Connecticut, Ctr Hlth, Dept Psychiat, 263 Farmington Ave, Farmington, CT 06030 USA. EM petry@psychiatry.uchc.edu RI Blanco, Carlos/I-4906-2013 OI Blanco, Carlos/0000-0001-6187-3057 FU Intramural NIH HHS; NIAAA NIH HHS [P50-AA03510]; NIDA NIH HHS [P50-DA09241, R01-DA016855, R01-DA13444, R01-DA14618]; NIMH NIH HHS [R01-MH60417, R01-MH60417-SUPP] NR 58 TC 52 Z9 52 U1 2 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD APR PY 2007 VL 15 IS 4 BP 301 EP 313 DI 10.1097/01.JGP.0000239353.40880.cc PG 13 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 149NX UT WOS:000245154800005 PM 17095749 ER PT J AU Moran, A Roux, AVD Jackson, SA Kramer, H Manolio, TA Shrager, S Shea, S AF Moran, Andrew Roux, Ana V. Diez Jackson, Sharon A. Kramer, Holly Manolio, Teri A. Shrager, Sandi Shea, Steven TI Acculturation is associated with hypertension in a multiethnic sample SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE hypertension; acculturation; ethnicity; Chinese; hispanic; African-American ID MEXICAN-AMERICAN ADULTS; HIGH BLOOD-PRESSURE; RISK-FACTORS; UNITED-STATES; NHANES-III; PREVALENCE; HEALTH; IMMIGRANTS; BEHAVIORS; MIGRATION AB Background: Hypertension varies in prevalence among race/ethnic groups in the United States. Within-ethnic group differences associated with acculturation have been less frequently examined. We studied the association of three measures of acculturation (language spoken at home, place of birth, and years living in the US) with hypertension in a population sample of 2619 white, 1898 African American, 1,494 Hispanic, and 803 Chinese participants in the Multiethnic Study of Atherosclerosis. Methods: Multivariate Poisson regression was used to estimate the association between the acculturation variables and hypertension. Results: Birthplace outside the US and speaking a non-English language at home were each associated with a lower prevalence of hypertension after adjustment for age, gender, and socioeconomic status (prevalence ratio [95% confidence intervals] 0.82 (0.77-0.87) for non-US born versus US born and 0.80 (0.74-0.85) for those not speaking English at home versus speakers of English at home, both P<.001). For participants born outside of the US, each 10-year increment of years in the US was associated with a higher prevalence of hypertension after adjustment for age, gender, and socioeconomic status (P for trend <.01). The associations between acculturation variables and hypertension were weakened after adjustment for race/ethnic category and risk factors for hypertension. Compared to US-born Hispanics, those born in Mexico or South America had lower prevalence of hypertension, but those born in the Caribbean and Central America had higher prevalence of hypertension. Conclusions: Acculturation and place of birth are associated with hypertension in a multiethnic sample. C1 Univ Michigan, Ctr Social Epidemiol & Populat Hlth, Dept Epidemiol, Ann Arbor, MI 48104 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. Ctr Dis Control & Prevent, Atlanta, GA USA. Loyola Univ, Dept Prevent Med, Maguire Ctr, Maywood, IL 60153 USA. NHLBI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA. Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. Columbia Univ, Dept Med, New York, NY USA. Columbia Univ, Dept Epidemiol, Joseph Mailman Sch Publ Hlth, New York, NY USA. RP Roux, AVD (reprint author), Univ Michigan, Ctr Social Epidemiol & Populat Hlth, Dept Epidemiol, 1214 S Univ, Ann Arbor, MI 48104 USA. EM adiezrou@umich.edu OI Kramer, Holly/0000-0002-6374-837X FU NHLBI NIH HHS [N01 HC095161, N01-HC-95159, N01-HC-95165, N01-HC-95166] NR 29 TC 53 Z9 53 U1 4 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD APR PY 2007 VL 20 IS 4 BP 354 EP 363 DI 10.1016/j.amjhyper.2006.09.025 PG 10 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 156YQ UT WOS:000245686200003 PM 17386340 ER PT J AU Kunkel, CF Figoni, SF Baumgarten, JM Carvalho, CM Kim, HS Oshiro, RL Zirovich, MD Scremin, OU Scremin, AME AF Kunkel, Charles F. Figoni, Stephen F. Baumgarten, Jana M. Carvalho, Claudio M. Kim, Hyung S. Oshiro, Resa L. Zirovich, Milena D. Scremin, Oscar U. Scremin, A. M. Erika TI Scanning laser-Doppler imaging of leg- and foot-skin perfusion in normal subjects - Analysis of age, gender, site, and laser-type effects SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE microcirculation; laser Doppler flowmetry; rehabilitation; wound healing ID TRANS-CUTANEOUS OXYGEN; AMPUTATION LEVEL SELECTION; BLOOD-FLOW; ARTERIAL-DISEASE; PRESSURE; FLOWMETER; TENSION AB Objectives: To report normal values of skin perfusion in healthy subjects in three age groups using a laser Doppler imager; to determine differences attributable to gender, age, site, and use of red or near-infrared lasers; and to correlate transcutaneous oxygen with laser flux values Design: Flux and transcutaneous oxygen were measured at ten sites in the lower extremity in 60 subjects from three age groups. Heated and unheated sites were scanned with red and near-infrared lasers. Results: Heat hyperemia was prominent at all sites. Small, statistically significant mean +/- SD differences were found between heated and nonheated sites for the red and near-infrared lasers (P = 0.02). All flux ratios were independent of gender but were higher in the oldest group. Plantar sites demonstrated higher flux in unheated areas and lower flux ratios compared with leg sites. Transcutaneous oxygen did not correlate significantly with flux for either laser type. Conclusions: Scanning laser-Doppler imaging flux values provide a reference for identifying patients at risk for tissue ischemia. and poor healing potential caused by impaired circulatory reserve in the legs and distal feet. The lack of correlation between flux and transcutaneous oxygen in healthy individuals suggests that they measure different physiologic processes. C1 VA Greater Los Angeles Healthcare Ctr, Dept Phys Med & Rehabil, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Ctr, Res Serv, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Physiol, David Geffen Sch Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, VA Greater Los Angeles Phys Med & Rehabil Residen, Los Angeles, CA USA. RP Kunkel, CF (reprint author), VA W Los Angeles Healthcare Ctr, 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 33 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD APR PY 2007 VL 86 IS 4 BP 262 EP 271 DI 10.1097/PHM.0b013e3180353526 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 150QV UT WOS:000245232200003 PM 17413539 ER PT J AU Huang, D Khoe, M Befekadu, M Chung, S Takata, Y Ilic, D Bryer-Ash, M AF Huang, Danshan Khoe, Michelle Befekadu, Merone Chung, Sue Takata, Yasunori Ilic, Dusko Bryer-Ash, Michael TI Focal adhesion kinase mediates cell survival via NF-kappa B and ERK signaling pathways SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE apoptosis; ERK1/2; insulin; TNF-alpha; IGF-1 ID TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-I; INSULIN-RECEPTOR SUBSTRATE-1; ALPHA-INDUCED APOPTOSIS; PEROXIDE-INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-MECHANISMS; BROWN ADIPOCYTES; GENE-EXPRESSION; GLUCOSE-UPTAKE AB Focal adhesion kinase ( FAK) is important to cellular functions such as proliferation, migration, and survival of anchorage- dependent cells. We investigated the role of FAK in modulating normal cellular responses, specifically cell survival in response to inflammatory stimuli and serum withdrawal, using FAK- knockout ( FAK(-/-)) embryonic fibroblasts. FAK(-/-) fibroblasts were more vulnerable to TNF-alpha- induced apoptosis, as measured by terminal deoxynucleotidyl transferase positivity. FAK(-/-) fibroblasts also demonstrated increased procaspase- 3 cleavage to p17 subunit, whereas this was undetectable in FAK(-/-) fibroblasts. Insulin receptor substrate- 1 expression was completely abolished and NF-kappa B activity was reduced, with a concomitant decrease in abundance of the anti- apoptotic protein Bcl- x(L) in FAK(-/-) cells. Upon serum withdrawal, FAK(-/-) cells exhibited marked attenuation of basal ERK phosphorylation, while FAK(-/-) cells, in contrast, maintained high basal ERK phosphorylation. Moreover, inhibition of ERK phosphorylation potentiated serum withdrawal- induced caspase- 3 activity. This was paralleled by increased insulin receptor substrate ( IRS)- 2 expression in FAK(-/-) cells, although both insulin- and IGF-1-mediated phosphorylation of Akt/ PKB and GSK-3 were impaired. This suggests that IRS-2 protects against apoptosis upon serum withdrawal via the ERK signaling pathway. The specific role of FAK to protect cells from apoptosis is regulated by activation and phosphorylation of NF-kappa B and interaction between activated growth factor anti-apoptotic signaling pathways involving both phosphatidylinositol 3- kinase/ Akt and MAPK/ ERK1/2. We demonstrate that FAK is necessary for upregulation of the anti- apoptotic NF-kappa B response, as well as for normal expression of growth factor signaling proteins. Thus we propose a novel role for FAK in protection from cytokine- mediated apoptosis. C1 Univ Calif Los Angeles, Div Endocrinol Diabet & Hypertens, David Geffen Sch Med, W Los Angeles Vet Adm Med Ctr, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Div Endocrinol Diabet & Hypertens, David Geffen Sch Med, Gonda Goldschmied Diabet Ctr, Los Angeles, CA 90095 USA. Univ Calif San Francisco, Dept Stomatol & Anat, San Francisco, CA 94143 USA. RP Bryer-Ash, M (reprint author), Univ Calif Los Angeles, Div Endocrinol Diabet & Hypertens, David Geffen Sch Med, W Los Angeles Vet Adm Med Ctr, 900 Vet Ave,Warren Hall,Rm 24-130, Los Angeles, CA 90095 USA. EM mbryerash@mednet.ucla.edu NR 69 TC 44 Z9 48 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD APR PY 2007 VL 292 IS 4 BP C1339 EP C1352 DI 10.1152/ajpcell.00144.2006 PG 14 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 188RG UT WOS:000247936400016 PM 17135301 ER PT J AU Morinelli, TA Raymond, JR Baldys, A Yang, Q Lee, MH Luttrell, L Ullian, ME AF Morinelli, Thomas A. Raymond, John R. Baldys, Aleksander Yang, Qing Lee, Mi-hye Luttrell, Louis Ullian, Michael E. TI Identification of a putative nuclear localization sequence within ANG II AT(1A) receptor associated with nuclear activation SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE G protein-coupled receptors; cyclooxygenase 2 transcription; laser scanning confocal microscopy ID SMOOTH-MUSCLE-CELLS; INTRACELLULAR ANGIOTENSIN-II; SIGNAL-TRANSDUCTION; CYTOPLASMIC TAIL; BINDING SITES; MESSENGER-RNA; PROTEIN; TRANSCRIPTION; INTERNALIZATION; PATHWAY AB Angiotensin II ( ANG II) type 1 ( AT(1)) receptors, similar to other G protein- coupled receptors, undergo desensitization and internalization, and potentially nuclear localization, subsequent to agonist interaction. Evidence suggests that the carboxy- terminal tail may be involved in receptor nuclear localization. In the present study, we examined the carboxyterminal tail of the receptor for specific regions responsible for the nuclear translocation phenomenon and resultant nuclear activation. Human embryonic kidney cells stably expressing either a wild- type AT(1A) receptor- green fluorescent protein ( AT(1A)R/ GFP) construct or a site- directed mutation of a putative nuclear localization sequence ( NLS) [ K307Q] AT(1A)R/ GFP ( KQ/ AT(1A)R/ GFP), were examined for differences in receptor nuclear trafficking and nuclear activation. Receptor expression, intracellular signaling, and ANG II- induced internalization of the wild- type/ GFP construct and of the KQ/ AT(1A)R/ GFP mutant was similar. Laser scanning confocal microscopy showed that in cells expressing the AT(1A)R/ GFP, trafficking of the receptor to the nuclear area and colocalization with lamin B occurred within 30 min of ANG II ( 100 nM) stimulation, whereas the KQ/ AT(1A)R/ GFP mutant failed to demonstrate nuclear localization. Immunoblotting of nuclear lysates with an anti- GFP antibody confirmed these observations. Nuclear localization of the wild- type receptor correlated with increase transcription for both EGR- 1 and PTGS- 2 genes while the nucleardeficient KQ/ AT(1A)R/ GFP mutant demonstrated increases for only the EGR- 1 gene. These results suggest that a NLS ( KKFKKY; aa307 312) is located within the cytoplasmic tail of the AT(1A) receptor and that nuclear localization of the receptor corresponds with specific activation of transcription for the COX- 2 gene PTGS- 2. C1 Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Div Endocrinol, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Hosp, Charleston, SC USA. RP Morinelli, TA (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 829 Clin Sci Bldg,96 Jonathan Lucas St, Charleston, SC 29425 USA. EM morinelt@musc.edu RI Yang, Qing /H-5342-2012 OI Yang, Qing /0000-0002-5068-6085 NR 45 TC 27 Z9 27 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD APR PY 2007 VL 292 IS 4 BP C1398 EP C1408 DI 10.1152/ajpcell.00337.2006 PG 11 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 188RG UT WOS:000247936400022 PM 17166941 ER PT J AU Yamamoto, M Reeve, JR Green, GM AF Yamamoto, Mitsuyoshi Reeve, Joseph R., Jr. Green, Gary M. TI Supramaximal CCK-58 does not induce pancreatitis in the rat: role of pancreatic water secretion SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE pancreatic fluid secretion; cholecystokinin 8; cholecystokinin 58; acinar fluid secretion; pancreatic chloride secretion ID ACINAR-CELL; ENDOGENOUS CHOLECYSTOKININ; ZYMOGEN ACTIVATION; EXOCRINE PANCREAS; ENZYME-SECRETION; SUBSTANCE-P; CERULEIN; ANTAGONIST; GRANULES; CHANNELS AB In contrast to supramaximal CCK- 8 or caerulein, acute or prolonged supraphysiological levels of endogenous CCK- 58 do not cause pancreatitis. Compared with CCK- 8, CCK- 58 is a much stronger stimulant of pancreatic chloride and water secretion, equivalent to maximally effective secretin, but with a chloride- to- bicarbonate ratio characteristic of acinar fluid. Because supraphysiological endogenous CCK does not cause pancreatitis and because coadministration of secretin ameliorated caerulein- or CCK- 8- induced pancreatitis, coincident with restoring pancreatic water secretion, we hypothesized that supramaximal CCK- 58 would not induce pancreatitis. Conscious rats were infused intravenously with 2 or 4 nmol . kg(-1) . h(-1) of CCK-8 or synthetic rat CCK- 58 for 6 h, and pancreases were examined for morphological and biochemical indexes of acute pancreatitis. A second group was treated as above while monitoring pancreatic protein and water secretion. CCK- 8 at 2 nmol . kg(-1) . h(-1) caused severe edematous pancreatitis as evidenced by morphological and biochemical criteria. CCK- 58 at this dose had minimal or no effect on these indexes. CCK- 58 at 4 nmol . kg(-1) . h(-1) increased some indexes of pancreatic damage but less than either the 2 or 4 nmol . kg(-1) . h(-1) dose of CCK- 8. Pancreatic water and protein secretion were nearly or completely abolished within 3 h of onset of CCK- 8 infusion, whereas water and protein secretion were maintained near basal levels in CCK- 58- treated rats. We hypothesize that supramaximal CCK- 58 does not induce pancreatitis because it maintains pancreatic acinar chloride and water secretion, which are essential for exocytosis of activated zymogens. We conclude that CCK- 58 may be a valuable tool for investigating events that trigger pancreatitis. C1 CURE, Digest Dis Res Ctr, Res Serv 151, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA. Univ Calif Los Angeles, Sch Med, Div Digest Dis, Los Angeles, CA USA. RP Reeve, JR (reprint author), CURE, Digest Dis Res Ctr, Res Serv 151, Vet Affairs Greater Los Angeles Healthcare Syst, Bldg 115,Rm 117, Los Angeles, CA 90073 USA. EM jreeve@ucla.edu FU NIDDK NIH HHS [DK-41301, DK-33850, DK-37482] NR 46 TC 11 Z9 11 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD APR PY 2007 VL 292 IS 4 BP G964 EP G974 DI 10.1152/ajpgi.00338.2004 PG 11 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 153KP UT WOS:000245433400003 PM 17158258 ER PT J AU Million, M Wang, L Stenzel-Poore, MP Coste, SC Yuan, PQ Lamy, C Rivier, J Buffington, T Tache, Y AF Million, M. Wang, L. Stenzel-Poore, M. P. Coste, S. C. Yuan, P. Q. Lamy, C. Rivier, J. Buffington, T. Tache, Y. TI Enhanced pelvic responses to stressors in female CRF-overexpressing mice SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE chronic stress; colon; urine; locomotor activity; astressin B; mouse urocortin 2 ID CORTICOTROPIN-RELEASING-FACTOR; IRRITABLE-BOWEL-SYNDROME; ESTROGEN-RECEPTOR-BETA; ENTERIC NERVOUS-SYSTEM; INDUCED VISCERAL PAIN; ANXIETY-LIKE BEHAVIOR; GASTROINTESTINAL-TRACT; INTERSTITIAL CYSTITIS; TRANSGENIC MICE; BARRINGTONS NUCLEUS AB Acute stress affects gut functions through the activation of corticotropin-releasing factor (CRF) receptors. The impact of acute stress on pelvic viscera in the context of chronic stress is not well characterized. We investigated the colonic, urinary, and locomotor responses monitored as fecal pellet output (FPO), urine voiding, and ambulatory activity, respectively, in female and male CRF-overexpressing (CRF-OE) mice, a chronic stress model, and their wild-type littermates (WTL). Female CRF-OE mice, compared with WTL, had enhanced FPO to 2-min handling (150%) and 60-min novel environment (155%) but displayed a similar response to a 60-min partial restraint stress. Female CRF-OE mice, compared with WTL, also had a significantly increased number of urine spots (7.3 +/- 1.4 vs. 1.3 +/- 0.8 spots/h) and lower locomotor activity (246.8 +/- 47.8 vs. 388.2 +/- 31.9 entries/h) to a novel environment. Male CRF-OE mice and WTL both responded to a novel environment but failed to show differences between them in colonic and locomotor responses. Male WTL, compared with female WTL, had higher FPO (113%). In female CRF-OE mice, the CRF1/CRF2 receptor antagonist astressin B and the selective CRF2 receptor agonist mouse urocortin 2 (injected peripherally) prevented the enhanced defecation without affecting urine or locomotor responses to novel environment. RT-PCR showed that CRF1 and CRF2 receptors are expressed in the mouse colonic tissues. The data show that chronic stress, due to continuous central CRF overdrive, renders female CRF-OE mice to have enhanced pelvic and altered behavioral responses to superimposed mild stressors and that CRF1-initiated colonic response is counteracted by selective activation of CRF2 receptor. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, Dept Med, Div Digest Dis, Los Angeles, CA 90024 USA. Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA. Ohio State Univ, Dept Vet Clin Sci, Columbus, OH 43210 USA. RP Million, M (reprint author), VA Greater Los Angeles Healthcare Syst, CURE CNS Bldg,115 Rm 118B, Los Angeles, CA 90073 USA. EM mmuluget@ucla.edu RI Lamy, Christophe/B-6432-2016 OI Lamy, Christophe/0000-0001-6944-9787 FU NIDDK NIH HHS [DK-26741, P50 DK-64539, R21 DK-068155, R01 DK-33061, R01 DK-57238]; NIMH NIH HHS [R01 MH-65689] NR 78 TC 33 Z9 33 U1 0 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD APR PY 2007 VL 292 IS 4 BP R1429 EP R1438 DI 10.1152/ajpregu.00626.2006 PG 10 WC Physiology SC Physiology GA 153KM UT WOS:000245432800007 PM 17194724 ER PT J AU Parimon, T Chien, JW Bryson, CL McDonell, MB Udris, EM Au, DH AF Parimon, Tanyalak Chien, Jason W. Bryson, Chris L. McDonell, Mary B. Udris, Edmunds M. Au, David H. TI Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE chronic obstructive pulmonary disease; pharmacoepidemiology; lung cancer; adherence ID RANDOMIZED CONTROLLED-TRIAL; FLUTICASONE PROPIONATE; CHLAMYDIA-PNEUMONIAE; AIRWAY INFLAMMATION; SMOKING-CESSATION; PHARMACY RECORDS; DOUBLE-BLIND; A/J MICE; COPD; HEALTH AB Rationale and Objectives: Lung cancer is a frequent cause of death among patients with chronic obstructive pulmonary disease (COPD). We examined whether the use of inhaled corticosteroids among patients with COPD was associated with a decreased risk of lung cancer. Methods: We performed a cohort study of United States veterans enrolled in primary care clinics between December 1996 and May 2001. Participants had received treatment for, had an International Classification of Disease, 9th edition, diagnosis of, or a self-reported diagnosis of COPD. Patients with a history of lung cancer were excluded. To be exposed, patients must have been at least 80% adherent to inhaled corticosteroids. We used Cox regression models to estimate the risk of cancer and adjust for potential confounding factors. Findings: We identified 10,474 patients with a median follow-up of 3.8 years. In comparison to nonusers of inhaled corticosteroids, adjusting for age, smoking status, smoking intensity, previous history of non-lung cancer malignancy, coexisting illnesses, and bronchodilator use, there was a dose-dependent decreased risk of lung cancer associated with inhaled corticosteroids (ICS dose < 1,200 mu g/d: adjusted HR, 1.3; 95% confidence interval, 0.67-1.90; ICS dose >= 1,200 mu g/d: adjusted HR, 0.39; 95% confidence interval, 0.16-0.96). Changes in cohort definitions had minimal effects on the estimated risk. Analyses examining confounding by indication suggest biases in the opposite direction of the described effects. Interpretation: Results suggest that inhaled corticosteroids may have a potential role in lung cancer prevention among patients with COPD. These initial findings require confirmation in separate and larger cohorts. C1 VA Puget Sound Healthcare Syst, Hlth Serv Red & Dev MS152, Seattle, WA 98101 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. RP Au, DH (reprint author), VA Puget Sound Healthcare Syst, Hlth Serv Red & Dev MS152, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM dau@u.washington.edu FU NHLBI NIH HHS [K23HL69860] NR 77 TC 87 Z9 93 U1 0 U2 7 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD APR 1 PY 2007 VL 175 IS 7 BP 712 EP 719 DI 10.1164/rccm.200608-1125OC PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 152RS UT WOS:000245380100014 PM 17185647 ER PT J AU Deitrick, G Charalel, J Bauman, W Tuckman, J AF Deitrick, George Charalel, Joseph Bauman, William Tuckman, John TI Reduced arterial circulation to the legs in spinal cord injury as a cause of skin breakdown lesions SO ANGIOLOGY LA English DT Article ID PERIPHERAL VASCULAR-DISEASE; DOPPLER TISSUE FLOWMETERS; SUBCUTANEOUS BLOOD-FLOW; CUTANEOUS MICROCIRCULATION; FEMORAL-ARTERY; REFLEX; POSTURE; OCCLUSION; RESPONSES; VETERANS AB Skin breakdown lesions (SBLs) of the legs are common in spinal cord injury (SCI). It is assumed that the cause is deficient sensitivity and immobility of the limbs, which result in areas subjected to prolonged pressures. However, poor circulation may also be a significant factor. Indeed, strong reasons suggest that small vessel circulation is decreased in SCI because these patients have increased arteriosclerotic risk factors. Patients in the SCI population have advanced age, are sedentary, often have abnormal carbohydrate and lipid metabolism, and many use tobacco products. Total blood flow (TBF) to the legs and skin blood flows (SBFs) to 4 areas of the feet were measured simultaneously by duplex Doppler sonography and laser Doppler flowmetry in 10 healthy control and 10 chronic subjects with SCI when supine and during 30 minutes in a wheelchair. The average supine control TBF was 540 mL/minute, but greatly reduced between 24-76 mL/minute in 4 of the subjects. During sitting, the average TBF fell by 41% in the controls and increased by 6% in SCI. Nonetheless, in all control and SCI subjects the average sitting SBFs were severely decreased in all areas between 53-75%, similar to results found by others elsewhere in the foreleg. Ischemia of the skin and underlying muscles is important as a cause for the poor healing of SBLs in persons with SCI who daily spend many hours in a wheelchair. C1 Bronx Vet Adm Med Ctr, Bronx, NY 10468 USA. Mt Sinai Med Ctr, Div Diagnost Serv, New York, NY 10021 USA. Mt Sinai Med Ctr, Spinal Cord Damage Res Ctr, New York, NY 10021 USA. Mt Sinai Med Ctr, Vet Affairs Rehabil Res & Dev Ctr Excellence, New York, NY 10021 USA. Bronx Vet Adm Med Ctr, Dept Surg, Bronx, NY 10468 USA. Bronx Vet Adm Med Ctr, Dept Radiol, Bronx, NY 10468 USA. Bronx Vet Adm Med Ctr, Dept Med, Bronx, NY 10468 USA. Bronx Vet Adm Med Ctr, Dept Rehabil, Bronx, NY 10468 USA. RP Deitrick, G (reprint author), Bronx Vet Adm Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM george.deitrick@med.va.gov NR 30 TC 16 Z9 17 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0003-3197 J9 ANGIOLOGY JI Angiology PD APR-MAY PY 2007 VL 58 IS 2 BP 175 EP 184 DI 10.1177/0003319707300353 PG 10 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 161QQ UT WOS:000246030900006 PM 17495266 ER PT J AU Sun, BC Mangione, CM Merchant, G Weiss, T Shlamovitz, GZ Zargaraff, G Shiraga, S Hoffman, JR Mower, WR AF Sun, Benjamin C. Mangione, Carol M. Merchant, Guy Weiss, Timothy Shlamovitz, Gil Z. Zargaraff, Gelareh Shiraga, Sharon Hoffman, Jerome R. Mower, William R. TI External validation of the San Francisco Syncope Rule SO ANNALS OF EMERGENCY MEDICINE LA English DT Article ID EMERGENCY ROOM PATIENTS; RISK STRATIFICATION; SERIOUS OUTCOMES; PREDICT PATIENTS; POPULATION; SCORE AB Study objective: We externally validate the ability of the San Francisco Syncope Rule to accurately identify syncope patients who will experience a 7-day serious clinical event. Methods: Patients who presented to a single academic emergency department (ED) between 8 AM and 10 Pm with syncope or near-syncope were prospectively enrolled. Treating physicians recorded the presence or absence of all San Francisco Syncope Rule risk factors. Patients were contacted by telephone at 14 days for a structured interview. A 3-physician panel, blinded to the San Francisco Syncope Rule score, reviewed ED medical records, hospital records, and telephone interview forms to identify predefined serious clinical events. The primary outcome was the ability of the San Francisco Syncope Rule to predict any 7-day serious clinical event. A secondary outcome was the ability of the San Francisco Syncope Rule to predict 7-day serious clinical events that were not identified during the initial ED evaluation. Results: Of 592 eligible patients, 477 (81%) provided informed consent. Direct telephone contact or admission/outpatient records were successfully obtained for 463 (97%) patients. There were 56 (12%) patients who had a serious 7-day clinical event, including 16 (3%) who received a diagnosis after the initial ED evaluation. Sensitivity and specificity of the San Francisco Syncope Rule for the primary outcome were 89% (95% confidence interval [CI] 81% to 97%) and 42% (95% Cl 37% to 48%), respectively, and 69% (95% Cl 46% to 92%) and 42% (95% Cl 37% to 48%), respectively, for the secondary outcome. Estimates of sensitivity were minimally affected by missing data and most optimistic assumptions for missing follow-up information. Conclusion: In this external validation cohort, the San Francisco Syncope Rule had a lower sensitivity and specificity than in previous reports. C1 W Los Angeles Vet Affairs Med Ctr, Off 3214A, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Ctr Emergency Med, Los Angeles, CA 90024 USA. RP Sun, BC (reprint author), W Los Angeles Vet Affairs Med Ctr, Off 3214A, Dept Med, Mail Stop 111,Bldg 500,Wing 3E,11301 Wilshire Blv, Los Angeles, CA 90073 USA. EM bsun@post.harvard.edu FU NIA NIH HHS [K12AG001004, AG 02-004] NR 19 TC 55 Z9 58 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD APR PY 2007 VL 49 IS 4 BP 420 EP 427 DI 10.1016/j.annemergmed.2006.11.012 PG 8 WC Emergency Medicine SC Emergency Medicine GA 151ME UT WOS:000245293700005 PM 17210201 ER PT J AU Aslam, S Trautner, BW Ramanathan, V Darouiche, RO AF Aslam, Saima Trautner, Barbara W. Ramanathan, Venkat Darouiche, Rabih O. TI Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID BLOOD-STREAM INFECTIONS; CRITICALLY-ILL PATIENTS; IN-VITRO; STAPHYLOCOCCUS-EPIDERMIDIS; ANTIBIOTIC LOCK; ATTRIBUTABLE MORTALITY; HEMODIALYSIS; VANCOMYCIN; PREVENTION; MODEL AB To assess the efficacy of an antibiofilm/antimicrobial agent combination, we incubated catheter segments colonized with one of six studied bacterial organisms in N-acetylcysteine, tigecycline, N-acetylcysteine-tigecy-cline, or saline. Segments were washed, sonicated, and cultured. N-acetylcysteine-tigecycline significantly decreased all viable biofilm-associated bacteria and was synergistic for methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. C1 Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Med Serv, Houston, TX 77030 USA. Baylor Coll Med, Infect Dis Sect, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Nephrol Sect, Dept Med, Houston, TX 77030 USA. RP Aslam, S (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Med Serv, Room 4B-370,2002 Holcombe Blvd, Houston, TX 77030 USA. EM saslam@bcm.tmc.edu; rdarouiche@aol.com FU NICHD NIH HHS [K23 HD042014-04, K23 HD042014, K23 HD042014-05] NR 27 TC 66 Z9 70 U1 1 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD APR PY 2007 VL 51 IS 4 BP 1556 EP 1558 DI 10.1128/AAC.00893-06 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 153FD UT WOS:000245416500069 PM 17220399 ER PT J AU Price, R Ashwell, ZR Chang, MW Boninger, ML Koontz, AM Sisto, SA AF Price, Robert Ashwell, Zachary R. Chang, Michael W. Boninger, Michael L. Koontz, Alicia M. Sisto, Sue Ann TI Upper-limb joint power and its distribution in spinal cord injured wheelchair users: Steady-state self-selected speed versus maximal acceleration trials SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE biomechanics; kinetics; movement; rehabilitation; wheelchairs ID MECHANICAL ENERGY; FORCE APPLICATION; PUSH-OFF; PROPULSION; BIOMECHANICS; GAIT; ACCURACY; DIAMETER; STROKE; SYSTEM AB Objective: To compare upper-limb joint power magnitude and distribution between the shoulder, elbow, and wrist during maximal acceleration (MAC) versus steady-state, self-selected speed (SSS) manual wheelchair propulsion. Design: Cross-sectional biomechanic study. Setting: Research university and teaching hospital. Participants: Volunteer sample of 13 manual wheelchair users with spinal cord injury below T1. Interventions: Not applicable. Main Outcome Measures: Propulsive joint power magnitude and fractional distribution among upper-limb joints. Results: Wilcoxon signed-rank testing revealed shoulder power was larger for MAC versus SSS (median peak, 101.5W; interquartile range [IQR], 74.6; median peak, 37.7W; IQR, 22.9; respectively) (P <.01). Elbow and wrist power were unchanged. Peak shoulder power fraction was larger for MAC versus SSS (median peak, 1.055; lQR, 110 vs peak,.870; IQR,.252) (P <.01). Peak elbow power fraction was smaller for MAC versus SSS (median peak, -.012; IQR,.144 vs peak,.146; IQR,.206) (P <.05). Peak wrist power fraction was smaller for MAC versus SSS (median peak, -.058; IQR,.057 vs peak, -.010; IQR,.150) (P <.05). Conclusions: Power at the shoulder was larger than at other joints. Peak shoulder joint power and power fraction was larger during MAC versus SSS propulsion. Elbow and wrist power fractions were smaller for MAC versus SSS propulsion. Higher joint power, present under MAC, may predispose manual wheelchair users to injury, particularly at the shoulder. C1 Univ Washington, Dept Rehabil Med, Seattle, WA 98053 USA. Vet Affairs Pittsburgh HealthCare Syst, Human Engn Res Labs, Pittsburgh, PA USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr Hlth Syst, Dept Phys Med & Rehabil, Pittsburgh, PA USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA. RP Price, R (reprint author), Univ Washington, Dept Rehabil Med, Box 356490,1959 NE Pacific St, Seattle, WA 98053 USA. EM pricer@u.washington.edu OI Boninger, Michael/0000-0001-6966-919X NR 25 TC 9 Z9 9 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD APR PY 2007 VL 88 IS 4 BP 456 EP 463 DI 10.1016/j.apmr.2007.01.016 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 160CC UT WOS:000245913400010 PM 17398246 ER PT J AU Kosten, TA Zhang, XY Haile, CN AF Kosten, Therese A. Zhang, Xiang Yang Haile, Colin N. TI Strain differences in maintenance of cocaine self-administration and their relationship to novelty activity responses SO BEHAVIORAL NEUROSCIENCE LA English DT Article DE Lewis inbred rats; Fischer 344 inbred rats; progressive ratio; locomotor activity ID CORTICOTROPIN RELEASING HORMONE; CONDITIONED PLACE PREFERENCE; INBRED RAT STRAINS; LOCOMOTOR-ACTIVITY; FISCHER-344 RATS; FEMALE RATS; DOPAMINE-TRANSPORTER; NUCLEUS ACCUMBENS; LEWIS; ACQUISITION AB The authors previously demonstrated that Fischer 344 (F344) and Lewis inbred rats differ in acquisition of cocaine self-administration. Other studies show that acquisition and maintenance of drug self-administration are predicted by locomotor activity in a novel environment among outbred Sprague-Dawley rats. The present study was designed to determine whether this relationship extended to F344 and Lewis rats. In Experiment 1, F344, Lewis, and Sprague-Dawley rats were trained to self-administer cocaine and tested with several doses under fixed- and progressive-ratio schedules of reinforcement. Self-administered infusions and ineffective active lever presses-those emitted during infusion and time-out periods-were assessed. In Experiment 2, separate sets of rats of each strain were examined for locomotor responses (distance traveled and center time) under novelty conditions. Results show that F344 rats self-administer more cocaine than Lewis or Sprague-Dawley rats under both schedules and emit more ineffective lever presses-a possible measure of craving. Strain comparisons of locomotor responses suggest that center time, not activity, relates to self-administration behavior. Maintenance studies of cocaine self-administration rather than acquisition may better reflect vulnerability to addiction. C1 Michael E DeBakey Vet Affairs Med Ctr, Res Serv Line 151, Houston, TX 77030 USA. Baylor Coll Med, Menninger Dept Psychiat, Houston, TX 77030 USA. RP Kosten, TA (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Res Serv Line 151, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM tkosten@bcm.edu OI Haile, Colin/0000-0001-8293-7291 NR 58 TC 31 Z9 31 U1 1 U2 3 PU AMER PSYCHOLOGICAL ASSOC/EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7044 J9 BEHAV NEUROSCI JI Behav. Neurosci. PD APR PY 2007 VL 121 IS 2 BP 380 EP 388 DI 10.1037/0735-7044.121.2.380 PG 9 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 157CM UT WOS:000245696200016 PM 17469928 ER PT J AU Georges, GE Maris, MB Maloney, DG Sandmaier, BM Sorror, ML Shizuru, JA Lange, T Agura, ED Bruno, B McSweeney, PA Pulsipher, MA Chauncey, TR Mielcarek, M Storer, BE Storb, R AF Georges, George E. Maris, Michael B. Maloney, David G. Sandmaier, Brenda M. Sorror, Mohamed L. Shizuru, Judith A. Lange, Thoralf Agura, Edward D. Bruno, Benedetto McSweeney, Peter A. Pulsipher, Michael A. Chauncey, Thomas R. Mielcarek, Marco Storer, Barry E. Storb, Rainer TI Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE multiple myeloma; nonmyeloablative conditioning; allogeneic hematopoietic cell transplantation; unrelated donor; graft-versus-tumor effect; chronic graft-versus-host disease; peripheral blood stem cell transplantation ID HIGH-DOSE THERAPY; BONE-MARROW-TRANSPLANTATION; COLONY-STIMULATING FACTOR; VERSUS-HOST-DISEASE; ALLOGENEIC TRANSPLANTATION; HEMATOLOGIC MALIGNANCIES; PROGNOSTIC-FACTORS; LYMPHOCYTE INFUSIONS; RANDOMIZED-TRIAL; CHEMOTHERAPY AB The purpose of this study was to determine long-term outcome of unrelated donor nomnyeloablative hematopoietic cell transplantation (HCT) in patients with poor-risk multiple myeloma. A total of 24 patients were enrolled; 17 patients (71%) had chemotherapy-refractory disease, and 14 (58%) experienced disease relapse or progression after previous autologous transplantation. Thirteen patients underwent planned autologous transplantation followed 43-135 days later with unrelated transplantation, whereas 11 proceeded directly to unrelated transplantation. All 24 patients were treated with fludarabine (90 mg/m(2)) and 2 Gy of total body irradiation before HLA-matched unrelated peripheral blood stem cell transplantation. Postgrafting immunosuppression consisted of cyclosporine and mycophenolate mofetil. The median follow-up was 3 years after allografting. One patient experienced nonfatal graft rejection. The incidences of acute grades II and III and chronic graft-versus-host disease were 54%, 13%, and 75%, respectively. The 3-year nonrelapse mortality (NRM) was 21%. Complete responses were observed in 10 patients (42%); partial responses, in 4 (17%). At 3 years, overall survival (OS) and progression-free survival (PFS) rates were 61% and 33%, respectively. Patients receiving tandem autologous-unrelated transplantation had superior OS and PFS (77% and 51%) compared with patients proceeding directly to unrelated donor transplantation (44% and 11%) (PFS P value =.03). In summary, for patients with poor-risk, relapsed, or refractory multiple myeloma, cytoreductive autologous HCT followed by nonmyeloablative conditioning and unrelated HCT is an effective treatment approach, with low NRM, high complete remission rates, and prolonged disease-free survival. (c) 2007 American Society for Blood and Marrow Transplantation. C1 Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. Univ Washington, Dept Med, Seattle, WA USA. Stanford Univ, Dept Med, Palo Alto, CA 94304 USA. Univ Leipzig, Dept Med, D-7010 Leipzig, Germany. Baylor Univ, Med Ctr, Dept Med, Dallas, TX USA. Univ Turin, Div Ematol, Turin, Italy. Rocky Mt Canc Ctr, Dept Blood & Marrow Transplantat, Denver, CO USA. Univ Utah, Dept Med, Salt Lake City, UT 84112 USA. VA Puget Sound Hlth Care Syst, Dept Med Oncol, Seattle, WA USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Georges, GE (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D1-100,POB 19024, Seattle, WA 98109 USA. EM ggeorges@fhcrc.org FU NCI NIH HHS [P30 CA015704-33, P01 CA018029-270047, CA 15704, P01 CA018029, P30 CA015704-32S1, P01 CA018029-32, P01 CA018029-29, P30 CA015704-31S2, P30 CA015704-34S1, P01 CA018029-25, P30 CA015704-346232, CA 18029, P30 CA015704-34, P30 CA015704, P01 CA018029-27, CA 92058, P01 CA078902, K23 CA092058-04, P30 CA015704-30, CA 78902, P30 CA015704-33S1, P30 CA015704-32S2, P30 CA015704-33S2, P01 CA018029-30, P01 CA078902-09, P30 CA015704-31S1, P01 CA018029-31, K23 CA092058-02, P30 CA015704-31, P01 CA018029-24, P30 CA015704-32, R01 CA109381-03, P01 CA018029-26, K23 CA092058-05, K23 CA092058-03, P30 CA015704-30S1, K23 CA092058, K23 CA092058-01, P01 CA018029-28] NR 50 TC 23 Z9 25 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD APR PY 2007 VL 13 IS 4 BP 423 EP 432 DI 10.1016/j.bbmt.2006.11.011 PG 10 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 154XC UT WOS:000245540300005 PM 17287157 ER PT J AU Marlar, RA Potts, RM Welsh, CH AF Marlar, Richard A. Potts, Robyn M. Welsh, Carolyn H. TI A systems biology approach to the diagnosis of venous thrombosis risk SO BLOOD COAGULATION & FIBRINOLYSIS LA English DT Editorial Material DE complex disease; hemostasis; systems biology; thrombophilia C1 Oklahoma City Vet Adm Med Ctr, Lab Serv 113, Oklahoma City, OK 73104 USA. Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA. Univ Colorado, Hlth Sci Ctr, Denver VA Med Ctr, Denver, CO 80202 USA. RP Marlar, RA (reprint author), Oklahoma City Vet Adm Med Ctr, Lab Serv 113, 921 13th St, Oklahoma City, OK 73104 USA. EM Richard-Marlar@ouhsc.edu NR 5 TC 3 Z9 3 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0957-5235 J9 BLOOD COAGUL FIBRIN JI Blood Coagul. Fibrinolysis PD APR PY 2007 VL 18 IS 3 BP 215 EP 217 DI 10.1097/MBC.0b013e3280116c84 PG 3 WC Hematology SC Hematology GA 158YN UT WOS:000245831700001 PM 17413756 ER PT J AU Leverenz, JB Umar, I Wang, Q Montine, TJ McMillan, PJ Tsuang, DW Jin, JH Pan, C Shin, J Zhu, D Zhang, J AF Leverenz, James B. Umar, Imran Wang, Qing Montine, Thomas J. McMillan, Pamela J. Tsuang, Debby W. Jin, Jinghua Pan, Catherine Shin, Jenny Zhu, David Zhang, Jing TI Proteomic identification of novel proteins in cortical Lewy bodies SO BRAIN PATHOLOGY LA English DT Article ID SPORADIC PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; NEURODEGENERATIVE DISEASES; NEUROFILAMENT SUBUNIT; ALZHEIMERS-DISEASE; MASS-SPECTROMETRY; FIBRIL FORMATION; BODY DISEASE; DEMENTIA; PROMOTES AB Lewy body (LB) inclusions are one of the pathological hallmarks of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). One way to better understand the process leading to LB formation and associated pathogenesis responsible for neurodegeneration in PD and DLB is to examine the content of LB inclusions. Here, we performed a proteomic investigation of cortical LBs, obtained by laser capture microdissection from neurons in the temporal cortex of dementia patients with cortical LB disease. Analysis of over 2500 cortical LBs discovered 296 proteins; of those, 17 had been associated previously with brainstem and/or cortical LBs. We validated several proteins with immunohistochemical staining followed by confocal microscopy. The results demonstrated that heat shock cognate 71 kDa protein (also known as HSC70, HSP73, or HSPA10) was indeed not only colocalized with the majority of LBs in the temporal cortex but also colocalized to LBs in the frontal cortex of patients with diffuse LB disease. Our investigation represents the first extensive proteomic investigation of cortical LBs, and it is expected that characterization of the proteins in the cortical LBs may reveal novel mechanisms by which LB forms and pathways leading to neurodegeneration in DLB and/or advanced PD. Further investigation of these novel candidates is also necessary to ensure that the potential proteins in cortical LBs are not identified incorrectly because of incomplete current human protein database. C1 Univ Washington, Harborview Med Ctr, Sch Med, Div Neuropathol,Dept Pathol, Seattle, WA 98104 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98104 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA. VA Puget Sound Hlth Care Syst, Dept Mental Illness, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Dept Parkinsons Dis, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. RP Zhang, J (reprint author), Univ Washington, Harborview Med Ctr, Sch Med, Div Neuropathol,Dept Pathol, Box 359635, Seattle, WA 98104 USA. EM zhangj@u.washington.edu RI Jin, Jinghua/G-6385-2010; Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 FU NIA NIH HHS [AG025327, AG05136]; NIEHS NIH HHS [ES012703]; NINDS NIH HHS [NS048595] NR 57 TC 99 Z9 104 U1 0 U2 10 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1015-6305 J9 BRAIN PATHOL JI Brain Pathol. PD APR PY 2007 VL 17 IS 2 BP 139 EP 145 DI 10.1111/j.1750-3639.2007.00048.x PG 7 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 149AL UT WOS:000245118600002 PM 17388944 ER PT J AU Beer, TM Javle, MM Ryan, CW Garzotto, M Lam, GN Wong, A Henner, WD Johnson, CS Trump, DL AF Beer, Tomasz M. Javle, Milind M. Ryan, Christopher W. Garzotto, Mark Lam, Gilbert N. Wong, Alvin Henner, W. David Johnson, Candace S. Trump, Donald L. TI Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer SO CANCER CHEMOTHERAPY AND PHARMACOLOGY LA English DT Article DE calcitriol; vitamin D; pulse dosing; phase I ID INDEPENDENT PROSTATE-CANCER; HIGH-DOSE CALCITRIOL; BREAST-TUMOR CELLS; VITAMIN-D ANALOG; ANTITUMOR-ACTIVITY; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; ORAL CALCITRIOL; CARCINOMA; TRIAL; DEXAMETHASONE AB DN-101 is a new, high-dose, oral formulation of calcitriol under investigation for the treatment of cancer. We sought to evaluate the tolerability and pharmacokinetics (PK) of weekly doses of DN-101 in patients with advanced cancer. Patients who completed a previously reported single dose escalation study of DN-101 [Beer et al. (2005) Clin Cancer Res 11:7794-7799] were eligible for this continuation weekly dosing study. Cohorts of 3-10 patients were treated at doses of 15, 30, 45, 60, and 75 mu g calcitriol. Once 45 mu g was established as the maximum tolerated dose (MTD), this cohort was expanded to include 18 patients. Dose limiting toxicity (DLT) was defined as >= grade 2 hypercalcemia or >= grade 3 persistent treatment-related toxicities. Thirty-seven patients were recruited. DLT of transient reversible grade 2 hypercalcemia (serum calcium of 11.6-12.5 mg/dL) occurred in two of six patients treated with 60 mu g of DN-101. No DLT was observed in the 18 patients who received DN-101 weekly at 45 mu g. Overall, DN-101 was well tolerated. The most frequent adverse events were fatigue (27%), hypercalcemia (19%, including five grade 1, two grade 2, and no grade 3 or 4 events), and grade 1 nausea (16%). PK parameters following repeat dosing were comparable to those for the initial dose (n = 4). The MTD for weekly DN-101 was established as 45 mu g. The DLTs observed were two episodes of rapidly reversible grade 2 hypercalcemia in two of the six patients treated at 60 mu g weekly. Repeat doses of DN-101 at 45 mu g weekly are well tolerated and this dose is suitable for studies of weekly DN-101 in cancer patients. C1 Oregon Hlth Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97239 USA. Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA. Oregon Hlth Sci Univ, Div Urol, Portland, OR 97201 USA. Portland VA Med Ctr, Urol Sect, Portland, OR USA. MicroConstants Inc, San Diego, CA USA. Novacea Inc, San Francisco, CA USA. Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA. RP Beer, TM (reprint author), Oregon Hlth Sci Univ, Dept Med, Div Hematol & Med Oncol, Mail Code CR-145,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM beert@ohsu.edu NR 34 TC 27 Z9 28 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0344-5704 J9 CANCER CHEMOTH PHARM JI Cancer Chemother. Pharmacol. PD APR PY 2007 VL 59 IS 5 BP 581 EP 587 DI 10.1007/s00280-006-0299-1 PG 7 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA 137LE UT WOS:000244293300003 PM 17066293 ER PT J AU Patel, KB Gupta, H Nath, H Aqel, RA Zoghbi, GJ Soto, B Perry, GJ Lloyd, SG AF Patel, Kashyap B. Gupta, Himanshu Nath, Hrudaya Aqel, Raed A. Zoghbi, Gilbert J. Soto, Benigno Perry, Gilbert J. Lloyd, Steven G. TI Origin of all three major coronary arteries from the right sinus of valsalva: Clinical, angiographic, and magnetic resonance imaging findings and incidence in a select referral population SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE imaging (CT/MR); angiography coronary; anomalous coronaries ID ANOMALOUS AORTIC ORIGIN; 2 SEPARATE OSTIA; MYOCARDIAL-INFARCTION; CT ANGIOGRAPHY; CIRCUMFLEX; VISUALIZATION; ADULTS; RARE AB Objective: We sought to determine the incidence and imaging features by coronary angiography and cardiac magnetic resonance imaging (MRI) of anomalies in which the right, circumflex, and left anterior descending coronary arteries arise separately from the right sinus of Valsalva. Background: The anomalous origin of all major coronary arteries from separate ostia in the right sinus of Valsalva has been reported as exceedingly rare, with mainly isolated cases reported. A knowledge of the origin and proximal courses of aberrant arteries is critical for patient management. Methods: 42 consecutive patients without other congenital heart disease referred to our institution for MRI evaluation of anomalous coronary artery over a six year period were evaluated. Analysis of angiograms and MRI was done to determine the anatomic origin and proximal pathway of coronary arteries (determined by conventional angiography and MRI) and degree of any stenosis (by angiography). Results: Seven of the 42 patients (17%) in this referral population had the described anatomy. Both conventional angiography and MRI depicted the origin and proximal courses of these arteries. In all patients, the circumflex passed behind the aorta. In three, the left anterior descending passed through the ventricular septum; in four, it passed anterior to the pulmonary trunk. Conclusions: This series is the largest ever reported on this complex anatomical variant and the first to give a systematic analysis of the anatomy by angiography and MRI. This constellation of multiple anomalous coronary arterial origins and proximal courses may not be as rare as previously reported. Published 2007 Wiley-Liss, Inc.(dagger) C1 Univ Alabama, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. Univ Alabama, Dept Radiol, Birmingham, AL USA. Birmingham VA Med Ctr, Div Cardiol, Birmingham, AL USA. RP Lloyd, SG (reprint author), D-101 Cardiovasc MRI,1530 3rd Ave S, Birmingham, AL 35294 USA. EM sglloyd@uab.edu NR 30 TC 9 Z9 10 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1522-1946 J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD APR 1 PY 2007 VL 69 IS 5 BP 711 EP 718 DI 10.1002/ccd.21078 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 155KO UT WOS:000245576500017 PM 17330267 ER PT J AU Wasfi, YS Margolis, ML AF Wasfi, Yasinine S. Margolis, Mitchell L. TI A 45-year-old man with severe dysphagia and pulmonary infiltrates SO CHEST LA English DT Editorial Material ID SARCOIDOSIS C1 Philadelphia Vet Affairs Med Ctr, Pulm Sect, Philadelphia, PA 19104 USA. Univ Penn, Dept Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA. RP Margolis, ML (reprint author), Philadelphia Vet Affairs Med Ctr, Pulm Sect, Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM Mitchell.Margolis@med.va.gov NR 10 TC 3 Z9 3 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD APR PY 2007 VL 131 IS 4 BP 1256 EP 1259 DI 10.1378/chest.06-0977 PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 158DE UT WOS:000245770600051 PM 17426240 ER PT J AU Jeske, WP McDonald, MK Hoppensteadt, DA Bau, EC Mendes, A Dietrich, CP Walenga, JM Coyne, E AF Jeske, Walter P. McDonald, Meredith K. Hoppensteadt, Debra A. Bau, Elaine C. Mendes, Aline Dietrich, Carl P. Walenga, Jeanine M. Coyne, Erwin TI Isolation and characterization of heparin from tuna skins SO CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS LA English DT Article DE heparin; anticoagulant; fish skin ID SHRIMP PENAEUS-BRASILIENSIS; HIGH ANTICOAGULANT ACTIVITY; MOLECULAR-WEIGHT HEPARINS; CHONDROITIN SULFATES; MUCOPOLYSACCHARIDES; PENTASACCHARIDE; THERAPY; HAGFISH AB This study characterized heparin isolated from tuna skins. Glycosaminoglycans were isolated from tuna skin after digestion using anion exchange resin. Heparin was eluted from the resin by sodium chloride gradient and was further fractionated by acetone fractionation. Anticoagulant activity was determined using the activated partial thromboplastin time and Heptest assays. Potency was determined using amidolytic antifactor IIa and antifactor Xa assays. The presence of heparin in the extracted tuna skin glycosaminoglycans was confirmed using C-13-nuclear magnetic resonance. The activated partial thromboplastin time and Heptest clotting times were doubled at concentrations of about 4 and 1 mu g/mL, respectively. The clotting time prolongation and antiprotease activity induced by tuna heparin was readily neutralized by 25 mu g/mL protamine sulfate. These results demonstrate that biologically active heparin with properties similar to clinical grade heparin can be derived from tuna skin, a raw material with other-wise relatively little economic value. C1 Loyola Univ, Ctr Med, Cardiovasc Inst, Maywood, IL 60153 USA. Loyola Univ, Ctr Med, Dept Pathol, Maywood, IL 60153 USA. Univ Fed Sao Paulo, Dept Bioquim, Sao Paulo, Brazil. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. RP Jeske, WP (reprint author), Loyola Univ, Ctr Med, Cardiovasc Inst, 2160 S 1st Ave, Maywood, IL 60153 USA. EM wjeske@lumc.edu NR 28 TC 2 Z9 3 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1076-0296 J9 CLIN APPL THROMB-HEM JI Clin. Appl. Thromb.-Hemost. PD APR PY 2007 VL 13 IS 2 BP 137 EP 145 DI 10.1177/1076029606298982 PG 9 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 148YN UT WOS:000245113400004 PM 17456622 ER PT J AU Young, MRI Neville, BW Chi, AC Lathers, DMR Gillespie, MB Day, TA AF Young, M. Rita I. Neville, Brad W. Chi, Angela C. Lathers, Deanne M. R. Gillespie, M. Boyd Day, Terry A. TI Autocrine motility-stimulatory pathways of oral premalignant lesion cells SO CLINICAL & EXPERIMENTAL METASTASIS LA English DT Article DE ceramide; oral cancer; IL-10; migration; PP-2A; premalignant lesions ID PROTEIN PHOSPHATASE-2A; CERAMIDE PRODUCTION; CARCINOMA-CELLS; TUMOR-CELLS; HL-60 CELLS; ACTIVATION; CANCER; PHOSPHORYLATION; INTERLEUKIN-10; INDUCTION AB Patients with premalignant oral lesions have varying levels of risk of developing oral squamous cell carcinoma (OSCC), whose aggressiveness requires increased motility. Not known is if and how premalignant oral lesion cells acquire the increased motility characteristic of OSCC. This was addressed by immunohistochemical analysis of banked premalignant lesion tissues and by functional analyses using cultures established from premalignant oral lesions and OSCC. These studies showed premalignant oral lesion cells and OSCC to be more motile than normal keratinocytes. Concomitantly, levels of ceramide were reduced. The activity of the protein phosphatase PP-2A, which restricts motility and which can be activated by ceramide, was also diminished. This was due to IL-10 released from premalignant lesion cells. Treatment with a membrane-permeable ceramide restored PP-2A activity and blocked migration. These studies show an autocrine motility-stimulatory pathway that is mediated in premalignant lesion cells by IL-10 through its reduction of ceramide levels and inhibition of PP-2A activity. C1 Ralph H Johnson Vet Affairs Hosp, Ralph H Johnson VA Med Ctr, Res Serv 151, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Stomatol, Charleston, SC 29425 USA. RP Young, MRI (reprint author), Ralph H Johnson Vet Affairs Hosp, Ralph H Johnson VA Med Ctr, Res Serv 151, 109 Bee St, Charleston, SC 29401 USA. EM rita.young@va.gov FU NCI NIH HHS [CA97813, CA85266] NR 29 TC 4 Z9 4 U1 0 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0262-0898 J9 CLIN EXP METASTAS JI Clin. Exp. Metastasis PD APR PY 2007 VL 24 IS 2 BP 131 EP 139 DI 10.1007/s10585-007-9063-0 PG 9 WC Oncology SC Oncology GA 162QM UT WOS:000246103400007 PM 17370039 ER PT J AU Leykum, LK El-Serag, HB Cornell, J Papadopoulos, KP AF Leykum, Luci K. El-Serag, Hashem B. Cornell, John Papadopoulos, Kyriakos P. TI Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; UNITED-STATES; LIVER-CANCER; MANAGEMENT AB Background & Aims: The incidence of hepatocellular carcinoma (HCC) is increasing. Despite recommendations for HCC screening from the American Association for the Study of Liver Disease, the National Cancer Institute does not recommend screening. The question of whether screening is of benefit is an important one. The purpose of this study was to examine the determinants of screening, as well as the impact of screening on disease stage, treatment received, and survival in a US veteran population. Methods: Patients with hepatitis C and HCC who receive care in the South Texas Veteran Health Care System were identified using the Veterans Affairs national hepatitis C registry. Screening status was determined by chart review. Potential determinants of screening were assessed. Screened and unscreened patients were compared on the basis of disease stage at diagnosis, treatment: received, and survival. Results: Seventy-two patients were identified and included in the analysis, of whom only 16 (22%) were screened. Patients seen by a hepatologist before diagnosis were more likely to be screened. All screened patients were diagnosed with early stage disease, compared with 22% of unscreened patients (P <.001). Screened patients were 10 times more likely to have received potentially curative treatment (95% confidence interval, 2.91-31.35). Log-rank test of equality of survivor functions was statistically significant for differences between screened and unscreened groups (P = .0005). Conclusions: Our findings support the American Association for the Study of Liver Disease screening recommendations, and suggest that screening is underused. C1 Univ Texas, Ctr Hlth Sci, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. Univ Texas, Ctr Hlth Sci, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Leykum, LK (reprint author), Univ Texas, Ctr Hlth Sci, S Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd,Ambulatory Care 11C6, San Antonio, TX 78229 USA. EM Leykum@uthscsa.edu NR 17 TC 38 Z9 39 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD APR PY 2007 VL 5 IS 4 BP 508 EP 512 DI 10.1016/j.cgh.2007.01.014 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 162BR UT WOS:000246062000021 PM 17382601 ER PT J AU Link, JM Rich, CM Korat, M Burrows, GG Offner, H Vandenbark, AA AF Link, Jason M. Rich, Cathleen M. Korat, Maya Burrows, Gregory G. Offner, Halina Vandenbark, Arthur A. TI Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice SO CLINICAL IMMUNOLOGY LA English DT Article DE recombinant TCR ligand; experimental autoimmune; encephalomyelitis; minimum effective dose; multiple sclerosis; HLA-DR2; myelin oligodendrocyte glycoprotein; autoimmunity ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; T-CELL-RECEPTOR; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; PROTEOLIPID PROTEIN; MULTIPLE-SCLEROSIS; DENDRITIC CELLS; PEPTIDE; TOLERANCE; THERAPY; AMELIORATION AB Treatment of human autoimmune diseases such as multiple sclerosis (MS) will likely require agents that can prevent or reverse the inflammatory process that results in clinical relapses and disease progression. We evaluated the ability of a newly designed monomeric recombinant TCR ligand (RTL342M) containing HLA-DR2 peptide-binding domains covalently linked to MOG-35-55 peptide to prevent and treat both the initial episode and subsequent relapses of experimental autoimmune encephalomyelitis (EAE) in HLA-DR2 transgenic mice. Single doses of RTL342M given either i.v. or s.c. to HLA-DR2 mice produced a rapid (within 24 h) and dose-dependent reversal of clinical signs of paralytic EAE, and even a single dose <= 2 mu g could produce a significant treatment effect. Multiple daily doses were even more effective than the same total amount of RTL given as a single dose. By establishing the minimal effective dose, we determined that RTLs may be 50 times more potent than molar equivalent doses of myelin peptide alone. RTL342M given prior to induction of EAE prevented disease in most mice, and the remainder could be successfully retreated with RTL. Most important for clinical application, RTL342M was highly effective for treating EAE relapses when given periodically prior to the relapse or even after relapses had occurred. These data demonstrate the rapid and potent clinical effects of RTL342M at disease onset and during relapses in EAE and establish important principles governing the application of this novel approach as a possible therapy for patients with MS. (c) 2006 Elsevier Inc. All rights reserved. C1 Portland VA Med Ctr, Neuroimmunol Res R&D 31, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. RP Link, JM (reprint author), Portland VA Med Ctr, Neuroimmunol Res R&D 31, SW US Vet Hosp Rd, Portland, OR 97239 USA. EM linkja@ohsu.edu OI Link, Jason/0000-0002-6892-0431 FU NIAID NIH HHS [AI43960]; NINDS NIH HHS [NS46877, NS41965, NS47661] NR 28 TC 14 Z9 14 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PD APR PY 2007 VL 123 IS 1 BP 95 EP 104 DI 10.1016/j.clim.2006.12.002 PG 10 WC Immunology SC Immunology GA 150XJ UT WOS:000245252600013 PM 17257899 ER PT J AU Lipsky, BA AF Lipsky, B. A. TI Empirical therapy for diabetic foot infections: are there clinical clues to guide antibiotic selection? SO CLINICAL MICROBIOLOGY AND INFECTION LA English DT Editorial Material DE antibiotic therapy; diabetic foot infections; empirical therapy; foot infections; guidelines; treatment ID RESISTANT STAPHYLOCOCCUS-AUREUS; LOWER-EXTREMITY INFECTIONS; ULCERS; BACTERIOLOGY; MULTICENTER; PREVALENCE; PATHOGENS; TRIAL AB Initial antibiotic therapy for diabetic foot infections is usually empirical. Several principles may help to avoid selecting either an unnecessarily broad or inappropriately narrow regimen. First, clinically severe infections require broad-spectrum therapy, while less severe infections may not. Second, aerobic Gram-positive cocci, particularly Staphylococcus aureus (including methicillin-resistant S. aureus (MRSA) for patients at high-risk) should always be covered. Third, therapy should also be targeted at aerobic Gram-negative pathogens if the infection is chronic or has failed to respond to previous antibiotic therapy. Fourth, anti-anaerobe agents should be considered for necrotic or gangrenous infections on an ischaemic limb. Parenteral therapy is needed for severe infections, but oral therapy is adequate for most mild or moderate infections. C1 VA Puget Sound Hlth Care Syst, Primary Care Clin, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98195 USA. RP Lipsky, BA (reprint author), VA Puget Sound Hlth Care Syst, Primary Care Clin, 1660 S Columbian Way, Seattle, WA 98108 USA. EM Benjamin.lipsky@med.va.gov OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 20 TC 27 Z9 28 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1198-743X J9 CLIN MICROBIOL INFEC JI Clin. Microbiol. Infect. PD APR PY 2007 VL 13 IS 4 BP 351 EP 353 DI 10.1111/j.1469-0691.2007.01697.x PG 3 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 143JT UT WOS:000244718200001 PM 17359317 ER PT J AU Duda, JE AF Duda, John E. TI History and prevalence of involuntary emotional expression disorder SO CNS SPECTRUMS LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; PSEUDOBULBAR AFFECT; PATHOLOGICAL LAUGHTER; MULTIPLE-SCLEROSIS; STROKE; INCONTINENCE; DISEASE; DIAGNOSIS; LABILITY AB The syndrome now known as involuntary emotional expression disorder (IEED) is a condition characterized by uncontrollable episodes of laughing and/or crying. It has been known for more than a century, but confusing and conflicting terminology may have hampered the progress of physicians in recognizing this condition. IEED is associated with various neurological disorders and neurodegenerative diseases, including amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease and other dementias, and neurological injuries such as stroke and traumatic brain injury. It is hoped that better defined terminology for IEED may help in the future diagnosis of this debilitating condition, the establishment of accurate prevalence rates for IEED in the varying underlying conditions, and also in removing blame and stigma from sufferers by providing reassurance about the nature of their condition. C1 Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. Univ Penn, Philadelphia, PA 19104 USA. RP Duda, JE (reprint author), Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. EM john.duda@med.va.gov NR 49 TC 3 Z9 4 U1 2 U2 4 PU M B L COMMUNICATIONS, INC PI NEW YORK PA 333 HUDSON ST, 7TH FLOOR, NEW YORK, NY 10013 USA SN 1092-8529 J9 CNS SPECTRUMS JI CNS Spectr. PD APR PY 2007 VL 12 IS 4 SU 5 BP 6 EP 10 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 170WT UT WOS:000246697600002 PM 17426669 ER PT J AU Barnato, AE Kahn, JM Rubenfeld, GD McCauley, K Fontaine, D Frassica, JJ Hubmayr, R Jacobi, J Brower, RG Chalfin, D Sibbald, W Asch, DA Kelley, M Angus, DC AF Barnato, Amber E. Kahn, Jeremy M. Rubenfeld, Gordon D. McCauley, Kathleen Fontaine, Dorrie Frassica, Joseph J. Hubmayr, Rolf Jacobi, Judith Brower, Roy G. Chalfin, Donald Sibbald, William Asch, David A. Kelley, Mark Angus, Derek C. TI Prioritizing the organization and management of intensive care services in the United States: The PrOMIS Conference SO CRITICAL CARE MEDICINE LA English DT Article DE intensive care units; critical care; organization; organization and administration; health priorities ID CRITICALLY ILL; WORKFORCE REQUIREMENTS; TRAUMA CENTERS; MORTALITY; LIFE; SHORTAGE; OUTCOMES; SYSTEM; END; EPIDEMIOLOGY AB Objective., Adult critical care services are a large, expensive part of U.S. health care. The current agenda for response to workforce shortages and rising costs has largely been determined by members of the critical care profession without input from other stakeholders. We sought to elicit the perceived problems and solutions to the delivery of critical care services from a broad set of U.S. stakeholders. Design. A consensus process involving purposive sampling of identified stakeholders, preconference Web-based survey, and 2-day conference. Setting: Participants represented healthcare providers, accreditation and quality-oversight groups, federal sponsoring institutions, healthcare vendors, and institutional and individual payers. Subjects. We identified 39 stakeholders for the field of critical care medicine. Thirty-six (92%) completed the preconference survey and 37 (95%) attended the conference. Interventions, None. Measurements and Main Results., Participants expressed moderate to strong agreement with the concerns identified by the critical care professionals and additionally expressed consternation that the critical care delivery system was fragmented, variable, and not patient-centered. Recommended solutions included regionalizing the adult critical care system into "tiers" defined by explicit triage criteria and professional competencies, achieved through voluntary hospital accreditation, supported through an expanded process of competency certification, and monitored through process and outcome surveillance; implementing mechanisms for improved communication across providers and settings and between providers and patients/families; and conducting market research and a public education campaign regarding critical care's promises and limitations. Conclusions. This consensus conference confirms that agreement on solutions to complex healthcare delivery problems can be achieved and that problem and solution frames expand with broader stakeholder participation. This process can be used as a model by other specialties to address priority setting in an era of shifting demographics and increasing resource constraints. C1 Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15260 USA. Univ Pittsburgh, CRISMA Lab, Dept Crit Care Med, Pittsburgh, PA USA. Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA. Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. Baystate Med Ctr, Harvard MIT Div Hlth Sci & Technol, Div Pediat Crit Care, Springfield, MA 01199 USA. Mayo Clin Coll Med, Dept Internal Med, Div Pulm & Crit Care Med, Rochester, MN USA. Methodist Hosp Clarian Hlth Partners, Indianapolis, IN USA. Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD USA. Montefiore Med Ctr, Dept Crit Care Med, New York, NY USA. Albert Einstein Coll Med, New York, NY USA. Sunnybrook & Womens Hlth Sci Ctr, Toronto, ON, Canada. Univ Toronto, Dept Med, Toronto, ON, Canada. Univ Penn, Ctr Hlth Equity Res & Promot, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Henry Ford Hlth Syst, Detroit, MI USA. RP Angus, DC (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15260 USA. EM angusdc@ccm.upmc.edu RI Angus, Derek/E-9671-2012 OI Frassica, Joseph/0000-0001-6453-6726; Asch, David/0000-0002-7970-286X NR 52 TC 59 Z9 61 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD APR PY 2007 VL 35 IS 4 BP 1003 EP 1011 DI 10.1097/01.CCM.0000259535.06205.B4 PG 9 WC Critical Care Medicine SC General & Internal Medicine GA 151PJ UT WOS:000245302400001 PM 17334242 ER PT J AU Yaffe, K AF Yaffe, Kristine TI Metabolic syndrome and cognitive decline SO CURRENT ALZHEIMER RESEARCH LA English DT Article; Proceedings Paper CT Workshop on Exploring the Links between Obesity and Alzheimers Disease CY JUN 20-21, 2006 CL Bethesda, MD DE metabolic syndrome; cognition; dementia; insulin resistance ID CARDIOVASCULAR RISK-FACTORS; TYPE-2 DIABETES-MELLITUS; C-REACTIVE PROTEIN; ALZHEIMER-DISEASE; OLDER WOMEN; BLOOD-PRESSURE; ELDERLY-WOMEN; LATE-LIFE; DEMENTIA; INFLAMMATION AB Over 33% of women and 20% of men aged 65 and older will develop dementia during their lifetime, and many more will develop a milder form of cognitive impairment. Given the anticipated exponential increase in both the incidence and prevalence of cognitive impairment in the next century, it is critical to identify preventative strategies to thwart this critical public health issue. The metabolic syndrome is comprised of five cardiovascular risk factors that include abdominal obesity, hypertriglyceridemia, low high density lipoprotein (HDL) levels, hypertension, and hyperglycemia. The prevalence of the metabolic syndrome, similar to that for cognitive disorders, increases dramatically with age. While several of the individual components of the metabolic syndrome have been linked to risk of developing dementia and cognitive impairment, few studies have looked at the components of the metabolic syndrome as a whole. We found, in two separate studies involving elders of different ethnicities, that the metabolic syndrome is a risk factor for accelerated cognitive aging. This was especially true for elders with the metabolic syndrome and with elevated serum level of inflammation. Several possible mechanisms may explain the association between the metabolic syndrome and cognitive decline including micro- and macro-vascular disease, inflammation, adiposity and insulin resistance. If metabolic syndrome is associated with increased risk of developing cognitive impairment, regardless of mechanism, then early identification and treatment of these individuals might offer avenues for disease course modification. C1 Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat, Box 181,4150 Clement St, San Francisco, CA 94121 USA. EM Kristine.yaffe@ucsf.edu FU NIDDK NIH HHS [DK070713] NR 39 TC 52 Z9 54 U1 3 U2 9 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1567-2050 J9 CURR ALZHEIMER RES JI Curr. Alzheimer Res. PD APR PY 2007 VL 4 IS 2 BP 123 EP 126 DI 10.2174/156720507780362191 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 156BH UT WOS:000245622400006 PM 17430234 ER PT J AU Anawalt, BD AF Anawalt, Bradley D. TI Update on the development of male hormonal contraceptives SO CURRENT OPINION IN INVESTIGATIONAL DRUGS LA English DT Review DE androgen; gonadotropin; gonadotropin-releasing hormone antagonist; male contraception; progestin; spermatogenesis; testosterone ID TESTOSTERONE-INDUCED AZOOSPERMIA; NORMAL MEN; CHINESE MEN; SPERMATOGENIC SUPPRESSION; NORETHISTERONE ENANTHATE; LEVONORGESTREL IMPLANTS; CYPROTERONE-ACETATE; YOUNG MEN; ANTAGONIST; UNDECANOATE AB Efficacy trials have shown that male hormonal contraceptives can be effective, safe and reversible. A combination of a long-acting injectable testosterone plus a progestin is most likely to be the first commercially available male hormonal contraceptive. Some potential daily oral or transdermal testosterone plus progestin formulations are also being investigated. In addition, researchers have discovered promising novel drugs such as selective androgen receptor modulators and oral gonadotropin-releasing hormone antagonists that may prove useful in male hormonal contraceptive regimens. This review briefly summarizes some of the more recent findings in the development of male hormonal contraceptives. C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Anawalt, BD (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM bradley.anawalt@va.gov NR 42 TC 0 Z9 0 U1 0 U2 0 PU THOMSON REUTERS (SCIENTIFIC) LTD PI LONDON PA 77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND SN 1472-4472 EI 2040-3429 J9 CURR OPIN INVEST DR JI Curr. Opin. Investig. Drugs PD APR PY 2007 VL 8 IS 4 BP 318 EP 323 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 151AQ UT WOS:000245261100007 PM 17458182 ER PT J AU Myaskovsky, L Switzer, GE Crowley-Matoka, M Unruh, M DiMartini, AF Dew, MA AF Myaskovsky, Larissa Switzer, Galen E. Crowley-Matoka, Megan Unruh, Mark DiMartini, Andrea F. Dew, Mary Amanda TI Psychosocial factors associated with ethnic differences in transplantation SO CURRENT OPINION IN ORGAN TRANSPLANTATION LA English DT Review DE psychosocial issues; racial/ethnic differences; transplantation ID CADAVER KIDNEY-TRANSPLANT; ORGAN DONATION; AFRICAN-AMERICANS; LIVER-TRANSPLANTATION; RACIAL-DIFFERENCES; EDUCATION-PROGRAM; UNITED-STATES; HEALTH-CARE; WILLINGNESS; ATTITUDES AB Purpose of review Ethnic minorities in the United States are overrepresented among patients in need of organ transplantation. This review highlights how psychosocial factors are associated with ethnic differences in the use of transplantation to treat end-stage organ disease. Recent findings Recent empirical work has examined ethnic group differences in deceased organ donation, living organ donation, willingness to undergo transplantation, and choosing living versus deceased organ transplantation. There are marked differences, however, in the extent of available research across types of transplantation, with the bulk of research focusing on kidney transplantation. Summary Psychosocial factors, including mistrust of the medical system, perceived discrimination, social support and coping, and transplant knowledge and attitudes, are associated with ethnic differences in solid organ donation and transplantation. Recent research demonstrates that ethnic minorities are less willing to donate organs for a variety of psychosocial reasons. There is a paucity of research focused on ethnic minority groups other than African-Americans and considering end-organ diseases aside from kidney failure. Finally, studies of ethnic differences in transplantation are often limited by cross-sectional designs. Longitudinal research would better indicate whether known ethnic differences in psychosocial factors predict differences in physical or mental health outcomes after donation and transplantation. C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Anthropol, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Epidemiol, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Psychol, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Dept Anthropol, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Dept Epidemiol, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Dept Psychol, Pittsburgh, PA USA. RP Myaskovsky, L (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr C 151C-U, Pittsburgh, PA 15240 USA. EM myaskovskyl@upmc.edu NR 55 TC 6 Z9 6 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1087-2418 J9 CURR OPIN ORGAN TRAN JI Curr. Opin. Organ Transpl. PD APR PY 2007 VL 12 IS 2 BP 182 EP 187 DI 10.1097/MOT.0b013e32805b7192 PG 6 WC Transplantation SC Transplantation GA 155JT UT WOS:000245574400013 ER PT J AU Pielop, JA Phillips, R Rosen, T AF Pielop, Josie A. Phillips, Rhea Rosen, Ted TI Actinobacillus actinomycetemcomitans isolated from a case of cutaneous botryomycosis SO CUTIS LA English DT Article ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; INFECTION; MYCETOMA AB Cutaneous botryomycosis is an uncommon chronic skin infection that appears as a localized suppurative plaque or nodule with superficial crusting or ulceration. Although clinically suggestive of a deep fungal or atypical mycobacterial infection, botryomycosis is bacterial in origin. Staphylococcus aureus is the most frequent organism cultured; however, gram-negative bacilli including Pseudomonas aeruginosa, Proteus species, and Escherichia coli also have been isolated from botryomycotic infections.(1) Histologic examination reveals characteristic granules with basophilic centers composed of clumped nonfilamentous bacteria surrounded by an eosinophilic periphery (Splendore-Hoeppli phenomenon). Foreign bodies, impaired host immunity, and virulent organisms are possible pathogenic factors. C1 Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA. Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. RP Rosen, T (reprint author), Baylor Coll Med, Dept Dermatol, 1 Baylor Plaza FB840, Houston, TX 77030 USA. EM vampireted@aol.com NR 22 TC 1 Z9 1 U1 0 U2 0 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 0011-4162 J9 CUTIS JI Cutis PD APR PY 2007 VL 79 IS 4 BP 293 EP 296 PG 4 WC Dermatology SC Dermatology GA 160VI UT WOS:000245970000007 PM 17500377 ER PT J AU Wilson, M Weinrebi, J Hoo, GWS AF Wilson, Mark Weinrebi, Jane Hoo, Guy W. Soo TI Intensive insulin therapy in critical care - A review of 12 protocols SO DIABETES CARE LA English DT Review ID BLOOD-GLUCOSE CONTROL; ACUTE MYOCARDIAL-INFARCTION; ILL PATIENTS; DIABETES-MELLITUS; INFUSION PROTOCOL; GLYCEMIC CONTROL; PERIOPERATIVE MANAGEMENT; STRESS HYPERGLYCEMIA; INPATIENT MANAGEMENT; HOSPITAL MORTALITY AB OBJECTIVE - To review performance characteristics of 12 insulin infusion protocols. RESEARCH DESIGN AND METHODS - We systematically identify and compare 12 protocols and then apply the protocols to generate insulin recommendations in the management of a patient with hyperglycemia. The main focus involves a comparison of insulin doses and patterns of insulin administration. RESULTS - There is great variability in protocols. Areas of variation include differences in initiation and titration of insulin, use of bolus dosing, requirements for calculation in adjustment of the insulin infusion, and method of insulin protocol adjustments. Insulin recommendations for a sample patient are calculated to highlight differences between protocols, including the patterns and ranges of insulin dose recommended (range 27-115 units [mean +/- SD 66.7 +/- 27.9]), amount recommended for glucose readings >200 mg/dl, and adjustments nearing target glucose. CONCLUSIONS - The lack of consensus in the delivery of intravenous insulin infusions is reflected in the wide variability of practice noted in this survey. This mandates close attention to the choice of a protocol. One protocol may not suffice for all patients. C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare syst, Endocrine Sect, W Los Angeles Healthcare Ctr,David Geffen Sch Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare syst, Pulm & Crit Care Sect, W Los Angeles Healthcare Ctr,David Geffen Sch Med, Los Angeles, CA 90073 USA. RP Hoo, GWS (reprint author), W Los Angeles Healthcare Ctr, Pulm & Crit Care Sect 111Q, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM guy.soohoo@med.va.gov NR 55 TC 91 Z9 98 U1 1 U2 6 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD APR PY 2007 VL 30 IS 4 BP 1005 EP 1011 DI 10.2337/dc06-1964 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 157DA UT WOS:000245697600042 PM 17213376 ER PT J AU Shiotani, A Opekun, AR Graham, DY AF Shiotani, Akiko Opekun, Antone R. Graham, David Y. TI Visualization of the small intestine using capsule endoscopy in healthy subjects SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE capsule endoscopy; small bowel prep; polyethylene glycol; visualization; clinical trial ID SMALL-BOWEL; METOCLOPRAMIDE; STOMACH; LAVAGE AB The actual extent of lumen visualized by capsule endoscopy has not been studied systematically. Volunteers were randomized to receive a bowel preparation (prep) consisting of an isotonic solution containing polyethylene glycol and simethicone. The prep (200 ml) was given 30 min before the capsule. The capsule was taken with 100 ml of prep and 100 ml of water; 100 ml of prep was given 45 and 75 min later. The control administration was 100 ml of water and no simethicone. Forty percent of all frames taken in the small bowel were examined and individually scored for circumference, bubbles, debris, and lighting. Nine volunteers were studied twice. Only 50% of the circumference is seen normally. The prep improved the circumference to 62.5% as well as decreasing luminal debris and bubbles and improving the lighting. We conclude that the prep solution improved small bowel visualization, however, improvements are still needed to optimize visualization. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Room 3A-320,111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu FU NIDDK NIH HHS [DK 56338, DK 53659] NR 23 TC 28 Z9 30 U1 1 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD APR PY 2007 VL 52 IS 4 BP 1019 EP 1025 DI 10.1007/s10620-006-9558-6 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 149FG UT WOS:000245131900025 PM 17380402 ER PT J AU Wu, SV Yuan, PQ Wang, LX Peng, YL Chen, CY Tache, Y AF Wu, S. Vincent Yuan, Pu-qing Wang, Lixin Peng, Yen L. Chen, Chih-Yen Tache, Yvette TI Identification and characterization of multiple corticotropin-releasing factor type 2 receptor isoforms in the rat esophagus SO ENDOCRINOLOGY LA English DT Article ID SIGNAL-TRANSDUCTION PATHWAY; MESSENGER-RIBONUCLEIC-ACID; ACTIVATED PROTEIN-KINASE; CENTRAL-NERVOUS-SYSTEM; FACTOR CRF RECEPTOR; HORMONE-RECEPTOR; UROCORTIN-II; CARDIOVASCULAR-SYSTEM; SKELETAL-MUSCLE; PHARMACOLOGICAL CHARACTERIZATION AB The rat esophagus shares some cellular features with skin squamous epithelium and striated muscle that express high levels of corticotropin-releasing factor type 2 (CRF2) receptors or their cognate ligand urocortin (Ucn) 1, 2, and 3. We investigated the expression and cell signaling of CRF2 receptors and ligands in the rat esophagus and lower esophageal sphincter (LES) by RT-PCR and quantitative PCR in normal and corticosterone-treated whole esophageal tissue, laser capture microdissected layers, and isolated esophageal cells. The expression of CRF2 receptor protein and intracellular cAMP and ERK1/2 responses to CRF agonists and CRF2 antagonist were determined in cultured esophageal cells and HEK-293 cells transfected with CRF2b receptors. CRF2 was abundantly expressed in the mucosa and longitudinal muscle layers of the esophagus and LES, whereas CRF1 expression was scarce. CRF2b wild-type transcript was predominantly expressed in the esophagus, and in addition, several new CRF2 splice variants including six CRF2a isoforms were identified. Expression of Ucn 1, Ucn 2, and to a smaller extent Ucn 3, but not CRF mRNA, was detected in the esophagus and LES. Ucn 1 and Ucn 2 stimulated dose-dependent cAMP production and ERK1/ 2 phosphorylation in the esophageal cells, whereas CRF and CRF1 agonist, cortagine, had less potent effects. In addition, Ucn 2-stimulated cAMP and ERK responses were blocked by the CRF2 antagonist, astressin(2)-B. These data established the presence of a prominent CRF2 signaling system in the esophagus and LES- encompassing multiple CRF2 receptor variants and Ucn, suggesting a functional role in secretomotor activity and epithelial and muscle cell proliferation. C1 Univ Calif Los Angeles, Ctr Ulcer Res & Educ, Digest Dis Res Ctr, David Geffen Sch Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, David Geffen Sch Med, Div Digest Dis,Dept Med, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan. Taipei Vet Gen Hosp, Div Gastroenterol, Taipei 112, Taiwan. RP Wu, SV (reprint author), Univ Calif Los Angeles, Ctr Ulcer Res & Educ, Digest Dis Res Ctr, David Geffen Sch Med, Los Angeles, CA 90095 USA. EM vwu@ucla.edu FU NIDDK NIH HHS [DK 33061, DK 41301] NR 67 TC 34 Z9 35 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD APR PY 2007 VL 148 IS 4 BP 1675 EP 1687 DI 10.1210/en.2006-0565 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 147GZ UT WOS:000244992700027 PM 17218420 ER PT J AU da Silveira, EB Barkun, AN AF da Silveira, E. B. Barkun, A. N. TI EUS-first versus ERC-first for patients with intermediate probability of bile duct stones: is one strategy superior to the other? SO ENDOSCOPY LA English DT Editorial Material ID LAPAROSCOPIC CHOLECYSTECTOMY C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Gastroenterol, Portland, OR USA. McGill Univ, Div Gastroenterol & Epidemiol, Ctr Hlth, Montreal, PQ, Canada. RP Barkun, AN (reprint author), 1650 Cedar Ave,Room D7-148, Montreal, PQ H3G 1A4, Canada. EM alan.barkun@muhc.mcgill.ca NR 8 TC 3 Z9 3 U1 0 U2 0 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X J9 ENDOSCOPY JI Endoscopy PD APR PY 2007 VL 39 IS 4 BP 357 EP 358 DI 10.1055/s-2007-966255 PG 2 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 159TS UT WOS:000245890500014 PM 17427072 ER PT J AU Jansen, PL Kever, M Rosch, R Krott, E Jansen, M Alfonso-Jaume, A Dooley, S Klinge, U Lovett, DH Mertens, PR AF Jansen, Petra Lynen Kever, Mona Rosch, Raphael Krott, Ellen Jansen, Marc Alfonso-Jaume, Alexandra Dooley, Steven Klinge, Uwe Lovett, David H. Mertens, Peter R. TI Polymeric meshes induce zonal regulation of matrix metalloproteinase-2 gene expression by macrophages and fibroblasts SO FASEB JOURNAL LA English DT Article DE polymers; wound healing; cell-specific gene regulation; transgene ID GLOMERULAR MESANGIAL CELLS; GELATINASE-A TRANSCRIPTION; Y-BOX PROTEIN-1; IV COLLAGENASE; ENHANCER; YB-1; MMP-2; ACTIVATION; INHIBITION; HERNIA AB Matrix metalloproteinase-2 (MMP-2) is a key regulator in wound healing that orchestrates tissue remodeling. In the present study the spatial and temporal distribution of MMP-2 gene transcription, protein synthesis, and enzymatic activity were analyzed following polymeric mesh (polyglactin, polypropylene) implantation in transgenic reporter mice harboring MMP-2 regulatory sequences -1686/+423 or -1241/+423. Polymers induced MMP-2 promoter activity in macrophages within the foreign body granuloma via sequences -1686/+423 with concomitantly up-regulated protein synthesis and enzymatic activity. Macrophages distant from mesh filaments exhibited low MMP-2 expression levels. Fibroblasts surrounding mesh material displayed strong MMP-2 gene transcription independent of the included promoter sequences, whereas fibroblasts without close contact to mesh material had low MMP-2 synthesis rates due to silencing activity of sequences -1686/+1241. In vitro studies support a cellular crosstalk concept, as macrophages trans-repressed MMP-2 gene transcription in fibroblasts. The zonal and cell-specific regulation of MMP-2 gene transcription illuminates an intimate cellular crosstalk in foreign body reaction that may provide a new approach for mesh modification. C1 Univ Hosp, Interdisciplinary Ctr Clin Res BIOMAT, D-52074 Aachen, Germany. Univ Hosp, RWTH Aachen, Dept Surg, Aachen, Germany. William Middleton Mem Univ Wisconsin, Dept Med, Madison, WI USA. Univ Hosp, Dept Med 2, Mannheim, Germany. Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. Univ Hosp, Dept Nephrol & Clin Immunol, Aachen, Germany. RP Jansen, PL (reprint author), Univ Hosp, Interdisciplinary Ctr Clin Res BIOMAT, Pauwelsstr 30, D-52074 Aachen, Germany. EM plynen@ukaachen.de FU NIDDK NIH HHS [DK039776] NR 48 TC 19 Z9 20 U1 2 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2007 VL 21 IS 4 BP 1047 EP 1057 DI 10.1096/fj.06-6755com PG 11 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 156LS UT WOS:000245650400009 PM 17215487 ER PT J AU Argraves, KM Wilkerson, BA Hunter, AW Gazzolo, PJ Argraves, WS Obeid, LM Drake, CJ AF Argraves, Kelley M. Wilkerson, Brent A. Hunter, Andrew W. Gazzolo, Patrick J. Argraves, W. Scott Obeid, Lina M. Drake, Christopher J. TI Sphingolipid signaling in the regulation of vascular network assembly SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2007 Annual Meeting CY APR 28-MAY 02, 2007 CL Washington, DC C1 Med Univ S Carolina, Dept Med, Dept Biochem, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Dept Vet Affairs, Charleston, SC 29401 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2007 VL 21 IS 5 BP A35 EP A35 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157HD UT WOS:000245708500163 ER PT J AU Ayasolla, KR Singh, AK Singh, I AF Ayasolla, Kamesh R. Singh, Avtar K. Singh, Inderjit TI Differential effects of aluminum and lithium on LPS and A beta-(25-35) induced iNOS gene expression in glia and in Tau hyper-phosphorylation, and on neurite inhibition. SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2007 Annual Meeting CY APR 28-MAY 02, 2007 CL Washington, DC C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Dept Pathol, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2007 VL 21 IS 6 BP A1039 EP A1040 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157HF UT WOS:000245708702343 ER PT J AU Cardozo, C Zhao, JA Wu, Y Zhao, WD Zhang, YF Wecht, JM Wen, XL Zeman, R Bauman, WA AF Cardozo, Christopher Zhao, Jingbo A. Wu, Yong Zhao, Weidong Zhang, Yuanfei Wecht, Jill M. Wen, Xialing Zeman, Richard Bauman, William A. TI Differential skeletal muscle gene expression after SCI as compared to denervation SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2007 Annual Meeting CY APR 28-MAY 02, 2007 CL Washington, DC C1 James J Peters VA Med Ctr, Ctr Excellence Med Consequences SCI, Bronx, NY USA. New York Med Coll, Dept Cell Biol, Basis Sci Bldg, Valhalla, NY 10595 USA. RI Zeman, Richard/A-9295-2009 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2007 VL 21 IS 6 BP A1307 EP A1307 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157HF UT WOS:000245708704466 ER PT J AU Kaur, M Paintlia, A Contreras, M Khan, M Singh, I Singh, A AF Kaur, Manjeet Paintlia, Ajaib Contreras, Miguel Khan, Mushfiquddin Singh, Inderjit Singh, Avtar TI Peroxisomal proliferation prevents loss of oligodendrocyte progenitors and hypomyelination in periventricular leukomalacia-like brain SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2007 Annual Meeting CY APR 28-MAY 02, 2007 CL Washington, DC SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut C1 Med Univ S Carolina, Charleston, SC 29425 USA. Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2007 VL 21 IS 6 BP A990 EP A990 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157HF UT WOS:000245708702094 ER PT J AU Kucik, DF Wu, X Gupta, K AF Kucik, Dennis F. Wu, Xing Gupta, Kiran TI ICAM-1 diffusion enhances leukocyte adhesion under flow conditions SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2007 Annual Meeting CY APR 28-MAY 02, 2007 CL Washington, DC C1 Univ Alabama, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Pathol & Lab Med, Birmingham, AL 35233 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2007 VL 21 IS 5 BP A126 EP A127 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157HD UT WOS:000245708501037 ER PT J AU Mulvaney, JM Brooks, VL Roberts, D Chapleau, MW Goldman, RK AF Mulvaney, J. M. Brooks, V. L. Roberts, D. Chapleau, M. W. Goldman, R. K. TI Gain of baroreflex control of heart rate decreases during late pregnancy in rats SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2007 Annual Meeting CY APR 28-MAY 02, 2007 CL Washington, DC C1 Oregon Hlth & Sci Univ, Portland, OR 97239 USA. Univ Iowa, VAMC, Iowa City, IA 52242 USA. Portland VA Med Ctr, Portland, OR 97207 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2007 VL 21 IS 5 BP A512 EP A512 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157HD UT WOS:000245708504210 ER PT J AU Munson, KB AF Munson, Keith Bennett TI Analysis of the gastric H,K ATPase for ion pathways and inhibitor binding sites SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2007 Annual Meeting CY APR 28-MAY 02, 2007 CL Washington, DC C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2007 VL 21 IS 5 BP A535 EP A535 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157HD UT WOS:000245708504316 ER PT J AU Sarmasik, A Wang, G Wang, KZQ Anton, PE Galson, DL AF Sarmasik, Aliye - Wang, Guangqing - Wang, Kent Z. Q. Anton, Philip E. Galson, Deborah L. TI Membrane recruitment of tee kinase by RANKL activates NFATc1 in osteoclasts SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2007 Annual Meeting CY APR 28-MAY 02, 2007 CL Washington, DC C1 Univ Pittsburgh, Sch Med, Dept Med, VA Pittsburgh Healthcare Syst,R&D, Pittsburgh, PA 15240 USA. Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2007 VL 21 IS 5 BP A249 EP A250 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157HD UT WOS:000245708502044 ER PT J AU Wu, Y Zhao, WD Zhao, JB Zhang, YF Bauman, WA Cardozo, C AF Wu, Yong Zhao, Weidong Zhao, Jingbo Zhang, Yuanfei Bauman, William A. Cardozo, Christopher TI Evidence from DNA microarray analysis of skeletal muscle that testosterone reverses multiple glucocorticoid-induced defects in IGF-1 signaling networks. SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2007 Annual Meeting CY APR 28-MAY 02, 2007 CL Washington, DC C1 James J Peters VA Med Ctr, Ctr Excellence Med Consequences SCI, Bronx, NY USA. Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2007 VL 21 IS 6 BP A1304 EP A1304 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157HF UT WOS:000245708704451 ER PT J AU Zhao, JB Zhao, WD Wu, Y Zhang, YF Bauman, W Cardozo, C AF Zhao, Jingbo Zhao, Weidong Wu, Yong Zhang, Yuanfei Bauman, William Cardozo, Christopher TI Attenuation by nandrolone of chronic but not acute denervation atrophy. SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2007 Annual Meeting CY APR 28-MAY 02, 2007 CL Washington, DC C1 VA Med Ctr, Ctr Excellence Med Consequences SCI, Bronx, NY USA. Mt Sinai Sch Med, New York, NY USA. James J Peters Med Ctr, Bronx, NY 10468 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2007 VL 21 IS 6 BP A1305 EP A1305 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157HF UT WOS:000245708704457 ER PT J AU Mittal, V Rosen, J Govind, R Degenholtz, H Shingala, S Hulland, S Rhee, Y Kastango, KB Mulsant, BH Castle, N Rubin, FH Nace, D AF Mittal, Vikas Rosen, Jules Govind, Rahul Degenholtz, Howard Shingala, Sunil Hulland, Shelley Rhee, Yongjoo Kastango, Karl B. Mulsant, Benoit H. Castle, Nick Rubin, Fred H. Nace, David TI Perception gap in quality-of-life ratings: An empirical investigation of nursing home residents and Caregivers SO GERONTOLOGIST LA English DT Article DE adaptation-level theory; job satisfaction; perception gap; quality of life ID PATIENT HEALTH; CARE AB Purpose: Several studies have previously documented the existence of a perception gap-the extent to which quality-of-life ratings provided by nursing home residents and caregivers diverge. In this study we use Helson's adaptation-level theory to investigate three types of antecedents: (a) focal factors, (b) background factors, and (c) residual factors. Design and Methods: We calculated the perception gap for 11 quality-of-life domains. Caregivers rated both job satisfaction and their perception of quality of life of residents in the unit where they provided service. Concurrently, residents from these units completed quality-of-life interviews. We computed the perception gap by subtracting the residents' ratings from the caregivers' ratings for each quality-of-life domain. We conducted a hierarchical linear model using 3,850 observations to predict the perception gap. Results: Caregivers perceive quality of life to be lower than residents do across all domains fairly consistently. Caregiver demographics do not directly predict the perception gap. However, satisfaction with work, pay, and promotion were significant predictors (p < .05), and satisfaction with supervisor was a marginally significant predictor (p < . 10), of the perception gap. As satisfaction with these job dimensions increased, the perception gap decreased. Additional models show that several caregiver demographics directly influence job-satisfaction dimensions, though they did not influence the perception gap. Implications: Jobsatisfaction dimensions, rather than caregiver characteristics, are the appropriate predictors of the perception gap. However, caregiver demographics exert their influence indirectly by means of job satisfaction. A key finding is that higher job satisfaction leads to a smaller perception gap. Helson's adaptation-level theory appears to be a useful approach for understanding the antecedents of the perception gap. C1 Univ Pittsburgh, Katz Grad Sch Business, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA. VA Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RAND Corp, Pittsburgh, PA USA. Univ Pittsburgh, Dept Internal Med, Pittsburgh, PA 15260 USA. Univ Mississippi, Sch Business, Oxford, MS USA. RP Rosen, J (reprint author), 3811 Ohara St, Pittsburgh, PA 15213 USA. EM rosenji@upmc.edu RI Nace, David/D-2638-2014 OI Degenholtz, Howard/0000-0003-1986-7360 FU AHRQ HHS [HS11976]; NIMH NIH HHS [MH52247, MH01613] NR 27 TC 4 Z9 4 U1 1 U2 13 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD APR PY 2007 VL 47 IS 2 BP 159 EP 168 PG 10 WC Gerontology SC Geriatrics & Gerontology GA 226SJ UT WOS:000250608500002 PM 17440121 ER PT J AU Goodfriend, TL AF Goodfriend, Theodore L. TI Treating resistant hypertension with a neglected old drug SO HYPERTENSION LA English DT Editorial Material ID HEART-FAILURE; SPIRONOLACTONE; CANRENONE; TURNOVER C1 William S Middleton Mem Vet Adm Med Ctr, Res Serv, Madison, WI 53705 USA. Univ Wisconsin, Sch Med & Publ Hlth, Dept Med & Pharmacol, Madison, WI 53706 USA. RP Goodfriend, TL (reprint author), William S Middleton Mem Vet Adm Med Ctr, Res Serv, 2500 Overlook Terr, Madison, WI 53705 USA. EM Theodore.goodfriend@med.va.gov NR 14 TC 14 Z9 15 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD APR PY 2007 VL 49 IS 4 BP 763 EP 764 DI 10.1161/01.HYP.0000259806.91169.01 PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 148VG UT WOS:000245104300006 PM 17309945 ER PT J AU Fasching, CE Grossman, T Corthesy, B Plaut, AG Weiser, JN Janoff, EN AF Fasching, Claudine E. Grossman, Tracy Corthesy, Blaise Plaut, Andrew G. Weiser, Jeffrey N. Janoff, Edward N. TI Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae SO INFECTION AND IMMUNITY LA English DT Article ID PNEUMOCOCCAL CAPSULAR POLYSACCHARIDES; LINKED-IMMUNOSORBENT-ASSAY; SECRETORY IGA; POLYMERIC IGA; OPSONOPHAGOCYTIC ASSAY; CONJUGATE VACCINE; ANTIBODY AVIDITY; ANTIGEN-BINDING; POLYMORPHONUCLEAR LEUKOCYTES; NEISSERIA-MENINGITIDIS AB Antibodies of the immunoglobulin A (IgA) class react with capsular polysaccharides of Streptococcus pneumoniae and support complement-dependent opsonophagocytosis (OPC) of the organism by phagocytes. We characterized the biologic impact of the molecular forms of human monoclonal capsule-specific IgA (monomeric IgA [mIgA], polymeric IgA [pIgA], and secretory IgA [SIgA]) on OPC and susceptibility to cleavage by IgA1 protease. The efficiency of SIgA in support of OPC of S. pneumoniae was comparable to that of pIgA, and both forms exceeded that of mIgA by a fivefold margin. This structure-function relationship was associated with three factors. First, the avidities, or functional affinities, of both pIgA and SIgA for pneumococcal capsules exceeded those of mIgA. Second, both pIgA and SIgA required less complement to achieve similar levels of bacterial OPC than did mIgA, indicating that secretory component does not hinder the effect of complement. Third, both pIgA and SIgA mediated agglutination of the organism, whereas mIgA did not. All three forms of capsule-specific IgA showed comparable susceptibilities to cleavage and functional inhibition by bacterial IgA1 protease, demonstrating that secretory component does not prevent the proteolytic degradation of IgA1 by IgA1 protease. IgA1 cleavage results in formation of identical Fab fragments for each of the molecular forms, thereby abolishing the contribution of multivalence of pIgA and SIgA. In summary, the polymeric forms of IgA (both pIgA and SIgA) provide a substantial advantage in binding, agglutination, and OPC of the organism. C1 Univ Colorado, Hlth Sci Ctr, Div Infect Dis, Colorado CFAR,Denver Vet Affairs Med Ctr, Denver, CO 80262 USA. Univ Minnesota, Vet Affairs Med Ctr, Div Infect Dis & Int Med, Minneapolis, MN 55455 USA. Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. Univ Minnesota, Sch Dent, Minneapolis, MN 55455 USA. CHU Vaudois, Div Immunol & Allergie, CH-1011 Lausanne, Switzerland. Tufts Univ, Sch Med, Div Gastroenterol, Boston, MA 02111 USA. Tufts Univ, Sch Med, New England Med Ctr Hosp, GRASP Digest Dis Ctr, Boston, MA 02111 USA. Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. Denver Vet Affairs Med Ctr, Hlth Sci Ctr, Denver, CO USA. RP Janoff, EN (reprint author), Univ Colorado, Hlth Sci Ctr, Div Infect Dis, Colorado CFAR,Denver Vet Affairs Med Ctr, 4200 E 9th Ave,Room 1813, Denver, CO 80262 USA. EM Edward.Janoff@uchsc.edu RI Medecine, Bibliotheque/A-5279-2012 OI Weiser, Jeffrey/0000-0001-7168-8090 FU NIAID NIH HHS [AI 38446, AI 44231, AI 48796, R01 AI038446, R01 AI044231, R01 AI048796, R21 AI044231]; NICHD NIH HHS [HD 41361, R01 HD041361]; NIDCR NIH HHS [DE 015072, R01 DE 15844, R01 DE015844, R21 DE015072]; NIDDK NIH HHS [P30 DK034928, P30 DK 34928] NR 60 TC 17 Z9 19 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD APR PY 2007 VL 75 IS 4 BP 1801 EP 1810 DI 10.1128/IAI.01758-06 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 153GY UT WOS:000245421400031 PM 17261616 ER PT J AU Zhang, ZL Hinrichs, DJ Lu, HY Chen, H Zhong, WW Kolls, JK AF Zhang, Zili Hinrichs, David J. Lu, Huiying Chen, Hong Zhong, Wenwei Kolls, Jay K. TI After interleukin-12p4O, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease? SO INTERNATIONAL IMMUNOPHARMACOLOGY LA English DT Review DE CD4(+) T cells; Crohn's disease; inflammatory bowel disease; interleukin-17; interleukin-23; ThIL-17 cells; ulcerative colitis ID HUMAN COLONIC MYOFIBROBLASTS; IL-17-PRODUCING T-CELLS; ACTIVE CROHNS-DISEASE; NF-KAPPA-B; INDUCED COLITIS; AUTOIMMUNE ENCEPHALOMYELITIS; NEUTROPHIL RECRUITMENT; STIMULATING FACTOR; CYTOKINE RECEPTOR; EPITHELIAL-CELLS AB Inflammatory bowel disease (IBD), typified by Crohn's disease and ulcerative colitis, is a common disorder characterized by recurrent and serious inflammation of the gastrointestinal tract. Recent immunologic advances have established that T cells and inflammatory cytokines play a pivotal role in the gastrointestinal inflammation of IBD. However, many cytokines not only elicit inflammation but also protect host against microbial invasion. Hence, suppression of these dual-purpose cytokines often exposes the patients to significant risk of infection. Recent research on Interleukin (IL)-23, IL-17, and IL-17 producing T cells has become the vanguard of further understanding the contribution of cytokines to autoimmune and inflammatory diseases. IL-23 is a newly discovered member of the IL-12-related cytokine family, and is primarily involved in the differentiation of pathogenic T cells characterized by their production of IL-17. IL-17 is a potent inflammatory mediator implicated in a number of autoimmune diseases. The discovery of this IL-23/IL-17-mediated inflammatory axis is having a profound impact on the elucidation of T cell-mediated pathogenesis as well as development of novel therapeutic targets. In this review, we discuss the current literature and present our recent studies on the role of IL-23 and IL-17 in the pathogenesis of IBD. Controlling the expression/production of IL-23 and IL-17 is an approach that would allow the development of a novel treatment strategy with more anti-inflammatory efficacy and potentially with less suppressive effects on host defenses. (c) 2007 Published by Elsevier B.V. C1 Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA. Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. RP Kolls, JK (reprint author), Childrens Hosp Pittsburgh, 3705 5th Ave,Suite 3765, Pittsburgh, PA 15213 USA. EM jkolls@lsuhsc.edu NR 63 TC 47 Z9 48 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-5769 J9 INT IMMUNOPHARMACOL JI Int. Immunopharmacol. PD APR PY 2007 VL 7 IS 4 BP 409 EP 416 DI 10.1016/j.intimp.2006.09.024 PG 8 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA 149KI UT WOS:000245145400001 PM 17321463 ER PT J AU Williams, BR Baker, PS Allman, RM Roseman, JM AF Williams, Beverly Rosa Baker, Patricia Sawyer Allman, Richard M. Roseman, Jeffrey M. TI Bereavement among African American and White older adults SO JOURNAL OF AGING AND HEALTH LA English DT Article DE African American and White older adults; geriatric bereavement events; spousal loss; nonspousalfiamily loss; friendship loss ID SOCIAL SUPPORT; LATE-LIFE; FICTIVE KIN; FAMILY; DEATH; AGE; FRIENDSHIPS; NETWORKS; PATTERNS; WOMEN AB Purpose: The authors examined epidemiology and sociodemographic predictors of spousal, nonspousal family, and friendship bereavement among African American and White community-dwelling older adults using longitudinal data from 839 participants of the University of Alabama at Birmingham Study of Aging, a prospective cohort study of a random sample of Alabama Medicare beneficiaries. Method: Authors calculated cumulative incidences of each type of loss and used logistic regression to identify factors significantly and independently associated with loss. Results: Of participants, 71% reported at least one loss; 50% reported nonspousal family loss, and 37% reported friendship loss. For married participants, the cumulative incidence of spousal loss was 8.1%. Female sex and income < $12,000 were predictors of spousal loss. Female sex and education >= 12 years were predictors of friendship loss. Higher educated African American women were at greater risk of nonspousal family loss. Discussion: Future research should examine bereavement burden and identify health outcomes of multiple losses. C1 Univ Alabama, Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, GRECC, Birmingham VA Med Ctr, Birmingham, AL 35233 USA. RP Williams, BR (reprint author), Univ Alabama, Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, GRECC, Birmingham VA Med Ctr, 700 W 19th St, Birmingham, AL 35233 USA. EM beverly.williams3@va.gov FU NIA NIH HHS [R01 AG015062, R01 AG15062] NR 60 TC 13 Z9 13 U1 2 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0898-2643 J9 J AGING HEALTH JI J. Aging Health PD APR PY 2007 VL 19 IS 2 BP 313 EP 333 DI 10.1177/0898264307299301 PG 21 WC Gerontology; Health Policy & Services SC Geriatrics & Gerontology; Health Care Sciences & Services GA 147NQ UT WOS:000245010100009 PM 17413138 ER PT J AU Quijano, LM Stanley, MA Petersen, NJ Casado, BL Steinberg, EH Cully, JA Wilson, NL AF Quijano, Louise M. Stanley, Melinda A. Petersen, Nancy J. Casado, Banghwa Lee Steinberg, Esther H. Cully, Jeffrey A. Wilson, Nancy L. TI Healthy IDEAS: A depression intervention delivered by community-based case managers serving older adults SO JOURNAL OF APPLIED GERONTOLOGY LA English DT Article DE depression; community-based; case managers; evidence-based ID RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE PATIENTS; LATE-LIFE DEPRESSION; BEHAVIORAL ACTIVATION; DISORDERS; FRAMEWORK; SELECTION; SYMPTOMS; SCREENER; OUTCOMES AB This study evaluated an evidence-based intervention for depression delivered by case managers in three community-based service agencies to high-risk, diverse older adults. Case managers were trained to provide screening and assessment, education, referral and linkage, and behavioral activation. Outcomes addressed depression, general health status, social and physical activation, and mental health services use at baseline and 6 months. Participants (n = 94) were predominantly women (79%) and Hispanic (44%), with a mean age of 72 years. Mean Geriatric Depression Scale-15 scores differed significantly between baseline and 6 months (9.0 versus 5.5). At 6 months, significantly more participants knew how to get help for depression (68% versus 93%), reported that increasing activity helped them feel better (72% versus 89%), and reported reduced pain (16% versus 45%). The authors conclude that nonspecialty providers can be trained to successfully implement an evidence-based self-management intervention for depression with frail, high-risk, and diverse older adults. C1 Baylor Coll Med, Ctr Qual Care & Utilizat Studies, Michael E DeBakey Vet Affairs Med Ctr, Huffington Ctr Aging, Houston, TX 77030 USA. Univ Maryland, Baltimore, MD 21201 USA. Sheltering Arms Senior Serv, Houston, TX USA. RP Wilson, NL (reprint author), Baylor Coll Med, Ctr Qual Care & Utilizat Studies, Michael E DeBakey Vet Affairs Med Ctr, Huffington Ctr Aging, 1 Baylor Plaza M-320, Houston, TX 77030 USA. EM nwilson@bcm.edu NR 32 TC 46 Z9 46 U1 4 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0733-4648 J9 J APPL GERONTOL JI J. Appl. Gerontol. PD APR PY 2007 VL 26 IS 2 BP 139 EP 156 DI 10.1177/0733464807299354 PG 18 WC Gerontology SC Geriatrics & Gerontology GA 157WM UT WOS:000245752100002 ER PT J AU Darouiche, RO Mansouri, MD Zakarevicz, D AlSharif, A Landon, GC AF Darouiche, Rabih O. Mansouri, Mohammad D. Zakarevicz, Devin AlSharif, Atef Landon, Glenn C. TI In vivo efficacy of antimicrobial-coated devices SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID CENTRAL VENOUS CATHETERS; RANDOMIZED CONTROLLED-TRIAL; STAPHYLOCOCCUS-AUREUS; SURGICAL IMPLANTS; 2-STAGE REVISION; MINOCYCLINE; RIFAMPIN; INFECTIONS; COLONIZATION; ANTIBIOTICS AB Background: Since device colonization is a prelude to infection, an anti microbia I-coated device that reduces bacterial colonization can potentially protect against infection. The objective of this animal study was to assess the efficacy of a coating with minocycline and rifampin to prevent colonization of a grit-blasted titanium implant and subsequent osteomyelitis. Methods: Twenty-five rabbits underwent implantation of a titanium-alloy pin, either coated with minocycline and rifampin (thirteen rabbits) or uncoated (twelve rabbits), into the right femoral medullary canal. The implanted devices were inoculated with 500 CFU (colony-forming units) of Staphylococcus aureus prior to wound closure. The rabbits were killed one week later, and the removed device, femoral bone, a specimen obtained by swabbing the track surrounding the device, and blood were cultured. The rates of device colonization, osteomyelitis, and device-related osteomyelitis were compared between the two groups of rabbits. Results: The antimicrobial-coated devices had a significantly lower rate of colonization than the uncoated devices (five of thirteen compared with twelve of twelve, p = 0.0016) and were associated with significantly lower rates of osteomyelitis (six of thirteen compared with twelve of twelve, p = 0.005) and device-related osteomyelitis (five of thirteen compared with twelve of twelve, p = 0.0016). Bacteremia did not develop in any rabbit. Conclusions: Orthopaedic devices coated with minocycline and rifampin significantly protected against device colonization and infection due to Staphylococcus aureus in this in vivo rabbit model. Clinical Relevance: It is possible that orthopaedic devices coated with this unique combination of antimicrobial agents may protect against the development of clinical infection in humans. C1 Baylor Coll Med, Ctr Prostheses Infect, Houston, TX 77030 USA. Kelsey Seybold Clin, Sect Orthoped Surg, Houston, TX 77025 USA. Michael E DeBakey Vet Affairs Med Ctr, Spinal Cord Injury Lab, Houston, TX 77030 USA. RP Darouiche, RO (reprint author), Baylor Coll Med, Ctr Prostheses Infect, 1333 Moursund Ave,Suite A221, Houston, TX 77030 USA. EM rdarouiche@aol.com; mansouri@bcm.tmc.edu; dmzakarevicz@kelsey-seybold.com; alsharif@bcm.tmc.edu; gclandon@kelsey-seybold.com NR 33 TC 61 Z9 62 U1 2 U2 10 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD APR PY 2007 VL 89A IS 4 BP 792 EP 797 DI 10.2106/JBJS.F.00414 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 154PL UT WOS:000245519600014 PM 17403802 ER PT J AU Richardson, JA Amantea, CM Kianmahd, B Tetradis, S Lieberman, JR Hahn, TJ Parhami, F AF Richardson, Jennifer A. Amantea, Christopher M. Kianmahd, Benjamin Tetradis, Sotirios Lieberman, Jay R. Hahn, Theodore J. Parhami, Farhad TI Oxysterol-induced osteoblastic differentiation of pluripotent mesenchyrnal cells is mediated through a PKC- and PKA-dependent pathway SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE oxysterols; marrow stromal cells; osteoblastic differentiation; Runx2; PKC; PKA ID MARROW STROMAL CELLS; TRANSCRIPTION FACTOR; BONE-FORMATION; STEM-CELLS; IN-VITRO; SKELETAL DEVELOPMENT; SIGNALING PATHWAYS; GENE-EXPRESSION; PROTEIN-KINASE; RUNX2 AB Oxysterols form a large family of oxygenated derivatives of cholesterol that are present in circulation, and in human and animal tissues. The discovery of osteoinductive molecules that can induce the lineage-specific differentiation of cells into osteoblastic cells and therefore enhance bone formation is crucial for better management of bone fractures and osteoporosis. We previously reported that specific oxysterols have potent osteoinductive properties and induce the osteoblastic differentiation of pluripotent mesenchymal cells. In the present report we demonstrate that the induction of osteoblastic differentiation by oxysterols is mediated through a protein kinase C (PKC)- and protein kinase A (PKA)-dependent mechanism(s). Furthermore, oxysterol-incluced-osteoblastic differentiation is marked by the prolonged DNA-binding activity of Runx2 in M2-10B4 bone marrow stromal cells (MSCs) and C3H10T1/2 embryonic fibroblastic cells. This increased activity of Runx2 is almost completely inhibited by PKC inhibitors Bisindolylmaleimide and Rottlerin, and only minimally inhibited by PKA inihibitor H-89. PKC- and PKA-dependent mechanisms appear to also regulate other markers of osteoblastic differentiation including alkaline phosphatase (ALP) activity and osteocalcin mRNA expression in response to oxysterols. Finally, osteogenic oxysterols induce osteoblastic differentiation with BMP7 and BMP14 in a synergistic manner as demonstrated by the enhanced Runx2 DNA-binding activity, ALP activity, and osteocalcin mRNA expression. Since Runx2 is an indispensable factor that regulates the differentiation of osteoblastic cells and bone formation in vitro and in vivo, its increased activity in oxysterol-treated cells further validates the potential role of oxysterols in lineage-specific differentiation of pluripotent mesenchymal cells and their potential therapeutic use as bone anabolic factors. C1 Univ Calif Los Angeles, David Geffen Sch Med, Hlth Sci Ctr, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Orthoped Surg, Los Angeles, CA 90095 USA. Ctr Geriatr Res Educ & Clin, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. RP Parhami, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Hlth Sci Ctr, Dept Med, BH-307,10833 Conte Ave, Los Angeles, CA 90095 USA. EM fparhami@mednet.ucla.edu FU NHLBI NIH HHS [HL3056]; NIAMS NIH HHS [R01AR050426] NR 49 TC 33 Z9 34 U1 2 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD APR 1 PY 2007 VL 100 IS 5 BP 1131 EP 1145 DI 10.1002/jcb.21112 PG 15 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 149NR UT WOS:000245154200006 PM 17031848 ER PT J AU Aujesky, D Long, JA Fine, MJ Ibrahim, SA AF Aujesky, Drahomir Long, Judith A. Fine, Michael J. Ibrahim, Said A. TI African American race was associated with an increased risk of complications following venous thromboembolism SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE quality; equity; race; anticoagulation; outcomes; venous thromboembolism ID DEEP-VEIN THROMBOSIS; PULMONARY-EMBOLISM MORTALITY; ANTICOAGULATION THERAPY; ANTITHROMBOTIC THERAPY; UNFRACTIONATED HEPARIN; ORAL ANTICOAGULATION; CONTROLLED-TRIAL; UNITED-STATES; DISEASE; METAANALYSIS AB Objective: Limited data exist on the quality of care for patients with venous thromboembolism (VTE), and it is unknown whether the processes and outcomes of care for this illness differ between African Americans and whites. Study Design and Setting: We retrospectively studied 168 patients hospitalized for VTE in two Veterans Affairs hospitals during fiscal years 2000-2002. Patient characteristics, information about processes of care, and medical outcomes at 90 days after the index VTE event were abstracted from medical records. We used logistic regression to explore associations between race, processes of care, and the overall 90-day complication rate (i.e., death, bleeding, or recurrent VTE), adjusting for patient baseline characteristics. Results: Multivariable analysis demonstrated that administration of warfarin within 1 day of starting heparin (odds ratio [OR] 0.20, 95% confidence interval [CI]: 0.05-0.42) and overlap of heparin and warfarin treatment >= 4 days (OR 0.09, 95% CI: 0.02-0.50) were associated with a lower complication rate, and African American race was associated with a higher complication rate (OR 5.2, 95% CI: 1.3-21.6). Race was not significantly associated with the performance of processes of care in multivariable analysis. Conclusion: Although African Americans had an increased risk of complications following VTE, race was not independently associated with the use of processes of care for VTE. (C) 2007 Elsevier Inc. All rights reserved. C1 Univ Lausanne, Clin Epidemiol Ctr, Div Internal Med, Lausanne, Switzerland. Univ Lausanne, Univ Outpatient Clin, Lausanne, Switzerland. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. RP Aujesky, D (reprint author), CHU Vaudois, Serv Med Interne, BH 10-622, CH-1011 Lausanne, Switzerland. EM drahomir.aujesky@chuv.ch NR 37 TC 16 Z9 16 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD APR PY 2007 VL 60 IS 4 BP 410 EP 416 DI 10.1016/j.jclinepi.2006.06.023 PG 7 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 148SF UT WOS:000245094200014 PM 17346616 ER PT J AU Holmes, WC AF Holmes, William C. TI Men's childhood sexual abuse histories by one-parent versus two-parent status of childhood home SO JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH LA English DT Article ID SINGLE-MOTHER; RISK-FACTORS; CHILDREN; HEALTH; DISORDERS; VIOLENCE; BOYS; ASSOCIATION; PREVALENCE; DEPRESSION AB Objectives: To estimate the association between number of parents in the childhood home and childhood sexual abuse (CSA) with adjustment for childhood socioeconomic status (CSES). Methods: Probability sample of 298, 18-49-year-old men from Philadelphia County, number of parents living in childhood home, socioeconomic data and CSA histories were obtained. Results: 197 (66%) men participated. 186 (94%) of these lived with at least one parent; 76 (39%) and 110 (56%) lived with one parent versus two parents, respectively. 22 (29%) of 76 and 18 (16%) of 110 reported CSA histories, respectively (OR 2.08, p = 0.04). Two approaches to adjustment for CSES indicated continued association between parent number and CSA (OR 2.38-2.39, p = 0.05-0.07). Parent number was associated with numerous differences in CSA perpetrator characteristics and abuse experiences. Men from one-parent versus two-parent families reported significantly more non-family and female perpetrators (p = 0.03 and 0.01, respectively) and fondling experiences (p = 0.04). Conclusions: Findings provide additional support for the association between parent number and CSA in boys, suggesting that parent number is not just a proxy for CSES. CSA experiences also differed between one-parent and two-parent homes. Findings generate numerous hypotheses for future study. C1 Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Holmes, WC (reprint author), Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, 733 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM holmeswc@mail.med.upenn.edu FU NIDA NIH HHS [DA015635, R03 DA015635] NR 39 TC 5 Z9 5 U1 0 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0143-005X J9 J EPIDEMIOL COMMUN H JI J. Epidemiol. Community Health PD APR PY 2007 VL 61 IS 4 BP 319 EP 325 DI 10.1136/jech.2005.040188 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 147XG UT WOS:000245037600010 PM 17372292 ER PT J AU Lawrence, V Hazuda, H Cornell, J AF Lawrence, V. Hazuda, H. Cornell, J. TI How elders help themselves recover from major surgery SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Lawrence, V.; Cornell, J.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Hazuda, H.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 6 EP 6 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700020 ER PT J AU Fihn, SD Bryson, C Mcdonell, M Diehr, PH Fan, VS AF Fihn, S. D. Bryson, C. Mcdonell, M. Diehr, P. H. Fan, V. S. TI Do primary care providers worry about worrisome results? Effects of feedback on processes and outcomes of care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Fihn, S. D.; Bryson, C.; Fan, V. S.] HSR&D Ctr Excellence, VA Puget Sound, Seattle, WA USA. [Mcdonell, M.] HSR&D VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Diehr, P. H.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 18 EP 18 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700061 ER PT J AU Kutner, JS Smith, MC Corbin, L Hemphill, L Fairclough, D AF Kutner, J. S. Smith, M. C. Corbin, L. Hemphill, L. Fairclough, D. TI Efficacy of massage therapy for decreasing physical and emotional symptom distress and improving qualityoflife in advanced cancer SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Kutner, J. S.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. [Smith, M. C.] Florida Atlantic Univ, Boca Raton, FL 33431 USA. [Corbin, L.; Fairclough, D.] Univ Colorado, Hlth Sci Ctr, Aurora, CO USA. [Hemphill, L.] Denver VAMC, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 20 EP 20 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700068 ER PT J AU Shacter, HE Iqbal, N Akhubue, E Long, JA AF Shacter, H. E. Iqbal, N. Akhubue, E. Long, J. A. TI Glucose control among veterans with poorly controlled diabetes: A guide for potential interventions SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Shacter, H. E.; Iqbal, N.; Long, J. A.] Vet Affairs Med Ctr, CHERP, Philadelphia, PA USA. [Akhubue, E.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 22 EP 22 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700075 ER PT J AU Lorenz, K Sherbourne, C Cohen, A Hagenmaier, E Kroenke, K Rubenstein, LV Simon, B Lanto, A Asch, S AF Lorenz, K. Sherbourne, C. Cohen, A. Hagenmaier, E. Kroenke, K. Rubenstein, L. V. Simon, B. Lanto, A. Asch, S. TI How does recall timeframe affect pain screening in routine outpatient care? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Lorenz, K.; Cohen, A.] Vet Adm Greater Los Angeles Hlthcare Syst, Los Angeles, CA USA. [Sherbourne, C.] RAND Hlth, Santa Monica, CA USA. [Hagenmaier, E.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Kroenke, K.] Indiana Univ Purdue Univ, Indianapolis, IN USA. [Simon, B.] Vet Affairs Greater Los Angeles, Los Angeles, CA USA. [Lanto, A.] Vet Affairs Greater Los Angeles HSR&D Ctr Excelle, Sepulveda, CA USA. [Asch, S.] Vet Adm Greater W Lost Angeles Hlthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 23 EP 23 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700078 ER PT J AU Rodriguez, KL Appelt, CJ Switzer, GE Sonel, AF Arnold, RM AF Rodriguez, K. L. Appelt, C. J. Switzer, G. E. Sonel, A. F. Arnold, R. M. TI Heart failure patients' decision making preferences and perceived involvement in cardiac care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Rodriguez, K. L.; Appelt, C. J.; Sonel, A. F.] Vet Affairs Pittsburg Hlthcare Syst, Pittsburgh, PA USA. [Switzer, G. E.; Arnold, R. M.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 23 EP 23 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700077 ER PT J AU Leykum, L Pugh, J Lawrence, V Parchman, M Noel, P Cornell, J Mcdaniel, R AF Leykum, L. Pugh, J. Lawrence, V. Parchman, M. Noel, P. Cornell, J. Mcdaniel, R. TI Making sense of organizational interventions using complexity science SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Leykum, L.; Lawrence, V.; Parchman, M.; Cornell, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Pugh, J.; Noel, P.] So Texas Vet Hlth Care Syst, San Antonio, TX USA. [Mcdaniel, R.] Univ Texas Austin, Austin, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 26 EP 27 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700090 ER PT J AU Mortensen, E Leykum, L Noel, PH Zeber, J Pugh, M Lawrence, V AF Mortensen, E. Leykum, L. Noel, P. Hitchcock Zeber, J. Pugh, M. Lawrence, V. TI Organizational interventions to improve outcomes for patients with COPD SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Mortensen, E.; Leykum, L.; Noel, P. Hitchcock; Zeber, J.; Pugh, M.; Lawrence, V.] So Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 28 EP 28 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700096 ER PT J AU Groeneveld, PW Matta, A Suh, JJ Olah, JF Yang, F Shea, JA AF Groeneveld, P. W. Matta, A. Suh, J. J. Olah, J. F. Yang, F. Shea, J. A. TI Quality of life for drug eluting stent recipients: Are avoided revascularizations valued? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Groeneveld, P. W.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Matta, A.; Suh, J. J.; Olah, J. F.; Yang, F.; Shea, J. A.] Univ Penn, Div Gen Internal Med, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 40 EP 40 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700137 ER PT J AU Ling, B Trauth, JM Fine, MJ Mor, MK Abby, R Braddock, CH Bereknyei, S Weissfeld, J Schoen, R Whittle, J AF Ling, B. Trauth, J. M. Fine, M. J. Mor, M. K. Abby, R. Braddock, C. H. Bereknyei, S. Weissfeld, J. Schoen, R. Whittle, J. TI Informed decision making and colorectal cancer screening: Is it occurring in primary care and what is the impact on screening rates? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Ling, B.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Trauth, J. M.; Fine, M. J.; Weissfeld, J.; Schoen, R.] Univ Pittsburgh, Pittsburgh, PA USA. [Mor, M. K.] Univ Pittsburgh, Pittsburgh VA Hlth Care Syst, Sch Med, Pittsburgh, PA USA. [Abby, R.] VA Pittsburg Healthcare Syst, Pittsburgh, PA USA. [Braddock, C. H.; Bereknyei, S.] Stanford Univ, Palo Alto, CA 94304 USA. [Whittle, J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 40 EP 40 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700135 ER PT J AU Mortensen, E Restrepo, M Copeland, L Anzueto, A Pugh, J AF Mortensen, E. Restrepo, M. Copeland, L. Anzueto, A. Pugh, J. TI Association of lipophilic and hydrophilic ace inhibitor use with pneumonia-related mortality SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Mortensen, E.; Copeland, L.; Pugh, J.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Restrepo, M.; Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy VA Hosp, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 44 EP 44 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700150 ER PT J AU Groeneveld, PW Yang, F Matta, MA AF Groeneveld, P. W. Yang, F. Matta, M. A. TI Costs and outcomes of drug eluting coronary stents versus bare metal stents among the elderly SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Groeneveld, P. W.] Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Yang, F.; Matta, M. A.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 48 EP 48 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700162 ER PT J AU Shlipak, MG Katz, R Fried, L Kestenbaum, B Stevens, L Newman, A Siscovick, DS Samak, MJ AF Shlipak, M. G. Katz, R. Fried, L. Kestenbaum, B. Stevens, L. Newman, A. Siscovick, D. S. Samak, M. J. TI Kidney function loss in black and white elderly persons - A comparison using creatinine and cystatin SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Shlipak, M. G.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA USA. [Katz, R.; Kestenbaum, B.; Siscovick, D. S.] Univ Washington, Seattle, WA USA. [Fried, L.] VA Pittsburg Healthcare Syst, Pittsburgh, PA USA. [Stevens, L.; Samak, M. J.] Tufts Univ New England Med Ctr, Boston, MA USA. [Newman, A.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 52 EP 53 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700178 ER PT J AU Singh, HS Bibbins-Domingo, K Sadia, A Whooley, MA AF Singh, H. S. Bibbins-Domingo, K. Sadia, A. Whooley, M. A. TI N-terminal pro-B-type natriuretic peptide and inducible ischemia in patients with coronary heart disease from the heart and soul study SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Singh, H. S.; Bibbins-Domingo, K.] Univ Calif San Francisco, San Francisco, CA USA. [Sadia, A.; Whooley, M. A.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 54 EP 54 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700183 ER PT J AU Seal, KH Bertenthal, D Chu, A Gima, KS Marmar, C AF Seal, K. H. Bertenthal, D. Chu, A. Gima, K. S. Marmar, C. TI Va post-deployment screening for mental health disorders among veterans returning from Iraq and Afghanistan - Are we doing a good job? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Seal, K. H.; Marmar, C.] Univ Calif San Francisco, San Francisco, CA USA. [Bertenthal, D.; Chu, A.; Gima, K. S.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 61 EP 61 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700208 ER PT J AU Keyhani, S Ross, J Hebert, P Dellenbaugh, C Penrod, J Siu, AL AF Keyhani, S. Ross, J. Hebert, P. Dellenbaugh, C. Penrod, J. Siu, A. L. TI Does the va provide veterans with better quality preventive care compared to medicare HMO plans? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Keyhani, S.; Ross, J.; Siu, A. L.] James J Peters VAMC, Mt Sinai Sch Med, New York, NY USA. [Hebert, P.] Mt Sinai Sch Med, New York, NY USA. [Dellenbaugh, C.] James J Peters VAMC, Bronx, NY USA. [Penrod, J.] James J Peters VAMC, Mt Sinai Sch Med, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 65 EP 66 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700222 ER PT J AU Volpp, K Rosen, A Rosenbaum, P Romano, PS Even-Shoshan, O Canamucio, A Bellini, LM Behringer, T Silber, JH AF Volpp, K. Rosen, A. Rosenbaum, P. Romano, P. S. Even-Shoshan, O. Canamucio, A. Bellini, L. M. Behringer, T. Silber, J. H. TI The impact of the ACGME duty hour rules on mortality rates in teaching hospitals SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Volpp, K.] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Rosen, A.] Boston Univ, Bedford VA, Boston, MA 02215 USA. [Rosenbaum, P.] Univ Penn Wharton Sch, Philadelphia, PA USA. [Romano, P. S.] Univ Calif Davis, Davis, CA 95616 USA. [Even-Shoshan, O.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Canamucio, A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Bellini, L. M.; Behringer, T.] Univ Penn, Philadelphia, PA 19104 USA. [Silber, J. H.] Childrens Hosp Philadelphia, Wharton Sch, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RI Romano, Patrick/N-4225-2014 OI Romano, Patrick/0000-0001-6749-3979 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 69 EP 69 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700233 ER PT J AU Barrett, TW Mori, M Koudelka, C AF Barrett, T. W. Mori, M. Koudelka, C. TI Perioperative beta-blockers, but not statins, are associated with decreased short term mortality after vascular surgery SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Barrett, T. W.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. [Mori, M.; Koudelka, C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 76 EP 76 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700255 ER PT J AU Massie, F Castiglioni, A Caldwell, JA Wood, A Estrada, CA AF Massie, F. Castiglioni, A. Caldwell, J. A. Wood, A. Estrada, C. A. TI Does performance of physical exam skills during medical school improve with clinical experience? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Massie, F.; Caldwell, J. A.; Wood, A.; Estrada, C. A.] Univ Alabama, Birmingham, AL USA. [Castiglioni, A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 82 EP 83 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700279 ER PT J AU Caverzagie, KJ Kogan, JR Shea, JA AF Caverzagie, K. J. Kogan, J. R. Shea, J. A. TI Have we moved beyond assessing medical knowledge? Resident identified learning goals after self-assessment SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Caverzagie, K. J.] Vet Affairs Med Ctr, Philadelphia, PA USA. [Kogan, J. R.] Univ Penn, Huntingdon, PA USA. [Shea, J. A.] Society Directors Res Med Educ, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 84 EP 84 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700284 ER PT J AU Salanitro, AH Castiglioni, A Willett, LL Shewchuk, RM Heudebert, GR Milne, C Watson, P Capps, L Caverzagie, KJ Centor, RM AF Salanitro, A. H. Castiglioni, A. Willett, L. L. Shewchuk, R. M. Heudebert, G. R. Milne, C. Watson, P. Capps, L. Caverzagie, K. J. Centor, R. M. TI Housestaff views on successful attending rounds. A multiinstitutional study SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Salanitro, A. H.; Willett, L. L.; Shewchuk, R. M.; Heudebert, G. R.; Centor, R. M.] Univ Alabama, Birmingham, AL USA. [Castiglioni, A.] Vet Affairs Med Ctr, Birmingham, AL USA. [Milne, C.] Univ Utah, Salt Lake City, UT 84112 USA. [Watson, P.] Henry Ford Hosp, Detroit, MI USA. [Capps, L.] Columbia Univ, New York, NY 10027 USA. [Caverzagie, K. J.] Vet Affairs Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 84 EP 84 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700285 ER PT J AU Gopal, RK Radhakrishnan, P Gateley, A Glasheen, JJ Prochazka, AV AF Gopal, R. K. Radhakrishnan, P. Gateley, A. Glasheen, J. J. Prochazka, A. V. TI Predictors of internal medicine internship burnout: Importance of cognitive factors SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Gopal, R. K.; Prochazka, A. V.] US Dept Vet Affairs, Denver, CO USA. [Radhakrishnan, P.] St Joseph Med Ctr, Phoenix, AZ USA. [Gateley, A.] Univ New Mexico, Albuquerque, NM USA. [Glasheen, J. J.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 89 EP 89 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700303 ER PT J AU Branch, WT Frankel, RM Gracey, C Haidel, PM Weissmann, P Cantey, P Mitchell, GA Inui, T AF Branch, W. T. Frankel, R. M. Gracey, C. Haidel, P. M. Weissmann, P. Cantey, P. Mitchell, G. A. Inui, T. TI The arthur vining davis foundations faculty development workshops for teaching the human dimensions of care: Longitudinal faculty development enhances the effectiveness of clinical teachers SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Branch, W. T.] Emory Hlthcare, Atlanta, GA USA. [Frankel, R. M.; Mitchell, G. A.; Inui, T.] Indiana Univ Purdue Univ, Indianapolis, IN USA. [Gracey, C.] Houston VA Med Ctr, Rochester, MN USA. [Haidel, P. M.] Houston VA Med Ctr, Houston, TX USA. [Weissmann, P.] Hennepin Cty Med Ctr, Minneapolis, MN USA. [Cantey, P.] Emory Univ, Sch Med, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 93 EP 93 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700315 ER PT J AU Paige, NM Liu, H Goldzweig, CL Wong, E Zhou, A Munjas, B Shekelle, P AF Paige, N. M. Liu, H. Goldzweig, C. L. Wong, E. Zhou, A. Munjas, B. Shekelle, P. TI A systematic review of screening tests for male osteoporosis SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Paige, N. M.; Goldzweig, C. L.; Munjas, B.] VA Greater Los Angels Healthcare Syst, Los Angeles, CA USA. [Liu, H.] Stanford Univ, Sch Med, Div Endocrinol & Metab, Stanford, CA 94305 USA. [Wong, E.] VA Greater Los Angeles Healthcare Syst, Div Endocrinol & Metab, Los Angeles, CA USA. [Zhou, A.] RAND Corp, Santa Monica, CA USA. [Shekelle, P.] RAND Corp, VA Greater Los Angeles Healthcare Syst, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 99 EP 99 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700334 ER PT J AU Huang, AJ Iwaoka-Scott, Y Kim, SE Wong, ST Perez-Stable, EJ Washington, E Sawaya, GF AF Huang, A. J. Iwaoka-Scott, Y. Kim, S. E. Wong, S. T. Perez-Stable, E. J. Washington, E. Sawaya, G. F. TI Preferences for HPV testing among ethnically-diverse older women SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Huang, A. J.] San Francisco VA Med Ctr, San Francisco, CA USA. [Iwaoka-Scott, Y.; Kim, S. E.; Perez-Stable, E. J.; Washington, E.; Sawaya, G. F.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Wong, S. T.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 107 EP 108 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700365 ER PT J AU Walter, L Lindquist, K Schull, T Nugent, S Casadei, M Partin, M AF Walter, L. Lindquist, K. Schull, T. Nugent, S. Casadei, M. Partin, M. TI Relationship of health status and colorectal cancer screening among elderly veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Walter, L.; Casadei, M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Lindquist, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Schull, T.; Nugent, S.; Partin, M.] Minneapolis VA Med Ctr, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 109 EP 109 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700370 ER PT J AU Williams, EC Achtmeyer, CE Frey, MS Volpp, B Kivlahan, DR Bradley, KA AF Williams, E. C. Achtmeyer, C. E. Frey, M. S. Volpp, B. Kivlahan, D. R. Bradley, K. A. TI Sustained improvements in documented brief alcohol counseling 2 years after implementation of an electronic clinical reminder SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Williams, E. C.; Kivlahan, D. R.; Bradley, K. A.] Univ Washington, Seattle, WA 98195 USA. [Achtmeyer, C. E.] VA Puget Sound, Seattle, WA USA. [Frey, M. S.] VA Puget Sound, Hlth Serv Res & Dev, Seattle, WA USA. [Frey, M. S.] VA No Calif Healthcare Syst, Martinez, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 110 EP 110 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700373 ER PT J AU Haidet, P Hatem, DS Stein, H Fecile, ML Haley, HA Kimmel, B Mossbarger, DL Inui, TS AF Haidet, P. Hatem, D. S. Stein, H. Fecile, M. L. Haley, H. A. Kimmel, B. Mossbarger, D. L. Inui, T. S. TI The role of relationships in the professional formation of physicians SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Haidet, P.; Kimmel, B.] Houston VAMC, Houston, TX USA. [Hatem, D. S.; Haley, H. A.] Univ Massachusetts, Med Ctr, Worcester, MA USA. [Stein, H.] Univ Oklahoma, Oklahoma City, OK USA. [Fecile, M. L.] Univ Texas Med Branch Galveston, Galveston, TX USA. [Mossbarger, D. L.; Inui, T. S.] Regenstrief Inst Inc, Indianapolis, IN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 116 EP 116 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700394 ER PT J AU Rodriguez, KL Appelt, CJ Switzer, GE Sonel, AF Arnold, RM AF Rodriguez, K. L. Appelt, C. J. Switzer, G. E. Sonel, A. F. Arnold, R. M. TI "They diagnosed bad heart": A qualitative exploration of patients' knowledge about and experiences with heart failure SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Rodriguez, K. L.; Appelt, C. J.; Sonel, A. F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Switzer, G. E.; Arnold, R. M.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 116 EP 117 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700396 ER PT J AU Singh, H Arora, H Vij, M Rao, R Khan, M Petersen, LA AF Singh, H. Arora, H. Vij, M. Rao, R. Khan, M. Petersen, L. A. TI Communication outcomes of critical imaging results in a computerized notification system SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Singh, H.; Petersen, L. A.] Baylor Coll Med, Houston Ctr Quality Care & Utilizat Studies, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Arora, H.; Rao, R.; Khan, M.] Baylor Coll Med, Houston, TX USA. [Vij, M.] Michaele E DeBakey Vet Affairs Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 122 EP 122 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700416 ER PT J AU Aujesky, D Stone, RA Crick, E Fine, MJ AF Aujesky, D. Stone, R. A. Crick, E. Fine, M. J. TI Length of hospital stayand post-discharge mortality in patients with pulmonary embolism: A state-wide perspective SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Aujesky, D.] Univ Lausanne, CH-1015 Lausanne, Switzerland. [Stone, R. A.; Crick, E.; Fine, M. J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 129 EP 130 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700444 ER PT J AU Singh, H Thomas, EJ Petersen, LA Studdert, D AF Singh, H. Thomas, E. J. Petersen, L. A. Studdert, D. TI Medical errors involving housestaff: A study of closed malpractice claims from 5 insurers SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Singh, H.; Petersen, L. A.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Thomas, E. J.] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA. [Studdert, D.] Harvard Sch Publ Hlth, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 131 EP 131 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700449 ER PT J AU Leykum, L Padgett, C Gustke, D Baruch-Bienen, D Patterson, J AF Leykum, L. Padgett, C. Gustke, D. Baruch-Bienen, D. Patterson, J. TI The association between nurse staffing levels and inpatient falls SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Leykum, L.; Padgett, C.; Gustke, D.; Baruch-Bienen, D.] So Texas Vet Hlth Care Syst, San Antonio, TX USA. [Patterson, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 137 EP 137 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700472 ER PT J AU Metlay, J Hennessy, S Localio, R Leonard, C Haynes, K Cohen, A Kimmel, S Feldman, H Strom, B AF Metlay, J. Hennessy, S. Localio, R. Leonard, C. Haynes, K. Cohen, A. Kimmel, S. Feldman, H. Strom, B. TI The importance of patient medication education and coordination in preventing serious events for older adults on warfarin SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Metlay, J.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Hennessy, S.; Localio, R.; Leonard, C.; Haynes, K.; Cohen, A.; Kimmel, S.; Feldman, H.; Strom, B.] Univ Penn, Philadelphia, PA 19104 USA. RI Cohen, Abigail/K-9180-2013 OI Cohen, Abigail/0000-0002-7425-7218 NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 138 EP 138 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700478 ER PT J AU Woodard, L Urech, T Kuebeler, M Pietz, K Capistrano, L Petersen, LA AF Woodard, L. Urech, T. Kuebeler, M. Pietz, K. Capistrano, L. Petersen, L. A. TI The impact of comorbid medical conditions on the quality of diabetes care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Woodard, L.] Baylor Coll Med, Houston, TX 77030 USA. [Urech, T.; Kuebeler, M.; Pietz, K.; Capistrano, L.; Petersen, L. A.] HSR&D Ctr Excellence, Michael E DeBakey Vet Affair Med Ctr, Houston, TX USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 138 EP 138 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700477 ER PT J AU Rose, AJ Berlowitz, DR Orner, MB Kressin, NR AF Rose, A. J. Berlowitz, D. R. Orner, M. B. Kressin, N. R. TI Understanding uncontrolled hypertension: Is it the patient or the provider? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Rose, A. J.; Berlowitz, D. R.; Orner, M. B.; Kressin, N. R.] US Dept Vet Affairs, Bedford, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 140 EP 140 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700485 ER PT J AU Conigliaro, J Maisto, SA Gordon, A Mcginnis, KA Justice, AC AF Conigliaro, J. Maisto, S. A. Gordon, A. Mcginnis, K. A. Justice, A. C. TI A comparison of the self-administered 30 day TLFB method compared to the phone interview method among clinical samples of HIV plus and HIV-patients SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Conigliaro, J.] Univ Kentucky, Lexington, KY USA. [Maisto, S. A.] Syracuse Univ, Dept Psychol, Syracuse, NY USA. [Gordon, A.] VA Pittsburgh Healtcare Syst, Pittsburgh, PA USA. [Mcginnis, K. A.] Univ Pittsburgh, Pittsburgh, PA USA. [Justice, A. C.] Yale Univ, West Haven, CT USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 143 EP 143 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700495 ER PT J AU Kressin, NR Orner, MB Manze, M Glickman, M Davidson, PK Borzecki, A Berlowitz, DR AF Kressin, N. R. Orner, M. B. Manze, M. Glickman, M. Davidson, P. K. Borzecki, A. Berlowitz, D. R. TI African Americans and beliefs about hypertension, its therapy, and etiology: More worries, fewer benefits, less control SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Kressin, N. R.] Ctr Hlth Qual, Outcomes & Econ Res, VA HSR&D Ctr Excellence, Bedford, MA USA. [Orner, M. B.] US Dept Vet Affairs, Bedford, MA USA. [Manze, M.] Med Ctr, Boston, MA USA. [Glickman, M.; Davidson, P. K.; Borzecki, A.] Boston Univ, Boston, MA 02215 USA. [Berlowitz, D. R.] Boston Univ, Bedford, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 143 EP 143 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700496 ER PT J AU Dookeran, NM Burgess, J Bowman, C Chen, Y Asch, S Gifford, A AF Dookeran, N. M. Burgess, J. Bowman, C. Chen, Y. Asch, S. Gifford, A. TI HIV testing in adults with alcohol and other substance use disorders. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Dookeran, N. M.; Burgess, J.; Gifford, A.] Boston Univ, Vet Affairs Bedford, Bedford, MA USA. [Bowman, C.; Chen, Y.] VA San Diego, San Diego, CA USA. [Asch, S.] VA Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 150 EP 150 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700519 ER PT J AU Frank, D Gallagher, TH Cooper, LA Odunlami, B Sellers, S Price, EG Phillips, E Bonham, VL AF Frank, D. Gallagher, T. H. Cooper, L. A. Odunlami, B. Sellers, S. Price, E. G. Phillips, E. Bonham, V. L. TI Physicians' attitudes regarding race-based therapeutics SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Frank, D.] VA Puget Sound, Seattle, WA USA. [Gallagher, T. H.] Univ Washington, Seattle, WA 98195 USA. [Cooper, L. A.] Johns Hopkins Univ, Baltimore, MD 21218 USA. [Odunlami, B.; Phillips, E.; Bonham, V. L.] Natl Inst Hlth, Bethesda, MD USA. [Sellers, S.] Univ Wisconsin, Madison, WI 53706 USA. [Price, E. G.] Tulane Univ, New Orleans, LA 70118 USA. RI Price-Haywood, Eboni/L-5527-2014 OI Price-Haywood, Eboni/0000-0003-2901-3852 NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 155 EP 156 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700540 ER PT J AU Groeneveld, PW Kwoh, C Mor, MK Geng, M Appelt, CJ Gutierrez, JC Ibrahim, SA AF Groeneveld, P. W. Kwoh, C. Mor, M. K. Geng, M. Appelt, C. J. Gutierrez, J. C. Ibrahim, S. A. TI Racial differences in joint replacement expectations among veterans with osteoarthritis SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Groeneveld, P. W.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Kwoh, C.] Univ Pittsburgh, Pittsburgh VA Hlth Care Syst, Philadelphia, PA 19104 USA. [Mor, M. K.] Univ Pittsburgh, Sch Med, Pittsburgh VA Hlth Care Syst, Philadelphia, PA 19104 USA. [Geng, M.; Appelt, C. J.; Ibrahim, S. A.] Pittsburgh VA Hlth Care Syst, Pittsburgh, PA USA. [Gutierrez, J. C.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 158 EP 158 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700548 ER PT J AU Binswanger, I Takahashi, T Dellit, TH Bradley, K Benton, KL Merrill, JO AF Binswanger, I. Takahashi, T. Dellit, T. H. Bradley, K. Benton, K. L. Merrill, J. O. TI Risk of hospitalizations and death among injection drug users seeking care for soft tissue infections SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Binswanger, I.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. [Takahashi, T.; Bradley, K.] Univ Washington, VA Puget Sound, Seattle, WA 98195 USA. [Dellit, T. H.; Merrill, J. O.] Univ Washington, Seattle, WA 98195 USA. [Benton, K. L.] Univ Colorado, Hlth Sci Ctr, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 159 EP 159 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700552 ER PT J AU Pollack, C Chideya, S Cubbin, C Williams, B Dekker, M Braveman, P AF Pollack, C. Chideya, S. Cubbin, C. Williams, B. Dekker, M. Braveman, P. TI Should health studies measure wealth? A systematic review SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Pollack, C.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Chideya, S.] CDC, Ctr Dis Control & Prevent, Atlanta, GA USA. [Cubbin, C.; Williams, B.; Dekker, M.; Braveman, P.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Cubbin, C.] Univ Texas Austin, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 160 EP 160 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700554 ER PT J AU Bean-Mayberry, B Yano, E Wang, M Mor, MK Fine, MJ AF Bean-Mayberry, B. Yano, E. Wang, M. Mor, M. K. Fine, M. J. TI Do gender and race affect quality of care in the VA healthcare system? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Bean-Mayberry, B.; Yano, E.; Wang, M.] VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA. [Mor, M. K.; Fine, M. J.] Univ Pittsburgh, VA Pittsburgh Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 165 EP 166 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700574 ER PT J AU Huang, AJ Grady, DG Blackwell, TL Bauer, DC Sawaya, GF AF Huang, A. J. Grady, D. G. Blackwell, T. L. Bauer, D. C. Sawaya, G. F. TI Persistent hot flashes in older postmenopausal women SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Huang, A. J.] San Francisco VA Med Ctr, San Francisco, CA USA. [Grady, D. G.; Bauer, D. C.; Sawaya, G. F.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Blackwell, T. L.] California Pacific Med Ctr, San Francisco, CA 94143 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 168 EP 168 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700583 ER PT J AU Rehman, SU Hutchison, FN AF Rehman, S. U. Hutchison, F. N. TI The effectiveness of multidisciplinary primary care morning report SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Rehman, S. U.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Mt Pleasant, MI USA. [Hutchison, F. N.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 188 EP 188 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700650 ER PT J AU Kressin, NR Orner, MB Berlowitz, DR AF Kressin, N. R. Orner, M. B. Berlowitz, D. R. TI Strategies for improving provider-patient communication about medication adherence: Can behavior change be effected? Does it affect patient outcomes? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Kressin, N. R.] VA HSR&D Ctr Excellence, Outcomes & Econ Res, Ctr Hlth Qaulity, Bedford, MA USA. [Orner, M. B.] US Dept Vet Affairs, Bedford, MA USA. [Berlowitz, D. R.] Boston Univ, Bedford, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 202 EP 202 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700696 ER PT J AU Lu, LC Davis, LG AF Lu, L. C. Davis, L. G. TI Asymptomatic disseminated Coccidioidomycosis presenting with elevated prostatic serum antigen SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Lu, L. C.; Davis, L. G.] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 239 EP 239 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700833 ER PT J AU Chen, T Haidet, PM AF Chen, T. Haidet, P. M. TI A very deadly rash SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med C1 [Chen, T.] Baylor Coll Med, Houston, TX USA. [Haidet, P. M.] Houston VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 SU 1 BP 250 EP 250 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 240TQ UT WOS:000251610700872 ER PT J AU Nelson, KM McFarland, L Reiber, G AF Nelson, Karin M. McFarland, Lynne Reiber, Gayle TI Factors influencing disease self-management among veterans with diabetes and poor glycemic control SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT Annual Meeting of the VA-Health-Services-Research-and-Development CY FEB 21-23, 2007 CL Washington, DC DE diabetes; diabetes self-management; veterans ID PHYSICAL-ACTIVITY SCALE; AFFAIRS HEALTH-CARE; QUALITY-OF-LIFE; BEHAVIORAL-APPROACH; EXERCISE BEHAVIOR; CONTROLLED TRIAL; GLUCOSE CONTROL; ELDERLY PASE; OLDER-ADULTS; ADHERENCE AB SPECIFIC AIM: Although the Department of Veterans Affairs (VA) has made significant organizational changes to improve diabetes care, diabetes self-management has received limited attention. The purpose of this study is to assess factors influencing diabetes self-management among veterans with poorly controlled diabetes. METHODS: Surveys were mailed to patients with type 2 diabetes and a HbA1c of 8% or greater who attended 1 of 2 VA Medical Centers in Washington State (n=1,286). Validated survey instruments assessed readiness to change, self-efficacy, provider advice, and diabetes self-care practices. RESULTS: Our response rate was 56% (n=717). Most respondents reported appropriate advice from physicians regarding physical activity, nutrition, and glucose monitoring (73%, 92%, and 98%, respectively), but many were not ready to change self-management behaviors. Forty-five percent reported non-adherence to medications, 42% ate a high-fat diet, and only 28% obtained either moderate or vigorous physical activity. The mean self-efficacy score for diabetes self-care was low and half of the sample reported readiness to change nutrition (52%) or physical activity (51%). Individuals with higher self-efficacy scores were more likely to adhere to medications, follow a diabetic meal plan, eat a lower fat diet, have higher levels of physical activity, and monitor their blood sugars (P <.001 for all). CONCLUSIONS: Although veterans with poor diabetes control receive appropriate medical advice, many were not sufficiently confident or motivated to make and maintain self-management changes. Targeted patient-centered interventions may need to emphasize increasing self-efficacy and readiness to change to further improve VA diabetes outcomes. C1 VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Nelson, KM (reprint author), 1660 S Columbian Way,S-111 GIMC, Seattle, WA 98108 USA. EM Karin.Nelson@va.gov NR 50 TC 39 Z9 40 U1 1 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 IS 4 BP 442 EP 447 DI 10.1007/s11606-006-0053-8 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 148WJ UT WOS:000245107800003 PM 17372790 ER PT J AU Ruelaz, AR Diefenbach, P Simon, B Lanto, A Arterburn, D Shekelle, PG AF Ruelaz, Alicia R. Diefenbach, Pamela Simon, Barbara Lanto, Andy Arterburn, David Shekelle, Paul G. TI Perceived barriers to weight management in primary care - Perspectives of patients and providers SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE weight management; primary care; attitudes; beliefs; barriers ID OBESITY; PREVALENCE; OVERWEIGHT; WOMEN AB BACKGROUND: Despite the consequences of overweight and obesity, effective weight management is not occurring in primary care. OBJECTIVE: To identify beliefs about obesity that act as barriers to weight management in primary care by surveying both patients and providers and comparing their responses. DESIGN: Anonymous, cross-sectional, self-administered survey of patients and providers of a Veteran's Administration Primary Care Clinic, distributed at the clinic site. SUBJECTS: Forty-eight Internal Medicine providers and 488 patients. MEASUREMENTS: Beliefs, attitudes, and experiences with weight management as well as demographic characteristics were collected through a questionnaire. RESULTS: Providers and patients differed significantly on many beliefs about weight. Providers were more likely than patients to perceive that patients lack self-control to stay on a diet and that fattening food in society and lack of time for exercise were prime factors in weight gain. They also expressed more interest in helping patients with weight management than patients desiring this. Patients were more likely to state that weight problems should be managed on one's own, talking to a provider is not helpful, providers blame them for their weight problem, and that appointments contain sufficient time for weight discussion. CONCLUSION: Providers and patients emphasize different barriers to weight management. Providers need to be aware of the beliefs that their patients hold to improve weight management discussions and interventions in primary care. C1 Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. VA Hlth Serv Res & Dev Ctr Excellence Study Provi, Los Angeles, CA USA. Grp Hlth Ctr Hlth Studies, Seattle, WA USA. RP Ruelaz, AR (reprint author), Cedars Sinai Med Ctr, MD-8700 Beverly Blvd,8th Floor,Room 8631, Los Angeles, CA 90048 USA. EM ruelaza@cshs.org NR 13 TC 55 Z9 55 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2007 VL 22 IS 4 BP 518 EP 522 DI 10.1007/s11606-007-0125-4 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 148WJ UT WOS:000245107800016 PM 17372803 ER PT J AU Lathers, DMR Kearney, PL Gibbs, K Young, MR AF Lathers, Deanne M. R. Kearney, Patricia L. Gibbs, Kiki Young, M. Rita TI Tumor modulation of T-helper cytokine secretion SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Lathers, Deanne M. R.; Kearney, Patricia L.; Gibbs, Kiki] Ralph H Johnson VAMC, Otolaryngol, Charleston, SC 29401 USA. [Young, M. Rita] Ralph H Johnson VAMC, Med & Otolaryngol, Charleston, SC 29401 USA. [Young, M. Rita] Med Univ South Carolina, Charleston, SC 29401 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2007 VL 178 SU 1 MA 49.6 PG 1 WC Immunology SC Immunology GA V44OL UT WOS:000209758203264 ER PT J AU Link, JM Meza-Romero, R Afentoulis, M Agotsch, M LaTocha, D Burrows, G Vandenbark, AA AF Link, Jason M. Meza-Romero, Roberto Afentoulis, Michael Agotsch, Marisa LaTocha, Dorian Burrows, Gregory Vandenbark, Arthur A. TI Partial MHC Class II molecules preferentially bind to B cells SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Link, Jason M.; Afentoulis, Michael; LaTocha, Dorian; Vandenbark, Arthur A.] Portland VA Med Ctr, Portland, OR 97239 USA. [Meza-Romero, Roberto; Agotsch, Marisa; Burrows, Gregory; Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Neurol, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2007 VL 178 SU 1 MA 93.22 PG 1 WC Immunology SC Immunology GA V44OL UT WOS:000209758202050 ER PT J AU Mailloux, AW Lathers, DMR Young, MRI AF Mailloux, Adam William Lathers, Deanne M. R. Young, M. Rita I. TI Lewis Lung Carcinoma-derived CCL22 recruitment of T regulatory cells SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Mailloux, Adam William] Med Univ South Carolina, Microbiol & Immunol, Charleston, SC 29407 USA. [Lathers, Deanne M. R.] Med Univ South Carolina, Dept Otolaryngol, Charleston, SC 29403 USA. [Lathers, Deanne M. R.; Young, M. Rita I.] Ralph H Johnson VAMC, Res Serv, Charleston, SC 29403 USA. [Young, M. Rita I.] Med Univ South Carolina, Med, Charleston, SC 29403 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2007 VL 178 SU 1 MA B148 PG 2 WC Immunology SC Immunology GA V44OL UT WOS:000209758200131 ER PT J AU Mulligan, JK Lathers, DMR Young, RI AF Mulligan, Jennifer Konopa Lathers, Deanne M. R. Young, Rita I. TI TUMOR-SECRETED VEGF-A DISRUPTS ENDOTHELIAL CELL STIMULATION OF T-CELL, MACROPHAGE AND NK CELL FUNCTIONS SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Mulligan, Jennifer Konopa] Med Univ South Carolina, Med, Charleston, SC 29485 USA. [Lathers, Deanne M. R.; Young, Rita I.] Ralph Johnson VA Med Ctr, Res Serv, Charleston, SC 29485 USA. [Lathers, Deanne M. R.] MUSC, Otolaryngol, Charleston, SC 29485 USA. [Young, Rita I.] MUSC, Hematol Oncol, Charleston, SC 29485 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2007 VL 178 SU 1 MA 49.5 PG 1 WC Immunology SC Immunology GA V44OL UT WOS:000209758203242 ER PT J AU Myers, RC You, YY Wang, Y Carter, RH AF Myers, Riley C. You, Yuying Wang, Yue Carter, Robert H. TI Diminished FDC activation within germinal centers of CD19-deficient mice SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Myers, Riley C.; You, Yuying] Univ Alabama Birmingham, Microbiol, Birmingham, AL 35294 USA. [Carter, Robert H.] Univ Alabama Birmingham, Med & Microbiol, Birmingham, AL 35294 USA. [Wang, Yue] Medlmmune, Gaithersburg, MD 20878 USA. [Carter, Robert H.] Birmingham VAMC, Birmingham, AL 35223 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2007 VL 178 SU 1 MA 92.8 PG 2 WC Immunology SC Immunology GA V44OL UT WOS:000209758200154 ER PT J AU Walsh, JE Young, MRI AF Walsh, Jarrett Elbert Young, M. Rita I. TI TGF-beta Induces Microvascular Endothelial Cell Migration and PP-2A Inactivation SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Walsh, Jarrett Elbert] Med Univ South Carolina, Microbiol & Immunol, Charleston, SC 29425 USA. [Young, M. Rita I.] Med Univ South Carolina, Otolaryngol & Med, Charleston, SC 29425 USA. [Young, M. Rita I.] Ralph H Johnson VAMC, Res Serv, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2007 VL 178 SU 1 MA B65 PG 2 WC Immunology SC Immunology GA V44OL UT WOS:000209758200167 ER PT J AU Wang, JH Hsu, HC Yang, P Wu, Q Job, G Chen, J Timares, L Mountz, JD AF Wang, John Hsien Hsu, Hui-Chen Yang, PingAr Wu, Qi Job, Godwin Chen, Jian Timares, Laura Mountz, John D. TI INCREASED EXPRESSION OF IFN-ALPHA AND IL-6 BY HYPERACTIVE PLASMACYTOID DENDRITIC CELLS IN BXD2 AUTOIMMUNE MICE SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Hoover, AL 35226 USA. Birmingham VA Med Ctr, Hoover, AL 35226 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2007 VL 178 SU 1 MA 130.25 PG 2 WC Immunology SC Immunology GA V44OL UT WOS:000209758200052 ER PT J AU Asgari, M Bertenthal, D Sen, S Sahay, A Chren, M AF Asgari, M. Bertenthal, D. Sen, S. Sahay, A. Chren, M. TI Patient satisfaction with treatments of nonmelanoma skin cancer SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 68th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 09-12, 2007 CL Los Angeles, CA SP Soc Investigat Dermatol C1 Kaiser Permanente No CA, Oakland, CA USA. San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RI Asgari, Maryam/O-4947-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2007 VL 127 SU 1 MA 378 BP S63 EP S63 PG 1 WC Dermatology SC Dermatology GA 152UP UT WOS:000245387800375 ER PT J AU Friedman, AJ Phan, J Tang, D Oren, A Modlin, R Kim, J AF Friedman, A. J. Phan, J. Tang, D. Oren, A. Modlin, R. Kim, J. TI Chitosan nanoparticles: Agent for topical treatment of cutaneous inflammatory and infectious diseases SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 68th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 09-12, 2007 CL Los Angeles, CA SP Soc Investigat Dermatol C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Dermatol, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. W Los Angeles Vet Adm, Ctr Med, Los Angeles, CA USA. New York Hosp Queens, Queens, NY USA. RI Liu, Philip/C-9638-2011 NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2007 VL 127 SU 1 MA 776 BP S130 EP S130 PG 1 WC Dermatology SC Dermatology GA 152UP UT WOS:000245387800773 ER PT J AU Hu, J Chiu, MW Cotliar, J Kim, J Peng, D AF Hu, J. Chiu, M. W. Cotliar, J. Kim, J. Peng, D. TI The effectiveness of teledermatology in pigmented skin SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 68th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 09-12, 2007 CL Los Angeles, CA SP Soc Investigat Dermatol C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA USA. Univ So Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Ctr, Div Dermatol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2007 VL 127 SU 1 MA 366 BP S61 EP S61 PG 1 WC Dermatology SC Dermatology GA 152UP UT WOS:000245387800363 ER PT J AU Katiyar, SK Katiyar, S Elmets, CA Meeren, SM AF Katiyar, S. K. Katiyar, S. Elmets, C. A. Meeren, S. M. TI Interleukin-12-deficiency promotes angiogenesis in UV-induced skin tumors SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 68th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 09-12, 2007 CL Los Angeles, CA SP Soc Investigat Dermatol C1 Univ Alabama, Birmingham, AL USA. Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2007 VL 127 SU 1 MA 9 BP S2 EP S2 PG 1 WC Dermatology SC Dermatology GA 152UP UT WOS:000245387800009 ER PT J AU Li, W Li, Y Guan, S Fan, J Cheng, C Bright, A Chin, C Chen, M Woodley, D AF Li, W. Li, Y. Guan, S. Fan, J. Cheng, C. Bright, A. Chin, C. Chen, M. Woodley, D. TI Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 68th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 09-12, 2007 CL Los Angeles, CA SP Soc Investigat Dermatol C1 Univ So Calif, Los Angeles, CA USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2007 VL 127 SU 1 MA 213 BP S36 EP S36 PG 1 WC Dermatology SC Dermatology GA 152UP UT WOS:000245387800211 ER PT J AU Liao, JC Mastali, M Li, Y Gau, V Suchard, MA Babbitt, J Gornbein, J Landaw, EM McCabe, ERB Churchill, BM Haake, DA AF Liao, Joseph C. Mastali, Mitra Li, Yang Gau, Vincent Suchard, Marc A. Babbitt, Jane Gornbein, Jeffrey Landaw, Elliot M. McCabe, Edward R. B. Churchill, Bernard M. Haake, David A. TI Development of an advanced electrochemical DNA biosensor for bacterial pathogen detection SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Article ID URINARY-TRACT-INFECTIONS; 16S RIBOSOMAL-RNA; UROLOGIC DISEASES; ESCHERICHIA-COLI; AMERICA PROJECT; NUCLEIC-ACIDS; RESOURCE USE; ELECTRODE; SENSORS; TRENDS AB Electrochemical sensors have the capacity for rapid and accurate detection of a wide variety of target molecules in biological fluids. We have developed an electrochemical sensor assay involving hybridization of bacterial 16S rRNA to fluorescein-modified detector probes and to biotin-modified capture probes anchored to the sensor surface. Signal is generated by an oxidation-reduction current produced by the action of horseradish peroxidase conjugated to an anti-fluorescein monoclonal Fab. A previous study found that this electrochemical sensor strategy could identify uropathogens in clinical urine specimens. To improve assay sensitivity, we examined the key steps that affect the current amplitude of the electrochemical signal. Efficient lysis and release of 16S rRNA from both gram-negative and -positive bacteria was achieved with an initial treatment with Triton X-100 and lysozyme followed by alkaline lysis, resulting in a 12-fold increase in electrochemical signal compared with alkaline lysis alone. The distance in nucleotides between the target hybridization sites of the detector and capture probes and the location of fluorescein modification on the detector probe contributed to a 23-fold change in signal intensity. These results demonstrate the importance of target-probe and probe-probe interactions in the detection of bacterial 16S rRNA using an electrochemical DNA sensor approach. C1 VA Greater LA Healthcare, Div Infect Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90024 USA. GeneFluidics Inc, Monterey, CA USA. RP Haake, DA (reprint author), VA Greater LA Healthcare, Div Infect Dis, 111F, Los Angeles, CA 90073 USA. EM dhaake@ucla.edu RI Liao, Joseph/J-5874-2015 FU NIBIB NIH HHS [R01 EB000127] NR 24 TC 70 Z9 71 U1 2 U2 21 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA SN 1525-1578 J9 J MOL DIAGN JI J. Mol. Diagn. PD APR PY 2007 VL 9 IS 2 BP 158 EP 168 DI 10.2353/jmoldx.2007.060052 PG 11 WC Pathology SC Pathology GA 153JB UT WOS:000245427600005 PM 17384207 ER PT J AU Niv, N Lopez, SR Glynn, SM Mueser, K AF Niv, Noosha Lopez, Steven R. Glynn, Shirley M. Mueser, Kim TI The role of substance use in families' attributions and affective reactions to their relative with severe mental illness SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE dual diagnosis; drug abuse; schizophrenia; bipolar disorder; caregivers ID EXPRESSED EMOTION; SYMPTOM DIMENSIONS; SCHIZOPHRENIA; ALCOHOLISM; ABUSE; ADDICTION; DISORDER; MEXICAN; RELAPSE AB This study compared relatives' attributions and affective reactions toward patients with severe mental illness (SMI) only (N = 32) and patients with dual SMI and a substance use disorder (N = 36). Family members of patients with dual disorders perceived their ill relatives to have greater control over the causes of their psychiatric symptoms and to be more responsible for their symptoms than did family members of patients with SMI only. Key relatives of dual-diagnosed patients also reported more negative affect toward the patient than did key relatives of patients with SMI only, but the two groups did not differ in their level of positive affect. Consistent with attribution theory, severity of patients' substance abuse was positively associated with relatives' attributions of controllability, which, in turn, were positively associated with judgments of responsibility. Furthermore, judgments of responsibility were positively related to negative affect and inversely related to positive affect. C1 Calif State Univ Los Angeles, Integrated Subst Abuse Program, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90025 USA. Calif State Univ Los Angeles, Dept Psychol, Los Angeles, CA 90025 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Dartmouth Coll Sch Med, Concord, NH USA. RP Niv, N (reprint author), Calif State Univ Los Angeles, Integrated Subst Abuse Program, Dept Psychiat & Biobehav Sci, 1640 S Sepulveda Blvd,Suite 200, Los Angeles, CA 90025 USA. EM noosha23@yahoo.com FU NIMH NIH HHS [MH62629, MH14584] NR 43 TC 6 Z9 7 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD APR PY 2007 VL 195 IS 4 BP 307 EP 314 DI 10.1097/01.nmd.0000243793.64279.48 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 158KM UT WOS:000245790400005 PM 17435480 ER PT J AU Pannu, R Christie, DK Barbosa, E Singh, I Singh, AK AF Pannu, Ravinder Christie, Douglas K. Barbosa, Ernest Singh, Inderjit Singh, Avtar K. TI Post-trauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE endothelium; gliosis; MMP9; RhoA; spinal cord injury; statins ID NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; BLOOD-BRAIN-BARRIER; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; AMYLOID PRECURSOR PROTEIN; COA REDUCTASE INHIBITORS; RAT PRIMARY ASTROCYTES; GROWTH CONE COLLAPSE; FUNCTIONAL RECOVERY; MULTIPLE-SCLEROSIS AB We have previously reported neuroprotection in spinal cord injury (SCI) by Lipitor [atorvastatin (AT)]-pre-treatment. Though informative, pre-treatment studies find only limited clinical application as trauma occurrence is unpredictable. Therefore, this study investigates the efficacy of AT treatment post-SCI. In a rat model of contusion-SCI resulting in complete hindlimb paralysis, AT treatment (5 mg/kg; gavage) was begun 2, 4, or 6 h post-SCI followed by a once daily dose thereafter for 6 weeks. While the placebo vehicle (VHC)-SCI rats showed substantial functional deficit, AT-SCI animals exhibited significant functional recovery. AT diminished injury-induced blood-spinal cord barrier (BSCB) dysfunction with significantly reduced infiltration and tumor necrosis factor-alpha/interleukin-1 beta/inducible nitric oxide synthase expression at site of injury. BSCB protection in AT-SCI was attributable to attenuated matrix metalloproteinase-9 (MMP9) expression - a central player in BSCB disruption. Furthermore, endothelial MMP9 expression was found to be RhoA/ROCK pathway-mediated and regulated by AT through an isoprenoid-dependent mechanism. Attenuation of these early inflammatory events reduced secondary damage. Significant reduction in axonal degeneration, myelin degradation, gliosis, and neuronal apoptosis with resultant enhancement in tissue sparing was observed in AT-SCI compared with VHC-SCI. In summary, this novel report presenting the efficacy of post-injury AT treatment might be of critical therapeutic value as effective treatments are currently unavailable for SCI. C1 Med Univ S Carolina, Charles Darby Childrens Res Inst, Dept Pediat, Ctr Dev Neurol Disorders, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA. RP Singh, AK (reprint author), Med Univ S Carolina, Charles Darby Childrens Res Inst, Dept Pediat, Ctr Dev Neurol Disorders, Room 509,173 Ashley Ave, Charleston, SC 29425 USA. EM singhi@musc.edu FU NCRR NIH HHS [C06RR018823]; NINDS NIH HHS [NS-22576, NS-34741, NS-37766, NS-40810] NR 77 TC 51 Z9 57 U1 0 U2 6 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD APR PY 2007 VL 101 IS 1 BP 182 EP 200 DI 10.1111/j.1471-4159.2006.04354.x PG 19 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 145SU UT WOS:000244885600017 PM 17217414 ER PT J AU Price, DA Owens, WA Gould, GG Frazer, A Roberts, JL Daws, LC Giuffrida, A AF Price, David A. Owens, William A. Gould, Georgianna G. Frazer, Alan Roberts, James L. Daws, Lynette C. Giuffrida, Andrea TI CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE anandamide; basal ganglia; cannabinoid; chronoamperometry; dopamine transporter; striatum ID NIGRA PARS RETICULATA; NUCLEUS-ACCUMBENS; SUBSTANTIA-NIGRA; GABAERGIC NEUROTRANSMISSION; ENDOGENOUS CANNABINOIDS; NEURONAL SUBPOPULATIONS; GLOBUS-PALLIDUS; AWAKE RATS; RECEPTOR; RELEASE AB Cannabinoid drugs are known to affect dopaminergic neurotransmission in the basal ganglia circuitry. In this study, we used in vitro and in vivo techniques to investigate whether cannabinoid agonists and antagonist could affect dopaminergic transmission in the striatum by acting at the dopamine transporter. Incubation of striatal synaptosomes with the cannabinoid agonists WIN55,212-2 or methanandamide decreased dopamine uptake (IC50 = 2.0 mu mol/L and 3.1 mu mol/L, respectively). A similar inhibitory effect was observed after application of the inactive WIN55,212-2 isomer, S(-)WIN55,212-3. The CB1 antagonist AM251 did not reverse WIN55,212-2 effect but rather mimicked it. WIN55,212-2 and AM251 partially displaced the binding of the cocaine analog [H-3]WIN35,428, thus acting as dopamine transporter pseudo-substrates in the high micromolar range. High-speed chronoamperometry measurements showed that WIN55,212-2 (4 mg/kg, i.p.) caused significant release of endogenous dopamine via activation of CB1 receptors, followed by a reduction of dopamine clearance. This reduction was CB1-independent, as it was mimicked by S(-)WIN55,212-3. Administration of AM251 (1 and 4 mg/kg, i.p.) increased the signal amplitude and reduced the clearance of dopamine pressure ejected into the striatum. These results indicate that both cannabinoid agonists and antagonists inhibit dopamine transporter activity via molecular targets other than CB1 receptors. C1 Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA. Audie L Murphy Vet Affairs Med Ctr, San Antonio, TX USA. RP Giuffrida, A (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr,MC 6205, San Antonio, TX 78229 USA. EM giuffrida@uthscsa.edu OI Gould, Georgianna/0000-0002-5470-8763 FU NIA NIH HHS [T32 AG021890]; NIDA NIH HHS [DA 018922]; NINDS NIH HHS [NS 050401] NR 52 TC 24 Z9 27 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD APR PY 2007 VL 101 IS 2 BP 389 EP 396 DI 10.1111/j.1471-4159.2006.04383.x PG 8 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 151TD UT WOS:000245312800009 PM 17250681 ER EF